<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title>Pancreatobiliary Pathology Society Journal Watch</title>

<script>/*! jQuery v1.11.3 | (c) 2005, 2015 jQuery Foundation, Inc. | jquery.org/license */
!function(a,b){"object"==typeof module&&"object"==typeof module.exports?module.exports=a.document?b(a,!0):function(a){if(!a.document)throw new Error("jQuery requires a window with a document");return b(a)}:b(a)}("undefined"!=typeof window?window:this,function(a,b){var c=[],d=c.slice,e=c.concat,f=c.push,g=c.indexOf,h={},i=h.toString,j=h.hasOwnProperty,k={},l="1.11.3",m=function(a,b){return new m.fn.init(a,b)},n=/^[\s\uFEFF\xA0]+|[\s\uFEFF\xA0]+$/g,o=/^-ms-/,p=/-([\da-z])/gi,q=function(a,b){return b.toUpperCase()};m.fn=m.prototype={jquery:l,constructor:m,selector:"",length:0,toArray:function(){return d.call(this)},get:function(a){return null!=a?0>a?this[a+this.length]:this[a]:d.call(this)},pushStack:function(a){var b=m.merge(this.constructor(),a);return b.prevObject=this,b.context=this.context,b},each:function(a,b){return m.each(this,a,b)},map:function(a){return this.pushStack(m.map(this,function(b,c){return a.call(b,c,b)}))},slice:function(){return this.pushStack(d.apply(this,arguments))},first:function(){return this.eq(0)},last:function(){return this.eq(-1)},eq:function(a){var b=this.length,c=+a+(0>a?b:0);return this.pushStack(c>=0&&b>c?[this[c]]:[])},end:function(){return this.prevObject||this.constructor(null)},push:f,sort:c.sort,splice:c.splice},m.extend=m.fn.extend=function(){var a,b,c,d,e,f,g=arguments[0]||{},h=1,i=arguments.length,j=!1;for("boolean"==typeof g&&(j=g,g=arguments[h]||{},h++),"object"==typeof g||m.isFunction(g)||(g={}),h===i&&(g=this,h--);i>h;h++)if(null!=(e=arguments[h]))for(d in e)a=g[d],c=e[d],g!==c&&(j&&c&&(m.isPlainObject(c)||(b=m.isArray(c)))?(b?(b=!1,f=a&&m.isArray(a)?a:[]):f=a&&m.isPlainObject(a)?a:{},g[d]=m.extend(j,f,c)):void 0!==c&&(g[d]=c));return g},m.extend({expando:"jQuery"+(l+Math.random()).replace(/\D/g,""),isReady:!0,error:function(a){throw new Error(a)},noop:function(){},isFunction:function(a){return"function"===m.type(a)},isArray:Array.isArray||function(a){return"array"===m.type(a)},isWindow:function(a){return null!=a&&a==a.window},isNumeric:function(a){return!m.isArray(a)&&a-parseFloat(a)+1>=0},isEmptyObject:function(a){var b;for(b in a)return!1;return!0},isPlainObject:function(a){var b;if(!a||"object"!==m.type(a)||a.nodeType||m.isWindow(a))return!1;try{if(a.constructor&&!j.call(a,"constructor")&&!j.call(a.constructor.prototype,"isPrototypeOf"))return!1}catch(c){return!1}if(k.ownLast)for(b in a)return j.call(a,b);for(b in a);return void 0===b||j.call(a,b)},type:function(a){return null==a?a+"":"object"==typeof a||"function"==typeof a?h[i.call(a)]||"object":typeof a},globalEval:function(b){b&&m.trim(b)&&(a.execScript||function(b){a.eval.call(a,b)})(b)},camelCase:function(a){return a.replace(o,"ms-").replace(p,q)},nodeName:function(a,b){return a.nodeName&&a.nodeName.toLowerCase()===b.toLowerCase()},each:function(a,b,c){var d,e=0,f=a.length,g=r(a);if(c){if(g){for(;f>e;e++)if(d=b.apply(a[e],c),d===!1)break}else for(e in a)if(d=b.apply(a[e],c),d===!1)break}else if(g){for(;f>e;e++)if(d=b.call(a[e],e,a[e]),d===!1)break}else for(e in a)if(d=b.call(a[e],e,a[e]),d===!1)break;return a},trim:function(a){return null==a?"":(a+"").replace(n,"")},makeArray:function(a,b){var c=b||[];return null!=a&&(r(Object(a))?m.merge(c,"string"==typeof a?[a]:a):f.call(c,a)),c},inArray:function(a,b,c){var d;if(b){if(g)return g.call(b,a,c);for(d=b.length,c=c?0>c?Math.max(0,d+c):c:0;d>c;c++)if(c in b&&b[c]===a)return c}return-1},merge:function(a,b){var c=+b.length,d=0,e=a.length;while(c>d)a[e++]=b[d++];if(c!==c)while(void 0!==b[d])a[e++]=b[d++];return a.length=e,a},grep:function(a,b,c){for(var d,e=[],f=0,g=a.length,h=!c;g>f;f++)d=!b(a[f],f),d!==h&&e.push(a[f]);return e},map:function(a,b,c){var d,f=0,g=a.length,h=r(a),i=[];if(h)for(;g>f;f++)d=b(a[f],f,c),null!=d&&i.push(d);else for(f in a)d=b(a[f],f,c),null!=d&&i.push(d);return e.apply([],i)},guid:1,proxy:function(a,b){var c,e,f;return"string"==typeof b&&(f=a[b],b=a,a=f),m.isFunction(a)?(c=d.call(arguments,2),e=function(){return a.apply(b||this,c.concat(d.call(arguments)))},e.guid=a.guid=a.guid||m.guid++,e):void 0},now:function(){return+new Date},support:k}),m.each("Boolean Number String Function Array Date RegExp Object Error".split(" "),function(a,b){h["[object "+b+"]"]=b.toLowerCase()});function r(a){var b="length"in a&&a.length,c=m.type(a);return"function"===c||m.isWindow(a)?!1:1===a.nodeType&&b?!0:"array"===c||0===b||"number"==typeof b&&b>0&&b-1 in a}var s=function(a){var b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u="sizzle"+1*new Date,v=a.document,w=0,x=0,y=ha(),z=ha(),A=ha(),B=function(a,b){return a===b&&(l=!0),0},C=1<<31,D={}.hasOwnProperty,E=[],F=E.pop,G=E.push,H=E.push,I=E.slice,J=function(a,b){for(var c=0,d=a.length;d>c;c++)if(a[c]===b)return c;return-1},K="checked|selected|async|autofocus|autoplay|controls|defer|disabled|hidden|ismap|loop|multiple|open|readonly|required|scoped",L="[\\x20\\t\\r\\n\\f]",M="(?:\\\\.|[\\w-]|[^\\x00-\\xa0])+",N=M.replace("w","w#"),O="\\["+L+"*("+M+")(?:"+L+"*([*^$|!~]?=)"+L+"*(?:'((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\"|("+N+"))|)"+L+"*\\]",P=":("+M+")(?:\\((('((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\")|((?:\\\\.|[^\\\\()[\\]]|"+O+")*)|.*)\\)|)",Q=new RegExp(L+"+","g"),R=new RegExp("^"+L+"+|((?:^|[^\\\\])(?:\\\\.)*)"+L+"+$","g"),S=new RegExp("^"+L+"*,"+L+"*"),T=new RegExp("^"+L+"*([>+~]|"+L+")"+L+"*"),U=new RegExp("="+L+"*([^\\]'\"]*?)"+L+"*\\]","g"),V=new RegExp(P),W=new RegExp("^"+N+"$"),X={ID:new RegExp("^#("+M+")"),CLASS:new RegExp("^\\.("+M+")"),TAG:new RegExp("^("+M.replace("w","w*")+")"),ATTR:new RegExp("^"+O),PSEUDO:new RegExp("^"+P),CHILD:new RegExp("^:(only|first|last|nth|nth-last)-(child|of-type)(?:\\("+L+"*(even|odd|(([+-]|)(\\d*)n|)"+L+"*(?:([+-]|)"+L+"*(\\d+)|))"+L+"*\\)|)","i"),bool:new RegExp("^(?:"+K+")$","i"),needsContext:new RegExp("^"+L+"*[>+~]|:(even|odd|eq|gt|lt|nth|first|last)(?:\\("+L+"*((?:-\\d)?\\d*)"+L+"*\\)|)(?=[^-]|$)","i")},Y=/^(?:input|select|textarea|button)$/i,Z=/^h\d$/i,$=/^[^{]+\{\s*\[native \w/,_=/^(?:#([\w-]+)|(\w+)|\.([\w-]+))$/,aa=/[+~]/,ba=/'|\\/g,ca=new RegExp("\\\\([\\da-f]{1,6}"+L+"?|("+L+")|.)","ig"),da=function(a,b,c){var d="0x"+b-65536;return d!==d||c?b:0>d?String.fromCharCode(d+65536):String.fromCharCode(d>>10|55296,1023&d|56320)},ea=function(){m()};try{H.apply(E=I.call(v.childNodes),v.childNodes),E[v.childNodes.length].nodeType}catch(fa){H={apply:E.length?function(a,b){G.apply(a,I.call(b))}:function(a,b){var c=a.length,d=0;while(a[c++]=b[d++]);a.length=c-1}}}function ga(a,b,d,e){var f,h,j,k,l,o,r,s,w,x;if((b?b.ownerDocument||b:v)!==n&&m(b),b=b||n,d=d||[],k=b.nodeType,"string"!=typeof a||!a||1!==k&&9!==k&&11!==k)return d;if(!e&&p){if(11!==k&&(f=_.exec(a)))if(j=f[1]){if(9===k){if(h=b.getElementById(j),!h||!h.parentNode)return d;if(h.id===j)return d.push(h),d}else if(b.ownerDocument&&(h=b.ownerDocument.getElementById(j))&&t(b,h)&&h.id===j)return d.push(h),d}else{if(f[2])return H.apply(d,b.getElementsByTagName(a)),d;if((j=f[3])&&c.getElementsByClassName)return H.apply(d,b.getElementsByClassName(j)),d}if(c.qsa&&(!q||!q.test(a))){if(s=r=u,w=b,x=1!==k&&a,1===k&&"object"!==b.nodeName.toLowerCase()){o=g(a),(r=b.getAttribute("id"))?s=r.replace(ba,"\\$&"):b.setAttribute("id",s),s="[id='"+s+"'] ",l=o.length;while(l--)o[l]=s+ra(o[l]);w=aa.test(a)&&pa(b.parentNode)||b,x=o.join(",")}if(x)try{return H.apply(d,w.querySelectorAll(x)),d}catch(y){}finally{r||b.removeAttribute("id")}}}return i(a.replace(R,"$1"),b,d,e)}function ha(){var a=[];function b(c,e){return a.push(c+" ")>d.cacheLength&&delete b[a.shift()],b[c+" "]=e}return b}function ia(a){return a[u]=!0,a}function ja(a){var b=n.createElement("div");try{return!!a(b)}catch(c){return!1}finally{b.parentNode&&b.parentNode.removeChild(b),b=null}}function ka(a,b){var c=a.split("|"),e=a.length;while(e--)d.attrHandle[c[e]]=b}function la(a,b){var c=b&&a,d=c&&1===a.nodeType&&1===b.nodeType&&(~b.sourceIndex||C)-(~a.sourceIndex||C);if(d)return d;if(c)while(c=c.nextSibling)if(c===b)return-1;return a?1:-1}function ma(a){return function(b){var c=b.nodeName.toLowerCase();return"input"===c&&b.type===a}}function na(a){return function(b){var c=b.nodeName.toLowerCase();return("input"===c||"button"===c)&&b.type===a}}function oa(a){return ia(function(b){return b=+b,ia(function(c,d){var e,f=a([],c.length,b),g=f.length;while(g--)c[e=f[g]]&&(c[e]=!(d[e]=c[e]))})})}function pa(a){return a&&"undefined"!=typeof a.getElementsByTagName&&a}c=ga.support={},f=ga.isXML=function(a){var b=a&&(a.ownerDocument||a).documentElement;return b?"HTML"!==b.nodeName:!1},m=ga.setDocument=function(a){var b,e,g=a?a.ownerDocument||a:v;return g!==n&&9===g.nodeType&&g.documentElement?(n=g,o=g.documentElement,e=g.defaultView,e&&e!==e.top&&(e.addEventListener?e.addEventListener("unload",ea,!1):e.attachEvent&&e.attachEvent("onunload",ea)),p=!f(g),c.attributes=ja(function(a){return a.className="i",!a.getAttribute("className")}),c.getElementsByTagName=ja(function(a){return a.appendChild(g.createComment("")),!a.getElementsByTagName("*").length}),c.getElementsByClassName=$.test(g.getElementsByClassName),c.getById=ja(function(a){return o.appendChild(a).id=u,!g.getElementsByName||!g.getElementsByName(u).length}),c.getById?(d.find.ID=function(a,b){if("undefined"!=typeof b.getElementById&&p){var c=b.getElementById(a);return c&&c.parentNode?[c]:[]}},d.filter.ID=function(a){var b=a.replace(ca,da);return function(a){return a.getAttribute("id")===b}}):(delete d.find.ID,d.filter.ID=function(a){var b=a.replace(ca,da);return function(a){var c="undefined"!=typeof a.getAttributeNode&&a.getAttributeNode("id");return c&&c.value===b}}),d.find.TAG=c.getElementsByTagName?function(a,b){return"undefined"!=typeof b.getElementsByTagName?b.getElementsByTagName(a):c.qsa?b.querySelectorAll(a):void 0}:function(a,b){var c,d=[],e=0,f=b.getElementsByTagName(a);if("*"===a){while(c=f[e++])1===c.nodeType&&d.push(c);return d}return f},d.find.CLASS=c.getElementsByClassName&&function(a,b){return p?b.getElementsByClassName(a):void 0},r=[],q=[],(c.qsa=$.test(g.querySelectorAll))&&(ja(function(a){o.appendChild(a).innerHTML="<a id='"+u+"'></a><select id='"+u+"-\f]' msallowcapture=''><option selected=''></option></select>",a.querySelectorAll("[msallowcapture^='']").length&&q.push("[*^$]="+L+"*(?:''|\"\")"),a.querySelectorAll("[selected]").length||q.push("\\["+L+"*(?:value|"+K+")"),a.querySelectorAll("[id~="+u+"-]").length||q.push("~="),a.querySelectorAll(":checked").length||q.push(":checked"),a.querySelectorAll("a#"+u+"+*").length||q.push(".#.+[+~]")}),ja(function(a){var b=g.createElement("input");b.setAttribute("type","hidden"),a.appendChild(b).setAttribute("name","D"),a.querySelectorAll("[name=d]").length&&q.push("name"+L+"*[*^$|!~]?="),a.querySelectorAll(":enabled").length||q.push(":enabled",":disabled"),a.querySelectorAll("*,:x"),q.push(",.*:")})),(c.matchesSelector=$.test(s=o.matches||o.webkitMatchesSelector||o.mozMatchesSelector||o.oMatchesSelector||o.msMatchesSelector))&&ja(function(a){c.disconnectedMatch=s.call(a,"div"),s.call(a,"[s!='']:x"),r.push("!=",P)}),q=q.length&&new RegExp(q.join("|")),r=r.length&&new RegExp(r.join("|")),b=$.test(o.compareDocumentPosition),t=b||$.test(o.contains)?function(a,b){var c=9===a.nodeType?a.documentElement:a,d=b&&b.parentNode;return a===d||!(!d||1!==d.nodeType||!(c.contains?c.contains(d):a.compareDocumentPosition&&16&a.compareDocumentPosition(d)))}:function(a,b){if(b)while(b=b.parentNode)if(b===a)return!0;return!1},B=b?function(a,b){if(a===b)return l=!0,0;var d=!a.compareDocumentPosition-!b.compareDocumentPosition;return d?d:(d=(a.ownerDocument||a)===(b.ownerDocument||b)?a.compareDocumentPosition(b):1,1&d||!c.sortDetached&&b.compareDocumentPosition(a)===d?a===g||a.ownerDocument===v&&t(v,a)?-1:b===g||b.ownerDocument===v&&t(v,b)?1:k?J(k,a)-J(k,b):0:4&d?-1:1)}:function(a,b){if(a===b)return l=!0,0;var c,d=0,e=a.parentNode,f=b.parentNode,h=[a],i=[b];if(!e||!f)return a===g?-1:b===g?1:e?-1:f?1:k?J(k,a)-J(k,b):0;if(e===f)return la(a,b);c=a;while(c=c.parentNode)h.unshift(c);c=b;while(c=c.parentNode)i.unshift(c);while(h[d]===i[d])d++;return d?la(h[d],i[d]):h[d]===v?-1:i[d]===v?1:0},g):n},ga.matches=function(a,b){return ga(a,null,null,b)},ga.matchesSelector=function(a,b){if((a.ownerDocument||a)!==n&&m(a),b=b.replace(U,"='$1']"),!(!c.matchesSelector||!p||r&&r.test(b)||q&&q.test(b)))try{var d=s.call(a,b);if(d||c.disconnectedMatch||a.document&&11!==a.document.nodeType)return d}catch(e){}return ga(b,n,null,[a]).length>0},ga.contains=function(a,b){return(a.ownerDocument||a)!==n&&m(a),t(a,b)},ga.attr=function(a,b){(a.ownerDocument||a)!==n&&m(a);var e=d.attrHandle[b.toLowerCase()],f=e&&D.call(d.attrHandle,b.toLowerCase())?e(a,b,!p):void 0;return void 0!==f?f:c.attributes||!p?a.getAttribute(b):(f=a.getAttributeNode(b))&&f.specified?f.value:null},ga.error=function(a){throw new Error("Syntax error, unrecognized expression: "+a)},ga.uniqueSort=function(a){var b,d=[],e=0,f=0;if(l=!c.detectDuplicates,k=!c.sortStable&&a.slice(0),a.sort(B),l){while(b=a[f++])b===a[f]&&(e=d.push(f));while(e--)a.splice(d[e],1)}return k=null,a},e=ga.getText=function(a){var b,c="",d=0,f=a.nodeType;if(f){if(1===f||9===f||11===f){if("string"==typeof a.textContent)return a.textContent;for(a=a.firstChild;a;a=a.nextSibling)c+=e(a)}else if(3===f||4===f)return a.nodeValue}else while(b=a[d++])c+=e(b);return c},d=ga.selectors={cacheLength:50,createPseudo:ia,match:X,attrHandle:{},find:{},relative:{">":{dir:"parentNode",first:!0}," ":{dir:"parentNode"},"+":{dir:"previousSibling",first:!0},"~":{dir:"previousSibling"}},preFilter:{ATTR:function(a){return a[1]=a[1].replace(ca,da),a[3]=(a[3]||a[4]||a[5]||"").replace(ca,da),"~="===a[2]&&(a[3]=" "+a[3]+" "),a.slice(0,4)},CHILD:function(a){return a[1]=a[1].toLowerCase(),"nth"===a[1].slice(0,3)?(a[3]||ga.error(a[0]),a[4]=+(a[4]?a[5]+(a[6]||1):2*("even"===a[3]||"odd"===a[3])),a[5]=+(a[7]+a[8]||"odd"===a[3])):a[3]&&ga.error(a[0]),a},PSEUDO:function(a){var b,c=!a[6]&&a[2];return X.CHILD.test(a[0])?null:(a[3]?a[2]=a[4]||a[5]||"":c&&V.test(c)&&(b=g(c,!0))&&(b=c.indexOf(")",c.length-b)-c.length)&&(a[0]=a[0].slice(0,b),a[2]=c.slice(0,b)),a.slice(0,3))}},filter:{TAG:function(a){var b=a.replace(ca,da).toLowerCase();return"*"===a?function(){return!0}:function(a){return a.nodeName&&a.nodeName.toLowerCase()===b}},CLASS:function(a){var b=y[a+" "];return b||(b=new RegExp("(^|"+L+")"+a+"("+L+"|$)"))&&y(a,function(a){return b.test("string"==typeof a.className&&a.className||"undefined"!=typeof a.getAttribute&&a.getAttribute("class")||"")})},ATTR:function(a,b,c){return function(d){var e=ga.attr(d,a);return null==e?"!="===b:b?(e+="","="===b?e===c:"!="===b?e!==c:"^="===b?c&&0===e.indexOf(c):"*="===b?c&&e.indexOf(c)>-1:"$="===b?c&&e.slice(-c.length)===c:"~="===b?(" "+e.replace(Q," ")+" ").indexOf(c)>-1:"|="===b?e===c||e.slice(0,c.length+1)===c+"-":!1):!0}},CHILD:function(a,b,c,d,e){var f="nth"!==a.slice(0,3),g="last"!==a.slice(-4),h="of-type"===b;return 1===d&&0===e?function(a){return!!a.parentNode}:function(b,c,i){var j,k,l,m,n,o,p=f!==g?"nextSibling":"previousSibling",q=b.parentNode,r=h&&b.nodeName.toLowerCase(),s=!i&&!h;if(q){if(f){while(p){l=b;while(l=l[p])if(h?l.nodeName.toLowerCase()===r:1===l.nodeType)return!1;o=p="only"===a&&!o&&"nextSibling"}return!0}if(o=[g?q.firstChild:q.lastChild],g&&s){k=q[u]||(q[u]={}),j=k[a]||[],n=j[0]===w&&j[1],m=j[0]===w&&j[2],l=n&&q.childNodes[n];while(l=++n&&l&&l[p]||(m=n=0)||o.pop())if(1===l.nodeType&&++m&&l===b){k[a]=[w,n,m];break}}else if(s&&(j=(b[u]||(b[u]={}))[a])&&j[0]===w)m=j[1];else while(l=++n&&l&&l[p]||(m=n=0)||o.pop())if((h?l.nodeName.toLowerCase()===r:1===l.nodeType)&&++m&&(s&&((l[u]||(l[u]={}))[a]=[w,m]),l===b))break;return m-=e,m===d||m%d===0&&m/d>=0}}},PSEUDO:function(a,b){var c,e=d.pseudos[a]||d.setFilters[a.toLowerCase()]||ga.error("unsupported pseudo: "+a);return e[u]?e(b):e.length>1?(c=[a,a,"",b],d.setFilters.hasOwnProperty(a.toLowerCase())?ia(function(a,c){var d,f=e(a,b),g=f.length;while(g--)d=J(a,f[g]),a[d]=!(c[d]=f[g])}):function(a){return e(a,0,c)}):e}},pseudos:{not:ia(function(a){var b=[],c=[],d=h(a.replace(R,"$1"));return d[u]?ia(function(a,b,c,e){var f,g=d(a,null,e,[]),h=a.length;while(h--)(f=g[h])&&(a[h]=!(b[h]=f))}):function(a,e,f){return b[0]=a,d(b,null,f,c),b[0]=null,!c.pop()}}),has:ia(function(a){return function(b){return ga(a,b).length>0}}),contains:ia(function(a){return a=a.replace(ca,da),function(b){return(b.textContent||b.innerText||e(b)).indexOf(a)>-1}}),lang:ia(function(a){return W.test(a||"")||ga.error("unsupported lang: "+a),a=a.replace(ca,da).toLowerCase(),function(b){var c;do if(c=p?b.lang:b.getAttribute("xml:lang")||b.getAttribute("lang"))return c=c.toLowerCase(),c===a||0===c.indexOf(a+"-");while((b=b.parentNode)&&1===b.nodeType);return!1}}),target:function(b){var c=a.location&&a.location.hash;return c&&c.slice(1)===b.id},root:function(a){return a===o},focus:function(a){return a===n.activeElement&&(!n.hasFocus||n.hasFocus())&&!!(a.type||a.href||~a.tabIndex)},enabled:function(a){return a.disabled===!1},disabled:function(a){return a.disabled===!0},checked:function(a){var b=a.nodeName.toLowerCase();return"input"===b&&!!a.checked||"option"===b&&!!a.selected},selected:function(a){return a.parentNode&&a.parentNode.selectedIndex,a.selected===!0},empty:function(a){for(a=a.firstChild;a;a=a.nextSibling)if(a.nodeType<6)return!1;return!0},parent:function(a){return!d.pseudos.empty(a)},header:function(a){return Z.test(a.nodeName)},input:function(a){return Y.test(a.nodeName)},button:function(a){var b=a.nodeName.toLowerCase();return"input"===b&&"button"===a.type||"button"===b},text:function(a){var b;return"input"===a.nodeName.toLowerCase()&&"text"===a.type&&(null==(b=a.getAttribute("type"))||"text"===b.toLowerCase())},first:oa(function(){return[0]}),last:oa(function(a,b){return[b-1]}),eq:oa(function(a,b,c){return[0>c?c+b:c]}),even:oa(function(a,b){for(var c=0;b>c;c+=2)a.push(c);return a}),odd:oa(function(a,b){for(var c=1;b>c;c+=2)a.push(c);return a}),lt:oa(function(a,b,c){for(var d=0>c?c+b:c;--d>=0;)a.push(d);return a}),gt:oa(function(a,b,c){for(var d=0>c?c+b:c;++d<b;)a.push(d);return a})}},d.pseudos.nth=d.pseudos.eq;for(b in{radio:!0,checkbox:!0,file:!0,password:!0,image:!0})d.pseudos[b]=ma(b);for(b in{submit:!0,reset:!0})d.pseudos[b]=na(b);function qa(){}qa.prototype=d.filters=d.pseudos,d.setFilters=new qa,g=ga.tokenize=function(a,b){var c,e,f,g,h,i,j,k=z[a+" "];if(k)return b?0:k.slice(0);h=a,i=[],j=d.preFilter;while(h){(!c||(e=S.exec(h)))&&(e&&(h=h.slice(e[0].length)||h),i.push(f=[])),c=!1,(e=T.exec(h))&&(c=e.shift(),f.push({value:c,type:e[0].replace(R," ")}),h=h.slice(c.length));for(g in d.filter)!(e=X[g].exec(h))||j[g]&&!(e=j[g](e))||(c=e.shift(),f.push({value:c,type:g,matches:e}),h=h.slice(c.length));if(!c)break}return b?h.length:h?ga.error(a):z(a,i).slice(0)};function ra(a){for(var b=0,c=a.length,d="";c>b;b++)d+=a[b].value;return d}function sa(a,b,c){var d=b.dir,e=c&&"parentNode"===d,f=x++;return b.first?function(b,c,f){while(b=b[d])if(1===b.nodeType||e)return a(b,c,f)}:function(b,c,g){var h,i,j=[w,f];if(g){while(b=b[d])if((1===b.nodeType||e)&&a(b,c,g))return!0}else while(b=b[d])if(1===b.nodeType||e){if(i=b[u]||(b[u]={}),(h=i[d])&&h[0]===w&&h[1]===f)return j[2]=h[2];if(i[d]=j,j[2]=a(b,c,g))return!0}}}function ta(a){return a.length>1?function(b,c,d){var e=a.length;while(e--)if(!a[e](b,c,d))return!1;return!0}:a[0]}function ua(a,b,c){for(var d=0,e=b.length;e>d;d++)ga(a,b[d],c);return c}function va(a,b,c,d,e){for(var f,g=[],h=0,i=a.length,j=null!=b;i>h;h++)(f=a[h])&&(!c||c(f,d,e))&&(g.push(f),j&&b.push(h));return g}function wa(a,b,c,d,e,f){return d&&!d[u]&&(d=wa(d)),e&&!e[u]&&(e=wa(e,f)),ia(function(f,g,h,i){var j,k,l,m=[],n=[],o=g.length,p=f||ua(b||"*",h.nodeType?[h]:h,[]),q=!a||!f&&b?p:va(p,m,a,h,i),r=c?e||(f?a:o||d)?[]:g:q;if(c&&c(q,r,h,i),d){j=va(r,n),d(j,[],h,i),k=j.length;while(k--)(l=j[k])&&(r[n[k]]=!(q[n[k]]=l))}if(f){if(e||a){if(e){j=[],k=r.length;while(k--)(l=r[k])&&j.push(q[k]=l);e(null,r=[],j,i)}k=r.length;while(k--)(l=r[k])&&(j=e?J(f,l):m[k])>-1&&(f[j]=!(g[j]=l))}}else r=va(r===g?r.splice(o,r.length):r),e?e(null,g,r,i):H.apply(g,r)})}function xa(a){for(var b,c,e,f=a.length,g=d.relative[a[0].type],h=g||d.relative[" "],i=g?1:0,k=sa(function(a){return a===b},h,!0),l=sa(function(a){return J(b,a)>-1},h,!0),m=[function(a,c,d){var e=!g&&(d||c!==j)||((b=c).nodeType?k(a,c,d):l(a,c,d));return b=null,e}];f>i;i++)if(c=d.relative[a[i].type])m=[sa(ta(m),c)];else{if(c=d.filter[a[i].type].apply(null,a[i].matches),c[u]){for(e=++i;f>e;e++)if(d.relative[a[e].type])break;return wa(i>1&&ta(m),i>1&&ra(a.slice(0,i-1).concat({value:" "===a[i-2].type?"*":""})).replace(R,"$1"),c,e>i&&xa(a.slice(i,e)),f>e&&xa(a=a.slice(e)),f>e&&ra(a))}m.push(c)}return ta(m)}function ya(a,b){var c=b.length>0,e=a.length>0,f=function(f,g,h,i,k){var l,m,o,p=0,q="0",r=f&&[],s=[],t=j,u=f||e&&d.find.TAG("*",k),v=w+=null==t?1:Math.random()||.1,x=u.length;for(k&&(j=g!==n&&g);q!==x&&null!=(l=u[q]);q++){if(e&&l){m=0;while(o=a[m++])if(o(l,g,h)){i.push(l);break}k&&(w=v)}c&&((l=!o&&l)&&p--,f&&r.push(l))}if(p+=q,c&&q!==p){m=0;while(o=b[m++])o(r,s,g,h);if(f){if(p>0)while(q--)r[q]||s[q]||(s[q]=F.call(i));s=va(s)}H.apply(i,s),k&&!f&&s.length>0&&p+b.length>1&&ga.uniqueSort(i)}return k&&(w=v,j=t),r};return c?ia(f):f}return h=ga.compile=function(a,b){var c,d=[],e=[],f=A[a+" "];if(!f){b||(b=g(a)),c=b.length;while(c--)f=xa(b[c]),f[u]?d.push(f):e.push(f);f=A(a,ya(e,d)),f.selector=a}return f},i=ga.select=function(a,b,e,f){var i,j,k,l,m,n="function"==typeof a&&a,o=!f&&g(a=n.selector||a);if(e=e||[],1===o.length){if(j=o[0]=o[0].slice(0),j.length>2&&"ID"===(k=j[0]).type&&c.getById&&9===b.nodeType&&p&&d.relative[j[1].type]){if(b=(d.find.ID(k.matches[0].replace(ca,da),b)||[])[0],!b)return e;n&&(b=b.parentNode),a=a.slice(j.shift().value.length)}i=X.needsContext.test(a)?0:j.length;while(i--){if(k=j[i],d.relative[l=k.type])break;if((m=d.find[l])&&(f=m(k.matches[0].replace(ca,da),aa.test(j[0].type)&&pa(b.parentNode)||b))){if(j.splice(i,1),a=f.length&&ra(j),!a)return H.apply(e,f),e;break}}}return(n||h(a,o))(f,b,!p,e,aa.test(a)&&pa(b.parentNode)||b),e},c.sortStable=u.split("").sort(B).join("")===u,c.detectDuplicates=!!l,m(),c.sortDetached=ja(function(a){return 1&a.compareDocumentPosition(n.createElement("div"))}),ja(function(a){return a.innerHTML="<a href='#'></a>","#"===a.firstChild.getAttribute("href")})||ka("type|href|height|width",function(a,b,c){return c?void 0:a.getAttribute(b,"type"===b.toLowerCase()?1:2)}),c.attributes&&ja(function(a){return a.innerHTML="<input/>",a.firstChild.setAttribute("value",""),""===a.firstChild.getAttribute("value")})||ka("value",function(a,b,c){return c||"input"!==a.nodeName.toLowerCase()?void 0:a.defaultValue}),ja(function(a){return null==a.getAttribute("disabled")})||ka(K,function(a,b,c){var d;return c?void 0:a[b]===!0?b.toLowerCase():(d=a.getAttributeNode(b))&&d.specified?d.value:null}),ga}(a);m.find=s,m.expr=s.selectors,m.expr[":"]=m.expr.pseudos,m.unique=s.uniqueSort,m.text=s.getText,m.isXMLDoc=s.isXML,m.contains=s.contains;var t=m.expr.match.needsContext,u=/^<(\w+)\s*\/?>(?:<\/\1>|)$/,v=/^.[^:#\[\.,]*$/;function w(a,b,c){if(m.isFunction(b))return m.grep(a,function(a,d){return!!b.call(a,d,a)!==c});if(b.nodeType)return m.grep(a,function(a){return a===b!==c});if("string"==typeof b){if(v.test(b))return m.filter(b,a,c);b=m.filter(b,a)}return m.grep(a,function(a){return m.inArray(a,b)>=0!==c})}m.filter=function(a,b,c){var d=b[0];return c&&(a=":not("+a+")"),1===b.length&&1===d.nodeType?m.find.matchesSelector(d,a)?[d]:[]:m.find.matches(a,m.grep(b,function(a){return 1===a.nodeType}))},m.fn.extend({find:function(a){var b,c=[],d=this,e=d.length;if("string"!=typeof a)return this.pushStack(m(a).filter(function(){for(b=0;e>b;b++)if(m.contains(d[b],this))return!0}));for(b=0;e>b;b++)m.find(a,d[b],c);return c=this.pushStack(e>1?m.unique(c):c),c.selector=this.selector?this.selector+" "+a:a,c},filter:function(a){return this.pushStack(w(this,a||[],!1))},not:function(a){return this.pushStack(w(this,a||[],!0))},is:function(a){return!!w(this,"string"==typeof a&&t.test(a)?m(a):a||[],!1).length}});var x,y=a.document,z=/^(?:\s*(<[\w\W]+>)[^>]*|#([\w-]*))$/,A=m.fn.init=function(a,b){var c,d;if(!a)return this;if("string"==typeof a){if(c="<"===a.charAt(0)&&">"===a.charAt(a.length-1)&&a.length>=3?[null,a,null]:z.exec(a),!c||!c[1]&&b)return!b||b.jquery?(b||x).find(a):this.constructor(b).find(a);if(c[1]){if(b=b instanceof m?b[0]:b,m.merge(this,m.parseHTML(c[1],b&&b.nodeType?b.ownerDocument||b:y,!0)),u.test(c[1])&&m.isPlainObject(b))for(c in b)m.isFunction(this[c])?this[c](b[c]):this.attr(c,b[c]);return this}if(d=y.getElementById(c[2]),d&&d.parentNode){if(d.id!==c[2])return x.find(a);this.length=1,this[0]=d}return this.context=y,this.selector=a,this}return a.nodeType?(this.context=this[0]=a,this.length=1,this):m.isFunction(a)?"undefined"!=typeof x.ready?x.ready(a):a(m):(void 0!==a.selector&&(this.selector=a.selector,this.context=a.context),m.makeArray(a,this))};A.prototype=m.fn,x=m(y);var B=/^(?:parents|prev(?:Until|All))/,C={children:!0,contents:!0,next:!0,prev:!0};m.extend({dir:function(a,b,c){var d=[],e=a[b];while(e&&9!==e.nodeType&&(void 0===c||1!==e.nodeType||!m(e).is(c)))1===e.nodeType&&d.push(e),e=e[b];return d},sibling:function(a,b){for(var c=[];a;a=a.nextSibling)1===a.nodeType&&a!==b&&c.push(a);return c}}),m.fn.extend({has:function(a){var b,c=m(a,this),d=c.length;return this.filter(function(){for(b=0;d>b;b++)if(m.contains(this,c[b]))return!0})},closest:function(a,b){for(var c,d=0,e=this.length,f=[],g=t.test(a)||"string"!=typeof a?m(a,b||this.context):0;e>d;d++)for(c=this[d];c&&c!==b;c=c.parentNode)if(c.nodeType<11&&(g?g.index(c)>-1:1===c.nodeType&&m.find.matchesSelector(c,a))){f.push(c);break}return this.pushStack(f.length>1?m.unique(f):f)},index:function(a){return a?"string"==typeof a?m.inArray(this[0],m(a)):m.inArray(a.jquery?a[0]:a,this):this[0]&&this[0].parentNode?this.first().prevAll().length:-1},add:function(a,b){return this.pushStack(m.unique(m.merge(this.get(),m(a,b))))},addBack:function(a){return this.add(null==a?this.prevObject:this.prevObject.filter(a))}});function D(a,b){do a=a[b];while(a&&1!==a.nodeType);return a}m.each({parent:function(a){var b=a.parentNode;return b&&11!==b.nodeType?b:null},parents:function(a){return m.dir(a,"parentNode")},parentsUntil:function(a,b,c){return m.dir(a,"parentNode",c)},next:function(a){return D(a,"nextSibling")},prev:function(a){return D(a,"previousSibling")},nextAll:function(a){return m.dir(a,"nextSibling")},prevAll:function(a){return m.dir(a,"previousSibling")},nextUntil:function(a,b,c){return m.dir(a,"nextSibling",c)},prevUntil:function(a,b,c){return m.dir(a,"previousSibling",c)},siblings:function(a){return m.sibling((a.parentNode||{}).firstChild,a)},children:function(a){return m.sibling(a.firstChild)},contents:function(a){return m.nodeName(a,"iframe")?a.contentDocument||a.contentWindow.document:m.merge([],a.childNodes)}},function(a,b){m.fn[a]=function(c,d){var e=m.map(this,b,c);return"Until"!==a.slice(-5)&&(d=c),d&&"string"==typeof d&&(e=m.filter(d,e)),this.length>1&&(C[a]||(e=m.unique(e)),B.test(a)&&(e=e.reverse())),this.pushStack(e)}});var E=/\S+/g,F={};function G(a){var b=F[a]={};return m.each(a.match(E)||[],function(a,c){b[c]=!0}),b}m.Callbacks=function(a){a="string"==typeof a?F[a]||G(a):m.extend({},a);var b,c,d,e,f,g,h=[],i=!a.once&&[],j=function(l){for(c=a.memory&&l,d=!0,f=g||0,g=0,e=h.length,b=!0;h&&e>f;f++)if(h[f].apply(l[0],l[1])===!1&&a.stopOnFalse){c=!1;break}b=!1,h&&(i?i.length&&j(i.shift()):c?h=[]:k.disable())},k={add:function(){if(h){var d=h.length;!function f(b){m.each(b,function(b,c){var d=m.type(c);"function"===d?a.unique&&k.has(c)||h.push(c):c&&c.length&&"string"!==d&&f(c)})}(arguments),b?e=h.length:c&&(g=d,j(c))}return this},remove:function(){return h&&m.each(arguments,function(a,c){var d;while((d=m.inArray(c,h,d))>-1)h.splice(d,1),b&&(e>=d&&e--,f>=d&&f--)}),this},has:function(a){return a?m.inArray(a,h)>-1:!(!h||!h.length)},empty:function(){return h=[],e=0,this},disable:function(){return h=i=c=void 0,this},disabled:function(){return!h},lock:function(){return i=void 0,c||k.disable(),this},locked:function(){return!i},fireWith:function(a,c){return!h||d&&!i||(c=c||[],c=[a,c.slice?c.slice():c],b?i.push(c):j(c)),this},fire:function(){return k.fireWith(this,arguments),this},fired:function(){return!!d}};return k},m.extend({Deferred:function(a){var b=[["resolve","done",m.Callbacks("once memory"),"resolved"],["reject","fail",m.Callbacks("once memory"),"rejected"],["notify","progress",m.Callbacks("memory")]],c="pending",d={state:function(){return c},always:function(){return e.done(arguments).fail(arguments),this},then:function(){var a=arguments;return m.Deferred(function(c){m.each(b,function(b,f){var g=m.isFunction(a[b])&&a[b];e[f[1]](function(){var a=g&&g.apply(this,arguments);a&&m.isFunction(a.promise)?a.promise().done(c.resolve).fail(c.reject).progress(c.notify):c[f[0]+"With"](this===d?c.promise():this,g?[a]:arguments)})}),a=null}).promise()},promise:function(a){return null!=a?m.extend(a,d):d}},e={};return d.pipe=d.then,m.each(b,function(a,f){var g=f[2],h=f[3];d[f[1]]=g.add,h&&g.add(function(){c=h},b[1^a][2].disable,b[2][2].lock),e[f[0]]=function(){return e[f[0]+"With"](this===e?d:this,arguments),this},e[f[0]+"With"]=g.fireWith}),d.promise(e),a&&a.call(e,e),e},when:function(a){var b=0,c=d.call(arguments),e=c.length,f=1!==e||a&&m.isFunction(a.promise)?e:0,g=1===f?a:m.Deferred(),h=function(a,b,c){return function(e){b[a]=this,c[a]=arguments.length>1?d.call(arguments):e,c===i?g.notifyWith(b,c):--f||g.resolveWith(b,c)}},i,j,k;if(e>1)for(i=new Array(e),j=new Array(e),k=new Array(e);e>b;b++)c[b]&&m.isFunction(c[b].promise)?c[b].promise().done(h(b,k,c)).fail(g.reject).progress(h(b,j,i)):--f;return f||g.resolveWith(k,c),g.promise()}});var H;m.fn.ready=function(a){return m.ready.promise().done(a),this},m.extend({isReady:!1,readyWait:1,holdReady:function(a){a?m.readyWait++:m.ready(!0)},ready:function(a){if(a===!0?!--m.readyWait:!m.isReady){if(!y.body)return setTimeout(m.ready);m.isReady=!0,a!==!0&&--m.readyWait>0||(H.resolveWith(y,[m]),m.fn.triggerHandler&&(m(y).triggerHandler("ready"),m(y).off("ready")))}}});function I(){y.addEventListener?(y.removeEventListener("DOMContentLoaded",J,!1),a.removeEventListener("load",J,!1)):(y.detachEvent("onreadystatechange",J),a.detachEvent("onload",J))}function J(){(y.addEventListener||"load"===event.type||"complete"===y.readyState)&&(I(),m.ready())}m.ready.promise=function(b){if(!H)if(H=m.Deferred(),"complete"===y.readyState)setTimeout(m.ready);else if(y.addEventListener)y.addEventListener("DOMContentLoaded",J,!1),a.addEventListener("load",J,!1);else{y.attachEvent("onreadystatechange",J),a.attachEvent("onload",J);var c=!1;try{c=null==a.frameElement&&y.documentElement}catch(d){}c&&c.doScroll&&!function e(){if(!m.isReady){try{c.doScroll("left")}catch(a){return setTimeout(e,50)}I(),m.ready()}}()}return H.promise(b)};var K="undefined",L;for(L in m(k))break;k.ownLast="0"!==L,k.inlineBlockNeedsLayout=!1,m(function(){var a,b,c,d;c=y.getElementsByTagName("body")[0],c&&c.style&&(b=y.createElement("div"),d=y.createElement("div"),d.style.cssText="position:absolute;border:0;width:0;height:0;top:0;left:-9999px",c.appendChild(d).appendChild(b),typeof b.style.zoom!==K&&(b.style.cssText="display:inline;margin:0;border:0;padding:1px;width:1px;zoom:1",k.inlineBlockNeedsLayout=a=3===b.offsetWidth,a&&(c.style.zoom=1)),c.removeChild(d))}),function(){var a=y.createElement("div");if(null==k.deleteExpando){k.deleteExpando=!0;try{delete a.test}catch(b){k.deleteExpando=!1}}a=null}(),m.acceptData=function(a){var b=m.noData[(a.nodeName+" ").toLowerCase()],c=+a.nodeType||1;return 1!==c&&9!==c?!1:!b||b!==!0&&a.getAttribute("classid")===b};var M=/^(?:\{[\w\W]*\}|\[[\w\W]*\])$/,N=/([A-Z])/g;function O(a,b,c){if(void 0===c&&1===a.nodeType){var d="data-"+b.replace(N,"-$1").toLowerCase();if(c=a.getAttribute(d),"string"==typeof c){try{c="true"===c?!0:"false"===c?!1:"null"===c?null:+c+""===c?+c:M.test(c)?m.parseJSON(c):c}catch(e){}m.data(a,b,c)}else c=void 0}return c}function P(a){var b;for(b in a)if(("data"!==b||!m.isEmptyObject(a[b]))&&"toJSON"!==b)return!1;

return!0}function Q(a,b,d,e){if(m.acceptData(a)){var f,g,h=m.expando,i=a.nodeType,j=i?m.cache:a,k=i?a[h]:a[h]&&h;if(k&&j[k]&&(e||j[k].data)||void 0!==d||"string"!=typeof b)return k||(k=i?a[h]=c.pop()||m.guid++:h),j[k]||(j[k]=i?{}:{toJSON:m.noop}),("object"==typeof b||"function"==typeof b)&&(e?j[k]=m.extend(j[k],b):j[k].data=m.extend(j[k].data,b)),g=j[k],e||(g.data||(g.data={}),g=g.data),void 0!==d&&(g[m.camelCase(b)]=d),"string"==typeof b?(f=g[b],null==f&&(f=g[m.camelCase(b)])):f=g,f}}function R(a,b,c){if(m.acceptData(a)){var d,e,f=a.nodeType,g=f?m.cache:a,h=f?a[m.expando]:m.expando;if(g[h]){if(b&&(d=c?g[h]:g[h].data)){m.isArray(b)?b=b.concat(m.map(b,m.camelCase)):b in d?b=[b]:(b=m.camelCase(b),b=b in d?[b]:b.split(" ")),e=b.length;while(e--)delete d[b[e]];if(c?!P(d):!m.isEmptyObject(d))return}(c||(delete g[h].data,P(g[h])))&&(f?m.cleanData([a],!0):k.deleteExpando||g!=g.window?delete g[h]:g[h]=null)}}}m.extend({cache:{},noData:{"applet ":!0,"embed ":!0,"object ":"clsid:D27CDB6E-AE6D-11cf-96B8-444553540000"},hasData:function(a){return a=a.nodeType?m.cache[a[m.expando]]:a[m.expando],!!a&&!P(a)},data:function(a,b,c){return Q(a,b,c)},removeData:function(a,b){return R(a,b)},_data:function(a,b,c){return Q(a,b,c,!0)},_removeData:function(a,b){return R(a,b,!0)}}),m.fn.extend({data:function(a,b){var c,d,e,f=this[0],g=f&&f.attributes;if(void 0===a){if(this.length&&(e=m.data(f),1===f.nodeType&&!m._data(f,"parsedAttrs"))){c=g.length;while(c--)g[c]&&(d=g[c].name,0===d.indexOf("data-")&&(d=m.camelCase(d.slice(5)),O(f,d,e[d])));m._data(f,"parsedAttrs",!0)}return e}return"object"==typeof a?this.each(function(){m.data(this,a)}):arguments.length>1?this.each(function(){m.data(this,a,b)}):f?O(f,a,m.data(f,a)):void 0},removeData:function(a){return this.each(function(){m.removeData(this,a)})}}),m.extend({queue:function(a,b,c){var d;return a?(b=(b||"fx")+"queue",d=m._data(a,b),c&&(!d||m.isArray(c)?d=m._data(a,b,m.makeArray(c)):d.push(c)),d||[]):void 0},dequeue:function(a,b){b=b||"fx";var c=m.queue(a,b),d=c.length,e=c.shift(),f=m._queueHooks(a,b),g=function(){m.dequeue(a,b)};"inprogress"===e&&(e=c.shift(),d--),e&&("fx"===b&&c.unshift("inprogress"),delete f.stop,e.call(a,g,f)),!d&&f&&f.empty.fire()},_queueHooks:function(a,b){var c=b+"queueHooks";return m._data(a,c)||m._data(a,c,{empty:m.Callbacks("once memory").add(function(){m._removeData(a,b+"queue"),m._removeData(a,c)})})}}),m.fn.extend({queue:function(a,b){var c=2;return"string"!=typeof a&&(b=a,a="fx",c--),arguments.length<c?m.queue(this[0],a):void 0===b?this:this.each(function(){var c=m.queue(this,a,b);m._queueHooks(this,a),"fx"===a&&"inprogress"!==c[0]&&m.dequeue(this,a)})},dequeue:function(a){return this.each(function(){m.dequeue(this,a)})},clearQueue:function(a){return this.queue(a||"fx",[])},promise:function(a,b){var c,d=1,e=m.Deferred(),f=this,g=this.length,h=function(){--d||e.resolveWith(f,[f])};"string"!=typeof a&&(b=a,a=void 0),a=a||"fx";while(g--)c=m._data(f[g],a+"queueHooks"),c&&c.empty&&(d++,c.empty.add(h));return h(),e.promise(b)}});var S=/[+-]?(?:\d*\.|)\d+(?:[eE][+-]?\d+|)/.source,T=["Top","Right","Bottom","Left"],U=function(a,b){return a=b||a,"none"===m.css(a,"display")||!m.contains(a.ownerDocument,a)},V=m.access=function(a,b,c,d,e,f,g){var h=0,i=a.length,j=null==c;if("object"===m.type(c)){e=!0;for(h in c)m.access(a,b,h,c[h],!0,f,g)}else if(void 0!==d&&(e=!0,m.isFunction(d)||(g=!0),j&&(g?(b.call(a,d),b=null):(j=b,b=function(a,b,c){return j.call(m(a),c)})),b))for(;i>h;h++)b(a[h],c,g?d:d.call(a[h],h,b(a[h],c)));return e?a:j?b.call(a):i?b(a[0],c):f},W=/^(?:checkbox|radio)$/i;!function(){var a=y.createElement("input"),b=y.createElement("div"),c=y.createDocumentFragment();if(b.innerHTML="  <link/><table></table><a href='/a'>a</a><input type='checkbox'/>",k.leadingWhitespace=3===b.firstChild.nodeType,k.tbody=!b.getElementsByTagName("tbody").length,k.htmlSerialize=!!b.getElementsByTagName("link").length,k.html5Clone="<:nav></:nav>"!==y.createElement("nav").cloneNode(!0).outerHTML,a.type="checkbox",a.checked=!0,c.appendChild(a),k.appendChecked=a.checked,b.innerHTML="<textarea>x</textarea>",k.noCloneChecked=!!b.cloneNode(!0).lastChild.defaultValue,c.appendChild(b),b.innerHTML="<input type='radio' checked='checked' name='t'/>",k.checkClone=b.cloneNode(!0).cloneNode(!0).lastChild.checked,k.noCloneEvent=!0,b.attachEvent&&(b.attachEvent("onclick",function(){k.noCloneEvent=!1}),b.cloneNode(!0).click()),null==k.deleteExpando){k.deleteExpando=!0;try{delete b.test}catch(d){k.deleteExpando=!1}}}(),function(){var b,c,d=y.createElement("div");for(b in{submit:!0,change:!0,focusin:!0})c="on"+b,(k[b+"Bubbles"]=c in a)||(d.setAttribute(c,"t"),k[b+"Bubbles"]=d.attributes[c].expando===!1);d=null}();var X=/^(?:input|select|textarea)$/i,Y=/^key/,Z=/^(?:mouse|pointer|contextmenu)|click/,$=/^(?:focusinfocus|focusoutblur)$/,_=/^([^.]*)(?:\.(.+)|)$/;function aa(){return!0}function ba(){return!1}function ca(){try{return y.activeElement}catch(a){}}m.event={global:{},add:function(a,b,c,d,e){var f,g,h,i,j,k,l,n,o,p,q,r=m._data(a);if(r){c.handler&&(i=c,c=i.handler,e=i.selector),c.guid||(c.guid=m.guid++),(g=r.events)||(g=r.events={}),(k=r.handle)||(k=r.handle=function(a){return typeof m===K||a&&m.event.triggered===a.type?void 0:m.event.dispatch.apply(k.elem,arguments)},k.elem=a),b=(b||"").match(E)||[""],h=b.length;while(h--)f=_.exec(b[h])||[],o=q=f[1],p=(f[2]||"").split(".").sort(),o&&(j=m.event.special[o]||{},o=(e?j.delegateType:j.bindType)||o,j=m.event.special[o]||{},l=m.extend({type:o,origType:q,data:d,handler:c,guid:c.guid,selector:e,needsContext:e&&m.expr.match.needsContext.test(e),namespace:p.join(".")},i),(n=g[o])||(n=g[o]=[],n.delegateCount=0,j.setup&&j.setup.call(a,d,p,k)!==!1||(a.addEventListener?a.addEventListener(o,k,!1):a.attachEvent&&a.attachEvent("on"+o,k))),j.add&&(j.add.call(a,l),l.handler.guid||(l.handler.guid=c.guid)),e?n.splice(n.delegateCount++,0,l):n.push(l),m.event.global[o]=!0);a=null}},remove:function(a,b,c,d,e){var f,g,h,i,j,k,l,n,o,p,q,r=m.hasData(a)&&m._data(a);if(r&&(k=r.events)){b=(b||"").match(E)||[""],j=b.length;while(j--)if(h=_.exec(b[j])||[],o=q=h[1],p=(h[2]||"").split(".").sort(),o){l=m.event.special[o]||{},o=(d?l.delegateType:l.bindType)||o,n=k[o]||[],h=h[2]&&new RegExp("(^|\\.)"+p.join("\\.(?:.*\\.|)")+"(\\.|$)"),i=f=n.length;while(f--)g=n[f],!e&&q!==g.origType||c&&c.guid!==g.guid||h&&!h.test(g.namespace)||d&&d!==g.selector&&("**"!==d||!g.selector)||(n.splice(f,1),g.selector&&n.delegateCount--,l.remove&&l.remove.call(a,g));i&&!n.length&&(l.teardown&&l.teardown.call(a,p,r.handle)!==!1||m.removeEvent(a,o,r.handle),delete k[o])}else for(o in k)m.event.remove(a,o+b[j],c,d,!0);m.isEmptyObject(k)&&(delete r.handle,m._removeData(a,"events"))}},trigger:function(b,c,d,e){var f,g,h,i,k,l,n,o=[d||y],p=j.call(b,"type")?b.type:b,q=j.call(b,"namespace")?b.namespace.split("."):[];if(h=l=d=d||y,3!==d.nodeType&&8!==d.nodeType&&!$.test(p+m.event.triggered)&&(p.indexOf(".")>=0&&(q=p.split("."),p=q.shift(),q.sort()),g=p.indexOf(":")<0&&"on"+p,b=b[m.expando]?b:new m.Event(p,"object"==typeof b&&b),b.isTrigger=e?2:3,b.namespace=q.join("."),b.namespace_re=b.namespace?new RegExp("(^|\\.)"+q.join("\\.(?:.*\\.|)")+"(\\.|$)"):null,b.result=void 0,b.target||(b.target=d),c=null==c?[b]:m.makeArray(c,[b]),k=m.event.special[p]||{},e||!k.trigger||k.trigger.apply(d,c)!==!1)){if(!e&&!k.noBubble&&!m.isWindow(d)){for(i=k.delegateType||p,$.test(i+p)||(h=h.parentNode);h;h=h.parentNode)o.push(h),l=h;l===(d.ownerDocument||y)&&o.push(l.defaultView||l.parentWindow||a)}n=0;while((h=o[n++])&&!b.isPropagationStopped())b.type=n>1?i:k.bindType||p,f=(m._data(h,"events")||{})[b.type]&&m._data(h,"handle"),f&&f.apply(h,c),f=g&&h[g],f&&f.apply&&m.acceptData(h)&&(b.result=f.apply(h,c),b.result===!1&&b.preventDefault());if(b.type=p,!e&&!b.isDefaultPrevented()&&(!k._default||k._default.apply(o.pop(),c)===!1)&&m.acceptData(d)&&g&&d[p]&&!m.isWindow(d)){l=d[g],l&&(d[g]=null),m.event.triggered=p;try{d[p]()}catch(r){}m.event.triggered=void 0,l&&(d[g]=l)}return b.result}},dispatch:function(a){a=m.event.fix(a);var b,c,e,f,g,h=[],i=d.call(arguments),j=(m._data(this,"events")||{})[a.type]||[],k=m.event.special[a.type]||{};if(i[0]=a,a.delegateTarget=this,!k.preDispatch||k.preDispatch.call(this,a)!==!1){h=m.event.handlers.call(this,a,j),b=0;while((f=h[b++])&&!a.isPropagationStopped()){a.currentTarget=f.elem,g=0;while((e=f.handlers[g++])&&!a.isImmediatePropagationStopped())(!a.namespace_re||a.namespace_re.test(e.namespace))&&(a.handleObj=e,a.data=e.data,c=((m.event.special[e.origType]||{}).handle||e.handler).apply(f.elem,i),void 0!==c&&(a.result=c)===!1&&(a.preventDefault(),a.stopPropagation()))}return k.postDispatch&&k.postDispatch.call(this,a),a.result}},handlers:function(a,b){var c,d,e,f,g=[],h=b.delegateCount,i=a.target;if(h&&i.nodeType&&(!a.button||"click"!==a.type))for(;i!=this;i=i.parentNode||this)if(1===i.nodeType&&(i.disabled!==!0||"click"!==a.type)){for(e=[],f=0;h>f;f++)d=b[f],c=d.selector+" ",void 0===e[c]&&(e[c]=d.needsContext?m(c,this).index(i)>=0:m.find(c,this,null,[i]).length),e[c]&&e.push(d);e.length&&g.push({elem:i,handlers:e})}return h<b.length&&g.push({elem:this,handlers:b.slice(h)}),g},fix:function(a){if(a[m.expando])return a;var b,c,d,e=a.type,f=a,g=this.fixHooks[e];g||(this.fixHooks[e]=g=Z.test(e)?this.mouseHooks:Y.test(e)?this.keyHooks:{}),d=g.props?this.props.concat(g.props):this.props,a=new m.Event(f),b=d.length;while(b--)c=d[b],a[c]=f[c];return a.target||(a.target=f.srcElement||y),3===a.target.nodeType&&(a.target=a.target.parentNode),a.metaKey=!!a.metaKey,g.filter?g.filter(a,f):a},props:"altKey bubbles cancelable ctrlKey currentTarget eventPhase metaKey relatedTarget shiftKey target timeStamp view which".split(" "),fixHooks:{},keyHooks:{props:"char charCode key keyCode".split(" "),filter:function(a,b){return null==a.which&&(a.which=null!=b.charCode?b.charCode:b.keyCode),a}},mouseHooks:{props:"button buttons clientX clientY fromElement offsetX offsetY pageX pageY screenX screenY toElement".split(" "),filter:function(a,b){var c,d,e,f=b.button,g=b.fromElement;return null==a.pageX&&null!=b.clientX&&(d=a.target.ownerDocument||y,e=d.documentElement,c=d.body,a.pageX=b.clientX+(e&&e.scrollLeft||c&&c.scrollLeft||0)-(e&&e.clientLeft||c&&c.clientLeft||0),a.pageY=b.clientY+(e&&e.scrollTop||c&&c.scrollTop||0)-(e&&e.clientTop||c&&c.clientTop||0)),!a.relatedTarget&&g&&(a.relatedTarget=g===a.target?b.toElement:g),a.which||void 0===f||(a.which=1&f?1:2&f?3:4&f?2:0),a}},special:{load:{noBubble:!0},focus:{trigger:function(){if(this!==ca()&&this.focus)try{return this.focus(),!1}catch(a){}},delegateType:"focusin"},blur:{trigger:function(){return this===ca()&&this.blur?(this.blur(),!1):void 0},delegateType:"focusout"},click:{trigger:function(){return m.nodeName(this,"input")&&"checkbox"===this.type&&this.click?(this.click(),!1):void 0},_default:function(a){return m.nodeName(a.target,"a")}},beforeunload:{postDispatch:function(a){void 0!==a.result&&a.originalEvent&&(a.originalEvent.returnValue=a.result)}}},simulate:function(a,b,c,d){var e=m.extend(new m.Event,c,{type:a,isSimulated:!0,originalEvent:{}});d?m.event.trigger(e,null,b):m.event.dispatch.call(b,e),e.isDefaultPrevented()&&c.preventDefault()}},m.removeEvent=y.removeEventListener?function(a,b,c){a.removeEventListener&&a.removeEventListener(b,c,!1)}:function(a,b,c){var d="on"+b;a.detachEvent&&(typeof a[d]===K&&(a[d]=null),a.detachEvent(d,c))},m.Event=function(a,b){return this instanceof m.Event?(a&&a.type?(this.originalEvent=a,this.type=a.type,this.isDefaultPrevented=a.defaultPrevented||void 0===a.defaultPrevented&&a.returnValue===!1?aa:ba):this.type=a,b&&m.extend(this,b),this.timeStamp=a&&a.timeStamp||m.now(),void(this[m.expando]=!0)):new m.Event(a,b)},m.Event.prototype={isDefaultPrevented:ba,isPropagationStopped:ba,isImmediatePropagationStopped:ba,preventDefault:function(){var a=this.originalEvent;this.isDefaultPrevented=aa,a&&(a.preventDefault?a.preventDefault():a.returnValue=!1)},stopPropagation:function(){var a=this.originalEvent;this.isPropagationStopped=aa,a&&(a.stopPropagation&&a.stopPropagation(),a.cancelBubble=!0)},stopImmediatePropagation:function(){var a=this.originalEvent;this.isImmediatePropagationStopped=aa,a&&a.stopImmediatePropagation&&a.stopImmediatePropagation(),this.stopPropagation()}},m.each({mouseenter:"mouseover",mouseleave:"mouseout",pointerenter:"pointerover",pointerleave:"pointerout"},function(a,b){m.event.special[a]={delegateType:b,bindType:b,handle:function(a){var c,d=this,e=a.relatedTarget,f=a.handleObj;return(!e||e!==d&&!m.contains(d,e))&&(a.type=f.origType,c=f.handler.apply(this,arguments),a.type=b),c}}}),k.submitBubbles||(m.event.special.submit={setup:function(){return m.nodeName(this,"form")?!1:void m.event.add(this,"click._submit keypress._submit",function(a){var b=a.target,c=m.nodeName(b,"input")||m.nodeName(b,"button")?b.form:void 0;c&&!m._data(c,"submitBubbles")&&(m.event.add(c,"submit._submit",function(a){a._submit_bubble=!0}),m._data(c,"submitBubbles",!0))})},postDispatch:function(a){a._submit_bubble&&(delete a._submit_bubble,this.parentNode&&!a.isTrigger&&m.event.simulate("submit",this.parentNode,a,!0))},teardown:function(){return m.nodeName(this,"form")?!1:void m.event.remove(this,"._submit")}}),k.changeBubbles||(m.event.special.change={setup:function(){return X.test(this.nodeName)?(("checkbox"===this.type||"radio"===this.type)&&(m.event.add(this,"propertychange._change",function(a){"checked"===a.originalEvent.propertyName&&(this._just_changed=!0)}),m.event.add(this,"click._change",function(a){this._just_changed&&!a.isTrigger&&(this._just_changed=!1),m.event.simulate("change",this,a,!0)})),!1):void m.event.add(this,"beforeactivate._change",function(a){var b=a.target;X.test(b.nodeName)&&!m._data(b,"changeBubbles")&&(m.event.add(b,"change._change",function(a){!this.parentNode||a.isSimulated||a.isTrigger||m.event.simulate("change",this.parentNode,a,!0)}),m._data(b,"changeBubbles",!0))})},handle:function(a){var b=a.target;return this!==b||a.isSimulated||a.isTrigger||"radio"!==b.type&&"checkbox"!==b.type?a.handleObj.handler.apply(this,arguments):void 0},teardown:function(){return m.event.remove(this,"._change"),!X.test(this.nodeName)}}),k.focusinBubbles||m.each({focus:"focusin",blur:"focusout"},function(a,b){var c=function(a){m.event.simulate(b,a.target,m.event.fix(a),!0)};m.event.special[b]={setup:function(){var d=this.ownerDocument||this,e=m._data(d,b);e||d.addEventListener(a,c,!0),m._data(d,b,(e||0)+1)},teardown:function(){var d=this.ownerDocument||this,e=m._data(d,b)-1;e?m._data(d,b,e):(d.removeEventListener(a,c,!0),m._removeData(d,b))}}}),m.fn.extend({on:function(a,b,c,d,e){var f,g;if("object"==typeof a){"string"!=typeof b&&(c=c||b,b=void 0);for(f in a)this.on(f,b,c,a[f],e);return this}if(null==c&&null==d?(d=b,c=b=void 0):null==d&&("string"==typeof b?(d=c,c=void 0):(d=c,c=b,b=void 0)),d===!1)d=ba;else if(!d)return this;return 1===e&&(g=d,d=function(a){return m().off(a),g.apply(this,arguments)},d.guid=g.guid||(g.guid=m.guid++)),this.each(function(){m.event.add(this,a,d,c,b)})},one:function(a,b,c,d){return this.on(a,b,c,d,1)},off:function(a,b,c){var d,e;if(a&&a.preventDefault&&a.handleObj)return d=a.handleObj,m(a.delegateTarget).off(d.namespace?d.origType+"."+d.namespace:d.origType,d.selector,d.handler),this;if("object"==typeof a){for(e in a)this.off(e,b,a[e]);return this}return(b===!1||"function"==typeof b)&&(c=b,b=void 0),c===!1&&(c=ba),this.each(function(){m.event.remove(this,a,c,b)})},trigger:function(a,b){return this.each(function(){m.event.trigger(a,b,this)})},triggerHandler:function(a,b){var c=this[0];return c?m.event.trigger(a,b,c,!0):void 0}});function da(a){var b=ea.split("|"),c=a.createDocumentFragment();if(c.createElement)while(b.length)c.createElement(b.pop());return c}var ea="abbr|article|aside|audio|bdi|canvas|data|datalist|details|figcaption|figure|footer|header|hgroup|mark|meter|nav|output|progress|section|summary|time|video",fa=/ jQuery\d+="(?:null|\d+)"/g,ga=new RegExp("<(?:"+ea+")[\\s/>]","i"),ha=/^\s+/,ia=/<(?!area|br|col|embed|hr|img|input|link|meta|param)(([\w:]+)[^>]*)\/>/gi,ja=/<([\w:]+)/,ka=/<tbody/i,la=/<|&#?\w+;/,ma=/<(?:script|style|link)/i,na=/checked\s*(?:[^=]|=\s*.checked.)/i,oa=/^$|\/(?:java|ecma)script/i,pa=/^true\/(.*)/,qa=/^\s*<!(?:\[CDATA\[|--)|(?:\]\]|--)>\s*$/g,ra={option:[1,"<select multiple='multiple'>","</select>"],legend:[1,"<fieldset>","</fieldset>"],area:[1,"<map>","</map>"],param:[1,"<object>","</object>"],thead:[1,"<table>","</table>"],tr:[2,"<table><tbody>","</tbody></table>"],col:[2,"<table><tbody></tbody><colgroup>","</colgroup></table>"],td:[3,"<table><tbody><tr>","</tr></tbody></table>"],_default:k.htmlSerialize?[0,"",""]:[1,"X<div>","</div>"]},sa=da(y),ta=sa.appendChild(y.createElement("div"));ra.optgroup=ra.option,ra.tbody=ra.tfoot=ra.colgroup=ra.caption=ra.thead,ra.th=ra.td;function ua(a,b){var c,d,e=0,f=typeof a.getElementsByTagName!==K?a.getElementsByTagName(b||"*"):typeof a.querySelectorAll!==K?a.querySelectorAll(b||"*"):void 0;if(!f)for(f=[],c=a.childNodes||a;null!=(d=c[e]);e++)!b||m.nodeName(d,b)?f.push(d):m.merge(f,ua(d,b));return void 0===b||b&&m.nodeName(a,b)?m.merge([a],f):f}function va(a){W.test(a.type)&&(a.defaultChecked=a.checked)}function wa(a,b){return m.nodeName(a,"table")&&m.nodeName(11!==b.nodeType?b:b.firstChild,"tr")?a.getElementsByTagName("tbody")[0]||a.appendChild(a.ownerDocument.createElement("tbody")):a}function xa(a){return a.type=(null!==m.find.attr(a,"type"))+"/"+a.type,a}function ya(a){var b=pa.exec(a.type);return b?a.type=b[1]:a.removeAttribute("type"),a}function za(a,b){for(var c,d=0;null!=(c=a[d]);d++)m._data(c,"globalEval",!b||m._data(b[d],"globalEval"))}function Aa(a,b){if(1===b.nodeType&&m.hasData(a)){var c,d,e,f=m._data(a),g=m._data(b,f),h=f.events;if(h){delete g.handle,g.events={};for(c in h)for(d=0,e=h[c].length;e>d;d++)m.event.add(b,c,h[c][d])}g.data&&(g.data=m.extend({},g.data))}}function Ba(a,b){var c,d,e;if(1===b.nodeType){if(c=b.nodeName.toLowerCase(),!k.noCloneEvent&&b[m.expando]){e=m._data(b);for(d in e.events)m.removeEvent(b,d,e.handle);b.removeAttribute(m.expando)}"script"===c&&b.text!==a.text?(xa(b).text=a.text,ya(b)):"object"===c?(b.parentNode&&(b.outerHTML=a.outerHTML),k.html5Clone&&a.innerHTML&&!m.trim(b.innerHTML)&&(b.innerHTML=a.innerHTML)):"input"===c&&W.test(a.type)?(b.defaultChecked=b.checked=a.checked,b.value!==a.value&&(b.value=a.value)):"option"===c?b.defaultSelected=b.selected=a.defaultSelected:("input"===c||"textarea"===c)&&(b.defaultValue=a.defaultValue)}}m.extend({clone:function(a,b,c){var d,e,f,g,h,i=m.contains(a.ownerDocument,a);if(k.html5Clone||m.isXMLDoc(a)||!ga.test("<"+a.nodeName+">")?f=a.cloneNode(!0):(ta.innerHTML=a.outerHTML,ta.removeChild(f=ta.firstChild)),!(k.noCloneEvent&&k.noCloneChecked||1!==a.nodeType&&11!==a.nodeType||m.isXMLDoc(a)))for(d=ua(f),h=ua(a),g=0;null!=(e=h[g]);++g)d[g]&&Ba(e,d[g]);if(b)if(c)for(h=h||ua(a),d=d||ua(f),g=0;null!=(e=h[g]);g++)Aa(e,d[g]);else Aa(a,f);return d=ua(f,"script"),d.length>0&&za(d,!i&&ua(a,"script")),d=h=e=null,f},buildFragment:function(a,b,c,d){for(var e,f,g,h,i,j,l,n=a.length,o=da(b),p=[],q=0;n>q;q++)if(f=a[q],f||0===f)if("object"===m.type(f))m.merge(p,f.nodeType?[f]:f);else if(la.test(f)){h=h||o.appendChild(b.createElement("div")),i=(ja.exec(f)||["",""])[1].toLowerCase(),l=ra[i]||ra._default,h.innerHTML=l[1]+f.replace(ia,"<$1></$2>")+l[2],e=l[0];while(e--)h=h.lastChild;if(!k.leadingWhitespace&&ha.test(f)&&p.push(b.createTextNode(ha.exec(f)[0])),!k.tbody){f="table"!==i||ka.test(f)?"<table>"!==l[1]||ka.test(f)?0:h:h.firstChild,e=f&&f.childNodes.length;while(e--)m.nodeName(j=f.childNodes[e],"tbody")&&!j.childNodes.length&&f.removeChild(j)}m.merge(p,h.childNodes),h.textContent="";while(h.firstChild)h.removeChild(h.firstChild);h=o.lastChild}else p.push(b.createTextNode(f));h&&o.removeChild(h),k.appendChecked||m.grep(ua(p,"input"),va),q=0;while(f=p[q++])if((!d||-1===m.inArray(f,d))&&(g=m.contains(f.ownerDocument,f),h=ua(o.appendChild(f),"script"),g&&za(h),c)){e=0;while(f=h[e++])oa.test(f.type||"")&&c.push(f)}return h=null,o},cleanData:function(a,b){for(var d,e,f,g,h=0,i=m.expando,j=m.cache,l=k.deleteExpando,n=m.event.special;null!=(d=a[h]);h++)if((b||m.acceptData(d))&&(f=d[i],g=f&&j[f])){if(g.events)for(e in g.events)n[e]?m.event.remove(d,e):m.removeEvent(d,e,g.handle);j[f]&&(delete j[f],l?delete d[i]:typeof d.removeAttribute!==K?d.removeAttribute(i):d[i]=null,c.push(f))}}}),m.fn.extend({text:function(a){return V(this,function(a){return void 0===a?m.text(this):this.empty().append((this[0]&&this[0].ownerDocument||y).createTextNode(a))},null,a,arguments.length)},append:function(){return this.domManip(arguments,function(a){if(1===this.nodeType||11===this.nodeType||9===this.nodeType){var b=wa(this,a);b.appendChild(a)}})},prepend:function(){return this.domManip(arguments,function(a){if(1===this.nodeType||11===this.nodeType||9===this.nodeType){var b=wa(this,a);b.insertBefore(a,b.firstChild)}})},before:function(){return this.domManip(arguments,function(a){this.parentNode&&this.parentNode.insertBefore(a,this)})},after:function(){return this.domManip(arguments,function(a){this.parentNode&&this.parentNode.insertBefore(a,this.nextSibling)})},remove:function(a,b){for(var c,d=a?m.filter(a,this):this,e=0;null!=(c=d[e]);e++)b||1!==c.nodeType||m.cleanData(ua(c)),c.parentNode&&(b&&m.contains(c.ownerDocument,c)&&za(ua(c,"script")),c.parentNode.removeChild(c));return this},empty:function(){for(var a,b=0;null!=(a=this[b]);b++){1===a.nodeType&&m.cleanData(ua(a,!1));while(a.firstChild)a.removeChild(a.firstChild);a.options&&m.nodeName(a,"select")&&(a.options.length=0)}return this},clone:function(a,b){return a=null==a?!1:a,b=null==b?a:b,this.map(function(){return m.clone(this,a,b)})},html:function(a){return V(this,function(a){var b=this[0]||{},c=0,d=this.length;if(void 0===a)return 1===b.nodeType?b.innerHTML.replace(fa,""):void 0;if(!("string"!=typeof a||ma.test(a)||!k.htmlSerialize&&ga.test(a)||!k.leadingWhitespace&&ha.test(a)||ra[(ja.exec(a)||["",""])[1].toLowerCase()])){a=a.replace(ia,"<$1></$2>");try{for(;d>c;c++)b=this[c]||{},1===b.nodeType&&(m.cleanData(ua(b,!1)),b.innerHTML=a);b=0}catch(e){}}b&&this.empty().append(a)},null,a,arguments.length)},replaceWith:function(){var a=arguments[0];return this.domManip(arguments,function(b){a=this.parentNode,m.cleanData(ua(this)),a&&a.replaceChild(b,this)}),a&&(a.length||a.nodeType)?this:this.remove()},detach:function(a){return this.remove(a,!0)},domManip:function(a,b){a=e.apply([],a);var c,d,f,g,h,i,j=0,l=this.length,n=this,o=l-1,p=a[0],q=m.isFunction(p);if(q||l>1&&"string"==typeof p&&!k.checkClone&&na.test(p))return this.each(function(c){var d=n.eq(c);q&&(a[0]=p.call(this,c,d.html())),d.domManip(a,b)});if(l&&(i=m.buildFragment(a,this[0].ownerDocument,!1,this),c=i.firstChild,1===i.childNodes.length&&(i=c),c)){for(g=m.map(ua(i,"script"),xa),f=g.length;l>j;j++)d=i,j!==o&&(d=m.clone(d,!0,!0),f&&m.merge(g,ua(d,"script"))),b.call(this[j],d,j);if(f)for(h=g[g.length-1].ownerDocument,m.map(g,ya),j=0;f>j;j++)d=g[j],oa.test(d.type||"")&&!m._data(d,"globalEval")&&m.contains(h,d)&&(d.src?m._evalUrl&&m._evalUrl(d.src):m.globalEval((d.text||d.textContent||d.innerHTML||"").replace(qa,"")));i=c=null}return this}}),m.each({appendTo:"append",prependTo:"prepend",insertBefore:"before",insertAfter:"after",replaceAll:"replaceWith"},function(a,b){m.fn[a]=function(a){for(var c,d=0,e=[],g=m(a),h=g.length-1;h>=d;d++)c=d===h?this:this.clone(!0),m(g[d])[b](c),f.apply(e,c.get());return this.pushStack(e)}});var Ca,Da={};function Ea(b,c){var d,e=m(c.createElement(b)).appendTo(c.body),f=a.getDefaultComputedStyle&&(d=a.getDefaultComputedStyle(e[0]))?d.display:m.css(e[0],"display");return e.detach(),f}function Fa(a){var b=y,c=Da[a];return c||(c=Ea(a,b),"none"!==c&&c||(Ca=(Ca||m("<iframe frameborder='0' width='0' height='0'/>")).appendTo(b.documentElement),b=(Ca[0].contentWindow||Ca[0].contentDocument).document,b.write(),b.close(),c=Ea(a,b),Ca.detach()),Da[a]=c),c}!function(){var a;k.shrinkWrapBlocks=function(){if(null!=a)return a;a=!1;var b,c,d;return c=y.getElementsByTagName("body")[0],c&&c.style?(b=y.createElement("div"),d=y.createElement("div"),d.style.cssText="position:absolute;border:0;width:0;height:0;top:0;left:-9999px",c.appendChild(d).appendChild(b),typeof b.style.zoom!==K&&(b.style.cssText="-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box;display:block;margin:0;border:0;padding:1px;width:1px;zoom:1",b.appendChild(y.createElement("div")).style.width="5px",a=3!==b.offsetWidth),c.removeChild(d),a):void 0}}();var Ga=/^margin/,Ha=new RegExp("^("+S+")(?!px)[a-z%]+$","i"),Ia,Ja,Ka=/^(top|right|bottom|left)$/;a.getComputedStyle?(Ia=function(b){return b.ownerDocument.defaultView.opener?b.ownerDocument.defaultView.getComputedStyle(b,null):a.getComputedStyle(b,null)},Ja=function(a,b,c){var d,e,f,g,h=a.style;return c=c||Ia(a),g=c?c.getPropertyValue(b)||c[b]:void 0,c&&(""!==g||m.contains(a.ownerDocument,a)||(g=m.style(a,b)),Ha.test(g)&&Ga.test(b)&&(d=h.width,e=h.minWidth,f=h.maxWidth,h.minWidth=h.maxWidth=h.width=g,g=c.width,h.width=d,h.minWidth=e,h.maxWidth=f)),void 0===g?g:g+""}):y.documentElement.currentStyle&&(Ia=function(a){return a.currentStyle},Ja=function(a,b,c){var d,e,f,g,h=a.style;return c=c||Ia(a),g=c?c[b]:void 0,null==g&&h&&h[b]&&(g=h[b]),Ha.test(g)&&!Ka.test(b)&&(d=h.left,e=a.runtimeStyle,f=e&&e.left,f&&(e.left=a.currentStyle.left),h.left="fontSize"===b?"1em":g,g=h.pixelLeft+"px",h.left=d,f&&(e.left=f)),void 0===g?g:g+""||"auto"});function La(a,b){return{get:function(){var c=a();if(null!=c)return c?void delete this.get:(this.get=b).apply(this,arguments)}}}!function(){var b,c,d,e,f,g,h;if(b=y.createElement("div"),b.innerHTML="  <link/><table></table><a href='/a'>a</a><input type='checkbox'/>",d=b.getElementsByTagName("a")[0],c=d&&d.style){c.cssText="float:left;opacity:.5",k.opacity="0.5"===c.opacity,k.cssFloat=!!c.cssFloat,b.style.backgroundClip="content-box",b.cloneNode(!0).style.backgroundClip="",k.clearCloneStyle="content-box"===b.style.backgroundClip,k.boxSizing=""===c.boxSizing||""===c.MozBoxSizing||""===c.WebkitBoxSizing,m.extend(k,{reliableHiddenOffsets:function(){return null==g&&i(),g},boxSizingReliable:function(){return null==f&&i(),f},pixelPosition:function(){return null==e&&i(),e},reliableMarginRight:function(){return null==h&&i(),h}});function i(){var b,c,d,i;c=y.getElementsByTagName("body")[0],c&&c.style&&(b=y.createElement("div"),d=y.createElement("div"),d.style.cssText="position:absolute;border:0;width:0;height:0;top:0;left:-9999px",c.appendChild(d).appendChild(b),b.style.cssText="-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box;display:block;margin-top:1%;top:1%;border:1px;padding:1px;width:4px;position:absolute",e=f=!1,h=!0,a.getComputedStyle&&(e="1%"!==(a.getComputedStyle(b,null)||{}).top,f="4px"===(a.getComputedStyle(b,null)||{width:"4px"}).width,i=b.appendChild(y.createElement("div")),i.style.cssText=b.style.cssText="-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box;display:block;margin:0;border:0;padding:0",i.style.marginRight=i.style.width="0",b.style.width="1px",h=!parseFloat((a.getComputedStyle(i,null)||{}).marginRight),b.removeChild(i)),b.innerHTML="<table><tr><td></td><td>t</td></tr></table>",i=b.getElementsByTagName("td"),i[0].style.cssText="margin:0;border:0;padding:0;display:none",g=0===i[0].offsetHeight,g&&(i[0].style.display="",i[1].style.display="none",g=0===i[0].offsetHeight),c.removeChild(d))}}}(),m.swap=function(a,b,c,d){var e,f,g={};for(f in b)g[f]=a.style[f],a.style[f]=b[f];e=c.apply(a,d||[]);for(f in b)a.style[f]=g[f];return e};var Ma=/alpha\([^)]*\)/i,Na=/opacity\s*=\s*([^)]*)/,Oa=/^(none|table(?!-c[ea]).+)/,Pa=new RegExp("^("+S+")(.*)$","i"),Qa=new RegExp("^([+-])=("+S+")","i"),Ra={position:"absolute",visibility:"hidden",display:"block"},Sa={letterSpacing:"0",fontWeight:"400"},Ta=["Webkit","O","Moz","ms"];function Ua(a,b){if(b in a)return b;var c=b.charAt(0).toUpperCase()+b.slice(1),d=b,e=Ta.length;while(e--)if(b=Ta[e]+c,b in a)return b;return d}function Va(a,b){for(var c,d,e,f=[],g=0,h=a.length;h>g;g++)d=a[g],d.style&&(f[g]=m._data(d,"olddisplay"),c=d.style.display,b?(f[g]||"none"!==c||(d.style.display=""),""===d.style.display&&U(d)&&(f[g]=m._data(d,"olddisplay",Fa(d.nodeName)))):(e=U(d),(c&&"none"!==c||!e)&&m._data(d,"olddisplay",e?c:m.css(d,"display"))));for(g=0;h>g;g++)d=a[g],d.style&&(b&&"none"!==d.style.display&&""!==d.style.display||(d.style.display=b?f[g]||"":"none"));return a}function Wa(a,b,c){var d=Pa.exec(b);return d?Math.max(0,d[1]-(c||0))+(d[2]||"px"):b}function Xa(a,b,c,d,e){for(var f=c===(d?"border":"content")?4:"width"===b?1:0,g=0;4>f;f+=2)"margin"===c&&(g+=m.css(a,c+T[f],!0,e)),d?("content"===c&&(g-=m.css(a,"padding"+T[f],!0,e)),"margin"!==c&&(g-=m.css(a,"border"+T[f]+"Width",!0,e))):(g+=m.css(a,"padding"+T[f],!0,e),"padding"!==c&&(g+=m.css(a,"border"+T[f]+"Width",!0,e)));return g}function Ya(a,b,c){var d=!0,e="width"===b?a.offsetWidth:a.offsetHeight,f=Ia(a),g=k.boxSizing&&"border-box"===m.css(a,"boxSizing",!1,f);if(0>=e||null==e){if(e=Ja(a,b,f),(0>e||null==e)&&(e=a.style[b]),Ha.test(e))return e;d=g&&(k.boxSizingReliable()||e===a.style[b]),e=parseFloat(e)||0}return e+Xa(a,b,c||(g?"border":"content"),d,f)+"px"}m.extend({cssHooks:{opacity:{get:function(a,b){if(b){var c=Ja(a,"opacity");return""===c?"1":c}}}},cssNumber:{columnCount:!0,fillOpacity:!0,flexGrow:!0,flexShrink:!0,fontWeight:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,widows:!0,zIndex:!0,zoom:!0},cssProps:{"float":k.cssFloat?"cssFloat":"styleFloat"},style:function(a,b,c,d){if(a&&3!==a.nodeType&&8!==a.nodeType&&a.style){var e,f,g,h=m.camelCase(b),i=a.style;if(b=m.cssProps[h]||(m.cssProps[h]=Ua(i,h)),g=m.cssHooks[b]||m.cssHooks[h],void 0===c)return g&&"get"in g&&void 0!==(e=g.get(a,!1,d))?e:i[b];if(f=typeof c,"string"===f&&(e=Qa.exec(c))&&(c=(e[1]+1)*e[2]+parseFloat(m.css(a,b)),f="number"),null!=c&&c===c&&("number"!==f||m.cssNumber[h]||(c+="px"),k.clearCloneStyle||""!==c||0!==b.indexOf("background")||(i[b]="inherit"),!(g&&"set"in g&&void 0===(c=g.set(a,c,d)))))try{i[b]=c}catch(j){}}},css:function(a,b,c,d){var e,f,g,h=m.camelCase(b);return b=m.cssProps[h]||(m.cssProps[h]=Ua(a.style,h)),g=m.cssHooks[b]||m.cssHooks[h],g&&"get"in g&&(f=g.get(a,!0,c)),void 0===f&&(f=Ja(a,b,d)),"normal"===f&&b in Sa&&(f=Sa[b]),""===c||c?(e=parseFloat(f),c===!0||m.isNumeric(e)?e||0:f):f}}),m.each(["height","width"],function(a,b){m.cssHooks[b]={get:function(a,c,d){return c?Oa.test(m.css(a,"display"))&&0===a.offsetWidth?m.swap(a,Ra,function(){return Ya(a,b,d)}):Ya(a,b,d):void 0},set:function(a,c,d){var e=d&&Ia(a);return Wa(a,c,d?Xa(a,b,d,k.boxSizing&&"border-box"===m.css(a,"boxSizing",!1,e),e):0)}}}),k.opacity||(m.cssHooks.opacity={get:function(a,b){return Na.test((b&&a.currentStyle?a.currentStyle.filter:a.style.filter)||"")?.01*parseFloat(RegExp.$1)+"":b?"1":""},set:function(a,b){var c=a.style,d=a.currentStyle,e=m.isNumeric(b)?"alpha(opacity="+100*b+")":"",f=d&&d.filter||c.filter||"";c.zoom=1,(b>=1||""===b)&&""===m.trim(f.replace(Ma,""))&&c.removeAttribute&&(c.removeAttribute("filter"),""===b||d&&!d.filter)||(c.filter=Ma.test(f)?f.replace(Ma,e):f+" "+e)}}),m.cssHooks.marginRight=La(k.reliableMarginRight,function(a,b){return b?m.swap(a,{display:"inline-block"},Ja,[a,"marginRight"]):void 0}),m.each({margin:"",padding:"",border:"Width"},function(a,b){m.cssHooks[a+b]={expand:function(c){for(var d=0,e={},f="string"==typeof c?c.split(" "):[c];4>d;d++)e[a+T[d]+b]=f[d]||f[d-2]||f[0];return e}},Ga.test(a)||(m.cssHooks[a+b].set=Wa)}),m.fn.extend({css:function(a,b){return V(this,function(a,b,c){var d,e,f={},g=0;if(m.isArray(b)){for(d=Ia(a),e=b.length;e>g;g++)f[b[g]]=m.css(a,b[g],!1,d);return f}return void 0!==c?m.style(a,b,c):m.css(a,b)},a,b,arguments.length>1)},show:function(){return Va(this,!0)},hide:function(){return Va(this)},toggle:function(a){return"boolean"==typeof a?a?this.show():this.hide():this.each(function(){U(this)?m(this).show():m(this).hide()})}});function Za(a,b,c,d,e){
return new Za.prototype.init(a,b,c,d,e)}m.Tween=Za,Za.prototype={constructor:Za,init:function(a,b,c,d,e,f){this.elem=a,this.prop=c,this.easing=e||"swing",this.options=b,this.start=this.now=this.cur(),this.end=d,this.unit=f||(m.cssNumber[c]?"":"px")},cur:function(){var a=Za.propHooks[this.prop];return a&&a.get?a.get(this):Za.propHooks._default.get(this)},run:function(a){var b,c=Za.propHooks[this.prop];return this.options.duration?this.pos=b=m.easing[this.easing](a,this.options.duration*a,0,1,this.options.duration):this.pos=b=a,this.now=(this.end-this.start)*b+this.start,this.options.step&&this.options.step.call(this.elem,this.now,this),c&&c.set?c.set(this):Za.propHooks._default.set(this),this}},Za.prototype.init.prototype=Za.prototype,Za.propHooks={_default:{get:function(a){var b;return null==a.elem[a.prop]||a.elem.style&&null!=a.elem.style[a.prop]?(b=m.css(a.elem,a.prop,""),b&&"auto"!==b?b:0):a.elem[a.prop]},set:function(a){m.fx.step[a.prop]?m.fx.step[a.prop](a):a.elem.style&&(null!=a.elem.style[m.cssProps[a.prop]]||m.cssHooks[a.prop])?m.style(a.elem,a.prop,a.now+a.unit):a.elem[a.prop]=a.now}}},Za.propHooks.scrollTop=Za.propHooks.scrollLeft={set:function(a){a.elem.nodeType&&a.elem.parentNode&&(a.elem[a.prop]=a.now)}},m.easing={linear:function(a){return a},swing:function(a){return.5-Math.cos(a*Math.PI)/2}},m.fx=Za.prototype.init,m.fx.step={};var $a,_a,ab=/^(?:toggle|show|hide)$/,bb=new RegExp("^(?:([+-])=|)("+S+")([a-z%]*)$","i"),cb=/queueHooks$/,db=[ib],eb={"*":[function(a,b){var c=this.createTween(a,b),d=c.cur(),e=bb.exec(b),f=e&&e[3]||(m.cssNumber[a]?"":"px"),g=(m.cssNumber[a]||"px"!==f&&+d)&&bb.exec(m.css(c.elem,a)),h=1,i=20;if(g&&g[3]!==f){f=f||g[3],e=e||[],g=+d||1;do h=h||".5",g/=h,m.style(c.elem,a,g+f);while(h!==(h=c.cur()/d)&&1!==h&&--i)}return e&&(g=c.start=+g||+d||0,c.unit=f,c.end=e[1]?g+(e[1]+1)*e[2]:+e[2]),c}]};function fb(){return setTimeout(function(){$a=void 0}),$a=m.now()}function gb(a,b){var c,d={height:a},e=0;for(b=b?1:0;4>e;e+=2-b)c=T[e],d["margin"+c]=d["padding"+c]=a;return b&&(d.opacity=d.width=a),d}function hb(a,b,c){for(var d,e=(eb[b]||[]).concat(eb["*"]),f=0,g=e.length;g>f;f++)if(d=e[f].call(c,b,a))return d}function ib(a,b,c){var d,e,f,g,h,i,j,l,n=this,o={},p=a.style,q=a.nodeType&&U(a),r=m._data(a,"fxshow");c.queue||(h=m._queueHooks(a,"fx"),null==h.unqueued&&(h.unqueued=0,i=h.empty.fire,h.empty.fire=function(){h.unqueued||i()}),h.unqueued++,n.always(function(){n.always(function(){h.unqueued--,m.queue(a,"fx").length||h.empty.fire()})})),1===a.nodeType&&("height"in b||"width"in b)&&(c.overflow=[p.overflow,p.overflowX,p.overflowY],j=m.css(a,"display"),l="none"===j?m._data(a,"olddisplay")||Fa(a.nodeName):j,"inline"===l&&"none"===m.css(a,"float")&&(k.inlineBlockNeedsLayout&&"inline"!==Fa(a.nodeName)?p.zoom=1:p.display="inline-block")),c.overflow&&(p.overflow="hidden",k.shrinkWrapBlocks()||n.always(function(){p.overflow=c.overflow[0],p.overflowX=c.overflow[1],p.overflowY=c.overflow[2]}));for(d in b)if(e=b[d],ab.exec(e)){if(delete b[d],f=f||"toggle"===e,e===(q?"hide":"show")){if("show"!==e||!r||void 0===r[d])continue;q=!0}o[d]=r&&r[d]||m.style(a,d)}else j=void 0;if(m.isEmptyObject(o))"inline"===("none"===j?Fa(a.nodeName):j)&&(p.display=j);else{r?"hidden"in r&&(q=r.hidden):r=m._data(a,"fxshow",{}),f&&(r.hidden=!q),q?m(a).show():n.done(function(){m(a).hide()}),n.done(function(){var b;m._removeData(a,"fxshow");for(b in o)m.style(a,b,o[b])});for(d in o)g=hb(q?r[d]:0,d,n),d in r||(r[d]=g.start,q&&(g.end=g.start,g.start="width"===d||"height"===d?1:0))}}function jb(a,b){var c,d,e,f,g;for(c in a)if(d=m.camelCase(c),e=b[d],f=a[c],m.isArray(f)&&(e=f[1],f=a[c]=f[0]),c!==d&&(a[d]=f,delete a[c]),g=m.cssHooks[d],g&&"expand"in g){f=g.expand(f),delete a[d];for(c in f)c in a||(a[c]=f[c],b[c]=e)}else b[d]=e}function kb(a,b,c){var d,e,f=0,g=db.length,h=m.Deferred().always(function(){delete i.elem}),i=function(){if(e)return!1;for(var b=$a||fb(),c=Math.max(0,j.startTime+j.duration-b),d=c/j.duration||0,f=1-d,g=0,i=j.tweens.length;i>g;g++)j.tweens[g].run(f);return h.notifyWith(a,[j,f,c]),1>f&&i?c:(h.resolveWith(a,[j]),!1)},j=h.promise({elem:a,props:m.extend({},b),opts:m.extend(!0,{specialEasing:{}},c),originalProperties:b,originalOptions:c,startTime:$a||fb(),duration:c.duration,tweens:[],createTween:function(b,c){var d=m.Tween(a,j.opts,b,c,j.opts.specialEasing[b]||j.opts.easing);return j.tweens.push(d),d},stop:function(b){var c=0,d=b?j.tweens.length:0;if(e)return this;for(e=!0;d>c;c++)j.tweens[c].run(1);return b?h.resolveWith(a,[j,b]):h.rejectWith(a,[j,b]),this}}),k=j.props;for(jb(k,j.opts.specialEasing);g>f;f++)if(d=db[f].call(j,a,k,j.opts))return d;return m.map(k,hb,j),m.isFunction(j.opts.start)&&j.opts.start.call(a,j),m.fx.timer(m.extend(i,{elem:a,anim:j,queue:j.opts.queue})),j.progress(j.opts.progress).done(j.opts.done,j.opts.complete).fail(j.opts.fail).always(j.opts.always)}m.Animation=m.extend(kb,{tweener:function(a,b){m.isFunction(a)?(b=a,a=["*"]):a=a.split(" ");for(var c,d=0,e=a.length;e>d;d++)c=a[d],eb[c]=eb[c]||[],eb[c].unshift(b)},prefilter:function(a,b){b?db.unshift(a):db.push(a)}}),m.speed=function(a,b,c){var d=a&&"object"==typeof a?m.extend({},a):{complete:c||!c&&b||m.isFunction(a)&&a,duration:a,easing:c&&b||b&&!m.isFunction(b)&&b};return d.duration=m.fx.off?0:"number"==typeof d.duration?d.duration:d.duration in m.fx.speeds?m.fx.speeds[d.duration]:m.fx.speeds._default,(null==d.queue||d.queue===!0)&&(d.queue="fx"),d.old=d.complete,d.complete=function(){m.isFunction(d.old)&&d.old.call(this),d.queue&&m.dequeue(this,d.queue)},d},m.fn.extend({fadeTo:function(a,b,c,d){return this.filter(U).css("opacity",0).show().end().animate({opacity:b},a,c,d)},animate:function(a,b,c,d){var e=m.isEmptyObject(a),f=m.speed(b,c,d),g=function(){var b=kb(this,m.extend({},a),f);(e||m._data(this,"finish"))&&b.stop(!0)};return g.finish=g,e||f.queue===!1?this.each(g):this.queue(f.queue,g)},stop:function(a,b,c){var d=function(a){var b=a.stop;delete a.stop,b(c)};return"string"!=typeof a&&(c=b,b=a,a=void 0),b&&a!==!1&&this.queue(a||"fx",[]),this.each(function(){var b=!0,e=null!=a&&a+"queueHooks",f=m.timers,g=m._data(this);if(e)g[e]&&g[e].stop&&d(g[e]);else for(e in g)g[e]&&g[e].stop&&cb.test(e)&&d(g[e]);for(e=f.length;e--;)f[e].elem!==this||null!=a&&f[e].queue!==a||(f[e].anim.stop(c),b=!1,f.splice(e,1));(b||!c)&&m.dequeue(this,a)})},finish:function(a){return a!==!1&&(a=a||"fx"),this.each(function(){var b,c=m._data(this),d=c[a+"queue"],e=c[a+"queueHooks"],f=m.timers,g=d?d.length:0;for(c.finish=!0,m.queue(this,a,[]),e&&e.stop&&e.stop.call(this,!0),b=f.length;b--;)f[b].elem===this&&f[b].queue===a&&(f[b].anim.stop(!0),f.splice(b,1));for(b=0;g>b;b++)d[b]&&d[b].finish&&d[b].finish.call(this);delete c.finish})}}),m.each(["toggle","show","hide"],function(a,b){var c=m.fn[b];m.fn[b]=function(a,d,e){return null==a||"boolean"==typeof a?c.apply(this,arguments):this.animate(gb(b,!0),a,d,e)}}),m.each({slideDown:gb("show"),slideUp:gb("hide"),slideToggle:gb("toggle"),fadeIn:{opacity:"show"},fadeOut:{opacity:"hide"},fadeToggle:{opacity:"toggle"}},function(a,b){m.fn[a]=function(a,c,d){return this.animate(b,a,c,d)}}),m.timers=[],m.fx.tick=function(){var a,b=m.timers,c=0;for($a=m.now();c<b.length;c++)a=b[c],a()||b[c]!==a||b.splice(c--,1);b.length||m.fx.stop(),$a=void 0},m.fx.timer=function(a){m.timers.push(a),a()?m.fx.start():m.timers.pop()},m.fx.interval=13,m.fx.start=function(){_a||(_a=setInterval(m.fx.tick,m.fx.interval))},m.fx.stop=function(){clearInterval(_a),_a=null},m.fx.speeds={slow:600,fast:200,_default:400},m.fn.delay=function(a,b){return a=m.fx?m.fx.speeds[a]||a:a,b=b||"fx",this.queue(b,function(b,c){var d=setTimeout(b,a);c.stop=function(){clearTimeout(d)}})},function(){var a,b,c,d,e;b=y.createElement("div"),b.setAttribute("className","t"),b.innerHTML="  <link/><table></table><a href='/a'>a</a><input type='checkbox'/>",d=b.getElementsByTagName("a")[0],c=y.createElement("select"),e=c.appendChild(y.createElement("option")),a=b.getElementsByTagName("input")[0],d.style.cssText="top:1px",k.getSetAttribute="t"!==b.className,k.style=/top/.test(d.getAttribute("style")),k.hrefNormalized="/a"===d.getAttribute("href"),k.checkOn=!!a.value,k.optSelected=e.selected,k.enctype=!!y.createElement("form").enctype,c.disabled=!0,k.optDisabled=!e.disabled,a=y.createElement("input"),a.setAttribute("value",""),k.input=""===a.getAttribute("value"),a.value="t",a.setAttribute("type","radio"),k.radioValue="t"===a.value}();var lb=/\r/g;m.fn.extend({val:function(a){var b,c,d,e=this[0];{if(arguments.length)return d=m.isFunction(a),this.each(function(c){var e;1===this.nodeType&&(e=d?a.call(this,c,m(this).val()):a,null==e?e="":"number"==typeof e?e+="":m.isArray(e)&&(e=m.map(e,function(a){return null==a?"":a+""})),b=m.valHooks[this.type]||m.valHooks[this.nodeName.toLowerCase()],b&&"set"in b&&void 0!==b.set(this,e,"value")||(this.value=e))});if(e)return b=m.valHooks[e.type]||m.valHooks[e.nodeName.toLowerCase()],b&&"get"in b&&void 0!==(c=b.get(e,"value"))?c:(c=e.value,"string"==typeof c?c.replace(lb,""):null==c?"":c)}}}),m.extend({valHooks:{option:{get:function(a){var b=m.find.attr(a,"value");return null!=b?b:m.trim(m.text(a))}},select:{get:function(a){for(var b,c,d=a.options,e=a.selectedIndex,f="select-one"===a.type||0>e,g=f?null:[],h=f?e+1:d.length,i=0>e?h:f?e:0;h>i;i++)if(c=d[i],!(!c.selected&&i!==e||(k.optDisabled?c.disabled:null!==c.getAttribute("disabled"))||c.parentNode.disabled&&m.nodeName(c.parentNode,"optgroup"))){if(b=m(c).val(),f)return b;g.push(b)}return g},set:function(a,b){var c,d,e=a.options,f=m.makeArray(b),g=e.length;while(g--)if(d=e[g],m.inArray(m.valHooks.option.get(d),f)>=0)try{d.selected=c=!0}catch(h){d.scrollHeight}else d.selected=!1;return c||(a.selectedIndex=-1),e}}}}),m.each(["radio","checkbox"],function(){m.valHooks[this]={set:function(a,b){return m.isArray(b)?a.checked=m.inArray(m(a).val(),b)>=0:void 0}},k.checkOn||(m.valHooks[this].get=function(a){return null===a.getAttribute("value")?"on":a.value})});var mb,nb,ob=m.expr.attrHandle,pb=/^(?:checked|selected)$/i,qb=k.getSetAttribute,rb=k.input;m.fn.extend({attr:function(a,b){return V(this,m.attr,a,b,arguments.length>1)},removeAttr:function(a){return this.each(function(){m.removeAttr(this,a)})}}),m.extend({attr:function(a,b,c){var d,e,f=a.nodeType;if(a&&3!==f&&8!==f&&2!==f)return typeof a.getAttribute===K?m.prop(a,b,c):(1===f&&m.isXMLDoc(a)||(b=b.toLowerCase(),d=m.attrHooks[b]||(m.expr.match.bool.test(b)?nb:mb)),void 0===c?d&&"get"in d&&null!==(e=d.get(a,b))?e:(e=m.find.attr(a,b),null==e?void 0:e):null!==c?d&&"set"in d&&void 0!==(e=d.set(a,c,b))?e:(a.setAttribute(b,c+""),c):void m.removeAttr(a,b))},removeAttr:function(a,b){var c,d,e=0,f=b&&b.match(E);if(f&&1===a.nodeType)while(c=f[e++])d=m.propFix[c]||c,m.expr.match.bool.test(c)?rb&&qb||!pb.test(c)?a[d]=!1:a[m.camelCase("default-"+c)]=a[d]=!1:m.attr(a,c,""),a.removeAttribute(qb?c:d)},attrHooks:{type:{set:function(a,b){if(!k.radioValue&&"radio"===b&&m.nodeName(a,"input")){var c=a.value;return a.setAttribute("type",b),c&&(a.value=c),b}}}}}),nb={set:function(a,b,c){return b===!1?m.removeAttr(a,c):rb&&qb||!pb.test(c)?a.setAttribute(!qb&&m.propFix[c]||c,c):a[m.camelCase("default-"+c)]=a[c]=!0,c}},m.each(m.expr.match.bool.source.match(/\w+/g),function(a,b){var c=ob[b]||m.find.attr;ob[b]=rb&&qb||!pb.test(b)?function(a,b,d){var e,f;return d||(f=ob[b],ob[b]=e,e=null!=c(a,b,d)?b.toLowerCase():null,ob[b]=f),e}:function(a,b,c){return c?void 0:a[m.camelCase("default-"+b)]?b.toLowerCase():null}}),rb&&qb||(m.attrHooks.value={set:function(a,b,c){return m.nodeName(a,"input")?void(a.defaultValue=b):mb&&mb.set(a,b,c)}}),qb||(mb={set:function(a,b,c){var d=a.getAttributeNode(c);return d||a.setAttributeNode(d=a.ownerDocument.createAttribute(c)),d.value=b+="","value"===c||b===a.getAttribute(c)?b:void 0}},ob.id=ob.name=ob.coords=function(a,b,c){var d;return c?void 0:(d=a.getAttributeNode(b))&&""!==d.value?d.value:null},m.valHooks.button={get:function(a,b){var c=a.getAttributeNode(b);return c&&c.specified?c.value:void 0},set:mb.set},m.attrHooks.contenteditable={set:function(a,b,c){mb.set(a,""===b?!1:b,c)}},m.each(["width","height"],function(a,b){m.attrHooks[b]={set:function(a,c){return""===c?(a.setAttribute(b,"auto"),c):void 0}}})),k.style||(m.attrHooks.style={get:function(a){return a.style.cssText||void 0},set:function(a,b){return a.style.cssText=b+""}});var sb=/^(?:input|select|textarea|button|object)$/i,tb=/^(?:a|area)$/i;m.fn.extend({prop:function(a,b){return V(this,m.prop,a,b,arguments.length>1)},removeProp:function(a){return a=m.propFix[a]||a,this.each(function(){try{this[a]=void 0,delete this[a]}catch(b){}})}}),m.extend({propFix:{"for":"htmlFor","class":"className"},prop:function(a,b,c){var d,e,f,g=a.nodeType;if(a&&3!==g&&8!==g&&2!==g)return f=1!==g||!m.isXMLDoc(a),f&&(b=m.propFix[b]||b,e=m.propHooks[b]),void 0!==c?e&&"set"in e&&void 0!==(d=e.set(a,c,b))?d:a[b]=c:e&&"get"in e&&null!==(d=e.get(a,b))?d:a[b]},propHooks:{tabIndex:{get:function(a){var b=m.find.attr(a,"tabindex");return b?parseInt(b,10):sb.test(a.nodeName)||tb.test(a.nodeName)&&a.href?0:-1}}}}),k.hrefNormalized||m.each(["href","src"],function(a,b){m.propHooks[b]={get:function(a){return a.getAttribute(b,4)}}}),k.optSelected||(m.propHooks.selected={get:function(a){var b=a.parentNode;return b&&(b.selectedIndex,b.parentNode&&b.parentNode.selectedIndex),null}}),m.each(["tabIndex","readOnly","maxLength","cellSpacing","cellPadding","rowSpan","colSpan","useMap","frameBorder","contentEditable"],function(){m.propFix[this.toLowerCase()]=this}),k.enctype||(m.propFix.enctype="encoding");var ub=/[\t\r\n\f]/g;m.fn.extend({addClass:function(a){var b,c,d,e,f,g,h=0,i=this.length,j="string"==typeof a&&a;if(m.isFunction(a))return this.each(function(b){m(this).addClass(a.call(this,b,this.className))});if(j)for(b=(a||"").match(E)||[];i>h;h++)if(c=this[h],d=1===c.nodeType&&(c.className?(" "+c.className+" ").replace(ub," "):" ")){f=0;while(e=b[f++])d.indexOf(" "+e+" ")<0&&(d+=e+" ");g=m.trim(d),c.className!==g&&(c.className=g)}return this},removeClass:function(a){var b,c,d,e,f,g,h=0,i=this.length,j=0===arguments.length||"string"==typeof a&&a;if(m.isFunction(a))return this.each(function(b){m(this).removeClass(a.call(this,b,this.className))});if(j)for(b=(a||"").match(E)||[];i>h;h++)if(c=this[h],d=1===c.nodeType&&(c.className?(" "+c.className+" ").replace(ub," "):"")){f=0;while(e=b[f++])while(d.indexOf(" "+e+" ")>=0)d=d.replace(" "+e+" "," ");g=a?m.trim(d):"",c.className!==g&&(c.className=g)}return this},toggleClass:function(a,b){var c=typeof a;return"boolean"==typeof b&&"string"===c?b?this.addClass(a):this.removeClass(a):this.each(m.isFunction(a)?function(c){m(this).toggleClass(a.call(this,c,this.className,b),b)}:function(){if("string"===c){var b,d=0,e=m(this),f=a.match(E)||[];while(b=f[d++])e.hasClass(b)?e.removeClass(b):e.addClass(b)}else(c===K||"boolean"===c)&&(this.className&&m._data(this,"__className__",this.className),this.className=this.className||a===!1?"":m._data(this,"__className__")||"")})},hasClass:function(a){for(var b=" "+a+" ",c=0,d=this.length;d>c;c++)if(1===this[c].nodeType&&(" "+this[c].className+" ").replace(ub," ").indexOf(b)>=0)return!0;return!1}}),m.each("blur focus focusin focusout load resize scroll unload click dblclick mousedown mouseup mousemove mouseover mouseout mouseenter mouseleave change select submit keydown keypress keyup error contextmenu".split(" "),function(a,b){m.fn[b]=function(a,c){return arguments.length>0?this.on(b,null,a,c):this.trigger(b)}}),m.fn.extend({hover:function(a,b){return this.mouseenter(a).mouseleave(b||a)},bind:function(a,b,c){return this.on(a,null,b,c)},unbind:function(a,b){return this.off(a,null,b)},delegate:function(a,b,c,d){return this.on(b,a,c,d)},undelegate:function(a,b,c){return 1===arguments.length?this.off(a,"**"):this.off(b,a||"**",c)}});var vb=m.now(),wb=/\?/,xb=/(,)|(\[|{)|(}|])|"(?:[^"\\\r\n]|\\["\\\/bfnrt]|\\u[\da-fA-F]{4})*"\s*:?|true|false|null|-?(?!0\d)\d+(?:\.\d+|)(?:[eE][+-]?\d+|)/g;m.parseJSON=function(b){if(a.JSON&&a.JSON.parse)return a.JSON.parse(b+"");var c,d=null,e=m.trim(b+"");return e&&!m.trim(e.replace(xb,function(a,b,e,f){return c&&b&&(d=0),0===d?a:(c=e||b,d+=!f-!e,"")}))?Function("return "+e)():m.error("Invalid JSON: "+b)},m.parseXML=function(b){var c,d;if(!b||"string"!=typeof b)return null;try{a.DOMParser?(d=new DOMParser,c=d.parseFromString(b,"text/xml")):(c=new ActiveXObject("Microsoft.XMLDOM"),c.async="false",c.loadXML(b))}catch(e){c=void 0}return c&&c.documentElement&&!c.getElementsByTagName("parsererror").length||m.error("Invalid XML: "+b),c};var yb,zb,Ab=/#.*$/,Bb=/([?&])_=[^&]*/,Cb=/^(.*?):[ \t]*([^\r\n]*)\r?$/gm,Db=/^(?:about|app|app-storage|.+-extension|file|res|widget):$/,Eb=/^(?:GET|HEAD)$/,Fb=/^\/\//,Gb=/^([\w.+-]+:)(?:\/\/(?:[^\/?#]*@|)([^\/?#:]*)(?::(\d+)|)|)/,Hb={},Ib={},Jb="*/".concat("*");try{zb=location.href}catch(Kb){zb=y.createElement("a"),zb.href="",zb=zb.href}yb=Gb.exec(zb.toLowerCase())||[];function Lb(a){return function(b,c){"string"!=typeof b&&(c=b,b="*");var d,e=0,f=b.toLowerCase().match(E)||[];if(m.isFunction(c))while(d=f[e++])"+"===d.charAt(0)?(d=d.slice(1)||"*",(a[d]=a[d]||[]).unshift(c)):(a[d]=a[d]||[]).push(c)}}function Mb(a,b,c,d){var e={},f=a===Ib;function g(h){var i;return e[h]=!0,m.each(a[h]||[],function(a,h){var j=h(b,c,d);return"string"!=typeof j||f||e[j]?f?!(i=j):void 0:(b.dataTypes.unshift(j),g(j),!1)}),i}return g(b.dataTypes[0])||!e["*"]&&g("*")}function Nb(a,b){var c,d,e=m.ajaxSettings.flatOptions||{};for(d in b)void 0!==b[d]&&((e[d]?a:c||(c={}))[d]=b[d]);return c&&m.extend(!0,a,c),a}function Ob(a,b,c){var d,e,f,g,h=a.contents,i=a.dataTypes;while("*"===i[0])i.shift(),void 0===e&&(e=a.mimeType||b.getResponseHeader("Content-Type"));if(e)for(g in h)if(h[g]&&h[g].test(e)){i.unshift(g);break}if(i[0]in c)f=i[0];else{for(g in c){if(!i[0]||a.converters[g+" "+i[0]]){f=g;break}d||(d=g)}f=f||d}return f?(f!==i[0]&&i.unshift(f),c[f]):void 0}function Pb(a,b,c,d){var e,f,g,h,i,j={},k=a.dataTypes.slice();if(k[1])for(g in a.converters)j[g.toLowerCase()]=a.converters[g];f=k.shift();while(f)if(a.responseFields[f]&&(c[a.responseFields[f]]=b),!i&&d&&a.dataFilter&&(b=a.dataFilter(b,a.dataType)),i=f,f=k.shift())if("*"===f)f=i;else if("*"!==i&&i!==f){if(g=j[i+" "+f]||j["* "+f],!g)for(e in j)if(h=e.split(" "),h[1]===f&&(g=j[i+" "+h[0]]||j["* "+h[0]])){g===!0?g=j[e]:j[e]!==!0&&(f=h[0],k.unshift(h[1]));break}if(g!==!0)if(g&&a["throws"])b=g(b);else try{b=g(b)}catch(l){return{state:"parsererror",error:g?l:"No conversion from "+i+" to "+f}}}return{state:"success",data:b}}m.extend({active:0,lastModified:{},etag:{},ajaxSettings:{url:zb,type:"GET",isLocal:Db.test(yb[1]),global:!0,processData:!0,async:!0,contentType:"application/x-www-form-urlencoded; charset=UTF-8",accepts:{"*":Jb,text:"text/plain",html:"text/html",xml:"application/xml, text/xml",json:"application/json, text/javascript"},contents:{xml:/xml/,html:/html/,json:/json/},responseFields:{xml:"responseXML",text:"responseText",json:"responseJSON"},converters:{"* text":String,"text html":!0,"text json":m.parseJSON,"text xml":m.parseXML},flatOptions:{url:!0,context:!0}},ajaxSetup:function(a,b){return b?Nb(Nb(a,m.ajaxSettings),b):Nb(m.ajaxSettings,a)},ajaxPrefilter:Lb(Hb),ajaxTransport:Lb(Ib),ajax:function(a,b){"object"==typeof a&&(b=a,a=void 0),b=b||{};var c,d,e,f,g,h,i,j,k=m.ajaxSetup({},b),l=k.context||k,n=k.context&&(l.nodeType||l.jquery)?m(l):m.event,o=m.Deferred(),p=m.Callbacks("once memory"),q=k.statusCode||{},r={},s={},t=0,u="canceled",v={readyState:0,getResponseHeader:function(a){var b;if(2===t){if(!j){j={};while(b=Cb.exec(f))j[b[1].toLowerCase()]=b[2]}b=j[a.toLowerCase()]}return null==b?null:b},getAllResponseHeaders:function(){return 2===t?f:null},setRequestHeader:function(a,b){var c=a.toLowerCase();return t||(a=s[c]=s[c]||a,r[a]=b),this},overrideMimeType:function(a){return t||(k.mimeType=a),this},statusCode:function(a){var b;if(a)if(2>t)for(b in a)q[b]=[q[b],a[b]];else v.always(a[v.status]);return this},abort:function(a){var b=a||u;return i&&i.abort(b),x(0,b),this}};if(o.promise(v).complete=p.add,v.success=v.done,v.error=v.fail,k.url=((a||k.url||zb)+"").replace(Ab,"").replace(Fb,yb[1]+"//"),k.type=b.method||b.type||k.method||k.type,k.dataTypes=m.trim(k.dataType||"*").toLowerCase().match(E)||[""],null==k.crossDomain&&(c=Gb.exec(k.url.toLowerCase()),k.crossDomain=!(!c||c[1]===yb[1]&&c[2]===yb[2]&&(c[3]||("http:"===c[1]?"80":"443"))===(yb[3]||("http:"===yb[1]?"80":"443")))),k.data&&k.processData&&"string"!=typeof k.data&&(k.data=m.param(k.data,k.traditional)),Mb(Hb,k,b,v),2===t)return v;h=m.event&&k.global,h&&0===m.active++&&m.event.trigger("ajaxStart"),k.type=k.type.toUpperCase(),k.hasContent=!Eb.test(k.type),e=k.url,k.hasContent||(k.data&&(e=k.url+=(wb.test(e)?"&":"?")+k.data,delete k.data),k.cache===!1&&(k.url=Bb.test(e)?e.replace(Bb,"$1_="+vb++):e+(wb.test(e)?"&":"?")+"_="+vb++)),k.ifModified&&(m.lastModified[e]&&v.setRequestHeader("If-Modified-Since",m.lastModified[e]),m.etag[e]&&v.setRequestHeader("If-None-Match",m.etag[e])),(k.data&&k.hasContent&&k.contentType!==!1||b.contentType)&&v.setRequestHeader("Content-Type",k.contentType),v.setRequestHeader("Accept",k.dataTypes[0]&&k.accepts[k.dataTypes[0]]?k.accepts[k.dataTypes[0]]+("*"!==k.dataTypes[0]?", "+Jb+"; q=0.01":""):k.accepts["*"]);for(d in k.headers)v.setRequestHeader(d,k.headers[d]);if(k.beforeSend&&(k.beforeSend.call(l,v,k)===!1||2===t))return v.abort();u="abort";for(d in{success:1,error:1,complete:1})v[d](k[d]);if(i=Mb(Ib,k,b,v)){v.readyState=1,h&&n.trigger("ajaxSend",[v,k]),k.async&&k.timeout>0&&(g=setTimeout(function(){v.abort("timeout")},k.timeout));try{t=1,i.send(r,x)}catch(w){if(!(2>t))throw w;x(-1,w)}}else x(-1,"No Transport");function x(a,b,c,d){var j,r,s,u,w,x=b;2!==t&&(t=2,g&&clearTimeout(g),i=void 0,f=d||"",v.readyState=a>0?4:0,j=a>=200&&300>a||304===a,c&&(u=Ob(k,v,c)),u=Pb(k,u,v,j),j?(k.ifModified&&(w=v.getResponseHeader("Last-Modified"),w&&(m.lastModified[e]=w),w=v.getResponseHeader("etag"),w&&(m.etag[e]=w)),204===a||"HEAD"===k.type?x="nocontent":304===a?x="notmodified":(x=u.state,r=u.data,s=u.error,j=!s)):(s=x,(a||!x)&&(x="error",0>a&&(a=0))),v.status=a,v.statusText=(b||x)+"",j?o.resolveWith(l,[r,x,v]):o.rejectWith(l,[v,x,s]),v.statusCode(q),q=void 0,h&&n.trigger(j?"ajaxSuccess":"ajaxError",[v,k,j?r:s]),p.fireWith(l,[v,x]),h&&(n.trigger("ajaxComplete",[v,k]),--m.active||m.event.trigger("ajaxStop")))}return v},getJSON:function(a,b,c){return m.get(a,b,c,"json")},getScript:function(a,b){return m.get(a,void 0,b,"script")}}),m.each(["get","post"],function(a,b){m[b]=function(a,c,d,e){return m.isFunction(c)&&(e=e||d,d=c,c=void 0),m.ajax({url:a,type:b,dataType:e,data:c,success:d})}}),m._evalUrl=function(a){return m.ajax({url:a,type:"GET",dataType:"script",async:!1,global:!1,"throws":!0})},m.fn.extend({wrapAll:function(a){if(m.isFunction(a))return this.each(function(b){m(this).wrapAll(a.call(this,b))});if(this[0]){var b=m(a,this[0].ownerDocument).eq(0).clone(!0);this[0].parentNode&&b.insertBefore(this[0]),b.map(function(){var a=this;while(a.firstChild&&1===a.firstChild.nodeType)a=a.firstChild;return a}).append(this)}return this},wrapInner:function(a){return this.each(m.isFunction(a)?function(b){m(this).wrapInner(a.call(this,b))}:function(){var b=m(this),c=b.contents();c.length?c.wrapAll(a):b.append(a)})},wrap:function(a){var b=m.isFunction(a);return this.each(function(c){m(this).wrapAll(b?a.call(this,c):a)})},unwrap:function(){return this.parent().each(function(){m.nodeName(this,"body")||m(this).replaceWith(this.childNodes)}).end()}}),m.expr.filters.hidden=function(a){return a.offsetWidth<=0&&a.offsetHeight<=0||!k.reliableHiddenOffsets()&&"none"===(a.style&&a.style.display||m.css(a,"display"))},m.expr.filters.visible=function(a){return!m.expr.filters.hidden(a)};var Qb=/%20/g,Rb=/\[\]$/,Sb=/\r?\n/g,Tb=/^(?:submit|button|image|reset|file)$/i,Ub=/^(?:input|select|textarea|keygen)/i;function Vb(a,b,c,d){var e;if(m.isArray(b))m.each(b,function(b,e){c||Rb.test(a)?d(a,e):Vb(a+"["+("object"==typeof e?b:"")+"]",e,c,d)});else if(c||"object"!==m.type(b))d(a,b);else for(e in b)Vb(a+"["+e+"]",b[e],c,d)}m.param=function(a,b){var c,d=[],e=function(a,b){b=m.isFunction(b)?b():null==b?"":b,d[d.length]=encodeURIComponent(a)+"="+encodeURIComponent(b)};if(void 0===b&&(b=m.ajaxSettings&&m.ajaxSettings.traditional),m.isArray(a)||a.jquery&&!m.isPlainObject(a))m.each(a,function(){e(this.name,this.value)});else for(c in a)Vb(c,a[c],b,e);return d.join("&").replace(Qb,"+")},m.fn.extend({serialize:function(){return m.param(this.serializeArray())},serializeArray:function(){return this.map(function(){var a=m.prop(this,"elements");return a?m.makeArray(a):this}).filter(function(){var a=this.type;return this.name&&!m(this).is(":disabled")&&Ub.test(this.nodeName)&&!Tb.test(a)&&(this.checked||!W.test(a))}).map(function(a,b){var c=m(this).val();return null==c?null:m.isArray(c)?m.map(c,function(a){return{name:b.name,value:a.replace(Sb,"\r\n")}}):{name:b.name,value:c.replace(Sb,"\r\n")}}).get()}}),m.ajaxSettings.xhr=void 0!==a.ActiveXObject?function(){return!this.isLocal&&/^(get|post|head|put|delete|options)$/i.test(this.type)&&Zb()||$b()}:Zb;var Wb=0,Xb={},Yb=m.ajaxSettings.xhr();a.attachEvent&&a.attachEvent("onunload",function(){for(var a in Xb)Xb[a](void 0,!0)}),k.cors=!!Yb&&"withCredentials"in Yb,Yb=k.ajax=!!Yb,Yb&&m.ajaxTransport(function(a){if(!a.crossDomain||k.cors){var b;return{send:function(c,d){var e,f=a.xhr(),g=++Wb;if(f.open(a.type,a.url,a.async,a.username,a.password),a.xhrFields)for(e in a.xhrFields)f[e]=a.xhrFields[e];a.mimeType&&f.overrideMimeType&&f.overrideMimeType(a.mimeType),a.crossDomain||c["X-Requested-With"]||(c["X-Requested-With"]="XMLHttpRequest");for(e in c)void 0!==c[e]&&f.setRequestHeader(e,c[e]+"");f.send(a.hasContent&&a.data||null),b=function(c,e){var h,i,j;if(b&&(e||4===f.readyState))if(delete Xb[g],b=void 0,f.onreadystatechange=m.noop,e)4!==f.readyState&&f.abort();else{j={},h=f.status,"string"==typeof f.responseText&&(j.text=f.responseText);try{i=f.statusText}catch(k){i=""}h||!a.isLocal||a.crossDomain?1223===h&&(h=204):h=j.text?200:404}j&&d(h,i,j,f.getAllResponseHeaders())},a.async?4===f.readyState?setTimeout(b):f.onreadystatechange=Xb[g]=b:b()},abort:function(){b&&b(void 0,!0)}}}});function Zb(){try{return new a.XMLHttpRequest}catch(b){}}function $b(){try{return new a.ActiveXObject("Microsoft.XMLHTTP")}catch(b){}}m.ajaxSetup({accepts:{script:"text/javascript, application/javascript, application/ecmascript, application/x-ecmascript"},contents:{script:/(?:java|ecma)script/},converters:{"text script":function(a){return m.globalEval(a),a}}}),m.ajaxPrefilter("script",function(a){void 0===a.cache&&(a.cache=!1),a.crossDomain&&(a.type="GET",a.global=!1)}),m.ajaxTransport("script",function(a){if(a.crossDomain){var b,c=y.head||m("head")[0]||y.documentElement;return{send:function(d,e){b=y.createElement("script"),b.async=!0,a.scriptCharset&&(b.charset=a.scriptCharset),b.src=a.url,b.onload=b.onreadystatechange=function(a,c){(c||!b.readyState||/loaded|complete/.test(b.readyState))&&(b.onload=b.onreadystatechange=null,b.parentNode&&b.parentNode.removeChild(b),b=null,c||e(200,"success"))},c.insertBefore(b,c.firstChild)},abort:function(){b&&b.onload(void 0,!0)}}}});var _b=[],ac=/(=)\?(?=&|$)|\?\?/;m.ajaxSetup({jsonp:"callback",jsonpCallback:function(){var a=_b.pop()||m.expando+"_"+vb++;return this[a]=!0,a}}),m.ajaxPrefilter("json jsonp",function(b,c,d){var e,f,g,h=b.jsonp!==!1&&(ac.test(b.url)?"url":"string"==typeof b.data&&!(b.contentType||"").indexOf("application/x-www-form-urlencoded")&&ac.test(b.data)&&"data");return h||"jsonp"===b.dataTypes[0]?(e=b.jsonpCallback=m.isFunction(b.jsonpCallback)?b.jsonpCallback():b.jsonpCallback,h?b[h]=b[h].replace(ac,"$1"+e):b.jsonp!==!1&&(b.url+=(wb.test(b.url)?"&":"?")+b.jsonp+"="+e),b.converters["script json"]=function(){return g||m.error(e+" was not called"),g[0]},b.dataTypes[0]="json",f=a[e],a[e]=function(){g=arguments},d.always(function(){a[e]=f,b[e]&&(b.jsonpCallback=c.jsonpCallback,_b.push(e)),g&&m.isFunction(f)&&f(g[0]),g=f=void 0}),"script"):void 0}),m.parseHTML=function(a,b,c){if(!a||"string"!=typeof a)return null;"boolean"==typeof b&&(c=b,b=!1),b=b||y;var d=u.exec(a),e=!c&&[];return d?[b.createElement(d[1])]:(d=m.buildFragment([a],b,e),e&&e.length&&m(e).remove(),m.merge([],d.childNodes))};var bc=m.fn.load;m.fn.load=function(a,b,c){if("string"!=typeof a&&bc)return bc.apply(this,arguments);var d,e,f,g=this,h=a.indexOf(" ");return h>=0&&(d=m.trim(a.slice(h,a.length)),a=a.slice(0,h)),m.isFunction(b)?(c=b,b=void 0):b&&"object"==typeof b&&(f="POST"),g.length>0&&m.ajax({url:a,type:f,dataType:"html",data:b}).done(function(a){e=arguments,g.html(d?m("<div>").append(m.parseHTML(a)).find(d):a)}).complete(c&&function(a,b){g.each(c,e||[a.responseText,b,a])}),this},m.each(["ajaxStart","ajaxStop","ajaxComplete","ajaxError","ajaxSuccess","ajaxSend"],function(a,b){m.fn[b]=function(a){return this.on(b,a)}}),m.expr.filters.animated=function(a){return m.grep(m.timers,function(b){return a===b.elem}).length};var cc=a.document.documentElement;function dc(a){return m.isWindow(a)?a:9===a.nodeType?a.defaultView||a.parentWindow:!1}m.offset={setOffset:function(a,b,c){var d,e,f,g,h,i,j,k=m.css(a,"position"),l=m(a),n={};"static"===k&&(a.style.position="relative"),h=l.offset(),f=m.css(a,"top"),i=m.css(a,"left"),j=("absolute"===k||"fixed"===k)&&m.inArray("auto",[f,i])>-1,j?(d=l.position(),g=d.top,e=d.left):(g=parseFloat(f)||0,e=parseFloat(i)||0),m.isFunction(b)&&(b=b.call(a,c,h)),null!=b.top&&(n.top=b.top-h.top+g),null!=b.left&&(n.left=b.left-h.left+e),"using"in b?b.using.call(a,n):l.css(n)}},m.fn.extend({offset:function(a){if(arguments.length)return void 0===a?this:this.each(function(b){m.offset.setOffset(this,a,b)});var b,c,d={top:0,left:0},e=this[0],f=e&&e.ownerDocument;if(f)return b=f.documentElement,m.contains(b,e)?(typeof e.getBoundingClientRect!==K&&(d=e.getBoundingClientRect()),c=dc(f),{top:d.top+(c.pageYOffset||b.scrollTop)-(b.clientTop||0),left:d.left+(c.pageXOffset||b.scrollLeft)-(b.clientLeft||0)}):d},position:function(){if(this[0]){var a,b,c={top:0,left:0},d=this[0];return"fixed"===m.css(d,"position")?b=d.getBoundingClientRect():(a=this.offsetParent(),b=this.offset(),m.nodeName(a[0],"html")||(c=a.offset()),c.top+=m.css(a[0],"borderTopWidth",!0),c.left+=m.css(a[0],"borderLeftWidth",!0)),{top:b.top-c.top-m.css(d,"marginTop",!0),left:b.left-c.left-m.css(d,"marginLeft",!0)}}},offsetParent:function(){return this.map(function(){var a=this.offsetParent||cc;while(a&&!m.nodeName(a,"html")&&"static"===m.css(a,"position"))a=a.offsetParent;return a||cc})}}),m.each({scrollLeft:"pageXOffset",scrollTop:"pageYOffset"},function(a,b){var c=/Y/.test(b);m.fn[a]=function(d){return V(this,function(a,d,e){var f=dc(a);return void 0===e?f?b in f?f[b]:f.document.documentElement[d]:a[d]:void(f?f.scrollTo(c?m(f).scrollLeft():e,c?e:m(f).scrollTop()):a[d]=e)},a,d,arguments.length,null)}}),m.each(["top","left"],function(a,b){m.cssHooks[b]=La(k.pixelPosition,function(a,c){return c?(c=Ja(a,b),Ha.test(c)?m(a).position()[b]+"px":c):void 0})}),m.each({Height:"height",Width:"width"},function(a,b){m.each({padding:"inner"+a,content:b,"":"outer"+a},function(c,d){m.fn[d]=function(d,e){var f=arguments.length&&(c||"boolean"!=typeof d),g=c||(d===!0||e===!0?"margin":"border");return V(this,function(b,c,d){var e;return m.isWindow(b)?b.document.documentElement["client"+a]:9===b.nodeType?(e=b.documentElement,Math.max(b.body["scroll"+a],e["scroll"+a],b.body["offset"+a],e["offset"+a],e["client"+a])):void 0===d?m.css(b,c,g):m.style(b,c,d,g)},b,f?d:void 0,f,null)}})}),m.fn.size=function(){return this.length},m.fn.andSelf=m.fn.addBack,"function"==typeof define&&define.amd&&define("jquery",[],function(){return m});var ec=a.jQuery,fc=a.$;return m.noConflict=function(b){return a.$===m&&(a.$=fc),b&&a.jQuery===m&&(a.jQuery=ec),m},typeof b===K&&(a.jQuery=a.$=m),m});
</script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<style type="text/css">@font-face {
font-family: 'Roboto';
font-style: normal;
font-weight: 300;
src: url(data:application/x-font-truetype;base64,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) format('truetype');
}
@font-face {
font-family: 'Roboto';
font-style: normal;
font-weight: 400;
src: url(data:application/x-font-truetype;base64,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) format('truetype');
}
@font-face {
font-family: 'Roboto';
font-style: normal;
font-weight: 500;
src: url(data:application/x-font-truetype;base64,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) format('truetype');
}
@font-face {
font-family: 'Roboto';
font-style: normal;
font-weight: 700;
src: url(data:application/x-font-truetype;base64,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) format('truetype');
}
html{font-family:sans-serif;-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%}body{margin:0}article,aside,details,figcaption,figure,footer,header,hgroup,main,menu,nav,section,summary{display:block}audio,canvas,progress,video{display:inline-block;vertical-align:baseline}audio:not([controls]){display:none;height:0}[hidden],template{display:none}a{background-color:transparent}a:active,a:hover{outline:0}abbr[title]{border-bottom:1px dotted}b,strong{font-weight:bold}dfn{font-style:italic}h1{font-size:2em;margin:0.67em 0}mark{background:#ff0;color:#000}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sup{top:-0.5em}sub{bottom:-0.25em}img{border:0}svg:not(:root){overflow:hidden}figure{margin:1em 40px}hr{-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box;height:0}pre{overflow:auto}code,kbd,pre,samp{font-family:monospace, monospace;font-size:1em}button,input,optgroup,select,textarea{color:inherit;font:inherit;margin:0}button{overflow:visible}button,select{text-transform:none}button,html input[type="button"],input[type="reset"],input[type="submit"]{-webkit-appearance:button;cursor:pointer}button[disabled],html input[disabled]{cursor:default}button::-moz-focus-inner,input::-moz-focus-inner{border:0;padding:0}input{line-height:normal}input[type="checkbox"],input[type="radio"]{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box;padding:0}input[type="number"]::-webkit-inner-spin-button,input[type="number"]::-webkit-outer-spin-button{height:auto}input[type="search"]{-webkit-appearance:textfield;-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box}input[type="search"]::-webkit-search-cancel-button,input[type="search"]::-webkit-search-decoration{-webkit-appearance:none}fieldset{border:1px solid #c0c0c0;margin:0 2px;padding:0.35em 0.625em 0.75em}legend{border:0;padding:0}textarea{overflow:auto}optgroup{font-weight:bold}table{border-collapse:collapse;border-spacing:0}td,th{padding:0}@media print{*,*:before,*:after{background:transparent !important;color:#000 !important;-webkit-box-shadow:none !important;box-shadow:none !important;text-shadow:none !important}a,a:visited{text-decoration:underline}a[href]:after{content:" (" attr(href) ")"}abbr[title]:after{content:" (" attr(title) ")"}a[href^="#"]:after,a[href^="javascript:"]:after{content:""}pre,blockquote{border:1px solid #999;page-break-inside:avoid}thead{display:table-header-group}tr,img{page-break-inside:avoid}img{max-width:100% !important}p,h2,h3{orphans:3;widows:3}h2,h3{page-break-after:avoid}.navbar{display:none}.btn>.caret,.dropup>.btn>.caret{border-top-color:#000 !important}.label{border:1px solid #000}.table{border-collapse:collapse !important}.table td,.table th{background-color:#fff !important}.table-bordered th,.table-bordered td{border:1px solid #ddd !important}}@font-face{font-family:'Glyphicons Halflings';src:url(data:application/vnd.ms-fontobject;base64,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);src:url(data:application/vnd.ms-fontobject;base64,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) format('embedded-opentype'),url(data:application/font-woff;base64,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) format('woff'),url(data:application/x-font-truetype;base64,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) format('truetype'),url(data:image/svg+xml;base64,<?xml version="1.0" standalone="no"?>
<!DOCTYPE svg PUBLIC "-//W3C//DTD SVG 1.1//EN" "http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd" >
<svg xmlns="http://www.w3.org/2000/svg">
<metadata></metadata>
<defs>
<font id="glyphicons_halflingsregular" horiz-adv-x="1200" >
<font-face units-per-em="1200" ascent="960" descent="-240" />
<missing-glyph horiz-adv-x="500" />
<glyph horiz-adv-x="0" />
<glyph horiz-adv-x="400" />
<glyph unicode=" " />
<glyph unicode="*" d="M600 1100q15 0 34 -1.5t30 -3.5l11 -1q10 -2 17.5 -10.5t7.5 -18.5v-224l158 158q7 7 18 8t19 -6l106 -106q7 -8 6 -19t-8 -18l-158 -158h224q10 0 18.5 -7.5t10.5 -17.5q6 -41 6 -75q0 -15 -1.5 -34t-3.5 -30l-1 -11q-2 -10 -10.5 -17.5t-18.5 -7.5h-224l158 -158 q7 -7 8 -18t-6 -19l-106 -106q-8 -7 -19 -6t-18 8l-158 158v-224q0 -10 -7.5 -18.5t-17.5 -10.5q-41 -6 -75 -6q-15 0 -34 1.5t-30 3.5l-11 1q-10 2 -17.5 10.5t-7.5 18.5v224l-158 -158q-7 -7 -18 -8t-19 6l-106 106q-7 8 -6 19t8 18l158 158h-224q-10 0 -18.5 7.5 t-10.5 17.5q-6 41 -6 75q0 15 1.5 34t3.5 30l1 11q2 10 10.5 17.5t18.5 7.5h224l-158 158q-7 7 -8 18t6 19l106 106q8 7 19 6t18 -8l158 -158v224q0 10 7.5 18.5t17.5 10.5q41 6 75 6z" />
<glyph unicode="+" d="M450 1100h200q21 0 35.5 -14.5t14.5 -35.5v-350h350q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-350v-350q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v350h-350q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5 h350v350q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xa0;" />
<glyph unicode="&#xa5;" d="M825 1100h250q10 0 12.5 -5t-5.5 -13l-364 -364q-6 -6 -11 -18h268q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-125v-100h275q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-125v-174q0 -11 -7.5 -18.5t-18.5 -7.5h-148q-11 0 -18.5 7.5t-7.5 18.5v174 h-275q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h125v100h-275q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h118q-5 12 -11 18l-364 364q-8 8 -5.5 13t12.5 5h250q25 0 43 -18l164 -164q8 -8 18 -8t18 8l164 164q18 18 43 18z" />
<glyph unicode="&#x2000;" horiz-adv-x="650" />
<glyph unicode="&#x2001;" horiz-adv-x="1300" />
<glyph unicode="&#x2002;" horiz-adv-x="650" />
<glyph unicode="&#x2003;" horiz-adv-x="1300" />
<glyph unicode="&#x2004;" horiz-adv-x="433" />
<glyph unicode="&#x2005;" horiz-adv-x="325" />
<glyph unicode="&#x2006;" horiz-adv-x="216" />
<glyph unicode="&#x2007;" horiz-adv-x="216" />
<glyph unicode="&#x2008;" horiz-adv-x="162" />
<glyph unicode="&#x2009;" horiz-adv-x="260" />
<glyph unicode="&#x200a;" horiz-adv-x="72" />
<glyph unicode="&#x202f;" horiz-adv-x="260" />
<glyph unicode="&#x205f;" horiz-adv-x="325" />
<glyph unicode="&#x20ac;" d="M744 1198q242 0 354 -189q60 -104 66 -209h-181q0 45 -17.5 82.5t-43.5 61.5t-58 40.5t-60.5 24t-51.5 7.5q-19 0 -40.5 -5.5t-49.5 -20.5t-53 -38t-49 -62.5t-39 -89.5h379l-100 -100h-300q-6 -50 -6 -100h406l-100 -100h-300q9 -74 33 -132t52.5 -91t61.5 -54.5t59 -29 t47 -7.5q22 0 50.5 7.5t60.5 24.5t58 41t43.5 61t17.5 80h174q-30 -171 -128 -278q-107 -117 -274 -117q-206 0 -324 158q-36 48 -69 133t-45 204h-217l100 100h112q1 47 6 100h-218l100 100h134q20 87 51 153.5t62 103.5q117 141 297 141z" />
<glyph unicode="&#x20bd;" d="M428 1200h350q67 0 120 -13t86 -31t57 -49.5t35 -56.5t17 -64.5t6.5 -60.5t0.5 -57v-16.5v-16.5q0 -36 -0.5 -57t-6.5 -61t-17 -65t-35 -57t-57 -50.5t-86 -31.5t-120 -13h-178l-2 -100h288q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-138v-175q0 -11 -5.5 -18 t-15.5 -7h-149q-10 0 -17.5 7.5t-7.5 17.5v175h-267q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h117v100h-267q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h117v475q0 10 7.5 17.5t17.5 7.5zM600 1000v-300h203q64 0 86.5 33t22.5 119q0 84 -22.5 116t-86.5 32h-203z" />
<glyph unicode="&#x2212;" d="M250 700h800q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#x231b;" d="M1000 1200v-150q0 -21 -14.5 -35.5t-35.5 -14.5h-50v-100q0 -91 -49.5 -165.5t-130.5 -109.5q81 -35 130.5 -109.5t49.5 -165.5v-150h50q21 0 35.5 -14.5t14.5 -35.5v-150h-800v150q0 21 14.5 35.5t35.5 14.5h50v150q0 91 49.5 165.5t130.5 109.5q-81 35 -130.5 109.5 t-49.5 165.5v100h-50q-21 0 -35.5 14.5t-14.5 35.5v150h800zM400 1000v-100q0 -60 32.5 -109.5t87.5 -73.5q28 -12 44 -37t16 -55t-16 -55t-44 -37q-55 -24 -87.5 -73.5t-32.5 -109.5v-150h400v150q0 60 -32.5 109.5t-87.5 73.5q-28 12 -44 37t-16 55t16 55t44 37 q55 24 87.5 73.5t32.5 109.5v100h-400z" />
<glyph unicode="&#x25fc;" horiz-adv-x="500" d="M0 0z" />
<glyph unicode="&#x2601;" d="M503 1089q110 0 200.5 -59.5t134.5 -156.5q44 14 90 14q120 0 205 -86.5t85 -206.5q0 -121 -85 -207.5t-205 -86.5h-750q-79 0 -135.5 57t-56.5 137q0 69 42.5 122.5t108.5 67.5q-2 12 -2 37q0 153 108 260.5t260 107.5z" />
<glyph unicode="&#x26fa;" d="M774 1193.5q16 -9.5 20.5 -27t-5.5 -33.5l-136 -187l467 -746h30q20 0 35 -18.5t15 -39.5v-42h-1200v42q0 21 15 39.5t35 18.5h30l468 746l-135 183q-10 16 -5.5 34t20.5 28t34 5.5t28 -20.5l111 -148l112 150q9 16 27 20.5t34 -5zM600 200h377l-182 112l-195 534v-646z " />
<glyph unicode="&#x2709;" d="M25 1100h1150q10 0 12.5 -5t-5.5 -13l-564 -567q-8 -8 -18 -8t-18 8l-564 567q-8 8 -5.5 13t12.5 5zM18 882l264 -264q8 -8 8 -18t-8 -18l-264 -264q-8 -8 -13 -5.5t-5 12.5v550q0 10 5 12.5t13 -5.5zM918 618l264 264q8 8 13 5.5t5 -12.5v-550q0 -10 -5 -12.5t-13 5.5 l-264 264q-8 8 -8 18t8 18zM818 482l364 -364q8 -8 5.5 -13t-12.5 -5h-1150q-10 0 -12.5 5t5.5 13l364 364q8 8 18 8t18 -8l164 -164q8 -8 18 -8t18 8l164 164q8 8 18 8t18 -8z" />
<glyph unicode="&#x270f;" d="M1011 1210q19 0 33 -13l153 -153q13 -14 13 -33t-13 -33l-99 -92l-214 214l95 96q13 14 32 14zM1013 800l-615 -614l-214 214l614 614zM317 96l-333 -112l110 335z" />
<glyph unicode="&#xe001;" d="M700 650v-550h250q21 0 35.5 -14.5t14.5 -35.5v-50h-800v50q0 21 14.5 35.5t35.5 14.5h250v550l-500 550h1200z" />
<glyph unicode="&#xe002;" d="M368 1017l645 163q39 15 63 0t24 -49v-831q0 -55 -41.5 -95.5t-111.5 -63.5q-79 -25 -147 -4.5t-86 75t25.5 111.5t122.5 82q72 24 138 8v521l-600 -155v-606q0 -42 -44 -90t-109 -69q-79 -26 -147 -5.5t-86 75.5t25.5 111.5t122.5 82.5q72 24 138 7v639q0 38 14.5 59 t53.5 34z" />
<glyph unicode="&#xe003;" d="M500 1191q100 0 191 -39t156.5 -104.5t104.5 -156.5t39 -191l-1 -2l1 -5q0 -141 -78 -262l275 -274q23 -26 22.5 -44.5t-22.5 -42.5l-59 -58q-26 -20 -46.5 -20t-39.5 20l-275 274q-119 -77 -261 -77l-5 1l-2 -1q-100 0 -191 39t-156.5 104.5t-104.5 156.5t-39 191 t39 191t104.5 156.5t156.5 104.5t191 39zM500 1022q-88 0 -162 -43t-117 -117t-43 -162t43 -162t117 -117t162 -43t162 43t117 117t43 162t-43 162t-117 117t-162 43z" />
<glyph unicode="&#xe005;" d="M649 949q48 68 109.5 104t121.5 38.5t118.5 -20t102.5 -64t71 -100.5t27 -123q0 -57 -33.5 -117.5t-94 -124.5t-126.5 -127.5t-150 -152.5t-146 -174q-62 85 -145.5 174t-150 152.5t-126.5 127.5t-93.5 124.5t-33.5 117.5q0 64 28 123t73 100.5t104 64t119 20 t120.5 -38.5t104.5 -104z" />
<glyph unicode="&#xe006;" d="M407 800l131 353q7 19 17.5 19t17.5 -19l129 -353h421q21 0 24 -8.5t-14 -20.5l-342 -249l130 -401q7 -20 -0.5 -25.5t-24.5 6.5l-343 246l-342 -247q-17 -12 -24.5 -6.5t-0.5 25.5l130 400l-347 251q-17 12 -14 20.5t23 8.5h429z" />
<glyph unicode="&#xe007;" d="M407 800l131 353q7 19 17.5 19t17.5 -19l129 -353h421q21 0 24 -8.5t-14 -20.5l-342 -249l130 -401q7 -20 -0.5 -25.5t-24.5 6.5l-343 246l-342 -247q-17 -12 -24.5 -6.5t-0.5 25.5l130 400l-347 251q-17 12 -14 20.5t23 8.5h429zM477 700h-240l197 -142l-74 -226 l193 139l195 -140l-74 229l192 140h-234l-78 211z" />
<glyph unicode="&#xe008;" d="M600 1200q124 0 212 -88t88 -212v-250q0 -46 -31 -98t-69 -52v-75q0 -10 6 -21.5t15 -17.5l358 -230q9 -5 15 -16.5t6 -21.5v-93q0 -10 -7.5 -17.5t-17.5 -7.5h-1150q-10 0 -17.5 7.5t-7.5 17.5v93q0 10 6 21.5t15 16.5l358 230q9 6 15 17.5t6 21.5v75q-38 0 -69 52 t-31 98v250q0 124 88 212t212 88z" />
<glyph unicode="&#xe009;" d="M25 1100h1150q10 0 17.5 -7.5t7.5 -17.5v-1050q0 -10 -7.5 -17.5t-17.5 -7.5h-1150q-10 0 -17.5 7.5t-7.5 17.5v1050q0 10 7.5 17.5t17.5 7.5zM100 1000v-100h100v100h-100zM875 1000h-550q-10 0 -17.5 -7.5t-7.5 -17.5v-350q0 -10 7.5 -17.5t17.5 -7.5h550 q10 0 17.5 7.5t7.5 17.5v350q0 10 -7.5 17.5t-17.5 7.5zM1000 1000v-100h100v100h-100zM100 800v-100h100v100h-100zM1000 800v-100h100v100h-100zM100 600v-100h100v100h-100zM1000 600v-100h100v100h-100zM875 500h-550q-10 0 -17.5 -7.5t-7.5 -17.5v-350q0 -10 7.5 -17.5 t17.5 -7.5h550q10 0 17.5 7.5t7.5 17.5v350q0 10 -7.5 17.5t-17.5 7.5zM100 400v-100h100v100h-100zM1000 400v-100h100v100h-100zM100 200v-100h100v100h-100zM1000 200v-100h100v100h-100z" />
<glyph unicode="&#xe010;" d="M50 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM650 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400 q0 21 14.5 35.5t35.5 14.5zM50 500h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM650 500h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe011;" d="M50 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200 q0 21 14.5 35.5t35.5 14.5zM850 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200 q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM850 700h200q21 0 35.5 -14.5t14.5 -35.5v-200 q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 300h200 q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM850 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5 t35.5 14.5z" />
<glyph unicode="&#xe012;" d="M50 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 1100h700q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v200 q0 21 14.5 35.5t35.5 14.5zM50 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 700h700q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-700 q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 300h700q21 0 35.5 -14.5t14.5 -35.5v-200 q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe013;" d="M465 477l571 571q8 8 18 8t17 -8l177 -177q8 -7 8 -17t-8 -18l-783 -784q-7 -8 -17.5 -8t-17.5 8l-384 384q-8 8 -8 18t8 17l177 177q7 8 17 8t18 -8l171 -171q7 -7 18 -7t18 7z" />
<glyph unicode="&#xe014;" d="M904 1083l178 -179q8 -8 8 -18.5t-8 -17.5l-267 -268l267 -268q8 -7 8 -17.5t-8 -18.5l-178 -178q-8 -8 -18.5 -8t-17.5 8l-268 267l-268 -267q-7 -8 -17.5 -8t-18.5 8l-178 178q-8 8 -8 18.5t8 17.5l267 268l-267 268q-8 7 -8 17.5t8 18.5l178 178q8 8 18.5 8t17.5 -8 l268 -267l268 268q7 7 17.5 7t18.5 -7z" />
<glyph unicode="&#xe015;" d="M507 1177q98 0 187.5 -38.5t154.5 -103.5t103.5 -154.5t38.5 -187.5q0 -141 -78 -262l300 -299q8 -8 8 -18.5t-8 -18.5l-109 -108q-7 -8 -17.5 -8t-18.5 8l-300 299q-119 -77 -261 -77q-98 0 -188 38.5t-154.5 103t-103 154.5t-38.5 188t38.5 187.5t103 154.5 t154.5 103.5t188 38.5zM506.5 1023q-89.5 0 -165.5 -44t-120 -120.5t-44 -166t44 -165.5t120 -120t165.5 -44t166 44t120.5 120t44 165.5t-44 166t-120.5 120.5t-166 44zM425 900h150q10 0 17.5 -7.5t7.5 -17.5v-75h75q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5 t-17.5 -7.5h-75v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-75q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h75v75q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe016;" d="M507 1177q98 0 187.5 -38.5t154.5 -103.5t103.5 -154.5t38.5 -187.5q0 -141 -78 -262l300 -299q8 -8 8 -18.5t-8 -18.5l-109 -108q-7 -8 -17.5 -8t-18.5 8l-300 299q-119 -77 -261 -77q-98 0 -188 38.5t-154.5 103t-103 154.5t-38.5 188t38.5 187.5t103 154.5 t154.5 103.5t188 38.5zM506.5 1023q-89.5 0 -165.5 -44t-120 -120.5t-44 -166t44 -165.5t120 -120t165.5 -44t166 44t120.5 120t44 165.5t-44 166t-120.5 120.5t-166 44zM325 800h350q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-350q-10 0 -17.5 7.5 t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe017;" d="M550 1200h100q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM800 975v166q167 -62 272 -209.5t105 -331.5q0 -117 -45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5 t-184.5 123t-123 184.5t-45.5 224q0 184 105 331.5t272 209.5v-166q-103 -55 -165 -155t-62 -220q0 -116 57 -214.5t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5q0 120 -62 220t-165 155z" />
<glyph unicode="&#xe018;" d="M1025 1200h150q10 0 17.5 -7.5t7.5 -17.5v-1150q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v1150q0 10 7.5 17.5t17.5 7.5zM725 800h150q10 0 17.5 -7.5t7.5 -17.5v-750q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v750 q0 10 7.5 17.5t17.5 7.5zM425 500h150q10 0 17.5 -7.5t7.5 -17.5v-450q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v450q0 10 7.5 17.5t17.5 7.5zM125 300h150q10 0 17.5 -7.5t7.5 -17.5v-250q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5 v250q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe019;" d="M600 1174q33 0 74 -5l38 -152l5 -1q49 -14 94 -39l5 -2l134 80q61 -48 104 -105l-80 -134l3 -5q25 -44 39 -93l1 -6l152 -38q5 -43 5 -73q0 -34 -5 -74l-152 -38l-1 -6q-15 -49 -39 -93l-3 -5l80 -134q-48 -61 -104 -105l-134 81l-5 -3q-44 -25 -94 -39l-5 -2l-38 -151 q-43 -5 -74 -5q-33 0 -74 5l-38 151l-5 2q-49 14 -94 39l-5 3l-134 -81q-60 48 -104 105l80 134l-3 5q-25 45 -38 93l-2 6l-151 38q-6 42 -6 74q0 33 6 73l151 38l2 6q13 48 38 93l3 5l-80 134q47 61 105 105l133 -80l5 2q45 25 94 39l5 1l38 152q43 5 74 5zM600 815 q-89 0 -152 -63t-63 -151.5t63 -151.5t152 -63t152 63t63 151.5t-63 151.5t-152 63z" />
<glyph unicode="&#xe020;" d="M500 1300h300q41 0 70.5 -29.5t29.5 -70.5v-100h275q10 0 17.5 -7.5t7.5 -17.5v-75h-1100v75q0 10 7.5 17.5t17.5 7.5h275v100q0 41 29.5 70.5t70.5 29.5zM500 1200v-100h300v100h-300zM1100 900v-800q0 -41 -29.5 -70.5t-70.5 -29.5h-700q-41 0 -70.5 29.5t-29.5 70.5 v800h900zM300 800v-700h100v700h-100zM500 800v-700h100v700h-100zM700 800v-700h100v700h-100zM900 800v-700h100v700h-100z" />
<glyph unicode="&#xe021;" d="M18 618l620 608q8 7 18.5 7t17.5 -7l608 -608q8 -8 5.5 -13t-12.5 -5h-175v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v375h-300v-375q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v575h-175q-10 0 -12.5 5t5.5 13z" />
<glyph unicode="&#xe022;" d="M600 1200v-400q0 -41 29.5 -70.5t70.5 -29.5h300v-650q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v1100q0 21 14.5 35.5t35.5 14.5h450zM1000 800h-250q-21 0 -35.5 14.5t-14.5 35.5v250z" />
<glyph unicode="&#xe023;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM525 900h50q10 0 17.5 -7.5t7.5 -17.5v-275h175q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe024;" d="M1300 0h-538l-41 400h-242l-41 -400h-538l431 1200h209l-21 -300h162l-20 300h208zM515 800l-27 -300h224l-27 300h-170z" />
<glyph unicode="&#xe025;" d="M550 1200h200q21 0 35.5 -14.5t14.5 -35.5v-450h191q20 0 25.5 -11.5t-7.5 -27.5l-327 -400q-13 -16 -32 -16t-32 16l-327 400q-13 16 -7.5 27.5t25.5 11.5h191v450q0 21 14.5 35.5t35.5 14.5zM1125 400h50q10 0 17.5 -7.5t7.5 -17.5v-350q0 -10 -7.5 -17.5t-17.5 -7.5 h-1050q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h50q10 0 17.5 -7.5t7.5 -17.5v-175h900v175q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe026;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM525 900h150q10 0 17.5 -7.5t7.5 -17.5v-275h137q21 0 26 -11.5t-8 -27.5l-223 -275q-13 -16 -32 -16t-32 16l-223 275q-13 16 -8 27.5t26 11.5h137v275q0 10 7.5 17.5t17.5 7.5z " />
<glyph unicode="&#xe027;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM632 914l223 -275q13 -16 8 -27.5t-26 -11.5h-137v-275q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v275h-137q-21 0 -26 11.5t8 27.5l223 275q13 16 32 16 t32 -16z" />
<glyph unicode="&#xe028;" d="M225 1200h750q10 0 19.5 -7t12.5 -17l186 -652q7 -24 7 -49v-425q0 -12 -4 -27t-9 -17q-12 -6 -37 -6h-1100q-12 0 -27 4t-17 8q-6 13 -6 38l1 425q0 25 7 49l185 652q3 10 12.5 17t19.5 7zM878 1000h-556q-10 0 -19 -7t-11 -18l-87 -450q-2 -11 4 -18t16 -7h150 q10 0 19.5 -7t11.5 -17l38 -152q2 -10 11.5 -17t19.5 -7h250q10 0 19.5 7t11.5 17l38 152q2 10 11.5 17t19.5 7h150q10 0 16 7t4 18l-87 450q-2 11 -11 18t-19 7z" />
<glyph unicode="&#xe029;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM540 820l253 -190q17 -12 17 -30t-17 -30l-253 -190q-16 -12 -28 -6.5t-12 26.5v400q0 21 12 26.5t28 -6.5z" />
<glyph unicode="&#xe030;" d="M947 1060l135 135q7 7 12.5 5t5.5 -13v-362q0 -10 -7.5 -17.5t-17.5 -7.5h-362q-11 0 -13 5.5t5 12.5l133 133q-109 76 -238 76q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5h150q0 -117 -45.5 -224 t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5q192 0 347 -117z" />
<glyph unicode="&#xe031;" d="M947 1060l135 135q7 7 12.5 5t5.5 -13v-361q0 -11 -7.5 -18.5t-18.5 -7.5h-361q-11 0 -13 5.5t5 12.5l134 134q-110 75 -239 75q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5h-150q0 117 45.5 224t123 184.5t184.5 123t224 45.5q192 0 347 -117zM1027 600h150 q0 -117 -45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5q-192 0 -348 118l-134 -134q-7 -8 -12.5 -5.5t-5.5 12.5v360q0 11 7.5 18.5t18.5 7.5h360q10 0 12.5 -5.5t-5.5 -12.5l-133 -133q110 -76 240 -76q116 0 214.5 57t155.5 155.5t57 214.5z" />
<glyph unicode="&#xe032;" d="M125 1200h1050q10 0 17.5 -7.5t7.5 -17.5v-1150q0 -10 -7.5 -17.5t-17.5 -7.5h-1050q-10 0 -17.5 7.5t-7.5 17.5v1150q0 10 7.5 17.5t17.5 7.5zM1075 1000h-850q-10 0 -17.5 -7.5t-7.5 -17.5v-850q0 -10 7.5 -17.5t17.5 -7.5h850q10 0 17.5 7.5t7.5 17.5v850 q0 10 -7.5 17.5t-17.5 7.5zM325 900h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 900h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 700h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 700h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 500h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 500h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 300h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 300h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe033;" d="M900 800v200q0 83 -58.5 141.5t-141.5 58.5h-300q-82 0 -141 -59t-59 -141v-200h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-600q0 -41 29.5 -70.5t70.5 -29.5h900q41 0 70.5 29.5t29.5 70.5v600q0 41 -29.5 70.5t-70.5 29.5h-100zM400 800v150q0 21 15 35.5t35 14.5h200 q20 0 35 -14.5t15 -35.5v-150h-300z" />
<glyph unicode="&#xe034;" d="M125 1100h50q10 0 17.5 -7.5t7.5 -17.5v-1075h-100v1075q0 10 7.5 17.5t17.5 7.5zM1075 1052q4 0 9 -2q16 -6 16 -23v-421q0 -6 -3 -12q-33 -59 -66.5 -99t-65.5 -58t-56.5 -24.5t-52.5 -6.5q-26 0 -57.5 6.5t-52.5 13.5t-60 21q-41 15 -63 22.5t-57.5 15t-65.5 7.5 q-85 0 -160 -57q-7 -5 -15 -5q-6 0 -11 3q-14 7 -14 22v438q22 55 82 98.5t119 46.5q23 2 43 0.5t43 -7t32.5 -8.5t38 -13t32.5 -11q41 -14 63.5 -21t57 -14t63.5 -7q103 0 183 87q7 8 18 8z" />
<glyph unicode="&#xe035;" d="M600 1175q116 0 227 -49.5t192.5 -131t131 -192.5t49.5 -227v-300q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v300q0 127 -70.5 231.5t-184.5 161.5t-245 57t-245 -57t-184.5 -161.5t-70.5 -231.5v-300q0 -10 -7.5 -17.5t-17.5 -7.5h-50 q-10 0 -17.5 7.5t-7.5 17.5v300q0 116 49.5 227t131 192.5t192.5 131t227 49.5zM220 500h160q8 0 14 -6t6 -14v-460q0 -8 -6 -14t-14 -6h-160q-8 0 -14 6t-6 14v460q0 8 6 14t14 6zM820 500h160q8 0 14 -6t6 -14v-460q0 -8 -6 -14t-14 -6h-160q-8 0 -14 6t-6 14v460 q0 8 6 14t14 6z" />
<glyph unicode="&#xe036;" d="M321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM900 668l120 120q7 7 17 7t17 -7l34 -34q7 -7 7 -17t-7 -17l-120 -120l120 -120q7 -7 7 -17 t-7 -17l-34 -34q-7 -7 -17 -7t-17 7l-120 119l-120 -119q-7 -7 -17 -7t-17 7l-34 34q-7 7 -7 17t7 17l119 120l-119 120q-7 7 -7 17t7 17l34 34q7 8 17 8t17 -8z" />
<glyph unicode="&#xe037;" d="M321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM766 900h4q10 -1 16 -10q96 -129 96 -290q0 -154 -90 -281q-6 -9 -17 -10l-3 -1q-9 0 -16 6 l-29 23q-7 7 -8.5 16.5t4.5 17.5q72 103 72 229q0 132 -78 238q-6 8 -4.5 18t9.5 17l29 22q7 5 15 5z" />
<glyph unicode="&#xe038;" d="M967 1004h3q11 -1 17 -10q135 -179 135 -396q0 -105 -34 -206.5t-98 -185.5q-7 -9 -17 -10h-3q-9 0 -16 6l-42 34q-8 6 -9 16t5 18q111 150 111 328q0 90 -29.5 176t-84.5 157q-6 9 -5 19t10 16l42 33q7 5 15 5zM321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5 t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM766 900h4q10 -1 16 -10q96 -129 96 -290q0 -154 -90 -281q-6 -9 -17 -10l-3 -1q-9 0 -16 6l-29 23q-7 7 -8.5 16.5t4.5 17.5q72 103 72 229q0 132 -78 238 q-6 8 -4.5 18.5t9.5 16.5l29 22q7 5 15 5z" />
<glyph unicode="&#xe039;" d="M500 900h100v-100h-100v-100h-400v-100h-100v600h500v-300zM1200 700h-200v-100h200v-200h-300v300h-200v300h-100v200h600v-500zM100 1100v-300h300v300h-300zM800 1100v-300h300v300h-300zM300 900h-100v100h100v-100zM1000 900h-100v100h100v-100zM300 500h200v-500 h-500v500h200v100h100v-100zM800 300h200v-100h-100v-100h-200v100h-100v100h100v200h-200v100h300v-300zM100 400v-300h300v300h-300zM300 200h-100v100h100v-100zM1200 200h-100v100h100v-100zM700 0h-100v100h100v-100zM1200 0h-300v100h300v-100z" />
<glyph unicode="&#xe040;" d="M100 200h-100v1000h100v-1000zM300 200h-100v1000h100v-1000zM700 200h-200v1000h200v-1000zM900 200h-100v1000h100v-1000zM1200 200h-200v1000h200v-1000zM400 0h-300v100h300v-100zM600 0h-100v91h100v-91zM800 0h-100v91h100v-91zM1100 0h-200v91h200v-91z" />
<glyph unicode="&#xe041;" d="M500 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-682 682l1 475q0 10 7.5 17.5t17.5 7.5h474zM319.5 1024.5q-29.5 29.5 -71 29.5t-71 -29.5t-29.5 -71.5t29.5 -71.5t71 -29.5t71 29.5t29.5 71.5t-29.5 71.5z" />
<glyph unicode="&#xe042;" d="M500 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-682 682l1 475q0 10 7.5 17.5t17.5 7.5h474zM800 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-56 56l424 426l-700 700h150zM319.5 1024.5q-29.5 29.5 -71 29.5t-71 -29.5 t-29.5 -71.5t29.5 -71.5t71 -29.5t71 29.5t29.5 71.5t-29.5 71.5z" />
<glyph unicode="&#xe043;" d="M300 1200h825q75 0 75 -75v-900q0 -25 -18 -43l-64 -64q-8 -8 -13 -5.5t-5 12.5v950q0 10 -7.5 17.5t-17.5 7.5h-700q-25 0 -43 -18l-64 -64q-8 -8 -5.5 -13t12.5 -5h700q10 0 17.5 -7.5t7.5 -17.5v-950q0 -10 -7.5 -17.5t-17.5 -7.5h-850q-10 0 -17.5 7.5t-7.5 17.5v975 q0 25 18 43l139 139q18 18 43 18z" />
<glyph unicode="&#xe044;" d="M250 1200h800q21 0 35.5 -14.5t14.5 -35.5v-1150l-450 444l-450 -445v1151q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe045;" d="M822 1200h-444q-11 0 -19 -7.5t-9 -17.5l-78 -301q-7 -24 7 -45l57 -108q6 -9 17.5 -15t21.5 -6h450q10 0 21.5 6t17.5 15l62 108q14 21 7 45l-83 301q-1 10 -9 17.5t-19 7.5zM1175 800h-150q-10 0 -21 -6.5t-15 -15.5l-78 -156q-4 -9 -15 -15.5t-21 -6.5h-550 q-10 0 -21 6.5t-15 15.5l-78 156q-4 9 -15 15.5t-21 6.5h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-650q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h750q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5 t7.5 17.5v650q0 10 -7.5 17.5t-17.5 7.5zM850 200h-500q-10 0 -19.5 -7t-11.5 -17l-38 -152q-2 -10 3.5 -17t15.5 -7h600q10 0 15.5 7t3.5 17l-38 152q-2 10 -11.5 17t-19.5 7z" />
<glyph unicode="&#xe046;" d="M500 1100h200q56 0 102.5 -20.5t72.5 -50t44 -59t25 -50.5l6 -20h150q41 0 70.5 -29.5t29.5 -70.5v-600q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v600q0 41 29.5 70.5t70.5 29.5h150q2 8 6.5 21.5t24 48t45 61t72 48t102.5 21.5zM900 800v-100 h100v100h-100zM600 730q-95 0 -162.5 -67.5t-67.5 -162.5t67.5 -162.5t162.5 -67.5t162.5 67.5t67.5 162.5t-67.5 162.5t-162.5 67.5zM600 603q43 0 73 -30t30 -73t-30 -73t-73 -30t-73 30t-30 73t30 73t73 30z" />
<glyph unicode="&#xe047;" d="M681 1199l385 -998q20 -50 60 -92q18 -19 36.5 -29.5t27.5 -11.5l10 -2v-66h-417v66q53 0 75 43.5t5 88.5l-82 222h-391q-58 -145 -92 -234q-11 -34 -6.5 -57t25.5 -37t46 -20t55 -6v-66h-365v66q56 24 84 52q12 12 25 30.5t20 31.5l7 13l399 1006h93zM416 521h340 l-162 457z" />
<glyph unicode="&#xe048;" d="M753 641q5 -1 14.5 -4.5t36 -15.5t50.5 -26.5t53.5 -40t50.5 -54.5t35.5 -70t14.5 -87q0 -67 -27.5 -125.5t-71.5 -97.5t-98.5 -66.5t-108.5 -40.5t-102 -13h-500v89q41 7 70.5 32.5t29.5 65.5v827q0 24 -0.5 34t-3.5 24t-8.5 19.5t-17 13.5t-28 12.5t-42.5 11.5v71 l471 -1q57 0 115.5 -20.5t108 -57t80.5 -94t31 -124.5q0 -51 -15.5 -96.5t-38 -74.5t-45 -50.5t-38.5 -30.5zM400 700h139q78 0 130.5 48.5t52.5 122.5q0 41 -8.5 70.5t-29.5 55.5t-62.5 39.5t-103.5 13.5h-118v-350zM400 200h216q80 0 121 50.5t41 130.5q0 90 -62.5 154.5 t-156.5 64.5h-159v-400z" />
<glyph unicode="&#xe049;" d="M877 1200l2 -57q-83 -19 -116 -45.5t-40 -66.5l-132 -839q-9 -49 13 -69t96 -26v-97h-500v97q186 16 200 98l173 832q3 17 3 30t-1.5 22.5t-9 17.5t-13.5 12.5t-21.5 10t-26 8.5t-33.5 10q-13 3 -19 5v57h425z" />
<glyph unicode="&#xe050;" d="M1300 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-850q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v850h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM175 1000h-75v-800h75l-125 -167l-125 167h75v800h-75l125 167z" />
<glyph unicode="&#xe051;" d="M1100 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-650q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v650h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM1167 50l-167 -125v75h-800v-75l-167 125l167 125v-75h800v75z" />
<glyph unicode="&#xe052;" d="M50 1100h600q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 500h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe053;" d="M250 1100h700q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM250 500h700q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe054;" d="M500 950v100q0 21 14.5 35.5t35.5 14.5h600q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5zM100 650v100q0 21 14.5 35.5t35.5 14.5h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000 q-21 0 -35.5 14.5t-14.5 35.5zM300 350v100q0 21 14.5 35.5t35.5 14.5h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5zM0 50v100q0 21 14.5 35.5t35.5 14.5h1100q21 0 35.5 -14.5t14.5 -35.5v-100 q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5z" />
<glyph unicode="&#xe055;" d="M50 1100h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 500h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe056;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 1100h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 800h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 500h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 500h800q21 0 35.5 -14.5t14.5 -35.5v-100 q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 200h800 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe057;" d="M400 0h-100v1100h100v-1100zM550 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM550 800h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM267 550l-167 -125v75h-200v100h200v75zM550 500h300q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM550 200h600 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe058;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM900 0h-100v1100h100v-1100zM50 800h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM1100 600h200v-100h-200v-75l-167 125l167 125v-75zM50 500h300q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h600 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe059;" d="M75 1000h750q31 0 53 -22t22 -53v-650q0 -31 -22 -53t-53 -22h-750q-31 0 -53 22t-22 53v650q0 31 22 53t53 22zM1200 300l-300 300l300 300v-600z" />
<glyph unicode="&#xe060;" d="M44 1100h1112q18 0 31 -13t13 -31v-1012q0 -18 -13 -31t-31 -13h-1112q-18 0 -31 13t-13 31v1012q0 18 13 31t31 13zM100 1000v-737l247 182l298 -131l-74 156l293 318l236 -288v500h-1000zM342 884q56 0 95 -39t39 -94.5t-39 -95t-95 -39.5t-95 39.5t-39 95t39 94.5 t95 39z" />
<glyph unicode="&#xe062;" d="M648 1169q117 0 216 -60t156.5 -161t57.5 -218q0 -115 -70 -258q-69 -109 -158 -225.5t-143 -179.5l-54 -62q-9 8 -25.5 24.5t-63.5 67.5t-91 103t-98.5 128t-95.5 148q-60 132 -60 249q0 88 34 169.5t91.5 142t137 96.5t166.5 36zM652.5 974q-91.5 0 -156.5 -65 t-65 -157t65 -156.5t156.5 -64.5t156.5 64.5t65 156.5t-65 157t-156.5 65z" />
<glyph unicode="&#xe063;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 173v854q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57z" />
<glyph unicode="&#xe064;" d="M554 1295q21 -72 57.5 -143.5t76 -130t83 -118t82.5 -117t70 -116t49.5 -126t18.5 -136.5q0 -71 -25.5 -135t-68.5 -111t-99 -82t-118.5 -54t-125.5 -23q-84 5 -161.5 34t-139.5 78.5t-99 125t-37 164.5q0 69 18 136.5t49.5 126.5t69.5 116.5t81.5 117.5t83.5 119 t76.5 131t58.5 143zM344 710q-23 -33 -43.5 -70.5t-40.5 -102.5t-17 -123q1 -37 14.5 -69.5t30 -52t41 -37t38.5 -24.5t33 -15q21 -7 32 -1t13 22l6 34q2 10 -2.5 22t-13.5 19q-5 4 -14 12t-29.5 40.5t-32.5 73.5q-26 89 6 271q2 11 -6 11q-8 1 -15 -10z" />
<glyph unicode="&#xe065;" d="M1000 1013l108 115q2 1 5 2t13 2t20.5 -1t25 -9.5t28.5 -21.5q22 -22 27 -43t0 -32l-6 -10l-108 -115zM350 1100h400q50 0 105 -13l-187 -187h-368q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v182l200 200v-332 q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5zM1009 803l-362 -362l-161 -50l55 170l355 355z" />
<glyph unicode="&#xe066;" d="M350 1100h361q-164 -146 -216 -200h-195q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5l200 153v-103q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5z M824 1073l339 -301q8 -7 8 -17.5t-8 -17.5l-340 -306q-7 -6 -12.5 -4t-6.5 11v203q-26 1 -54.5 0t-78.5 -7.5t-92 -17.5t-86 -35t-70 -57q10 59 33 108t51.5 81.5t65 58.5t68.5 40.5t67 24.5t56 13.5t40 4.5v210q1 10 6.5 12.5t13.5 -4.5z" />
<glyph unicode="&#xe067;" d="M350 1100h350q60 0 127 -23l-178 -177h-349q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v69l200 200v-219q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5z M643 639l395 395q7 7 17.5 7t17.5 -7l101 -101q7 -7 7 -17.5t-7 -17.5l-531 -532q-7 -7 -17.5 -7t-17.5 7l-248 248q-7 7 -7 17.5t7 17.5l101 101q7 7 17.5 7t17.5 -7l111 -111q8 -7 18 -7t18 7z" />
<glyph unicode="&#xe068;" d="M318 918l264 264q8 8 18 8t18 -8l260 -264q7 -8 4.5 -13t-12.5 -5h-170v-200h200v173q0 10 5 12t13 -5l264 -260q8 -7 8 -17.5t-8 -17.5l-264 -265q-8 -7 -13 -5t-5 12v173h-200v-200h170q10 0 12.5 -5t-4.5 -13l-260 -264q-8 -8 -18 -8t-18 8l-264 264q-8 8 -5.5 13 t12.5 5h175v200h-200v-173q0 -10 -5 -12t-13 5l-264 265q-8 7 -8 17.5t8 17.5l264 260q8 7 13 5t5 -12v-173h200v200h-175q-10 0 -12.5 5t5.5 13z" />
<glyph unicode="&#xe069;" d="M250 1100h100q21 0 35.5 -14.5t14.5 -35.5v-438l464 453q15 14 25.5 10t10.5 -25v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v1000q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe070;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-438l464 453q15 14 25.5 10t10.5 -25v-438l464 453q15 14 25.5 10t10.5 -25v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5 t-14.5 35.5v1000q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe071;" d="M1200 1050v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -10.5 -25t-25.5 10l-492 480q-15 14 -15 35t15 35l492 480q15 14 25.5 10t10.5 -25v-438l464 453q15 14 25.5 10t10.5 -25z" />
<glyph unicode="&#xe072;" d="M243 1074l814 -498q18 -11 18 -26t-18 -26l-814 -498q-18 -11 -30.5 -4t-12.5 28v1000q0 21 12.5 28t30.5 -4z" />
<glyph unicode="&#xe073;" d="M250 1000h200q21 0 35.5 -14.5t14.5 -35.5v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5zM650 1000h200q21 0 35.5 -14.5t14.5 -35.5v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v800 q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe074;" d="M1100 950v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5h800q21 0 35.5 -14.5t14.5 -35.5z" />
<glyph unicode="&#xe075;" d="M500 612v438q0 21 10.5 25t25.5 -10l492 -480q15 -14 15 -35t-15 -35l-492 -480q-15 -14 -25.5 -10t-10.5 25v438l-464 -453q-15 -14 -25.5 -10t-10.5 25v1000q0 21 10.5 25t25.5 -10z" />
<glyph unicode="&#xe076;" d="M1048 1102l100 1q20 0 35 -14.5t15 -35.5l5 -1000q0 -21 -14.5 -35.5t-35.5 -14.5l-100 -1q-21 0 -35.5 14.5t-14.5 35.5l-2 437l-463 -454q-14 -15 -24.5 -10.5t-10.5 25.5l-2 437l-462 -455q-15 -14 -25.5 -9.5t-10.5 24.5l-5 1000q0 21 10.5 25.5t25.5 -10.5l466 -450 l-2 438q0 20 10.5 24.5t25.5 -9.5l466 -451l-2 438q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe077;" d="M850 1100h100q21 0 35.5 -14.5t14.5 -35.5v-1000q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v438l-464 -453q-15 -14 -25.5 -10t-10.5 25v1000q0 21 10.5 25t25.5 -10l464 -453v438q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe078;" d="M686 1081l501 -540q15 -15 10.5 -26t-26.5 -11h-1042q-22 0 -26.5 11t10.5 26l501 540q15 15 36 15t36 -15zM150 400h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe079;" d="M885 900l-352 -353l352 -353l-197 -198l-552 552l552 550z" />
<glyph unicode="&#xe080;" d="M1064 547l-551 -551l-198 198l353 353l-353 353l198 198z" />
<glyph unicode="&#xe081;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM650 900h-100q-21 0 -35.5 -14.5t-14.5 -35.5v-150h-150 q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5t35.5 -14.5h150v-150q0 -21 14.5 -35.5t35.5 -14.5h100q21 0 35.5 14.5t14.5 35.5v150h150q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5h-150v150q0 21 -14.5 35.5t-35.5 14.5z" />
<glyph unicode="&#xe082;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM850 700h-500q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5 t35.5 -14.5h500q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5z" />
<glyph unicode="&#xe083;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM741.5 913q-12.5 0 -21.5 -9l-120 -120l-120 120q-9 9 -21.5 9 t-21.5 -9l-141 -141q-9 -9 -9 -21.5t9 -21.5l120 -120l-120 -120q-9 -9 -9 -21.5t9 -21.5l141 -141q9 -9 21.5 -9t21.5 9l120 120l120 -120q9 -9 21.5 -9t21.5 9l141 141q9 9 9 21.5t-9 21.5l-120 120l120 120q9 9 9 21.5t-9 21.5l-141 141q-9 9 -21.5 9z" />
<glyph unicode="&#xe084;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM546 623l-84 85q-7 7 -17.5 7t-18.5 -7l-139 -139q-7 -8 -7 -18t7 -18 l242 -241q7 -8 17.5 -8t17.5 8l375 375q7 7 7 17.5t-7 18.5l-139 139q-7 7 -17.5 7t-17.5 -7z" />
<glyph unicode="&#xe085;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM588 941q-29 0 -59 -5.5t-63 -20.5t-58 -38.5t-41.5 -63t-16.5 -89.5 q0 -25 20 -25h131q30 -5 35 11q6 20 20.5 28t45.5 8q20 0 31.5 -10.5t11.5 -28.5q0 -23 -7 -34t-26 -18q-1 0 -13.5 -4t-19.5 -7.5t-20 -10.5t-22 -17t-18.5 -24t-15.5 -35t-8 -46q-1 -8 5.5 -16.5t20.5 -8.5h173q7 0 22 8t35 28t37.5 48t29.5 74t12 100q0 47 -17 83 t-42.5 57t-59.5 34.5t-64 18t-59 4.5zM675 400h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe086;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM675 1000h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5 t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5zM675 700h-250q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h75v-200h-75q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h350q10 0 17.5 7.5t7.5 17.5v50q0 10 -7.5 17.5 t-17.5 7.5h-75v275q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe087;" d="M525 1200h150q10 0 17.5 -7.5t7.5 -17.5v-194q103 -27 178.5 -102.5t102.5 -178.5h194q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-194q-27 -103 -102.5 -178.5t-178.5 -102.5v-194q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v194 q-103 27 -178.5 102.5t-102.5 178.5h-194q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h194q27 103 102.5 178.5t178.5 102.5v194q0 10 7.5 17.5t17.5 7.5zM700 893v-168q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v168q-68 -23 -119 -74 t-74 -119h168q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-168q23 -68 74 -119t119 -74v168q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-168q68 23 119 74t74 119h-168q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h168 q-23 68 -74 119t-119 74z" />
<glyph unicode="&#xe088;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM759 823l64 -64q7 -7 7 -17.5t-7 -17.5l-124 -124l124 -124q7 -7 7 -17.5t-7 -17.5l-64 -64q-7 -7 -17.5 -7t-17.5 7l-124 124l-124 -124q-7 -7 -17.5 -7t-17.5 7l-64 64 q-7 7 -7 17.5t7 17.5l124 124l-124 124q-7 7 -7 17.5t7 17.5l64 64q7 7 17.5 7t17.5 -7l124 -124l124 124q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe089;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM782 788l106 -106q7 -7 7 -17.5t-7 -17.5l-320 -321q-8 -7 -18 -7t-18 7l-202 203q-8 7 -8 17.5t8 17.5l106 106q7 8 17.5 8t17.5 -8l79 -79l197 197q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe090;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5q0 -120 65 -225 l587 587q-105 65 -225 65zM965 819l-584 -584q104 -62 219 -62q116 0 214.5 57t155.5 155.5t57 214.5q0 115 -62 219z" />
<glyph unicode="&#xe091;" d="M39 582l522 427q16 13 27.5 8t11.5 -26v-291h550q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-550v-291q0 -21 -11.5 -26t-27.5 8l-522 427q-16 13 -16 32t16 32z" />
<glyph unicode="&#xe092;" d="M639 1009l522 -427q16 -13 16 -32t-16 -32l-522 -427q-16 -13 -27.5 -8t-11.5 26v291h-550q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h550v291q0 21 11.5 26t27.5 -8z" />
<glyph unicode="&#xe093;" d="M682 1161l427 -522q13 -16 8 -27.5t-26 -11.5h-291v-550q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v550h-291q-21 0 -26 11.5t8 27.5l427 522q13 16 32 16t32 -16z" />
<glyph unicode="&#xe094;" d="M550 1200h200q21 0 35.5 -14.5t14.5 -35.5v-550h291q21 0 26 -11.5t-8 -27.5l-427 -522q-13 -16 -32 -16t-32 16l-427 522q-13 16 -8 27.5t26 11.5h291v550q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe095;" d="M639 1109l522 -427q16 -13 16 -32t-16 -32l-522 -427q-16 -13 -27.5 -8t-11.5 26v291q-94 -2 -182 -20t-170.5 -52t-147 -92.5t-100.5 -135.5q5 105 27 193.5t67.5 167t113 135t167 91.5t225.5 42v262q0 21 11.5 26t27.5 -8z" />
<glyph unicode="&#xe096;" d="M850 1200h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94l-249 -249q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l249 249l-94 94q-14 14 -10 24.5t25 10.5zM350 0h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l249 249 q8 7 18 7t18 -7l106 -106q7 -8 7 -18t-7 -18l-249 -249l94 -94q14 -14 10 -24.5t-25 -10.5z" />
<glyph unicode="&#xe097;" d="M1014 1120l106 -106q7 -8 7 -18t-7 -18l-249 -249l94 -94q14 -14 10 -24.5t-25 -10.5h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l249 249q8 7 18 7t18 -7zM250 600h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94 l-249 -249q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l249 249l-94 94q-14 14 -10 24.5t25 10.5z" />
<glyph unicode="&#xe101;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM704 900h-208q-20 0 -32 -14.5t-8 -34.5l58 -302q4 -20 21.5 -34.5 t37.5 -14.5h54q20 0 37.5 14.5t21.5 34.5l58 302q4 20 -8 34.5t-32 14.5zM675 400h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe102;" d="M260 1200q9 0 19 -2t15 -4l5 -2q22 -10 44 -23l196 -118q21 -13 36 -24q29 -21 37 -12q11 13 49 35l196 118q22 13 45 23q17 7 38 7q23 0 47 -16.5t37 -33.5l13 -16q14 -21 18 -45l25 -123l8 -44q1 -9 8.5 -14.5t17.5 -5.5h61q10 0 17.5 -7.5t7.5 -17.5v-50 q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 -7.5t-7.5 -17.5v-175h-400v300h-200v-300h-400v175q0 10 -7.5 17.5t-17.5 7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5h61q11 0 18 3t7 8q0 4 9 52l25 128q5 25 19 45q2 3 5 7t13.5 15t21.5 19.5t26.5 15.5 t29.5 7zM915 1079l-166 -162q-7 -7 -5 -12t12 -5h219q10 0 15 7t2 17l-51 149q-3 10 -11 12t-15 -6zM463 917l-177 157q-8 7 -16 5t-11 -12l-51 -143q-3 -10 2 -17t15 -7h231q11 0 12.5 5t-5.5 12zM500 0h-375q-10 0 -17.5 7.5t-7.5 17.5v375h400v-400zM1100 400v-375 q0 -10 -7.5 -17.5t-17.5 -7.5h-375v400h400z" />
<glyph unicode="&#xe103;" d="M1165 1190q8 3 21 -6.5t13 -17.5q-2 -178 -24.5 -323.5t-55.5 -245.5t-87 -174.5t-102.5 -118.5t-118 -68.5t-118.5 -33t-120 -4.5t-105 9.5t-90 16.5q-61 12 -78 11q-4 1 -12.5 0t-34 -14.5t-52.5 -40.5l-153 -153q-26 -24 -37 -14.5t-11 43.5q0 64 42 102q8 8 50.5 45 t66.5 58q19 17 35 47t13 61q-9 55 -10 102.5t7 111t37 130t78 129.5q39 51 80 88t89.5 63.5t94.5 45t113.5 36t129 31t157.5 37t182 47.5zM1116 1098q-8 9 -22.5 -3t-45.5 -50q-38 -47 -119 -103.5t-142 -89.5l-62 -33q-56 -30 -102 -57t-104 -68t-102.5 -80.5t-85.5 -91 t-64 -104.5q-24 -56 -31 -86t2 -32t31.5 17.5t55.5 59.5q25 30 94 75.5t125.5 77.5t147.5 81q70 37 118.5 69t102 79.5t99 111t86.5 148.5q22 50 24 60t-6 19z" />
<glyph unicode="&#xe104;" d="M653 1231q-39 -67 -54.5 -131t-10.5 -114.5t24.5 -96.5t47.5 -80t63.5 -62.5t68.5 -46.5t65 -30q-4 7 -17.5 35t-18.5 39.5t-17 39.5t-17 43t-13 42t-9.5 44.5t-2 42t4 43t13.5 39t23 38.5q96 -42 165 -107.5t105 -138t52 -156t13 -159t-19 -149.5q-13 -55 -44 -106.5 t-68 -87t-78.5 -64.5t-72.5 -45t-53 -22q-72 -22 -127 -11q-31 6 -13 19q6 3 17 7q13 5 32.5 21t41 44t38.5 63.5t21.5 81.5t-6.5 94.5t-50 107t-104 115.5q10 -104 -0.5 -189t-37 -140.5t-65 -93t-84 -52t-93.5 -11t-95 24.5q-80 36 -131.5 114t-53.5 171q-2 23 0 49.5 t4.5 52.5t13.5 56t27.5 60t46 64.5t69.5 68.5q-8 -53 -5 -102.5t17.5 -90t34 -68.5t44.5 -39t49 -2q31 13 38.5 36t-4.5 55t-29 64.5t-36 75t-26 75.5q-15 85 2 161.5t53.5 128.5t85.5 92.5t93.5 61t81.5 25.5z" />
<glyph unicode="&#xe105;" d="M600 1094q82 0 160.5 -22.5t140 -59t116.5 -82.5t94.5 -95t68 -95t42.5 -82.5t14 -57.5t-14 -57.5t-43 -82.5t-68.5 -95t-94.5 -95t-116.5 -82.5t-140 -59t-159.5 -22.5t-159.5 22.5t-140 59t-116.5 82.5t-94.5 95t-68.5 95t-43 82.5t-14 57.5t14 57.5t42.5 82.5t68 95 t94.5 95t116.5 82.5t140 59t160.5 22.5zM888 829q-15 15 -18 12t5 -22q25 -57 25 -119q0 -124 -88 -212t-212 -88t-212 88t-88 212q0 59 23 114q8 19 4.5 22t-17.5 -12q-70 -69 -160 -184q-13 -16 -15 -40.5t9 -42.5q22 -36 47 -71t70 -82t92.5 -81t113 -58.5t133.5 -24.5 t133.5 24t113 58.5t92.5 81.5t70 81.5t47 70.5q11 18 9 42.5t-14 41.5q-90 117 -163 189zM448 727l-35 -36q-15 -15 -19.5 -38.5t4.5 -41.5q37 -68 93 -116q16 -13 38.5 -11t36.5 17l35 34q14 15 12.5 33.5t-16.5 33.5q-44 44 -89 117q-11 18 -28 20t-32 -12z" />
<glyph unicode="&#xe106;" d="M592 0h-148l31 120q-91 20 -175.5 68.5t-143.5 106.5t-103.5 119t-66.5 110t-22 76q0 21 14 57.5t42.5 82.5t68 95t94.5 95t116.5 82.5t140 59t160.5 22.5q61 0 126 -15l32 121h148zM944 770l47 181q108 -85 176.5 -192t68.5 -159q0 -26 -19.5 -71t-59.5 -102t-93 -112 t-129 -104.5t-158 -75.5l46 173q77 49 136 117t97 131q11 18 9 42.5t-14 41.5q-54 70 -107 130zM310 824q-70 -69 -160 -184q-13 -16 -15 -40.5t9 -42.5q18 -30 39 -60t57 -70.5t74 -73t90 -61t105 -41.5l41 154q-107 18 -178.5 101.5t-71.5 193.5q0 59 23 114q8 19 4.5 22 t-17.5 -12zM448 727l-35 -36q-15 -15 -19.5 -38.5t4.5 -41.5q37 -68 93 -116q16 -13 38.5 -11t36.5 17l12 11l22 86l-3 4q-44 44 -89 117q-11 18 -28 20t-32 -12z" />
<glyph unicode="&#xe107;" d="M-90 100l642 1066q20 31 48 28.5t48 -35.5l642 -1056q21 -32 7.5 -67.5t-50.5 -35.5h-1294q-37 0 -50.5 34t7.5 66zM155 200h345v75q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-75h345l-445 723zM496 700h208q20 0 32 -14.5t8 -34.5l-58 -252 q-4 -20 -21.5 -34.5t-37.5 -14.5h-54q-20 0 -37.5 14.5t-21.5 34.5l-58 252q-4 20 8 34.5t32 14.5z" />
<glyph unicode="&#xe108;" d="M650 1200q62 0 106 -44t44 -106v-339l363 -325q15 -14 26 -38.5t11 -44.5v-41q0 -20 -12 -26.5t-29 5.5l-359 249v-263q100 -93 100 -113v-64q0 -21 -13 -29t-32 1l-205 128l-205 -128q-19 -9 -32 -1t-13 29v64q0 20 100 113v263l-359 -249q-17 -12 -29 -5.5t-12 26.5v41 q0 20 11 44.5t26 38.5l363 325v339q0 62 44 106t106 44z" />
<glyph unicode="&#xe109;" d="M850 1200h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-150h-1100v150q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5h100q21 0 35.5 -14.5t14.5 -35.5v-50h500v50q0 21 14.5 35.5t35.5 14.5zM1100 800v-750q0 -21 -14.5 -35.5 t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v750h1100zM100 600v-100h100v100h-100zM300 600v-100h100v100h-100zM500 600v-100h100v100h-100zM700 600v-100h100v100h-100zM900 600v-100h100v100h-100zM100 400v-100h100v100h-100zM300 400v-100h100v100h-100zM500 400 v-100h100v100h-100zM700 400v-100h100v100h-100zM900 400v-100h100v100h-100zM100 200v-100h100v100h-100zM300 200v-100h100v100h-100zM500 200v-100h100v100h-100zM700 200v-100h100v100h-100zM900 200v-100h100v100h-100z" />
<glyph unicode="&#xe110;" d="M1135 1165l249 -230q15 -14 15 -35t-15 -35l-249 -230q-14 -14 -24.5 -10t-10.5 25v150h-159l-600 -600h-291q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h209l600 600h241v150q0 21 10.5 25t24.5 -10zM522 819l-141 -141l-122 122h-209q-21 0 -35.5 14.5 t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h291zM1135 565l249 -230q15 -14 15 -35t-15 -35l-249 -230q-14 -14 -24.5 -10t-10.5 25v150h-241l-181 181l141 141l122 -122h159v150q0 21 10.5 25t24.5 -10z" />
<glyph unicode="&#xe111;" d="M100 1100h1000q41 0 70.5 -29.5t29.5 -70.5v-600q0 -41 -29.5 -70.5t-70.5 -29.5h-596l-304 -300v300h-100q-41 0 -70.5 29.5t-29.5 70.5v600q0 41 29.5 70.5t70.5 29.5z" />
<glyph unicode="&#xe112;" d="M150 1200h200q21 0 35.5 -14.5t14.5 -35.5v-250h-300v250q0 21 14.5 35.5t35.5 14.5zM850 1200h200q21 0 35.5 -14.5t14.5 -35.5v-250h-300v250q0 21 14.5 35.5t35.5 14.5zM1100 800v-300q0 -41 -3 -77.5t-15 -89.5t-32 -96t-58 -89t-89 -77t-129 -51t-174 -20t-174 20 t-129 51t-89 77t-58 89t-32 96t-15 89.5t-3 77.5v300h300v-250v-27v-42.5t1.5 -41t5 -38t10 -35t16.5 -30t25.5 -24.5t35 -19t46.5 -12t60 -4t60 4.5t46.5 12.5t35 19.5t25 25.5t17 30.5t10 35t5 38t2 40.5t-0.5 42v25v250h300z" />
<glyph unicode="&#xe113;" d="M1100 411l-198 -199l-353 353l-353 -353l-197 199l551 551z" />
<glyph unicode="&#xe114;" d="M1101 789l-550 -551l-551 551l198 199l353 -353l353 353z" />
<glyph unicode="&#xe115;" d="M404 1000h746q21 0 35.5 -14.5t14.5 -35.5v-551h150q21 0 25 -10.5t-10 -24.5l-230 -249q-14 -15 -35 -15t-35 15l-230 249q-14 14 -10 24.5t25 10.5h150v401h-381zM135 984l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-400h385l215 -200h-750q-21 0 -35.5 14.5 t-14.5 35.5v550h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe116;" d="M56 1200h94q17 0 31 -11t18 -27l38 -162h896q24 0 39 -18.5t10 -42.5l-100 -475q-5 -21 -27 -42.5t-55 -21.5h-633l48 -200h535q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-50q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v50h-300v-50 q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v50h-31q-18 0 -32.5 10t-20.5 19l-5 10l-201 961h-54q-20 0 -35 14.5t-15 35.5t15 35.5t35 14.5z" />
<glyph unicode="&#xe117;" d="M1200 1000v-100h-1200v100h200q0 41 29.5 70.5t70.5 29.5h300q41 0 70.5 -29.5t29.5 -70.5h500zM0 800h1200v-800h-1200v800z" />
<glyph unicode="&#xe118;" d="M200 800l-200 -400v600h200q0 41 29.5 70.5t70.5 29.5h300q42 0 71 -29.5t29 -70.5h500v-200h-1000zM1500 700l-300 -700h-1200l300 700h1200z" />
<glyph unicode="&#xe119;" d="M635 1184l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-601h150q21 0 25 -10.5t-10 -24.5l-230 -249q-14 -15 -35 -15t-35 15l-230 249q-14 14 -10 24.5t25 10.5h150v601h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe120;" d="M936 864l249 -229q14 -15 14 -35.5t-14 -35.5l-249 -229q-15 -15 -25.5 -10.5t-10.5 24.5v151h-600v-151q0 -20 -10.5 -24.5t-25.5 10.5l-249 229q-14 15 -14 35.5t14 35.5l249 229q15 15 25.5 10.5t10.5 -25.5v-149h600v149q0 21 10.5 25.5t25.5 -10.5z" />
<glyph unicode="&#xe121;" d="M1169 400l-172 732q-5 23 -23 45.5t-38 22.5h-672q-20 0 -38 -20t-23 -41l-172 -739h1138zM1100 300h-1000q-41 0 -70.5 -29.5t-29.5 -70.5v-100q0 -41 29.5 -70.5t70.5 -29.5h1000q41 0 70.5 29.5t29.5 70.5v100q0 41 -29.5 70.5t-70.5 29.5zM800 100v100h100v-100h-100 zM1000 100v100h100v-100h-100z" />
<glyph unicode="&#xe122;" d="M1150 1100q21 0 35.5 -14.5t14.5 -35.5v-850q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v850q0 21 14.5 35.5t35.5 14.5zM1000 200l-675 200h-38l47 -276q3 -16 -5.5 -20t-29.5 -4h-7h-84q-20 0 -34.5 14t-18.5 35q-55 337 -55 351v250v6q0 16 1 23.5t6.5 14 t17.5 6.5h200l675 250v-850zM0 750v-250q-4 0 -11 0.5t-24 6t-30 15t-24 30t-11 48.5v50q0 26 10.5 46t25 30t29 16t25.5 7z" />
<glyph unicode="&#xe123;" d="M553 1200h94q20 0 29 -10.5t3 -29.5l-18 -37q83 -19 144 -82.5t76 -140.5l63 -327l118 -173h17q19 0 33 -14.5t14 -35t-13 -40.5t-31 -27q-8 -4 -23 -9.5t-65 -19.5t-103 -25t-132.5 -20t-158.5 -9q-57 0 -115 5t-104 12t-88.5 15.5t-73.5 17.5t-54.5 16t-35.5 12l-11 4 q-18 8 -31 28t-13 40.5t14 35t33 14.5h17l118 173l63 327q15 77 76 140t144 83l-18 32q-6 19 3.5 32t28.5 13zM498 110q50 -6 102 -6q53 0 102 6q-12 -49 -39.5 -79.5t-62.5 -30.5t-63 30.5t-39 79.5z" />
<glyph unicode="&#xe124;" d="M800 946l224 78l-78 -224l234 -45l-180 -155l180 -155l-234 -45l78 -224l-224 78l-45 -234l-155 180l-155 -180l-45 234l-224 -78l78 224l-234 45l180 155l-180 155l234 45l-78 224l224 -78l45 234l155 -180l155 180z" />
<glyph unicode="&#xe125;" d="M650 1200h50q40 0 70 -40.5t30 -84.5v-150l-28 -125h328q40 0 70 -40.5t30 -84.5v-100q0 -45 -29 -74l-238 -344q-16 -24 -38 -40.5t-45 -16.5h-250q-7 0 -42 25t-66 50l-31 25h-61q-45 0 -72.5 18t-27.5 57v400q0 36 20 63l145 196l96 198q13 28 37.5 48t51.5 20z M650 1100l-100 -212l-150 -213v-375h100l136 -100h214l250 375v125h-450l50 225v175h-50zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe126;" d="M600 1100h250q23 0 45 -16.5t38 -40.5l238 -344q29 -29 29 -74v-100q0 -44 -30 -84.5t-70 -40.5h-328q28 -118 28 -125v-150q0 -44 -30 -84.5t-70 -40.5h-50q-27 0 -51.5 20t-37.5 48l-96 198l-145 196q-20 27 -20 63v400q0 39 27.5 57t72.5 18h61q124 100 139 100z M50 1000h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5zM636 1000l-136 -100h-100v-375l150 -213l100 -212h50v175l-50 225h450v125l-250 375h-214z" />
<glyph unicode="&#xe127;" d="M356 873l363 230q31 16 53 -6l110 -112q13 -13 13.5 -32t-11.5 -34l-84 -121h302q84 0 138 -38t54 -110t-55 -111t-139 -39h-106l-131 -339q-6 -21 -19.5 -41t-28.5 -20h-342q-7 0 -90 81t-83 94v525q0 17 14 35.5t28 28.5zM400 792v-503l100 -89h293l131 339 q6 21 19.5 41t28.5 20h203q21 0 30.5 25t0.5 50t-31 25h-456h-7h-6h-5.5t-6 0.5t-5 1.5t-5 2t-4 2.5t-4 4t-2.5 4.5q-12 25 5 47l146 183l-86 83zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500 q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe128;" d="M475 1103l366 -230q2 -1 6 -3.5t14 -10.5t18 -16.5t14.5 -20t6.5 -22.5v-525q0 -13 -86 -94t-93 -81h-342q-15 0 -28.5 20t-19.5 41l-131 339h-106q-85 0 -139.5 39t-54.5 111t54 110t138 38h302l-85 121q-11 15 -10.5 34t13.5 32l110 112q22 22 53 6zM370 945l146 -183 q17 -22 5 -47q-2 -2 -3.5 -4.5t-4 -4t-4 -2.5t-5 -2t-5 -1.5t-6 -0.5h-6h-6.5h-6h-475v-100h221q15 0 29 -20t20 -41l130 -339h294l106 89v503l-342 236zM1050 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5 v500q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe129;" d="M550 1294q72 0 111 -55t39 -139v-106l339 -131q21 -6 41 -19.5t20 -28.5v-342q0 -7 -81 -90t-94 -83h-525q-17 0 -35.5 14t-28.5 28l-9 14l-230 363q-16 31 6 53l112 110q13 13 32 13.5t34 -11.5l121 -84v302q0 84 38 138t110 54zM600 972v203q0 21 -25 30.5t-50 0.5 t-25 -31v-456v-7v-6v-5.5t-0.5 -6t-1.5 -5t-2 -5t-2.5 -4t-4 -4t-4.5 -2.5q-25 -12 -47 5l-183 146l-83 -86l236 -339h503l89 100v293l-339 131q-21 6 -41 19.5t-20 28.5zM450 200h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe130;" d="M350 1100h500q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5h-500q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5t35.5 -14.5zM600 306v-106q0 -84 -39 -139t-111 -55t-110 54t-38 138v302l-121 -84q-15 -12 -34 -11.5t-32 13.5l-112 110 q-22 22 -6 53l230 363q1 2 3.5 6t10.5 13.5t16.5 17t20 13.5t22.5 6h525q13 0 94 -83t81 -90v-342q0 -15 -20 -28.5t-41 -19.5zM308 900l-236 -339l83 -86l183 146q22 17 47 5q2 -1 4.5 -2.5t4 -4t2.5 -4t2 -5t1.5 -5t0.5 -6v-5.5v-6v-7v-456q0 -22 25 -31t50 0.5t25 30.5 v203q0 15 20 28.5t41 19.5l339 131v293l-89 100h-503z" />
<glyph unicode="&#xe131;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM914 632l-275 223q-16 13 -27.5 8t-11.5 -26v-137h-275 q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h275v-137q0 -21 11.5 -26t27.5 8l275 223q16 13 16 32t-16 32z" />
<glyph unicode="&#xe132;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM561 855l-275 -223q-16 -13 -16 -32t16 -32l275 -223q16 -13 27.5 -8 t11.5 26v137h275q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5h-275v137q0 21 -11.5 26t-27.5 -8z" />
<glyph unicode="&#xe133;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM855 639l-223 275q-13 16 -32 16t-32 -16l-223 -275q-13 -16 -8 -27.5 t26 -11.5h137v-275q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v275h137q21 0 26 11.5t-8 27.5z" />
<glyph unicode="&#xe134;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM675 900h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-275h-137q-21 0 -26 -11.5 t8 -27.5l223 -275q13 -16 32 -16t32 16l223 275q13 16 8 27.5t-26 11.5h-137v275q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe135;" d="M600 1176q116 0 222.5 -46t184 -123.5t123.5 -184t46 -222.5t-46 -222.5t-123.5 -184t-184 -123.5t-222.5 -46t-222.5 46t-184 123.5t-123.5 184t-46 222.5t46 222.5t123.5 184t184 123.5t222.5 46zM627 1101q-15 -12 -36.5 -20.5t-35.5 -12t-43 -8t-39 -6.5 q-15 -3 -45.5 0t-45.5 -2q-20 -7 -51.5 -26.5t-34.5 -34.5q-3 -11 6.5 -22.5t8.5 -18.5q-3 -34 -27.5 -91t-29.5 -79q-9 -34 5 -93t8 -87q0 -9 17 -44.5t16 -59.5q12 0 23 -5t23.5 -15t19.5 -14q16 -8 33 -15t40.5 -15t34.5 -12q21 -9 52.5 -32t60 -38t57.5 -11 q7 -15 -3 -34t-22.5 -40t-9.5 -38q13 -21 23 -34.5t27.5 -27.5t36.5 -18q0 -7 -3.5 -16t-3.5 -14t5 -17q104 -2 221 112q30 29 46.5 47t34.5 49t21 63q-13 8 -37 8.5t-36 7.5q-15 7 -49.5 15t-51.5 19q-18 0 -41 -0.5t-43 -1.5t-42 -6.5t-38 -16.5q-51 -35 -66 -12 q-4 1 -3.5 25.5t0.5 25.5q-6 13 -26.5 17.5t-24.5 6.5q1 15 -0.5 30.5t-7 28t-18.5 11.5t-31 -21q-23 -25 -42 4q-19 28 -8 58q6 16 22 22q6 -1 26 -1.5t33.5 -4t19.5 -13.5q7 -12 18 -24t21.5 -20.5t20 -15t15.5 -10.5l5 -3q2 12 7.5 30.5t8 34.5t-0.5 32q-3 18 3.5 29 t18 22.5t15.5 24.5q6 14 10.5 35t8 31t15.5 22.5t34 22.5q-6 18 10 36q8 0 24 -1.5t24.5 -1.5t20 4.5t20.5 15.5q-10 23 -31 42.5t-37.5 29.5t-49 27t-43.5 23q0 1 2 8t3 11.5t1.5 10.5t-1 9.5t-4.5 4.5q31 -13 58.5 -14.5t38.5 2.5l12 5q5 28 -9.5 46t-36.5 24t-50 15 t-41 20q-18 -4 -37 0zM613 994q0 -17 8 -42t17 -45t9 -23q-8 1 -39.5 5.5t-52.5 10t-37 16.5q3 11 16 29.5t16 25.5q10 -10 19 -10t14 6t13.5 14.5t16.5 12.5z" />
<glyph unicode="&#xe136;" d="M756 1157q164 92 306 -9l-259 -138l145 -232l251 126q6 -89 -34 -156.5t-117 -110.5q-60 -34 -127 -39.5t-126 16.5l-596 -596q-15 -16 -36.5 -16t-36.5 16l-111 110q-15 15 -15 36.5t15 37.5l600 599q-34 101 5.5 201.5t135.5 154.5z" />
<glyph unicode="&#xe137;" horiz-adv-x="1220" d="M100 1196h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 1096h-200v-100h200v100zM100 796h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000 q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 696h-500v-100h500v100zM100 396h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 296h-300v-100h300v100z " />
<glyph unicode="&#xe138;" d="M150 1200h900q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM700 500v-300l-200 -200v500l-350 500h900z" />
<glyph unicode="&#xe139;" d="M500 1200h200q41 0 70.5 -29.5t29.5 -70.5v-100h300q41 0 70.5 -29.5t29.5 -70.5v-400h-500v100h-200v-100h-500v400q0 41 29.5 70.5t70.5 29.5h300v100q0 41 29.5 70.5t70.5 29.5zM500 1100v-100h200v100h-200zM1200 400v-200q0 -41 -29.5 -70.5t-70.5 -29.5h-1000 q-41 0 -70.5 29.5t-29.5 70.5v200h1200z" />
<glyph unicode="&#xe140;" d="M50 1200h300q21 0 25 -10.5t-10 -24.5l-94 -94l199 -199q7 -8 7 -18t-7 -18l-106 -106q-8 -7 -18 -7t-18 7l-199 199l-94 -94q-14 -14 -24.5 -10t-10.5 25v300q0 21 14.5 35.5t35.5 14.5zM850 1200h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94 l-199 -199q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l199 199l-94 94q-14 14 -10 24.5t25 10.5zM364 470l106 -106q7 -8 7 -18t-7 -18l-199 -199l94 -94q14 -14 10 -24.5t-25 -10.5h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l199 199 q8 7 18 7t18 -7zM1071 271l94 94q14 14 24.5 10t10.5 -25v-300q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -25 10.5t10 24.5l94 94l-199 199q-7 8 -7 18t7 18l106 106q8 7 18 7t18 -7z" />
<glyph unicode="&#xe141;" d="M596 1192q121 0 231.5 -47.5t190 -127t127 -190t47.5 -231.5t-47.5 -231.5t-127 -190.5t-190 -127t-231.5 -47t-231.5 47t-190.5 127t-127 190.5t-47 231.5t47 231.5t127 190t190.5 127t231.5 47.5zM596 1010q-112 0 -207.5 -55.5t-151 -151t-55.5 -207.5t55.5 -207.5 t151 -151t207.5 -55.5t207.5 55.5t151 151t55.5 207.5t-55.5 207.5t-151 151t-207.5 55.5zM454.5 905q22.5 0 38.5 -16t16 -38.5t-16 -39t-38.5 -16.5t-38.5 16.5t-16 39t16 38.5t38.5 16zM754.5 905q22.5 0 38.5 -16t16 -38.5t-16 -39t-38 -16.5q-14 0 -29 10l-55 -145 q17 -23 17 -51q0 -36 -25.5 -61.5t-61.5 -25.5t-61.5 25.5t-25.5 61.5q0 32 20.5 56.5t51.5 29.5l122 126l1 1q-9 14 -9 28q0 23 16 39t38.5 16zM345.5 709q22.5 0 38.5 -16t16 -38.5t-16 -38.5t-38.5 -16t-38.5 16t-16 38.5t16 38.5t38.5 16zM854.5 709q22.5 0 38.5 -16 t16 -38.5t-16 -38.5t-38.5 -16t-38.5 16t-16 38.5t16 38.5t38.5 16z" />
<glyph unicode="&#xe142;" d="M546 173l469 470q91 91 99 192q7 98 -52 175.5t-154 94.5q-22 4 -47 4q-34 0 -66.5 -10t-56.5 -23t-55.5 -38t-48 -41.5t-48.5 -47.5q-376 -375 -391 -390q-30 -27 -45 -41.5t-37.5 -41t-32 -46.5t-16 -47.5t-1.5 -56.5q9 -62 53.5 -95t99.5 -33q74 0 125 51l548 548 q36 36 20 75q-7 16 -21.5 26t-32.5 10q-26 0 -50 -23q-13 -12 -39 -38l-341 -338q-15 -15 -35.5 -15.5t-34.5 13.5t-14 34.5t14 34.5q327 333 361 367q35 35 67.5 51.5t78.5 16.5q14 0 29 -1q44 -8 74.5 -35.5t43.5 -68.5q14 -47 2 -96.5t-47 -84.5q-12 -11 -32 -32 t-79.5 -81t-114.5 -115t-124.5 -123.5t-123 -119.5t-96.5 -89t-57 -45q-56 -27 -120 -27q-70 0 -129 32t-93 89q-48 78 -35 173t81 163l511 511q71 72 111 96q91 55 198 55q80 0 152 -33q78 -36 129.5 -103t66.5 -154q17 -93 -11 -183.5t-94 -156.5l-482 -476 q-15 -15 -36 -16t-37 14t-17.5 34t14.5 35z" />
<glyph unicode="&#xe143;" d="M649 949q48 68 109.5 104t121.5 38.5t118.5 -20t102.5 -64t71 -100.5t27 -123q0 -57 -33.5 -117.5t-94 -124.5t-126.5 -127.5t-150 -152.5t-146 -174q-62 85 -145.5 174t-150 152.5t-126.5 127.5t-93.5 124.5t-33.5 117.5q0 64 28 123t73 100.5t104 64t119 20 t120.5 -38.5t104.5 -104zM896 972q-33 0 -64.5 -19t-56.5 -46t-47.5 -53.5t-43.5 -45.5t-37.5 -19t-36 19t-40 45.5t-43 53.5t-54 46t-65.5 19q-67 0 -122.5 -55.5t-55.5 -132.5q0 -23 13.5 -51t46 -65t57.5 -63t76 -75l22 -22q15 -14 44 -44t50.5 -51t46 -44t41 -35t23 -12 t23.5 12t42.5 36t46 44t52.5 52t44 43q4 4 12 13q43 41 63.5 62t52 55t46 55t26 46t11.5 44q0 79 -53 133.5t-120 54.5z" />
<glyph unicode="&#xe144;" d="M776.5 1214q93.5 0 159.5 -66l141 -141q66 -66 66 -160q0 -42 -28 -95.5t-62 -87.5l-29 -29q-31 53 -77 99l-18 18l95 95l-247 248l-389 -389l212 -212l-105 -106l-19 18l-141 141q-66 66 -66 159t66 159l283 283q65 66 158.5 66zM600 706l105 105q10 -8 19 -17l141 -141 q66 -66 66 -159t-66 -159l-283 -283q-66 -66 -159 -66t-159 66l-141 141q-66 66 -66 159.5t66 159.5l55 55q29 -55 75 -102l18 -17l-95 -95l247 -248l389 389z" />
<glyph unicode="&#xe145;" d="M603 1200q85 0 162 -15t127 -38t79 -48t29 -46v-953q0 -41 -29.5 -70.5t-70.5 -29.5h-600q-41 0 -70.5 29.5t-29.5 70.5v953q0 21 30 46.5t81 48t129 37.5t163 15zM300 1000v-700h600v700h-600zM600 254q-43 0 -73.5 -30.5t-30.5 -73.5t30.5 -73.5t73.5 -30.5t73.5 30.5 t30.5 73.5t-30.5 73.5t-73.5 30.5z" />
<glyph unicode="&#xe146;" d="M902 1185l283 -282q15 -15 15 -36t-14.5 -35.5t-35.5 -14.5t-35 15l-36 35l-279 -267v-300l-212 210l-308 -307l-280 -203l203 280l307 308l-210 212h300l267 279l-35 36q-15 14 -15 35t14.5 35.5t35.5 14.5t35 -15z" />
<glyph unicode="&#xe148;" d="M700 1248v-78q38 -5 72.5 -14.5t75.5 -31.5t71 -53.5t52 -84t24 -118.5h-159q-4 36 -10.5 59t-21 45t-40 35.5t-64.5 20.5v-307l64 -13q34 -7 64 -16.5t70 -32t67.5 -52.5t47.5 -80t20 -112q0 -139 -89 -224t-244 -97v-77h-100v79q-150 16 -237 103q-40 40 -52.5 93.5 t-15.5 139.5h139q5 -77 48.5 -126t117.5 -65v335l-27 8q-46 14 -79 26.5t-72 36t-63 52t-40 72.5t-16 98q0 70 25 126t67.5 92t94.5 57t110 27v77h100zM600 754v274q-29 -4 -50 -11t-42 -21.5t-31.5 -41.5t-10.5 -65q0 -29 7 -50.5t16.5 -34t28.5 -22.5t31.5 -14t37.5 -10 q9 -3 13 -4zM700 547v-310q22 2 42.5 6.5t45 15.5t41.5 27t29 42t12 59.5t-12.5 59.5t-38 44.5t-53 31t-66.5 24.5z" />
<glyph unicode="&#xe149;" d="M561 1197q84 0 160.5 -40t123.5 -109.5t47 -147.5h-153q0 40 -19.5 71.5t-49.5 48.5t-59.5 26t-55.5 9q-37 0 -79 -14.5t-62 -35.5q-41 -44 -41 -101q0 -26 13.5 -63t26.5 -61t37 -66q6 -9 9 -14h241v-100h-197q8 -50 -2.5 -115t-31.5 -95q-45 -62 -99 -112 q34 10 83 17.5t71 7.5q32 1 102 -16t104 -17q83 0 136 30l50 -147q-31 -19 -58 -30.5t-55 -15.5t-42 -4.5t-46 -0.5q-23 0 -76 17t-111 32.5t-96 11.5q-39 -3 -82 -16t-67 -25l-23 -11l-55 145q4 3 16 11t15.5 10.5t13 9t15.5 12t14.5 14t17.5 18.5q48 55 54 126.5 t-30 142.5h-221v100h166q-23 47 -44 104q-7 20 -12 41.5t-6 55.5t6 66.5t29.5 70.5t58.5 71q97 88 263 88z" />
<glyph unicode="&#xe150;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM935 1184l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-900h-200v900h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe151;" d="M1000 700h-100v100h-100v-100h-100v500h300v-500zM400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM801 1100v-200h100v200h-100zM1000 350l-200 -250h200v-100h-300v150l200 250h-200v100h300v-150z " />
<glyph unicode="&#xe152;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1000 1050l-200 -250h200v-100h-300v150l200 250h-200v100h300v-150zM1000 0h-100v100h-100v-100h-100v500h300v-500zM801 400v-200h100v200h-100z " />
<glyph unicode="&#xe153;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1000 700h-100v400h-100v100h200v-500zM1100 0h-100v100h-200v400h300v-500zM901 400v-200h100v200h-100z" />
<glyph unicode="&#xe154;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1100 700h-100v100h-200v400h300v-500zM901 1100v-200h100v200h-100zM1000 0h-100v400h-100v100h200v-500z" />
<glyph unicode="&#xe155;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM900 1000h-200v200h200v-200zM1000 700h-300v200h300v-200zM1100 400h-400v200h400v-200zM1200 100h-500v200h500v-200z" />
<glyph unicode="&#xe156;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1200 1000h-500v200h500v-200zM1100 700h-400v200h400v-200zM1000 400h-300v200h300v-200zM900 100h-200v200h200v-200z" />
<glyph unicode="&#xe157;" d="M350 1100h400q162 0 256 -93.5t94 -256.5v-400q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5z" />
<glyph unicode="&#xe158;" d="M350 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-163 0 -256.5 92.5t-93.5 257.5v400q0 163 94 256.5t256 93.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM440 770l253 -190q17 -12 17 -30t-17 -30l-253 -190q-16 -12 -28 -6.5t-12 26.5v400q0 21 12 26.5t28 -6.5z" />
<glyph unicode="&#xe159;" d="M350 1100h400q163 0 256.5 -94t93.5 -256v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 163 92.5 256.5t257.5 93.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM350 700h400q21 0 26.5 -12t-6.5 -28l-190 -253q-12 -17 -30 -17t-30 17l-190 253q-12 16 -6.5 28t26.5 12z" />
<glyph unicode="&#xe160;" d="M350 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -163 -92.5 -256.5t-257.5 -93.5h-400q-163 0 -256.5 94t-93.5 256v400q0 165 92.5 257.5t257.5 92.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM580 693l190 -253q12 -16 6.5 -28t-26.5 -12h-400q-21 0 -26.5 12t6.5 28l190 253q12 17 30 17t30 -17z" />
<glyph unicode="&#xe161;" d="M550 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h450q41 0 70.5 29.5t29.5 70.5v500q0 41 -29.5 70.5t-70.5 29.5h-450q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM338 867l324 -284q16 -14 16 -33t-16 -33l-324 -284q-16 -14 -27 -9t-11 26v150h-250q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h250v150q0 21 11 26t27 -9z" />
<glyph unicode="&#xe162;" d="M793 1182l9 -9q8 -10 5 -27q-3 -11 -79 -225.5t-78 -221.5l300 1q24 0 32.5 -17.5t-5.5 -35.5q-1 0 -133.5 -155t-267 -312.5t-138.5 -162.5q-12 -15 -26 -15h-9l-9 8q-9 11 -4 32q2 9 42 123.5t79 224.5l39 110h-302q-23 0 -31 19q-10 21 6 41q75 86 209.5 237.5 t228 257t98.5 111.5q9 16 25 16h9z" />
<glyph unicode="&#xe163;" d="M350 1100h400q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-450q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h450q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400 q0 165 92.5 257.5t257.5 92.5zM938 867l324 -284q16 -14 16 -33t-16 -33l-324 -284q-16 -14 -27 -9t-11 26v150h-250q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h250v150q0 21 11 26t27 -9z" />
<glyph unicode="&#xe164;" d="M750 1200h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -10.5 -25t-24.5 10l-109 109l-312 -312q-15 -15 -35.5 -15t-35.5 15l-141 141q-15 15 -15 35.5t15 35.5l312 312l-109 109q-14 14 -10 24.5t25 10.5zM456 900h-156q-41 0 -70.5 -29.5t-29.5 -70.5v-500 q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v148l200 200v-298q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5h300z" />
<glyph unicode="&#xe165;" d="M600 1186q119 0 227.5 -46.5t187 -125t125 -187t46.5 -227.5t-46.5 -227.5t-125 -187t-187 -125t-227.5 -46.5t-227.5 46.5t-187 125t-125 187t-46.5 227.5t46.5 227.5t125 187t187 125t227.5 46.5zM600 1022q-115 0 -212 -56.5t-153.5 -153.5t-56.5 -212t56.5 -212 t153.5 -153.5t212 -56.5t212 56.5t153.5 153.5t56.5 212t-56.5 212t-153.5 153.5t-212 56.5zM600 794q80 0 137 -57t57 -137t-57 -137t-137 -57t-137 57t-57 137t57 137t137 57z" />
<glyph unicode="&#xe166;" d="M450 1200h200q21 0 35.5 -14.5t14.5 -35.5v-350h245q20 0 25 -11t-9 -26l-383 -426q-14 -15 -33.5 -15t-32.5 15l-379 426q-13 15 -8.5 26t25.5 11h250v350q0 21 14.5 35.5t35.5 14.5zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5z M900 200v-50h100v50h-100z" />
<glyph unicode="&#xe167;" d="M583 1182l378 -435q14 -15 9 -31t-26 -16h-244v-250q0 -20 -17 -35t-39 -15h-200q-20 0 -32 14.5t-12 35.5v250h-250q-20 0 -25.5 16.5t8.5 31.5l383 431q14 16 33.5 17t33.5 -14zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5z M900 200v-50h100v50h-100z" />
<glyph unicode="&#xe168;" d="M396 723l369 369q7 7 17.5 7t17.5 -7l139 -139q7 -8 7 -18.5t-7 -17.5l-525 -525q-7 -8 -17.5 -8t-17.5 8l-292 291q-7 8 -7 18t7 18l139 139q8 7 18.5 7t17.5 -7zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50 h-100z" />
<glyph unicode="&#xe169;" d="M135 1023l142 142q14 14 35 14t35 -14l77 -77l-212 -212l-77 76q-14 15 -14 36t14 35zM655 855l210 210q14 14 24.5 10t10.5 -25l-2 -599q-1 -20 -15.5 -35t-35.5 -15l-597 -1q-21 0 -25 10.5t10 24.5l208 208l-154 155l212 212zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5 v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50h-100z" />
<glyph unicode="&#xe170;" d="M350 1200l599 -2q20 -1 35 -15.5t15 -35.5l1 -597q0 -21 -10.5 -25t-24.5 10l-208 208l-155 -154l-212 212l155 154l-210 210q-14 14 -10 24.5t25 10.5zM524 512l-76 -77q-15 -14 -36 -14t-35 14l-142 142q-14 14 -14 35t14 35l77 77zM50 300h1000q21 0 35.5 -14.5 t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50h-100z" />
<glyph unicode="&#xe171;" d="M1200 103l-483 276l-314 -399v423h-399l1196 796v-1096zM483 424v-230l683 953z" />
<glyph unicode="&#xe172;" d="M1100 1000v-850q0 -21 -14.5 -35.5t-35.5 -14.5h-150v400h-700v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200z" />
<glyph unicode="&#xe173;" d="M1100 1000l-2 -149l-299 -299l-95 95q-9 9 -21.5 9t-21.5 -9l-149 -147h-312v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM1132 638l106 -106q7 -7 7 -17.5t-7 -17.5l-420 -421q-8 -7 -18 -7 t-18 7l-202 203q-8 7 -8 17.5t8 17.5l106 106q7 8 17.5 8t17.5 -8l79 -79l297 297q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe174;" d="M1100 1000v-269l-103 -103l-134 134q-15 15 -33.5 16.5t-34.5 -12.5l-266 -266h-329v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM1202 572l70 -70q15 -15 15 -35.5t-15 -35.5l-131 -131 l131 -131q15 -15 15 -35.5t-15 -35.5l-70 -70q-15 -15 -35.5 -15t-35.5 15l-131 131l-131 -131q-15 -15 -35.5 -15t-35.5 15l-70 70q-15 15 -15 35.5t15 35.5l131 131l-131 131q-15 15 -15 35.5t15 35.5l70 70q15 15 35.5 15t35.5 -15l131 -131l131 131q15 15 35.5 15 t35.5 -15z" />
<glyph unicode="&#xe175;" d="M1100 1000v-300h-350q-21 0 -35.5 -14.5t-14.5 -35.5v-150h-500v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM850 600h100q21 0 35.5 -14.5t14.5 -35.5v-250h150q21 0 25 -10.5t-10 -24.5 l-230 -230q-14 -14 -35 -14t-35 14l-230 230q-14 14 -10 24.5t25 10.5h150v250q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe176;" d="M1100 1000v-400l-165 165q-14 15 -35 15t-35 -15l-263 -265h-402v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM935 565l230 -229q14 -15 10 -25.5t-25 -10.5h-150v-250q0 -20 -14.5 -35 t-35.5 -15h-100q-21 0 -35.5 15t-14.5 35v250h-150q-21 0 -25 10.5t10 25.5l230 229q14 15 35 15t35 -15z" />
<glyph unicode="&#xe177;" d="M50 1100h1100q21 0 35.5 -14.5t14.5 -35.5v-150h-1200v150q0 21 14.5 35.5t35.5 14.5zM1200 800v-550q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v550h1200zM100 500v-200h400v200h-400z" />
<glyph unicode="&#xe178;" d="M935 1165l248 -230q14 -14 14 -35t-14 -35l-248 -230q-14 -14 -24.5 -10t-10.5 25v150h-400v200h400v150q0 21 10.5 25t24.5 -10zM200 800h-50q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v-200zM400 800h-100v200h100v-200zM18 435l247 230 q14 14 24.5 10t10.5 -25v-150h400v-200h-400v-150q0 -21 -10.5 -25t-24.5 10l-247 230q-15 14 -15 35t15 35zM900 300h-100v200h100v-200zM1000 500h51q20 0 34.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-34.5 -14.5h-51v200z" />
<glyph unicode="&#xe179;" d="M862 1073l276 116q25 18 43.5 8t18.5 -41v-1106q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v397q-4 1 -11 5t-24 17.5t-30 29t-24 42t-11 56.5v359q0 31 18.5 65t43.5 52zM550 1200q22 0 34.5 -12.5t14.5 -24.5l1 -13v-450q0 -28 -10.5 -59.5 t-25 -56t-29 -45t-25.5 -31.5l-10 -11v-447q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v447q-4 4 -11 11.5t-24 30.5t-30 46t-24 55t-11 60v450q0 2 0.5 5.5t4 12t8.5 15t14.5 12t22.5 5.5q20 0 32.5 -12.5t14.5 -24.5l3 -13v-350h100v350v5.5t2.5 12 t7 15t15 12t25.5 5.5q23 0 35.5 -12.5t13.5 -24.5l1 -13v-350h100v350q0 2 0.5 5.5t3 12t7 15t15 12t24.5 5.5z" />
<glyph unicode="&#xe180;" d="M1200 1100v-56q-4 0 -11 -0.5t-24 -3t-30 -7.5t-24 -15t-11 -24v-888q0 -22 25 -34.5t50 -13.5l25 -2v-56h-400v56q75 0 87.5 6.5t12.5 43.5v394h-500v-394q0 -37 12.5 -43.5t87.5 -6.5v-56h-400v56q4 0 11 0.5t24 3t30 7.5t24 15t11 24v888q0 22 -25 34.5t-50 13.5 l-25 2v56h400v-56q-75 0 -87.5 -6.5t-12.5 -43.5v-394h500v394q0 37 -12.5 43.5t-87.5 6.5v56h400z" />
<glyph unicode="&#xe181;" d="M675 1000h375q21 0 35.5 -14.5t14.5 -35.5v-150h-105l-295 -98v98l-200 200h-400l100 100h375zM100 900h300q41 0 70.5 -29.5t29.5 -70.5v-500q0 -41 -29.5 -70.5t-70.5 -29.5h-300q-41 0 -70.5 29.5t-29.5 70.5v500q0 41 29.5 70.5t70.5 29.5zM100 800v-200h300v200 h-300zM1100 535l-400 -133v163l400 133v-163zM100 500v-200h300v200h-300zM1100 398v-248q0 -21 -14.5 -35.5t-35.5 -14.5h-375l-100 -100h-375l-100 100h400l200 200h105z" />
<glyph unicode="&#xe182;" d="M17 1007l162 162q17 17 40 14t37 -22l139 -194q14 -20 11 -44.5t-20 -41.5l-119 -118q102 -142 228 -268t267 -227l119 118q17 17 42.5 19t44.5 -12l192 -136q19 -14 22.5 -37.5t-13.5 -40.5l-163 -162q-3 -1 -9.5 -1t-29.5 2t-47.5 6t-62.5 14.5t-77.5 26.5t-90 42.5 t-101.5 60t-111 83t-119 108.5q-74 74 -133.5 150.5t-94.5 138.5t-60 119.5t-34.5 100t-15 74.5t-4.5 48z" />
<glyph unicode="&#xe183;" d="M600 1100q92 0 175 -10.5t141.5 -27t108.5 -36.5t81.5 -40t53.5 -37t31 -27l9 -10v-200q0 -21 -14.5 -33t-34.5 -9l-202 34q-20 3 -34.5 20t-14.5 38v146q-141 24 -300 24t-300 -24v-146q0 -21 -14.5 -38t-34.5 -20l-202 -34q-20 -3 -34.5 9t-14.5 33v200q3 4 9.5 10.5 t31 26t54 37.5t80.5 39.5t109 37.5t141 26.5t175 10.5zM600 795q56 0 97 -9.5t60 -23.5t30 -28t12 -24l1 -10v-50l365 -303q14 -15 24.5 -40t10.5 -45v-212q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v212q0 20 10.5 45t24.5 40l365 303v50 q0 4 1 10.5t12 23t30 29t60 22.5t97 10z" />
<glyph unicode="&#xe184;" d="M1100 700l-200 -200h-600l-200 200v500h200v-200h200v200h200v-200h200v200h200v-500zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-12l137 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5 t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe185;" d="M700 1100h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-1000h300v1000q0 41 -29.5 70.5t-70.5 29.5zM1100 800h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-700h300v700q0 41 -29.5 70.5t-70.5 29.5zM400 0h-300v400q0 41 29.5 70.5t70.5 29.5h100q41 0 70.5 -29.5t29.5 -70.5v-400z " />
<glyph unicode="&#xe186;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-100h200v-300h-300v100h200v100h-200v300h300v-100zM900 700v-300l-100 -100h-200v500h200z M700 700v-300h100v300h-100z" />
<glyph unicode="&#xe187;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 300h-100v200h-100v-200h-100v500h100v-200h100v200h100v-500zM900 700v-300l-100 -100h-200v500h200z M700 700v-300h100v300h-100z" />
<glyph unicode="&#xe188;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-300h200v-100h-300v500h300v-100zM900 700h-200v-300h200v-100h-300v500h300v-100z" />
<glyph unicode="&#xe189;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 400l-300 150l300 150v-300zM900 550l-300 -150v300z" />
<glyph unicode="&#xe190;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM900 300h-700v500h700v-500zM800 700h-130q-38 0 -66.5 -43t-28.5 -108t27 -107t68 -42h130v300zM300 700v-300 h130q41 0 68 42t27 107t-28.5 108t-66.5 43h-130z" />
<glyph unicode="&#xe191;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-100h200v-300h-300v100h200v100h-200v300h300v-100zM900 300h-100v400h-100v100h200v-500z M700 300h-100v100h100v-100z" />
<glyph unicode="&#xe192;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM300 700h200v-400h-300v500h100v-100zM900 300h-100v400h-100v100h200v-500zM300 600v-200h100v200h-100z M700 300h-100v100h100v-100z" />
<glyph unicode="&#xe193;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 500l-199 -200h-100v50l199 200v150h-200v100h300v-300zM900 300h-100v400h-100v100h200v-500zM701 300h-100 v100h100v-100z" />
<glyph unicode="&#xe194;" d="M600 1191q120 0 229.5 -47t188.5 -126t126 -188.5t47 -229.5t-47 -229.5t-126 -188.5t-188.5 -126t-229.5 -47t-229.5 47t-188.5 126t-126 188.5t-47 229.5t47 229.5t126 188.5t188.5 126t229.5 47zM600 1021q-114 0 -211 -56.5t-153.5 -153.5t-56.5 -211t56.5 -211 t153.5 -153.5t211 -56.5t211 56.5t153.5 153.5t56.5 211t-56.5 211t-153.5 153.5t-211 56.5zM800 700h-300v-200h300v-100h-300l-100 100v200l100 100h300v-100z" />
<glyph unicode="&#xe195;" d="M600 1191q120 0 229.5 -47t188.5 -126t126 -188.5t47 -229.5t-47 -229.5t-126 -188.5t-188.5 -126t-229.5 -47t-229.5 47t-188.5 126t-126 188.5t-47 229.5t47 229.5t126 188.5t188.5 126t229.5 47zM600 1021q-114 0 -211 -56.5t-153.5 -153.5t-56.5 -211t56.5 -211 t153.5 -153.5t211 -56.5t211 56.5t153.5 153.5t56.5 211t-56.5 211t-153.5 153.5t-211 56.5zM800 700v-100l-50 -50l100 -100v-50h-100l-100 100h-150v-100h-100v400h300zM500 700v-100h200v100h-200z" />
<glyph unicode="&#xe197;" d="M503 1089q110 0 200.5 -59.5t134.5 -156.5q44 14 90 14q120 0 205 -86.5t85 -207t-85 -207t-205 -86.5h-128v250q0 21 -14.5 35.5t-35.5 14.5h-300q-21 0 -35.5 -14.5t-14.5 -35.5v-250h-222q-80 0 -136 57.5t-56 136.5q0 69 43 122.5t108 67.5q-2 19 -2 37q0 100 49 185 t134 134t185 49zM525 500h150q10 0 17.5 -7.5t7.5 -17.5v-275h137q21 0 26 -11.5t-8 -27.5l-223 -244q-13 -16 -32 -16t-32 16l-223 244q-13 16 -8 27.5t26 11.5h137v275q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe198;" d="M502 1089q110 0 201 -59.5t135 -156.5q43 15 89 15q121 0 206 -86.5t86 -206.5q0 -99 -60 -181t-150 -110l-378 360q-13 16 -31.5 16t-31.5 -16l-381 -365h-9q-79 0 -135.5 57.5t-56.5 136.5q0 69 43 122.5t108 67.5q-2 19 -2 38q0 100 49 184.5t133.5 134t184.5 49.5z M632 467l223 -228q13 -16 8 -27.5t-26 -11.5h-137v-275q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v275h-137q-21 0 -26 11.5t8 27.5q199 204 223 228q19 19 31.5 19t32.5 -19z" />
<glyph unicode="&#xe199;" d="M700 100v100h400l-270 300h170l-270 300h170l-300 333l-300 -333h170l-270 -300h170l-270 -300h400v-100h-50q-21 0 -35.5 -14.5t-14.5 -35.5v-50h400v50q0 21 -14.5 35.5t-35.5 14.5h-50z" />
<glyph unicode="&#xe200;" d="M600 1179q94 0 167.5 -56.5t99.5 -145.5q89 -6 150.5 -71.5t61.5 -155.5q0 -61 -29.5 -112.5t-79.5 -82.5q9 -29 9 -55q0 -74 -52.5 -126.5t-126.5 -52.5q-55 0 -100 30v-251q21 0 35.5 -14.5t14.5 -35.5v-50h-300v50q0 21 14.5 35.5t35.5 14.5v251q-45 -30 -100 -30 q-74 0 -126.5 52.5t-52.5 126.5q0 18 4 38q-47 21 -75.5 65t-28.5 97q0 74 52.5 126.5t126.5 52.5q5 0 23 -2q0 2 -1 10t-1 13q0 116 81.5 197.5t197.5 81.5z" />
<glyph unicode="&#xe201;" d="M1010 1010q111 -111 150.5 -260.5t0 -299t-150.5 -260.5q-83 -83 -191.5 -126.5t-218.5 -43.5t-218.5 43.5t-191.5 126.5q-111 111 -150.5 260.5t0 299t150.5 260.5q83 83 191.5 126.5t218.5 43.5t218.5 -43.5t191.5 -126.5zM476 1065q-4 0 -8 -1q-121 -34 -209.5 -122.5 t-122.5 -209.5q-4 -12 2.5 -23t18.5 -14l36 -9q3 -1 7 -1q23 0 29 22q27 96 98 166q70 71 166 98q11 3 17.5 13.5t3.5 22.5l-9 35q-3 13 -14 19q-7 4 -15 4zM512 920q-4 0 -9 -2q-80 -24 -138.5 -82.5t-82.5 -138.5q-4 -13 2 -24t19 -14l34 -9q4 -1 8 -1q22 0 28 21 q18 58 58.5 98.5t97.5 58.5q12 3 18 13.5t3 21.5l-9 35q-3 12 -14 19q-7 4 -15 4zM719.5 719.5q-49.5 49.5 -119.5 49.5t-119.5 -49.5t-49.5 -119.5t49.5 -119.5t119.5 -49.5t119.5 49.5t49.5 119.5t-49.5 119.5zM855 551q-22 0 -28 -21q-18 -58 -58.5 -98.5t-98.5 -57.5 q-11 -4 -17 -14.5t-3 -21.5l9 -35q3 -12 14 -19q7 -4 15 -4q4 0 9 2q80 24 138.5 82.5t82.5 138.5q4 13 -2.5 24t-18.5 14l-34 9q-4 1 -8 1zM1000 515q-23 0 -29 -22q-27 -96 -98 -166q-70 -71 -166 -98q-11 -3 -17.5 -13.5t-3.5 -22.5l9 -35q3 -13 14 -19q7 -4 15 -4 q4 0 8 1q121 34 209.5 122.5t122.5 209.5q4 12 -2.5 23t-18.5 14l-36 9q-3 1 -7 1z" />
<glyph unicode="&#xe202;" d="M700 800h300v-380h-180v200h-340v-200h-380v755q0 10 7.5 17.5t17.5 7.5h575v-400zM1000 900h-200v200zM700 300h162l-212 -212l-212 212h162v200h100v-200zM520 0h-395q-10 0 -17.5 7.5t-7.5 17.5v395zM1000 220v-195q0 -10 -7.5 -17.5t-17.5 -7.5h-195z" />
<glyph unicode="&#xe203;" d="M700 800h300v-520l-350 350l-550 -550v1095q0 10 7.5 17.5t17.5 7.5h575v-400zM1000 900h-200v200zM862 200h-162v-200h-100v200h-162l212 212zM480 0h-355q-10 0 -17.5 7.5t-7.5 17.5v55h380v-80zM1000 80v-55q0 -10 -7.5 -17.5t-17.5 -7.5h-155v80h180z" />
<glyph unicode="&#xe204;" d="M1162 800h-162v-200h100l100 -100h-300v300h-162l212 212zM200 800h200q27 0 40 -2t29.5 -10.5t23.5 -30t7 -57.5h300v-100h-600l-200 -350v450h100q0 36 7 57.5t23.5 30t29.5 10.5t40 2zM800 400h240l-240 -400h-800l300 500h500v-100z" />
<glyph unicode="&#xe205;" d="M650 1100h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5zM1000 850v150q41 0 70.5 -29.5t29.5 -70.5v-800 q0 -41 -29.5 -70.5t-70.5 -29.5h-600q-1 0 -20 4l246 246l-326 326v324q0 41 29.5 70.5t70.5 29.5v-150q0 -62 44 -106t106 -44h300q62 0 106 44t44 106zM412 250l-212 -212v162h-200v100h200v162z" />
<glyph unicode="&#xe206;" d="M450 1100h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5zM800 850v150q41 0 70.5 -29.5t29.5 -70.5v-500 h-200v-300h200q0 -36 -7 -57.5t-23.5 -30t-29.5 -10.5t-40 -2h-600q-41 0 -70.5 29.5t-29.5 70.5v800q0 41 29.5 70.5t70.5 29.5v-150q0 -62 44 -106t106 -44h300q62 0 106 44t44 106zM1212 250l-212 -212v162h-200v100h200v162z" />
<glyph unicode="&#xe209;" d="M658 1197l637 -1104q23 -38 7 -65.5t-60 -27.5h-1276q-44 0 -60 27.5t7 65.5l637 1104q22 39 54 39t54 -39zM704 800h-208q-20 0 -32 -14.5t-8 -34.5l58 -302q4 -20 21.5 -34.5t37.5 -14.5h54q20 0 37.5 14.5t21.5 34.5l58 302q4 20 -8 34.5t-32 14.5zM500 300v-100h200 v100h-200z" />
<glyph unicode="&#xe210;" d="M425 1100h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM425 800h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5 t17.5 7.5zM825 800h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM25 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150 q0 10 7.5 17.5t17.5 7.5zM425 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM825 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5 v150q0 10 7.5 17.5t17.5 7.5zM25 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM425 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5 t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM825 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe211;" d="M700 1200h100v-200h-100v-100h350q62 0 86.5 -39.5t-3.5 -94.5l-66 -132q-41 -83 -81 -134h-772q-40 51 -81 134l-66 132q-28 55 -3.5 94.5t86.5 39.5h350v100h-100v200h100v100h200v-100zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-12l137 -100 h-950l138 100h-13q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe212;" d="M600 1300q40 0 68.5 -29.5t28.5 -70.5h-194q0 41 28.5 70.5t68.5 29.5zM443 1100h314q18 -37 18 -75q0 -8 -3 -25h328q41 0 44.5 -16.5t-30.5 -38.5l-175 -145h-678l-178 145q-34 22 -29 38.5t46 16.5h328q-3 17 -3 25q0 38 18 75zM250 700h700q21 0 35.5 -14.5 t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-150v-200l275 -200h-950l275 200v200h-150q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe213;" d="M600 1181q75 0 128 -53t53 -128t-53 -128t-128 -53t-128 53t-53 128t53 128t128 53zM602 798h46q34 0 55.5 -28.5t21.5 -86.5q0 -76 39 -183h-324q39 107 39 183q0 58 21.5 86.5t56.5 28.5h45zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13 l138 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe214;" d="M600 1300q47 0 92.5 -53.5t71 -123t25.5 -123.5q0 -78 -55.5 -133.5t-133.5 -55.5t-133.5 55.5t-55.5 133.5q0 62 34 143l144 -143l111 111l-163 163q34 26 63 26zM602 798h46q34 0 55.5 -28.5t21.5 -86.5q0 -76 39 -183h-324q39 107 39 183q0 58 21.5 86.5t56.5 28.5h45 zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13l138 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe215;" d="M600 1200l300 -161v-139h-300q0 -57 18.5 -108t50 -91.5t63 -72t70 -67.5t57.5 -61h-530q-60 83 -90.5 177.5t-30.5 178.5t33 164.5t87.5 139.5t126 96.5t145.5 41.5v-98zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13l138 -100h-950l137 100 h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe216;" d="M600 1300q41 0 70.5 -29.5t29.5 -70.5v-78q46 -26 73 -72t27 -100v-50h-400v50q0 54 27 100t73 72v78q0 41 29.5 70.5t70.5 29.5zM400 800h400q54 0 100 -27t72 -73h-172v-100h200v-100h-200v-100h200v-100h-200v-100h200q0 -83 -58.5 -141.5t-141.5 -58.5h-400 q-83 0 -141.5 58.5t-58.5 141.5v400q0 83 58.5 141.5t141.5 58.5z" />
<glyph unicode="&#xe218;" d="M150 1100h900q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5zM125 400h950q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-283l224 -224q13 -13 13 -31.5t-13 -32 t-31.5 -13.5t-31.5 13l-88 88h-524l-87 -88q-13 -13 -32 -13t-32 13.5t-13 32t13 31.5l224 224h-289q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM541 300l-100 -100h324l-100 100h-124z" />
<glyph unicode="&#xe219;" d="M200 1100h800q83 0 141.5 -58.5t58.5 -141.5v-200h-100q0 41 -29.5 70.5t-70.5 29.5h-250q-41 0 -70.5 -29.5t-29.5 -70.5h-100q0 41 -29.5 70.5t-70.5 29.5h-250q-41 0 -70.5 -29.5t-29.5 -70.5h-100v200q0 83 58.5 141.5t141.5 58.5zM100 600h1000q41 0 70.5 -29.5 t29.5 -70.5v-300h-1200v300q0 41 29.5 70.5t70.5 29.5zM300 100v-50q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v50h200zM1100 100v-50q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v50h200z" />
<glyph unicode="&#xe221;" d="M480 1165l682 -683q31 -31 31 -75.5t-31 -75.5l-131 -131h-481l-517 518q-32 31 -32 75.5t32 75.5l295 296q31 31 75.5 31t76.5 -31zM108 794l342 -342l303 304l-341 341zM250 100h800q21 0 35.5 -14.5t14.5 -35.5v-50h-900v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe223;" d="M1057 647l-189 506q-8 19 -27.5 33t-40.5 14h-400q-21 0 -40.5 -14t-27.5 -33l-189 -506q-8 -19 1.5 -33t30.5 -14h625v-150q0 -21 14.5 -35.5t35.5 -14.5t35.5 14.5t14.5 35.5v150h125q21 0 30.5 14t1.5 33zM897 0h-595v50q0 21 14.5 35.5t35.5 14.5h50v50 q0 21 14.5 35.5t35.5 14.5h48v300h200v-300h47q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-50z" />
<glyph unicode="&#xe224;" d="M900 800h300v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-375v591l-300 300v84q0 10 7.5 17.5t17.5 7.5h375v-400zM1200 900h-200v200zM400 600h300v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-650q-10 0 -17.5 7.5t-7.5 17.5v950q0 10 7.5 17.5t17.5 7.5h375v-400zM700 700h-200v200z " />
<glyph unicode="&#xe225;" d="M484 1095h195q75 0 146 -32.5t124 -86t89.5 -122.5t48.5 -142q18 -14 35 -20q31 -10 64.5 6.5t43.5 48.5q10 34 -15 71q-19 27 -9 43q5 8 12.5 11t19 -1t23.5 -16q41 -44 39 -105q-3 -63 -46 -106.5t-104 -43.5h-62q-7 -55 -35 -117t-56 -100l-39 -234q-3 -20 -20 -34.5 t-38 -14.5h-100q-21 0 -33 14.5t-9 34.5l12 70q-49 -14 -91 -14h-195q-24 0 -65 8l-11 -64q-3 -20 -20 -34.5t-38 -14.5h-100q-21 0 -33 14.5t-9 34.5l26 157q-84 74 -128 175l-159 53q-19 7 -33 26t-14 40v50q0 21 14.5 35.5t35.5 14.5h124q11 87 56 166l-111 95 q-16 14 -12.5 23.5t24.5 9.5h203q116 101 250 101zM675 1000h-250q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h250q10 0 17.5 7.5t7.5 17.5v50q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe226;" d="M641 900l423 247q19 8 42 2.5t37 -21.5l32 -38q14 -15 12.5 -36t-17.5 -34l-139 -120h-390zM50 1100h106q67 0 103 -17t66 -71l102 -212h823q21 0 35.5 -14.5t14.5 -35.5v-50q0 -21 -14 -40t-33 -26l-737 -132q-23 -4 -40 6t-26 25q-42 67 -100 67h-300q-62 0 -106 44 t-44 106v200q0 62 44 106t106 44zM173 928h-80q-19 0 -28 -14t-9 -35v-56q0 -51 42 -51h134q16 0 21.5 8t5.5 24q0 11 -16 45t-27 51q-18 28 -43 28zM550 727q-32 0 -54.5 -22.5t-22.5 -54.5t22.5 -54.5t54.5 -22.5t54.5 22.5t22.5 54.5t-22.5 54.5t-54.5 22.5zM130 389 l152 130q18 19 34 24t31 -3.5t24.5 -17.5t25.5 -28q28 -35 50.5 -51t48.5 -13l63 5l48 -179q13 -61 -3.5 -97.5t-67.5 -79.5l-80 -69q-47 -40 -109 -35.5t-103 51.5l-130 151q-40 47 -35.5 109.5t51.5 102.5zM380 377l-102 -88q-31 -27 2 -65l37 -43q13 -15 27.5 -19.5 t31.5 6.5l61 53q19 16 14 49q-2 20 -12 56t-17 45q-11 12 -19 14t-23 -8z" />
<glyph unicode="&#xe227;" d="M625 1200h150q10 0 17.5 -7.5t7.5 -17.5v-109q79 -33 131 -87.5t53 -128.5q1 -46 -15 -84.5t-39 -61t-46 -38t-39 -21.5l-17 -6q6 0 15 -1.5t35 -9t50 -17.5t53 -30t50 -45t35.5 -64t14.5 -84q0 -59 -11.5 -105.5t-28.5 -76.5t-44 -51t-49.5 -31.5t-54.5 -16t-49.5 -6.5 t-43.5 -1v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-100v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-175q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h75v600h-75q-10 0 -17.5 7.5t-7.5 17.5v150 q0 10 7.5 17.5t17.5 7.5h175v75q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-75h100v75q0 10 7.5 17.5t17.5 7.5zM400 900v-200h263q28 0 48.5 10.5t30 25t15 29t5.5 25.5l1 10q0 4 -0.5 11t-6 24t-15 30t-30 24t-48.5 11h-263zM400 500v-200h363q28 0 48.5 10.5 t30 25t15 29t5.5 25.5l1 10q0 4 -0.5 11t-6 24t-15 30t-30 24t-48.5 11h-363z" />
<glyph unicode="&#xe230;" d="M212 1198h780q86 0 147 -61t61 -147v-416q0 -51 -18 -142.5t-36 -157.5l-18 -66q-29 -87 -93.5 -146.5t-146.5 -59.5h-572q-82 0 -147 59t-93 147q-8 28 -20 73t-32 143.5t-20 149.5v416q0 86 61 147t147 61zM600 1045q-70 0 -132.5 -11.5t-105.5 -30.5t-78.5 -41.5 t-57 -45t-36 -41t-20.5 -30.5l-6 -12l156 -243h560l156 243q-2 5 -6 12.5t-20 29.5t-36.5 42t-57 44.5t-79 42t-105 29.5t-132.5 12zM762 703h-157l195 261z" />
<glyph unicode="&#xe231;" d="M475 1300h150q103 0 189 -86t86 -189v-500q0 -41 -42 -83t-83 -42h-450q-41 0 -83 42t-42 83v500q0 103 86 189t189 86zM700 300v-225q0 -21 -27 -48t-48 -27h-150q-21 0 -48 27t-27 48v225h300z" />
<glyph unicode="&#xe232;" d="M475 1300h96q0 -150 89.5 -239.5t239.5 -89.5v-446q0 -41 -42 -83t-83 -42h-450q-41 0 -83 42t-42 83v500q0 103 86 189t189 86zM700 300v-225q0 -21 -27 -48t-48 -27h-150q-21 0 -48 27t-27 48v225h300z" />
<glyph unicode="&#xe233;" d="M1294 767l-638 -283l-378 170l-78 -60v-224l100 -150v-199l-150 148l-150 -149v200l100 150v250q0 4 -0.5 10.5t0 9.5t1 8t3 8t6.5 6l47 40l-147 65l642 283zM1000 380l-350 -166l-350 166v147l350 -165l350 165v-147z" />
<glyph unicode="&#xe234;" d="M250 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM650 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM1050 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44z" />
<glyph unicode="&#xe235;" d="M550 1100q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM550 700q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM550 300q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44z" />
<glyph unicode="&#xe236;" d="M125 1100h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM125 700h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5 t17.5 7.5zM125 300h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe237;" d="M350 1200h500q162 0 256 -93.5t94 -256.5v-500q0 -165 -93.5 -257.5t-256.5 -92.5h-500q-165 0 -257.5 92.5t-92.5 257.5v500q0 165 92.5 257.5t257.5 92.5zM900 1000h-600q-41 0 -70.5 -29.5t-29.5 -70.5v-600q0 -41 29.5 -70.5t70.5 -29.5h600q41 0 70.5 29.5 t29.5 70.5v600q0 41 -29.5 70.5t-70.5 29.5zM350 900h500q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -14.5 -35.5t-35.5 -14.5h-500q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 14.5 35.5t35.5 14.5zM400 800v-200h400v200h-400z" />
<glyph unicode="&#xe238;" d="M150 1100h1000q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5 t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe239;" d="M650 1187q87 -67 118.5 -156t0 -178t-118.5 -155q-87 66 -118.5 155t0 178t118.5 156zM300 800q124 0 212 -88t88 -212q-124 0 -212 88t-88 212zM1000 800q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM300 500q124 0 212 -88t88 -212q-124 0 -212 88t-88 212z M1000 500q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM700 199v-144q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v142q40 -4 43 -4q17 0 57 6z" />
<glyph unicode="&#xe240;" d="M745 878l69 19q25 6 45 -12l298 -295q11 -11 15 -26.5t-2 -30.5q-5 -14 -18 -23.5t-28 -9.5h-8q1 0 1 -13q0 -29 -2 -56t-8.5 -62t-20 -63t-33 -53t-51 -39t-72.5 -14h-146q-184 0 -184 288q0 24 10 47q-20 4 -62 4t-63 -4q11 -24 11 -47q0 -288 -184 -288h-142 q-48 0 -84.5 21t-56 51t-32 71.5t-16 75t-3.5 68.5q0 13 2 13h-7q-15 0 -27.5 9.5t-18.5 23.5q-6 15 -2 30.5t15 25.5l298 296q20 18 46 11l76 -19q20 -5 30.5 -22.5t5.5 -37.5t-22.5 -31t-37.5 -5l-51 12l-182 -193h891l-182 193l-44 -12q-20 -5 -37.5 6t-22.5 31t6 37.5 t31 22.5z" />
<glyph unicode="&#xe241;" d="M1200 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-850q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v850h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM500 450h-25q0 15 -4 24.5t-9 14.5t-17 7.5t-20 3t-25 0.5h-100v-425q0 -11 12.5 -17.5t25.5 -7.5h12v-50h-200v50q50 0 50 25v425h-100q-17 0 -25 -0.5t-20 -3t-17 -7.5t-9 -14.5t-4 -24.5h-25v150h500v-150z" />
<glyph unicode="&#xe242;" d="M1000 300v50q-25 0 -55 32q-14 14 -25 31t-16 27l-4 11l-289 747h-69l-300 -754q-18 -35 -39 -56q-9 -9 -24.5 -18.5t-26.5 -14.5l-11 -5v-50h273v50q-49 0 -78.5 21.5t-11.5 67.5l69 176h293l61 -166q13 -34 -3.5 -66.5t-55.5 -32.5v-50h312zM412 691l134 342l121 -342 h-255zM1100 150v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h1000q21 0 35.5 -14.5t14.5 -35.5z" />
<glyph unicode="&#xe243;" d="M50 1200h1100q21 0 35.5 -14.5t14.5 -35.5v-1100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v1100q0 21 14.5 35.5t35.5 14.5zM611 1118h-70q-13 0 -18 -12l-299 -753q-17 -32 -35 -51q-18 -18 -56 -34q-12 -5 -12 -18v-50q0 -8 5.5 -14t14.5 -6 h273q8 0 14 6t6 14v50q0 8 -6 14t-14 6q-55 0 -71 23q-10 14 0 39l63 163h266l57 -153q11 -31 -6 -55q-12 -17 -36 -17q-8 0 -14 -6t-6 -14v-50q0 -8 6 -14t14 -6h313q8 0 14 6t6 14v50q0 7 -5.5 13t-13.5 7q-17 0 -42 25q-25 27 -40 63h-1l-288 748q-5 12 -19 12zM639 611 h-197l103 264z" />
<glyph unicode="&#xe244;" d="M1200 1100h-1200v100h1200v-100zM50 1000h400q21 0 35.5 -14.5t14.5 -35.5v-900q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v900q0 21 14.5 35.5t35.5 14.5zM650 1000h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM700 900v-300h300v300h-300z" />
<glyph unicode="&#xe245;" d="M50 1200h400q21 0 35.5 -14.5t14.5 -35.5v-900q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v900q0 21 14.5 35.5t35.5 14.5zM650 700h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400 q0 21 14.5 35.5t35.5 14.5zM700 600v-300h300v300h-300zM1200 0h-1200v100h1200v-100z" />
<glyph unicode="&#xe246;" d="M50 1000h400q21 0 35.5 -14.5t14.5 -35.5v-350h100v150q0 21 14.5 35.5t35.5 14.5h400q21 0 35.5 -14.5t14.5 -35.5v-150h100v-100h-100v-150q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v150h-100v-350q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5zM700 700v-300h300v300h-300z" />
<glyph unicode="&#xe247;" d="M100 0h-100v1200h100v-1200zM250 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM300 1000v-300h300v300h-300zM250 500h900q21 0 35.5 -14.5t14.5 -35.5v-400 q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe248;" d="M600 1100h150q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-150v-100h450q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5h350v100h-150q-21 0 -35.5 14.5 t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5h150v100h100v-100zM400 1000v-300h300v300h-300z" />
<glyph unicode="&#xe249;" d="M1200 0h-100v1200h100v-1200zM550 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM600 1000v-300h300v300h-300zM50 500h900q21 0 35.5 -14.5t14.5 -35.5v-400 q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe250;" d="M865 565l-494 -494q-23 -23 -41 -23q-14 0 -22 13.5t-8 38.5v1000q0 25 8 38.5t22 13.5q18 0 41 -23l494 -494q14 -14 14 -35t-14 -35z" />
<glyph unicode="&#xe251;" d="M335 635l494 494q29 29 50 20.5t21 -49.5v-1000q0 -41 -21 -49.5t-50 20.5l-494 494q-14 14 -14 35t14 35z" />
<glyph unicode="&#xe252;" d="M100 900h1000q41 0 49.5 -21t-20.5 -50l-494 -494q-14 -14 -35 -14t-35 14l-494 494q-29 29 -20.5 50t49.5 21z" />
<glyph unicode="&#xe253;" d="M635 865l494 -494q29 -29 20.5 -50t-49.5 -21h-1000q-41 0 -49.5 21t20.5 50l494 494q14 14 35 14t35 -14z" />
<glyph unicode="&#xe254;" d="M700 741v-182l-692 -323v221l413 193l-413 193v221zM1200 0h-800v200h800v-200z" />
<glyph unicode="&#xe255;" d="M1200 900h-200v-100h200v-100h-300v300h200v100h-200v100h300v-300zM0 700h50q0 21 4 37t9.5 26.5t18 17.5t22 11t28.5 5.5t31 2t37 0.5h100v-550q0 -22 -25 -34.5t-50 -13.5l-25 -2v-100h400v100q-4 0 -11 0.5t-24 3t-30 7t-24 15t-11 24.5v550h100q25 0 37 -0.5t31 -2 t28.5 -5.5t22 -11t18 -17.5t9.5 -26.5t4 -37h50v300h-800v-300z" />
<glyph unicode="&#xe256;" d="M800 700h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-100v-550q0 -22 25 -34.5t50 -14.5l25 -1v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v550h-100q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h800v-300zM1100 200h-200v-100h200v-100h-300v300h200v100h-200v100h300v-300z" />
<glyph unicode="&#xe257;" d="M701 1098h160q16 0 21 -11t-7 -23l-464 -464l464 -464q12 -12 7 -23t-21 -11h-160q-13 0 -23 9l-471 471q-7 8 -7 18t7 18l471 471q10 9 23 9z" />
<glyph unicode="&#xe258;" d="M339 1098h160q13 0 23 -9l471 -471q7 -8 7 -18t-7 -18l-471 -471q-10 -9 -23 -9h-160q-16 0 -21 11t7 23l464 464l-464 464q-12 12 -7 23t21 11z" />
<glyph unicode="&#xe259;" d="M1087 882q11 -5 11 -21v-160q0 -13 -9 -23l-471 -471q-8 -7 -18 -7t-18 7l-471 471q-9 10 -9 23v160q0 16 11 21t23 -7l464 -464l464 464q12 12 23 7z" />
<glyph unicode="&#xe260;" d="M618 993l471 -471q9 -10 9 -23v-160q0 -16 -11 -21t-23 7l-464 464l-464 -464q-12 -12 -23 -7t-11 21v160q0 13 9 23l471 471q8 7 18 7t18 -7z" />
<glyph unicode="&#xf8ff;" d="M1000 1200q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM450 1000h100q21 0 40 -14t26 -33l79 -194q5 1 16 3q34 6 54 9.5t60 7t65.5 1t61 -10t56.5 -23t42.5 -42t29 -64t5 -92t-19.5 -121.5q-1 -7 -3 -19.5t-11 -50t-20.5 -73t-32.5 -81.5t-46.5 -83t-64 -70 t-82.5 -50q-13 -5 -42 -5t-65.5 2.5t-47.5 2.5q-14 0 -49.5 -3.5t-63 -3.5t-43.5 7q-57 25 -104.5 78.5t-75 111.5t-46.5 112t-26 90l-7 35q-15 63 -18 115t4.5 88.5t26 64t39.5 43.5t52 25.5t58.5 13t62.5 2t59.5 -4.5t55.5 -8l-147 192q-12 18 -5.5 30t27.5 12z" />
<glyph unicode="&#x1f511;" d="M250 1200h600q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-150v-500l-255 -178q-19 -9 -32 -1t-13 29v650h-150q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM400 1100v-100h300v100h-300z" />
<glyph unicode="&#x1f6aa;" d="M250 1200h750q39 0 69.5 -40.5t30.5 -84.5v-933l-700 -117v950l600 125h-700v-1000h-100v1025q0 23 15.5 49t34.5 26zM500 525v-100l100 20v100z" />
</font>
</defs></svg> ) format('svg')}.glyphicon{position:relative;top:1px;display:inline-block;font-family:'Glyphicons Halflings';font-style:normal;font-weight:normal;line-height:1;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale}.glyphicon-asterisk:before{content:"\002a"}.glyphicon-plus:before{content:"\002b"}.glyphicon-euro:before,.glyphicon-eur:before{content:"\20ac"}.glyphicon-minus:before{content:"\2212"}.glyphicon-cloud:before{content:"\2601"}.glyphicon-envelope:before{content:"\2709"}.glyphicon-pencil:before{content:"\270f"}.glyphicon-glass:before{content:"\e001"}.glyphicon-music:before{content:"\e002"}.glyphicon-search:before{content:"\e003"}.glyphicon-heart:before{content:"\e005"}.glyphicon-star:before{content:"\e006"}.glyphicon-star-empty:before{content:"\e007"}.glyphicon-user:before{content:"\e008"}.glyphicon-film:before{content:"\e009"}.glyphicon-th-large:before{content:"\e010"}.glyphicon-th:before{content:"\e011"}.glyphicon-th-list:before{content:"\e012"}.glyphicon-ok:before{content:"\e013"}.glyphicon-remove:before{content:"\e014"}.glyphicon-zoom-in:before{content:"\e015"}.glyphicon-zoom-out:before{content:"\e016"}.glyphicon-off:before{content:"\e017"}.glyphicon-signal:before{content:"\e018"}.glyphicon-cog:before{content:"\e019"}.glyphicon-trash:before{content:"\e020"}.glyphicon-home:before{content:"\e021"}.glyphicon-file:before{content:"\e022"}.glyphicon-time:before{content:"\e023"}.glyphicon-road:before{content:"\e024"}.glyphicon-download-alt:before{content:"\e025"}.glyphicon-download:before{content:"\e026"}.glyphicon-upload:before{content:"\e027"}.glyphicon-inbox:before{content:"\e028"}.glyphicon-play-circle:before{content:"\e029"}.glyphicon-repeat:before{content:"\e030"}.glyphicon-refresh:before{content:"\e031"}.glyphicon-list-alt:before{content:"\e032"}.glyphicon-lock:before{content:"\e033"}.glyphicon-flag:before{content:"\e034"}.glyphicon-headphones:before{content:"\e035"}.glyphicon-volume-off:before{content:"\e036"}.glyphicon-volume-down:before{content:"\e037"}.glyphicon-volume-up:before{content:"\e038"}.glyphicon-qrcode:before{content:"\e039"}.glyphicon-barcode:before{content:"\e040"}.glyphicon-tag:before{content:"\e041"}.glyphicon-tags:before{content:"\e042"}.glyphicon-book:before{content:"\e043"}.glyphicon-bookmark:before{content:"\e044"}.glyphicon-print:before{content:"\e045"}.glyphicon-camera:before{content:"\e046"}.glyphicon-font:before{content:"\e047"}.glyphicon-bold:before{content:"\e048"}.glyphicon-italic:before{content:"\e049"}.glyphicon-text-height:before{content:"\e050"}.glyphicon-text-width:before{content:"\e051"}.glyphicon-align-left:before{content:"\e052"}.glyphicon-align-center:before{content:"\e053"}.glyphicon-align-right:before{content:"\e054"}.glyphicon-align-justify:before{content:"\e055"}.glyphicon-list:before{content:"\e056"}.glyphicon-indent-left:before{content:"\e057"}.glyphicon-indent-right:before{content:"\e058"}.glyphicon-facetime-video:before{content:"\e059"}.glyphicon-picture:before{content:"\e060"}.glyphicon-map-marker:before{content:"\e062"}.glyphicon-adjust:before{content:"\e063"}.glyphicon-tint:before{content:"\e064"}.glyphicon-edit:before{content:"\e065"}.glyphicon-share:before{content:"\e066"}.glyphicon-check:before{content:"\e067"}.glyphicon-move:before{content:"\e068"}.glyphicon-step-backward:before{content:"\e069"}.glyphicon-fast-backward:before{content:"\e070"}.glyphicon-backward:before{content:"\e071"}.glyphicon-play:before{content:"\e072"}.glyphicon-pause:before{content:"\e073"}.glyphicon-stop:before{content:"\e074"}.glyphicon-forward:before{content:"\e075"}.glyphicon-fast-forward:before{content:"\e076"}.glyphicon-step-forward:before{content:"\e077"}.glyphicon-eject:before{content:"\e078"}.glyphicon-chevron-left:before{content:"\e079"}.glyphicon-chevron-right:before{content:"\e080"}.glyphicon-plus-sign:before{content:"\e081"}.glyphicon-minus-sign:before{content:"\e082"}.glyphicon-remove-sign:before{content:"\e083"}.glyphicon-ok-sign:before{content:"\e084"}.glyphicon-question-sign:before{content:"\e085"}.glyphicon-info-sign:before{content:"\e086"}.glyphicon-screenshot:before{content:"\e087"}.glyphicon-remove-circle:before{content:"\e088"}.glyphicon-ok-circle:before{content:"\e089"}.glyphicon-ban-circle:before{content:"\e090"}.glyphicon-arrow-left:before{content:"\e091"}.glyphicon-arrow-right:before{content:"\e092"}.glyphicon-arrow-up:before{content:"\e093"}.glyphicon-arrow-down:before{content:"\e094"}.glyphicon-share-alt:before{content:"\e095"}.glyphicon-resize-full:before{content:"\e096"}.glyphicon-resize-small:before{content:"\e097"}.glyphicon-exclamation-sign:before{content:"\e101"}.glyphicon-gift:before{content:"\e102"}.glyphicon-leaf:before{content:"\e103"}.glyphicon-fire:before{content:"\e104"}.glyphicon-eye-open:before{content:"\e105"}.glyphicon-eye-close:before{content:"\e106"}.glyphicon-warning-sign:before{content:"\e107"}.glyphicon-plane:before{content:"\e108"}.glyphicon-calendar:before{content:"\e109"}.glyphicon-random:before{content:"\e110"}.glyphicon-comment:before{content:"\e111"}.glyphicon-magnet:before{content:"\e112"}.glyphicon-chevron-up:before{content:"\e113"}.glyphicon-chevron-down:before{content:"\e114"}.glyphicon-retweet:before{content:"\e115"}.glyphicon-shopping-cart:before{content:"\e116"}.glyphicon-folder-close:before{content:"\e117"}.glyphicon-folder-open:before{content:"\e118"}.glyphicon-resize-vertical:before{content:"\e119"}.glyphicon-resize-horizontal:before{content:"\e120"}.glyphicon-hdd:before{content:"\e121"}.glyphicon-bullhorn:before{content:"\e122"}.glyphicon-bell:before{content:"\e123"}.glyphicon-certificate:before{content:"\e124"}.glyphicon-thumbs-up:before{content:"\e125"}.glyphicon-thumbs-down:before{content:"\e126"}.glyphicon-hand-right:before{content:"\e127"}.glyphicon-hand-left:before{content:"\e128"}.glyphicon-hand-up:before{content:"\e129"}.glyphicon-hand-down:before{content:"\e130"}.glyphicon-circle-arrow-right:before{content:"\e131"}.glyphicon-circle-arrow-left:before{content:"\e132"}.glyphicon-circle-arrow-up:before{content:"\e133"}.glyphicon-circle-arrow-down:before{content:"\e134"}.glyphicon-globe:before{content:"\e135"}.glyphicon-wrench:before{content:"\e136"}.glyphicon-tasks:before{content:"\e137"}.glyphicon-filter:before{content:"\e138"}.glyphicon-briefcase:before{content:"\e139"}.glyphicon-fullscreen:before{content:"\e140"}.glyphicon-dashboard:before{content:"\e141"}.glyphicon-paperclip:before{content:"\e142"}.glyphicon-heart-empty:before{content:"\e143"}.glyphicon-link:before{content:"\e144"}.glyphicon-phone:before{content:"\e145"}.glyphicon-pushpin:before{content:"\e146"}.glyphicon-usd:before{content:"\e148"}.glyphicon-gbp:before{content:"\e149"}.glyphicon-sort:before{content:"\e150"}.glyphicon-sort-by-alphabet:before{content:"\e151"}.glyphicon-sort-by-alphabet-alt:before{content:"\e152"}.glyphicon-sort-by-order:before{content:"\e153"}.glyphicon-sort-by-order-alt:before{content:"\e154"}.glyphicon-sort-by-attributes:before{content:"\e155"}.glyphicon-sort-by-attributes-alt:before{content:"\e156"}.glyphicon-unchecked:before{content:"\e157"}.glyphicon-expand:before{content:"\e158"}.glyphicon-collapse-down:before{content:"\e159"}.glyphicon-collapse-up:before{content:"\e160"}.glyphicon-log-in:before{content:"\e161"}.glyphicon-flash:before{content:"\e162"}.glyphicon-log-out:before{content:"\e163"}.glyphicon-new-window:before{content:"\e164"}.glyphicon-record:before{content:"\e165"}.glyphicon-save:before{content:"\e166"}.glyphicon-open:before{content:"\e167"}.glyphicon-saved:before{content:"\e168"}.glyphicon-import:before{content:"\e169"}.glyphicon-export:before{content:"\e170"}.glyphicon-send:before{content:"\e171"}.glyphicon-floppy-disk:before{content:"\e172"}.glyphicon-floppy-saved:before{content:"\e173"}.glyphicon-floppy-remove:before{content:"\e174"}.glyphicon-floppy-save:before{content:"\e175"}.glyphicon-floppy-open:before{content:"\e176"}.glyphicon-credit-card:before{content:"\e177"}.glyphicon-transfer:before{content:"\e178"}.glyphicon-cutlery:before{content:"\e179"}.glyphicon-header:before{content:"\e180"}.glyphicon-compressed:before{content:"\e181"}.glyphicon-earphone:before{content:"\e182"}.glyphicon-phone-alt:before{content:"\e183"}.glyphicon-tower:before{content:"\e184"}.glyphicon-stats:before{content:"\e185"}.glyphicon-sd-video:before{content:"\e186"}.glyphicon-hd-video:before{content:"\e187"}.glyphicon-subtitles:before{content:"\e188"}.glyphicon-sound-stereo:before{content:"\e189"}.glyphicon-sound-dolby:before{content:"\e190"}.glyphicon-sound-5-1:before{content:"\e191"}.glyphicon-sound-6-1:before{content:"\e192"}.glyphicon-sound-7-1:before{content:"\e193"}.glyphicon-copyright-mark:before{content:"\e194"}.glyphicon-registration-mark:before{content:"\e195"}.glyphicon-cloud-download:before{content:"\e197"}.glyphicon-cloud-upload:before{content:"\e198"}.glyphicon-tree-conifer:before{content:"\e199"}.glyphicon-tree-deciduous:before{content:"\e200"}.glyphicon-cd:before{content:"\e201"}.glyphicon-save-file:before{content:"\e202"}.glyphicon-open-file:before{content:"\e203"}.glyphicon-level-up:before{content:"\e204"}.glyphicon-copy:before{content:"\e205"}.glyphicon-paste:before{content:"\e206"}.glyphicon-alert:before{content:"\e209"}.glyphicon-equalizer:before{content:"\e210"}.glyphicon-king:before{content:"\e211"}.glyphicon-queen:before{content:"\e212"}.glyphicon-pawn:before{content:"\e213"}.glyphicon-bishop:before{content:"\e214"}.glyphicon-knight:before{content:"\e215"}.glyphicon-baby-formula:before{content:"\e216"}.glyphicon-tent:before{content:"\26fa"}.glyphicon-blackboard:before{content:"\e218"}.glyphicon-bed:before{content:"\e219"}.glyphicon-apple:before{content:"\f8ff"}.glyphicon-erase:before{content:"\e221"}.glyphicon-hourglass:before{content:"\231b"}.glyphicon-lamp:before{content:"\e223"}.glyphicon-duplicate:before{content:"\e224"}.glyphicon-piggy-bank:before{content:"\e225"}.glyphicon-scissors:before{content:"\e226"}.glyphicon-bitcoin:before{content:"\e227"}.glyphicon-btc:before{content:"\e227"}.glyphicon-xbt:before{content:"\e227"}.glyphicon-yen:before{content:"\00a5"}.glyphicon-jpy:before{content:"\00a5"}.glyphicon-ruble:before{content:"\20bd"}.glyphicon-rub:before{content:"\20bd"}.glyphicon-scale:before{content:"\e230"}.glyphicon-ice-lolly:before{content:"\e231"}.glyphicon-ice-lolly-tasted:before{content:"\e232"}.glyphicon-education:before{content:"\e233"}.glyphicon-option-horizontal:before{content:"\e234"}.glyphicon-option-vertical:before{content:"\e235"}.glyphicon-menu-hamburger:before{content:"\e236"}.glyphicon-modal-window:before{content:"\e237"}.glyphicon-oil:before{content:"\e238"}.glyphicon-grain:before{content:"\e239"}.glyphicon-sunglasses:before{content:"\e240"}.glyphicon-text-size:before{content:"\e241"}.glyphicon-text-color:before{content:"\e242"}.glyphicon-text-background:before{content:"\e243"}.glyphicon-object-align-top:before{content:"\e244"}.glyphicon-object-align-bottom:before{content:"\e245"}.glyphicon-object-align-horizontal:before{content:"\e246"}.glyphicon-object-align-left:before{content:"\e247"}.glyphicon-object-align-vertical:before{content:"\e248"}.glyphicon-object-align-right:before{content:"\e249"}.glyphicon-triangle-right:before{content:"\e250"}.glyphicon-triangle-left:before{content:"\e251"}.glyphicon-triangle-bottom:before{content:"\e252"}.glyphicon-triangle-top:before{content:"\e253"}.glyphicon-console:before{content:"\e254"}.glyphicon-superscript:before{content:"\e255"}.glyphicon-subscript:before{content:"\e256"}.glyphicon-menu-left:before{content:"\e257"}.glyphicon-menu-right:before{content:"\e258"}.glyphicon-menu-down:before{content:"\e259"}.glyphicon-menu-up:before{content:"\e260"}*{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}*:before,*:after{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}html{font-size:10px;-webkit-tap-highlight-color:rgba(0,0,0,0)}body{font-family:"Roboto","Helvetica Neue",Helvetica,Arial,sans-serif;font-size:13px;line-height:1.846;color:#666666;background-color:#ffffff}input,button,select,textarea{font-family:inherit;font-size:inherit;line-height:inherit}a{color:#2196f3;text-decoration:none}a:hover,a:focus{color:#0a6ebd;text-decoration:underline}a:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}figure{margin:0}img{vertical-align:middle}.img-responsive,.thumbnail>img,.thumbnail a>img,.carousel-inner>.item>img,.carousel-inner>.item>a>img{display:block;max-width:100%;height:auto}.img-rounded{border-radius:3px}.img-thumbnail{padding:4px;line-height:1.846;background-color:#ffffff;border:1px solid #dddddd;border-radius:3px;-webkit-transition:all .2s ease-in-out;-o-transition:all .2s ease-in-out;transition:all .2s ease-in-out;display:inline-block;max-width:100%;height:auto}.img-circle{border-radius:50%}hr{margin-top:23px;margin-bottom:23px;border:0;border-top:1px solid #eeeeee}.sr-only{position:absolute;width:1px;height:1px;margin:-1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);border:0}.sr-only-focusable:active,.sr-only-focusable:focus{position:static;width:auto;height:auto;margin:0;overflow:visible;clip:auto}[role="button"]{cursor:pointer}h1,h2,h3,h4,h5,h6,.h1,.h2,.h3,.h4,.h5,.h6{font-family:inherit;font-weight:400;line-height:1.1;color:#444444}h1 small,h2 small,h3 small,h4 small,h5 small,h6 small,.h1 small,.h2 small,.h3 small,.h4 small,.h5 small,.h6 small,h1 .small,h2 .small,h3 .small,h4 .small,h5 .small,h6 .small,.h1 .small,.h2 .small,.h3 .small,.h4 .small,.h5 .small,.h6 .small{font-weight:normal;line-height:1;color:#bbbbbb}h1,.h1,h2,.h2,h3,.h3{margin-top:23px;margin-bottom:11.5px}h1 small,.h1 small,h2 small,.h2 small,h3 small,.h3 small,h1 .small,.h1 .small,h2 .small,.h2 .small,h3 .small,.h3 .small{font-size:65%}h4,.h4,h5,.h5,h6,.h6{margin-top:11.5px;margin-bottom:11.5px}h4 small,.h4 small,h5 small,.h5 small,h6 small,.h6 small,h4 .small,.h4 .small,h5 .small,.h5 .small,h6 .small,.h6 .small{font-size:75%}h1,.h1{font-size:56px}h2,.h2{font-size:45px}h3,.h3{font-size:34px}h4,.h4{font-size:24px}h5,.h5{font-size:20px}h6,.h6{font-size:14px}p{margin:0 0 11.5px}.lead{margin-bottom:23px;font-size:14px;font-weight:300;line-height:1.4}@media (min-width:768px){.lead{font-size:19.5px}}small,.small{font-size:92%}mark,.mark{background-color:#ffe0b2;padding:.2em}.text-left{text-align:left}.text-right{text-align:right}.text-center{text-align:center}.text-justify{text-align:justify}.text-nowrap{white-space:nowrap}.text-lowercase{text-transform:lowercase}.text-uppercase{text-transform:uppercase}.text-capitalize{text-transform:capitalize}.text-muted{color:#bbbbbb}.text-primary{color:#2196f3}a.text-primary:hover,a.text-primary:focus{color:#0c7cd5}.text-success{color:#4caf50}a.text-success:hover,a.text-success:focus{color:#3d8b40}.text-info{color:#9c27b0}a.text-info:hover,a.text-info:focus{color:#771e86}.text-warning{color:#ff9800}a.text-warning:hover,a.text-warning:focus{color:#cc7a00}.text-danger{color:#e51c23}a.text-danger:hover,a.text-danger:focus{color:#b9151b}.bg-primary{color:#fff;background-color:#2196f3}a.bg-primary:hover,a.bg-primary:focus{background-color:#0c7cd5}.bg-success{background-color:#dff0d8}a.bg-success:hover,a.bg-success:focus{background-color:#c1e2b3}.bg-info{background-color:#e1bee7}a.bg-info:hover,a.bg-info:focus{background-color:#d099d9}.bg-warning{background-color:#ffe0b2}a.bg-warning:hover,a.bg-warning:focus{background-color:#ffcb7f}.bg-danger{background-color:#f9bdbb}a.bg-danger:hover,a.bg-danger:focus{background-color:#f5908c}.page-header{padding-bottom:10.5px;margin:46px 0 23px;border-bottom:1px solid #eeeeee}ul,ol{margin-top:0;margin-bottom:11.5px}ul ul,ol ul,ul ol,ol ol{margin-bottom:0}.list-unstyled{padding-left:0;list-style:none}.list-inline{padding-left:0;list-style:none;margin-left:-5px}.list-inline>li{display:inline-block;padding-left:5px;padding-right:5px}dl{margin-top:0;margin-bottom:23px}dt,dd{line-height:1.846}dt{font-weight:bold}dd{margin-left:0}@media (min-width:768px){.dl-horizontal dt{float:left;width:160px;clear:left;text-align:right;overflow:hidden;text-overflow:ellipsis;white-space:nowrap}.dl-horizontal dd{margin-left:180px}}abbr[title],abbr[data-original-title]{cursor:help;border-bottom:1px dotted #bbbbbb}.initialism{font-size:90%;text-transform:uppercase}blockquote{padding:11.5px 23px;margin:0 0 23px;font-size:16.25px;border-left:5px solid #eeeeee}blockquote p:last-child,blockquote ul:last-child,blockquote ol:last-child{margin-bottom:0}blockquote footer,blockquote small,blockquote .small{display:block;font-size:80%;line-height:1.846;color:#bbbbbb}blockquote footer:before,blockquote small:before,blockquote .small:before{content:'\2014 \00A0'}.blockquote-reverse,blockquote.pull-right{padding-right:15px;padding-left:0;border-right:5px solid #eeeeee;border-left:0;text-align:right}.blockquote-reverse footer:before,blockquote.pull-right footer:before,.blockquote-reverse small:before,blockquote.pull-right small:before,.blockquote-reverse .small:before,blockquote.pull-right .small:before{content:''}.blockquote-reverse footer:after,blockquote.pull-right footer:after,.blockquote-reverse small:after,blockquote.pull-right small:after,.blockquote-reverse .small:after,blockquote.pull-right .small:after{content:'\00A0 \2014'}address{margin-bottom:23px;font-style:normal;line-height:1.846}code,kbd,pre,samp{font-family:monospace}code{padding:2px 4px;font-size:90%;color:#c7254e;background-color:#f9f2f4;border-radius:3px}kbd{padding:2px 4px;font-size:90%;color:#ffffff;background-color:#333333;border-radius:3px;-webkit-box-shadow:inset 0 -1px 0 rgba(0,0,0,0.25);box-shadow:inset 0 -1px 0 rgba(0,0,0,0.25)}kbd kbd{padding:0;font-size:100%;font-weight:bold;-webkit-box-shadow:none;box-shadow:none}pre{display:block;padding:11px;margin:0 0 11.5px;font-size:12px;line-height:1.846;word-break:break-all;word-wrap:break-word;color:#212121;background-color:#f5f5f5;border:1px solid #cccccc;border-radius:3px}pre code{padding:0;font-size:inherit;color:inherit;white-space:pre-wrap;background-color:transparent;border-radius:0}.pre-scrollable{max-height:340px;overflow-y:scroll}.container{margin-right:auto;margin-left:auto;padding-left:15px;padding-right:15px}@media (min-width:768px){.container{width:750px}}@media (min-width:992px){.container{width:970px}}@media (min-width:1200px){.container{width:1170px}}.container-fluid{margin-right:auto;margin-left:auto;padding-left:15px;padding-right:15px}.row{margin-left:-15px;margin-right:-15px}.col-xs-1,.col-sm-1,.col-md-1,.col-lg-1,.col-xs-2,.col-sm-2,.col-md-2,.col-lg-2,.col-xs-3,.col-sm-3,.col-md-3,.col-lg-3,.col-xs-4,.col-sm-4,.col-md-4,.col-lg-4,.col-xs-5,.col-sm-5,.col-md-5,.col-lg-5,.col-xs-6,.col-sm-6,.col-md-6,.col-lg-6,.col-xs-7,.col-sm-7,.col-md-7,.col-lg-7,.col-xs-8,.col-sm-8,.col-md-8,.col-lg-8,.col-xs-9,.col-sm-9,.col-md-9,.col-lg-9,.col-xs-10,.col-sm-10,.col-md-10,.col-lg-10,.col-xs-11,.col-sm-11,.col-md-11,.col-lg-11,.col-xs-12,.col-sm-12,.col-md-12,.col-lg-12{position:relative;min-height:1px;padding-left:15px;padding-right:15px}.col-xs-1,.col-xs-2,.col-xs-3,.col-xs-4,.col-xs-5,.col-xs-6,.col-xs-7,.col-xs-8,.col-xs-9,.col-xs-10,.col-xs-11,.col-xs-12{float:left}.col-xs-12{width:100%}.col-xs-11{width:91.66666667%}.col-xs-10{width:83.33333333%}.col-xs-9{width:75%}.col-xs-8{width:66.66666667%}.col-xs-7{width:58.33333333%}.col-xs-6{width:50%}.col-xs-5{width:41.66666667%}.col-xs-4{width:33.33333333%}.col-xs-3{width:25%}.col-xs-2{width:16.66666667%}.col-xs-1{width:8.33333333%}.col-xs-pull-12{right:100%}.col-xs-pull-11{right:91.66666667%}.col-xs-pull-10{right:83.33333333%}.col-xs-pull-9{right:75%}.col-xs-pull-8{right:66.66666667%}.col-xs-pull-7{right:58.33333333%}.col-xs-pull-6{right:50%}.col-xs-pull-5{right:41.66666667%}.col-xs-pull-4{right:33.33333333%}.col-xs-pull-3{right:25%}.col-xs-pull-2{right:16.66666667%}.col-xs-pull-1{right:8.33333333%}.col-xs-pull-0{right:auto}.col-xs-push-12{left:100%}.col-xs-push-11{left:91.66666667%}.col-xs-push-10{left:83.33333333%}.col-xs-push-9{left:75%}.col-xs-push-8{left:66.66666667%}.col-xs-push-7{left:58.33333333%}.col-xs-push-6{left:50%}.col-xs-push-5{left:41.66666667%}.col-xs-push-4{left:33.33333333%}.col-xs-push-3{left:25%}.col-xs-push-2{left:16.66666667%}.col-xs-push-1{left:8.33333333%}.col-xs-push-0{left:auto}.col-xs-offset-12{margin-left:100%}.col-xs-offset-11{margin-left:91.66666667%}.col-xs-offset-10{margin-left:83.33333333%}.col-xs-offset-9{margin-left:75%}.col-xs-offset-8{margin-left:66.66666667%}.col-xs-offset-7{margin-left:58.33333333%}.col-xs-offset-6{margin-left:50%}.col-xs-offset-5{margin-left:41.66666667%}.col-xs-offset-4{margin-left:33.33333333%}.col-xs-offset-3{margin-left:25%}.col-xs-offset-2{margin-left:16.66666667%}.col-xs-offset-1{margin-left:8.33333333%}.col-xs-offset-0{margin-left:0%}@media (min-width:768px){.col-sm-1,.col-sm-2,.col-sm-3,.col-sm-4,.col-sm-5,.col-sm-6,.col-sm-7,.col-sm-8,.col-sm-9,.col-sm-10,.col-sm-11,.col-sm-12{float:left}.col-sm-12{width:100%}.col-sm-11{width:91.66666667%}.col-sm-10{width:83.33333333%}.col-sm-9{width:75%}.col-sm-8{width:66.66666667%}.col-sm-7{width:58.33333333%}.col-sm-6{width:50%}.col-sm-5{width:41.66666667%}.col-sm-4{width:33.33333333%}.col-sm-3{width:25%}.col-sm-2{width:16.66666667%}.col-sm-1{width:8.33333333%}.col-sm-pull-12{right:100%}.col-sm-pull-11{right:91.66666667%}.col-sm-pull-10{right:83.33333333%}.col-sm-pull-9{right:75%}.col-sm-pull-8{right:66.66666667%}.col-sm-pull-7{right:58.33333333%}.col-sm-pull-6{right:50%}.col-sm-pull-5{right:41.66666667%}.col-sm-pull-4{right:33.33333333%}.col-sm-pull-3{right:25%}.col-sm-pull-2{right:16.66666667%}.col-sm-pull-1{right:8.33333333%}.col-sm-pull-0{right:auto}.col-sm-push-12{left:100%}.col-sm-push-11{left:91.66666667%}.col-sm-push-10{left:83.33333333%}.col-sm-push-9{left:75%}.col-sm-push-8{left:66.66666667%}.col-sm-push-7{left:58.33333333%}.col-sm-push-6{left:50%}.col-sm-push-5{left:41.66666667%}.col-sm-push-4{left:33.33333333%}.col-sm-push-3{left:25%}.col-sm-push-2{left:16.66666667%}.col-sm-push-1{left:8.33333333%}.col-sm-push-0{left:auto}.col-sm-offset-12{margin-left:100%}.col-sm-offset-11{margin-left:91.66666667%}.col-sm-offset-10{margin-left:83.33333333%}.col-sm-offset-9{margin-left:75%}.col-sm-offset-8{margin-left:66.66666667%}.col-sm-offset-7{margin-left:58.33333333%}.col-sm-offset-6{margin-left:50%}.col-sm-offset-5{margin-left:41.66666667%}.col-sm-offset-4{margin-left:33.33333333%}.col-sm-offset-3{margin-left:25%}.col-sm-offset-2{margin-left:16.66666667%}.col-sm-offset-1{margin-left:8.33333333%}.col-sm-offset-0{margin-left:0%}}@media (min-width:992px){.col-md-1,.col-md-2,.col-md-3,.col-md-4,.col-md-5,.col-md-6,.col-md-7,.col-md-8,.col-md-9,.col-md-10,.col-md-11,.col-md-12{float:left}.col-md-12{width:100%}.col-md-11{width:91.66666667%}.col-md-10{width:83.33333333%}.col-md-9{width:75%}.col-md-8{width:66.66666667%}.col-md-7{width:58.33333333%}.col-md-6{width:50%}.col-md-5{width:41.66666667%}.col-md-4{width:33.33333333%}.col-md-3{width:25%}.col-md-2{width:16.66666667%}.col-md-1{width:8.33333333%}.col-md-pull-12{right:100%}.col-md-pull-11{right:91.66666667%}.col-md-pull-10{right:83.33333333%}.col-md-pull-9{right:75%}.col-md-pull-8{right:66.66666667%}.col-md-pull-7{right:58.33333333%}.col-md-pull-6{right:50%}.col-md-pull-5{right:41.66666667%}.col-md-pull-4{right:33.33333333%}.col-md-pull-3{right:25%}.col-md-pull-2{right:16.66666667%}.col-md-pull-1{right:8.33333333%}.col-md-pull-0{right:auto}.col-md-push-12{left:100%}.col-md-push-11{left:91.66666667%}.col-md-push-10{left:83.33333333%}.col-md-push-9{left:75%}.col-md-push-8{left:66.66666667%}.col-md-push-7{left:58.33333333%}.col-md-push-6{left:50%}.col-md-push-5{left:41.66666667%}.col-md-push-4{left:33.33333333%}.col-md-push-3{left:25%}.col-md-push-2{left:16.66666667%}.col-md-push-1{left:8.33333333%}.col-md-push-0{left:auto}.col-md-offset-12{margin-left:100%}.col-md-offset-11{margin-left:91.66666667%}.col-md-offset-10{margin-left:83.33333333%}.col-md-offset-9{margin-left:75%}.col-md-offset-8{margin-left:66.66666667%}.col-md-offset-7{margin-left:58.33333333%}.col-md-offset-6{margin-left:50%}.col-md-offset-5{margin-left:41.66666667%}.col-md-offset-4{margin-left:33.33333333%}.col-md-offset-3{margin-left:25%}.col-md-offset-2{margin-left:16.66666667%}.col-md-offset-1{margin-left:8.33333333%}.col-md-offset-0{margin-left:0%}}@media (min-width:1200px){.col-lg-1,.col-lg-2,.col-lg-3,.col-lg-4,.col-lg-5,.col-lg-6,.col-lg-7,.col-lg-8,.col-lg-9,.col-lg-10,.col-lg-11,.col-lg-12{float:left}.col-lg-12{width:100%}.col-lg-11{width:91.66666667%}.col-lg-10{width:83.33333333%}.col-lg-9{width:75%}.col-lg-8{width:66.66666667%}.col-lg-7{width:58.33333333%}.col-lg-6{width:50%}.col-lg-5{width:41.66666667%}.col-lg-4{width:33.33333333%}.col-lg-3{width:25%}.col-lg-2{width:16.66666667%}.col-lg-1{width:8.33333333%}.col-lg-pull-12{right:100%}.col-lg-pull-11{right:91.66666667%}.col-lg-pull-10{right:83.33333333%}.col-lg-pull-9{right:75%}.col-lg-pull-8{right:66.66666667%}.col-lg-pull-7{right:58.33333333%}.col-lg-pull-6{right:50%}.col-lg-pull-5{right:41.66666667%}.col-lg-pull-4{right:33.33333333%}.col-lg-pull-3{right:25%}.col-lg-pull-2{right:16.66666667%}.col-lg-pull-1{right:8.33333333%}.col-lg-pull-0{right:auto}.col-lg-push-12{left:100%}.col-lg-push-11{left:91.66666667%}.col-lg-push-10{left:83.33333333%}.col-lg-push-9{left:75%}.col-lg-push-8{left:66.66666667%}.col-lg-push-7{left:58.33333333%}.col-lg-push-6{left:50%}.col-lg-push-5{left:41.66666667%}.col-lg-push-4{left:33.33333333%}.col-lg-push-3{left:25%}.col-lg-push-2{left:16.66666667%}.col-lg-push-1{left:8.33333333%}.col-lg-push-0{left:auto}.col-lg-offset-12{margin-left:100%}.col-lg-offset-11{margin-left:91.66666667%}.col-lg-offset-10{margin-left:83.33333333%}.col-lg-offset-9{margin-left:75%}.col-lg-offset-8{margin-left:66.66666667%}.col-lg-offset-7{margin-left:58.33333333%}.col-lg-offset-6{margin-left:50%}.col-lg-offset-5{margin-left:41.66666667%}.col-lg-offset-4{margin-left:33.33333333%}.col-lg-offset-3{margin-left:25%}.col-lg-offset-2{margin-left:16.66666667%}.col-lg-offset-1{margin-left:8.33333333%}.col-lg-offset-0{margin-left:0%}}table{background-color:transparent}caption{padding-top:8px;padding-bottom:8px;color:#bbbbbb;text-align:left}th{}.table{width:100%;max-width:100%;margin-bottom:23px}.table>thead>tr>th,.table>tbody>tr>th,.table>tfoot>tr>th,.table>thead>tr>td,.table>tbody>tr>td,.table>tfoot>tr>td{padding:8px;line-height:1.846;vertical-align:top;border-top:1px solid #dddddd}.table>thead>tr>th{vertical-align:bottom;border-bottom:2px solid #dddddd}.table>caption+thead>tr:first-child>th,.table>colgroup+thead>tr:first-child>th,.table>thead:first-child>tr:first-child>th,.table>caption+thead>tr:first-child>td,.table>colgroup+thead>tr:first-child>td,.table>thead:first-child>tr:first-child>td{border-top:0}.table>tbody+tbody{border-top:2px solid #dddddd}.table .table{background-color:#ffffff}.table-condensed>thead>tr>th,.table-condensed>tbody>tr>th,.table-condensed>tfoot>tr>th,.table-condensed>thead>tr>td,.table-condensed>tbody>tr>td,.table-condensed>tfoot>tr>td{padding:5px}.table-bordered{border:1px solid #dddddd}.table-bordered>thead>tr>th,.table-bordered>tbody>tr>th,.table-bordered>tfoot>tr>th,.table-bordered>thead>tr>td,.table-bordered>tbody>tr>td,.table-bordered>tfoot>tr>td{border:1px solid #dddddd}.table-bordered>thead>tr>th,.table-bordered>thead>tr>td{border-bottom-width:2px}.table-striped>tbody>tr:nth-of-type(odd){background-color:#f9f9f9}.table-hover>tbody>tr:hover{background-color:#f5f5f5}table col[class*="col-"]{position:static;float:none;display:table-column}table td[class*="col-"],table th[class*="col-"]{position:static;float:none;display:table-cell}.table>thead>tr>td.active,.table>tbody>tr>td.active,.table>tfoot>tr>td.active,.table>thead>tr>th.active,.table>tbody>tr>th.active,.table>tfoot>tr>th.active,.table>thead>tr.active>td,.table>tbody>tr.active>td,.table>tfoot>tr.active>td,.table>thead>tr.active>th,.table>tbody>tr.active>th,.table>tfoot>tr.active>th{background-color:#f5f5f5}.table-hover>tbody>tr>td.active:hover,.table-hover>tbody>tr>th.active:hover,.table-hover>tbody>tr.active:hover>td,.table-hover>tbody>tr:hover>.active,.table-hover>tbody>tr.active:hover>th{background-color:#e8e8e8}.table>thead>tr>td.success,.table>tbody>tr>td.success,.table>tfoot>tr>td.success,.table>thead>tr>th.success,.table>tbody>tr>th.success,.table>tfoot>tr>th.success,.table>thead>tr.success>td,.table>tbody>tr.success>td,.table>tfoot>tr.success>td,.table>thead>tr.success>th,.table>tbody>tr.success>th,.table>tfoot>tr.success>th{background-color:#dff0d8}.table-hover>tbody>tr>td.success:hover,.table-hover>tbody>tr>th.success:hover,.table-hover>tbody>tr.success:hover>td,.table-hover>tbody>tr:hover>.success,.table-hover>tbody>tr.success:hover>th{background-color:#d0e9c6}.table>thead>tr>td.info,.table>tbody>tr>td.info,.table>tfoot>tr>td.info,.table>thead>tr>th.info,.table>tbody>tr>th.info,.table>tfoot>tr>th.info,.table>thead>tr.info>td,.table>tbody>tr.info>td,.table>tfoot>tr.info>td,.table>thead>tr.info>th,.table>tbody>tr.info>th,.table>tfoot>tr.info>th{background-color:#e1bee7}.table-hover>tbody>tr>td.info:hover,.table-hover>tbody>tr>th.info:hover,.table-hover>tbody>tr.info:hover>td,.table-hover>tbody>tr:hover>.info,.table-hover>tbody>tr.info:hover>th{background-color:#d8abe0}.table>thead>tr>td.warning,.table>tbody>tr>td.warning,.table>tfoot>tr>td.warning,.table>thead>tr>th.warning,.table>tbody>tr>th.warning,.table>tfoot>tr>th.warning,.table>thead>tr.warning>td,.table>tbody>tr.warning>td,.table>tfoot>tr.warning>td,.table>thead>tr.warning>th,.table>tbody>tr.warning>th,.table>tfoot>tr.warning>th{background-color:#ffe0b2}.table-hover>tbody>tr>td.warning:hover,.table-hover>tbody>tr>th.warning:hover,.table-hover>tbody>tr.warning:hover>td,.table-hover>tbody>tr:hover>.warning,.table-hover>tbody>tr.warning:hover>th{background-color:#ffd699}.table>thead>tr>td.danger,.table>tbody>tr>td.danger,.table>tfoot>tr>td.danger,.table>thead>tr>th.danger,.table>tbody>tr>th.danger,.table>tfoot>tr>th.danger,.table>thead>tr.danger>td,.table>tbody>tr.danger>td,.table>tfoot>tr.danger>td,.table>thead>tr.danger>th,.table>tbody>tr.danger>th,.table>tfoot>tr.danger>th{background-color:#f9bdbb}.table-hover>tbody>tr>td.danger:hover,.table-hover>tbody>tr>th.danger:hover,.table-hover>tbody>tr.danger:hover>td,.table-hover>tbody>tr:hover>.danger,.table-hover>tbody>tr.danger:hover>th{background-color:#f7a6a4}.table-responsive{overflow-x:auto;min-height:0.01%}@media screen and (max-width:767px){.table-responsive{width:100%;margin-bottom:17.25px;overflow-y:hidden;-ms-overflow-style:-ms-autohiding-scrollbar;border:1px solid #dddddd}.table-responsive>.table{margin-bottom:0}.table-responsive>.table>thead>tr>th,.table-responsive>.table>tbody>tr>th,.table-responsive>.table>tfoot>tr>th,.table-responsive>.table>thead>tr>td,.table-responsive>.table>tbody>tr>td,.table-responsive>.table>tfoot>tr>td{white-space:nowrap}.table-responsive>.table-bordered{border:0}.table-responsive>.table-bordered>thead>tr>th:first-child,.table-responsive>.table-bordered>tbody>tr>th:first-child,.table-responsive>.table-bordered>tfoot>tr>th:first-child,.table-responsive>.table-bordered>thead>tr>td:first-child,.table-responsive>.table-bordered>tbody>tr>td:first-child,.table-responsive>.table-bordered>tfoot>tr>td:first-child{border-left:0}.table-responsive>.table-bordered>thead>tr>th:last-child,.table-responsive>.table-bordered>tbody>tr>th:last-child,.table-responsive>.table-bordered>tfoot>tr>th:last-child,.table-responsive>.table-bordered>thead>tr>td:last-child,.table-responsive>.table-bordered>tbody>tr>td:last-child,.table-responsive>.table-bordered>tfoot>tr>td:last-child{border-right:0}.table-responsive>.table-bordered>tbody>tr:last-child>th,.table-responsive>.table-bordered>tfoot>tr:last-child>th,.table-responsive>.table-bordered>tbody>tr:last-child>td,.table-responsive>.table-bordered>tfoot>tr:last-child>td{border-bottom:0}}fieldset{padding:0;margin:0;border:0;min-width:0}legend{display:block;width:100%;padding:0;margin-bottom:23px;font-size:19.5px;line-height:inherit;color:#212121;border:0;border-bottom:1px solid #e5e5e5}label{display:inline-block;max-width:100%;margin-bottom:5px;font-weight:bold}input[type="search"]{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}input[type="radio"],input[type="checkbox"]{margin:4px 0 0;margin-top:1px \9;line-height:normal}input[type="file"]{display:block}input[type="range"]{display:block;width:100%}select[multiple],select[size]{height:auto}input[type="file"]:focus,input[type="radio"]:focus,input[type="checkbox"]:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}output{display:block;padding-top:7px;font-size:13px;line-height:1.846;color:#666666}.form-control{display:block;width:100%;height:37px;padding:6px 16px;font-size:13px;line-height:1.846;color:#666666;background-color:transparent;background-image:none;border:1px solid transparent;border-radius:3px;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,0.075);box-shadow:inset 0 1px 1px rgba(0,0,0,0.075);-webkit-transition:border-color ease-in-out .15s,-webkit-box-shadow ease-in-out .15s;-o-transition:border-color ease-in-out .15s,box-shadow ease-in-out .15s;transition:border-color ease-in-out .15s,box-shadow ease-in-out .15s}.form-control:focus{border-color:#66afe9;outline:0;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,0.075),0 0 8px rgba(102,175,233,0.6);box-shadow:inset 0 1px 1px rgba(0,0,0,0.075),0 0 8px rgba(102,175,233,0.6)}.form-control::-moz-placeholder{color:#bbbbbb;opacity:1}.form-control:-ms-input-placeholder{color:#bbbbbb}.form-control::-webkit-input-placeholder{color:#bbbbbb}.form-control::-ms-expand{border:0;background-color:transparent}.form-control[disabled],.form-control[readonly],fieldset[disabled] .form-control{background-color:transparent;opacity:1}.form-control[disabled],fieldset[disabled] .form-control{cursor:not-allowed}textarea.form-control{height:auto}input[type="search"]{-webkit-appearance:none}@media screen and (-webkit-min-device-pixel-ratio:0){input[type="date"].form-control,input[type="time"].form-control,input[type="datetime-local"].form-control,input[type="month"].form-control{line-height:37px}input[type="date"].input-sm,input[type="time"].input-sm,input[type="datetime-local"].input-sm,input[type="month"].input-sm,.input-group-sm input[type="date"],.input-group-sm input[type="time"],.input-group-sm input[type="datetime-local"],.input-group-sm input[type="month"]{line-height:30px}input[type="date"].input-lg,input[type="time"].input-lg,input[type="datetime-local"].input-lg,input[type="month"].input-lg,.input-group-lg input[type="date"],.input-group-lg input[type="time"],.input-group-lg input[type="datetime-local"],.input-group-lg input[type="month"]{line-height:45px}}.form-group{margin-bottom:15px}.radio,.checkbox{position:relative;display:block;margin-top:10px;margin-bottom:10px}.radio label,.checkbox label{min-height:23px;padding-left:20px;margin-bottom:0;font-weight:normal;cursor:pointer}.radio input[type="radio"],.radio-inline input[type="radio"],.checkbox input[type="checkbox"],.checkbox-inline input[type="checkbox"]{position:absolute;margin-left:-20px;margin-top:4px \9}.radio+.radio,.checkbox+.checkbox{margin-top:-5px}.radio-inline,.checkbox-inline{position:relative;display:inline-block;padding-left:20px;margin-bottom:0;vertical-align:middle;font-weight:normal;cursor:pointer}.radio-inline+.radio-inline,.checkbox-inline+.checkbox-inline{margin-top:0;margin-left:10px}input[type="radio"][disabled],input[type="checkbox"][disabled],input[type="radio"].disabled,input[type="checkbox"].disabled,fieldset[disabled] input[type="radio"],fieldset[disabled] input[type="checkbox"]{cursor:not-allowed}.radio-inline.disabled,.checkbox-inline.disabled,fieldset[disabled] .radio-inline,fieldset[disabled] .checkbox-inline{cursor:not-allowed}.radio.disabled label,.checkbox.disabled label,fieldset[disabled] .radio label,fieldset[disabled] .checkbox label{cursor:not-allowed}.form-control-static{padding-top:7px;padding-bottom:7px;margin-bottom:0;min-height:36px}.form-control-static.input-lg,.form-control-static.input-sm{padding-left:0;padding-right:0}.input-sm{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}select.input-sm{height:30px;line-height:30px}textarea.input-sm,select[multiple].input-sm{height:auto}.form-group-sm .form-control{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}.form-group-sm select.form-control{height:30px;line-height:30px}.form-group-sm textarea.form-control,.form-group-sm select[multiple].form-control{height:auto}.form-group-sm .form-control-static{height:30px;min-height:35px;padding:6px 10px;font-size:12px;line-height:1.5}.input-lg{height:45px;padding:10px 16px;font-size:17px;line-height:1.3333333;border-radius:3px}select.input-lg{height:45px;line-height:45px}textarea.input-lg,select[multiple].input-lg{height:auto}.form-group-lg .form-control{height:45px;padding:10px 16px;font-size:17px;line-height:1.3333333;border-radius:3px}.form-group-lg select.form-control{height:45px;line-height:45px}.form-group-lg textarea.form-control,.form-group-lg select[multiple].form-control{height:auto}.form-group-lg .form-control-static{height:45px;min-height:40px;padding:11px 16px;font-size:17px;line-height:1.3333333}.has-feedback{position:relative}.has-feedback .form-control{padding-right:46.25px}.form-control-feedback{position:absolute;top:0;right:0;z-index:2;display:block;width:37px;height:37px;line-height:37px;text-align:center;pointer-events:none}.input-lg+.form-control-feedback,.input-group-lg+.form-control-feedback,.form-group-lg .form-control+.form-control-feedback{width:45px;height:45px;line-height:45px}.input-sm+.form-control-feedback,.input-group-sm+.form-control-feedback,.form-group-sm .form-control+.form-control-feedback{width:30px;height:30px;line-height:30px}.has-success .help-block,.has-success .control-label,.has-success .radio,.has-success .checkbox,.has-success .radio-inline,.has-success .checkbox-inline,.has-success.radio label,.has-success.checkbox label,.has-success.radio-inline label,.has-success.checkbox-inline label{color:#4caf50}.has-success .form-control{border-color:#4caf50;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,0.075);box-shadow:inset 0 1px 1px rgba(0,0,0,0.075)}.has-success .form-control:focus{border-color:#3d8b40;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,0.075),0 0 6px #92cf94;box-shadow:inset 0 1px 1px rgba(0,0,0,0.075),0 0 6px #92cf94}.has-success .input-group-addon{color:#4caf50;border-color:#4caf50;background-color:#dff0d8}.has-success .form-control-feedback{color:#4caf50}.has-warning .help-block,.has-warning .control-label,.has-warning .radio,.has-warning .checkbox,.has-warning .radio-inline,.has-warning .checkbox-inline,.has-warning.radio label,.has-warning.checkbox label,.has-warning.radio-inline label,.has-warning.checkbox-inline label{color:#ff9800}.has-warning .form-control{border-color:#ff9800;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,0.075);box-shadow:inset 0 1px 1px rgba(0,0,0,0.075)}.has-warning .form-control:focus{border-color:#cc7a00;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,0.075),0 0 6px #ffc166;box-shadow:inset 0 1px 1px rgba(0,0,0,0.075),0 0 6px #ffc166}.has-warning .input-group-addon{color:#ff9800;border-color:#ff9800;background-color:#ffe0b2}.has-warning .form-control-feedback{color:#ff9800}.has-error .help-block,.has-error .control-label,.has-error .radio,.has-error .checkbox,.has-error .radio-inline,.has-error .checkbox-inline,.has-error.radio label,.has-error.checkbox label,.has-error.radio-inline label,.has-error.checkbox-inline label{color:#e51c23}.has-error .form-control{border-color:#e51c23;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,0.075);box-shadow:inset 0 1px 1px rgba(0,0,0,0.075)}.has-error .form-control:focus{border-color:#b9151b;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,0.075),0 0 6px #ef787c;box-shadow:inset 0 1px 1px rgba(0,0,0,0.075),0 0 6px #ef787c}.has-error .input-group-addon{color:#e51c23;border-color:#e51c23;background-color:#f9bdbb}.has-error .form-control-feedback{color:#e51c23}.has-feedback label~.form-control-feedback{top:28px}.has-feedback label.sr-only~.form-control-feedback{top:0}.help-block{display:block;margin-top:5px;margin-bottom:10px;color:#a6a6a6}@media (min-width:768px){.form-inline .form-group{display:inline-block;margin-bottom:0;vertical-align:middle}.form-inline .form-control{display:inline-block;width:auto;vertical-align:middle}.form-inline .form-control-static{display:inline-block}.form-inline .input-group{display:inline-table;vertical-align:middle}.form-inline .input-group .input-group-addon,.form-inline .input-group .input-group-btn,.form-inline .input-group .form-control{width:auto}.form-inline .input-group>.form-control{width:100%}.form-inline .control-label{margin-bottom:0;vertical-align:middle}.form-inline .radio,.form-inline .checkbox{display:inline-block;margin-top:0;margin-bottom:0;vertical-align:middle}.form-inline .radio label,.form-inline .checkbox label{padding-left:0}.form-inline .radio input[type="radio"],.form-inline .checkbox input[type="checkbox"]{position:relative;margin-left:0}.form-inline .has-feedback .form-control-feedback{top:0}}.form-horizontal .radio,.form-horizontal .checkbox,.form-horizontal .radio-inline,.form-horizontal .checkbox-inline{margin-top:0;margin-bottom:0;padding-top:7px}.form-horizontal .radio,.form-horizontal .checkbox{min-height:30px}.form-horizontal .form-group{margin-left:-15px;margin-right:-15px}@media (min-width:768px){.form-horizontal .control-label{text-align:right;margin-bottom:0;padding-top:7px}}.form-horizontal .has-feedback .form-control-feedback{right:15px}@media (min-width:768px){.form-horizontal .form-group-lg .control-label{padding-top:11px;font-size:17px}}@media (min-width:768px){.form-horizontal .form-group-sm .control-label{padding-top:6px;font-size:12px}}.btn{display:inline-block;margin-bottom:0;font-weight:normal;text-align:center;vertical-align:middle;-ms-touch-action:manipulation;touch-action:manipulation;cursor:pointer;background-image:none;border:1px solid transparent;white-space:nowrap;padding:6px 16px;font-size:13px;line-height:1.846;border-radius:3px;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none}.btn:focus,.btn:active:focus,.btn.active:focus,.btn.focus,.btn:active.focus,.btn.active.focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}.btn:hover,.btn:focus,.btn.focus{color:#444444;text-decoration:none}.btn:active,.btn.active{outline:0;background-image:none;-webkit-box-shadow:inset 0 3px 5px rgba(0,0,0,0.125);box-shadow:inset 0 3px 5px rgba(0,0,0,0.125)}.btn.disabled,.btn[disabled],fieldset[disabled] .btn{cursor:not-allowed;opacity:0.65;filter:alpha(opacity=65);-webkit-box-shadow:none;box-shadow:none}a.btn.disabled,fieldset[disabled] a.btn{pointer-events:none}.btn-default{color:#444444;background-color:#ffffff;border-color:transparent}.btn-default:focus,.btn-default.focus{color:#444444;background-color:#e6e6e6;border-color:rgba(0,0,0,0)}.btn-default:hover{color:#444444;background-color:#e6e6e6;border-color:rgba(0,0,0,0)}.btn-default:active,.btn-default.active,.open>.dropdown-toggle.btn-default{color:#444444;background-color:#e6e6e6;border-color:rgba(0,0,0,0)}.btn-default:active:hover,.btn-default.active:hover,.open>.dropdown-toggle.btn-default:hover,.btn-default:active:focus,.btn-default.active:focus,.open>.dropdown-toggle.btn-default:focus,.btn-default:active.focus,.btn-default.active.focus,.open>.dropdown-toggle.btn-default.focus{color:#444444;background-color:#d4d4d4;border-color:rgba(0,0,0,0)}.btn-default:active,.btn-default.active,.open>.dropdown-toggle.btn-default{background-image:none}.btn-default.disabled:hover,.btn-default[disabled]:hover,fieldset[disabled] .btn-default:hover,.btn-default.disabled:focus,.btn-default[disabled]:focus,fieldset[disabled] .btn-default:focus,.btn-default.disabled.focus,.btn-default[disabled].focus,fieldset[disabled] .btn-default.focus{background-color:#ffffff;border-color:transparent}.btn-default .badge{color:#ffffff;background-color:#444444}.btn-primary{color:#ffffff;background-color:#2196f3;border-color:transparent}.btn-primary:focus,.btn-primary.focus{color:#ffffff;background-color:#0c7cd5;border-color:rgba(0,0,0,0)}.btn-primary:hover{color:#ffffff;background-color:#0c7cd5;border-color:rgba(0,0,0,0)}.btn-primary:active,.btn-primary.active,.open>.dropdown-toggle.btn-primary{color:#ffffff;background-color:#0c7cd5;border-color:rgba(0,0,0,0)}.btn-primary:active:hover,.btn-primary.active:hover,.open>.dropdown-toggle.btn-primary:hover,.btn-primary:active:focus,.btn-primary.active:focus,.open>.dropdown-toggle.btn-primary:focus,.btn-primary:active.focus,.btn-primary.active.focus,.open>.dropdown-toggle.btn-primary.focus{color:#ffffff;background-color:#0a68b4;border-color:rgba(0,0,0,0)}.btn-primary:active,.btn-primary.active,.open>.dropdown-toggle.btn-primary{background-image:none}.btn-primary.disabled:hover,.btn-primary[disabled]:hover,fieldset[disabled] .btn-primary:hover,.btn-primary.disabled:focus,.btn-primary[disabled]:focus,fieldset[disabled] .btn-primary:focus,.btn-primary.disabled.focus,.btn-primary[disabled].focus,fieldset[disabled] .btn-primary.focus{background-color:#2196f3;border-color:transparent}.btn-primary .badge{color:#2196f3;background-color:#ffffff}.btn-success{color:#ffffff;background-color:#4caf50;border-color:transparent}.btn-success:focus,.btn-success.focus{color:#ffffff;background-color:#3d8b40;border-color:rgba(0,0,0,0)}.btn-success:hover{color:#ffffff;background-color:#3d8b40;border-color:rgba(0,0,0,0)}.btn-success:active,.btn-success.active,.open>.dropdown-toggle.btn-success{color:#ffffff;background-color:#3d8b40;border-color:rgba(0,0,0,0)}.btn-success:active:hover,.btn-success.active:hover,.open>.dropdown-toggle.btn-success:hover,.btn-success:active:focus,.btn-success.active:focus,.open>.dropdown-toggle.btn-success:focus,.btn-success:active.focus,.btn-success.active.focus,.open>.dropdown-toggle.btn-success.focus{color:#ffffff;background-color:#327334;border-color:rgba(0,0,0,0)}.btn-success:active,.btn-success.active,.open>.dropdown-toggle.btn-success{background-image:none}.btn-success.disabled:hover,.btn-success[disabled]:hover,fieldset[disabled] .btn-success:hover,.btn-success.disabled:focus,.btn-success[disabled]:focus,fieldset[disabled] .btn-success:focus,.btn-success.disabled.focus,.btn-success[disabled].focus,fieldset[disabled] .btn-success.focus{background-color:#4caf50;border-color:transparent}.btn-success .badge{color:#4caf50;background-color:#ffffff}.btn-info{color:#ffffff;background-color:#9c27b0;border-color:transparent}.btn-info:focus,.btn-info.focus{color:#ffffff;background-color:#771e86;border-color:rgba(0,0,0,0)}.btn-info:hover{color:#ffffff;background-color:#771e86;border-color:rgba(0,0,0,0)}.btn-info:active,.btn-info.active,.open>.dropdown-toggle.btn-info{color:#ffffff;background-color:#771e86;border-color:rgba(0,0,0,0)}.btn-info:active:hover,.btn-info.active:hover,.open>.dropdown-toggle.btn-info:hover,.btn-info:active:focus,.btn-info.active:focus,.open>.dropdown-toggle.btn-info:focus,.btn-info:active.focus,.btn-info.active.focus,.open>.dropdown-toggle.btn-info.focus{color:#ffffff;background-color:#5d1769;border-color:rgba(0,0,0,0)}.btn-info:active,.btn-info.active,.open>.dropdown-toggle.btn-info{background-image:none}.btn-info.disabled:hover,.btn-info[disabled]:hover,fieldset[disabled] .btn-info:hover,.btn-info.disabled:focus,.btn-info[disabled]:focus,fieldset[disabled] .btn-info:focus,.btn-info.disabled.focus,.btn-info[disabled].focus,fieldset[disabled] .btn-info.focus{background-color:#9c27b0;border-color:transparent}.btn-info .badge{color:#9c27b0;background-color:#ffffff}.btn-warning{color:#ffffff;background-color:#ff9800;border-color:transparent}.btn-warning:focus,.btn-warning.focus{color:#ffffff;background-color:#cc7a00;border-color:rgba(0,0,0,0)}.btn-warning:hover{color:#ffffff;background-color:#cc7a00;border-color:rgba(0,0,0,0)}.btn-warning:active,.btn-warning.active,.open>.dropdown-toggle.btn-warning{color:#ffffff;background-color:#cc7a00;border-color:rgba(0,0,0,0)}.btn-warning:active:hover,.btn-warning.active:hover,.open>.dropdown-toggle.btn-warning:hover,.btn-warning:active:focus,.btn-warning.active:focus,.open>.dropdown-toggle.btn-warning:focus,.btn-warning:active.focus,.btn-warning.active.focus,.open>.dropdown-toggle.btn-warning.focus{color:#ffffff;background-color:#a86400;border-color:rgba(0,0,0,0)}.btn-warning:active,.btn-warning.active,.open>.dropdown-toggle.btn-warning{background-image:none}.btn-warning.disabled:hover,.btn-warning[disabled]:hover,fieldset[disabled] .btn-warning:hover,.btn-warning.disabled:focus,.btn-warning[disabled]:focus,fieldset[disabled] .btn-warning:focus,.btn-warning.disabled.focus,.btn-warning[disabled].focus,fieldset[disabled] .btn-warning.focus{background-color:#ff9800;border-color:transparent}.btn-warning .badge{color:#ff9800;background-color:#ffffff}.btn-danger{color:#ffffff;background-color:#e51c23;border-color:transparent}.btn-danger:focus,.btn-danger.focus{color:#ffffff;background-color:#b9151b;border-color:rgba(0,0,0,0)}.btn-danger:hover{color:#ffffff;background-color:#b9151b;border-color:rgba(0,0,0,0)}.btn-danger:active,.btn-danger.active,.open>.dropdown-toggle.btn-danger{color:#ffffff;background-color:#b9151b;border-color:rgba(0,0,0,0)}.btn-danger:active:hover,.btn-danger.active:hover,.open>.dropdown-toggle.btn-danger:hover,.btn-danger:active:focus,.btn-danger.active:focus,.open>.dropdown-toggle.btn-danger:focus,.btn-danger:active.focus,.btn-danger.active.focus,.open>.dropdown-toggle.btn-danger.focus{color:#ffffff;background-color:#991216;border-color:rgba(0,0,0,0)}.btn-danger:active,.btn-danger.active,.open>.dropdown-toggle.btn-danger{background-image:none}.btn-danger.disabled:hover,.btn-danger[disabled]:hover,fieldset[disabled] .btn-danger:hover,.btn-danger.disabled:focus,.btn-danger[disabled]:focus,fieldset[disabled] .btn-danger:focus,.btn-danger.disabled.focus,.btn-danger[disabled].focus,fieldset[disabled] .btn-danger.focus{background-color:#e51c23;border-color:transparent}.btn-danger .badge{color:#e51c23;background-color:#ffffff}.btn-link{color:#2196f3;font-weight:normal;border-radius:0}.btn-link,.btn-link:active,.btn-link.active,.btn-link[disabled],fieldset[disabled] .btn-link{background-color:transparent;-webkit-box-shadow:none;box-shadow:none}.btn-link,.btn-link:hover,.btn-link:focus,.btn-link:active{border-color:transparent}.btn-link:hover,.btn-link:focus{color:#0a6ebd;text-decoration:underline;background-color:transparent}.btn-link[disabled]:hover,fieldset[disabled] .btn-link:hover,.btn-link[disabled]:focus,fieldset[disabled] .btn-link:focus{color:#bbbbbb;text-decoration:none}.btn-lg,.btn-group-lg>.btn{padding:10px 16px;font-size:17px;line-height:1.3333333;border-radius:3px}.btn-sm,.btn-group-sm>.btn{padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}.btn-xs,.btn-group-xs>.btn{padding:1px 5px;font-size:12px;line-height:1.5;border-radius:3px}.btn-block{display:block;width:100%}.btn-block+.btn-block{margin-top:5px}input[type="submit"].btn-block,input[type="reset"].btn-block,input[type="button"].btn-block{width:100%}.fade{opacity:0;-webkit-transition:opacity 0.15s linear;-o-transition:opacity 0.15s linear;transition:opacity 0.15s linear}.fade.in{opacity:1}.collapse{display:none}.collapse.in{display:block}tr.collapse.in{display:table-row}tbody.collapse.in{display:table-row-group}.collapsing{position:relative;height:0;overflow:hidden;-webkit-transition-property:height, visibility;-o-transition-property:height, visibility;transition-property:height, visibility;-webkit-transition-duration:0.35s;-o-transition-duration:0.35s;transition-duration:0.35s;-webkit-transition-timing-function:ease;-o-transition-timing-function:ease;transition-timing-function:ease}.caret{display:inline-block;width:0;height:0;margin-left:2px;vertical-align:middle;border-top:4px dashed;border-top:4px solid \9;border-right:4px solid transparent;border-left:4px solid transparent}.dropup,.dropdown{position:relative}.dropdown-toggle:focus{outline:0}.dropdown-menu{position:absolute;top:100%;left:0;z-index:1000;display:none;float:left;min-width:160px;padding:5px 0;margin:2px 0 0;list-style:none;font-size:13px;text-align:left;background-color:#ffffff;border:1px solid #cccccc;border:1px solid rgba(0,0,0,0.15);border-radius:3px;-webkit-box-shadow:0 6px 12px rgba(0,0,0,0.175);box-shadow:0 6px 12px rgba(0,0,0,0.175);-webkit-background-clip:padding-box;background-clip:padding-box}.dropdown-menu.pull-right{right:0;left:auto}.dropdown-menu .divider{height:1px;margin:10.5px 0;overflow:hidden;background-color:#e5e5e5}.dropdown-menu>li>a{display:block;padding:3px 20px;clear:both;font-weight:normal;line-height:1.846;color:#666666;white-space:nowrap}.dropdown-menu>li>a:hover,.dropdown-menu>li>a:focus{text-decoration:none;color:#141414;background-color:#eeeeee}.dropdown-menu>.active>a,.dropdown-menu>.active>a:hover,.dropdown-menu>.active>a:focus{color:#ffffff;text-decoration:none;outline:0;background-color:#2196f3}.dropdown-menu>.disabled>a,.dropdown-menu>.disabled>a:hover,.dropdown-menu>.disabled>a:focus{color:#bbbbbb}.dropdown-menu>.disabled>a:hover,.dropdown-menu>.disabled>a:focus{text-decoration:none;background-color:transparent;background-image:none;filter:progid:DXImageTransform.Microsoft.gradient(enabled=false);cursor:not-allowed}.open>.dropdown-menu{display:block}.open>a{outline:0}.dropdown-menu-right{left:auto;right:0}.dropdown-menu-left{left:0;right:auto}.dropdown-header{display:block;padding:3px 20px;font-size:12px;line-height:1.846;color:#bbbbbb;white-space:nowrap}.dropdown-backdrop{position:fixed;left:0;right:0;bottom:0;top:0;z-index:990}.pull-right>.dropdown-menu{right:0;left:auto}.dropup .caret,.navbar-fixed-bottom .dropdown .caret{border-top:0;border-bottom:4px dashed;border-bottom:4px solid \9;content:""}.dropup .dropdown-menu,.navbar-fixed-bottom .dropdown .dropdown-menu{top:auto;bottom:100%;margin-bottom:2px}@media (min-width:768px){.navbar-right .dropdown-menu{left:auto;right:0}.navbar-right .dropdown-menu-left{left:0;right:auto}}.btn-group,.btn-group-vertical{position:relative;display:inline-block;vertical-align:middle}.btn-group>.btn,.btn-group-vertical>.btn{position:relative;float:left}.btn-group>.btn:hover,.btn-group-vertical>.btn:hover,.btn-group>.btn:focus,.btn-group-vertical>.btn:focus,.btn-group>.btn:active,.btn-group-vertical>.btn:active,.btn-group>.btn.active,.btn-group-vertical>.btn.active{z-index:2}.btn-group .btn+.btn,.btn-group .btn+.btn-group,.btn-group .btn-group+.btn,.btn-group .btn-group+.btn-group{margin-left:-1px}.btn-toolbar{margin-left:-5px}.btn-toolbar .btn,.btn-toolbar .btn-group,.btn-toolbar .input-group{float:left}.btn-toolbar>.btn,.btn-toolbar>.btn-group,.btn-toolbar>.input-group{margin-left:5px}.btn-group>.btn:not(:first-child):not(:last-child):not(.dropdown-toggle){border-radius:0}.btn-group>.btn:first-child{margin-left:0}.btn-group>.btn:first-child:not(:last-child):not(.dropdown-toggle){border-bottom-right-radius:0;border-top-right-radius:0}.btn-group>.btn:last-child:not(:first-child),.btn-group>.dropdown-toggle:not(:first-child){border-bottom-left-radius:0;border-top-left-radius:0}.btn-group>.btn-group{float:left}.btn-group>.btn-group:not(:first-child):not(:last-child)>.btn{border-radius:0}.btn-group>.btn-group:first-child:not(:last-child)>.btn:last-child,.btn-group>.btn-group:first-child:not(:last-child)>.dropdown-toggle{border-bottom-right-radius:0;border-top-right-radius:0}.btn-group>.btn-group:last-child:not(:first-child)>.btn:first-child{border-bottom-left-radius:0;border-top-left-radius:0}.btn-group .dropdown-toggle:active,.btn-group.open .dropdown-toggle{outline:0}.btn-group>.btn+.dropdown-toggle{padding-left:8px;padding-right:8px}.btn-group>.btn-lg+.dropdown-toggle{padding-left:12px;padding-right:12px}.btn-group.open .dropdown-toggle{-webkit-box-shadow:inset 0 3px 5px rgba(0,0,0,0.125);box-shadow:inset 0 3px 5px rgba(0,0,0,0.125)}.btn-group.open .dropdown-toggle.btn-link{-webkit-box-shadow:none;box-shadow:none}.btn .caret{margin-left:0}.btn-lg .caret{border-width:5px 5px 0;border-bottom-width:0}.dropup .btn-lg .caret{border-width:0 5px 5px}.btn-group-vertical>.btn,.btn-group-vertical>.btn-group,.btn-group-vertical>.btn-group>.btn{display:block;float:none;width:100%;max-width:100%}.btn-group-vertical>.btn-group>.btn{float:none}.btn-group-vertical>.btn+.btn,.btn-group-vertical>.btn+.btn-group,.btn-group-vertical>.btn-group+.btn,.btn-group-vertical>.btn-group+.btn-group{margin-top:-1px;margin-left:0}.btn-group-vertical>.btn:not(:first-child):not(:last-child){border-radius:0}.btn-group-vertical>.btn:first-child:not(:last-child){border-top-right-radius:3px;border-top-left-radius:3px;border-bottom-right-radius:0;border-bottom-left-radius:0}.btn-group-vertical>.btn:last-child:not(:first-child){border-top-right-radius:0;border-top-left-radius:0;border-bottom-right-radius:3px;border-bottom-left-radius:3px}.btn-group-vertical>.btn-group:not(:first-child):not(:last-child)>.btn{border-radius:0}.btn-group-vertical>.btn-group:first-child:not(:last-child)>.btn:last-child,.btn-group-vertical>.btn-group:first-child:not(:last-child)>.dropdown-toggle{border-bottom-right-radius:0;border-bottom-left-radius:0}.btn-group-vertical>.btn-group:last-child:not(:first-child)>.btn:first-child{border-top-right-radius:0;border-top-left-radius:0}.btn-group-justified{display:table;width:100%;table-layout:fixed;border-collapse:separate}.btn-group-justified>.btn,.btn-group-justified>.btn-group{float:none;display:table-cell;width:1%}.btn-group-justified>.btn-group .btn{width:100%}.btn-group-justified>.btn-group .dropdown-menu{left:auto}[data-toggle="buttons"]>.btn input[type="radio"],[data-toggle="buttons"]>.btn-group>.btn input[type="radio"],[data-toggle="buttons"]>.btn input[type="checkbox"],[data-toggle="buttons"]>.btn-group>.btn input[type="checkbox"]{position:absolute;clip:rect(0, 0, 0, 0);pointer-events:none}.input-group{position:relative;display:table;border-collapse:separate}.input-group[class*="col-"]{float:none;padding-left:0;padding-right:0}.input-group .form-control{position:relative;z-index:2;float:left;width:100%;margin-bottom:0}.input-group .form-control:focus{z-index:3}.input-group-lg>.form-control,.input-group-lg>.input-group-addon,.input-group-lg>.input-group-btn>.btn{height:45px;padding:10px 16px;font-size:17px;line-height:1.3333333;border-radius:3px}select.input-group-lg>.form-control,select.input-group-lg>.input-group-addon,select.input-group-lg>.input-group-btn>.btn{height:45px;line-height:45px}textarea.input-group-lg>.form-control,textarea.input-group-lg>.input-group-addon,textarea.input-group-lg>.input-group-btn>.btn,select[multiple].input-group-lg>.form-control,select[multiple].input-group-lg>.input-group-addon,select[multiple].input-group-lg>.input-group-btn>.btn{height:auto}.input-group-sm>.form-control,.input-group-sm>.input-group-addon,.input-group-sm>.input-group-btn>.btn{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}select.input-group-sm>.form-control,select.input-group-sm>.input-group-addon,select.input-group-sm>.input-group-btn>.btn{height:30px;line-height:30px}textarea.input-group-sm>.form-control,textarea.input-group-sm>.input-group-addon,textarea.input-group-sm>.input-group-btn>.btn,select[multiple].input-group-sm>.form-control,select[multiple].input-group-sm>.input-group-addon,select[multiple].input-group-sm>.input-group-btn>.btn{height:auto}.input-group-addon,.input-group-btn,.input-group .form-control{display:table-cell}.input-group-addon:not(:first-child):not(:last-child),.input-group-btn:not(:first-child):not(:last-child),.input-group .form-control:not(:first-child):not(:last-child){border-radius:0}.input-group-addon,.input-group-btn{width:1%;white-space:nowrap;vertical-align:middle}.input-group-addon{padding:6px 16px;font-size:13px;font-weight:normal;line-height:1;color:#666666;text-align:center;background-color:transparent;border:1px solid transparent;border-radius:3px}.input-group-addon.input-sm{padding:5px 10px;font-size:12px;border-radius:3px}.input-group-addon.input-lg{padding:10px 16px;font-size:17px;border-radius:3px}.input-group-addon input[type="radio"],.input-group-addon input[type="checkbox"]{margin-top:0}.input-group .form-control:first-child,.input-group-addon:first-child,.input-group-btn:first-child>.btn,.input-group-btn:first-child>.btn-group>.btn,.input-group-btn:first-child>.dropdown-toggle,.input-group-btn:last-child>.btn:not(:last-child):not(.dropdown-toggle),.input-group-btn:last-child>.btn-group:not(:last-child)>.btn{border-bottom-right-radius:0;border-top-right-radius:0}.input-group-addon:first-child{border-right:0}.input-group .form-control:last-child,.input-group-addon:last-child,.input-group-btn:last-child>.btn,.input-group-btn:last-child>.btn-group>.btn,.input-group-btn:last-child>.dropdown-toggle,.input-group-btn:first-child>.btn:not(:first-child),.input-group-btn:first-child>.btn-group:not(:first-child)>.btn{border-bottom-left-radius:0;border-top-left-radius:0}.input-group-addon:last-child{border-left:0}.input-group-btn{position:relative;font-size:0;white-space:nowrap}.input-group-btn>.btn{position:relative}.input-group-btn>.btn+.btn{margin-left:-1px}.input-group-btn>.btn:hover,.input-group-btn>.btn:focus,.input-group-btn>.btn:active{z-index:2}.input-group-btn:first-child>.btn,.input-group-btn:first-child>.btn-group{margin-right:-1px}.input-group-btn:last-child>.btn,.input-group-btn:last-child>.btn-group{z-index:2;margin-left:-1px}.nav{margin-bottom:0;padding-left:0;list-style:none}.nav>li{position:relative;display:block}.nav>li>a{position:relative;display:block;padding:10px 15px}.nav>li>a:hover,.nav>li>a:focus{text-decoration:none;background-color:#eeeeee}.nav>li.disabled>a{color:#bbbbbb}.nav>li.disabled>a:hover,.nav>li.disabled>a:focus{color:#bbbbbb;text-decoration:none;background-color:transparent;cursor:not-allowed}.nav .open>a,.nav .open>a:hover,.nav .open>a:focus{background-color:#eeeeee;border-color:#2196f3}.nav .nav-divider{height:1px;margin:10.5px 0;overflow:hidden;background-color:#e5e5e5}.nav>li>a>img{max-width:none}.nav-tabs{border-bottom:1px solid transparent}.nav-tabs>li{float:left;margin-bottom:-1px}.nav-tabs>li>a{margin-right:2px;line-height:1.846;border:1px solid transparent;border-radius:3px 3px 0 0}.nav-tabs>li>a:hover{border-color:#eeeeee #eeeeee transparent}.nav-tabs>li.active>a,.nav-tabs>li.active>a:hover,.nav-tabs>li.active>a:focus{color:#666666;background-color:transparent;border:1px solid transparent;border-bottom-color:transparent;cursor:default}.nav-tabs.nav-justified{width:100%;border-bottom:0}.nav-tabs.nav-justified>li{float:none}.nav-tabs.nav-justified>li>a{text-align:center;margin-bottom:5px}.nav-tabs.nav-justified>.dropdown .dropdown-menu{top:auto;left:auto}@media (min-width:768px){.nav-tabs.nav-justified>li{display:table-cell;width:1%}.nav-tabs.nav-justified>li>a{margin-bottom:0}}.nav-tabs.nav-justified>li>a{margin-right:0;border-radius:3px}.nav-tabs.nav-justified>.active>a,.nav-tabs.nav-justified>.active>a:hover,.nav-tabs.nav-justified>.active>a:focus{border:1px solid transparent}@media (min-width:768px){.nav-tabs.nav-justified>li>a{border-bottom:1px solid transparent;border-radius:3px 3px 0 0}.nav-tabs.nav-justified>.active>a,.nav-tabs.nav-justified>.active>a:hover,.nav-tabs.nav-justified>.active>a:focus{border-bottom-color:#ffffff}}.nav-pills>li{float:left}.nav-pills>li>a{border-radius:3px}.nav-pills>li+li{margin-left:2px}.nav-pills>li.active>a,.nav-pills>li.active>a:hover,.nav-pills>li.active>a:focus{color:#ffffff;background-color:#2196f3}.nav-stacked>li{float:none}.nav-stacked>li+li{margin-top:2px;margin-left:0}.nav-justified{width:100%}.nav-justified>li{float:none}.nav-justified>li>a{text-align:center;margin-bottom:5px}.nav-justified>.dropdown .dropdown-menu{top:auto;left:auto}@media (min-width:768px){.nav-justified>li{display:table-cell;width:1%}.nav-justified>li>a{margin-bottom:0}}.nav-tabs-justified{border-bottom:0}.nav-tabs-justified>li>a{margin-right:0;border-radius:3px}.nav-tabs-justified>.active>a,.nav-tabs-justified>.active>a:hover,.nav-tabs-justified>.active>a:focus{border:1px solid transparent}@media (min-width:768px){.nav-tabs-justified>li>a{border-bottom:1px solid transparent;border-radius:3px 3px 0 0}.nav-tabs-justified>.active>a,.nav-tabs-justified>.active>a:hover,.nav-tabs-justified>.active>a:focus{border-bottom-color:#ffffff}}.tab-content>.tab-pane{display:none}.tab-content>.active{display:block}.nav-tabs .dropdown-menu{margin-top:-1px;border-top-right-radius:0;border-top-left-radius:0}.navbar{position:relative;min-height:64px;margin-bottom:23px;border:1px solid transparent}@media (min-width:768px){.navbar{border-radius:3px}}@media (min-width:768px){.navbar-header{float:left}}.navbar-collapse{overflow-x:visible;padding-right:15px;padding-left:15px;border-top:1px solid transparent;-webkit-box-shadow:inset 0 1px 0 rgba(255,255,255,0.1);box-shadow:inset 0 1px 0 rgba(255,255,255,0.1);-webkit-overflow-scrolling:touch}.navbar-collapse.in{overflow-y:auto}@media (min-width:768px){.navbar-collapse{width:auto;border-top:0;-webkit-box-shadow:none;box-shadow:none}.navbar-collapse.collapse{display:block !important;height:auto !important;padding-bottom:0;overflow:visible !important}.navbar-collapse.in{overflow-y:visible}.navbar-fixed-top .navbar-collapse,.navbar-static-top .navbar-collapse,.navbar-fixed-bottom .navbar-collapse{padding-left:0;padding-right:0}}.navbar-fixed-top .navbar-collapse,.navbar-fixed-bottom .navbar-collapse{max-height:340px}@media (max-device-width:480px) and (orientation:landscape){.navbar-fixed-top .navbar-collapse,.navbar-fixed-bottom .navbar-collapse{max-height:200px}}.container>.navbar-header,.container-fluid>.navbar-header,.container>.navbar-collapse,.container-fluid>.navbar-collapse{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.container>.navbar-header,.container-fluid>.navbar-header,.container>.navbar-collapse,.container-fluid>.navbar-collapse{margin-right:0;margin-left:0}}.navbar-static-top{z-index:1000;border-width:0 0 1px}@media (min-width:768px){.navbar-static-top{border-radius:0}}.navbar-fixed-top,.navbar-fixed-bottom{position:fixed;right:0;left:0;z-index:1030}@media (min-width:768px){.navbar-fixed-top,.navbar-fixed-bottom{border-radius:0}}.navbar-fixed-top{top:0;border-width:0 0 1px}.navbar-fixed-bottom{bottom:0;margin-bottom:0;border-width:1px 0 0}.navbar-brand{float:left;padding:20.5px 15px;font-size:17px;line-height:23px;height:64px}.navbar-brand:hover,.navbar-brand:focus{text-decoration:none}.navbar-brand>img{display:block}@media (min-width:768px){.navbar>.container .navbar-brand,.navbar>.container-fluid .navbar-brand{margin-left:-15px}}.navbar-toggle{position:relative;float:right;margin-right:15px;padding:9px 10px;margin-top:15px;margin-bottom:15px;background-color:transparent;background-image:none;border:1px solid transparent;border-radius:3px}.navbar-toggle:focus{outline:0}.navbar-toggle .icon-bar{display:block;width:22px;height:2px;border-radius:1px}.navbar-toggle .icon-bar+.icon-bar{margin-top:4px}@media (min-width:768px){.navbar-toggle{display:none}}.navbar-nav{margin:10.25px -15px}.navbar-nav>li>a{padding-top:10px;padding-bottom:10px;line-height:23px}@media (max-width:767px){.navbar-nav .open .dropdown-menu{position:static;float:none;width:auto;margin-top:0;background-color:transparent;border:0;-webkit-box-shadow:none;box-shadow:none}.navbar-nav .open .dropdown-menu>li>a,.navbar-nav .open .dropdown-menu .dropdown-header{padding:5px 15px 5px 25px}.navbar-nav .open .dropdown-menu>li>a{line-height:23px}.navbar-nav .open .dropdown-menu>li>a:hover,.navbar-nav .open .dropdown-menu>li>a:focus{background-image:none}}@media (min-width:768px){.navbar-nav{float:left;margin:0}.navbar-nav>li{float:left}.navbar-nav>li>a{padding-top:20.5px;padding-bottom:20.5px}}.navbar-form{margin-left:-15px;margin-right:-15px;padding:10px 15px;border-top:1px solid transparent;border-bottom:1px solid transparent;-webkit-box-shadow:inset 0 1px 0 rgba(255,255,255,0.1),0 1px 0 rgba(255,255,255,0.1);box-shadow:inset 0 1px 0 rgba(255,255,255,0.1),0 1px 0 rgba(255,255,255,0.1);margin-top:13.5px;margin-bottom:13.5px}@media (min-width:768px){.navbar-form .form-group{display:inline-block;margin-bottom:0;vertical-align:middle}.navbar-form .form-control{display:inline-block;width:auto;vertical-align:middle}.navbar-form .form-control-static{display:inline-block}.navbar-form .input-group{display:inline-table;vertical-align:middle}.navbar-form .input-group .input-group-addon,.navbar-form .input-group .input-group-btn,.navbar-form .input-group .form-control{width:auto}.navbar-form .input-group>.form-control{width:100%}.navbar-form .control-label{margin-bottom:0;vertical-align:middle}.navbar-form .radio,.navbar-form .checkbox{display:inline-block;margin-top:0;margin-bottom:0;vertical-align:middle}.navbar-form .radio label,.navbar-form .checkbox label{padding-left:0}.navbar-form .radio input[type="radio"],.navbar-form .checkbox input[type="checkbox"]{position:relative;margin-left:0}.navbar-form .has-feedback .form-control-feedback{top:0}}@media (max-width:767px){.navbar-form .form-group{margin-bottom:5px}.navbar-form .form-group:last-child{margin-bottom:0}}@media (min-width:768px){.navbar-form{width:auto;border:0;margin-left:0;margin-right:0;padding-top:0;padding-bottom:0;-webkit-box-shadow:none;box-shadow:none}}.navbar-nav>li>.dropdown-menu{margin-top:0;border-top-right-radius:0;border-top-left-radius:0}.navbar-fixed-bottom .navbar-nav>li>.dropdown-menu{margin-bottom:0;border-top-right-radius:3px;border-top-left-radius:3px;border-bottom-right-radius:0;border-bottom-left-radius:0}.navbar-btn{margin-top:13.5px;margin-bottom:13.5px}.navbar-btn.btn-sm{margin-top:17px;margin-bottom:17px}.navbar-btn.btn-xs{margin-top:21px;margin-bottom:21px}.navbar-text{margin-top:20.5px;margin-bottom:20.5px}@media (min-width:768px){.navbar-text{float:left;margin-left:15px;margin-right:15px}}@media (min-width:768px){.navbar-left{float:left !important}.navbar-right{float:right !important;margin-right:-15px}.navbar-right~.navbar-right{margin-right:0}}.navbar-default{background-color:#ffffff;border-color:transparent}.navbar-default .navbar-brand{color:#666666}.navbar-default .navbar-brand:hover,.navbar-default .navbar-brand:focus{color:#212121;background-color:transparent}.navbar-default .navbar-text{color:#bbbbbb}.navbar-default .navbar-nav>li>a{color:#666666}.navbar-default .navbar-nav>li>a:hover,.navbar-default .navbar-nav>li>a:focus{color:#212121;background-color:transparent}.navbar-default .navbar-nav>.active>a,.navbar-default .navbar-nav>.active>a:hover,.navbar-default .navbar-nav>.active>a:focus{color:#212121;background-color:#eeeeee}.navbar-default .navbar-nav>.disabled>a,.navbar-default .navbar-nav>.disabled>a:hover,.navbar-default .navbar-nav>.disabled>a:focus{color:#cccccc;background-color:transparent}.navbar-default .navbar-toggle{border-color:transparent}.navbar-default .navbar-toggle:hover,.navbar-default .navbar-toggle:focus{background-color:transparent}.navbar-default .navbar-toggle .icon-bar{background-color:rgba(0,0,0,0.5)}.navbar-default .navbar-collapse,.navbar-default .navbar-form{border-color:transparent}.navbar-default .navbar-nav>.open>a,.navbar-default .navbar-nav>.open>a:hover,.navbar-default .navbar-nav>.open>a:focus{background-color:#eeeeee;color:#212121}@media (max-width:767px){.navbar-default .navbar-nav .open .dropdown-menu>li>a{color:#666666}.navbar-default .navbar-nav .open .dropdown-menu>li>a:hover,.navbar-default .navbar-nav .open .dropdown-menu>li>a:focus{color:#212121;background-color:transparent}.navbar-default .navbar-nav .open .dropdown-menu>.active>a,.navbar-default .navbar-nav .open .dropdown-menu>.active>a:hover,.navbar-default .navbar-nav .open .dropdown-menu>.active>a:focus{color:#212121;background-color:#eeeeee}.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a,.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a:hover,.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a:focus{color:#cccccc;background-color:transparent}}.navbar-default .navbar-link{color:#666666}.navbar-default .navbar-link:hover{color:#212121}.navbar-default .btn-link{color:#666666}.navbar-default .btn-link:hover,.navbar-default .btn-link:focus{color:#212121}.navbar-default .btn-link[disabled]:hover,fieldset[disabled] .navbar-default .btn-link:hover,.navbar-default .btn-link[disabled]:focus,fieldset[disabled] .navbar-default .btn-link:focus{color:#cccccc}.navbar-inverse{background-color:#2196f3;border-color:transparent}.navbar-inverse .navbar-brand{color:#b2dbfb}.navbar-inverse .navbar-brand:hover,.navbar-inverse .navbar-brand:focus{color:#ffffff;background-color:transparent}.navbar-inverse .navbar-text{color:#bbbbbb}.navbar-inverse .navbar-nav>li>a{color:#b2dbfb}.navbar-inverse .navbar-nav>li>a:hover,.navbar-inverse .navbar-nav>li>a:focus{color:#ffffff;background-color:transparent}.navbar-inverse .navbar-nav>.active>a,.navbar-inverse .navbar-nav>.active>a:hover,.navbar-inverse .navbar-nav>.active>a:focus{color:#ffffff;background-color:#0c7cd5}.navbar-inverse .navbar-nav>.disabled>a,.navbar-inverse .navbar-nav>.disabled>a:hover,.navbar-inverse .navbar-nav>.disabled>a:focus{color:#444444;background-color:transparent}.navbar-inverse .navbar-toggle{border-color:transparent}.navbar-inverse .navbar-toggle:hover,.navbar-inverse .navbar-toggle:focus{background-color:transparent}.navbar-inverse .navbar-toggle .icon-bar{background-color:rgba(0,0,0,0.5)}.navbar-inverse .navbar-collapse,.navbar-inverse .navbar-form{border-color:#0c84e4}.navbar-inverse .navbar-nav>.open>a,.navbar-inverse .navbar-nav>.open>a:hover,.navbar-inverse .navbar-nav>.open>a:focus{background-color:#0c7cd5;color:#ffffff}@media (max-width:767px){.navbar-inverse .navbar-nav .open .dropdown-menu>.dropdown-header{border-color:transparent}.navbar-inverse .navbar-nav .open .dropdown-menu .divider{background-color:transparent}.navbar-inverse .navbar-nav .open .dropdown-menu>li>a{color:#b2dbfb}.navbar-inverse .navbar-nav .open .dropdown-menu>li>a:hover,.navbar-inverse .navbar-nav .open .dropdown-menu>li>a:focus{color:#ffffff;background-color:transparent}.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a,.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a:hover,.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a:focus{color:#ffffff;background-color:#0c7cd5}.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a,.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a:hover,.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a:focus{color:#444444;background-color:transparent}}.navbar-inverse .navbar-link{color:#b2dbfb}.navbar-inverse .navbar-link:hover{color:#ffffff}.navbar-inverse .btn-link{color:#b2dbfb}.navbar-inverse .btn-link:hover,.navbar-inverse .btn-link:focus{color:#ffffff}.navbar-inverse .btn-link[disabled]:hover,fieldset[disabled] .navbar-inverse .btn-link:hover,.navbar-inverse .btn-link[disabled]:focus,fieldset[disabled] .navbar-inverse .btn-link:focus{color:#444444}.breadcrumb{padding:8px 15px;margin-bottom:23px;list-style:none;background-color:#f5f5f5;border-radius:3px}.breadcrumb>li{display:inline-block}.breadcrumb>li+li:before{content:"/\00a0";padding:0 5px;color:#cccccc}.breadcrumb>.active{color:#bbbbbb}.pagination{display:inline-block;padding-left:0;margin:23px 0;border-radius:3px}.pagination>li{display:inline}.pagination>li>a,.pagination>li>span{position:relative;float:left;padding:6px 16px;line-height:1.846;text-decoration:none;color:#2196f3;background-color:#ffffff;border:1px solid #dddddd;margin-left:-1px}.pagination>li:first-child>a,.pagination>li:first-child>span{margin-left:0;border-bottom-left-radius:3px;border-top-left-radius:3px}.pagination>li:last-child>a,.pagination>li:last-child>span{border-bottom-right-radius:3px;border-top-right-radius:3px}.pagination>li>a:hover,.pagination>li>span:hover,.pagination>li>a:focus,.pagination>li>span:focus{z-index:2;color:#0a6ebd;background-color:#eeeeee;border-color:#dddddd}.pagination>.active>a,.pagination>.active>span,.pagination>.active>a:hover,.pagination>.active>span:hover,.pagination>.active>a:focus,.pagination>.active>span:focus{z-index:3;color:#ffffff;background-color:#2196f3;border-color:#2196f3;cursor:default}.pagination>.disabled>span,.pagination>.disabled>span:hover,.pagination>.disabled>span:focus,.pagination>.disabled>a,.pagination>.disabled>a:hover,.pagination>.disabled>a:focus{color:#bbbbbb;background-color:#ffffff;border-color:#dddddd;cursor:not-allowed}.pagination-lg>li>a,.pagination-lg>li>span{padding:10px 16px;font-size:17px;line-height:1.3333333}.pagination-lg>li:first-child>a,.pagination-lg>li:first-child>span{border-bottom-left-radius:3px;border-top-left-radius:3px}.pagination-lg>li:last-child>a,.pagination-lg>li:last-child>span{border-bottom-right-radius:3px;border-top-right-radius:3px}.pagination-sm>li>a,.pagination-sm>li>span{padding:5px 10px;font-size:12px;line-height:1.5}.pagination-sm>li:first-child>a,.pagination-sm>li:first-child>span{border-bottom-left-radius:3px;border-top-left-radius:3px}.pagination-sm>li:last-child>a,.pagination-sm>li:last-child>span{border-bottom-right-radius:3px;border-top-right-radius:3px}.pager{padding-left:0;margin:23px 0;list-style:none;text-align:center}.pager li{display:inline}.pager li>a,.pager li>span{display:inline-block;padding:5px 14px;background-color:#ffffff;border:1px solid #dddddd;border-radius:15px}.pager li>a:hover,.pager li>a:focus{text-decoration:none;background-color:#eeeeee}.pager .next>a,.pager .next>span{float:right}.pager .previous>a,.pager .previous>span{float:left}.pager .disabled>a,.pager .disabled>a:hover,.pager .disabled>a:focus,.pager .disabled>span{color:#bbbbbb;background-color:#ffffff;cursor:not-allowed}.label{display:inline;padding:.2em .6em .3em;font-size:75%;font-weight:bold;line-height:1;color:#ffffff;text-align:center;white-space:nowrap;vertical-align:baseline;border-radius:.25em}a.label:hover,a.label:focus{color:#ffffff;text-decoration:none;cursor:pointer}.label:empty{display:none}.btn .label{position:relative;top:-1px}.label-default{background-color:#bbbbbb}.label-default[href]:hover,.label-default[href]:focus{background-color:#a2a2a2}.label-primary{background-color:#2196f3}.label-primary[href]:hover,.label-primary[href]:focus{background-color:#0c7cd5}.label-success{background-color:#4caf50}.label-success[href]:hover,.label-success[href]:focus{background-color:#3d8b40}.label-info{background-color:#9c27b0}.label-info[href]:hover,.label-info[href]:focus{background-color:#771e86}.label-warning{background-color:#ff9800}.label-warning[href]:hover,.label-warning[href]:focus{background-color:#cc7a00}.label-danger{background-color:#e51c23}.label-danger[href]:hover,.label-danger[href]:focus{background-color:#b9151b}.badge{display:inline-block;min-width:10px;padding:3px 7px;font-size:12px;font-weight:normal;color:#ffffff;line-height:1;vertical-align:middle;white-space:nowrap;text-align:center;background-color:#bbbbbb;border-radius:10px}.badge:empty{display:none}.btn .badge{position:relative;top:-1px}.btn-xs .badge,.btn-group-xs>.btn .badge{top:0;padding:1px 5px}a.badge:hover,a.badge:focus{color:#ffffff;text-decoration:none;cursor:pointer}.list-group-item.active>.badge,.nav-pills>.active>a>.badge{color:#2196f3;background-color:#ffffff}.list-group-item>.badge{float:right}.list-group-item>.badge+.badge{margin-right:5px}.nav-pills>li>a>.badge{margin-left:3px}.jumbotron{padding-top:30px;padding-bottom:30px;margin-bottom:30px;color:inherit;background-color:#f9f9f9}.jumbotron h1,.jumbotron .h1{color:#444444}.jumbotron p{margin-bottom:15px;font-size:20px;font-weight:200}.jumbotron>hr{border-top-color:#e0e0e0}.container .jumbotron,.container-fluid .jumbotron{border-radius:3px;padding-left:15px;padding-right:15px}.jumbotron .container{max-width:100%}@media screen and (min-width:768px){.jumbotron{padding-top:48px;padding-bottom:48px}.container .jumbotron,.container-fluid .jumbotron{padding-left:60px;padding-right:60px}.jumbotron h1,.jumbotron .h1{font-size:59px}}.thumbnail{display:block;padding:4px;margin-bottom:23px;line-height:1.846;background-color:#ffffff;border:1px solid #dddddd;border-radius:3px;-webkit-transition:border .2s ease-in-out;-o-transition:border .2s ease-in-out;transition:border .2s ease-in-out}.thumbnail>img,.thumbnail a>img{margin-left:auto;margin-right:auto}a.thumbnail:hover,a.thumbnail:focus,a.thumbnail.active{border-color:#2196f3}.thumbnail .caption{padding:9px;color:#666666}.alert{padding:15px;margin-bottom:23px;border:1px solid transparent;border-radius:3px}.alert h4{margin-top:0;color:inherit}.alert .alert-link{font-weight:bold}.alert>p,.alert>ul{margin-bottom:0}.alert>p+p{margin-top:5px}.alert-dismissable,.alert-dismissible{padding-right:35px}.alert-dismissable .close,.alert-dismissible .close{position:relative;top:-2px;right:-21px;color:inherit}.alert-success{background-color:#dff0d8;border-color:#d6e9c6;color:#4caf50}.alert-success hr{border-top-color:#c9e2b3}.alert-success .alert-link{color:#3d8b40}.alert-info{background-color:#e1bee7;border-color:#cba4dd;color:#9c27b0}.alert-info hr{border-top-color:#c191d6}.alert-info .alert-link{color:#771e86}.alert-warning{background-color:#ffe0b2;border-color:#ffc599;color:#ff9800}.alert-warning hr{border-top-color:#ffb67f}.alert-warning .alert-link{color:#cc7a00}.alert-danger{background-color:#f9bdbb;border-color:#f7a4af;color:#e51c23}.alert-danger hr{border-top-color:#f58c9a}.alert-danger .alert-link{color:#b9151b}@-webkit-keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}@-o-keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}@keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}.progress{overflow:hidden;height:23px;margin-bottom:23px;background-color:#f5f5f5;border-radius:3px;-webkit-box-shadow:inset 0 1px 2px rgba(0,0,0,0.1);box-shadow:inset 0 1px 2px rgba(0,0,0,0.1)}.progress-bar{float:left;width:0%;height:100%;font-size:12px;line-height:23px;color:#ffffff;text-align:center;background-color:#2196f3;-webkit-box-shadow:inset 0 -1px 0 rgba(0,0,0,0.15);box-shadow:inset 0 -1px 0 rgba(0,0,0,0.15);-webkit-transition:width 0.6s ease;-o-transition:width 0.6s ease;transition:width 0.6s ease}.progress-striped .progress-bar,.progress-bar-striped{background-image:-webkit-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:-o-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);-webkit-background-size:40px 40px;background-size:40px 40px}.progress.active .progress-bar,.progress-bar.active{-webkit-animation:progress-bar-stripes 2s linear infinite;-o-animation:progress-bar-stripes 2s linear infinite;animation:progress-bar-stripes 2s linear infinite}.progress-bar-success{background-color:#4caf50}.progress-striped .progress-bar-success{background-image:-webkit-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:-o-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent)}.progress-bar-info{background-color:#9c27b0}.progress-striped .progress-bar-info{background-image:-webkit-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:-o-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent)}.progress-bar-warning{background-color:#ff9800}.progress-striped .progress-bar-warning{background-image:-webkit-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:-o-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent)}.progress-bar-danger{background-color:#e51c23}.progress-striped .progress-bar-danger{background-image:-webkit-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:-o-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent)}.media{margin-top:15px}.media:first-child{margin-top:0}.media,.media-body{zoom:1;overflow:hidden}.media-body{width:10000px}.media-object{display:block}.media-object.img-thumbnail{max-width:none}.media-right,.media>.pull-right{padding-left:10px}.media-left,.media>.pull-left{padding-right:10px}.media-left,.media-right,.media-body{display:table-cell;vertical-align:top}.media-middle{vertical-align:middle}.media-bottom{vertical-align:bottom}.media-heading{margin-top:0;margin-bottom:5px}.media-list{padding-left:0;list-style:none}.list-group{margin-bottom:20px;padding-left:0}.list-group-item{position:relative;display:block;padding:10px 15px;margin-bottom:-1px;background-color:#ffffff;border:1px solid #dddddd}.list-group-item:first-child{border-top-right-radius:3px;border-top-left-radius:3px}.list-group-item:last-child{margin-bottom:0;border-bottom-right-radius:3px;border-bottom-left-radius:3px}a.list-group-item,button.list-group-item{color:#555555}a.list-group-item .list-group-item-heading,button.list-group-item .list-group-item-heading{color:#333333}a.list-group-item:hover,button.list-group-item:hover,a.list-group-item:focus,button.list-group-item:focus{text-decoration:none;color:#555555;background-color:#f5f5f5}button.list-group-item{width:100%;text-align:left}.list-group-item.disabled,.list-group-item.disabled:hover,.list-group-item.disabled:focus{background-color:#eeeeee;color:#bbbbbb;cursor:not-allowed}.list-group-item.disabled .list-group-item-heading,.list-group-item.disabled:hover .list-group-item-heading,.list-group-item.disabled:focus .list-group-item-heading{color:inherit}.list-group-item.disabled .list-group-item-text,.list-group-item.disabled:hover .list-group-item-text,.list-group-item.disabled:focus .list-group-item-text{color:#bbbbbb}.list-group-item.active,.list-group-item.active:hover,.list-group-item.active:focus{z-index:2;color:#ffffff;background-color:#2196f3;border-color:#2196f3}.list-group-item.active .list-group-item-heading,.list-group-item.active:hover .list-group-item-heading,.list-group-item.active:focus .list-group-item-heading,.list-group-item.active .list-group-item-heading>small,.list-group-item.active:hover .list-group-item-heading>small,.list-group-item.active:focus .list-group-item-heading>small,.list-group-item.active .list-group-item-heading>.small,.list-group-item.active:hover .list-group-item-heading>.small,.list-group-item.active:focus .list-group-item-heading>.small{color:inherit}.list-group-item.active .list-group-item-text,.list-group-item.active:hover .list-group-item-text,.list-group-item.active:focus .list-group-item-text{color:#e3f2fd}.list-group-item-success{color:#4caf50;background-color:#dff0d8}a.list-group-item-success,button.list-group-item-success{color:#4caf50}a.list-group-item-success .list-group-item-heading,button.list-group-item-success .list-group-item-heading{color:inherit}a.list-group-item-success:hover,button.list-group-item-success:hover,a.list-group-item-success:focus,button.list-group-item-success:focus{color:#4caf50;background-color:#d0e9c6}a.list-group-item-success.active,button.list-group-item-success.active,a.list-group-item-success.active:hover,button.list-group-item-success.active:hover,a.list-group-item-success.active:focus,button.list-group-item-success.active:focus{color:#fff;background-color:#4caf50;border-color:#4caf50}.list-group-item-info{color:#9c27b0;background-color:#e1bee7}a.list-group-item-info,button.list-group-item-info{color:#9c27b0}a.list-group-item-info .list-group-item-heading,button.list-group-item-info .list-group-item-heading{color:inherit}a.list-group-item-info:hover,button.list-group-item-info:hover,a.list-group-item-info:focus,button.list-group-item-info:focus{color:#9c27b0;background-color:#d8abe0}a.list-group-item-info.active,button.list-group-item-info.active,a.list-group-item-info.active:hover,button.list-group-item-info.active:hover,a.list-group-item-info.active:focus,button.list-group-item-info.active:focus{color:#fff;background-color:#9c27b0;border-color:#9c27b0}.list-group-item-warning{color:#ff9800;background-color:#ffe0b2}a.list-group-item-warning,button.list-group-item-warning{color:#ff9800}a.list-group-item-warning .list-group-item-heading,button.list-group-item-warning .list-group-item-heading{color:inherit}a.list-group-item-warning:hover,button.list-group-item-warning:hover,a.list-group-item-warning:focus,button.list-group-item-warning:focus{color:#ff9800;background-color:#ffd699}a.list-group-item-warning.active,button.list-group-item-warning.active,a.list-group-item-warning.active:hover,button.list-group-item-warning.active:hover,a.list-group-item-warning.active:focus,button.list-group-item-warning.active:focus{color:#fff;background-color:#ff9800;border-color:#ff9800}.list-group-item-danger{color:#e51c23;background-color:#f9bdbb}a.list-group-item-danger,button.list-group-item-danger{color:#e51c23}a.list-group-item-danger .list-group-item-heading,button.list-group-item-danger .list-group-item-heading{color:inherit}a.list-group-item-danger:hover,button.list-group-item-danger:hover,a.list-group-item-danger:focus,button.list-group-item-danger:focus{color:#e51c23;background-color:#f7a6a4}a.list-group-item-danger.active,button.list-group-item-danger.active,a.list-group-item-danger.active:hover,button.list-group-item-danger.active:hover,a.list-group-item-danger.active:focus,button.list-group-item-danger.active:focus{color:#fff;background-color:#e51c23;border-color:#e51c23}.list-group-item-heading{margin-top:0;margin-bottom:5px}.list-group-item-text{margin-bottom:0;line-height:1.3}.panel{margin-bottom:23px;background-color:#ffffff;border:1px solid transparent;border-radius:3px;-webkit-box-shadow:0 1px 1px rgba(0,0,0,0.05);box-shadow:0 1px 1px rgba(0,0,0,0.05)}.panel-body{padding:15px}.panel-heading{padding:10px 15px;border-bottom:1px solid transparent;border-top-right-radius:2px;border-top-left-radius:2px}.panel-heading>.dropdown .dropdown-toggle{color:inherit}.panel-title{margin-top:0;margin-bottom:0;font-size:15px;color:inherit}.panel-title>a,.panel-title>small,.panel-title>.small,.panel-title>small>a,.panel-title>.small>a{color:inherit}.panel-footer{padding:10px 15px;background-color:#f5f5f5;border-top:1px solid #dddddd;border-bottom-right-radius:2px;border-bottom-left-radius:2px}.panel>.list-group,.panel>.panel-collapse>.list-group{margin-bottom:0}.panel>.list-group .list-group-item,.panel>.panel-collapse>.list-group .list-group-item{border-width:1px 0;border-radius:0}.panel>.list-group:first-child .list-group-item:first-child,.panel>.panel-collapse>.list-group:first-child .list-group-item:first-child{border-top:0;border-top-right-radius:2px;border-top-left-radius:2px}.panel>.list-group:last-child .list-group-item:last-child,.panel>.panel-collapse>.list-group:last-child .list-group-item:last-child{border-bottom:0;border-bottom-right-radius:2px;border-bottom-left-radius:2px}.panel>.panel-heading+.panel-collapse>.list-group .list-group-item:first-child{border-top-right-radius:0;border-top-left-radius:0}.panel-heading+.list-group .list-group-item:first-child{border-top-width:0}.list-group+.panel-footer{border-top-width:0}.panel>.table,.panel>.table-responsive>.table,.panel>.panel-collapse>.table{margin-bottom:0}.panel>.table caption,.panel>.table-responsive>.table caption,.panel>.panel-collapse>.table caption{padding-left:15px;padding-right:15px}.panel>.table:first-child,.panel>.table-responsive:first-child>.table:first-child{border-top-right-radius:2px;border-top-left-radius:2px}.panel>.table:first-child>thead:first-child>tr:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child{border-top-left-radius:2px;border-top-right-radius:2px}.panel>.table:first-child>thead:first-child>tr:first-child td:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child td:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child td:first-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child td:first-child,.panel>.table:first-child>thead:first-child>tr:first-child th:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child th:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child th:first-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child th:first-child{border-top-left-radius:2px}.panel>.table:first-child>thead:first-child>tr:first-child td:last-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child td:last-child,.panel>.table:first-child>tbody:first-child>tr:first-child td:last-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child td:last-child,.panel>.table:first-child>thead:first-child>tr:first-child th:last-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child th:last-child,.panel>.table:first-child>tbody:first-child>tr:first-child th:last-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child th:last-child{border-top-right-radius:2px}.panel>.table:last-child,.panel>.table-responsive:last-child>.table:last-child{border-bottom-right-radius:2px;border-bottom-left-radius:2px}.panel>.table:last-child>tbody:last-child>tr:last-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child{border-bottom-left-radius:2px;border-bottom-right-radius:2px}.panel>.table:last-child>tbody:last-child>tr:last-child td:first-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child td:first-child,.panel>.table:last-child>tfoot:last-child>tr:last-child td:first-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child td:first-child,.panel>.table:last-child>tbody:last-child>tr:last-child th:first-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child th:first-child,.panel>.table:last-child>tfoot:last-child>tr:last-child th:first-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child th:first-child{border-bottom-left-radius:2px}.panel>.table:last-child>tbody:last-child>tr:last-child td:last-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child td:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child td:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child td:last-child,.panel>.table:last-child>tbody:last-child>tr:last-child th:last-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child th:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child th:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child th:last-child{border-bottom-right-radius:2px}.panel>.panel-body+.table,.panel>.panel-body+.table-responsive,.panel>.table+.panel-body,.panel>.table-responsive+.panel-body{border-top:1px solid #dddddd}.panel>.table>tbody:first-child>tr:first-child th,.panel>.table>tbody:first-child>tr:first-child td{border-top:0}.panel>.table-bordered,.panel>.table-responsive>.table-bordered{border:0}.panel>.table-bordered>thead>tr>th:first-child,.panel>.table-responsive>.table-bordered>thead>tr>th:first-child,.panel>.table-bordered>tbody>tr>th:first-child,.panel>.table-responsive>.table-bordered>tbody>tr>th:first-child,.panel>.table-bordered>tfoot>tr>th:first-child,.panel>.table-responsive>.table-bordered>tfoot>tr>th:first-child,.panel>.table-bordered>thead>tr>td:first-child,.panel>.table-responsive>.table-bordered>thead>tr>td:first-child,.panel>.table-bordered>tbody>tr>td:first-child,.panel>.table-responsive>.table-bordered>tbody>tr>td:first-child,.panel>.table-bordered>tfoot>tr>td:first-child,.panel>.table-responsive>.table-bordered>tfoot>tr>td:first-child{border-left:0}.panel>.table-bordered>thead>tr>th:last-child,.panel>.table-responsive>.table-bordered>thead>tr>th:last-child,.panel>.table-bordered>tbody>tr>th:last-child,.panel>.table-responsive>.table-bordered>tbody>tr>th:last-child,.panel>.table-bordered>tfoot>tr>th:last-child,.panel>.table-responsive>.table-bordered>tfoot>tr>th:last-child,.panel>.table-bordered>thead>tr>td:last-child,.panel>.table-responsive>.table-bordered>thead>tr>td:last-child,.panel>.table-bordered>tbody>tr>td:last-child,.panel>.table-responsive>.table-bordered>tbody>tr>td:last-child,.panel>.table-bordered>tfoot>tr>td:last-child,.panel>.table-responsive>.table-bordered>tfoot>tr>td:last-child{border-right:0}.panel>.table-bordered>thead>tr:first-child>td,.panel>.table-responsive>.table-bordered>thead>tr:first-child>td,.panel>.table-bordered>tbody>tr:first-child>td,.panel>.table-responsive>.table-bordered>tbody>tr:first-child>td,.panel>.table-bordered>thead>tr:first-child>th,.panel>.table-responsive>.table-bordered>thead>tr:first-child>th,.panel>.table-bordered>tbody>tr:first-child>th,.panel>.table-responsive>.table-bordered>tbody>tr:first-child>th{border-bottom:0}.panel>.table-bordered>tbody>tr:last-child>td,.panel>.table-responsive>.table-bordered>tbody>tr:last-child>td,.panel>.table-bordered>tfoot>tr:last-child>td,.panel>.table-responsive>.table-bordered>tfoot>tr:last-child>td,.panel>.table-bordered>tbody>tr:last-child>th,.panel>.table-responsive>.table-bordered>tbody>tr:last-child>th,.panel>.table-bordered>tfoot>tr:last-child>th,.panel>.table-responsive>.table-bordered>tfoot>tr:last-child>th{border-bottom:0}.panel>.table-responsive{border:0;margin-bottom:0}.panel-group{margin-bottom:23px}.panel-group .panel{margin-bottom:0;border-radius:3px}.panel-group .panel+.panel{margin-top:5px}.panel-group .panel-heading{border-bottom:0}.panel-group .panel-heading+.panel-collapse>.panel-body,.panel-group .panel-heading+.panel-collapse>.list-group{border-top:1px solid #dddddd}.panel-group .panel-footer{border-top:0}.panel-group .panel-footer+.panel-collapse .panel-body{border-bottom:1px solid #dddddd}.panel-default{border-color:#dddddd}.panel-default>.panel-heading{color:#212121;background-color:#f5f5f5;border-color:#dddddd}.panel-default>.panel-heading+.panel-collapse>.panel-body{border-top-color:#dddddd}.panel-default>.panel-heading .badge{color:#f5f5f5;background-color:#212121}.panel-default>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#dddddd}.panel-primary{border-color:#2196f3}.panel-primary>.panel-heading{color:#ffffff;background-color:#2196f3;border-color:#2196f3}.panel-primary>.panel-heading+.panel-collapse>.panel-body{border-top-color:#2196f3}.panel-primary>.panel-heading .badge{color:#2196f3;background-color:#ffffff}.panel-primary>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#2196f3}.panel-success{border-color:#d6e9c6}.panel-success>.panel-heading{color:#ffffff;background-color:#4caf50;border-color:#d6e9c6}.panel-success>.panel-heading+.panel-collapse>.panel-body{border-top-color:#d6e9c6}.panel-success>.panel-heading .badge{color:#4caf50;background-color:#ffffff}.panel-success>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#d6e9c6}.panel-info{border-color:#cba4dd}.panel-info>.panel-heading{color:#ffffff;background-color:#9c27b0;border-color:#cba4dd}.panel-info>.panel-heading+.panel-collapse>.panel-body{border-top-color:#cba4dd}.panel-info>.panel-heading .badge{color:#9c27b0;background-color:#ffffff}.panel-info>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#cba4dd}.panel-warning{border-color:#ffc599}.panel-warning>.panel-heading{color:#ffffff;background-color:#ff9800;border-color:#ffc599}.panel-warning>.panel-heading+.panel-collapse>.panel-body{border-top-color:#ffc599}.panel-warning>.panel-heading .badge{color:#ff9800;background-color:#ffffff}.panel-warning>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#ffc599}.panel-danger{border-color:#f7a4af}.panel-danger>.panel-heading{color:#ffffff;background-color:#e51c23;border-color:#f7a4af}.panel-danger>.panel-heading+.panel-collapse>.panel-body{border-top-color:#f7a4af}.panel-danger>.panel-heading .badge{color:#e51c23;background-color:#ffffff}.panel-danger>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#f7a4af}.embed-responsive{position:relative;display:block;height:0;padding:0;overflow:hidden}.embed-responsive .embed-responsive-item,.embed-responsive iframe,.embed-responsive embed,.embed-responsive object,.embed-responsive video{position:absolute;top:0;left:0;bottom:0;height:100%;width:100%;border:0}.embed-responsive-16by9{padding-bottom:56.25%}.embed-responsive-4by3{padding-bottom:75%}.well{min-height:20px;padding:19px;margin-bottom:20px;background-color:#f9f9f9;border:1px solid transparent;border-radius:3px;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,0.05);box-shadow:inset 0 1px 1px rgba(0,0,0,0.05)}.well blockquote{border-color:#ddd;border-color:rgba(0,0,0,0.15)}.well-lg{padding:24px;border-radius:3px}.well-sm{padding:9px;border-radius:3px}.close{float:right;font-size:19.5px;font-weight:normal;line-height:1;color:#000000;text-shadow:none;opacity:0.2;filter:alpha(opacity=20)}.close:hover,.close:focus{color:#000000;text-decoration:none;cursor:pointer;opacity:0.5;filter:alpha(opacity=50)}button.close{padding:0;cursor:pointer;background:transparent;border:0;-webkit-appearance:none}.modal-open{overflow:hidden}.modal{display:none;overflow:hidden;position:fixed;top:0;right:0;bottom:0;left:0;z-index:1050;-webkit-overflow-scrolling:touch;outline:0}.modal.fade .modal-dialog{-webkit-transform:translate(0, -25%);-ms-transform:translate(0, -25%);-o-transform:translate(0, -25%);transform:translate(0, -25%);-webkit-transition:-webkit-transform .3s ease-out;-o-transition:-o-transform .3s ease-out;transition:transform .3s ease-out}.modal.in .modal-dialog{-webkit-transform:translate(0, 0);-ms-transform:translate(0, 0);-o-transform:translate(0, 0);transform:translate(0, 0)}.modal-open .modal{overflow-x:hidden;overflow-y:auto}.modal-dialog{position:relative;width:auto;margin:10px}.modal-content{position:relative;background-color:#ffffff;border:1px solid #999999;border:1px solid transparent;border-radius:3px;-webkit-box-shadow:0 3px 9px rgba(0,0,0,0.5);box-shadow:0 3px 9px rgba(0,0,0,0.5);-webkit-background-clip:padding-box;background-clip:padding-box;outline:0}.modal-backdrop{position:fixed;top:0;right:0;bottom:0;left:0;z-index:1040;background-color:#000000}.modal-backdrop.fade{opacity:0;filter:alpha(opacity=0)}.modal-backdrop.in{opacity:0.5;filter:alpha(opacity=50)}.modal-header{padding:15px;border-bottom:1px solid transparent}.modal-header .close{margin-top:-2px}.modal-title{margin:0;line-height:1.846}.modal-body{position:relative;padding:15px}.modal-footer{padding:15px;text-align:right;border-top:1px solid transparent}.modal-footer .btn+.btn{margin-left:5px;margin-bottom:0}.modal-footer .btn-group .btn+.btn{margin-left:-1px}.modal-footer .btn-block+.btn-block{margin-left:0}.modal-scrollbar-measure{position:absolute;top:-9999px;width:50px;height:50px;overflow:scroll}@media (min-width:768px){.modal-dialog{width:600px;margin:30px auto}.modal-content{-webkit-box-shadow:0 5px 15px rgba(0,0,0,0.5);box-shadow:0 5px 15px rgba(0,0,0,0.5)}.modal-sm{width:300px}}@media (min-width:992px){.modal-lg{width:900px}}.tooltip{position:absolute;z-index:1070;display:block;font-family:"Roboto","Helvetica Neue",Helvetica,Arial,sans-serif;font-style:normal;font-weight:normal;letter-spacing:normal;line-break:auto;line-height:1.846;text-align:left;text-align:start;text-decoration:none;text-shadow:none;text-transform:none;white-space:normal;word-break:normal;word-spacing:normal;word-wrap:normal;font-size:12px;opacity:0;filter:alpha(opacity=0)}.tooltip.in{opacity:0.9;filter:alpha(opacity=90)}.tooltip.top{margin-top:-3px;padding:5px 0}.tooltip.right{margin-left:3px;padding:0 5px}.tooltip.bottom{margin-top:3px;padding:5px 0}.tooltip.left{margin-left:-3px;padding:0 5px}.tooltip-inner{max-width:200px;padding:3px 8px;color:#ffffff;text-align:center;background-color:#727272;border-radius:3px}.tooltip-arrow{position:absolute;width:0;height:0;border-color:transparent;border-style:solid}.tooltip.top .tooltip-arrow{bottom:0;left:50%;margin-left:-5px;border-width:5px 5px 0;border-top-color:#727272}.tooltip.top-left .tooltip-arrow{bottom:0;right:5px;margin-bottom:-5px;border-width:5px 5px 0;border-top-color:#727272}.tooltip.top-right .tooltip-arrow{bottom:0;left:5px;margin-bottom:-5px;border-width:5px 5px 0;border-top-color:#727272}.tooltip.right .tooltip-arrow{top:50%;left:0;margin-top:-5px;border-width:5px 5px 5px 0;border-right-color:#727272}.tooltip.left .tooltip-arrow{top:50%;right:0;margin-top:-5px;border-width:5px 0 5px 5px;border-left-color:#727272}.tooltip.bottom .tooltip-arrow{top:0;left:50%;margin-left:-5px;border-width:0 5px 5px;border-bottom-color:#727272}.tooltip.bottom-left .tooltip-arrow{top:0;right:5px;margin-top:-5px;border-width:0 5px 5px;border-bottom-color:#727272}.tooltip.bottom-right .tooltip-arrow{top:0;left:5px;margin-top:-5px;border-width:0 5px 5px;border-bottom-color:#727272}.popover{position:absolute;top:0;left:0;z-index:1060;display:none;max-width:276px;padding:1px;font-family:"Roboto","Helvetica Neue",Helvetica,Arial,sans-serif;font-style:normal;font-weight:normal;letter-spacing:normal;line-break:auto;line-height:1.846;text-align:left;text-align:start;text-decoration:none;text-shadow:none;text-transform:none;white-space:normal;word-break:normal;word-spacing:normal;word-wrap:normal;font-size:13px;background-color:#ffffff;-webkit-background-clip:padding-box;background-clip:padding-box;border:1px solid transparent;border-radius:3px;-webkit-box-shadow:0 5px 10px rgba(0,0,0,0.2);box-shadow:0 5px 10px rgba(0,0,0,0.2)}.popover.top{margin-top:-10px}.popover.right{margin-left:10px}.popover.bottom{margin-top:10px}.popover.left{margin-left:-10px}.popover-title{margin:0;padding:8px 14px;font-size:13px;background-color:#f7f7f7;border-bottom:1px solid #ebebeb;border-radius:2px 2px 0 0}.popover-content{padding:9px 14px}.popover>.arrow,.popover>.arrow:after{position:absolute;display:block;width:0;height:0;border-color:transparent;border-style:solid}.popover>.arrow{border-width:11px}.popover>.arrow:after{border-width:10px;content:""}.popover.top>.arrow{left:50%;margin-left:-11px;border-bottom-width:0;border-top-color:rgba(0,0,0,0);border-top-color:rgba(0,0,0,0.075);bottom:-11px}.popover.top>.arrow:after{content:" ";bottom:1px;margin-left:-10px;border-bottom-width:0;border-top-color:#ffffff}.popover.right>.arrow{top:50%;left:-11px;margin-top:-11px;border-left-width:0;border-right-color:rgba(0,0,0,0);border-right-color:rgba(0,0,0,0.075)}.popover.right>.arrow:after{content:" ";left:1px;bottom:-10px;border-left-width:0;border-right-color:#ffffff}.popover.bottom>.arrow{left:50%;margin-left:-11px;border-top-width:0;border-bottom-color:rgba(0,0,0,0);border-bottom-color:rgba(0,0,0,0.075);top:-11px}.popover.bottom>.arrow:after{content:" ";top:1px;margin-left:-10px;border-top-width:0;border-bottom-color:#ffffff}.popover.left>.arrow{top:50%;right:-11px;margin-top:-11px;border-right-width:0;border-left-color:rgba(0,0,0,0);border-left-color:rgba(0,0,0,0.075)}.popover.left>.arrow:after{content:" ";right:1px;border-right-width:0;border-left-color:#ffffff;bottom:-10px}.carousel{position:relative}.carousel-inner{position:relative;overflow:hidden;width:100%}.carousel-inner>.item{display:none;position:relative;-webkit-transition:.6s ease-in-out left;-o-transition:.6s ease-in-out left;transition:.6s ease-in-out left}.carousel-inner>.item>img,.carousel-inner>.item>a>img{line-height:1}@media all and (transform-3d),(-webkit-transform-3d){.carousel-inner>.item{-webkit-transition:-webkit-transform .6s ease-in-out;-o-transition:-o-transform .6s ease-in-out;transition:transform .6s ease-in-out;-webkit-backface-visibility:hidden;backface-visibility:hidden;-webkit-perspective:1000px;perspective:1000px}.carousel-inner>.item.next,.carousel-inner>.item.active.right{-webkit-transform:translate3d(100%, 0, 0);transform:translate3d(100%, 0, 0);left:0}.carousel-inner>.item.prev,.carousel-inner>.item.active.left{-webkit-transform:translate3d(-100%, 0, 0);transform:translate3d(-100%, 0, 0);left:0}.carousel-inner>.item.next.left,.carousel-inner>.item.prev.right,.carousel-inner>.item.active{-webkit-transform:translate3d(0, 0, 0);transform:translate3d(0, 0, 0);left:0}}.carousel-inner>.active,.carousel-inner>.next,.carousel-inner>.prev{display:block}.carousel-inner>.active{left:0}.carousel-inner>.next,.carousel-inner>.prev{position:absolute;top:0;width:100%}.carousel-inner>.next{left:100%}.carousel-inner>.prev{left:-100%}.carousel-inner>.next.left,.carousel-inner>.prev.right{left:0}.carousel-inner>.active.left{left:-100%}.carousel-inner>.active.right{left:100%}.carousel-control{position:absolute;top:0;left:0;bottom:0;width:15%;opacity:0.5;filter:alpha(opacity=50);font-size:20px;color:#ffffff;text-align:center;text-shadow:0 1px 2px rgba(0,0,0,0.6);background-color:rgba(0,0,0,0)}.carousel-control.left{background-image:-webkit-linear-gradient(left, rgba(0,0,0,0.5) 0, rgba(0,0,0,0.0001) 100%);background-image:-o-linear-gradient(left, rgba(0,0,0,0.5) 0, rgba(0,0,0,0.0001) 100%);background-image:-webkit-gradient(linear, left top, right top, from(rgba(0,0,0,0.5)), to(rgba(0,0,0,0.0001)));background-image:linear-gradient(to right, rgba(0,0,0,0.5) 0, rgba(0,0,0,0.0001) 100%);background-repeat:repeat-x;filter:progid:DXImageTransform.Microsoft.gradient(startColorstr='#80000000', endColorstr='#00000000', GradientType=1)}.carousel-control.right{left:auto;right:0;background-image:-webkit-linear-gradient(left, rgba(0,0,0,0.0001) 0, rgba(0,0,0,0.5) 100%);background-image:-o-linear-gradient(left, rgba(0,0,0,0.0001) 0, rgba(0,0,0,0.5) 100%);background-image:-webkit-gradient(linear, left top, right top, from(rgba(0,0,0,0.0001)), to(rgba(0,0,0,0.5)));background-image:linear-gradient(to right, rgba(0,0,0,0.0001) 0, rgba(0,0,0,0.5) 100%);background-repeat:repeat-x;filter:progid:DXImageTransform.Microsoft.gradient(startColorstr='#00000000', endColorstr='#80000000', GradientType=1)}.carousel-control:hover,.carousel-control:focus{outline:0;color:#ffffff;text-decoration:none;opacity:0.9;filter:alpha(opacity=90)}.carousel-control .icon-prev,.carousel-control .icon-next,.carousel-control .glyphicon-chevron-left,.carousel-control .glyphicon-chevron-right{position:absolute;top:50%;margin-top:-10px;z-index:5;display:inline-block}.carousel-control .icon-prev,.carousel-control .glyphicon-chevron-left{left:50%;margin-left:-10px}.carousel-control .icon-next,.carousel-control .glyphicon-chevron-right{right:50%;margin-right:-10px}.carousel-control .icon-prev,.carousel-control .icon-next{width:20px;height:20px;line-height:1;font-family:serif}.carousel-control .icon-prev:before{content:'\2039'}.carousel-control .icon-next:before{content:'\203a'}.carousel-indicators{position:absolute;bottom:10px;left:50%;z-index:15;width:60%;margin-left:-30%;padding-left:0;list-style:none;text-align:center}.carousel-indicators li{display:inline-block;width:10px;height:10px;margin:1px;text-indent:-999px;border:1px solid #ffffff;border-radius:10px;cursor:pointer;background-color:#000 \9;background-color:rgba(0,0,0,0)}.carousel-indicators .active{margin:0;width:12px;height:12px;background-color:#ffffff}.carousel-caption{position:absolute;left:15%;right:15%;bottom:20px;z-index:10;padding-top:20px;padding-bottom:20px;color:#ffffff;text-align:center;text-shadow:0 1px 2px rgba(0,0,0,0.6)}.carousel-caption .btn{text-shadow:none}@media screen and (min-width:768px){.carousel-control .glyphicon-chevron-left,.carousel-control .glyphicon-chevron-right,.carousel-control .icon-prev,.carousel-control .icon-next{width:30px;height:30px;margin-top:-10px;font-size:30px}.carousel-control .glyphicon-chevron-left,.carousel-control .icon-prev{margin-left:-10px}.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next{margin-right:-10px}.carousel-caption{left:20%;right:20%;padding-bottom:30px}.carousel-indicators{bottom:20px}}.clearfix:before,.clearfix:after,.dl-horizontal dd:before,.dl-horizontal dd:after,.container:before,.container:after,.container-fluid:before,.container-fluid:after,.row:before,.row:after,.form-horizontal .form-group:before,.form-horizontal .form-group:after,.btn-toolbar:before,.btn-toolbar:after,.btn-group-vertical>.btn-group:before,.btn-group-vertical>.btn-group:after,.nav:before,.nav:after,.navbar:before,.navbar:after,.navbar-header:before,.navbar-header:after,.navbar-collapse:before,.navbar-collapse:after,.pager:before,.pager:after,.panel-body:before,.panel-body:after,.modal-header:before,.modal-header:after,.modal-footer:before,.modal-footer:after{content:" ";display:table}.clearfix:after,.dl-horizontal dd:after,.container:after,.container-fluid:after,.row:after,.form-horizontal .form-group:after,.btn-toolbar:after,.btn-group-vertical>.btn-group:after,.nav:after,.navbar:after,.navbar-header:after,.navbar-collapse:after,.pager:after,.panel-body:after,.modal-header:after,.modal-footer:after{clear:both}.center-block{display:block;margin-left:auto;margin-right:auto}.pull-right{float:right !important}.pull-left{float:left !important}.hide{display:none !important}.show{display:block !important}.invisible{visibility:hidden}.text-hide{font:0/0 a;color:transparent;text-shadow:none;background-color:transparent;border:0}.hidden{display:none !important}.affix{position:fixed}@-ms-viewport{width:device-width}.visible-xs,.visible-sm,.visible-md,.visible-lg{display:none !important}.visible-xs-block,.visible-xs-inline,.visible-xs-inline-block,.visible-sm-block,.visible-sm-inline,.visible-sm-inline-block,.visible-md-block,.visible-md-inline,.visible-md-inline-block,.visible-lg-block,.visible-lg-inline,.visible-lg-inline-block{display:none !important}@media (max-width:767px){.visible-xs{display:block !important}table.visible-xs{display:table !important}tr.visible-xs{display:table-row !important}th.visible-xs,td.visible-xs{display:table-cell !important}}@media (max-width:767px){.visible-xs-block{display:block !important}}@media (max-width:767px){.visible-xs-inline{display:inline !important}}@media (max-width:767px){.visible-xs-inline-block{display:inline-block !important}}@media (min-width:768px) and (max-width:991px){.visible-sm{display:block !important}table.visible-sm{display:table !important}tr.visible-sm{display:table-row !important}th.visible-sm,td.visible-sm{display:table-cell !important}}@media (min-width:768px) and (max-width:991px){.visible-sm-block{display:block !important}}@media (min-width:768px) and (max-width:991px){.visible-sm-inline{display:inline !important}}@media (min-width:768px) and (max-width:991px){.visible-sm-inline-block{display:inline-block !important}}@media (min-width:992px) and (max-width:1199px){.visible-md{display:block !important}table.visible-md{display:table !important}tr.visible-md{display:table-row !important}th.visible-md,td.visible-md{display:table-cell !important}}@media (min-width:992px) and (max-width:1199px){.visible-md-block{display:block !important}}@media (min-width:992px) and (max-width:1199px){.visible-md-inline{display:inline !important}}@media (min-width:992px) and (max-width:1199px){.visible-md-inline-block{display:inline-block !important}}@media (min-width:1200px){.visible-lg{display:block !important}table.visible-lg{display:table !important}tr.visible-lg{display:table-row !important}th.visible-lg,td.visible-lg{display:table-cell !important}}@media (min-width:1200px){.visible-lg-block{display:block !important}}@media (min-width:1200px){.visible-lg-inline{display:inline !important}}@media (min-width:1200px){.visible-lg-inline-block{display:inline-block !important}}@media (max-width:767px){.hidden-xs{display:none !important}}@media (min-width:768px) and (max-width:991px){.hidden-sm{display:none !important}}@media (min-width:992px) and (max-width:1199px){.hidden-md{display:none !important}}@media (min-width:1200px){.hidden-lg{display:none !important}}.visible-print{display:none !important}@media print{.visible-print{display:block !important}table.visible-print{display:table !important}tr.visible-print{display:table-row !important}th.visible-print,td.visible-print{display:table-cell !important}}.visible-print-block{display:none !important}@media print{.visible-print-block{display:block !important}}.visible-print-inline{display:none !important}@media print{.visible-print-inline{display:inline !important}}.visible-print-inline-block{display:none !important}@media print{.visible-print-inline-block{display:inline-block !important}}@media print{.hidden-print{display:none !important}}.navbar{border:none;-webkit-box-shadow:0 1px 2px rgba(0,0,0,0.3);box-shadow:0 1px 2px rgba(0,0,0,0.3)}.navbar-brand{font-size:24px}.navbar-inverse .navbar-form input[type=text],.navbar-inverse .navbar-form input[type=password]{color:#fff;-webkit-box-shadow:inset 0 -1px 0 #b2dbfb;box-shadow:inset 0 -1px 0 #b2dbfb}.navbar-inverse .navbar-form input[type=text]::-moz-placeholder,.navbar-inverse .navbar-form input[type=password]::-moz-placeholder{color:#b2dbfb;opacity:1}.navbar-inverse .navbar-form input[type=text]:-ms-input-placeholder,.navbar-inverse .navbar-form input[type=password]:-ms-input-placeholder{color:#b2dbfb}.navbar-inverse .navbar-form input[type=text]::-webkit-input-placeholder,.navbar-inverse .navbar-form input[type=password]::-webkit-input-placeholder{color:#b2dbfb}.navbar-inverse .navbar-form input[type=text]:focus,.navbar-inverse .navbar-form input[type=password]:focus{-webkit-box-shadow:inset 0 -2px 0 #fff;box-shadow:inset 0 -2px 0 #fff}.btn-default{-webkit-background-size:200% 200%;background-size:200%;background-position:50%}.btn-default:focus{background-color:#ffffff}.btn-default:hover,.btn-default:active:hover{background-color:#f0f0f0}.btn-default:active{background-color:#e0e0e0;background-image:-webkit-radial-gradient(circle, #e0e0e0 10%, #fff 11%);background-image:-o-radial-gradient(circle, #e0e0e0 10%, #fff 11%);background-image:radial-gradient(circle, #e0e0e0 10%, #fff 11%);background-repeat:no-repeat;-webkit-background-size:1000% 1000%;background-size:1000%;-webkit-box-shadow:2px 2px 4px rgba(0,0,0,0.4);box-shadow:2px 2px 4px rgba(0,0,0,0.4)}.btn-primary{-webkit-background-size:200% 200%;background-size:200%;background-position:50%}.btn-primary:focus{background-color:#2196f3}.btn-primary:hover,.btn-primary:active:hover{background-color:#0d87e9}.btn-primary:active{background-color:#0b76cc;background-image:-webkit-radial-gradient(circle, #0b76cc 10%, #2196f3 11%);background-image:-o-radial-gradient(circle, #0b76cc 10%, #2196f3 11%);background-image:radial-gradient(circle, #0b76cc 10%, #2196f3 11%);background-repeat:no-repeat;-webkit-background-size:1000% 1000%;background-size:1000%;-webkit-box-shadow:2px 2px 4px rgba(0,0,0,0.4);box-shadow:2px 2px 4px rgba(0,0,0,0.4)}.btn-success{-webkit-background-size:200% 200%;background-size:200%;background-position:50%}.btn-success:focus{background-color:#4caf50}.btn-success:hover,.btn-success:active:hover{background-color:#439a46}.btn-success:active{background-color:#39843c;background-image:-webkit-radial-gradient(circle, #39843c 10%, #4caf50 11%);background-image:-o-radial-gradient(circle, #39843c 10%, #4caf50 11%);background-image:radial-gradient(circle, #39843c 10%, #4caf50 11%);background-repeat:no-repeat;-webkit-background-size:1000% 1000%;background-size:1000%;-webkit-box-shadow:2px 2px 4px rgba(0,0,0,0.4);box-shadow:2px 2px 4px rgba(0,0,0,0.4)}.btn-info{-webkit-background-size:200% 200%;background-size:200%;background-position:50%}.btn-info:focus{background-color:#9c27b0}.btn-info:hover,.btn-info:active:hover{background-color:#862197}.btn-info:active{background-color:#701c7e;background-image:-webkit-radial-gradient(circle, #701c7e 10%, #9c27b0 11%);background-image:-o-radial-gradient(circle, #701c7e 10%, #9c27b0 11%);background-image:radial-gradient(circle, #701c7e 10%, #9c27b0 11%);background-repeat:no-repeat;-webkit-background-size:1000% 1000%;background-size:1000%;-webkit-box-shadow:2px 2px 4px rgba(0,0,0,0.4);box-shadow:2px 2px 4px rgba(0,0,0,0.4)}.btn-warning{-webkit-background-size:200% 200%;background-size:200%;background-position:50%}.btn-warning:focus{background-color:#ff9800}.btn-warning:hover,.btn-warning:active:hover{background-color:#e08600}.btn-warning:active{background-color:#c27400;background-image:-webkit-radial-gradient(circle, #c27400 10%, #ff9800 11%);background-image:-o-radial-gradient(circle, #c27400 10%, #ff9800 11%);background-image:radial-gradient(circle, #c27400 10%, #ff9800 11%);background-repeat:no-repeat;-webkit-background-size:1000% 1000%;background-size:1000%;-webkit-box-shadow:2px 2px 4px rgba(0,0,0,0.4);box-shadow:2px 2px 4px rgba(0,0,0,0.4)}.btn-danger{-webkit-background-size:200% 200%;background-size:200%;background-position:50%}.btn-danger:focus{background-color:#e51c23}.btn-danger:hover,.btn-danger:active:hover{background-color:#cb171e}.btn-danger:active{background-color:#b0141a;background-image:-webkit-radial-gradient(circle, #b0141a 10%, #e51c23 11%);background-image:-o-radial-gradient(circle, #b0141a 10%, #e51c23 11%);background-image:radial-gradient(circle, #b0141a 10%, #e51c23 11%);background-repeat:no-repeat;-webkit-background-size:1000% 1000%;background-size:1000%;-webkit-box-shadow:2px 2px 4px rgba(0,0,0,0.4);box-shadow:2px 2px 4px rgba(0,0,0,0.4)}.btn-link{-webkit-background-size:200% 200%;background-size:200%;background-position:50%}.btn-link:focus{background-color:#ffffff}.btn-link:hover,.btn-link:active:hover{background-color:#f0f0f0}.btn-link:active{background-color:#e0e0e0;background-image:-webkit-radial-gradient(circle, #e0e0e0 10%, #fff 11%);background-image:-o-radial-gradient(circle, #e0e0e0 10%, #fff 11%);background-image:radial-gradient(circle, #e0e0e0 10%, #fff 11%);background-repeat:no-repeat;-webkit-background-size:1000% 1000%;background-size:1000%;-webkit-box-shadow:2px 2px 4px rgba(0,0,0,0.4);box-shadow:2px 2px 4px rgba(0,0,0,0.4)}.btn{text-transform:uppercase;border:none;-webkit-box-shadow:1px 1px 4px rgba(0,0,0,0.4);box-shadow:1px 1px 4px rgba(0,0,0,0.4);-webkit-transition:all 0.4s;-o-transition:all 0.4s;transition:all 0.4s}.btn-link{border-radius:3px;-webkit-box-shadow:none;box-shadow:none;color:#444444}.btn-link:hover,.btn-link:focus{-webkit-box-shadow:none;box-shadow:none;color:#444444;text-decoration:none}.btn-default.disabled{background-color:rgba(0,0,0,0.1);color:rgba(0,0,0,0.4);opacity:1}.btn-group .btn+.btn,.btn-group .btn+.btn-group,.btn-group .btn-group+.btn,.btn-group .btn-group+.btn-group{margin-left:0}.btn-group-vertical>.btn+.btn,.btn-group-vertical>.btn+.btn-group,.btn-group-vertical>.btn-group+.btn,.btn-group-vertical>.btn-group+.btn-group{margin-top:0}body{-webkit-font-smoothing:antialiased;letter-spacing:.1px}p{margin:0 0 1em}input,button{-webkit-font-smoothing:antialiased;letter-spacing:.1px}a{-webkit-transition:all 0.2s;-o-transition:all 0.2s;transition:all 0.2s}.table-hover>tbody>tr,.table-hover>tbody>tr>th,.table-hover>tbody>tr>td{-webkit-transition:all 0.2s;-o-transition:all 0.2s;transition:all 0.2s}label{font-weight:normal}textarea,textarea.form-control,input.form-control,input[type=text],input[type=password],input[type=email],input[type=number],[type=text].form-control,[type=password].form-control,[type=email].form-control,[type=tel].form-control,[contenteditable].form-control{padding:0;border:none;border-radius:0;-webkit-appearance:none;-webkit-box-shadow:inset 0 -1px 0 #ddd;box-shadow:inset 0 -1px 0 #ddd;font-size:16px}textarea:focus,textarea.form-control:focus,input.form-control:focus,input[type=text]:focus,input[type=password]:focus,input[type=email]:focus,input[type=number]:focus,[type=text].form-control:focus,[type=password].form-control:focus,[type=email].form-control:focus,[type=tel].form-control:focus,[contenteditable].form-control:focus{-webkit-box-shadow:inset 0 -2px 0 #2196f3;box-shadow:inset 0 -2px 0 #2196f3}textarea[disabled],textarea.form-control[disabled],input.form-control[disabled],input[type=text][disabled],input[type=password][disabled],input[type=email][disabled],input[type=number][disabled],[type=text].form-control[disabled],[type=password].form-control[disabled],[type=email].form-control[disabled],[type=tel].form-control[disabled],[contenteditable].form-control[disabled],textarea[readonly],textarea.form-control[readonly],input.form-control[readonly],input[type=text][readonly],input[type=password][readonly],input[type=email][readonly],input[type=number][readonly],[type=text].form-control[readonly],[type=password].form-control[readonly],[type=email].form-control[readonly],[type=tel].form-control[readonly],[contenteditable].form-control[readonly]{-webkit-box-shadow:none;box-shadow:none;border-bottom:1px dotted #ddd}textarea.input-sm,textarea.form-control.input-sm,input.form-control.input-sm,input[type=text].input-sm,input[type=password].input-sm,input[type=email].input-sm,input[type=number].input-sm,[type=text].form-control.input-sm,[type=password].form-control.input-sm,[type=email].form-control.input-sm,[type=tel].form-control.input-sm,[contenteditable].form-control.input-sm{font-size:12px}textarea.input-lg,textarea.form-control.input-lg,input.form-control.input-lg,input[type=text].input-lg,input[type=password].input-lg,input[type=email].input-lg,input[type=number].input-lg,[type=text].form-control.input-lg,[type=password].form-control.input-lg,[type=email].form-control.input-lg,[type=tel].form-control.input-lg,[contenteditable].form-control.input-lg{font-size:17px}select,select.form-control{border:0;border-radius:0;-webkit-appearance:none;-moz-appearance:none;appearance:none;padding-left:0;padding-right:0\9;background-image:url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABoAAAAaCAMAAACelLz8AAAAJ1BMVEVmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmaP/QSjAAAADHRSTlMAAgMJC0uWpKa6wMxMdjkoAAAANUlEQVR4AeXJyQEAERAAsNl7Hf3X6xt0QL6JpZWq30pdvdadme+0PMdzvHm8YThHcT1H7K0BtOMDniZhWOgAAAAASUVORK5CYII=);-webkit-background-size:13px 13px;background-size:13px;background-repeat:no-repeat;background-position:right center;-webkit-box-shadow:inset 0 -1px 0 #ddd;box-shadow:inset 0 -1px 0 #ddd;font-size:16px;line-height:1.5}select::-ms-expand,select.form-control::-ms-expand{display:none}select.input-sm,select.form-control.input-sm{font-size:12px}select.input-lg,select.form-control.input-lg{font-size:17px}select:focus,select.form-control:focus{-webkit-box-shadow:inset 0 -2px 0 #2196f3;box-shadow:inset 0 -2px 0 #2196f3;background-image:url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABoAAAAaCAMAAACelLz8AAAAJ1BMVEUhISEhISEhISEhISEhISEhISEhISEhISEhISEhISEhISEhISEhISF8S9ewAAAADHRSTlMAAgMJC0uWpKa6wMxMdjkoAAAANUlEQVR4AeXJyQEAERAAsNl7Hf3X6xt0QL6JpZWq30pdvdadme+0PMdzvHm8YThHcT1H7K0BtOMDniZhWOgAAAAASUVORK5CYII=)}select[multiple],select.form-control[multiple]{background:none}.radio label,.radio-inline label,.checkbox label,.checkbox-inline label{padding-left:25px}.radio input[type="radio"],.radio-inline input[type="radio"],.checkbox input[type="radio"],.checkbox-inline input[type="radio"],.radio input[type="checkbox"],.radio-inline input[type="checkbox"],.checkbox input[type="checkbox"],.checkbox-inline input[type="checkbox"]{margin-left:-25px}input[type="radio"],.radio input[type="radio"],.radio-inline input[type="radio"]{position:relative;margin-top:6px;margin-right:4px;vertical-align:top;border:none;background-color:transparent;-webkit-appearance:none;appearance:none;cursor:pointer}input[type="radio"]:focus,.radio input[type="radio"]:focus,.radio-inline input[type="radio"]:focus{outline:none}input[type="radio"]:before,.radio input[type="radio"]:before,.radio-inline input[type="radio"]:before,input[type="radio"]:after,.radio input[type="radio"]:after,.radio-inline input[type="radio"]:after{content:"";display:block;width:18px;height:18px;border-radius:50%;-webkit-transition:240ms;-o-transition:240ms;transition:240ms}input[type="radio"]:before,.radio input[type="radio"]:before,.radio-inline input[type="radio"]:before{position:absolute;left:0;top:-3px;background-color:#2196f3;-webkit-transform:scale(0);-ms-transform:scale(0);-o-transform:scale(0);transform:scale(0)}input[type="radio"]:after,.radio input[type="radio"]:after,.radio-inline input[type="radio"]:after{position:relative;top:-3px;border:2px solid #666666}input[type="radio"]:checked:before,.radio input[type="radio"]:checked:before,.radio-inline input[type="radio"]:checked:before{-webkit-transform:scale(.5);-ms-transform:scale(.5);-o-transform:scale(.5);transform:scale(.5)}input[type="radio"]:disabled:checked:before,.radio input[type="radio"]:disabled:checked:before,.radio-inline input[type="radio"]:disabled:checked:before{background-color:#bbbbbb}input[type="radio"]:checked:after,.radio input[type="radio"]:checked:after,.radio-inline input[type="radio"]:checked:after{border-color:#2196f3}input[type="radio"]:disabled:after,.radio input[type="radio"]:disabled:after,.radio-inline input[type="radio"]:disabled:after,input[type="radio"]:disabled:checked:after,.radio input[type="radio"]:disabled:checked:after,.radio-inline input[type="radio"]:disabled:checked:after{border-color:#bbbbbb}input[type="checkbox"],.checkbox input[type="checkbox"],.checkbox-inline input[type="checkbox"]{position:relative;border:none;margin-bottom:-4px;-webkit-appearance:none;appearance:none;cursor:pointer}input[type="checkbox"]:focus,.checkbox input[type="checkbox"]:focus,.checkbox-inline input[type="checkbox"]:focus{outline:none}input[type="checkbox"]:focus:after,.checkbox input[type="checkbox"]:focus:after,.checkbox-inline input[type="checkbox"]:focus:after{border-color:#2196f3}input[type="checkbox"]:after,.checkbox input[type="checkbox"]:after,.checkbox-inline input[type="checkbox"]:after{content:"";display:block;width:18px;height:18px;margin-top:-2px;margin-right:5px;border:2px solid #666666;border-radius:2px;-webkit-transition:240ms;-o-transition:240ms;transition:240ms}input[type="checkbox"]:checked:before,.checkbox input[type="checkbox"]:checked:before,.checkbox-inline input[type="checkbox"]:checked:before{content:"";position:absolute;top:0;left:6px;display:table;width:6px;height:12px;border:2px solid #fff;border-top-width:0;border-left-width:0;-webkit-transform:rotate(45deg);-ms-transform:rotate(45deg);-o-transform:rotate(45deg);transform:rotate(45deg)}input[type="checkbox"]:checked:after,.checkbox input[type="checkbox"]:checked:after,.checkbox-inline input[type="checkbox"]:checked:after{background-color:#2196f3;border-color:#2196f3}input[type="checkbox"]:disabled:after,.checkbox input[type="checkbox"]:disabled:after,.checkbox-inline input[type="checkbox"]:disabled:after{border-color:#bbbbbb}input[type="checkbox"]:disabled:checked:after,.checkbox input[type="checkbox"]:disabled:checked:after,.checkbox-inline input[type="checkbox"]:disabled:checked:after{background-color:#bbbbbb;border-color:transparent}.has-warning input:not([type=checkbox]),.has-warning .form-control,.has-warning input.form-control[readonly],.has-warning input[type=text][readonly],.has-warning [type=text].form-control[readonly],.has-warning input:not([type=checkbox]):focus,.has-warning .form-control:focus{border-bottom:none;-webkit-box-shadow:inset 0 -2px 0 #ff9800;box-shadow:inset 0 -2px 0 #ff9800}.has-error input:not([type=checkbox]),.has-error .form-control,.has-error input.form-control[readonly],.has-error input[type=text][readonly],.has-error [type=text].form-control[readonly],.has-error input:not([type=checkbox]):focus,.has-error .form-control:focus{border-bottom:none;-webkit-box-shadow:inset 0 -2px 0 #e51c23;box-shadow:inset 0 -2px 0 #e51c23}.has-success input:not([type=checkbox]),.has-success .form-control,.has-success input.form-control[readonly],.has-success input[type=text][readonly],.has-success [type=text].form-control[readonly],.has-success input:not([type=checkbox]):focus,.has-success .form-control:focus{border-bottom:none;-webkit-box-shadow:inset 0 -2px 0 #4caf50;box-shadow:inset 0 -2px 0 #4caf50}.has-warning .input-group-addon,.has-error .input-group-addon,.has-success .input-group-addon{color:#666666;border-color:transparent;background-color:transparent}.nav-tabs>li>a,.nav-tabs>li>a:focus{margin-right:0;background-color:transparent;border:none;color:#666666;-webkit-box-shadow:inset 0 -1px 0 #ddd;box-shadow:inset 0 -1px 0 #ddd;-webkit-transition:all 0.2s;-o-transition:all 0.2s;transition:all 0.2s}.nav-tabs>li>a:hover,.nav-tabs>li>a:focus:hover{background-color:transparent;-webkit-box-shadow:inset 0 -2px 0 #2196f3;box-shadow:inset 0 -2px 0 #2196f3;color:#2196f3}.nav-tabs>li.active>a,.nav-tabs>li.active>a:focus{border:none;-webkit-box-shadow:inset 0 -2px 0 #2196f3;box-shadow:inset 0 -2px 0 #2196f3;color:#2196f3}.nav-tabs>li.active>a:hover,.nav-tabs>li.active>a:focus:hover{border:none;color:#2196f3}.nav-tabs>li.disabled>a{-webkit-box-shadow:inset 0 -1px 0 #ddd;box-shadow:inset 0 -1px 0 #ddd}.nav-tabs.nav-justified>li>a,.nav-tabs.nav-justified>li>a:hover,.nav-tabs.nav-justified>li>a:focus,.nav-tabs.nav-justified>.active>a,.nav-tabs.nav-justified>.active>a:hover,.nav-tabs.nav-justified>.active>a:focus{border:none}.nav-tabs .dropdown-menu{margin-top:0}.dropdown-menu{margin-top:0;border:none;-webkit-box-shadow:0 1px 4px rgba(0,0,0,0.3);box-shadow:0 1px 4px rgba(0,0,0,0.3)}.alert{border:none;color:#fff}.alert-success{background-color:#4caf50}.alert-info{background-color:#9c27b0}.alert-warning{background-color:#ff9800}.alert-danger{background-color:#e51c23}.alert a:not(.close),.alert .alert-link{color:#fff;font-weight:bold}.alert .close{color:#fff}.badge{padding:4px 6px 4px}.progress{position:relative;z-index:1;height:6px;border-radius:0;-webkit-box-shadow:none;box-shadow:none}.progress-bar{-webkit-box-shadow:none;box-shadow:none}.progress-bar:last-child{border-radius:0 3px 3px 0}.progress-bar:last-child:before{display:block;content:"";position:absolute;width:100%;height:100%;left:0;right:0;z-index:-1;background-color:#cae6fc}.progress-bar-success:last-child.progress-bar:before{background-color:#c7e7c8}.progress-bar-info:last-child.progress-bar:before{background-color:#edc9f3}.progress-bar-warning:last-child.progress-bar:before{background-color:#ffe0b3}.progress-bar-danger:last-child.progress-bar:before{background-color:#f28e92}.close{font-size:34px;font-weight:300;line-height:24px;opacity:0.6;-webkit-transition:all 0.2s;-o-transition:all 0.2s;transition:all 0.2s}.close:hover{opacity:1}.list-group-item{padding:15px}.list-group-item-text{color:#bbbbbb}.well{border-radius:0;-webkit-box-shadow:none;box-shadow:none}.panel{border:none;border-radius:2px;-webkit-box-shadow:0 1px 4px rgba(0,0,0,0.3);box-shadow:0 1px 4px rgba(0,0,0,0.3)}.panel-heading{border-bottom:none}.panel-footer{border-top:none}.popover{border:none;-webkit-box-shadow:0 1px 4px rgba(0,0,0,0.3);box-shadow:0 1px 4px rgba(0,0,0,0.3)}.carousel-caption h1,.carousel-caption h2,.carousel-caption h3,.carousel-caption h4,.carousel-caption h5,.carousel-caption h6{color:inherit}
</style>
<script>/*!
 * Bootstrap v3.3.5 (http://getbootstrap.com)
 * Copyright 2011-2015 Twitter, Inc.
 * Licensed under the MIT license
 */
if("undefined"==typeof jQuery)throw new Error("Bootstrap's JavaScript requires jQuery");+function(a){"use strict";var b=a.fn.jquery.split(" ")[0].split(".");if(b[0]<2&&b[1]<9||1==b[0]&&9==b[1]&&b[2]<1)throw new Error("Bootstrap's JavaScript requires jQuery version 1.9.1 or higher")}(jQuery),+function(a){"use strict";function b(){var a=document.createElement("bootstrap"),b={WebkitTransition:"webkitTransitionEnd",MozTransition:"transitionend",OTransition:"oTransitionEnd otransitionend",transition:"transitionend"};for(var c in b)if(void 0!==a.style[c])return{end:b[c]};return!1}a.fn.emulateTransitionEnd=function(b){var c=!1,d=this;a(this).one("bsTransitionEnd",function(){c=!0});var e=function(){c||a(d).trigger(a.support.transition.end)};return setTimeout(e,b),this},a(function(){a.support.transition=b(),a.support.transition&&(a.event.special.bsTransitionEnd={bindType:a.support.transition.end,delegateType:a.support.transition.end,handle:function(b){return a(b.target).is(this)?b.handleObj.handler.apply(this,arguments):void 0}})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var c=a(this),e=c.data("bs.alert");e||c.data("bs.alert",e=new d(this)),"string"==typeof b&&e[b].call(c)})}var c='[data-dismiss="alert"]',d=function(b){a(b).on("click",c,this.close)};d.VERSION="3.3.5",d.TRANSITION_DURATION=150,d.prototype.close=function(b){function c(){g.detach().trigger("closed.bs.alert").remove()}var e=a(this),f=e.attr("data-target");f||(f=e.attr("href"),f=f&&f.replace(/.*(?=#[^\s]*$)/,""));var g=a(f);b&&b.preventDefault(),g.length||(g=e.closest(".alert")),g.trigger(b=a.Event("close.bs.alert")),b.isDefaultPrevented()||(g.removeClass("in"),a.support.transition&&g.hasClass("fade")?g.one("bsTransitionEnd",c).emulateTransitionEnd(d.TRANSITION_DURATION):c())};var e=a.fn.alert;a.fn.alert=b,a.fn.alert.Constructor=d,a.fn.alert.noConflict=function(){return a.fn.alert=e,this},a(document).on("click.bs.alert.data-api",c,d.prototype.close)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.button"),f="object"==typeof b&&b;e||d.data("bs.button",e=new c(this,f)),"toggle"==b?e.toggle():b&&e.setState(b)})}var c=function(b,d){this.$element=a(b),this.options=a.extend({},c.DEFAULTS,d),this.isLoading=!1};c.VERSION="3.3.5",c.DEFAULTS={loadingText:"loading..."},c.prototype.setState=function(b){var c="disabled",d=this.$element,e=d.is("input")?"val":"html",f=d.data();b+="Text",null==f.resetText&&d.data("resetText",d[e]()),setTimeout(a.proxy(function(){d[e](null==f[b]?this.options[b]:f[b]),"loadingText"==b?(this.isLoading=!0,d.addClass(c).attr(c,c)):this.isLoading&&(this.isLoading=!1,d.removeClass(c).removeAttr(c))},this),0)},c.prototype.toggle=function(){var a=!0,b=this.$element.closest('[data-toggle="buttons"]');if(b.length){var c=this.$element.find("input");"radio"==c.prop("type")?(c.prop("checked")&&(a=!1),b.find(".active").removeClass("active"),this.$element.addClass("active")):"checkbox"==c.prop("type")&&(c.prop("checked")!==this.$element.hasClass("active")&&(a=!1),this.$element.toggleClass("active")),c.prop("checked",this.$element.hasClass("active")),a&&c.trigger("change")}else this.$element.attr("aria-pressed",!this.$element.hasClass("active")),this.$element.toggleClass("active")};var d=a.fn.button;a.fn.button=b,a.fn.button.Constructor=c,a.fn.button.noConflict=function(){return a.fn.button=d,this},a(document).on("click.bs.button.data-api",'[data-toggle^="button"]',function(c){var d=a(c.target);d.hasClass("btn")||(d=d.closest(".btn")),b.call(d,"toggle"),a(c.target).is('input[type="radio"]')||a(c.target).is('input[type="checkbox"]')||c.preventDefault()}).on("focus.bs.button.data-api blur.bs.button.data-api",'[data-toggle^="button"]',function(b){a(b.target).closest(".btn").toggleClass("focus",/^focus(in)?$/.test(b.type))})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.carousel"),f=a.extend({},c.DEFAULTS,d.data(),"object"==typeof b&&b),g="string"==typeof b?b:f.slide;e||d.data("bs.carousel",e=new c(this,f)),"number"==typeof b?e.to(b):g?e[g]():f.interval&&e.pause().cycle()})}var c=function(b,c){this.$element=a(b),this.$indicators=this.$element.find(".carousel-indicators"),this.options=c,this.paused=null,this.sliding=null,this.interval=null,this.$active=null,this.$items=null,this.options.keyboard&&this.$element.on("keydown.bs.carousel",a.proxy(this.keydown,this)),"hover"==this.options.pause&&!("ontouchstart"in document.documentElement)&&this.$element.on("mouseenter.bs.carousel",a.proxy(this.pause,this)).on("mouseleave.bs.carousel",a.proxy(this.cycle,this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=600,c.DEFAULTS={interval:5e3,pause:"hover",wrap:!0,keyboard:!0},c.prototype.keydown=function(a){if(!/input|textarea/i.test(a.target.tagName)){switch(a.which){case 37:this.prev();break;case 39:this.next();break;default:return}a.preventDefault()}},c.prototype.cycle=function(b){return b||(this.paused=!1),this.interval&&clearInterval(this.interval),this.options.interval&&!this.paused&&(this.interval=setInterval(a.proxy(this.next,this),this.options.interval)),this},c.prototype.getItemIndex=function(a){return this.$items=a.parent().children(".item"),this.$items.index(a||this.$active)},c.prototype.getItemForDirection=function(a,b){var c=this.getItemIndex(b),d="prev"==a&&0===c||"next"==a&&c==this.$items.length-1;if(d&&!this.options.wrap)return b;var e="prev"==a?-1:1,f=(c+e)%this.$items.length;return this.$items.eq(f)},c.prototype.to=function(a){var b=this,c=this.getItemIndex(this.$active=this.$element.find(".item.active"));return a>this.$items.length-1||0>a?void 0:this.sliding?this.$element.one("slid.bs.carousel",function(){b.to(a)}):c==a?this.pause().cycle():this.slide(a>c?"next":"prev",this.$items.eq(a))},c.prototype.pause=function(b){return b||(this.paused=!0),this.$element.find(".next, .prev").length&&a.support.transition&&(this.$element.trigger(a.support.transition.end),this.cycle(!0)),this.interval=clearInterval(this.interval),this},c.prototype.next=function(){return this.sliding?void 0:this.slide("next")},c.prototype.prev=function(){return this.sliding?void 0:this.slide("prev")},c.prototype.slide=function(b,d){var e=this.$element.find(".item.active"),f=d||this.getItemForDirection(b,e),g=this.interval,h="next"==b?"left":"right",i=this;if(f.hasClass("active"))return this.sliding=!1;var j=f[0],k=a.Event("slide.bs.carousel",{relatedTarget:j,direction:h});if(this.$element.trigger(k),!k.isDefaultPrevented()){if(this.sliding=!0,g&&this.pause(),this.$indicators.length){this.$indicators.find(".active").removeClass("active");var l=a(this.$indicators.children()[this.getItemIndex(f)]);l&&l.addClass("active")}var m=a.Event("slid.bs.carousel",{relatedTarget:j,direction:h});return a.support.transition&&this.$element.hasClass("slide")?(f.addClass(b),f[0].offsetWidth,e.addClass(h),f.addClass(h),e.one("bsTransitionEnd",function(){f.removeClass([b,h].join(" ")).addClass("active"),e.removeClass(["active",h].join(" ")),i.sliding=!1,setTimeout(function(){i.$element.trigger(m)},0)}).emulateTransitionEnd(c.TRANSITION_DURATION)):(e.removeClass("active"),f.addClass("active"),this.sliding=!1,this.$element.trigger(m)),g&&this.cycle(),this}};var d=a.fn.carousel;a.fn.carousel=b,a.fn.carousel.Constructor=c,a.fn.carousel.noConflict=function(){return a.fn.carousel=d,this};var e=function(c){var d,e=a(this),f=a(e.attr("data-target")||(d=e.attr("href"))&&d.replace(/.*(?=#[^\s]+$)/,""));if(f.hasClass("carousel")){var g=a.extend({},f.data(),e.data()),h=e.attr("data-slide-to");h&&(g.interval=!1),b.call(f,g),h&&f.data("bs.carousel").to(h),c.preventDefault()}};a(document).on("click.bs.carousel.data-api","[data-slide]",e).on("click.bs.carousel.data-api","[data-slide-to]",e),a(window).on("load",function(){a('[data-ride="carousel"]').each(function(){var c=a(this);b.call(c,c.data())})})}(jQuery),+function(a){"use strict";function b(b){var c,d=b.attr("data-target")||(c=b.attr("href"))&&c.replace(/.*(?=#[^\s]+$)/,"");return a(d)}function c(b){return this.each(function(){var c=a(this),e=c.data("bs.collapse"),f=a.extend({},d.DEFAULTS,c.data(),"object"==typeof b&&b);!e&&f.toggle&&/show|hide/.test(b)&&(f.toggle=!1),e||c.data("bs.collapse",e=new d(this,f)),"string"==typeof b&&e[b]()})}var d=function(b,c){this.$element=a(b),this.options=a.extend({},d.DEFAULTS,c),this.$trigger=a('[data-toggle="collapse"][href="#'+b.id+'"],[data-toggle="collapse"][data-target="#'+b.id+'"]'),this.transitioning=null,this.options.parent?this.$parent=this.getParent():this.addAriaAndCollapsedClass(this.$element,this.$trigger),this.options.toggle&&this.toggle()};d.VERSION="3.3.5",d.TRANSITION_DURATION=350,d.DEFAULTS={toggle:!0},d.prototype.dimension=function(){var a=this.$element.hasClass("width");return a?"width":"height"},d.prototype.show=function(){if(!this.transitioning&&!this.$element.hasClass("in")){var b,e=this.$parent&&this.$parent.children(".panel").children(".in, .collapsing");if(!(e&&e.length&&(b=e.data("bs.collapse"),b&&b.transitioning))){var f=a.Event("show.bs.collapse");if(this.$element.trigger(f),!f.isDefaultPrevented()){e&&e.length&&(c.call(e,"hide"),b||e.data("bs.collapse",null));var g=this.dimension();this.$element.removeClass("collapse").addClass("collapsing")[g](0).attr("aria-expanded",!0),this.$trigger.removeClass("collapsed").attr("aria-expanded",!0),this.transitioning=1;var h=function(){this.$element.removeClass("collapsing").addClass("collapse in")[g](""),this.transitioning=0,this.$element.trigger("shown.bs.collapse")};if(!a.support.transition)return h.call(this);var i=a.camelCase(["scroll",g].join("-"));this.$element.one("bsTransitionEnd",a.proxy(h,this)).emulateTransitionEnd(d.TRANSITION_DURATION)[g](this.$element[0][i])}}}},d.prototype.hide=function(){if(!this.transitioning&&this.$element.hasClass("in")){var b=a.Event("hide.bs.collapse");if(this.$element.trigger(b),!b.isDefaultPrevented()){var c=this.dimension();this.$element[c](this.$element[c]())[0].offsetHeight,this.$element.addClass("collapsing").removeClass("collapse in").attr("aria-expanded",!1),this.$trigger.addClass("collapsed").attr("aria-expanded",!1),this.transitioning=1;var e=function(){this.transitioning=0,this.$element.removeClass("collapsing").addClass("collapse").trigger("hidden.bs.collapse")};return a.support.transition?void this.$element[c](0).one("bsTransitionEnd",a.proxy(e,this)).emulateTransitionEnd(d.TRANSITION_DURATION):e.call(this)}}},d.prototype.toggle=function(){this[this.$element.hasClass("in")?"hide":"show"]()},d.prototype.getParent=function(){return a(this.options.parent).find('[data-toggle="collapse"][data-parent="'+this.options.parent+'"]').each(a.proxy(function(c,d){var e=a(d);this.addAriaAndCollapsedClass(b(e),e)},this)).end()},d.prototype.addAriaAndCollapsedClass=function(a,b){var c=a.hasClass("in");a.attr("aria-expanded",c),b.toggleClass("collapsed",!c).attr("aria-expanded",c)};var e=a.fn.collapse;a.fn.collapse=c,a.fn.collapse.Constructor=d,a.fn.collapse.noConflict=function(){return a.fn.collapse=e,this},a(document).on("click.bs.collapse.data-api",'[data-toggle="collapse"]',function(d){var e=a(this);e.attr("data-target")||d.preventDefault();var f=b(e),g=f.data("bs.collapse"),h=g?"toggle":e.data();c.call(f,h)})}(jQuery),+function(a){"use strict";function b(b){var c=b.attr("data-target");c||(c=b.attr("href"),c=c&&/#[A-Za-z]/.test(c)&&c.replace(/.*(?=#[^\s]*$)/,""));var d=c&&a(c);return d&&d.length?d:b.parent()}function c(c){c&&3===c.which||(a(e).remove(),a(f).each(function(){var d=a(this),e=b(d),f={relatedTarget:this};e.hasClass("open")&&(c&&"click"==c.type&&/input|textarea/i.test(c.target.tagName)&&a.contains(e[0],c.target)||(e.trigger(c=a.Event("hide.bs.dropdown",f)),c.isDefaultPrevented()||(d.attr("aria-expanded","false"),e.removeClass("open").trigger("hidden.bs.dropdown",f))))}))}function d(b){return this.each(function(){var c=a(this),d=c.data("bs.dropdown");d||c.data("bs.dropdown",d=new g(this)),"string"==typeof b&&d[b].call(c)})}var e=".dropdown-backdrop",f='[data-toggle="dropdown"]',g=function(b){a(b).on("click.bs.dropdown",this.toggle)};g.VERSION="3.3.5",g.prototype.toggle=function(d){var e=a(this);if(!e.is(".disabled, :disabled")){var f=b(e),g=f.hasClass("open");if(c(),!g){"ontouchstart"in document.documentElement&&!f.closest(".navbar-nav").length&&a(document.createElement("div")).addClass("dropdown-backdrop").insertAfter(a(this)).on("click",c);var h={relatedTarget:this};if(f.trigger(d=a.Event("show.bs.dropdown",h)),d.isDefaultPrevented())return;e.trigger("focus").attr("aria-expanded","true"),f.toggleClass("open").trigger("shown.bs.dropdown",h)}return!1}},g.prototype.keydown=function(c){if(/(38|40|27|32)/.test(c.which)&&!/input|textarea/i.test(c.target.tagName)){var d=a(this);if(c.preventDefault(),c.stopPropagation(),!d.is(".disabled, :disabled")){var e=b(d),g=e.hasClass("open");if(!g&&27!=c.which||g&&27==c.which)return 27==c.which&&e.find(f).trigger("focus"),d.trigger("click");var h=" li:not(.disabled):visible a",i=e.find(".dropdown-menu"+h);if(i.length){var j=i.index(c.target);38==c.which&&j>0&&j--,40==c.which&&j<i.length-1&&j++,~j||(j=0),i.eq(j).trigger("focus")}}}};var h=a.fn.dropdown;a.fn.dropdown=d,a.fn.dropdown.Constructor=g,a.fn.dropdown.noConflict=function(){return a.fn.dropdown=h,this},a(document).on("click.bs.dropdown.data-api",c).on("click.bs.dropdown.data-api",".dropdown form",function(a){a.stopPropagation()}).on("click.bs.dropdown.data-api",f,g.prototype.toggle).on("keydown.bs.dropdown.data-api",f,g.prototype.keydown).on("keydown.bs.dropdown.data-api",".dropdown-menu",g.prototype.keydown)}(jQuery),+function(a){"use strict";function b(b,d){return this.each(function(){var e=a(this),f=e.data("bs.modal"),g=a.extend({},c.DEFAULTS,e.data(),"object"==typeof b&&b);f||e.data("bs.modal",f=new c(this,g)),"string"==typeof b?f[b](d):g.show&&f.show(d)})}var c=function(b,c){this.options=c,this.$body=a(document.body),this.$element=a(b),this.$dialog=this.$element.find(".modal-dialog"),this.$backdrop=null,this.isShown=null,this.originalBodyPad=null,this.scrollbarWidth=0,this.ignoreBackdropClick=!1,this.options.remote&&this.$element.find(".modal-content").load(this.options.remote,a.proxy(function(){this.$element.trigger("loaded.bs.modal")},this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=300,c.BACKDROP_TRANSITION_DURATION=150,c.DEFAULTS={backdrop:!0,keyboard:!0,show:!0},c.prototype.toggle=function(a){return this.isShown?this.hide():this.show(a)},c.prototype.show=function(b){var d=this,e=a.Event("show.bs.modal",{relatedTarget:b});this.$element.trigger(e),this.isShown||e.isDefaultPrevented()||(this.isShown=!0,this.checkScrollbar(),this.setScrollbar(),this.$body.addClass("modal-open"),this.escape(),this.resize(),this.$element.on("click.dismiss.bs.modal",'[data-dismiss="modal"]',a.proxy(this.hide,this)),this.$dialog.on("mousedown.dismiss.bs.modal",function(){d.$element.one("mouseup.dismiss.bs.modal",function(b){a(b.target).is(d.$element)&&(d.ignoreBackdropClick=!0)})}),this.backdrop(function(){var e=a.support.transition&&d.$element.hasClass("fade");d.$element.parent().length||d.$element.appendTo(d.$body),d.$element.show().scrollTop(0),d.adjustDialog(),e&&d.$element[0].offsetWidth,d.$element.addClass("in"),d.enforceFocus();var f=a.Event("shown.bs.modal",{relatedTarget:b});e?d.$dialog.one("bsTransitionEnd",function(){d.$element.trigger("focus").trigger(f)}).emulateTransitionEnd(c.TRANSITION_DURATION):d.$element.trigger("focus").trigger(f)}))},c.prototype.hide=function(b){b&&b.preventDefault(),b=a.Event("hide.bs.modal"),this.$element.trigger(b),this.isShown&&!b.isDefaultPrevented()&&(this.isShown=!1,this.escape(),this.resize(),a(document).off("focusin.bs.modal"),this.$element.removeClass("in").off("click.dismiss.bs.modal").off("mouseup.dismiss.bs.modal"),this.$dialog.off("mousedown.dismiss.bs.modal"),a.support.transition&&this.$element.hasClass("fade")?this.$element.one("bsTransitionEnd",a.proxy(this.hideModal,this)).emulateTransitionEnd(c.TRANSITION_DURATION):this.hideModal())},c.prototype.enforceFocus=function(){a(document).off("focusin.bs.modal").on("focusin.bs.modal",a.proxy(function(a){this.$element[0]===a.target||this.$element.has(a.target).length||this.$element.trigger("focus")},this))},c.prototype.escape=function(){this.isShown&&this.options.keyboard?this.$element.on("keydown.dismiss.bs.modal",a.proxy(function(a){27==a.which&&this.hide()},this)):this.isShown||this.$element.off("keydown.dismiss.bs.modal")},c.prototype.resize=function(){this.isShown?a(window).on("resize.bs.modal",a.proxy(this.handleUpdate,this)):a(window).off("resize.bs.modal")},c.prototype.hideModal=function(){var a=this;this.$element.hide(),this.backdrop(function(){a.$body.removeClass("modal-open"),a.resetAdjustments(),a.resetScrollbar(),a.$element.trigger("hidden.bs.modal")})},c.prototype.removeBackdrop=function(){this.$backdrop&&this.$backdrop.remove(),this.$backdrop=null},c.prototype.backdrop=function(b){var d=this,e=this.$element.hasClass("fade")?"fade":"";if(this.isShown&&this.options.backdrop){var f=a.support.transition&&e;if(this.$backdrop=a(document.createElement("div")).addClass("modal-backdrop "+e).appendTo(this.$body),this.$element.on("click.dismiss.bs.modal",a.proxy(function(a){return this.ignoreBackdropClick?void(this.ignoreBackdropClick=!1):void(a.target===a.currentTarget&&("static"==this.options.backdrop?this.$element[0].focus():this.hide()))},this)),f&&this.$backdrop[0].offsetWidth,this.$backdrop.addClass("in"),!b)return;f?this.$backdrop.one("bsTransitionEnd",b).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):b()}else if(!this.isShown&&this.$backdrop){this.$backdrop.removeClass("in");var g=function(){d.removeBackdrop(),b&&b()};a.support.transition&&this.$element.hasClass("fade")?this.$backdrop.one("bsTransitionEnd",g).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):g()}else b&&b()},c.prototype.handleUpdate=function(){this.adjustDialog()},c.prototype.adjustDialog=function(){var a=this.$element[0].scrollHeight>document.documentElement.clientHeight;this.$element.css({paddingLeft:!this.bodyIsOverflowing&&a?this.scrollbarWidth:"",paddingRight:this.bodyIsOverflowing&&!a?this.scrollbarWidth:""})},c.prototype.resetAdjustments=function(){this.$element.css({paddingLeft:"",paddingRight:""})},c.prototype.checkScrollbar=function(){var a=window.innerWidth;if(!a){var b=document.documentElement.getBoundingClientRect();a=b.right-Math.abs(b.left)}this.bodyIsOverflowing=document.body.clientWidth<a,this.scrollbarWidth=this.measureScrollbar()},c.prototype.setScrollbar=function(){var a=parseInt(this.$body.css("padding-right")||0,10);this.originalBodyPad=document.body.style.paddingRight||"",this.bodyIsOverflowing&&this.$body.css("padding-right",a+this.scrollbarWidth)},c.prototype.resetScrollbar=function(){this.$body.css("padding-right",this.originalBodyPad)},c.prototype.measureScrollbar=function(){var a=document.createElement("div");a.className="modal-scrollbar-measure",this.$body.append(a);var b=a.offsetWidth-a.clientWidth;return this.$body[0].removeChild(a),b};var d=a.fn.modal;a.fn.modal=b,a.fn.modal.Constructor=c,a.fn.modal.noConflict=function(){return a.fn.modal=d,this},a(document).on("click.bs.modal.data-api",'[data-toggle="modal"]',function(c){var d=a(this),e=d.attr("href"),f=a(d.attr("data-target")||e&&e.replace(/.*(?=#[^\s]+$)/,"")),g=f.data("bs.modal")?"toggle":a.extend({remote:!/#/.test(e)&&e},f.data(),d.data());d.is("a")&&c.preventDefault(),f.one("show.bs.modal",function(a){a.isDefaultPrevented()||f.one("hidden.bs.modal",function(){d.is(":visible")&&d.trigger("focus")})}),b.call(f,g,this)})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tooltip"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.tooltip",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.type=null,this.options=null,this.enabled=null,this.timeout=null,this.hoverState=null,this.$element=null,this.inState=null,this.init("tooltip",a,b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.DEFAULTS={animation:!0,placement:"top",selector:!1,template:'<div class="tooltip" role="tooltip"><div class="tooltip-arrow"></div><div class="tooltip-inner"></div></div>',trigger:"hover focus",title:"",delay:0,html:!1,container:!1,viewport:{selector:"body",padding:0}},c.prototype.init=function(b,c,d){if(this.enabled=!0,this.type=b,this.$element=a(c),this.options=this.getOptions(d),this.$viewport=this.options.viewport&&a(a.isFunction(this.options.viewport)?this.options.viewport.call(this,this.$element):this.options.viewport.selector||this.options.viewport),this.inState={click:!1,hover:!1,focus:!1},this.$element[0]instanceof document.constructor&&!this.options.selector)throw new Error("`selector` option must be specified when initializing "+this.type+" on the window.document object!");for(var e=this.options.trigger.split(" "),f=e.length;f--;){var g=e[f];if("click"==g)this.$element.on("click."+this.type,this.options.selector,a.proxy(this.toggle,this));else if("manual"!=g){var h="hover"==g?"mouseenter":"focusin",i="hover"==g?"mouseleave":"focusout";this.$element.on(h+"."+this.type,this.options.selector,a.proxy(this.enter,this)),this.$element.on(i+"."+this.type,this.options.selector,a.proxy(this.leave,this))}}this.options.selector?this._options=a.extend({},this.options,{trigger:"manual",selector:""}):this.fixTitle()},c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.getOptions=function(b){return b=a.extend({},this.getDefaults(),this.$element.data(),b),b.delay&&"number"==typeof b.delay&&(b.delay={show:b.delay,hide:b.delay}),b},c.prototype.getDelegateOptions=function(){var b={},c=this.getDefaults();return this._options&&a.each(this._options,function(a,d){c[a]!=d&&(b[a]=d)}),b},c.prototype.enter=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusin"==b.type?"focus":"hover"]=!0),c.tip().hasClass("in")||"in"==c.hoverState?void(c.hoverState="in"):(clearTimeout(c.timeout),c.hoverState="in",c.options.delay&&c.options.delay.show?void(c.timeout=setTimeout(function(){"in"==c.hoverState&&c.show()},c.options.delay.show)):c.show())},c.prototype.isInStateTrue=function(){for(var a in this.inState)if(this.inState[a])return!0;return!1},c.prototype.leave=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusout"==b.type?"focus":"hover"]=!1),c.isInStateTrue()?void 0:(clearTimeout(c.timeout),c.hoverState="out",c.options.delay&&c.options.delay.hide?void(c.timeout=setTimeout(function(){"out"==c.hoverState&&c.hide()},c.options.delay.hide)):c.hide())},c.prototype.show=function(){var b=a.Event("show.bs."+this.type);if(this.hasContent()&&this.enabled){this.$element.trigger(b);var d=a.contains(this.$element[0].ownerDocument.documentElement,this.$element[0]);if(b.isDefaultPrevented()||!d)return;var e=this,f=this.tip(),g=this.getUID(this.type);this.setContent(),f.attr("id",g),this.$element.attr("aria-describedby",g),this.options.animation&&f.addClass("fade");var h="function"==typeof this.options.placement?this.options.placement.call(this,f[0],this.$element[0]):this.options.placement,i=/\s?auto?\s?/i,j=i.test(h);j&&(h=h.replace(i,"")||"top"),f.detach().css({top:0,left:0,display:"block"}).addClass(h).data("bs."+this.type,this),this.options.container?f.appendTo(this.options.container):f.insertAfter(this.$element),this.$element.trigger("inserted.bs."+this.type);var k=this.getPosition(),l=f[0].offsetWidth,m=f[0].offsetHeight;if(j){var n=h,o=this.getPosition(this.$viewport);h="bottom"==h&&k.bottom+m>o.bottom?"top":"top"==h&&k.top-m<o.top?"bottom":"right"==h&&k.right+l>o.width?"left":"left"==h&&k.left-l<o.left?"right":h,f.removeClass(n).addClass(h)}var p=this.getCalculatedOffset(h,k,l,m);this.applyPlacement(p,h);var q=function(){var a=e.hoverState;e.$element.trigger("shown.bs."+e.type),e.hoverState=null,"out"==a&&e.leave(e)};a.support.transition&&this.$tip.hasClass("fade")?f.one("bsTransitionEnd",q).emulateTransitionEnd(c.TRANSITION_DURATION):q()}},c.prototype.applyPlacement=function(b,c){var d=this.tip(),e=d[0].offsetWidth,f=d[0].offsetHeight,g=parseInt(d.css("margin-top"),10),h=parseInt(d.css("margin-left"),10);isNaN(g)&&(g=0),isNaN(h)&&(h=0),b.top+=g,b.left+=h,a.offset.setOffset(d[0],a.extend({using:function(a){d.css({top:Math.round(a.top),left:Math.round(a.left)})}},b),0),d.addClass("in");var i=d[0].offsetWidth,j=d[0].offsetHeight;"top"==c&&j!=f&&(b.top=b.top+f-j);var k=this.getViewportAdjustedDelta(c,b,i,j);k.left?b.left+=k.left:b.top+=k.top;var l=/top|bottom/.test(c),m=l?2*k.left-e+i:2*k.top-f+j,n=l?"offsetWidth":"offsetHeight";d.offset(b),this.replaceArrow(m,d[0][n],l)},c.prototype.replaceArrow=function(a,b,c){this.arrow().css(c?"left":"top",50*(1-a/b)+"%").css(c?"top":"left","")},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle();a.find(".tooltip-inner")[this.options.html?"html":"text"](b),a.removeClass("fade in top bottom left right")},c.prototype.hide=function(b){function d(){"in"!=e.hoverState&&f.detach(),e.$element.removeAttr("aria-describedby").trigger("hidden.bs."+e.type),b&&b()}var e=this,f=a(this.$tip),g=a.Event("hide.bs."+this.type);return this.$element.trigger(g),g.isDefaultPrevented()?void 0:(f.removeClass("in"),a.support.transition&&f.hasClass("fade")?f.one("bsTransitionEnd",d).emulateTransitionEnd(c.TRANSITION_DURATION):d(),this.hoverState=null,this)},c.prototype.fixTitle=function(){var a=this.$element;(a.attr("title")||"string"!=typeof a.attr("data-original-title"))&&a.attr("data-original-title",a.attr("title")||"").attr("title","")},c.prototype.hasContent=function(){return this.getTitle()},c.prototype.getPosition=function(b){b=b||this.$element;var c=b[0],d="BODY"==c.tagName,e=c.getBoundingClientRect();null==e.width&&(e=a.extend({},e,{width:e.right-e.left,height:e.bottom-e.top}));var f=d?{top:0,left:0}:b.offset(),g={scroll:d?document.documentElement.scrollTop||document.body.scrollTop:b.scrollTop()},h=d?{width:a(window).width(),height:a(window).height()}:null;return a.extend({},e,g,h,f)},c.prototype.getCalculatedOffset=function(a,b,c,d){return"bottom"==a?{top:b.top+b.height,left:b.left+b.width/2-c/2}:"top"==a?{top:b.top-d,left:b.left+b.width/2-c/2}:"left"==a?{top:b.top+b.height/2-d/2,left:b.left-c}:{top:b.top+b.height/2-d/2,left:b.left+b.width}},c.prototype.getViewportAdjustedDelta=function(a,b,c,d){var e={top:0,left:0};if(!this.$viewport)return e;var f=this.options.viewport&&this.options.viewport.padding||0,g=this.getPosition(this.$viewport);if(/right|left/.test(a)){var h=b.top-f-g.scroll,i=b.top+f-g.scroll+d;h<g.top?e.top=g.top-h:i>g.top+g.height&&(e.top=g.top+g.height-i)}else{var j=b.left-f,k=b.left+f+c;j<g.left?e.left=g.left-j:k>g.right&&(e.left=g.left+g.width-k)}return e},c.prototype.getTitle=function(){var a,b=this.$element,c=this.options;return a=b.attr("data-original-title")||("function"==typeof c.title?c.title.call(b[0]):c.title)},c.prototype.getUID=function(a){do a+=~~(1e6*Math.random());while(document.getElementById(a));return a},c.prototype.tip=function(){if(!this.$tip&&(this.$tip=a(this.options.template),1!=this.$tip.length))throw new Error(this.type+" `template` option must consist of exactly 1 top-level element!");return this.$tip},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".tooltip-arrow")},c.prototype.enable=function(){this.enabled=!0},c.prototype.disable=function(){this.enabled=!1},c.prototype.toggleEnabled=function(){this.enabled=!this.enabled},c.prototype.toggle=function(b){var c=this;b&&(c=a(b.currentTarget).data("bs."+this.type),c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c))),b?(c.inState.click=!c.inState.click,c.isInStateTrue()?c.enter(c):c.leave(c)):c.tip().hasClass("in")?c.leave(c):c.enter(c)},c.prototype.destroy=function(){var a=this;clearTimeout(this.timeout),this.hide(function(){a.$element.off("."+a.type).removeData("bs."+a.type),a.$tip&&a.$tip.detach(),a.$tip=null,a.$arrow=null,a.$viewport=null})};var d=a.fn.tooltip;a.fn.tooltip=b,a.fn.tooltip.Constructor=c,a.fn.tooltip.noConflict=function(){return a.fn.tooltip=d,this}}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.popover"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.popover",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.init("popover",a,b)};if(!a.fn.tooltip)throw new Error("Popover requires tooltip.js");c.VERSION="3.3.5",c.DEFAULTS=a.extend({},a.fn.tooltip.Constructor.DEFAULTS,{placement:"right",trigger:"click",content:"",template:'<div class="popover" role="tooltip"><div class="arrow"></div><h3 class="popover-title"></h3><div class="popover-content"></div></div>'}),c.prototype=a.extend({},a.fn.tooltip.Constructor.prototype),c.prototype.constructor=c,c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle(),c=this.getContent();a.find(".popover-title")[this.options.html?"html":"text"](b),a.find(".popover-content").children().detach().end()[this.options.html?"string"==typeof c?"html":"append":"text"](c),a.removeClass("fade top bottom left right in"),a.find(".popover-title").html()||a.find(".popover-title").hide()},c.prototype.hasContent=function(){return this.getTitle()||this.getContent()},c.prototype.getContent=function(){var a=this.$element,b=this.options;return a.attr("data-content")||("function"==typeof b.content?b.content.call(a[0]):b.content)},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".arrow")};var d=a.fn.popover;a.fn.popover=b,a.fn.popover.Constructor=c,a.fn.popover.noConflict=function(){return a.fn.popover=d,this}}(jQuery),+function(a){"use strict";function b(c,d){this.$body=a(document.body),this.$scrollElement=a(a(c).is(document.body)?window:c),this.options=a.extend({},b.DEFAULTS,d),this.selector=(this.options.target||"")+" .nav li > a",this.offsets=[],this.targets=[],this.activeTarget=null,this.scrollHeight=0,this.$scrollElement.on("scroll.bs.scrollspy",a.proxy(this.process,this)),this.refresh(),this.process()}function c(c){return this.each(function(){var d=a(this),e=d.data("bs.scrollspy"),f="object"==typeof c&&c;e||d.data("bs.scrollspy",e=new b(this,f)),"string"==typeof c&&e[c]()})}b.VERSION="3.3.5",b.DEFAULTS={offset:10},b.prototype.getScrollHeight=function(){return this.$scrollElement[0].scrollHeight||Math.max(this.$body[0].scrollHeight,document.documentElement.scrollHeight)},b.prototype.refresh=function(){var b=this,c="offset",d=0;this.offsets=[],this.targets=[],this.scrollHeight=this.getScrollHeight(),a.isWindow(this.$scrollElement[0])||(c="position",d=this.$scrollElement.scrollTop()),this.$body.find(this.selector).map(function(){var b=a(this),e=b.data("target")||b.attr("href"),f=/^#./.test(e)&&a(e);return f&&f.length&&f.is(":visible")&&[[f[c]().top+d,e]]||null}).sort(function(a,b){return a[0]-b[0]}).each(function(){b.offsets.push(this[0]),b.targets.push(this[1])})},b.prototype.process=function(){var a,b=this.$scrollElement.scrollTop()+this.options.offset,c=this.getScrollHeight(),d=this.options.offset+c-this.$scrollElement.height(),e=this.offsets,f=this.targets,g=this.activeTarget;if(this.scrollHeight!=c&&this.refresh(),b>=d)return g!=(a=f[f.length-1])&&this.activate(a);if(g&&b<e[0])return this.activeTarget=null,this.clear();for(a=e.length;a--;)g!=f[a]&&b>=e[a]&&(void 0===e[a+1]||b<e[a+1])&&this.activate(f[a])},b.prototype.activate=function(b){this.activeTarget=b,this.clear();var c=this.selector+'[data-target="'+b+'"],'+this.selector+'[href="'+b+'"]',d=a(c).parents("li").addClass("active");d.parent(".dropdown-menu").length&&(d=d.closest("li.dropdown").addClass("active")),
d.trigger("activate.bs.scrollspy")},b.prototype.clear=function(){a(this.selector).parentsUntil(this.options.target,".active").removeClass("active")};var d=a.fn.scrollspy;a.fn.scrollspy=c,a.fn.scrollspy.Constructor=b,a.fn.scrollspy.noConflict=function(){return a.fn.scrollspy=d,this},a(window).on("load.bs.scrollspy.data-api",function(){a('[data-spy="scroll"]').each(function(){var b=a(this);c.call(b,b.data())})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tab");e||d.data("bs.tab",e=new c(this)),"string"==typeof b&&e[b]()})}var c=function(b){this.element=a(b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.prototype.show=function(){var b=this.element,c=b.closest("ul:not(.dropdown-menu)"),d=b.data("target");if(d||(d=b.attr("href"),d=d&&d.replace(/.*(?=#[^\s]*$)/,"")),!b.parent("li").hasClass("active")){var e=c.find(".active:last a"),f=a.Event("hide.bs.tab",{relatedTarget:b[0]}),g=a.Event("show.bs.tab",{relatedTarget:e[0]});if(e.trigger(f),b.trigger(g),!g.isDefaultPrevented()&&!f.isDefaultPrevented()){var h=a(d);this.activate(b.closest("li"),c),this.activate(h,h.parent(),function(){e.trigger({type:"hidden.bs.tab",relatedTarget:b[0]}),b.trigger({type:"shown.bs.tab",relatedTarget:e[0]})})}}},c.prototype.activate=function(b,d,e){function f(){g.removeClass("active").find("> .dropdown-menu > .active").removeClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!1),b.addClass("active").find('[data-toggle="tab"]').attr("aria-expanded",!0),h?(b[0].offsetWidth,b.addClass("in")):b.removeClass("fade"),b.parent(".dropdown-menu").length&&b.closest("li.dropdown").addClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!0),e&&e()}var g=d.find("> .active"),h=e&&a.support.transition&&(g.length&&g.hasClass("fade")||!!d.find("> .fade").length);g.length&&h?g.one("bsTransitionEnd",f).emulateTransitionEnd(c.TRANSITION_DURATION):f(),g.removeClass("in")};var d=a.fn.tab;a.fn.tab=b,a.fn.tab.Constructor=c,a.fn.tab.noConflict=function(){return a.fn.tab=d,this};var e=function(c){c.preventDefault(),b.call(a(this),"show")};a(document).on("click.bs.tab.data-api",'[data-toggle="tab"]',e).on("click.bs.tab.data-api",'[data-toggle="pill"]',e)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.affix"),f="object"==typeof b&&b;e||d.data("bs.affix",e=new c(this,f)),"string"==typeof b&&e[b]()})}var c=function(b,d){this.options=a.extend({},c.DEFAULTS,d),this.$target=a(this.options.target).on("scroll.bs.affix.data-api",a.proxy(this.checkPosition,this)).on("click.bs.affix.data-api",a.proxy(this.checkPositionWithEventLoop,this)),this.$element=a(b),this.affixed=null,this.unpin=null,this.pinnedOffset=null,this.checkPosition()};c.VERSION="3.3.5",c.RESET="affix affix-top affix-bottom",c.DEFAULTS={offset:0,target:window},c.prototype.getState=function(a,b,c,d){var e=this.$target.scrollTop(),f=this.$element.offset(),g=this.$target.height();if(null!=c&&"top"==this.affixed)return c>e?"top":!1;if("bottom"==this.affixed)return null!=c?e+this.unpin<=f.top?!1:"bottom":a-d>=e+g?!1:"bottom";var h=null==this.affixed,i=h?e:f.top,j=h?g:b;return null!=c&&c>=e?"top":null!=d&&i+j>=a-d?"bottom":!1},c.prototype.getPinnedOffset=function(){if(this.pinnedOffset)return this.pinnedOffset;this.$element.removeClass(c.RESET).addClass("affix");var a=this.$target.scrollTop(),b=this.$element.offset();return this.pinnedOffset=b.top-a},c.prototype.checkPositionWithEventLoop=function(){setTimeout(a.proxy(this.checkPosition,this),1)},c.prototype.checkPosition=function(){if(this.$element.is(":visible")){var b=this.$element.height(),d=this.options.offset,e=d.top,f=d.bottom,g=Math.max(a(document).height(),a(document.body).height());"object"!=typeof d&&(f=e=d),"function"==typeof e&&(e=d.top(this.$element)),"function"==typeof f&&(f=d.bottom(this.$element));var h=this.getState(g,b,e,f);if(this.affixed!=h){null!=this.unpin&&this.$element.css("top","");var i="affix"+(h?"-"+h:""),j=a.Event(i+".bs.affix");if(this.$element.trigger(j),j.isDefaultPrevented())return;this.affixed=h,this.unpin="bottom"==h?this.getPinnedOffset():null,this.$element.removeClass(c.RESET).addClass(i).trigger(i.replace("affix","affixed")+".bs.affix")}"bottom"==h&&this.$element.offset({top:g-b-f})}};var d=a.fn.affix;a.fn.affix=b,a.fn.affix.Constructor=c,a.fn.affix.noConflict=function(){return a.fn.affix=d,this},a(window).on("load",function(){a('[data-spy="affix"]').each(function(){var c=a(this),d=c.data();d.offset=d.offset||{},null!=d.offsetBottom&&(d.offset.bottom=d.offsetBottom),null!=d.offsetTop&&(d.offset.top=d.offsetTop),b.call(c,d)})})}(jQuery);</script>
<script>/**
* @preserve HTML5 Shiv 3.7.2 | @afarkas @jdalton @jon_neal @rem | MIT/GPL2 Licensed
*/
// Only run this code in IE 8
if (!!window.navigator.userAgent.match("MSIE 8")) {
!function(a,b){function c(a,b){var c=a.createElement("p"),d=a.getElementsByTagName("head")[0]||a.documentElement;return c.innerHTML="x<style>"+b+"</style>",d.insertBefore(c.lastChild,d.firstChild)}function d(){var a=t.elements;return"string"==typeof a?a.split(" "):a}function e(a,b){var c=t.elements;"string"!=typeof c&&(c=c.join(" ")),"string"!=typeof a&&(a=a.join(" ")),t.elements=c+" "+a,j(b)}function f(a){var b=s[a[q]];return b||(b={},r++,a[q]=r,s[r]=b),b}function g(a,c,d){if(c||(c=b),l)return c.createElement(a);d||(d=f(c));var e;return e=d.cache[a]?d.cache[a].cloneNode():p.test(a)?(d.cache[a]=d.createElem(a)).cloneNode():d.createElem(a),!e.canHaveChildren||o.test(a)||e.tagUrn?e:d.frag.appendChild(e)}function h(a,c){if(a||(a=b),l)return a.createDocumentFragment();c=c||f(a);for(var e=c.frag.cloneNode(),g=0,h=d(),i=h.length;i>g;g++)e.createElement(h[g]);return e}function i(a,b){b.cache||(b.cache={},b.createElem=a.createElement,b.createFrag=a.createDocumentFragment,b.frag=b.createFrag()),a.createElement=function(c){return t.shivMethods?g(c,a,b):b.createElem(c)},a.createDocumentFragment=Function("h,f","return function(){var n=f.cloneNode(),c=n.createElement;h.shivMethods&&("+d().join().replace(/[\w\-:]+/g,function(a){return b.createElem(a),b.frag.createElement(a),'c("'+a+'")'})+");return n}")(t,b.frag)}function j(a){a||(a=b);var d=f(a);return!t.shivCSS||k||d.hasCSS||(d.hasCSS=!!c(a,"article,aside,dialog,figcaption,figure,footer,header,hgroup,main,nav,section{display:block}mark{background:#FF0;color:#000}template{display:none}")),l||i(a,d),a}var k,l,m="3.7.2",n=a.html5||{},o=/^<|^(?:button|map|select|textarea|object|iframe|option|optgroup)$/i,p=/^(?:a|b|code|div|fieldset|h1|h2|h3|h4|h5|h6|i|label|li|ol|p|q|span|strong|style|table|tbody|td|th|tr|ul)$/i,q="_html5shiv",r=0,s={};!function(){try{var a=b.createElement("a");a.innerHTML="<xyz></xyz>",k="hidden"in a,l=1==a.childNodes.length||function(){b.createElement("a");var a=b.createDocumentFragment();return"undefined"==typeof a.cloneNode||"undefined"==typeof a.createDocumentFragment||"undefined"==typeof a.createElement}()}catch(c){k=!0,l=!0}}();var t={elements:n.elements||"abbr article aside audio bdi canvas data datalist details dialog figcaption figure footer header hgroup main mark meter nav output picture progress section summary template time video",version:m,shivCSS:n.shivCSS!==!1,supportsUnknownElements:l,shivMethods:n.shivMethods!==!1,type:"default",shivDocument:j,createElement:g,createDocumentFragment:h,addElements:e};a.html5=t,j(b)}(this,document);
};
</script>
<script>/*! Respond.js v1.4.2: min/max-width media query polyfill * Copyright 2013 Scott Jehl
 * Licensed under https://github.com/scottjehl/Respond/blob/master/LICENSE-MIT
 *  */

// Only run this code in IE 8
if (!!window.navigator.userAgent.match("MSIE 8")) {
!function(a){"use strict";a.matchMedia=a.matchMedia||function(a){var b,c=a.documentElement,d=c.firstElementChild||c.firstChild,e=a.createElement("body"),f=a.createElement("div");return f.id="mq-test-1",f.style.cssText="position:absolute;top:-100em",e.style.background="none",e.appendChild(f),function(a){return f.innerHTML='&shy;<style media="'+a+'"> #mq-test-1 { width: 42px; }</style>',c.insertBefore(e,d),b=42===f.offsetWidth,c.removeChild(e),{matches:b,media:a}}}(a.document)}(this),function(a){"use strict";function b(){u(!0)}var c={};a.respond=c,c.update=function(){};var d=[],e=function(){var b=!1;try{b=new a.XMLHttpRequest}catch(c){b=new a.ActiveXObject("Microsoft.XMLHTTP")}return function(){return b}}(),f=function(a,b){var c=e();c&&(c.open("GET",a,!0),c.onreadystatechange=function(){4!==c.readyState||200!==c.status&&304!==c.status||b(c.responseText)},4!==c.readyState&&c.send(null))};if(c.ajax=f,c.queue=d,c.regex={media:/@media[^\{]+\{([^\{\}]*\{[^\}\{]*\})+/gi,keyframes:/@(?:\-(?:o|moz|webkit)\-)?keyframes[^\{]+\{(?:[^\{\}]*\{[^\}\{]*\})+[^\}]*\}/gi,urls:/(url\()['"]?([^\/\)'"][^:\)'"]+)['"]?(\))/g,findStyles:/@media *([^\{]+)\{([\S\s]+?)$/,only:/(only\s+)?([a-zA-Z]+)\s?/,minw:/\([\s]*min\-width\s*:[\s]*([\s]*[0-9\.]+)(px|em)[\s]*\)/,maxw:/\([\s]*max\-width\s*:[\s]*([\s]*[0-9\.]+)(px|em)[\s]*\)/},c.mediaQueriesSupported=a.matchMedia&&null!==a.matchMedia("only all")&&a.matchMedia("only all").matches,!c.mediaQueriesSupported){var g,h,i,j=a.document,k=j.documentElement,l=[],m=[],n=[],o={},p=30,q=j.getElementsByTagName("head")[0]||k,r=j.getElementsByTagName("base")[0],s=q.getElementsByTagName("link"),t=function(){var a,b=j.createElement("div"),c=j.body,d=k.style.fontSize,e=c&&c.style.fontSize,f=!1;return b.style.cssText="position:absolute;font-size:1em;width:1em",c||(c=f=j.createElement("body"),c.style.background="none"),k.style.fontSize="100%",c.style.fontSize="100%",c.appendChild(b),f&&k.insertBefore(c,k.firstChild),a=b.offsetWidth,f?k.removeChild(c):c.removeChild(b),k.style.fontSize=d,e&&(c.style.fontSize=e),a=i=parseFloat(a)},u=function(b){var c="clientWidth",d=k[c],e="CSS1Compat"===j.compatMode&&d||j.body[c]||d,f={},o=s[s.length-1],r=(new Date).getTime();if(b&&g&&p>r-g)return a.clearTimeout(h),h=a.setTimeout(u,p),void 0;g=r;for(var v in l)if(l.hasOwnProperty(v)){var w=l[v],x=w.minw,y=w.maxw,z=null===x,A=null===y,B="em";x&&(x=parseFloat(x)*(x.indexOf(B)>-1?i||t():1)),y&&(y=parseFloat(y)*(y.indexOf(B)>-1?i||t():1)),w.hasquery&&(z&&A||!(z||e>=x)||!(A||y>=e))||(f[w.media]||(f[w.media]=[]),f[w.media].push(m[w.rules]))}for(var C in n)n.hasOwnProperty(C)&&n[C]&&n[C].parentNode===q&&q.removeChild(n[C]);n.length=0;for(var D in f)if(f.hasOwnProperty(D)){var E=j.createElement("style"),F=f[D].join("\n");E.type="text/css",E.media=D,q.insertBefore(E,o.nextSibling),E.styleSheet?E.styleSheet.cssText=F:E.appendChild(j.createTextNode(F)),n.push(E)}},v=function(a,b,d){var e=a.replace(c.regex.keyframes,"").match(c.regex.media),f=e&&e.length||0;b=b.substring(0,b.lastIndexOf("/"));var g=function(a){return a.replace(c.regex.urls,"$1"+b+"$2$3")},h=!f&&d;b.length&&(b+="/"),h&&(f=1);for(var i=0;f>i;i++){var j,k,n,o;h?(j=d,m.push(g(a))):(j=e[i].match(c.regex.findStyles)&&RegExp.$1,m.push(RegExp.$2&&g(RegExp.$2))),n=j.split(","),o=n.length;for(var p=0;o>p;p++)k=n[p],l.push({media:k.split("(")[0].match(c.regex.only)&&RegExp.$2||"all",rules:m.length-1,hasquery:k.indexOf("(")>-1,minw:k.match(c.regex.minw)&&parseFloat(RegExp.$1)+(RegExp.$2||""),maxw:k.match(c.regex.maxw)&&parseFloat(RegExp.$1)+(RegExp.$2||"")})}u()},w=function(){if(d.length){var b=d.shift();f(b.href,function(c){v(c,b.href,b.media),o[b.href]=!0,a.setTimeout(function(){w()},0)})}},x=function(){for(var b=0;b<s.length;b++){var c=s[b],e=c.href,f=c.media,g=c.rel&&"stylesheet"===c.rel.toLowerCase();e&&g&&!o[e]&&(c.styleSheet&&c.styleSheet.rawCssText?(v(c.styleSheet.rawCssText,e,f),o[e]=!0):(!/^([a-zA-Z:]*\/\/)/.test(e)&&!r||e.replace(RegExp.$1,"").split("/")[0]===a.location.host)&&("//"===e.substring(0,2)&&(e=a.location.protocol+e),d.push({href:e,media:f})))}w()};x(),c.update=x,c.getEmValue=t,a.addEventListener?a.addEventListener("resize",b,!1):a.attachEvent&&a.attachEvent("onresize",b)}}(this);
};
</script>
<style type="text/css">.pagedtable {
overflow: auto;
padding-left: 8px;
padding-right: 8px;
}
.pagedtable-wrapper {
border: 1px solid #ccc;
border-radius: 4px;
margin-bottom: 10px;
}
.pagedtable table {
width: 100%;
max-width: 100%;
margin: 0;
}
.pagedtable th {
padding: 0 5px 0 5px;
border: none;
border-bottom: 2px solid #dddddd;
min-width: 45px;
}
.pagedtable-empty th {
display: none;
}
.pagedtable td {
padding: 0 4px 0 4px;
}
.pagedtable .even {
background-color: rgba(140, 140, 140, 0.1);
}
.pagedtable-padding-col {
display: none;
}
.pagedtable a {
-webkit-touch-callout: none;
-webkit-user-select: none;
-khtml-user-select: none;
-moz-user-select: none;
-ms-user-select: none;
user-select: none;
}
.pagedtable-index-nav {
cursor: pointer;
padding: 0 5px 0 5px;
float: right;
border: 0;
}
.pagedtable-index-nav-disabled {
cursor: default;
text-decoration: none;
color: #999;
}
a.pagedtable-index-nav-disabled:hover {
text-decoration: none;
color: #999;
}
.pagedtable-indexes {
cursor: pointer;
float: right;
border: 0;
}
.pagedtable-index-current {
cursor: default;
text-decoration: none;
font-weight: bold;
color: #333;
border: 0;
}
a.pagedtable-index-current:hover {
text-decoration: none;
font-weight: bold;
color: #333;
}
.pagedtable-index {
width: 30px;
display: inline-block;
text-align: center;
border: 0;
}
.pagedtable-index-separator-left {
display: inline-block;
color: #333;
font-size: 9px;
padding: 0 0 0 0;
cursor: default;
}
.pagedtable-index-separator-right {
display: inline-block;
color: #333;
font-size: 9px;
padding: 0 4px 0 0;
cursor: default;
}
.pagedtable-footer {
padding-top: 4px;
padding-bottom: 5px;
}
.pagedtable-not-empty .pagedtable-footer {
border-top: 2px solid #dddddd;
}
.pagedtable-info {
overflow: hidden;
color: #999;
white-space: nowrap;
text-overflow: ellipsis;
}
.pagedtable-header-name {
overflow: hidden;
text-overflow: ellipsis;
}
.pagedtable-header-type {
color: #999;
font-weight: 400;
}
.pagedtable-na-cell {
font-style: italic;
opacity: 0.3;
}
</style>
<script>// Production steps of ECMA-262, Edition 5, 15.4.4.18
// Reference: http://es5.github.io/#x15.4.4.18
if (!Array.prototype.forEach) {

  Array.prototype.forEach = function(callback, thisArg) {

    var T, k;

    if (this === null) {
      throw new TypeError(' this is null or not defined');
    }

    // 1. Let O be the result of calling toObject() passing the
    // |this| value as the argument.
    var O = Object(this);

    // 2. Let lenValue be the result of calling the Get() internal
    // method of O with the argument "length".
    // 3. Let len be toUint32(lenValue).
    var len = O.length >>> 0;

    // 4. If isCallable(callback) is false, throw a TypeError exception.
    // See: http://es5.github.com/#x9.11
    if (typeof callback !== "function") {
      throw new TypeError(callback + ' is not a function');
    }

    // 5. If thisArg was supplied, let T be thisArg; else let
    // T be undefined.
    if (arguments.length > 1) {
      T = thisArg;
    }

    // 6. Let k be 0
    k = 0;

    // 7. Repeat, while k < len
    while (k < len) {

      var kValue;

      // a. Let Pk be ToString(k).
      //    This is implicit for LHS operands of the in operator
      // b. Let kPresent be the result of calling the HasProperty
      //    internal method of O with argument Pk.
      //    This step can be combined with c
      // c. If kPresent is true, then
      if (k in O) {

        // i. Let kValue be the result of calling the Get internal
        // method of O with argument Pk.
        kValue = O[k];

        // ii. Call the Call internal method of callback with T as
        // the this value and argument list containing kValue, k, and O.
        callback.call(T, kValue, k, O);
      }
      // d. Increase k by 1.
      k++;
    }
    // 8. return undefined
  };
}

// Production steps of ECMA-262, Edition 5, 15.4.4.19
// Reference: http://es5.github.io/#x15.4.4.19
if (!Array.prototype.map) {

  Array.prototype.map = function(callback, thisArg) {

    var T, A, k;

    if (this == null) {
      throw new TypeError(' this is null or not defined');
    }

    // 1. Let O be the result of calling ToObject passing the |this|
    //    value as the argument.
    var O = Object(this);

    // 2. Let lenValue be the result of calling the Get internal
    //    method of O with the argument "length".
    // 3. Let len be ToUint32(lenValue).
    var len = O.length >>> 0;

    // 4. If IsCallable(callback) is false, throw a TypeError exception.
    // See: http://es5.github.com/#x9.11
    if (typeof callback !== 'function') {
      throw new TypeError(callback + ' is not a function');
    }

    // 5. If thisArg was supplied, let T be thisArg; else let T be undefined.
    if (arguments.length > 1) {
      T = thisArg;
    }

    // 6. Let A be a new array created as if by the expression new Array(len)
    //    where Array is the standard built-in constructor with that name and
    //    len is the value of len.
    A = new Array(len);

    // 7. Let k be 0
    k = 0;

    // 8. Repeat, while k < len
    while (k < len) {

      var kValue, mappedValue;

      // a. Let Pk be ToString(k).
      //   This is implicit for LHS operands of the in operator
      // b. Let kPresent be the result of calling the HasProperty internal
      //    method of O with argument Pk.
      //   This step can be combined with c
      // c. If kPresent is true, then
      if (k in O) {

        // i. Let kValue be the result of calling the Get internal
        //    method of O with argument Pk.
        kValue = O[k];

        // ii. Let mappedValue be the result of calling the Call internal
        //     method of callback with T as the this value and argument
        //     list containing kValue, k, and O.
        mappedValue = callback.call(T, kValue, k, O);

        // iii. Call the DefineOwnProperty internal method of A with arguments
        // Pk, Property Descriptor
        // { Value: mappedValue,
        //   Writable: true,
        //   Enumerable: true,
        //   Configurable: true },
        // and false.

        // In browsers that support Object.defineProperty, use the following:
        // Object.defineProperty(A, k, {
        //   value: mappedValue,
        //   writable: true,
        //   enumerable: true,
        //   configurable: true
        // });

        // For best browser support, use the following:
        A[k] = mappedValue;
      }
      // d. Increase k by 1.
      k++;
    }

    // 9. return A
    return A;
  };
}

var PagedTable = function (pagedTable) {
  var me = this;

  var source = function(pagedTable) {
    var sourceElems = [].slice.call(pagedTable.children).filter(function(e) {
      return e.hasAttribute("data-pagedtable-source");
    });

    if (sourceElems === null || sourceElems.length !== 1) {
      throw("A single data-pagedtable-source was not found");
    }

    return JSON.parse(sourceElems[0].innerHTML);
  }(pagedTable);

  var options = function(source) {
    var options = typeof(source.options) !== "undefined" &&
      source.options !== null ? source.options : {};

    var columns = typeof(options.columns) !== "undefined" ? options.columns : {};
    var rows = typeof(options.rows) !== "undefined" ? options.rows : {};

    var positiveIntOrNull = function(value) {
      return parseInt(value) >= 0 ? parseInt(value) : null;
    };

    return {
      pages: positiveIntOrNull(options.pages),
      rows: {
        min: positiveIntOrNull(rows.min),
        max: positiveIntOrNull(rows.max),
        total: positiveIntOrNull(rows.total)
      },
      columns: {
        min: positiveIntOrNull(columns.min),
        max: positiveIntOrNull(columns.max),
        total: positiveIntOrNull(columns.total)
      }
    };
  }(source);

  var Measurer = function() {

    // set some default initial values that will get adjusted in runtime
    me.measures = {
      padding: 12,
      character: 8,
      height: 15,
      defaults: true
    };

    me.calculate = function(measuresCell) {
      if (!me.measures.defaults)
        return;

      var measuresCellStyle = window.getComputedStyle(measuresCell, null);

      var newPadding = parsePadding(measuresCellStyle.paddingLeft) +
            parsePadding(measuresCellStyle.paddingRight);

      var sampleString = "ABCDEFGHIJ0123456789";
      var newCharacter = Math.ceil(measuresCell.clientWidth / sampleString.length);

      if (newPadding <= 0 || newCharacter <= 0)
        return;

      me.measures.padding = newPadding;
      me.measures.character = newCharacter;
      me.measures.height = measuresCell.clientHeight;
      me.measures.defaults = false;
    };

    return me;
  };

  var Page = function(data, options) {
    var me = this;

    var defaults = {
      max: 7,
      rows: 10
    };

    var totalPages = function() {
      return Math.ceil(data.length / me.rows);
    };

    me.number = 0;
    me.max = options.pages !== null ? options.pages : defaults.max;
    me.visible = me.max;
    me.rows = options.rows.min !== null ? options.rows.min : defaults.rows;
    me.total = totalPages();

    me.setRows = function(newRows) {
      me.rows = newRows;
      me.total = totalPages();
    };

    me.setPageNumber = function(newPageNumber) {
      if (newPageNumber < 0) newPageNumber = 0;
      if (newPageNumber >= me.total) newPageNumber = me.total - 1;

      me.number = newPageNumber;
    };

    me.setVisiblePages = function(visiblePages) {
      me.visible = Math.min(me.max, visiblePages);
      me.setPageNumber(me.number);
    };

    me.getVisiblePageRange = function() {
      var start = me.number - Math.max(Math.floor((me.visible - 1) / 2), 0);
      var end = me.number + Math.floor(me.visible / 2) + 1;
      var pageCount = me.total;

      if (start < 0) {
        var diffToStart = 0 - start;
        start += diffToStart;
        end += diffToStart;
      }

      if (end > pageCount) {
        var diffToEnd = end - pageCount;
        start -= diffToEnd;
        end -= diffToEnd;
      }

      start = start < 0 ? 0 : start;
      end = end >= pageCount ? pageCount : end;

      var first = false;
      var last = false;

      if (start > 0 && me.visible > 1) {
        start = start + 1;
        first = true;
      }

      if (end < pageCount && me.visible > 2) {
        end = end - 1;
        last = true;
      }

      return {
        first: first,
        start: start,
        end: end,
        last: last
      };
    };

    me.getRowStart = function() {
      var rowStart = page.number * page.rows;
      if (rowStart < 0)
        rowStart = 0;

      return rowStart;
    };

    me.getRowEnd = function() {
      var rowStart = me.getRowStart();
      return Math.min(rowStart + me.rows, data.length);
    };

    me.getPaddingRows = function() {
      var rowStart = me.getRowStart();
      var rowEnd = me.getRowEnd();
      return data.length > me.rows ? me.rows - (rowEnd - rowStart) : 0;
    };
  };

  var Columns = function(data, columns, options) {
    var me = this;

    me.defaults = {
      min: 5
    };

    me.number = 0;
    me.visible = 0;
    me.total = columns.length;
    me.subset = [];
    me.padding = 0;
    me.min = options.columns.min !== null ? options.columns.min : me.defaults.min;
    me.max = options.columns.max !== null ? options.columns.max : null;
    me.widths = {};

    var widthsLookAhead = Math.max(100, options.rows.min);
    var paddingColChars = 10;

    me.emptyNames = function() {
      columns.forEach(function(column) {
        if (columns.label !== null && columns.label !== "")
          return false;
      });

      return true;
    };

    var parsePadding = function(value) {
      return parseInt(value) >= 0 ? parseInt(value) : 0;
    };

    me.calculateWidths = function(measures) {
      columns.forEach(function(column) {
        var maxChars = Math.max(
          column.label.toString().length,
          column.type.toString().length
        );

        for (var idxRow = 0; idxRow < Math.min(widthsLookAhead, data.length); idxRow++) {
          maxChars = Math.max(maxChars, data[idxRow][column.name.toString()].length);
        }

        me.widths[column.name] = {
          // width in characters
          chars: maxChars,
          // width for the inner html columns
          inner: maxChars * measures.character,
          // width adding outer styles like padding
          outer: maxChars * measures.character + measures.padding
        };
      });
    };

    me.getWidth = function() {
      var widthOuter = 0;
      for (var idxCol = 0; idxCol < me.subset.length; idxCol++) {
        var columnName = me.subset[idxCol].name;
        widthOuter = widthOuter + me.widths[columnName].outer;
      }

      widthOuter = widthOuter + me.padding * paddingColChars * measurer.measures.character;

      if (me.hasMoreLeftColumns()) {
        widthOuter = widthOuter + columnNavigationWidthPX + measurer.measures.padding;
      }

      if (me.hasMoreRightColumns()) {
        widthOuter = widthOuter + columnNavigationWidthPX + measurer.measures.padding;
      }

      return widthOuter;
    };

    me.updateSlice = function() {
      if (me.number + me.visible >= me.total)
        me.number = me.total - me.visible;

      if (me.number < 0) me.number = 0;

      me.subset = columns.slice(me.number, Math.min(me.number + me.visible, me.total));

      me.subset = me.subset.map(function(column) {
        Object.keys(column).forEach(function(colKey) {
          column[colKey] = column[colKey] === null ? "" : column[colKey].toString();
        });

        column.width = null;
        return column;
      });
    };

    me.setVisibleColumns = function(columnNumber, newVisibleColumns, paddingCount) {
      me.number = columnNumber;
      me.visible = newVisibleColumns;
      me.padding = paddingCount;

      me.updateSlice();
    };

    me.incColumnNumber = function(increment) {
      me.number = me.number + increment;
    };

    me.setColumnNumber = function(newNumber) {
      me.number = newNumber;
    };

    me.setPaddingCount = function(newPadding) {
      me.padding = newPadding;
    };

    me.getPaddingCount = function() {
      return me.padding;
    };

    me.hasMoreLeftColumns = function() {
      return me.number > 0;
    };

    me.hasMoreRightColumns = function() {
      return me.number + me.visible < me.total;
    };

    me.updateSlice(0);
    return me;
  };

  var data = source.data;
  var page = new Page(data, options);
  var measurer = new Measurer(data, options);
  var columns = new Columns(data, source.columns, options);

  var table = null;
  var tableDiv = null;
  var header = null;
  var footer = null;
  var tbody = null;

  // Caches pagedTable.clientWidth, specially for webkit
  var cachedPagedTableClientWidth = null;

  var onChangeCallbacks = [];

  var clearSelection = function() {
    if(document.selection && document.selection.empty) {
      document.selection.empty();
    } else if(window.getSelection) {
      var sel = window.getSelection();
      sel.removeAllRanges();
    }
  };

  var columnNavigationWidthPX = 5;

  var renderColumnNavigation = function(increment, backwards) {
    var arrow = document.createElement("div");
    arrow.setAttribute("style",
      "border-top: " + columnNavigationWidthPX + "px solid transparent;" +
      "border-bottom: " + columnNavigationWidthPX + "px solid transparent;" +
      "border-" + (backwards ? "right" : "left") + ": " + columnNavigationWidthPX + "px solid;");

    var header = document.createElement("th");
    header.appendChild(arrow);
    header.setAttribute("style",
      "cursor: pointer;" +
      "vertical-align: middle;" +
      "min-width: " + columnNavigationWidthPX + "px;" +
      "width: " + columnNavigationWidthPX + "px;");

    header.onclick = function() {
      columns.incColumnNumber(backwards ? -1 : increment);

      me.animateColumns(backwards);
      renderFooter();

      clearSelection();
      triggerOnChange();
    };

    return header;
  };

  var maxColumnWidth = function(width) {
    var padding = 80;
    var columnMax = Math.max(cachedPagedTableClientWidth - padding, 0);

    return parseInt(width) > 0 ?
      Math.min(columnMax, parseInt(width)) + "px" :
      columnMax + "px";
  };

  var clearHeader = function() {
    var thead = pagedTable.querySelectorAll("thead")[0];
    thead.innerHTML = "";
  };

  var renderHeader = function(clear) {
    cachedPagedTableClientWidth = pagedTable.clientWidth;

    var fragment = document.createDocumentFragment();

    header = document.createElement("tr");
    fragment.appendChild(header);

    if (columns.number > 0)
      header.appendChild(renderColumnNavigation(-columns.visible, true));

    columns.subset = columns.subset.map(function(columnData) {
      var column = document.createElement("th");
      column.setAttribute("align", columnData.align);
      column.style.textAlign = columnData.align;

      column.style.maxWidth = maxColumnWidth(null);
      if (columnData.width) {
        column.style.minWidth =
          column.style.maxWidth = maxColumnWidth(columnData.width);
      }

      var columnName = document.createElement("div");
      columnName.setAttribute("class", "pagedtable-header-name");
      if (columnData.label === "") {
        columnName.innerHTML = "&nbsp;";
      }
      else {
        columnName.appendChild(document.createTextNode(columnData.label));
      }
      column.appendChild(columnName);

      var columnType = document.createElement("div");
      columnType.setAttribute("class", "pagedtable-header-type");
      if (columnData.type === "") {
        columnType.innerHTML = "&nbsp;";
      }
      else {
        columnType.appendChild(document.createTextNode("<" + columnData.type + ">"));
      }
      column.appendChild(columnType);

      header.appendChild(column);

      columnData.element = column;

      return columnData;
    });

    for (var idx = 0; idx < columns.getPaddingCount(); idx++) {
      var paddingCol = document.createElement("th");
      paddingCol.setAttribute("class", "pagedtable-padding-col");
      header.appendChild(paddingCol);
    }

    if (columns.number + columns.visible < columns.total)
      header.appendChild(renderColumnNavigation(columns.visible, false));

    if (typeof(clear) == "undefined" || clear) clearHeader();
    var thead = pagedTable.querySelectorAll("thead")[0];
    thead.appendChild(fragment);
  };

  me.animateColumns = function(backwards) {
    var thead = pagedTable.querySelectorAll("thead")[0];

    var headerOld = thead.querySelectorAll("tr")[0];
    var tbodyOld = table.querySelectorAll("tbody")[0];

    me.fitColumns(backwards);

    renderHeader(false);

    header.style.opacity = "0";
    header.style.transform = backwards ? "translateX(-30px)" : "translateX(30px)";
    header.style.transition = "transform 200ms linear, opacity 200ms";
    header.style.transitionDelay = "0";

    renderBody(false);

    if (headerOld) {
      headerOld.style.position = "absolute";
      headerOld.style.transform = "translateX(0px)";
      headerOld.style.opacity = "1";
      headerOld.style.transition = "transform 100ms linear, opacity 100ms";
      headerOld.setAttribute("class", "pagedtable-remove-head");
      if (headerOld.style.transitionEnd) {
        headerOld.addEventListener("transitionend", function() {
          var headerOldByClass = thead.querySelector(".pagedtable-remove-head");
          if (headerOldByClass) thead.removeChild(headerOldByClass);
        });
      }
      else {
        thead.removeChild(headerOld);
      }
    }

    if (tbodyOld) table.removeChild(tbodyOld);

    tbody.style.opacity = "0";
    tbody.style.transition = "transform 200ms linear, opacity 200ms";
    tbody.style.transitionDelay = "0ms";

    // force relayout
    window.getComputedStyle(header).opacity;
    window.getComputedStyle(tbody).opacity;

    if (headerOld) {
      headerOld.style.transform = backwards ? "translateX(20px)" : "translateX(-30px)";
      headerOld.style.opacity = "0";
    }

    header.style.transform = "translateX(0px)";
    header.style.opacity = "1";

    tbody.style.opacity = "1";
  }

  me.onChange = function(callback) {
    onChangeCallbacks.push(callback);
  };

  var triggerOnChange = function() {
    onChangeCallbacks.forEach(function(onChange) {
      onChange();
    });
  };

  var clearBody = function() {
    if (tbody) {
      table.removeChild(tbody);
      tbody = null;
    }
  };

  var renderBody = function(clear) {
    cachedPagedTableClientWidth = pagedTable.clientWidth

    var fragment = document.createDocumentFragment();

    var pageData = data.slice(page.getRowStart(), page.getRowEnd());

    pageData.forEach(function(dataRow, idxRow) {
      var htmlRow = document.createElement("tr");
      htmlRow.setAttribute("class", (idxRow % 2 !==0) ? "even" : "odd");

      if (columns.hasMoreLeftColumns())
        htmlRow.appendChild(document.createElement("td"));

      columns.subset.forEach(function(columnData) {
        var cellName = columnData.name;
        var dataCell = dataRow[cellName];
        var htmlCell = document.createElement("td");

        if (dataCell === "NA") htmlCell.setAttribute("class", "pagedtable-na-cell");
        if (dataCell === "__NA__") dataCell = "NA";

        var cellText = document.createTextNode(dataCell);
        htmlCell.appendChild(cellText);
        if (dataCell.length > 50) {
          htmlCell.setAttribute("title", dataCell);
        }
        htmlCell.setAttribute("align", columnData.align);
        htmlCell.style.textAlign = columnData.align;
        htmlCell.style.maxWidth = maxColumnWidth(null);
        if (columnData.width) {
          htmlCell.style.minWidth = htmlCell.style.maxWidth = maxColumnWidth(columnData.width);
        }
        htmlRow.appendChild(htmlCell);
      });

      for (var idx = 0; idx < columns.getPaddingCount(); idx++) {
        var paddingCol = document.createElement("td");
        paddingCol.setAttribute("class", "pagedtable-padding-col");
        htmlRow.appendChild(paddingCol);
      }

      if (columns.hasMoreRightColumns())
        htmlRow.appendChild(document.createElement("td"));

      fragment.appendChild(htmlRow);
    });

    for (var idxPadding = 0; idxPadding < page.getPaddingRows(); idxPadding++) {
      var paddingRow = document.createElement("tr");

      var paddingCellRow = document.createElement("td");
      paddingCellRow.innerHTML = "&nbsp;";
      paddingCellRow.setAttribute("colspan", "100%");
      paddingRow.appendChild(paddingCellRow);

      fragment.appendChild(paddingRow);
    }

    if (typeof(clear) == "undefined" || clear) clearBody();
    tbody = document.createElement("tbody");
    tbody.appendChild(fragment);

    table.appendChild(tbody);
  };

  var getLabelInfo = function() {
    var pageStart = page.getRowStart();
    var pageEnd = page.getRowEnd();
    var totalRows = data.length;

    var totalRowsLabel = options.rows.total ? options.rows.total : totalRows;
    var totalRowsLabelFormat = totalRowsLabel.toString().replace(/(\d)(?=(\d\d\d)+(?!\d))/g, '$1,');

    var infoText = (pageStart + 1) + "-" + pageEnd + " of " + totalRowsLabelFormat + " rows";
    if (totalRows < page.rows) {
      infoText = totalRowsLabel + " row" + (totalRows != 1 ? "s" : "");
    }
    if (columns.total > columns.visible) {
      var totalColumnsLabel = options.columns.total ? options.columns.total : columns.total;

      infoText = infoText + " | " + (columns.number + 1) + "-" +
        (Math.min(columns.number + columns.visible, columns.total)) +
        " of " + totalColumnsLabel + " columns";
    }

    return infoText;
  };

  var clearFooter = function() {
    footer = pagedTable.querySelectorAll("div.pagedtable-footer")[0];
    footer.innerHTML = "";

    return footer;
  };

  var createPageLink = function(idxPage) {
    var pageLink = document.createElement("a");
    pageLinkClass = idxPage === page.number ? "pagedtable-index pagedtable-index-current" : "pagedtable-index";
    pageLink.setAttribute("class", pageLinkClass);
    pageLink.setAttribute("data-page-index", idxPage);
    pageLink.onclick = function() {
      page.setPageNumber(parseInt(this.getAttribute("data-page-index")));
      renderBody();
      renderFooter();

      triggerOnChange();
    };

    pageLink.appendChild(document.createTextNode(idxPage + 1));

    return pageLink;
  }

  var renderFooter = function() {
    footer = clearFooter();

    var next = document.createElement("a");
    next.appendChild(document.createTextNode("Next"));
    next.onclick = function() {
      page.setPageNumber(page.number + 1);
      renderBody();
      renderFooter();

      triggerOnChange();
    };
    if (data.length > page.rows) footer.appendChild(next);

    var pageNumbers = document.createElement("div");
    pageNumbers.setAttribute("class", "pagedtable-indexes");

    var pageRange = page.getVisiblePageRange();

    if (pageRange.first) {
      var pageLink = createPageLink(0);
      pageNumbers.appendChild(pageLink);

      var pageSeparator = document.createElement("div");
      pageSeparator.setAttribute("class", "pagedtable-index-separator-left");
      pageSeparator.appendChild(document.createTextNode("..."))
      pageNumbers.appendChild(pageSeparator);
    }

    for (var idxPage = pageRange.start; idxPage < pageRange.end; idxPage++) {
      var pageLink = createPageLink(idxPage);

      pageNumbers.appendChild(pageLink);
    }

    if (pageRange.last) {
      var pageSeparator = document.createElement("div");
      pageSeparator.setAttribute("class", "pagedtable-index-separator-right");
      pageSeparator.appendChild(document.createTextNode("..."))
      pageNumbers.appendChild(pageSeparator);

      var pageLink = createPageLink(page.total - 1);
      pageNumbers.appendChild(pageLink);
    }

    if (data.length > page.rows) footer.appendChild(pageNumbers);

    var previous = document.createElement("a");
    previous.appendChild(document.createTextNode("Previous"));
    previous.onclick = function() {
      page.setPageNumber(page.number - 1);
      renderBody();
      renderFooter();

      triggerOnChange();
    };
    if (data.length > page.rows) footer.appendChild(previous);

    var infoLabel = document.createElement("div");
    infoLabel.setAttribute("class", "pagedtable-info");
    infoLabel.setAttribute("title", getLabelInfo());
    infoLabel.appendChild(document.createTextNode(getLabelInfo()));
    footer.appendChild(infoLabel);

    var enabledClass = "pagedtable-index-nav";
    var disabledClass = "pagedtable-index-nav pagedtable-index-nav-disabled";
    previous.setAttribute("class", page.number <= 0 ? disabledClass : enabledClass);
    next.setAttribute("class", (page.number + 1) * page.rows >= data.length ? disabledClass : enabledClass);
  };

  var measuresCell = null;

  var renderMeasures = function() {
    var measuresTable = document.createElement("table");
    measuresTable.style.visibility = "hidden";
    measuresTable.style.position = "absolute";
    measuresTable.style.whiteSpace = "nowrap";
    measuresTable.style.height = "auto";
    measuresTable.style.width = "auto";

    var measuresRow = document.createElement("tr");
    measuresTable.appendChild(measuresRow);

    measuresCell = document.createElement("td");
    var sampleString = "ABCDEFGHIJ0123456789";
    measuresCell.appendChild(document.createTextNode(sampleString));

    measuresRow.appendChild(measuresCell);

    tableDiv.appendChild(measuresTable);
  }

  me.init = function() {
    tableDiv = document.createElement("div");
    pagedTable.appendChild(tableDiv);
    var pagedTableClass = data.length > 0 ?
      "pagedtable pagedtable-not-empty" :
      "pagedtable pagedtable-empty";

    if (columns.total == 0 || (columns.emptyNames() && data.length == 0)) {
      pagedTableClass = pagedTableClass + " pagedtable-empty-columns";
    }

    tableDiv.setAttribute("class", pagedTableClass);

    renderMeasures();
    measurer.calculate(measuresCell);
    columns.calculateWidths(measurer.measures);

    table = document.createElement("table");
    table.setAttribute("cellspacing", "0");
    table.setAttribute("class", "table table-condensed");
    tableDiv.appendChild(table);

    table.appendChild(document.createElement("thead"));

    var footerDiv = document.createElement("div");
    footerDiv.setAttribute("class", "pagedtable-footer");
    tableDiv.appendChild(footerDiv);

    // if the host has not yet provided horizontal space, render hidden
    if (tableDiv.clientWidth <= 0) {
      tableDiv.style.opacity = "0";
    }

    me.render();

    // retry seizing columns later if the host has not provided space
    function retryFit() {
      if (tableDiv.clientWidth <= 0) {
        setTimeout(retryFit, 100);
      } else {
        me.render();
        triggerOnChange();
      }
    }
    if (tableDiv.clientWidth <= 0) {
      retryFit();
    }
  };

  var registerWidths = function() {
    columns.subset = columns.subset.map(function(column) {
      column.width = columns.widths[column.name].inner;
      return column;
    });
  };

  var parsePadding = function(value) {
    return parseInt(value) >= 0 ? parseInt(value) : 0;
  };

  me.fixedHeight = function() {
    return options.rows.max != null;
  }

  me.fitRows = function() {
    if (me.fixedHeight())
      return;

    measurer.calculate(measuresCell);

    var rows = options.rows.min !== null ? options.rows.min : 0;
    var headerHeight = header !== null && header.offsetHeight > 0 ? header.offsetHeight : 0;
    var footerHeight = footer !== null && footer.offsetHeight > 0 ? footer.offsetHeight : 0;

    if (pagedTable.offsetHeight > 0) {
      var availableHeight = pagedTable.offsetHeight - headerHeight - footerHeight;
      rows = Math.floor((availableHeight) / measurer.measures.height);
    }

    rows = options.rows.min !== null ? Math.max(options.rows.min, rows) : rows;

    page.setRows(rows);
  }

  // The goal of this function is to add as many columns as possible
  // starting from left-to-right, when the right most limit is reached
  // it tries to add columns from the left as well.
  //
  // When startBackwards is true columns are added from right-to-left
  me.fitColumns = function(startBackwards) {
    measurer.calculate(measuresCell);
    columns.calculateWidths(measurer.measures);

    if (tableDiv.clientWidth > 0) {
      tableDiv.style.opacity = 1;
    }

    var visibleColumns = tableDiv.clientWidth <= 0 ? Math.max(columns.min, 1) : 1;
    var columnNumber = columns.number;
    var paddingCount = 0;

    // track a list of added columns as we build the visible ones to allow us
    // to remove columns when they don't fit anymore.
    var columnHistory = [];

    var lastTableHeight = 0;
    var backwards = startBackwards;

    var tableDivStyle = window.getComputedStyle(tableDiv, null);
    var tableDivPadding = parsePadding(tableDivStyle.paddingLeft) +
      parsePadding(tableDivStyle.paddingRight);

    var addPaddingCol = false;
    var currentWidth = 0;

    while (true) {
      columns.setVisibleColumns(columnNumber, visibleColumns, paddingCount);
      currentWidth = columns.getWidth();

      if (tableDiv.clientWidth - tableDivPadding < currentWidth) {
        break;
      }

      columnHistory.push({
        columnNumber: columnNumber,
        visibleColumns: visibleColumns,
        paddingCount: paddingCount
      });

      if (columnHistory.length > 100) {
        console.error("More than 100 tries to fit columns, aborting");
        break;
      }

      if (columns.max !== null &&
        columns.visible + columns.getPaddingCount() >= columns.max) {
        break;
      }

      // if we run out of right-columns
      if (!backwards && columnNumber + columns.visible >= columns.total) {
        // if we started adding right-columns, try adding left-columns
        if (!startBackwards && columnNumber > 0) {
          backwards = true;
        }
        else if (columns.min === null || visibleColumns + columns.getPaddingCount() >= columns.min) {
          break;
        }
        else {
          paddingCount = paddingCount + 1;
        }
      }

      // if we run out of left-columns
      if (backwards && columnNumber == 0) {
        // if we started adding left-columns, try adding right-columns
        if (startBackwards && columnNumber + columns.visible < columns.total) {
          backwards = false;
        }
        else if (columns.min === null || visibleColumns + columns.getPaddingCount() >= columns.min) {
          break;
        }
        else {
          paddingCount = paddingCount + 1;
        }
      }

      // when moving backwards try fitting left columns first
      if (backwards && columnNumber > 0) {
        columnNumber = columnNumber - 1;
      }

      if (columnNumber + visibleColumns < columns.total) {
        visibleColumns = visibleColumns + 1;
      }
    }

    var lastRenderableColumn = {
        columnNumber: columnNumber,
        visibleColumns: visibleColumns,
        paddingCount: paddingCount
    };

    if (columnHistory.length > 0) {
      lastRenderableColumn = columnHistory[columnHistory.length - 1];
    }

    columns.setVisibleColumns(
      lastRenderableColumn.columnNumber,
      lastRenderableColumn.visibleColumns,
      lastRenderableColumn.paddingCount);

    if (pagedTable.offsetWidth > 0) {
      page.setVisiblePages(Math.max(Math.ceil(1.0 * (pagedTable.offsetWidth - 250) / 40), 2));
    }

    registerWidths();
  };

  me.fit = function(startBackwards) {
    me.fitRows();
    me.fitColumns(startBackwards);
  }

  me.render = function() {
    me.fitColumns(false);

    // render header/footer to measure height accurately
    renderHeader();
    renderFooter();

    me.fitRows();
    renderBody();

    // re-render footer to match new rows
    renderFooter();
  }

  var resizeLastWidth = -1;
  var resizeLastHeight = -1;
  var resizeNewWidth = -1;
  var resizeNewHeight = -1;
  var resizePending = false;

  me.resize = function(newWidth, newHeight) {

    function resizeDelayed() {
      resizePending = false;

      if (
        (resizeNewWidth !== resizeLastWidth) ||
        (!me.fixedHeight() && resizeNewHeight !== resizeLastHeight)
      ) {
        resizeLastWidth = resizeNewWidth;
        resizeLastHeight = resizeNewHeight;

        setTimeout(resizeDelayed, 200);
        resizePending = true;
      } else {
        me.render();
        triggerOnChange();

        resizeLastWidth = -1;
        resizeLastHeight = -1;
      }
    }

    resizeNewWidth = newWidth;
    resizeNewHeight = newHeight;

    if (!resizePending) resizeDelayed();
  };
};

var PagedTableDoc;
(function (PagedTableDoc) {
  var allPagedTables = [];

  PagedTableDoc.initAll = function() {
    allPagedTables = [];

    var pagedTables = [].slice.call(document.querySelectorAll('[data-pagedtable="false"],[data-pagedtable=""]'));
    pagedTables.forEach(function(pagedTable, idx) {
      pagedTable.setAttribute("data-pagedtable", "true");
      pagedTable.setAttribute("pagedtable-page", 0);
      pagedTable.setAttribute("class", "pagedtable-wrapper");

      var pagedTableInstance = new PagedTable(pagedTable);
      pagedTableInstance.init();

      allPagedTables.push(pagedTableInstance);
    });
  };

  PagedTableDoc.resizeAll = function() {
    allPagedTables.forEach(function(pagedTable) {
      pagedTable.render();
    });
  };

  window.addEventListener("resize", PagedTableDoc.resizeAll);

  return PagedTableDoc;
})(PagedTableDoc || (PagedTableDoc = {}));

window.onload = function() {
  PagedTableDoc.initAll();
};
</script>
<script>

/**
 * jQuery Plugin: Sticky Tabs
 *
 * @author Aidan Lister <aidan@php.net>
 * adapted by Ruben Arslan to activate parent tabs too
 * http://www.aidanlister.com/2014/03/persisting-the-tab-state-in-bootstrap/
 */
(function($) {
  "use strict";
  $.fn.rmarkdownStickyTabs = function() {
    var context = this;
    // Show the tab corresponding with the hash in the URL, or the first tab
    var showStuffFromHash = function() {
      var hash = window.location.hash;
      var selector = hash ? 'a[href="' + hash + '"]' : 'li.active > a';
      var $selector = $(selector, context);
      if($selector.data('toggle') === "tab") {
        $selector.tab('show');
        // walk up the ancestors of this element, show any hidden tabs
        $selector.parents('.section.tabset').each(function(i, elm) {
          var link = $('a[href="#' + $(elm).attr('id') + '"]');
          if(link.data('toggle') === "tab") {
            link.tab("show");
          }
        });
      }
    };


    // Set the correct tab when the page loads
    showStuffFromHash(context);

    // Set the correct tab when a user uses their back/forward button
    $(window).on('hashchange', function() {
      showStuffFromHash(context);
    });

    // Change the URL when tabs are clicked
    $('a', context).on('click', function(e) {
      history.pushState(null, null, this.href);
      showStuffFromHash(context);
    });

    return this;
  };
}(jQuery));

window.buildTabsets = function(tocID) {

  // build a tabset from a section div with the .tabset class
  function buildTabset(tabset) {

    // check for fade and pills options
    var fade = tabset.hasClass("tabset-fade");
    var pills = tabset.hasClass("tabset-pills");
    var navClass = pills ? "nav-pills" : "nav-tabs";

    // determine the heading level of the tabset and tabs
    var match = tabset.attr('class').match(/level(\d) /);
    if (match === null)
      return;
    var tabsetLevel = Number(match[1]);
    var tabLevel = tabsetLevel + 1;

    // find all subheadings immediately below
    var tabs = tabset.find("div.section.level" + tabLevel);
    if (!tabs.length)
      return;

    // create tablist and tab-content elements
    var tabList = $('<ul class="nav ' + navClass + '" role="tablist"></ul>');
    $(tabs[0]).before(tabList);
    var tabContent = $('<div class="tab-content"></div>');
    $(tabs[0]).before(tabContent);

    // build the tabset
    var activeTab = 0;
    tabs.each(function(i) {

      // get the tab div
      var tab = $(tabs[i]);

      // get the id then sanitize it for use with bootstrap tabs
      var id = tab.attr('id');

      // see if this is marked as the active tab
      if (tab.hasClass('active'))
        activeTab = i;

      // remove any table of contents entries associated with
      // this ID (since we'll be removing the heading element)
      $("div#" + tocID + " li a[href='#" + id + "']").parent().remove();

      // sanitize the id for use with bootstrap tabs
      id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
      tab.attr('id', id);

      // get the heading element within it, grab it's text, then remove it
      var heading = tab.find('h' + tabLevel + ':first');
      var headingText = heading.html();
      heading.remove();

      // build and append the tab list item
      var a = $('<a role="tab" data-toggle="tab">' + headingText + '</a>');
      a.attr('href', '#' + id);
      a.attr('aria-controls', id);
      var li = $('<li role="presentation"></li>');
      li.append(a);
      tabList.append(li);

      // set it's attributes
      tab.attr('role', 'tabpanel');
      tab.addClass('tab-pane');
      tab.addClass('tabbed-pane');
      if (fade)
        tab.addClass('fade');

      // move it into the tab content div
      tab.detach().appendTo(tabContent);
    });

    // set active tab
    $(tabList.children('li')[activeTab]).addClass('active');
    var active = $(tabContent.children('div.section')[activeTab]);
    active.addClass('active');
    if (fade)
      active.addClass('in');

    if (tabset.hasClass("tabset-sticky"))
      tabset.rmarkdownStickyTabs();
  }

  // convert section divs with the .tabset class to tabsets
  var tabsets = $("div.section.tabset");
  tabsets.each(function(i) {
    buildTabset($(tabsets[i]));
  });
};

</script>
<script>
window.initializeCodeFolding = function(show) {

  // handlers for show-all and hide all
  $("#rmd-show-all-code").click(function() {
    $('div.r-code-collapse').each(function() {
      $(this).collapse('show');
    });
  });
  $("#rmd-hide-all-code").click(function() {
    $('div.r-code-collapse').each(function() {
      $(this).collapse('hide');
    });
  });

  // index for unique code element ids
  var currentIndex = 1;

  // select all R code blocks
  var rCodeBlocks = $('pre.r, pre.python, pre.bash, pre.sql, pre.cpp, pre.stan, pre.julia');
  rCodeBlocks.each(function() {

    // create a collapsable div to wrap the code in
    var div = $('<div class="collapse r-code-collapse"></div>');
    if (show || $(this)[0].classList.contains('fold-show'))
      div.addClass('in');
    var id = 'rcode-643E0F36' + currentIndex++;
    div.attr('id', id);
    $(this).before(div);
    $(this).detach().appendTo(div);

    // add a show code button right above
    var showCodeText = $('<span>' + (show ? 'Hide' : 'Code') + '</span>');
    var showCodeButton = $('<button type="button" class="btn btn-default btn-xs code-folding-btn pull-right"></button>');
    showCodeButton.append(showCodeText);
    showCodeButton
        .attr('data-toggle', 'collapse')
        .attr('data-target', '#' + id)
        .attr('aria-expanded', show)
        .attr('aria-controls', id);

    var buttonRow = $('<div class="row"></div>');
    var buttonCol = $('<div class="col-md-12"></div>');

    buttonCol.append(showCodeButton);
    buttonRow.append(buttonCol);

    div.before(buttonRow);

    // update state of button on show/hide
    div.on('hidden.bs.collapse', function () {
      showCodeText.text('Code');
    });
    div.on('show.bs.collapse', function () {
      showCodeText.text('Hide');
    });
  });

}
</script>
<script>
window.initializeSourceEmbed = function(filename) {
  $("#rmd-download-source").click(function() {
    var src = $("#rmd-source-code").html();
    var a = document.createElement('a');
    a.href = "data:text/x-r-markdown;base64," + src;
    a.download = filename;
    document.body.appendChild(a);
    a.click();
    document.body.removeChild(a);
  });
};
</script>




<style type="text/css">
h1 {
  font-size: 34px;
}
h1.title {
  font-size: 38px;
}
h2 {
  font-size: 30px;
}
h3 {
  font-size: 24px;
}
h4 {
  font-size: 18px;
}
h5 {
  font-size: 16px;
}
h6 {
  font-size: 12px;
}
.table th:not([align]) {
  text-align: left;
}
#rmd-source-code {
  display: none;
}
</style>




<style type="text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
code {
  color: inherit;
  background-color: rgba(0, 0, 0, 0.04);
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
</style>

<style type="text/css">
.kable-table {
  border: 1px solid #ccc;
  border-radius: 4px;
  overflow: auto;
  padding-left: 8px;
  padding-right: 8px;
  margin-bottom: 20px;
  max-height: 350px;
}

.kable-table table {
  margin-bottom: 0px;
}

.kable-table table>thead>tr>th {
  border: none;
  border-bottom: 2px solid #dddddd;
}

.kable-table table>thead {
  background-color: #fff;
}
</style>


<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  background: white;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "";
  border: none;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->
<style type="text/css">
.code-folding-btn { margin-bottom: 4px; }
</style>




</head>

<body>


<div class="container-fluid main-container">




<div class="fluid-row" id="header">

<div class="btn-group pull-right">
<button type="button" class="btn btn-default btn-xs dropdown-toggle" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"><span>Code</span> <span class="caret"></span></button>
<ul class="dropdown-menu" style="min-width: 50px;">
<li><a id="rmd-download-source" href="#">Download Rmd</a></li>
</ul>
</div>



<h1 class="title toc-ignore">Pancreatobiliary Pathology Society Journal Watch</h1>
<h3 class="subtitle">Recent Articles that will be Selected</h3>
<h4 class="date">Last Update on 2019-12-22</h4>

</div>


<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<!-- Open all links in new tab-->
<p><base target="_blank"></base></p>
<hr />
<div id="pbpath-journal-watch-articles" class="section level1 tabset tabset-fade tabset-pills">
<h1>PBPath Journal Watch Articles</h1>
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<hr />
<p><strong>Wellcome to the PBPath Journal Watch!</strong></p>
<p>This bi-monthly journal watch features exciting recently published pancreas and biliary pathology articles that will provide up to date medical knowledge in our field. These articles will be showcased in several convenient categories, including surgical pathology, cytopathology, and molecular pathology among others. The articles in each category are in no particular order. See the list of journals we search regularly <a href="http://pbpath.org/pbpath-journal-watch/">here</a>. Previous months issues may be found in our <em><a href="http://pbpath.org/journal-watch-archive/">archive</a></em> and you may see <a href="http://pbpath.org/journal-watch-upcoming-issue/">drafts of the upcoming issue here</a>.</p>
<p>We encourage members to actively participate by recommending new articles and providing feedback using the <a href="#feedback" target="_self">forms provided below.</a></p>
<p><strong>We hope that you will enjoy the new PBPath Journal Watch!</strong></p>
<hr />
<p><a href="#top" target="_self">Back to top</a></p>
<hr />
<div style="page-break-after: always;"></div>
<div id="pancreas" class="section level2">
<h2>Pancreas</h2>
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Is the remnant pancreas still working over a year after surgery in patients undergoing pancreaticoduodenectomy with reconstruction by pancreaticogastrostomy?</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31862231" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31862231</a></p>
<p>BACKGROUND: Pancreaticogastrostomy (PG) has been widely used as an alternative to pancreatojejunostomy (PJ) in patients undergoing pancreaticoduodenectomy (PD), but its long-term exocrine function remains unclear. The present study aimed to measure the secretion of pancreatic -amylase (p-AMY) into the gastric cavity in patients who underwent PG reconstruction after PD over 1 year after surgery and to evaluate the relationship between gastric p-AMY level and clinically available indirect tests. METHODS: Clinical records of 39 patients who underwent PG reconstruction after PD were reviewed. Pancreatic exocrine function was evaluated over 1 year after surgery using the following methods: 1) Measurement of p-AMY level in gastric fluids (gastric p-AMY level) during routine gastrointestinal endoscopy, 2) Qualitative faecal fat determination by Sudan III staining on faeces and 3) Pancreatic function diagnostic (PFD) test using oral administration of N-benzoyl-l-tyrosyl-p-aminobenzoic acid. RESULTS: Gastric p-AMY level was detectable in 31 of 39 patients (79%), and 12 patients (30.8%) had steatorrhea over a year after surgery. Patients with steatorrhea had significantly lower gastric p-AMY level, larger diameter of remnant main pancreatic duct (MPD) and larger pancreatic duct to parenchymal thickness ratio than those without steatorrhea (84 IU/L vs 7979 IU/L, respectively; P&lt;0.001, 5.3mm vs 3.2mm, respectively; P=0.001, and 0.38 vs 0.23, respectively; P=0.007). Receiver operating characteristic analysis showed that the cut-off value of the diameter of the remnant MPD to predict steatorrhea was 3.5mm (sensitivity, 92.3%; specificity, 70.4%). PFD test was not associated with any clinical data. CONCLUSIONS: Pancreatic enzyme was detected in 79% of patients having PG reconstruction. Diameter of remnant MPD &gt;3.5mm and pancreatic parenchymal atrophy may be surrogate markers of postoperative exocrine insufficiency following PD.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.12.008" class="uri">https://doi.org/10.1016/j.pan.2019.12.008</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Validation and clinical usefulness of pre- and postoperative systemic inflammatory parameters as prognostic markers in patients with potentially resectable pancreatic cancer</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31862230" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31862230</a></p>
<p>BACKGROUND: Several preoperative systemic inflammatory parameters, such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), prognostic nutritional index (PNI), and Glasgow prognostic score, have been reported to be associated with the prognosis of solid tumors. In this study, we compared pre- and postoperative hematological inflammatory parameters and validated their prognostic significance in pancreatic cancer patients who underwent surgical resection. METHODS: Clinical records from 211 consecutive pancreatic cancer patients who underwent surgical resection at our institution were retrospectively analyzed. The optimal cutoff values of hematological inflammatory parameters, including lymphocyte count, NLR, PLR, LMR, and PNI, were determined by time-dependent receiver-operating characteristic analysis. RESULTS: The postoperative neutrophil count and serum albumin level were significantly decreased in patients who underwent pancreatoduodenectomy (PD group) and in those who underwent distal pancreatectomy (DP group) compared to the levels at baseline. The postoperative lymphocyte count, monocyte count, and platelet count were significantly increased in the DP group compared to those at baseline. As a result, the postoperative NLR and PNI significantly decreased in both groups. The multivariate analysis identified intraoperative peritoneal washing cytology, administration of adjuvant therapy, tumor size, extrapancreatic nerve plexus invasion, and preoperative PLR as independent prognostic factors for overall survival. CONCLUSIONS: Systemic inflammatory responses were altered after pancreatic resection in pancreatic cancer patients. Preoperative PLR may be a useful prognostic marker in pancreatic cancer patients undergoing surgical resection.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.12.004" class="uri">https://doi.org/10.1016/j.pan.2019.12.004</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Loss of nectin-3 expression as a marker of tumor aggressiveness in pancreatic neuroendocrine tumor</strong> </summary></p>
<p><em>Pathology international 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31855317" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31855317</a></p>
<p>Pancreatic neuroendocrine tumors (PanNETs) are rare, and prediction of aggressive characteristics, such as recurrence and metastasis and prognosis of PanNETs remain difficult. Nectins are cell adhesion molecules that regulate the formation of adherens and tight junctions. In this study, we investigated the clinicopathological significance of nectin-3 expression in patients with PanNETs. Immunohistochemical analysis of nectin-3 expression was performed on 78 cases of PanNET. Low nectin-3 expression in the membrane (positive ratio 25%) was observed in 62 cases (79.5%) and was significantly correlated with larger tumor size (&gt;20mm; P = 0.003), G2/G3 tumors (P = 0.025), higher Ki67 labeling index (3%; P = 0.009), lymphatic involvement (P = 0.047), advanced pT-factor (T2-T4; P = 0.003), lymph node metastasis (P = 0.006), advanced Union for International Cancer Control/American Joint Committee on Cancer-stage (Stage II-IV; P = 0.001), advanced ENETS stage (Stage IIa-IV; P = 0.001), nonfunctioning tumors (P = 0.002), and a shorter disease-free survival (P = 0.019). However, there was no significant correlation between nectin-3 expression in the membrane and/or cytoplasm and the clinicopathological parameters. The present results suggest that decreased nectin-3 expression in the membrane is associated with increased tumor aggressiveness of PanNETs. Clinically, immunohistochemical analysis of nectin-3 may help predict tumor aggressiveness for PanNETs.</p>
<p>doi: <a href="https://doi.org/10.1111/pin.12881" class="uri">https://doi.org/10.1111/pin.12881</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Single-session esophagogastroduodenoscopy and endoscopic ultrasound using a forward-viewing radial scan ultrasonic endoscope</strong> </summary></p>
<p><em>BMC gastroenterology 2019 Dec;19(1):220</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31852458" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31852458</a></p>
<p>BACKGROUND: Endoscopic ultrasound is useful for obtaining high-resolution images of pancreaticobiliary diseases, but is not readily available for physical checkups. In this study, we evaluated the safety and efficacy of single-session esophagogastroduodenoscopy and endoscopic ultrasound in the detection of upper-gastrointestinal and pancreaticobiliary diseases using a forward-viewing radial scan ultrasonic endoscope. METHODS: A total of 148 patients who were scheduled for upper-gastrointestinal screening using an endoscope were prospectively included. All patients were examined by EUS in combination with EGD using a forward-viewing radial scan ultrasonic endoscope. The primary endpoint was the safety of the procedures. The secondary endpoints were the prevalence of diseases, the basal imaging capability of EUS, the procedure time, total dose of propofol, and the correlation between background factors and the prevalence of pancreatic disease. The imaging capability at each region was scored as 0 (invisible) to 2 (sufficient visualization to evaluate the organs). RESULTS: Intraoperative hypotension occurred as an adverse event of intravenous anesthesia in one patient. There were 82 pancreaticobiliary findings and 165 upper-gastrointestinal findings (malignancy not included). Follicular lymphoma of the intra-abdominal lymph nodes was detected in one patient. The mean imaging scores of each section were 1.95 (pancreatic head and papilla), 2.0 (pancreatic body), 1.99 (pancreatic tail), and 1.89 (common bile duct and gallbladder). Age, history of diabetes mellitus, and smoking history were significantly associated with the prevalence of pancreatic diseases. CONCLUSION: The simultaneous performance of EGD and EUS using a new ultrasonic endoscope is tolerable and safe for upper-gastrointestinal and pancreaticobiliary screening.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-019-1141-7" class="uri">https://doi.org/10.1186/s12876-019-1141-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Impact of Socioeconomic Deprivation on Clinical Outcomes for Pancreatic Adenocarcinoma at a High-volume Cancer Center: A Retrospective Cohort Analysis</strong> </summary></p>
<p><em>Annals of surgery 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31851004" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31851004</a></p>
<p>OBJECTIVE: To assess the impact of a granular measure of SED on pancreatic surgical and cancer-related outcomes at a high-volume cancer center that employs a standardized clinic pathway. SUMMARY OF BACKGROUND DATA: Prior research has shown that low socioeconomic status leads to less treatment and worse outcomes for PDAC. However, these studies employed inconsistent definitions and categorizations of socioeconomic status, aggregated individual socioeconomic data using large geographic areas, and lacked detailed clinicopathologic variables. METHODS: We conducted a retrospective cohort study of 1552 PDAC patients between 2008 and 2015. Patients were stratified using the area deprivation index, a validated dataset that ranks census block groups based on SED. Multivariable models were used in the curative surgery cohort to predict the impact of SED on (1) grade 3/4 Clavien-Dindo complications, (2) initiation of adjuvant therapy, (3) completion of adjuvant therapy, and (4) overall survival RESULTS:: Patients from high SED neighborhoods constituted 29.9% of the cohort. Median overall survival was 28 months. The rate of Clavien-Dindo grade 3/4 complications was 14.2% and completion of adjuvant therapy was 65.6%. There was no evidence that SED impacted surgical evaluation, receipt of curative-intent surgery, postoperative complications, receipt of adjuvant therapy or overall survival. CONCLUSIONS: Although nearly one-quarter of curative-intent surgery patients were from high SED neighborhoods, this factor was not associated with measures of treatment quality or survival. These observations suggest that treatment at a high-volume cancer center employing a standardized clinical pathway may in part address socioeconomic disparities in pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003706" class="uri">https://doi.org/10.1097/SLA.0000000000003706</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>500 Minimally Invasive Robotic Pancreatoduodenectomies: One Decade of Optimizing Performance</strong> </summary></p>
<p><em>Annals of surgery 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31851003" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31851003</a></p>
<p>OBJECTIVES: This study aims to present the outcomes of our decade-long experience of robotic pancreatoduodenectomy and provide insights into successful program implementation. BACKGROUND: Despite significant improvement in mortality over the past 30 years, morbidity following open pancreatoduodenectomy remains high. We implemented a minimally invasive pancreatic surgery program based on the robotic platform as one potential method of improving outcomes for this operation. METHODS: A retrospective review of a prospectively maintained institutional database was performed to identify patients who underwent robotic pancreatoduodenectomy (RPD) between 2008 and 2017 at the University of Pittsburgh. RESULTS: In total, 500 consecutive RPDs were included. Operative time, conversion to open, blood loss, and clinically relevant postoperative pancreatic fistula improved early in the experience and have remained low despite increasing complexity of case selection as reflected by increasing number of patients with pancreatic cancer, vascular resections, and higher Charlson Comorbidity scores (all P&lt;0.05). Operating room time plateaued after 240 cases at a median time of 391 minutes (interquartile rang 340-477). Major complications (Clavien &gt;2) occurred in less than 24%, clinically relevant postoperative pancreatic fistula in 7.8%, 30- and 90-day mortality were 1.4% and 3.1% respectively, and median length of stay was 8 days. Outcomes were not impacted by integration of trainees or expansion of selection criteria. CONCLUSIONS: Structured implementation of robotic pancreatoduodenectomy can be associated with excellent outcomes. In the largest series of RPD, we establish benchmarks for the surgical community to consider when adopting this approach.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003550" class="uri">https://doi.org/10.1097/SLA.0000000000003550</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Revision of Pancreatic Neck Margins Based on Intraoperative Frozen Section Analysis Is Associated With Improved Survival in Patients Undergoing Pancreatectomy for Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Annals of surgery 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31851002" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31851002</a></p>
<p>OBJECTIVE: To test the hypothesis that complete, tumor-free resection at the pancreatic neck, achieved either en-bloc or non-en-bloc (ie, revision based on intraoperative frozen section [FS] analysis), is associated with improved survival as compared with incomplete resection (IR) in pancreatic ductal adenocarcinoma. SUMMARY BACKGROUND DATA: Given the likely systemic nature of pancreatic ductal adenocarcinoma, the oncologic benefit of achieving a histologically complete local resection, particularly through revision of a positive intraoperative FS at the pancreatic neck, remains controversial. METHODS: Clinicopathologic and treatment data were reviewed for 986 consecutive patients with ductal adenocarcinoma at the head, neck, or uncinate process of the pancreas who underwent open pancreatectomy as well as intraoperative FS analysis between 1998 and 2012 at Massachusetts General Hospital and between 1998 and 2013 at the University of Verona. Overall survival (OS) and perioperative morbidity and mortality were compared across 3 groups: complete resection achieved en-bloc (CR-EB), complete resection achieved non-en-bloc (CR-NEB), and IR. RESULTS: The CR-EB cohort comprised 749 (76%) patients, CR-NEB 159 patients (16%), and IR 78 patients (8%). Other than a higher incidence of vascular resection among CR-NEB and IR patients, no demographic, pathologic (eg, tumor grade, lymph node positivity, superior mesenteric artery involvement), or treatment factors (eg, neoadjuvant and adjuvant therapy use) differed between the groups. Median OS was significantly higher in patients with CR-EB (28 mo, P = 0.01) and CR-NEB resections (24 mo, P = 0.02) as compared with patients with IR resections (19 mo). After adjusting for clinicopathologic and treatment characteristics, CR-EB and CR-NEB margin status were found to be independent predictors of improved OS (relative to IR, CR-EB hazard ratio [HR] 0.65, 95% confidence interval [CI] 0.49-0.86; CR-NEB HR 0.69, 95% CI 0.50-0.96). There were no intergroup differences in perioperative morbidity and mortality, including rates of pancreatic fistula. CONCLUSIONS: For patients with ductal adenocarcinoma at the head, neck, or uncinate process of the pancreas undergoing pancreatectomy, complete tumor extirpation via either en-bloc or non-en-bloc complete resection based on FS analysis is associated with improved OS, without an associated increased perioperative morbidity or mortality.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003503" class="uri">https://doi.org/10.1097/SLA.0000000000003503</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Outcomes of Elective and Emergency Conversion in Minimally Invasive Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: An International Multicenter Propensity Score-matched Study</strong> </summary></p>
<p><em>Annals of surgery 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31850984" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31850984</a></p>
<p>OBJECTIVE: The aim of this study was to investigate the impact of conversion during minimally invasive distal pancreatectomy (MIDP) for pancreatic ductal adenocarcinoma (PDAC) on outcome by a propensity-matched comparison with open distal pancreatectomy (ODP). BACKGROUND: MIDP is associated with faster recovery as compared with ODP. The high conversion rate (15%-25%) in patients with PDAC, however, is worrisome and may negatively influence outcome. METHODS: A post hoc analysis of a retrospective cohort including distal pancreatectomies for PDAC from 34 centers in 11 countries. Patients requiring conversion were matched, using propensity scores, to ODP procedures (1:2 ratio). Indications for conversion were classified as elective conversions (eg, vascular involvement) or emergency conversions (eg, bleeding). RESULTS: Among 1212 distal pancreatectomies for PDAC, 345 patients underwent MIDP, with 68 (19.7%) conversions, mostly elective (n = 46, 67.6%). Vascular resection (other than splenic vessels) was required in 19.1% of the converted procedures. After matching (61 MIDP-converted vs 122 ODP), conversion did not affect R-status, recurrence of cancer, nor overall survival. However, emergency conversion was associated with increased overall morbidity (61.9% vs 31.1%, P= 0.007) and a trend to worse oncological outcome compared with ODP. Elective conversion was associated with comparable overall morbidity. CONCLUSIONS: Elective conversion in MIDP for PDAC was associated with comparable short-term and oncological outcomes in comparison with ODP. However, emergency conversions were associated with worse both short- and long-term outcomes, and should be prevented by careful patient selection, awareness of surgeons learning curve, and consideration of early conversion when unexpected intraoperative findings are encountered.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003717" class="uri">https://doi.org/10.1097/SLA.0000000000003717</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Prevalence and Significance of Jejunal and Duodenal Bulb Polyposis After Duodenectomy in Familial Adenomatous Polyposis: Retrospective Cohort Study</strong> </summary></p>
<p><em>Annals of surgery 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31850977" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31850977</a></p>
<p>OBJECTIVE: To evaluate the prevalence, natural history, and severity of polyposis of the duodenal bulb and jejunum after duodenectomy in patients with FAP. SUMMARY OF BACKGROUND DATA: Advanced duodenal polyposis stage in FAP requires consideration of duodenal resection to prevent cancer; pylorus-preserving approach of pancreas-sparing duodenectomy (PSD) is preferred. Post-duodenectomy data indicate polyps occur in the duodenal bulb and the post-anastomotic jejunum, but limited data exists regarding their significance. METHODS: We identified consecutive FAP patients After duodenal resection, including pancreaticoduodenectomy, PSD, or segmental duodenectomy, at Cleveland Clinic. Medical records were used to determine time to diagnosis of duodenal bulb or jejunal polyps, length of follow up, and severity of polyposis including maximal Spigelman stage (SS) of jejunal polyposis (neo-SS). RESULTS: 64 patients with FAP underwent duodenectomy and endoscopic follow up. 28% underwent pancreaticoduodenectomy, 61% PSD, and 11% segmental duodenectomy. Postoperatively, 38/64 (59%) were diagnosed with jejunal polyposis, with median time to diagnosis of 55 months and follow up time of 127 months. Jejunal polyposis was advanced in 21% (neo- SS III or IV). Fifty percent were treated endoscopically, 1 patient required surgery. Jejunal polyp-free survival after duodenectomy differed by surgery type (P = 0.008). A total of 55/64 patients underwent a pylorus-preserving procedure, and 6/55 (11%) developed duodenal bulb polyps. All bulb polyps were large (&gt;20mm) and found after PSD. Endoscopic resection was unsuccessful in 5 patients, but no surgical intervention was required. CONCLUSIONS: Polyposis occurs in the remaining duodenal and jejunal mucosa in the majority of patients after surgical duodenectomy. Jejunal polyposis is advanced in 1 in 5 patients, but rarely requires surgery. Endoscopic management of jejunal polyposis seems feasible but has proven difficult for duodenal bulb polyps.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003740" class="uri">https://doi.org/10.1097/SLA.0000000000003740</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comparison between two types of needles for Endoscopic Ultrasound (EUS)-guided fine aspiration biopsy of pancreatic and upper gastrointestinal masses</strong> </summary></p>
<p><em>Diagnostic cytopathology 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31850666" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31850666</a></p>
<p>BACKGROUND: EUS-guided fine-needle aspiration (FNA) has long been the main method for sampling pancreatic lesions. Recently, the method of fine-needle biopsy (FNB) was introduced in practice, allowing for the acquisition of tissue cores while aspirating the lesion. We hereby report our experience with a new FNB needle compared with the standard FNA needle. METHODS: Retrospective data from our department were collected on patients who underwent FNB using the Acquire EUS-FNB needle (Boston Scientific, Massachusetts) and FNA using the EchoTip Ultra EUS-FNA Needle (Cook Medical, Indiana) between January 2017 and February 2018. The cases were reviewed independently by two cytopathologists and evaluated for the presence of cell block or core tissue material, adequacy for potential ancillary testing, and number of passes. RESULTS: The number of passes ranged from 1 to 16, with a mean of 5.523.74 in the FNA group, and from 1 to 6, with a mean of 2.741.11 passes in the FNB group (P&lt;.0001). Tissue cores were present in 87.23% of the FNB needle samples. A cell block was adequate in 36.36% of cases using the FNA needle. The diagnostic yield as well as the adequacy for ancillary testing were significantly different between the two groups (P = .0001). The tumor size, location and patients demographics were not statistically significant between the two groups. CONCLUSION: Compared with the conventional needle, the new FNB needle was associated with a lower number of passes and a better yield for histological material.</p>
<p>doi: <a href="https://doi.org/10.1002/dc.24361" class="uri">https://doi.org/10.1002/dc.24361</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Association between the expression of secreted phosphoprotein - related genes and prognosis of human cancer</strong> </summary></p>
<p><em>BMC cancer 2019 Dec;19(1):1230</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31849319" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31849319</a></p>
<p>BACKGROUND: While many studies have assessed the predictive value of secreted phosphoprotein (SPP) genes in cancer, the findings have been inconsistent. To resolve these inconsistencies, we systematically analyzed the available data to determine whether SPP1 and SPP2 are prognostic markers in the context of human cancer. METHODS: The expression of SPP1 and SPP2 was assessed by Oncomine analysis. The PrognoScan database was used to assess the prognostic value of SPP1 and SPP2, with cBioPortal used to assess copy number variations. The STRING database was used to generate a Protein - Protein Interaction (PPI) network for SPP genes. RESULTS: SPP1 was more likely to be over-expressed in breast, bladder, colorectal, head, neck, liver, lung, and esophageal cancers. SPP2 was expressed at lower levels in colorectal cancer, leukemia, liver cancer and pancreatic cancer. In addition, SPP1 and SPP2 mutations mainly occurred in cutaneous melanoma and endometrial cancer. CONCLUSIONS: Our results suggest that SPP1 and SPP2 may be effective therapeutic or diagnostic targets in certain cancers. Further research is required to confirm these results and verify the value of SPP1 and SPP2 as clinical markers of cancer prognosis.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6441-3" class="uri">https://doi.org/10.1186/s12885-019-6441-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: The Naples Prognostic Score Predicts Long-Term Survival in Patients with Resected Pancreatic Cancer</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31848821" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31848821</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-08056-6" class="uri">https://doi.org/10.1245/s10434-019-08056-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: Neoadjuvant Therapy for Pancreatic Cancer-Standard of Care or Still Worth Debating?</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31848817" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31848817</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-08135-8" class="uri">https://doi.org/10.1245/s10434-019-08135-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body orTail on Surgical and Oncological Outcome: A Propensity-ScoreMatched Multicenter Study</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31848815" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31848815</a></p>
<p>BACKGROUND: Several studies have suggested a survival benefit of neoadjuvant therapy (NAT) for pancreatic ductal adenocarcinoma (PDAC) in the pancreatic head. Data concerning NAT for PDAC located in pancreatic body or tail are lacking. METHODS: Post hoc analysis of an international multicenter retrospective cohort of distal pancreatectomy for PDAC in 34 centers from 11 countries (2007-2015). Patients who underwent resection after NAT were matched (1:1 ratio), using propensity scores based on baseline characteristics, to patients who underwent upfront resection. Median overall survival was compared using the stratified log-rank test. RESULTS: Among 1236 patients, 136 (11.0%) received NAT, most frequently FOLFIRINOX (25.7%). In total, 94 patients receiving NAT were matched to 94 patients undergoing upfront resection. NAT was associated with less postoperative major morbidity (Clavien-Dindo3a, 10.6% vs.23.4%, P=0.020) and pancreatic fistula grade B/C (9.6% vs.21.3%, P=0.026). NAT did not improve overall survival [27 (95% CI 14-39) versus 31months (95% CI 19-42), P=0.277], as compared with upfront resection. In a sensitivity analysis of 251 patients with radiographic tumor involvement of splenic vessels, NAT (n=37, 14.7%) was associated with prolonged overall survival [36 (95% CI 18-53) versus 20months (95% CI 15-24), P=0.049], as compared with upfront resection. CONCLUSION: In this international multicenter cohort study, NAT for resected PDAC in pancreatic body or tail was associated with less morbidity and pancreatic fistula but similar overall survival in comparison with upfront resection. Prospective studies should confirm a survival benefit of NAT in patients with PDAC and splenic vessel involvement.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-08137-6" class="uri">https://doi.org/10.1245/s10434-019-08137-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Clinical Implications of Naples Prognostic Score in Patients with Resected Pancreatic Cancer</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31848811" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31848811</a></p>
<p>BACKGROUND: Nutritional and immunological statuses are attracting increasing attention for their ability to predict surgical outcomes in various cancers. The Naples prognostic score (NPS) consists of the serum albumin level, total cholesterol level, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio and could be useful for predicting survival. PATIENTS AND METHODS: We retrospectively analyzed 196 patients with pancreatic cancer who underwent curative R0/R1 resection with a surgery-first strategy between June 2003 and August 2016. The NPS of the patients was calculated from preoperative data, and the patients were then divided into three groups based on their NPS. Clinicopathological characteristics, surgical outcomes, and long-term survival were compared, and multivariate analysis of overall survival was conducted. RESULTS: Of a total of 196 patients, 22 were classified into group 0 (NPS 0), 113 into group 1 (NPS 1 or 2), and 61 into group 2 (NPS 3 or 4). Median survival time was 103.4months in group 0, 33.3months in group 1, and 21.3months in group 2. Significant survival differences were observed among the 3 groups (group 1 vs.2, group 0 vs.2, P=0.0380, P=0.0022, respectively). On multivariate analysis, NPS was identified as an independent prognostic factor [hazard ratio (HR)=1.78; P=0.0131]; however, there were no significant differences in the incidence of postoperative morbidity among the NPS groups. CONCLUSIONS: The NPS could be an easy scoring system and an independent preoperative predictor of survival.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-08047-7" class="uri">https://doi.org/10.1245/s10434-019-08047-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A first-in-human Phase I study to evaluate the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31848189" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31848189</a></p>
<p>PURPOSE: Extracellular signal-regulated kinase 1 and 2 (ERK1/2) signaling can be dysregulated in cancer. GDC-0994 is an oral inhibitor of ERK1/2. A first-in-human, Phase I dose escalation study of GDC-0994 was conducted in patients with locally advanced or metastatic solid tumors. EXPERIMENTAL DESIGN: GDC-0994 was administered once daily on a 21-day on/7-day off schedule to evaluate safety, pharmacokinetics, and preliminary signs of efficacy. Patients with pancreatic adenocarcinoma and BRAF-mutant colorectal cancer (CRC) were enrolled in the expansion stage. RESULTS: Forty-seven patients were enrolled in 6 successive cohorts (50-800 mg). A single DLT of Grade 3 rash occurred at 600 mg. The most common drug-related adverse events (AE) were diarrhea, rash, nausea, fatigue, and vomiting. PK data showed dose-proportional increases in exposure, with a mean half-life of 23 hours, supportive of once daily dosing. In evaluable paired biopsies, MAPK pathway inhibition ranged from 19-51%. Partial metabolic responses by FDG-PET were observed in 11/20 patients across dose levels in multiple tumor types. Overall, 15/45 (33%) patients had a best overall response of stable disease and 2 patients with BRAF-mutant CRC had a confirmed partial response. CONCLUSIONS: GDC-0994 had an acceptable safety profile and pharmacodynamic effects were observed by FDG-PET and in serial tumor biopsies. Single agent activity was observed in two patients with BRAF-mutant CRC.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-2574" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-2574</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31848187" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31848187</a></p>
<p>PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease that can be separated into distinct subtypes based on molecular signatures. Identifying PDAC subtype-specific therapeutic vulnerabilities is necessary to develop precision medicine approaches to treat PDAC. EXPERIMENTAL DESIGN: 56 PDAC liver metastases were obtained from the UNMC Rapid Autopsy Program and analyzed with quantitative proteomics. PDAC subtypes were identified by Principal Component Analysis based on protein expression profiling. Proteomic subtypes were further characterized by the associated clinical information, including but not limited to survival analysis, drug treatment response, smoking and drinking status. RESULTS: Over 3960 proteins were identified and used to delineated 4 distinct PDAC microenvironment subtypes: (1) Metabolic; (2) Progenitor-like; (3) Proliferative; and (4) Inflammatory. PDAC risk factors of alcohol and tobacco consumption correlate with subtype classifications. Enhanced survival is observed in FOLFIRINOX treated Metabolic and Progenitor-like subtypes compared to the Proliferative and Inflammatory subtypes. In addition, TYMP, PDCD6IP, ERAP1, and STMN showed significant association with patient survival in a subtype-specific manner. Gemcitabine-induced alterations in the proteome identify proteins, such as SHMT1, associated with drug resistance. CONCLUSIONS: These data demonstrate that proteomic analysis of clinical PDAC liver metastases can identify molecular signatures unique to disease subtypes and point to opportunities for therapeutic development to improve the treatment of PDAC.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-1496" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-1496</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Assessment of ARX expression, a novel biomarker for metastatic risk in pancreatic neuroendocrine tumors, in endoscopic ultrasound fine-needle aspiration</strong> </summary></p>
<p><em>Diagnostic cytopathology 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31846235" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31846235</a></p>
<p>BACKGROUND: The transcription factors ARX and PDX1, and alternative lengthening of telomeres (ALT) were recently described as prognostic markers for resected non-functional pancreatic neuroendocrine tumors (PanNETs). ALT positive tumors with ARX expression relapse most often. Currently, tumor size is the only preoperative marker used to decide whether or not to operate, thus additional preoperative prognostic markers are needed. Therefore, it is critical to assess the performance of these biomarkers on preoperative cytologic specimens. METHODS: Endoscopic fine-needle aspiration cellblock material and corresponding surgical specimens of 13 patients with PanNETs were assessed for histology, immunohistochemical staining of ARX, PDX1, Synaptophysin, Ki67, and telomere-specific fluorescence in situ hybridization to detect ALT, and then associated with clinicopathological features. Scoring for ARX and PDX1 was performed blinded by two independent observers. RESULTS: Of the 13 surgical specimens, 8 were ARX+/PDX1-, 2 ARX-/PDX1+, and 3 ARX+/PDX1+. Concordance between cytologic and surgical specimens for ARX protein expression was 100%, whereas concordance for PDX1, ALT, and WHO tumor grade was 85%, 91%, and 73%, respectively. There was a perfect inter-observer agreement in ARX and PDX1 scoring. CONCLUSION: ARX can reliably be determined in cytologic specimens and has low inter-observer variability. For cytology, false-positive PDX1 expression was observed, possibly due to contamination or sampling, while ALT had a false-negative case due to incomplete sampling. As previously observed, tumor grade is underestimated in cytologic specimens. Thus, ARX and ALT are the most promising markers to predict metastatic behavior in PanNETs, thereby warranting further validation in larger studies.</p>
<p>doi: <a href="https://doi.org/10.1002/dc.24368" class="uri">https://doi.org/10.1002/dc.24368</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma</strong> </summary></p>
<p><em>Proceedings of the National Academy of Sciences of the United States of America 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31843922" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31843922</a></p>
<p>Transcriptional profiling has defined pancreatic ductal adenocarcinoma (PDAC) into distinct subtypes with the majority being classical epithelial (E) or quasi-mesenchymal (QM). Despite clear differences in clinical behavior, growing evidence indicates these subtypes exist on a continuum with features of both subtypes present and suggestive of interconverting cell states. Here, we investigated the impact of different therapies being evaluated in PDAC on the phenotypic spectrum of the E/QM state. We demonstrate using RNA-sequencing and RNA-in situ hybridization (RNA-ISH) that FOLFIRINOX combination chemotherapy induces a common shift of both E and QM PDAC toward a more QM state in cell lines and patient tumors. In contrast, Vitamin D, another drug under clinical investigation in PDAC, induces distinct transcriptional responses in each PDAC subtype, with augmentation of the baseline E and QM state. Importantly, this translates to functional changes that increase metastatic propensity in QM PDAC, but decrease dissemination in E PDAC in vivo models. These data exemplify the importance of both the initial E/QM subtype and the plasticity of E/QM states in PDAC in influencing response to therapy, which highlights their relevance in guiding clinical trials.</p>
<p>doi: <a href="https://doi.org/10.1073/pnas.1914915116" class="uri">https://doi.org/10.1073/pnas.1914915116</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Interleukin 22 Signaling Regulates Acinar Cell Plasticity to Promote Pancreatic Tumor Development in Mice</strong> </summary></p>
<p><em>Gastroenterology 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31843590" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31843590</a></p>
<p>BACKGROUND &amp; AIMS: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that invades surrounding structures and metastasizes rapidly. Although inflammation is associated with tumor formation and progression, little is known about the mechanisms of this connection. We investigate the effects of interleukin 22 (IL22) in development of pancreatic tumors in mice. METHODS: We performed studies with Pdx1-Cre;LSL-KrasG12D;Trp53+/-;Rosa26EYFP/+ (PKCY) mice, which develop pancreatic tumors, and PKCY mice with disruption of IL22 (PKCY IL22-/-mice). Pancreata were collected at different stages of tumor development and analyzed by immunohistochemistry, immunoblotting, real-time PCR, and flow cytometry. Some mice were given cerulean to induce pancreatitis. Pancreatic cancer cell lines (PD2560) were orthotopically injected into C57BL/6 mice or Il22-/-mice and tumor development was monitored. Pancreatic cells were injected into tail veins of mice and lung metastases were quantified. Acini were collected from C57BL/6 mice and resected human pancreata and cultured. Cell lines and acini cultures were incubated with IL22, pharmacologic inhibitors and protein levels were knocked down with small hairpin RNAs. We performed immunohistochemical analyses of 26 PDACs and 5 non-neoplastic pancreas specimens. RESULTS: We observed increased expression of IL22 and the IL22 receptor (IL22R) in the pancreas compared with other tissues in mice; IL22 increased with pancreatitis and tumorigenesis. Flow cytometry indicated that the IL22 was produced primarily by T-helper 22 cells. PKCY IL22-/-mice did not develop precancerous lesions or pancreatic tumors. Addition of IL22 to cultured acinar cells increased their expression of markers of ductal metaplasia; these effects of IL22 were prevented with inhibitors of JAK signaling to STAT (ruxolitinib) or MEK (trametinib) and with STAT3 knockdown. Pancreatic cells injected into IL22-/-mice formed smaller tumors than those injected into C57BL/6. Incubation of IL22R-expressing PDAC cells with IL22 promoted spheroid formation and invasive activity, resulted increased expression of stem-associated transcription factors (GATA4, SOX2, SOX17, and NANOG), and increased markers of the epithelial-mesenchymal transition (CDH1, SNAI2, TWIST1, and beta catenin); ruxolitinib blocked these effects. Human PDAC tissues had higher levels of IL22, phosphorylated STAT3, and markers of the epithelial-mesenchymal transition than non-neoplastic tissues. Increased level of STAT3 in IL22R-positive cells was associated with shorter survival times of patients. CONCLUSIONS: We found levels of IL22 to be increased during pancreatitis and pancreatic tumor development, and to be required for tumor development and progression in mice. IL22 promotes acinar to ductal metaplasia, stem cell features, and increased expression of markers of the epithelial-mesenchymal transition; inhibitors of STAT3 block these effects. Increased expression of IL22 by PDACs is associated with reduced survival times.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.12.010" class="uri">https://doi.org/10.1053/j.gastro.2019.12.010</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Incidence of Venous Thromboembolism in Patients with Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes</strong> </summary></p>
<p><em>Gastroenterology 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31843588" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31843588</a></p>
<p>BACKGROUND &amp; AIMS: Pancreatic ductal adenocarcinoma (PDAC) is associated with the highest incidence of venous thromboembolism (VTE) of any cancer type. However, little is known about risk factors for VTE or its outcomes in patients with PDAC. METHODS: We collected data from a prospective, observational study performed at multiple centers in France from May 2014 through November 2018 (the Base Clinico-Biologique de lAdnocarcinome Pancratique [BACAP] study) linked to a database of patients with a new diagnosis of PDAC of any stage. Data were collected from 731 patients at baseline and during clinical follow-up or in the event of symptoms. The primary endpoint was the onset of VTE during follow up. The secondary end points were progression-free survival (PFS) and overall survival (OS) times. RESULTS: During a median follow-up of 19.3 months, 152 patients (20.79%) developed a VTE. The median time from PDAC diagnosis to the onset of VTE was 4.49 months. Cumulative incidence values of VTE were 8.07% (95% CI, 6.31-10.29) at 3 months and 19.21% (95% CI, 16.27-22.62) at 12 months. In multivariate analysis, PDAC primary tumor location (isthmus vs head, hazard ratio [HR], 2.06; 95% CI, 1.09-3.91; P=.027) and stage (locally advanced vs resectable or borderline HR, 1.66; 95% CI 1.10-2.51, P=.016 and metastatic vs resectable or borderline HR, 2.50; 95% CI, 1.64-3.79; P&lt;.001) were independent risk factors for onset of VTE. Patients who developed VTE during follow up had shorter times of PFS (HR, 1.74; 95% CI, 1.19-2.54; P=.004) and OS (HR, 2.02; 95% CI, 1.57-2.60; P&lt;.001). CONCLUSION: In an analysis of data from the BACAP study, we found that frequent and early onset of VTE after diagnoses of PDAC are associated with significant decreases in times of PFS and OS. Studies are needed to determine whether primary prophylaxis of VTE in patients with PDAC will improve morbidity and mortality related to VTE.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.12.009" class="uri">https://doi.org/10.1053/j.gastro.2019.12.009</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Differential diagnosis of pancreatic serous cystadenoma and mucinous cystadenoma: utility of textural features in combination with morphological characteristics</strong> </summary></p>
<p><em>BMC cancer 2019 Dec;19(1):1223</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31842793" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31842793</a></p>
<p>BACKGROUND: Texture analysis of medical images has been reported to be a reliable method for differential diagnosis of neoplasms. This study was to investigate the performance of textural features and the combined performance of textural features and morphological characteristics in the differential diagnosis of pancreatic serous and mucinous cystadenomas. METHODS: We retrospectively reviewed 59 patients with pancreatic serous cystadenoma and 32 patients with pancreatic mucinous cystadenoma at our hospital. A three-dimensional region of interest (ROI) around the margin of the lesion was drawn manually in the CT images of each patient, and textural parameters were retrieved from the ROI. Textural features were extracted using the LifeX software. The least absolute shrinkage and selection operator (LASSO) method was applied to select the textural features. The differential diagnostic capabilities of morphological features, textural features, and their combination were evaluated using receiver operating characteristic (ROC) analysis, and the area under the receiver operating characteristic curve (AUC) was used as the main indicator. The diagnostic accuracy based on the AUC value is defined as follows: 0.9-1.0, excellent; 0.8-0.9, good; 0.7-0.8, moderate; 0.6-0.7, fair; 0.5-0.6, poor. RESULTS: In the differential diagnosis of pancreatic serous and mucinous cystadenomas, the combination of morphological characteristics and textural features (AUC 0.893, 95% CI 0.816-0.970) is better than morphological characteristics (AUC 0.783, 95% CI 0.665-0.900) or textural features (AUC 0.777, 95% CI 0.673-0.880) alone. CONCLUSIONS: In conclusion, our preliminary results highlighted the potential of CT texture analysis in discriminating pancreatic serous cystadenoma from mucinous cystadenoma. Furthermore, the combination of morphological characteristics and textural features can significantly improve the diagnostic performance, which may provide a reliable method for selecting patients with surgical intervention indications in consideration of the different treatment principles of the two diseases.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6421-7" class="uri">https://doi.org/10.1186/s12885-019-6421-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Exploring the current status of neuroendocrine tumours: a population-based analysis of epidemiology, management and use of resources</strong> </summary></p>
<p><em>BMC cancer 2019 Dec;19(1):1226</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31842791" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31842791</a></p>
<p>BACKGROUND: Neuroendocrine tumours (NETs) are rare malignancies characterised by its capacity to synthesise and secrete monoamines, due to its neuroendocrine origin. Its varied locations and symptoms have traditionally been responsible for extended delays in their diagnosis. The interest of this study was to characterise the patient population diagnosed with NETs in Spain and to revise how the disease is managed, together with the hospitalisation costs of these patients. METHODS: The database included records of all patients diagnosed with a NET between 2010 and 2015. Admission records were used to evaluate hospitalisation, disease management data and costs, and single-patient files were used to characterise the population. RESULTS: Nine Thousand One Hundred Twenty patients were diagnosed with a neuroendocrine tumour between 2010 and 2015, with a 2 fold increase in the diagnosis rate over the study period. 42.25% of the patients were females, while 57.75% were males, and mean diagnosis age was 62.58years (SD=14.65). Considering all the registered neuroendocrine neoplasms, 46.86% of the patients had malignant well-differentiated NETs, 32.02% had a malignant poorly differentiated neuroendocrine carcinoma and 42.93% of patients developed metastatic NETs. In addition, 18.59% of patients were diagnosed with benign well-differentiated NETs. The most common tumour sites were the bronchus, lung and other sites, including pancreatic tumours; metastasis was found in the liver and distant lymph nodes. Pancreatic resection was the most common surgical procedure utilised in these patients, summing 19% of total expenses, the injection of an unspecified therapeutic substance (including targeted therapies) was registered in 11.40% of admissions, while chemotherapy was registered in only 6.85% of admissions. The annual healthcare cost of NETs was 15,373,961, corresponding to 9092 per patient. CONCLUSIONS: The implementation of standard diagnosis procedures should be prioritised, with a focus on the pancreas and lung, and taking into account that 42.93% of the patients develop a metastatic tumour. The presence of comorbidities and multimorbidities should be considered in order to develop more efficient disease management protocols.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6412-8" class="uri">https://doi.org/10.1186/s12885-019-6412-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Patient outcome according to the 2017 international consensus on the definition of borderline resectable pancreatic ductal adenocarcinoma</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31839458" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31839458</a></p>
<p>BACKGROUND/OBJECTIVE: We evaluated the usefulness of the 2017 definition of borderline pancreatic ductal adenocarcinoma (BR-PDAC) in fit patients (performance status 0-1) based on anatomical (A) and biological dimensions (B). METHODS: From 2011 to 2018, 139 resected patients with BR-PDAC according to the 2017 definition were included: 18 patients underwent upfront pancreatectomy (CA 19-9&gt;500 U/mL and/or regional lymph node metastasis; BR-B group), and 121 received FOLFIRINOX (FX) induction chemotherapy and were divided into BR-A (CA 19-9&lt;500 U/mL, no regional lymph node metastasis; n=68) and BR-AB (CA 19-9&gt;500 U/mL and/or regional lymph node metastasis; n=53) groups. RESULTS: The 3 groups were comparable according to patient characteristics (except for back pain (P&lt;.01) and CA 19-9 (P&lt;.01)), intraoperative data, and postoperative courses. BR-AB patients required more venous resections (P&lt;.01). The 3 groups were comparable on pathologic findings, except that BR-B patients had more lymph node invasions (P=.02). Median overall survival (OS) of the 121 patients was 45 months. In multivariate analysis, venous resection (P=.039) and R1 resection (P=.012) were poorly linked with OS, whereas BR-A classification (P&lt;.01) independently favored OS. Median survival times of BR-A, BR-AB, and BR-B groups were undetermined, 27 months, and 20 months (P &lt; .001), respectively. CONCLUSIONS: The 2017 definition was relevant for sub-classifying patients with BR-PDAC. The anatomical dimension (BR-A) was a favorable prognostic factor, whereas the biological dimension (BR-AB and BR-B) poorly impacted survival.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.12.001" class="uri">https://doi.org/10.1016/j.pan.2019.12.001</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Trends in the Number of Lymph Nodes Evaluated Among Patients with Pancreatic Neuroendocrine Tumors in the United States: A Multi-Institutional and National Database Analysis</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31838609" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31838609</a></p>
<p>BACKGROUND: The role of routine lymphadenectomy in the surgical treatment of pancreatic neuroendocrine tumors (pNET) remains poorly defined. The objective of the current study was to investigate trends in the number of lymph nodes (LN) evaluated for pNET treatment at a nationwide level. METHODS: Patients undergoing surgery for pNET between 2000 and 2016 were identified in the U.S. Neuroendocrine Tumor Study Group (US-NETSG) database as well as the Surveillance, Epidemiology, and End Results (SEER) database. The number of LNs examined was evaluated over time. RESULTS: The median number of evaluated LNs increased roughly fourfold over the study period (US-NETSG, 2000: 3 LNs vs.2016: 13 LNs; SEER, 2000: 3 LNs vs.2016: 11 LNs, both p&lt;0.001). While no difference in 5-year OS and RFS was noted among patients who had 1-3 lymph node metastases (LNM) vs.4 LNM between 2000-2007 (OS 73.5% vs.69.9%, p=0.12; RFS: 64.9% vs.40.1%, p=0.39), patients who underwent resection and LN evaluation during the period 2008-2016 had an incrementally worse survival if the patient had node negative disease, 1-3 LNM and4 LNM (OS 86.8% vs.82.7% vs.74.9%, p&lt;0.001; RFS: 86.3% vs.64.7% vs.50.4%, p&lt;0.001). On multivariable analysis, a more recent year of diagnosis, pancreatic head tumor location, and tumor size&gt;2cm were associated with 12 or more LNs evaluated in both US-NETSG and SEER databases. CONCLUSION: The number of LNs examined nearly quadrupled over the last decade. The increased number of LNs examined suggested a growing adoption of the AJCC staging manual recommendations regarding LN evaluation in the treatment of pNET.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-08120-1" class="uri">https://doi.org/10.1245/s10434-019-08120-1</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>TIMP-2 secreted by monocyte-like cells is a potent suppressor of invadopodia formation in pancreatic cancer cells</strong> </summary></p>
<p><em>BMC cancer 2019 Dec;19(1):1214</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31836008" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31836008</a></p>
<p>BACKGROUND: Monocytes are a major component of the tumor microenvironment (TME) in pancreatic ductal adenocarcinoma (PDAC). However, the complex interactions between tumor cells and monocytes and their role in tumor invasion have not been fully established. METHODS: To specifically test the impact of interaction on invasive potential two PDAC cell lines PaTu8902 and CFPAC-1 were selected on their ability to form invasive adhesions, otherwise known as invadopodia and invade in a spheroid invasion assay. RESULTS: Interestingly when the PDAC cells were co-cultured with undifferentiated THP1 monocyte-like cells invadopodia formation was significantly suppressed. Moreover, conditioned media of THP1 cells (CM) was also able to suppress invadopodia formation. Further investigation revealed that both tissue inhibitor of metalloproteinase (TIMP) 1 and 2 were present in the CM. However, suppression of invadopodia formation was found that was specific to TIMP2 activity. CONCLUSIONS: Our findings indicate that TIMP2 levels in the tumour microenvironment may have prognostic value in patients with PDAC. Furthermore, activation of TIMP2 expressing monocytes in the primary tumour could present a potential therapeutic opportunity to suppress cell invasion in PDAC.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6429-z" class="uri">https://doi.org/10.1186/s12885-019-6429-z</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Deep Learning Reveals Cancer Metastasis and Therapeutic Antibody Targeting in the Entire Body</strong> </summary></p>
<p><em>Cell 2019 Dec;179(7):1661-1676.e19</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31835038" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31835038</a></p>
<p>Reliable detection of disseminated tumor cells and of the biodistribution of tumor-targeting therapeutic antibodies within the entire body has long been needed to better understand and treat cancer metastasis. Here, we developed an integrated pipeline for automated quantification of cancer metastases and therapeutic antibody targeting, named DeepMACT. First, we enhanced the fluorescent signal of cancer cells more than 100-fold by applying the vDISCO method to image metastasis in transparent mice. Second, we developed deep learning algorithms for automated quantification of metastases with an accuracy matching human expert manual annotation. Deep learning-based quantification in 5 different metastatic cancer models including breast, lung, and pancreatic cancer with distinct organotropisms allowed us to systematically analyze features such as size, shape, spatial distribution, and the degree to which metastases are targeted by a therapeutic monoclonal antibody in entire mice. DeepMACT can thus considerably improve the discovery of effective antibody-based therapeutics at the pre-clinical stage. VIDEO ABSTRACT.</p>
<p>doi: <a href="https://doi.org/10.1016/j.cell.2019.11.013" class="uri">https://doi.org/10.1016/j.cell.2019.11.013</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: Trends in the Number of Lymph Nodes Evaluated Following Resection of Pancreatic Neuroendocrine Tumors-An Increasing Adoption of the AJCC Guidelines?</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31832917" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31832917</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-08134-9" class="uri">https://doi.org/10.1245/s10434-019-08134-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Preclinical assessment with clinical validation of Selinexor with gemcitabine and nab-paclitaxel for the treatment of pancreatic ductal adenocarcinoma</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31831564" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31831564</a></p>
<p>PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) remains a deadly disease urgently requiring new treatments. Over-expression of the protein transporter exportin-1 (XPO1) leads to mislocalization of tumor suppressor proteins (TSPs) and their inactivation. Earlier, we showed that blocking XPO1 by CRISPR/Cas9 validated Selective Inhibitor of Nuclear Export (SINE) compounds (selinexor and analogs) restores the anti-tumor activity of multiple TSPs leading to suppression of PDAC in vitro and in orthotopic models. METHODS: We evaluate the synergy between SINE compounds and standard of care treatments in pre-clinical models and in a PDAC Phase Ib trial. RESULTS: SINE compounds synergize with gemcitabine (GEM) and nanoparticle albumin-bound (nab)-paclitaxel leading to suppression of PDAC cellular growth and cancer stem cell (CSC) spheroids disintegration. Label-Free quantitative proteome profiling with nuclear and cytoplasmic enrichment showed superior enhancement in nuclear protein fraction in combination treatment. Selinexor inhibited the growth of PDAC CSC and two patient derived (PDX) sub-cutaneous xenograft. Selinexor-GEM-nab-paclitaxel blocked PDX and orthotopic tumor growth. In a Phase 1b study (NCT02178436), 9 patients were exposed to selinexor (60 mg oral) with GEM (1000 mg/m2 IV) and nab-paclitaxel (125 mg/m2 IV) on day 1, 8, 15 of 28-day cycle. Two patients showed partial response and 2 had stable disease. An outstanding, durable objective response was observed in one of the responders with progression free survival of 16 months and overall survival of 22 months. CONCLUSION: Our pre-clinical and ongoing clinical study lend support to the use of selinexor-gemcitabine-nab-paclitaxel as an effective therapy for metastatic PDAC.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-1728" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-1728</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Harmonic Motion Imaging of pancreatic tumor stiffness indicates disease state and treatment response</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31831559" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31831559</a></p>
<p>PURPOSE: Pancreatic ductal adenocarcinoma (PDA) is a common, deadly cancer that is challenging both to diagnose and to manage. Its hallmark is an expansive, desmoplastic stroma characterized by high mechanical stiffness. In this study, we sought to leverage this feature of PDA for two purposes: differential diagnosis and monitoring of response to treatment. EXPERIMENTAL DESIGN: Harmonic Motion Imaging is a functional ultrasound technique that yields a quantitative relative measurement of stiffness suitable for comparisons between individuals and over time. We used HMI to quantify pancreatic stiffness in mouse models of pancreatitis and PDA as well as in a series of freshly resected human pancreatic cancer specimens. RESULTS: In mice, we learned that stiffness increased during progression from pre-neoplasia to adenocarcinoma, and also effectively distinguished PDA from several forms of pancreatitis. In human specimens, the distinction of tumors versus adjacent pancreatitis or normal pancreas tissue was even more stark. Moreover, in both mice and humans, stiffness increased in proportion to tumor size, indicating that tuning of mechanical stiffness is an ongoing process during tumor progression. Finally, using a brca2-mutant mouse model of PDA that is sensitive to cisplatin, we found that tissue stiffness decreases when tumors respond successfully to chemotherapy. Consistent with this observation, we found that tumor tissues from patients who had undergone neoadjuvant therapy were less stiff than those of untreated patients. CONCLUSIONS: These findings support further development of HMI for clinical applications in disease staging and treatment response assessment in pancreatic ductal adenocarcinoma.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-18-3669" class="uri">https://doi.org/10.1158/1078-0432.CCR-18-3669</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>LncRNA THAP9-AS1 promotes pancreatic ductal adenocarcinoma growth and leads to a poor clinical outcome via sponging miR-484 and interacting with YAP</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31831555" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31831555</a></p>
<p>PURPOSE: Long non-coding RNAs (lncRNAs) has been observed in various cancer types. Our bioinformatic analysis of existing database demonstrated overexpression of lncRNA THAP9-AS1 in pancreatic ductal adenocarcinoma (PDAC). We aimed to investigate the roles and mechanisms of THAP9-AS1 in PDAC. EXPERIMENTAL DESIGN: The overexpression of THAP9-AS1 in samples of pancreatic cancer patients was characterized and was associated with clinical outcomes. The non-protein coding property of the THAP9-AS1 was verified. Various in vitro and in vivo experiments were performed to investigate the interaction between THAP9-AS1 and YAP signaling. RESULTS: We demonstrated that lncRNA THAP9-AS1 is overexpressed in PDAC in multiple patient sample sets, which is significantly associated with poor outcome of PDAC patients. THAP9-AS1 promotes PDAC cells growth both in vitro and in vivoTHAP9-AS1 exerts its effects via enhancing YAP signaling. Ectopic YAP expression overcame the effects of THAP9-AS1 knockdown. Inversely, YAP knockdown diminished the effects of THAP9-AS1 overexpression. THAP9-AS1 acts as a competing endogenous RNA for miR-484, leading to YAP upregulation. Moreover, THAP9-AS1 binds to YAP protein and inhibits the phosphorylation mediated inactivation of YAP by LATS1. Reciprocally, YAP/TEAD1 complex promotes THAP9-AS1 transcription to form a feed-forward circuit. Importantly, THAP9-AS1 level positively correlates with YAP expression in PDAC tissues. YAP overexpression also predicts a poor outcome of PDAC patients. CONCLUSIONS: Our findings indicate that THAP9-AS1 plays an important role in PDAC growth via enhancing YAP signaling which in return also modulates THAP9-AS1 transcription. THAP9-AS1/YAP axis may serve as a potential biomarker and therapeutic target for PDAC treatment.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-0674" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-0674</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Endoscopic ultrasound may be used to deliver gene expression signatures using digital mRNA detection methods to immunophenotype pancreatic ductal adenocarcinoma to facilitate personalized immunotherapy</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31831392" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31831392</a></p>
<p>BACKGROUND &amp; OBJECTIVES: Biomarkers are increasingly required to molecularly characterize pancreatic ductal adenocarcinoma (PDAC) subgroup populations, to determine who may benefit from immune based targeted therapy. We evaluated the feasibility of gene expression signature detection and the respective landscape of specific tumor infiltrating lymphocytes (TILs), cancer/testis (CT) antigens, and immune checkpoints for possible future personalized immunotherapy eligibility. METHODS: Dedicated digital mRNA oncologic immune profiling of 770 genes using a Nanostring nCounter PanCancer Immune Profiling Panel was performed using archived endoscopic ultrasound fine needle biopsy (EUS FNB) PDAC specimens as a case series in a tertiary care setting. RESULTS: The spectrum of mRNA gene expression within the tumor specimens revealed that 44.8%, 10.0% and 50.7% of evaluated genes had a  2-fold increase, a  2-fold reduction or between &lt;2 and &gt;2 change of mRNA expression, when compared to normal controls. The corresponding landscape of TILs, CT antigens, and immune checkpoints highlighted several possibilities that could potentially be amenable to targeted personalized immunotherapy. This includes members of the Tumor Associated Macrophage family (CD68, CXCL5, and MARCO), members of the CT antigen family (PRAME, TTK and PBK) and the second generation checkpoints TIM3 and BTLA. CONCLUSIONS: Our study represents the ability to successfully perform digital mRNA expression profile analyses to immunophenotype PDAC EUS FNB specimens by evaluating the expression of &gt;730 genes within the tumor immune microenvironment. This may facilitate the search for novel therapeutic targets, offering the opportunity to go beyond immune monotherapy, but perhaps to use combined immunomodulatory agents.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.12.002" class="uri">https://doi.org/10.1016/j.pan.2019.12.002</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Predictive factors for postoperative pancreatitis after pancreaticoduodenectomy: A single-center retrospective analysis of 1465 patients</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31831390" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31831390</a></p>
<p>BACKGROUND: Postoperative acute pancreatitis (POAP) after pancreaticoduodenectomy (PD) has been recently recognized as an independent complication that is associated with undesirable postoperative outcomes and often precedes other complications, yet predictive factors attributable to POAP after PD remain elusive. METHODS: The data from 1465 consecutive patients who underwent laparotomy or minimally invasive robotic PD from March 2010 to December 2018 were retrospectively reviewed. POAP was defined as an elevation of the serum amylase levels above the institutions normal upper limit (100 U/L) on postoperative day (POD) 1. Univariate and multivariate analyses were performed to investigate the predictive factors for POAP after PD and the association between POAP and clinically relevant postoperative pancreatic fistulas (CR-POPFs). RESULTS: Among the 1465 patients, 411 (28%) underwent minimally invasive robotic surgeries, and the overall POAP and CR-POPFs rates were 770 (53%) and 277 (19%), respectively. The female sex (OR 1.76), a normal bilirubin level (OR 1.55), the robotic surgery (OR 1.36), a main pancreatic duct (MPD) 3mm (OR 5.69) and a high-risk nonadenocarcinoma pathology (cystic disease: OR 4.33; pNETs: OR 4.34; others: OR 2.74) were considered independent risk factors for POAP. A nondilated MPD was a predominant predictor for POAP, with 72.2% sensitivity and 71.8% specificity. POAP was also an independent predictive factor for CR-POPFs (OR 3.48). CONCLUSION: A nondilated MPD, a high-risk pathology, the female sex, a normal bilirubin level and the robotic surgery were independent predictive factors for POAP after PD. Prevention and early treatment strategy changes can be made based on these preoperative predictive factors.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.11.014" class="uri">https://doi.org/10.1016/j.pan.2019.11.014</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Essential Contributions of Pathologists and Laboratory Physicians Leading to the Discovery of Insulin</strong> </summary></p>
<p><em>Archives of pathology &amp; laboratory medicine 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31825669" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31825669</a></p>
<p>CONTEXT.: Frederick Banting, Charles Best, J. Bertrand Collip, and J. J. R. Macleod contributed to the discovery of insulin in 1921-1922. Recent advances in anatomic pathology, experimental pathology, and clinical pathology were necessary for the research in Toronto, Ontario, Canada, to begin and to succeed. OBJECTIVE.: To explore the role of pathology and laboratory medicine in laying the foundation for the discovery of insulin. DESIGN.: Available primary and secondary historical sources were reviewed. RESULTS.: During a 3-decade period, pathologists, through autopsy pathology and experimental animal studies, were able to provide solid evidence that the pancreatic islets were the source of the internal secretion responsible for proper carbohydrate metabolism. Banting, a surgeon with no previous research experience, read about these studies in a case report with an extensive literature review by pathologist Moses Barron; this piqued Bantings interest and caused him to approach Macleod, a Toronto physiology professor, with an idea that initiated the research. Advances in clinical laboratory medicine, which allowed them to measure blood glucose levels using small blood volumes, were critical to their success. CONCLUSIONS.: By 1921-1922, the pieces necessary to solve the puzzle were available. The primary reason that the time was ripe for the discovery was because of the contributions of pathologists and laboratory physicians in the preceding 3 decades. As the 100th anniversary approaches, our profession can take pride in its important contributions to the discovery of insulin, which is broadly recognized as one of the most important medical research advances of the 20th century.</p>
<p>doi: <a href="https://doi.org/10.5858/arpa.2019-0400-HP" class="uri">https://doi.org/10.5858/arpa.2019-0400-HP</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Assessment of preoperative pancreatic biopsy, cytological/histological review of cell-block-specimens obtained by endoscopic ultrasound-guided fine-needle aspiration: Laboratory-based study</strong> </summary></p>
<p><em>Diagnostic cytopathology 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31825182" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31825182</a></p>
<p>BACKGROUND: Pancreatic cancer is among the most lethal cancers worldwide due to the limited availability of techniques for early detection of signs and symptoms. Reportedly, it is the fourth-leading cause of cancer-related mortality among Japanese adults. With the advent of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) for diagnosing pancreatic cancer, the rate of the cytological and histological diagnoses of cell-block-specimens has significantly increased in Japan. METHODS: The cytological specimens of 165 patients with pancreatic lesions obtained using EUS-FNA between January 2010 and July 2016 at the Kyorin University Hospital were investigated. The clinical course of 153 patients was assessed from their clinical records, which included information on their imaging diagnosis, laboratory data, final clinical diagnosis and treatment; moreover, the accuracy of the cytological/histological examination and clinical diagnosis at our hospital were analysed. RESULTS: The number of cells in cell-block-specimens was too small to estimate data. However, cytological specimens were sufficient to observe the findings of suspected malignancy such as necrosis. Biopsy was deemed necessary for diagnosis using both histological and cytological specimens. CONCLUSION: EUS-FNA can be used not only to diagnose benign or malignant types of pancreatic cancers but also to assess the sensitivity of molecular target drugs and chemotherapy methods. Therefore, both histological and cytological diagnoses are required to enhance diagnostic precision both in our hospital and at other institutions.</p>
<p>doi: <a href="https://doi.org/10.1002/dc.24358" class="uri">https://doi.org/10.1002/dc.24358</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: Systemic Immune-Inflammation Index (SII) as a Biomarker of Response to Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31823171" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31823171</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-08136-7" class="uri">https://doi.org/10.1245/s10434-019-08136-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Characterization of novel genetic alterations in salivary gland secretory carcinoma</strong> </summary></p>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31822803" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31822803</a></p>
<p>Secretory carcinoma is a salivary gland tumor with a characteristic chromosomal translocation that results in an ETV6-NTRK3 fusion gene. Secretory carcinoma shows relatively frequent rates of lymph-node metastasis and tumor recurrence and has a characteristic histology. Except for the ETV6 translocation, genomic alterations in secretory carcinoma have not been reported. In the present study, we characterized the novel recurrent genetic mutations of secretory carcinoma. On the basis of histology, immunohistochemistry, and ETV6 gene break-apart fluorescence in situ hybridization assays, 22 tumors were classified as secretory carcinomas (19 ETV6 translocation-positive and 3 ETV6 translocation-negative secretory carcinomas) and their clinicopathologic characteristics were reviewed. Targeted deep sequencing analyses were performed on 20 secretory carcinomas (17 ETV6 translocation-positive and 3 ETV6 translocation-negative secretory carcinomas) to investigate their genetic alterations. The A16V (CT) mutation in PRSS1, which encodes a cationic trypsinogen and has a mutation associated with hereditary pancreatitis and pancreatic adenocarcinoma, was observed in 40% (8/20) (7/17 of ETV6 translocation-positive and 1/3 of ETV6 translocation-negative secretory carcinomas). Pathogenic variants of MLH1, MUTYH, and STK11 were also identified. Variants of uncertain significance included mutations in KMT5A. These novel characteristic genetic alterations may advance current understandings of secretory carcinoma tumorigenesis and progression, leading to improved diagnoses and treatment strategies.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-019-0427-1" class="uri">https://doi.org/10.1038/s41379-019-0427-1</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreatic cancer organoids recapitulate disease and allow personalized drug screening</strong> </summary></p>
<p><em>Proceedings of the National Academy of Sciences of the United States of America 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31818951" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31818951</a></p>
<p>We report the derivation of 30 patient-derived organoid lines (PDOs) from tumors arising in the pancreas and distal bile duct. PDOs recapitulate tumor histology and contain genetic alterations typical of pancreatic cancer. In vitro testing of a panel of 76 therapeutic agents revealed sensitivities currently not exploited in the clinic, and underscores the importance of personalized approaches for effective cancer treatment. The PRMT5 inhibitor EZP015556, shown to target MTAP (a gene commonly lost in pancreatic cancer)-negative tumors, was validated as such, but also appeared to constitute an effective therapy for a subset of MTAP-positive tumors. Taken together, the work presented here provides a platform to identify novel therapeutics to target pancreatic tumor cells using PDOs.</p>
<p>doi: <a href="https://doi.org/10.1073/pnas.1911273116" class="uri">https://doi.org/10.1073/pnas.1911273116</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Re: Metastatic pheochromocytoma to the pancreas diagnosed by endoscopic ultrasound-guided fine needle aspiration: A case report and review of literature</strong> </summary></p>
<p><em>Diagnostic cytopathology 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31808998" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31808998</a></p>
<p>doi: <a href="https://doi.org/10.1002/dc.24362" class="uri">https://doi.org/10.1002/dc.24362</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Altered diversity and composition of gut microbiota in Chinese patients with chronic pancreatitis</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31806503" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31806503</a></p>
<p>BACKGROUND/OBJECTIVES: Gut microbiota alterations in chronic pancreatitis (CP) are seldomly described systematically. It is unknown whether pancreatic exocrine insufficiency (PEI) and different etiologies in patients with CP are associated with gut microbiota dysbiosis. METHODS: The fecal microbiota of 69 healthy controls (HCs) and 71 patients with CP were compared to investigate gut microbiome alterations in CP and the relationship among gut microbiome dysbiosis, PEI and different etiologies. Fecal microbiomes were analyzed through 16S ribosomal RNA gene profiling, based on next-generation sequencing. Pancreatic exocrine function was evaluated by determining fecal elastase 1 activity. RESULTS: Patients with CP showed gut microbiota dysbiosis with decreased diversity and richness, and taxa-composition changes. On the phylum level, the gut microbiome of the CP group showed lower Firmicutes and Actinobacteria abundances than the HC group and higher Proteobacteria abundances. The abundances of Escherichia-Shigella and other genera were high in gut microbiomes in the CP group, whereas that of Faecalibacterium was low. Kyoto Encyclopedia of Genes and Genomes pathways (lipopolysaccharide biosynthesis and bacterial invasion of epithelial cells) were predicted to be enriched in the CP group. Among the top 5 phyla and 8 genera (in terms of abundance), only Fusobacteria and Eubacterium rectale group showed significant differences between CP patients, with or without PEI. Correlation analysis showed that Bifidobacterium and Lachnoclostridium correlated positively with fecal elastase 1 (r=0.2616 and 0.2486, respectively, P&lt;0.05). CONCLUSIONS: The current findings indicate that patients with CP have gut microbiota dysbiosis that is partly affected by pancreatic exocrine function.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.11.013" class="uri">https://doi.org/10.1016/j.pan.2019.11.013</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Fatal myositis and spontaneous haematoma induced by combined immune checkpoint inhibitor treatment in a patient with pancreatic adenocarcinoma</strong> </summary></p>
<p><em>BMC cancer 2019 Dec;19(1):1193</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31805889" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31805889</a></p>
<p>BACKGROUND: Immune checkpoint inhibitors (ICIs) have achieved unprecedented success in cancer treatment over the past decade. The application of ICIs hasled to the discovery of various types of immune-related adverse events (irAEs). Here, we report a case of fatal myositis and spontaneous haematoma following concurrent treatment of nivolumab and ipilimumab for pancreatic adenocarcinoma. CASE PRESENTATION: A 71-year-old gentleman with pancreatic adenocarcinoma underwent the Whipple procedure in September 2014. The patient received 8cycles of adjuvant chemotherapy with gemcitabineand achieved a complete responsein April 2015. Treatment with the PD-1 inhibitor nivolumab was started due to suspected tumour recurrence in November 2015. In August 2016, the CTLA-4 inhibitor ipilimumab was added to nivolumab for 2cycles. Eight weeks after the last dose, the patient developed severe myositis complicated with spontaneous haematomain skeletalmuscle. Pathology of the skeletal muscle autopsy revealed lymphocytic infiltration. Intense immunosuppressive therapy, including high-dose corticosteroids and methotrexate, resulted in clinical success in the treatment of myositis. However, the patient died of cancer recurrence. CONCLUSION: Myositis due to immunotherapy can be a fatal adverse event of ICIs, which requires close monitoring and cautious management.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6372-z" class="uri">https://doi.org/10.1186/s12885-019-6372-z</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Intraductal Papillary Mucinous Neoplasms: Have IAP Consensus Guidelines Changed our Approach?: Results from a Multi-institutional Study</strong> </summary></p>
<p><em>Annals of surgery 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31804389" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31804389</a></p>
<p>OBJECTIVE: To evaluate the influence of consensus guidelines on the management of intraductal papillary mucinous neoplasms (IPMN) and the subsequent changes in pathologic outcomes. BACKGROUND: Over time, multiple guidelines have been developed to identify high-risk IPMN. We hypothesized that the development and implementation of guidelines should have increased the percentage of resected IPMN with high-risk disease. METHODS: Memorial Sloan-Kettering (MSK), Johns Hopkins (JH), and Massachusetts General Hospital (MGH) databases were queried for resected IPMN (2000-2015). Patients were categorized into main-duct (MD-IPMN) versus branch-duct (BD-IPMN). Guideline-specific radiographic/endoscopic features were recorded. High-risk disease was defined as high-grade dysplasia/carcinoma. Fishers exact test was used to detect differences between institutions. Logistic regression evaluated differences between time-points [preguidelines (pre-GL, before 2006), Sendai (SCG, 2006-2012), Fukuoka (FCG, after 2012)]. RESULTS: The study included 1210 patients. The percentage of BD-IPMN with 1 high-risk radiographic feature differed between centers (MSK 69%, JH 60%, MGH 45%; P &lt; 0.001). In MD-IPMN cohort, the presence of radiographic features such as solid component and main pancreatic duct diameter 10mm also differed (solid component: MSK 38%, JH 30%, MGH 18%; P &lt; 0.001; duct 10mm: MSK 49%, JH 32%, MGH 44%; P &lt; 0.001). The percentage of high-risk disease on pathology, however, was similar between institutions (BD-IPMN: P = 0.36, MD-IPMN: P = 0.48). During the study period, the percentage of BD-IPMN resected with 1 high-risk feature increased (52% pre-GL vs 67% FCG; P = 0.005), whereas the percentage of high-risk disease decreased (pre-GL vs FCG: 30% vs 20%). For MD-IPMN, there was not a clear trend towards guideline adherence, and the rate of high-risk disease was similar over the time (pre-GL vs FCG: 69% vs 67%; P = 0.63). CONCLUSION: Surgical management of IPMN based on radiographic criteria is variable between institutions, with similar percentages of high-risk disease. Over the 15-year study period, the rate of BD-IPMN resected with high-risk radiographic features increased; however, the rate of high-risk disease decreased. Better predictors are needed.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003703" class="uri">https://doi.org/10.1097/SLA.0000000000003703</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comment on Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer</strong> </summary></p>
<p><em>Annals of surgery 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31804387" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31804387</a></p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003667" class="uri">https://doi.org/10.1097/SLA.0000000000003667</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comment on Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer What Is Good for the Surgeon Is Just as Good for the Patient?</strong> </summary></p>
<p><em>Annals of surgery 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31804386" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31804386</a></p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003655" class="uri">https://doi.org/10.1097/SLA.0000000000003655</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The TRIANGLE Operation by Laparoscopy: Radical Pancreaticoduodenectomy with Major Vascular Resection for Borderline Resectable Pancreatic Head Cancer</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31802299" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31802299</a></p>
<p>BACKGROUND: It has recently been shown that the triangle operation1 may be associated with margin-free resection in selected patients with borderline resectable pancreatic cancer after neoadjuvant chemotherapy. Such a procedure consists of en bloc removal, following the adventitial plane of the whole mesopancreas from the triangular space delimited by the superior mesenteric artery, hepatic artery, and portal vein.2-11 In this video, we show how to safely perform this procedure by laparoscopy. METHODS: A 70-year-old male with persistent back pain and significant loss of weight underwent a computed tomography that showed a 3cm mass of the uncinate process of the pancreas with involvement of the superior mesenteric artery and venous axis. The biopsy, performed at the time of endoscopic retrograde cholangiopancreatography, showed an adenocarcinoma of the pancreas. Cancer antigen (CA) 19-9 was in the normal range. The patient received eight cycles of neoadjuvant chemotherapy (FOLFIRINOX). The chemotherapy induced a major tumoral radiological response with tumoral shrinkage, however the preoperative computed tomography showed persistent infiltration of the mesopancreas behind the superior mesenteric artery and venous axis. A radical laparoscopic pancreaticoduodenectomy with portal vein resection was performed, including the complete clearing of the superior mesenteric artery and the right side of the celiac trunk, as in the triangle operation. Venous reconstruction was achieved with an end-to-end 5/0 polypropylene running suture with growth factor, while intestinal reconstruction was achieved with an end-to-side hepaticojejunal anastomosis, a double purse-string pancreaticogastrostomy, and side-to-side mechanical linear gastrojejunostomy. The specimen was removed via a short Pfannenstiel incision. RESULTS: Operative time was 7h and 15min, and blood loss was 150. Frozen sections of the superior mesenteric artery margins were negative for tumoral cells. On postoperative day 5, the patient had a hematemesis with bleeding from the pancreaticogastrostomy, which was treated endoscopically. Hospital stay was 16days. Histopathological examination showed a well-differentiated adenocarcinoma of the pancreas [ypT3 N1 (3/36) R0]. CONCLUSION: The triangle operation for borderline resectable pancreatic head cancer can be achieved safely by laparoscopy in carefully selected patients.1-11 Proven experience in both open and laparoscopic pancreatic surgery is mandatory.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-08101-4" class="uri">https://doi.org/10.1245/s10434-019-08101-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31802297" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31802297</a></p>
<p>BACKGROUND: Neoadjuvant therapy has shown value in various cancer types. The role of neoadjuvant therapy in pancreatic ductal adenocarcinoma (PDAC), however, remains unknown. The aim of the present work is to evaluate the effect of neoadjuvant therapy on the survival of patients with borderline-resectable PDAC. PATIENTS AND METHODS: Between 2004 and 2015, 7730 patients with resectable PDAC and 1980 patients with borderline-resectable PDAC were identified from the National Cancer Database (NCDB). Survival was compared between resectable and borderline-resectable patients. Survival and pathologic characteristics were also compared within borderline-resectable patients who received neoadjuvant therapy and those who received adjuvant therapy alone. Kaplan-Meier method and Cox proportional-hazard models were used for analysis. RESULTS: Median overall survival (mOS) of all patients with resectable PDAC was similar to that of patients with borderline-resectable disease treated with neoadjuvant therapy (26.5 versus 25.7months, p=0.78). Patients with borderline-resectable disease treated with neoadjuvant therapy had improved mOS compared with borderline-resectable patients treated with adjuvant therapy alone (25.7 versus 19.6months, p&lt;0.0001). When comparing patients with borderline-resectable disease who received neoadjuvant therapy versus those who received adjuvant therapy alone, the former less often had node-positive pancreatic cancer (40.6% versus 76.3%, p&lt;0.001) and margin-positive resections (17.8% versus 44.4%, p&lt;0.001). CONCLUSION: Neoadjuvant therapy is associated with enhanced survival in patients with borderline-resectable pancreatic cancer, which may be attributed to tumor downstaging.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-08087-z" class="uri">https://doi.org/10.1245/s10434-019-08087-z</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comparison of pathology sampling protocols for pancreatoduodenectomy specimens</strong> </summary></p>
<p><em>Virchows Archiv : an international journal of pathology 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31802231" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31802231</a></p>
<p>Pancreatoduodenectomy is one of the most challenging surgical specimens for pathologists. Recently, two different, standardized protocols have been proposed: the axial slicing Leeds protocol (LP) and the bi-valving Adsay protocol (AP). Comparison between standardized and non-standardized protocols (NSP) was performed with emphasis on margin involvement and lymph node yield. Pancreatoduodenectomy cases were retrospectively recruited: 46 sampled with LP, 52 cases with AP and 46 cases with NSP. Clinico-pathologic data and rates of margin/surface involvement were collected and their prognostic influence on survival was assessed. Statistical differences between NSP and AP and LP were seen for nodal yield (p=0.0001), N+ (p=0.0001) and lymph node ratio - LNR (p&lt;0.0008) but not between AP and LP. Differences in R1/R0 status were statistically significant between NSP group (R1-15%) and both the LP (R1-73.9%) and AP (R1-70%) groups (p=0.0001) but not between LP and AP groups. At univariate survival analysis, grade (p=0.0023) and number of involved margins (p=0.0096) in AP and N-category (p=0.0057) resection margin status (p=0.0094), stage (p=0.0143), and number of involved margins (p=0.00398) in LP were statistically significant, while no variable was significant in the NSP group. At multivariate analysis N category, resection margin status, stage, number of involved margins, and LNR retained significance for the LP group. These results show that both LP and AP perform better than non-standardized sampling making standardization mandatory in pancreatoduodenectomy cut up. Both AP and LP show strengths and weaknesses, and these may impact on the choice of protocol in different institutions.</p>
<p>doi: <a href="https://doi.org/10.1007/s00428-019-02687-6" class="uri">https://doi.org/10.1007/s00428-019-02687-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Diagnosing pancreatic ductal adenocarcinoma using plasma extracellular vesicle RNA profiles</strong> </summary></p>
<p><em>Gut 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31801873" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31801873</a></p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2019-319896" class="uri">https://doi.org/10.1136/gutjnl-2019-319896</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Colonic hematoma after extracorporeal shock wave lithotripsy for pancreatic stones: a case report</strong> </summary></p>
<p><em>BMC gastroenterology 2019 Dec;19(1):208</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31801483" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31801483</a></p>
<p>BACKGROUND: Despite pancreatic extracorporeal shock wave lithotripsy (P-ESWL) is a minimally invasive treatment for pancreatic stones, complications exist. CASE PRESENTATION: A 37-year-old male was diagnosed with chronic pancreatitis and admitted to our hospital for recurrent acute pancreatitis. After the first P-ESWL session, the patient complained of a new type of pain different from the previous pain pattern. Computerized tomography and colonoscopy were arranged and colonic hematoma was found. Since the patient had stable vital signs, no special treatment was given focusing on the colonic hematoma. Five days later, P-ESWL treatment was repeatedly performed for four consecutive days. Two days after the last P-ESWL session, the patient underwent endoscopic retrograde cholangiopancreatography. At the three-month follow up visit, the colonic hematoma disappeared and pancreatic stones decreased significantly. CONCLUSIONS: To the best of our knowledge, colonic hematoma after P-ESWL for pancreatic stones has never been reported. Here, we present the only case of colonic hematoma after P-ESWL, which was coincidentally found in more than 6000 P-ESWL sessions in our hospital. As the symptoms of colonic hematoma are mild, we believe the incidence of colonic hematoma has been underestimated. Many people with colonic hematoma after P-ESWL may be undiagnosed or misdiagnosed. Treatment for colonic hematoma depends on whether there is severe clinical state. Exploration of more precise location method for pancreatic stones may reduce the probability of P-ESWL complication.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-019-1117-7" class="uri">https://doi.org/10.1186/s12876-019-1117-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comparison of tumour and serum specific microRNA changes dissecting their role in pancreatic ductal adenocarcinoma: a meta-analysis</strong> </summary></p>
<p><em>BMC cancer 2019 Dec;19(1):1175</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31795960" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31795960</a></p>
<p>BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is considered as one of the most aggressive cancers lacking efficient early detection biomarkers. Circulating miRNAs are now being considered to have potency to be used as diagnostic and prognostic biomarkers in different diseases as well as cancers. In case of cancer, a fraction of the circulating miRNAs is actually derived from the tumour tissue. This fraction would function as stable biomarker for the disease and also would contribute to the understanding of the disease development. There are not many studies exploring this aspect in pancreatic cancer and even there is not much overlap of results between existing studies. METHODS: In order to address that gap, we performed a miRNA microarray analysis to identify differentially expressed circulating miRNAs between PDAC patients and normal healthy individuals and also found two more similar datasets to perform a meta-analysis using a total of 182 PDAC patients and 170 normal, identifying a set of miRNAs significantly altered in patient serum. Next, we found five datasets studying miRNA expression profile in tumour tissues of PDAC patients as compared to normal pancreas and performed a second meta-analysis using data from a total of 183 pancreatic tumour and 47 normal pancreas to detect significantly deregulated miRNAs in pancreatic carcinoma. Comparison of these two lists and subsequent search for their target genes which were also deregulated in PDAC in inverse direction to miRNAs was done followed by investigation of their role in disease development. RESULTS: We identified 21 miRNAs altered in both pancreatic tumour tissue and serum. While deciphering the functions of their target genes, we characterized key miR-Gene interactions perturbing the biological pathways. We identified important cancer related pathways, pancreas specific pathways, AGE-RAGE signaling, prolactin signaling and insulin resistance signaling pathways among the most affected ones. We also reported the possible involvement of crucial transcription factors in the process. CONCLUSIONS: Our study identified a unique meta-signature of 21 miRNAs capable of explaining pancreatic carcinogenesis and possibly holding the potential to act as biomarker for the disease detection which could be explored further.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6380-z" class="uri">https://doi.org/10.1186/s12885-019-6380-z</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31792715" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31792715</a></p>
<p>BACKGROUND: The systemic immune-inflammation index (SII), calculated using absolute platelet, neutrophil, and lymphocyte counts, has recently emerged as a predictor of survival for patients with pancreatic ductal adenocarcinoma (PDAC) when assessed at diagnosis. Neoadjuvant therapy (NAT) is increasingly used in the treatment of PDAC. However, biomarkers of response are lacking. This study aimed to determine the prognostic significance of SII before and after NAT and its association with the pancreatic tumor biomarker carbohydrate-antigen 19-9 (CA 19-9). METHODS: This study retrospectively analyzed all PDAC patients treated with NAT before pancreatic resection at a single institution between 2007 and 2017. Pre- and post-NAT lab values were collected to calculate SII. Absolute pre-NAT, post-NAT, and change in SII after NAT were evaluated for their association with clinical outcomes. RESULTS: The study analyzed 419 patients and found no significant correlation between pre-NAT SII and clinical outcomes. Elevated post-NAT SII was an independent, negative predictor of overall survival (OS) when assessed as a continuous variable (hazard ratio [HR], 1.0001; 95% confidence interval [CI] 1.00003-1.00014; p=0.006). Patients with a post-NAT SII greater than 900 had a shorter median OS (31.9 vs 26.1months; p=0.050), and a post-NAT SII greater than 900 also was an independent negative predictor of OS (HR, 1.369; 95% CI 1.019-1.838; p=0.037). An 80% reduction in SII independently predicted a CA 19-9 response after NAT (HR, 4.22; 95% CI 1.209-14.750; p=0.024). CONCLUSION: Post-treatment SII may be a useful prognostic marker in PDAC patients receiving NAT.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-08094-0" class="uri">https://doi.org/10.1245/s10434-019-08094-0</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>CMS Hospital Compare System of Star Ratings and Surgical Outcomes Among Patients Undergoing Surgery for Cancer: Do the Ratings Matter?</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31792714" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31792714</a></p>
<p>BACKGROUND: The Centers for Medicare and Medicaid Services (CMS) Hospital Compare star rating system has been proposed as a means to assess hospital quality performance. The current study aimed to investigate outcomes and payments among patients undergoing surgery for colorectal, lung, esophageal, pancreatic, and liver cancer across hospital star rating groups. METHODS: The Medicare Standard Analytic Files (SAF) from 2013 to 2015 were used to derive the analytic cohort. The association of star ratings to perioperative outcomes and expenditures was examined. RESULTS: Among 119,854 patients, the majority underwent surgery at a 3-star (n=34,901, 29.1%) or 4-star (n=30,492, 25.4%) hospital. Only 12.2% (n=14,732) were treated at a 5-star hospital. Across all procedures examined, patients who underwent surgery at a 1-star hospital had greater odds of death within 90days than patients who had surgery at a 5-star hospital (colorectal, 1.41 [95% confidence interval {CI}, 1.25-1.60]; lung, 1.97 [95% CI 1.56-2.48]; esophagectomy, 1.83 [95% CI 0.81-4.16]; pancreatectomy, 1.70 [95% CI 1.20-2.41]; hepatectomy, 1.63 [95% CI 0.96-2.77]). A similar trend was noted for failure to rescue (FTR), with the greatest odds of FTR associated with 1-star hospitals. The median expenditure associated with an abdominal operation was $1661 more at a 1-star hospital than at a 5-star hospital (1-star: $17,399 vs 5-star: $15,738). A similar trend was noted for thoracic operations. CONCLUSION: The risk of FTR, 90-day mortality, and increased hospital expenditure were allhigher at a 1-star hospital. Further research is needed to investigate barriers to care at 5-star-rated hospitals and to target specific interventions to improve outcomes at 1-star hospitals.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-08088-y" class="uri">https://doi.org/10.1245/s10434-019-08088-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with nab-paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31792036" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31792036</a></p>
<p>PURPOSE: LMB-100 is a recombinant immunotoxin (iTox) consisting of a mesothelin-binding Fab for targeting and a modified Pseudomonas exotoxin A payload. Preclinical studies showed that combining taxanes with iTox results in synergistic anti-tumor activity. The objectives of this phase I/II study were to determine the maximum tolerated dose (MTD) of LMB-100 when administered with nanoalbumin bound (nab)-paclitaxel to patients with previously treated advanced pancreatic adenocarcinoma and to assess the objective response rate. PATIENTS AND METHODS: Patients (n = 20) received fixed dose nab-paclitaxel (125 mg/m2 on Days 1 &amp; 8) with LMB-100 (65 or 100 mcg/kg on Days 1, 3 &amp; 5) in 21-day cycles for 1-3 cycles. RESULTS: Fourteen patients were treated on the dose-escalation and an additional 6 in the phase II expansion. MTD of 65 mcg/kg was established for the combination. Dose-limiting toxicity (DLT) resulting from capillary leak syndrome (CLS) was seen in 2 of 5 patients treated at 100 mcg/kg and 1 of 6 evaluable phase I patients receiving the MTD. Severity of CLS was associated with increases in apoptotic circulating endothelial cells (CECs). LMB-100 exposure was unaffected by anti-LMB-100 antibody formation in 5 of 13 patients during cycle 2. Seven of 17 evaluable patients experienced &gt;50% decrease in CA 19-9, including 3 with previous exposure to nab-paclitaxel. One patient developed an objective partial response. Patients with biomarker responses had higher tumor mesothelin expression. CONCLUSIONS: Although clinical activity was observed, the combination was not well tolerated and alternative drug combinations with LMB-100 will be pursued.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-2586" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-2586</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Unique circulating immune signatures for recurrent acute pancreatitis, chronic pancreatitis and pancreatic cancer: A pilot study of these conditions with and without diabetes</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31791885" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31791885</a></p>
<p>OBJECTIVE: This exploratory study seeks to identify distinct circulating immune signatures among patients having recurrent acute pancreatitis (RAP), chronic pancreatitis (CP), and pancreatic adenocarcinoma (PDAC). METHODS: A retrospective analysis of human serum samples from collaborating institutions of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) was performed. Samples came from the North American Pancreatitis Studies 2 (NAPS2) cohort and the Pancreatic Adenocarcinoma Gene Environment Risk Study (PAGER) and were analyzed using a 62-plex Luminex assay in a blinded fashion. Group and pairwise comparisons were performed to identify unique immune signature panels and to calculate diagnostic utility using area under the curve analysis. RESULTS: A total of 179 patients samples were included: 41 controls, 40 CP, 78 PDAC and 20 RAP patients, of which 20 controls, 20 CP, and 58 PDAC patients had diabetes mellitus (DM). A unique immune signature panel could discriminate RAP, CP, and PDAC from controls with an AUC range from 0.77 to 0.86 (95% CI range: 0.64-0.94), RAP from CP, and CP from PDAC with an AUC of 0.77 (95% CI 0.64-0.90) and 0.76 (95% CI 0.67-0.86), respectively. Furthermore, an immune signature panel could also discriminate PDAC-DM from DM controls with an AUC of 0.96 (95% CI: 0.93-1.00) CONCLUSION: This study identifies unique immune analytes that may serve as novel diagnostic and predictive non-invasive biomarkers of RAP, CP, and PDAC. Further validation is warranted in prospective cohorts as developed by the CPDPC.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.11.008" class="uri">https://doi.org/10.1016/j.pan.2019.11.008</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Evaluation of metastases to the pancreas with fine needle aspiration (FNA): a case series from a single center with review of the literature</strong> </summary></p>
<p><em>Cytopathology : official journal of the British Society for Clinical Cytology 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31788890" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31788890</a></p>
<p>OBJECTIVE: Fine needle aspiration (FNA) is a minimally invasive albeit highly effective modality used to detect solid and cystic pancreatic lesions. This manuscript aims to present our experience in diagnosing metastases to the pancreas and highlight the importance of immunocytochemistry in the diagnostic process. It also aims to provide a brief review of the literature on this topic. METHODS: We retrospectively searched our archives for cases of metastatic deposits to the pancreas diagnosed with FNA over a 5-year-period. We also reviewed the literature for such cases. RESULTS: We describe seven cases from our archives that metastasized to the pancreas. Three of them (43%) represented metastatic renal cell carcinoma while the rest four comprised deposits from a lung adenocarcinoma, a colon adenocarcinoma, an adrenal leiomyosarcoma, and a small cell carcinoma (SCC) of the urinary bladder, respectively. History of primary malignancy was available for all seven patients. All diagnoses were confirmed with the use of immunostains. In our literature review, similar to our case series, renal cell carcinoma was the most common metastasis to the pancreas managed with FNA (around one out of three patients; 35%). Of interest, our EUS-FNA case of pancreatic metastasis from urinary bladder SCC is the first one reported. CONCLUSIONS: As metastases to the pancreas are commonly accompanied by diverse prognostic signatures and management strategies compared to primary pancreatic malignancies, their accurate identification is imperative. Pancreatic FNA is a diagnostic modality that can confirm or exclude metastasis to the organ, especially when immunocytochemistry is applied.</p>
<p>doi: <a href="https://doi.org/10.1111/cyt.12793" class="uri">https://doi.org/10.1111/cyt.12793</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Lung recurrence and its therapeutic strategy in patients with pancreatic cancer</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31787525" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31787525</a></p>
<p>BACKGROUND: /Objectives: The lung is a major metastatic site of pancreatic cancer (PC). We aimed to assess the features and prognosis of patients with PC according to the recurrence pattern and the effect of resection of recurrent lung lesion. METHODS: We enrolled 168PC patients who had undergone macroscopically curative resection. All resected lung tumors were evaluated immunohistochemically for expressions of thyroid transcription factor-1 (TTF-1) and napsin A. RESULTS: The most common site of first recurrence was the liver and local site, followed by the lung, peritoneum, and lymph node. Lung recurrence was observed significantly later than was liver recurrence. The median survival time (MST) after recurrence in patients with first recurrence in the lung was significantly longer than MST in patients with first recurrence in the liver (15.2 months vs 5.2 months, p=0.039). Seven patients with lung recurrence underwent resection of the recurrent lesion. Surgical resection of single metastasis limited to the lung showed favorable overall survival after recurrence (MST=36.5 months). Patients with single metastasis limited to the lung showed significantly lower value of FDG-PET SUVmax of the primary pancreatic tumor. CONCLUSIONS: Patients with first recurrence in the lung showed better prognosis than did patients with first recurrence in the liver. Single metastasis limited to the lung could benefit from surgical resection and was significantly associated with lower FDG-PET SUVmax of the primary pancreatic tumor.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.11.015" class="uri">https://doi.org/10.1016/j.pan.2019.11.015</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Tumor budding as a prognostic factor in pancreatic ductal adenocarcinoma</strong> </summary></p>
<p><em>Virchows Archiv : an international journal of pathology 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31786688" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31786688</a></p>
<p>In this retrospective study, we analyzed the association between tumor budding and perineural invasion as well as their prognostic role in pancreatic ductal adenocarcinoma. A total of N=119 patients resected for pancreatic ductal carcinoma from 1996 to 2015 were included. Clinical and standard histopathological parameters were retrieved from the patients records. One representative hematoxylin and eosin section from the tumor region was examined for perineural invasion and tumor budding using light microscopy. Tumor budding was assessed independently using two different methods: in the first approach, the number of buds was counted over three fields of 0.237mm2 at 40-fold magnification; in the second approach, tumor budding was quantified according to the recommendation of the International Tumor Budding Consensus Conference (ITBCC) over a field of 0.785mm2 at 20-fold magnification. Linear and logistic regression was applied to delineate association between perineural invasion, tumor budding, and other parameters; Kaplan-Meier and Cox regression were used in the survival analysis. Regardless of the quantification approach, high tumor budding was a significant negative prognostic factor in the univariable Cox regression (&gt;5 buds/0.237mm2, hazard ratio (HR) 1.66, 95% confidence interval (CI) 1.06-2.61, p=0.027; 10 buds/0.785mm2, HR 1.68, 95% CI 1.07-2.64, p=0.024). In the multivariable model adjusting for stage and standard histopathological parameters, lymph vessel invasion (HR=2.43, 95% CI 1.47-4.03, p=0.001) and tumor budding &gt;5 buds/0.237mm2 (HR=1.70, 95% CI 1.07-2.7, p=0.026) were independent negative prognostic factors, while adjuvant therapy was a positive prognostic factor (HR=0.54, 95% CI 0.33-0.86, p=0.009). No significant prognostic value could be delineated for perineural invasion. In conclusion, tumor budding is an independent negative prognostic factor in pancreatic ductal adenocarcinoma associated with lymph node metastasis. The prognostic role of perineural invasion remains uncertain.</p>
<p>doi: <a href="https://doi.org/10.1007/s00428-019-02719-1" class="uri">https://doi.org/10.1007/s00428-019-02719-1</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice</strong> </summary></p>
<p><em>Gastroenterology 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31786131" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31786131</a></p>
<p>BACKGROUND &amp; AIMS: Prolactin (PRL) signaling is upregulated in hormone-responsive cancers. The PRL receptor (PRLR) is class I cytokine receptor that signals via the JAK-STAT and MAPK pathways to regulate cell proliferation, migration, stem-cell features, and apoptosis. Patients with pancreatic ductal adenocarcinoma (PDAC) have high plasma levels of PRL. We investigated whether PRLR signaling contributes to growth of pancreatic tumors in mice. METHODS: We used immunohistochemical analyses to compare levels of PRL and PRLR in multi-tumor tissue microarrays. We used structure-based virtual screening and fragment-based drug discovery to identify compounds likely to bind PRLR and interfere with its signaling. Human pancreatic cell lines (AsPC-1, BxPC-3, Panc-1, and MiaPaCa-2), with or without knockdown of PRLR (CRISPR or small-hairpin RNA), were incubated with PRL or penfluridol and analyzed in proliferation, spheroid formation. C57BL/6 mice were given injections of UNKC-6141 cells, with or without knockdown of PRLR, into pancreas, and tumor development was monitored for 4 weeks, with some mice receiving penfluridol treatment for 21 days. Human pancreatic tumor tissues were implanted into interscapular fat pads of NSG mice and mice were given injections of penfluridol daily for 28 days. Nude mice were given injections of Panc-1 cells, xenograft tumors were grown for 2 weeks, and mice were then given intraperitoneal penfluridol for 21 days. Tumors were collected from mice and analyzed by histology, immunohistochemistry, and immunoblots. RESULTS: Levels of PRLR were increased in PDAC compared with non-tumor pancreatic tissues. Incubation of pancreatic cell lines with PRL activated signaling via JAK2-STAT3 and ERK, as well as formation of pancospheres and cell migration; these activities were not observed in cells with PRLR knock down. Pancreatic cancer cells with PRLR knockdown formed significantly smaller tumors in mice. We identified several diphenylbutylpiperidine-class antipsychotic drugs as agents that decreased PRL-induced JAK2 signaling; incubation of pancreatic cancer cells with these compounds reduced their proliferation and formation of spheres. Injections of 1 of these compounds, penfluridol, slowed growth of xenograft tumors in the different mouse models, reducing proliferation and inducing autophagy of the tumor cells. CONCLUSIONS: Levels of PRLR are increased in PDAC, and exposure to PRL increases proliferation and migration of pancreatic cancer cells. Antipsychotic drugs such as penfluridol block JAK2 signaling in pancreatic cancer cells to reduce their proliferation, induce autophagy, and slow growth of xenograft tumors in mice. These drugs might be tested in patients with PDAC.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.11.279" class="uri">https://doi.org/10.1053/j.gastro.2019.11.279</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31786057" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31786057</a></p>
<p>OBJECTIVES: FOLFIRINOX (FFX) or abraxane plus gemcitabine (AG)-based chemotherapy is used widely as firstline treatment for patients with pancreatic cancer. However, their use in the elderly is discouraged because of adverse events. More clinical data about the therapeutic response and tolerability to FFX or AG in elderly patents (over 70 years old) are required. METHODS: Patients with advanced pancreatic cancer (n=203; 131 metastatic pancreatic cancer patients (MPC) and 72 locally advanced pancreatic cancer patients (LAPC)) were treated using modified-FFX (mFFX) or AG and mFFX sequentially. The patients were grouped according to their age, patients below 70 years old and patients above 70 years old. The objective response rate (ORR), disease control rate (DCR), progression free survival (PFS), overall survival (OS) and adverse events were compared between the groups. RESULTS: The ORRs in the elderly and in patients below 70 were similar (30.0% versus 32.3%). The median OS and PFS were also similar between the groups (mOS 13.3m vs 12.7m, p=0.729, HR 0.874 (95% CI 0.5310 to 1.438); mPFS mPFS 10.6m vs 10.3m, p=0.363, HR 0.800 (95% CI 0.4954 to 1.293)). However, the elderly patients suffered a higher incidence of severe adverse events (50% vs.28.3%). CONCLUSIONS: These data could provide guidance for chemotherapy use in elderly patients with advanced pancreatic cancer. Age did not affect treatment outcome; however, supportive treatment is very important for elderly patients receiving chemotherapy.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.11.012" class="uri">https://doi.org/10.1016/j.pan.2019.11.012</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>EUS-FNA diagnosis of pancreatic serous cystadenoma with the aid of cell blocks and -inhibin immunochemistry: A case series</strong> </summary></p>
<p><em>Diagnostic cytopathology 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31785091" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31785091</a></p>
<p>Serous cystadenoma (SCA) is an uncommon benign pancreatic neoplasm that is most often managed conservatively with follow-up rather than surgical excision. Therefore, to avoid the serious complications of pancreatic surgery, SCA should be diagnosed accurately at the preoperative level. Preoperative SCA diagnosis requires a multimodal diagnostic approach that includes imaging, cystic fluid biochemical analysis and/or endoscopic ultrasound fine-needle aspiration (EUS-FNA). In this brief report, we describe six EUS-FNA cases from five patients that were reported as benign, consistent with serous cystadenoma. Samples were hypocellular, composed of loose clusters and single cuboidal, bland-looking cells among epithelial sheets representing gastrointestinal contamination. Cell blocks were prepared and all six FNA cases revealed cuboidal cells with a positive -inhibin immunophenotype, consistent with a diagnosis of SCA. As EUS-FNAs of SCA commonly result in non-diagnostic interpretations, cell block preparations with subsequent immunochemistry can increase their diagnostic accuracy and guide patient management.</p>
<p>doi: <a href="https://doi.org/10.1002/dc.24348" class="uri">https://doi.org/10.1002/dc.24348</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreatic lymphoma: A cytologic diagnosis challenge</strong> </summary></p>
<p><em>Diagnostic cytopathology 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31774250" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31774250</a></p>
<p>Very rarely lymphoma primarily or secondarily involves the pancreas. Involvement of the pancreatic parenchyma with lymphoma clinically may mimic pancreatic ductal adenocarcinoma (PDA) and other mass-forming pancreatic lesions. Endoscopic ultrasound fine needle aspiration (EUS-FNA) is the first step in the diagnostic pathway of managing these patients by providing a cytology specimen. Cytologically, lymphoma of pancreas can be misdiagnosed for a wide variety of pancreatic neoplastic and non-neoplastic lesions. Cytological differential diagnosis includes well-differentiated adenocarcinoma, acinar cell carcinoma, well differentiated neuroendocrine tumor, and autoimmune pancreatitis. Gastroenterologists skills in providing adequate sample for preparing smears, cell blocks and/or performing flow cytometry, and also cytopathologists skills in detecting atypical lymphocytic population are crucial factors. Although cytology examination has limitations to subclassify lymphoma, it plays a key role to redirect clinicians into the right patient-care pathway. In this article, we present two cases of pancreatic lymphoma with emphasis on the discriminating cytomorphological features, and we also review literatures with reports of primary pancreatic lymphoma (PPL) to better understand the characteristics of this rare lesion.</p>
<p>doi: <a href="https://doi.org/10.1002/dc.24349" class="uri">https://doi.org/10.1002/dc.24349</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: Can Minimally Invasive Techniques Improve Quality of Life following Pancreatic Resection?</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(Suppl 3):845-846</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31773518" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31773518</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07953-0" class="uri">https://doi.org/10.1245/s10434-019-07953-0</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Adult pancreatic cavernous hemangioma: case presentation of a benign tumor with a complex composition</strong> </summary></p>
<p><em>BMC gastroenterology 2019 Nov;19(1):197</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31771513" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31771513</a></p>
<p>BACKGROUND: Pancreatic cavernous hemangioma is an extremely rare benign tumor that is difficult to diagnose on an imaging examination, and its histopathological examination has rarely been reported. CASE PRESENTATION: Herein, we present the case of a 63-year-old man who was admitted to the hospital due to left upper abdominal pain and defecation unformed for more than 2years. None of the positive results obtained from the physical examination could explain his symptoms. The imaging examination indicated a multilocular cyst with septa in the head of the pancreas. The patient underwent a pancreaticoduodenectomy, and the pathologic diagnosis was pancreatic cavernous hemangioma. The histopathological examination showed that the lesion was positive for benign vascular markers, such as CD31, CD34 and F8, and negative for lymphocyte markers, such as D2-40. Moreover, it was also positive for ERG and cytokeratin markers, CAM5.2 and AE1/AE3, indicating the complexity of its components, and Ki-67 negativity revealed its benign nature. CONCLUSIONS: Pancreatic cavernous hemangioma has a complex composition that may be reflected not only in the imaging examination but also in the immunohistochemical detection, and it may achieve a good outcome by surgical excision.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-019-1119-5" class="uri">https://doi.org/10.1186/s12876-019-1119-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A Virus-Infected, Reprogrammed Somatic Cell-Derived Tumor Cell (VIReST) Vaccination Regime Can Prevent Initiation and Progression of Pancreatic Cancer</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31767564" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31767564</a></p>
<p>PURPOSE: Pancreatic cancer remains one of the most lethal cancers, and late detection renders most tumors refractory to conventional therapies. Development of cancer prophylaxis may be the most realistic option for improving mortality associated with this disease. Here, we develop a novel individualized prophylactic and therapeutic vaccination regimen using induced pluripotent stem cells (iPSC), gene editing, and tumor-targeted replicating oncolytic viruses. EXPERIMENTAL DESIGN: We created a Virus-Infected, Reprogrammed Somatic cell-derived Tumor cell (VIReST) regime. iPSCs from healthy cells were induced to pancreatic tumor cells using in situ gene editing via stable provision of KRasG12D and p53R172H tumor driver mutations. These cells were preinfected with oncolytic Adenovirus (AdV) as prime or Vaccinia virus (VV) as boost, to improve vaccine immunogenicity, prior to delivery of vaccines in a sequential regime to young KPC transgenic mice, genetically programmed to develop pancreatic cancer, to prevent and delay disease development. RESULTS: Tumor cells preinfected with oncolytic AdV as prime or VV as boost were the best regime to induce tumor-specific immunity. iPSC-derived tumor cells were highly related in antigen repertoire to pancreatic cancer cells of KPC transgenic mice, suggesting that an individuals stem cells can provide an antigenically matched whole tumor cell vaccine. The VIReST vaccination primed tumor-specific T-cell responses, resulting in delayed disease emergence and progression and significantly prolonged survival of KPC transgenic mice. Importantly, this regime was well-tolerated and nontoxic. CONCLUSIONS: These results provide both proof of concept and a robust technology platform for the development of personalized prophylactic cancer vaccines to prevent pancreatic malignancies in at-risk individuals.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-1395" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-1395</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Italys health performance, 1990-2017: findings from the Global Burden of Disease Study 2017</strong> </summary></p>
<p><em>The Lancet. Public health 2019 Dec;4(12):e645-e657</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31759893" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31759893</a></p>
<p>BACKGROUND: Through a comprehensive analysis of Italys estimates from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017, we aimed to understand the patterns of health loss and response of the health-care system, and offer evidence-based policy indications in light of the demographic transition and government health spending in the country. METHODS: Estimates for Italy were extracted from GBD 2017. Data on Italy are presented for 1990 and 2017, on prevalence, causes of death, years of life lost, years lived with disability, disability-adjusted life-years (DALYs), life expectancy at birth and at age 65 years, healthy life expectancy, and Healthcare Access and Quality (HAQ) Index. We compared the estimates for Italy with those of 15 other western European countries. FINDINGS: The quality of the universal health system and healthy behaviours contribute to favourable overall health, even in comparison with other western European countries. In 2017, life expectancy and HAQ Index score in Italy were among the highest globally, with life expectancy at birth reaching 853 years for females and 808 for males in 2017, ranking Italy eighth globally for females and sixth for males, and an HAQ Index score of 949 in 2016 compared with 8154 in 1990, keeping Italy ranked as ninth globally. Between 1990 and 2017 age-standardised death rates for cardiovascular diseases decreased by 537% (95% uncertainty interval -561 to -514), for neoplasms decreased by 282% (-323 to -246), and for transport injuries decreased by 621% (-646 to -592). However, population ageing is causing an increase in the burden of specific diseases, such as Alzheimers disease and other dementias (DALYs increased by 779% [684 to 872]) and pancreatic (DALYs increased by 397% [284 to 517]) and uterine cancers (DALYs increased by 1647% [1297 to 2025]). Behavioural risk factors, which are potentially modifiable, still have a strong effect, particularly on cardiovascular diseases and neoplasms. For instance, in 2017, 44400 (41200 to 47800) cancer deaths were attributed to smoking, 12000 (9600 to 14800) to alcohol use, and 9500 (5400 to 14200) to high body-mass index, while 47000 (31100 to 65700) deaths due to cardiovascular diseases could be attributed to high LDL cholesterol, 28700 (19700 to 38500) to diets low in whole grains, and 15900 (8500 to 24900) to low physical activity. INTERPRETATION: Italy provides an interesting example of the results that can be achieved by a mix of relatively healthy lifestyles and a universal health system. Two main issues require attention, population ageing and gradual decrease of public health financing, which both pose several challenges to the future of Italys health status. Our findings should be useful to Italys policy makers and health system experts elsewhere. FUNDING: Bill &amp; Melinda Gates Foundation.</p>
<p>doi: <a href="https://doi.org/10.1016/S2468-2667(19)30189-6" class="uri">https://doi.org/10.1016/S2468-2667(19)30189-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Response to Comment on Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer</strong> </summary></p>
<p><em>Annals of surgery 2019 Dec;270(6):e139-e141</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31730557" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31730557</a></p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003418" class="uri">https://doi.org/10.1097/SLA.0000000000003418</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>SPARC expression in desmoplastic and non desmoplastic pancreatic carcinoma and cholangiocarcinoma</strong> </summary></p>
<p><em>Pathology, research and practice 2019 Dec;215(12):152685</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31727501" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31727501</a></p>
<p>BACKGROUND: The pancreatobiliary carcinomas are characterized by presence of desmoplastic stroma. Overexpression of secreted protein acid and rich in cysteine (SPARC), a matrix producing agent has been documented in pancreatic ductal adenocarcinomas, with survival benefits. This study was targeted to see if SPARC expression in pancreatobiliary carcinomas is responsible for stromal desmoplasia and its prognostic significance. METHODS: In this retrospective study 48 cases of pancreatic cancer and 27 cases of cholangiocarcinoma were analyzed. The expression pattern of SPARC and vascular endothelial growth factor (VEGF) (angiogenic factors) was evaluated by immunohistochemistry on formalin fixed paraffin embedded tissues. Immunoreactivity was scored semi quantitatively based on stain intensity and stain distribution. SPARC expression was correlated with tumor histology, stromal desmoplasia, VEGF expression, various histological parameters and overall survival in patients. Real time polymerase chain reaction was performed in few cases to validate the immunohistochemistry expression pattern. RESULTS: SPARC expression was high in peritumoral stroma in pancreatic carcinoma than in pancreatic controls; however, SPARC expression pattern was not grossly different in desmoplastic and non-desmoplastic pancreatobiliary carcinomas and in cholangiocarcinomas. No definite correlation was noted between SPARC expression and histological markers of severity and overall survival data. CONCLUSIONS: The relevance of SPARC expression in pancreato-biliary carcinomas though may still be important for therapeutic decision making, it is not responsible for peritumoral stromal desmoplasia in these tumors and it does not have any significant prognostic implication.</p>
<p>doi: <a href="https://doi.org/10.1016/j.prp.2019.152685" class="uri">https://doi.org/10.1016/j.prp.2019.152685</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Response to Comment on Main Duct Dilatation is the Best Predictor of High-grade Dysplasia or Invasion in Intraductal Papillary Mucinous Neoplasms of the Pancreas</strong> </summary></p>
<p><em>Annals of surgery 2019 Dec;270(6):e109-e110</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31726634" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31726634</a></p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003677" class="uri">https://doi.org/10.1097/SLA.0000000000003677</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comment on Operable Pancreatic Cancer: Are We in an Era of Individualized Neoadjuvant Therapy?</strong> </summary></p>
<p><em>Annals of surgery 2019 Dec;270(6):e94-e95</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31726626" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31726626</a></p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003336" class="uri">https://doi.org/10.1097/SLA.0000000000003336</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>[Pancreatic cytology-morphology and ancillary markers]</strong> </summary></p>
<p><em>Der Pathologe 2019 Dec;40(Suppl 3):311-315</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31705231" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31705231</a></p>
<p>BACKGROUND: Cytology has akey role in thestep-wise diagnostic approach to pancreatic mass lesions. Brush cytology and ultrasound-guided endoscopic fine-needle aspiration provide specimens for diagnosis prior to surgical or conservative therapy. The diagnostic system of the Papanicolaou Society of Cytopathology provides aconceptual framework for reporting these specimens. Cystic lesions represent aparticular challenge in pancreatic cytology, as in many instances apurely morphological approach will not result in an adequate diagnostic interpretation. Noteworthy from aconceptual point of view is how the Papanicolaou Society System incorporates non-morphological methods: laboratory chemical (CEA &gt;192ng/ml) and molecular (KRAS and/or GNAS mutations) findings are part of the formal diagnostic criteria for neoplastic cysts. RESULTS: The Bern experience shows that such an integrated approach results in asignificantly increased diagnostic yield. Among 83samples analyzed, adequate DNA could be extracted in 79samples (95%). Next generation sequencing identified pathogenic mutations in 46cases (58%). Of these, in 35(76%) aneoplastic cyst could not have been diagnosed by morphology alone. CONCLUSION: These findings illustrate anew perspective for diagnostic situations, where morphology alone does allow for asufficient diagnostic work-up. Along this line of thinking, liquid biopsy should not be regarded as areplacement, but rather an extension of the cytologys diagnostic armamentarium, according to the principle of doing more with less.</p>
<p>doi: <a href="https://doi.org/10.1007/s00292-019-00697-4" class="uri">https://doi.org/10.1007/s00292-019-00697-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A set of microRNAs coordinately controls tumorigenesis, invasion, and metastasis</strong> </summary></p>
<p><em>Proceedings of the National Academy of Sciences of the United States of America 2019 Nov;116(48):24184-24195</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31704767" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31704767</a></p>
<p>MicroRNA-mediated gene regulation has been implicated in various diseases, including cancer. This study examined the role of microRNAs (miRNAs) during tumorigenesis and malignant progression of pancreatic neuroendocrine tumors (PanNETs) in a genetically engineered mouse model. Previously, a set of miRNAs was observed to be specifically up-regulated in a highly invasive and metastatic subtype of mouse and human PanNET. Using functional assays, we now implicate different miRNAs in distinct phenotypes: miR-137 stimulates tumor growth and local invasion, whereas the miR-23b cluster enables metastasis. An algorithm, Bio-miRTa, has been developed to facilitate the identification of biologically relevant miRNA target genes and applied to these miRNAs. We show that a top-ranked miR-137 candidate gene, Sorl1, has a tumor suppressor function in primary PanNETs. Among the top targets for the miR-23b cluster, Acvr1c/ALK7 has recently been described to be a metastasis suppressor, and we establish herein that it is down-regulated by the miR-23b cluster, which is crucial for its prometastatic activity. Two other miR-23b targets, Robo2 and P2ry1, also have demonstrable antimetastatic effects. Finally, we have used the Bio-miRTa algorithm in reverse to identify candidate miRNAs that might regulate activin B, the principal ligand for ALK7, identifying thereby a third family of miRNAs-miRNA-130/301-that is congruently up-regulated concomitant with down-regulation of activin B during tumorigenesis, suggestive of functional involvement in evasion of the proapoptotic barrier. Thus, dynamic up-regulation of miRNAs during multistep tumorigenesis and malignant progression serves to down-regulate distinctive suppressor mechanisms of tumor growth, invasion, and metastasis.</p>
<p>doi: <a href="https://doi.org/10.1073/pnas.1913307116" class="uri">https://doi.org/10.1073/pnas.1913307116</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Dendritic cells in pancreatic cancer immunotherapy: Vaccines and combination immunotherapies</strong> </summary></p>
<p><em>Pathology, research and practice 2019 Dec;215(12):152691</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31676092" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31676092</a></p>
<p>Despite significant advances over the past decades of research, pancreatic cancer (PC) continues to have the worst 5-year survival of any malignancy. Dendritic cells (DCs) are the most potent professional antigen-presenting cells and are involved in the induction and regulation of antitumor immune responses. DC-based immunotherapy has been used in clinical trials for PC. Although safety, efficacy, and immune activation were reported in patients with PC, DC vaccines have not yet fulfilled their promise. Additional strategies for combinatorial approaches aimed to augment and sustain the antitumor specific immune response elicited by DC vaccines are currently being investigated. Here, we will discuss DC vaccination immunotherapies that are currently under preclinical and clinical investigation and potential combination approaches for treating and improving the survival of PC patients.</p>
<p>doi: <a href="https://doi.org/10.1016/j.prp.2019.152691" class="uri">https://doi.org/10.1016/j.prp.2019.152691</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Treatment of Gastroenteropancreatic Neuroendocrine Tumors</strong> </summary></p>
<p><em>Surgical pathology clinics 2019 Dec;12(4):1045-1053</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31672293" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31672293</a></p>
<p>Neuroendocrine tumors (NETs) represent a group of biologically and clinically heterogeneous neoplasms arising from the diffuse neuroendocrine system. Although NETs may develop in almost any organ, they commonly arise in the gastrointestinal tract and pancreas and are referred to as gastroenteropancreatic (GEP)-NETs when they arise from these sites. In recent years, advances in understanding of the biology of NETs have resulted in an expansion in treatment options and improved survival for patients. This review focuses on treatment of GEP-NETS and highlights factors that govern the therapeutic approach.</p>
<p>doi: <a href="https://doi.org/10.1016/j.path.2019.08.011" class="uri">https://doi.org/10.1016/j.path.2019.08.011</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas</strong> </summary></p>
<p><em>Surgical pathology clinics 2019 Dec;12(4):1021-1044</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31672292" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31672292</a></p>
<p>Neuroendocrine neoplasms (NENs) of the gastrointestinal (GI) tract and pancreas are a rare and heterogeneous group of neoplasms characterized by common cellular features as well as unique site-specific traits. GI and pancreatic NENs are much rarer than the more common adenocarcinomas arising at these sites. However, the incidences of GI and pancreatic NENs have increased significantly, particularly in the stomach and common site, followed by rectum, appendix, colon, and stomach. Pancreatic NENs are also uncommon, with fewer than 1 per 100,000, accounting for 1% to 2% of all pancreatic neoplasms.</p>
<p>doi: <a href="https://doi.org/10.1016/j.path.2019.08.007" class="uri">https://doi.org/10.1016/j.path.2019.08.007</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Potentials of stem cell-therapy in pancreatic cancer: An update</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Dec;19(8):1034-1042</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31668563" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31668563</a></p>
<p>In recent times, cell-therapies like T-activated cells, dendritic cells and natural killer cells have shown increasing promise in treating cancers as evidenced by both animal and human studies in the literature. In addition, stem cells are also being considered as potent anti-cancer agents since they act through multi-pronged approaches (chemokines, cytokines, paracrine action). In this review, we have attempted to discuss the inferences of studies that have used different sub-types of stem cells namely mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs) and neural stem cells (NSCs) in in-vitro/in-vivo mice and/or human studies as a treatment modality for pancreatic cancer. Pancreatic cancers are diagnosed in late/metastatic stages hence limiting its progress to partial/disease-free status. Recent literature supports evidences of stem cell therapy in pancreatic cancer with promising results; yet their impact remains inconclusive due to limited studies in human subjects. With reference to the treatment options for pancreatic cancer, the most studied sub-type of stem cells was HSCs as evident from the available clinical trials. The suggested mechanism of the HSC-transplantation is presumably via the graft-versus-tumor effect that elicits an anti-tumor immune response activated by the T-cell repertoires. On the other hand, the property of MSCs like tropism, migration to tumor site and activation of host immune cells by its secretome, appear to be able to regulate pancreatic tumor microenvironment. Further, drug delivery potential could be mediated via engineered MSCs to enhance the bioavailability of drug/prodrug at tumor site. Conclusively, stem cells have shown great potentials as next-generation therapeutic options.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.09.016" class="uri">https://doi.org/10.1016/j.pan.2019.09.016</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreatic cancer: a growing burden</strong> </summary></p>
<p><em>The lancet. Gastroenterology &amp; hepatology 2019 Dec;4(12):895-896</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31648975" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31648975</a></p>
<p>doi: <a href="https://doi.org/10.1016/S2468-1253(19)30323-1" class="uri">https://doi.org/10.1016/S2468-1253(19)30323-1</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017</strong> </summary></p>
<p><em>The lancet. Gastroenterology &amp; hepatology 2019 Dec;4(12):934-947</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31648972" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31648972</a></p>
<p>BACKGROUND: Worldwide, both the incidence and death rates of pancreatic cancer are increasing. Evaluation of pancreatic cancer burden and its global, regional, and national patterns is crucial to policy making and better resource allocation for controlling pancreatic cancer risk factors, developing early detection methods, and providing faster and more effective treatments. METHODS: Vital registration, vital registration sample, and cancer registry data were used to generate mortality, incidence, and disability-adjusted life-years (DALYs) estimates. We used the comparative risk assessment framework to estimate the proportion of deaths attributable to risk factors for pancreatic cancer: smoking, high fasting plasma glucose, and high body-mass index. All of the estimates were reported as counts and age-standardised rates per 100000 person-years. 95% uncertainty intervals (UIs) were reported for all estimates. FINDINGS: In 2017, there were 448000 (95% UI 439000-456000) incident cases of pancreatic cancer globally, of which 232000 (210000-221000; 519%) were in males. The age-standardised incidence rate was 50 (49-51) per 100000 person-years in 1990 and increased to 57 (56-58) per 100000 person-years in 2017. There was a 23 times increase in number of deaths for both sexes from 196000 (193000-200000) in 1990 to 441000 (433000-449000) in 2017. There was a 21 times increase in DALYs due to pancreatic cancer, increasing from 44 million (43-45) in 1990 to 91 million (89-93) in 2017. The age-standardised death rate of pancreatic cancer was highest in the high-income super-region across all years from 1990 to 2017. In 2017, the highest age-standardised death rates were observed in Greenland (174 [158-190] per 100000 person-years) and Uruguay (121 [109-135] per 100000 person-years). These countries also had the highest age-standardised death rates in 1990. Bangladesh (19 [15-23] per 100000 person-years) had the lowest rate in 2017, and So Tom and Prncipe (13 [11-15] per 100000 person-years) had the lowest rate in 1990. The numbers of incident cases and deaths peaked at the ages of 65-69 years for males and at 75-79 years for females. Age-standardised pancreatic cancer deaths worldwide were primarily attributable to smoking (211% [188-237]), high fasting plasma glucose (89% [21-194]), and high body-mass index (62% [25-114]) in 2017. INTERPRETATION: Globally, the number of deaths, incident cases, and DALYs caused by pancreatic cancer has more than doubled from 1990 to 2017. The increase in incidence of pancreatic cancer is likely to continue as the population ages. Prevention strategies should focus on modifiable risk factors. Development of screening programmes for early detection and more effective treatment strategies for pancreatic cancer are needed. FUNDING: Bill &amp; Melinda Gates Foundation.</p>
<p>doi: <a href="https://doi.org/10.1016/S2468-1253(19)30347-4" class="uri">https://doi.org/10.1016/S2468-1253(19)30347-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Management of Acute Cholecystitis during Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(13):4515-4521</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31641946" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31641946</a></p>
<p>BACKGROUND: Patients with localized pancreatic cancer (PC) can develop acute cholecystitis during neoadjuvant therapy; optimal management remains undefined. METHODS: Consecutive patients with localized PC who had indwelling biliary stents and received neoadjuvant therapy were reviewed. Time from stent placement to the development of acute cholecystitis was calculated. Patients were categorized as having surgical versus nonoperative management of cholecystitis. Time to PC resection was defined as the time from the start of treatment to pancreatic resection. RESULTS: Of the 283 patients with indwelling biliary stents, acute cholecystitis occurred in 17 (6%) patients. The median time from the date of stent placement to the development of cholecystitis was 2.3months [interquartile range (IQR) 4.6months]. Acute cholecystitis was managed with cholecystostomy tube placement in 15 (88%) patients and cholecystectomy in 2 (12%). In total, 189 (67%) of the 283 patients completed all intended neoadjuvant therapy and surgery; 10 (59%) of the 17 patients with cholecystitis (10 of 15 managed with a cholecystostomy tube and 0 of 2 managed with cholecystectomy) and 179 (67%) of the 266 patients without cholecystitis (p=0.47). The median time to PC resection was 3.2months for the 179 patients without cholecystitis and 3.6months for the 10 patients with cholecystitis (p=1.00). CONCLUSIONS: Acute cholecystitis occurred in 6% of patients with indwelling biliary stents during neoadjuvant therapy. Management with a cholecystostomy tube did not delay the completion of neoadjuvant therapy and surgery and should be considered the optimal management of this complication.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07906-7" class="uri">https://doi.org/10.1245/s10434-019-07906-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Computed tomography based scoring system in a prospectively ascertained cohort of patients with chronic pancreatitis</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Dec;19(8):1027-1033</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31630919" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31630919</a></p>
<p>OBJECTIVE: No standardized system is currently used to report the presence or severity of parenchymal and ductal features of chronic pancreatitis (CP) on CT scan. We report a modification to the previously proposed Cambridge classification to serve this purpose. METHODS: Contrast-enhanced CT scans of 158 well-phenotyped patients with CP enrolled in the North American Pancreatitis Studies (NAPS2) during 2000-2014 from the University of Pittsburgh were retrospectively reviewed by a subspecialty trained abdominal radiologist. Presence and severity (score scale 0-4) of pancreatic duct (PD) dilation, obstruction and contour irregularity, pancreatic calcifications, atrophy and extent of pancreatic involvement were recorded to grade the morphological severity of CP and stratify patients into distinct morphologic patterns. Findings were also correlated with clinical features. RESULTS: Pancreatic atrophy, calcifications, PD dilation and PD irregularity were observed in 80%, 68%, 65%, 58% cases, respectively. An obstructive stone or PD stricture was present in 63%, and 86% had diffuse pancreatic involvement. Using these features, CP was noted to be moderate or severe in 61%, and classified morphologically as obstructive with/without calcifications, calcific but non-obstructive and non-calcific/non-obstructive in 65%, 20%, 15%, respectively. Functional abnormalities but not the presence of pain generally correlated with imaging findings. CONCLUSION: A structured scoring system can provide qualitative and quantitative assessment of imaging findings in CP and an opportunity for adoption into clinical practice and research for initial evaluation and longitudinal follow-up. Our findings need validation in a prospective cohort before widespread adoption.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.09.013" class="uri">https://doi.org/10.1016/j.pan.2019.09.013</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Peripheral blood monocyte counts are elevated in the pre-diagnostic phase of pancreatic cancer: A population based study</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Dec;19(8):1043-1048</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31630918" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31630918</a></p>
<p>BACKGROUND: Early diagnosis of pancreatic ductal adenocarcinoma (PDAC) is associated with improved outcomes. A biomarker with incremental change in the pre-diagnostic phase of the disease would be valuable for early detection. In our clinical experience, we have observed elevated peripheral blood monocyte (PBM) counts in PDAC patients at diagnosis. In this study, we aimed to compare PBM counts in PDAC cases and healthy controls at diagnosis and in the 2-year pre-diagnostic period. METHODS: Using the Rochester Epidemiology Project database, we identified all patients diagnosed with PDAC between 2000 and 2015 (n=219) and age-and gender-matched disease-free controls (n=438). PBM counts and temporal trends were analyzed over a 24 month period before PDAC diagnosis. The groups were compared using Fishers exact test and t-test. RESULTS: At diagnosis, compared to controls PDAC cases more often had monocytosis (23% vs 8%; p&lt;0.001) and higher mean PBM count (x109/L) (0.73 vs 0.59; p&lt;0.001). In the 2-year pre-diagnostic period, mean PBM counts were significantly higher in PDAC cases in the interval from 6 months to diagnosis (0.69 vs 0.61; p=0.03). PDAC cases with monocytosis at diagnosis had a significantly lower median survival (1.9 months vs.7.6 months; p=0.001). CONCLUSION: Monocytosis is more prevalent in PDAC patients at diagnosis compared to controls and is associated with lower median survival. In a subset of patients, PBM count elevation precedes PDAC diagnosis by 6 months. This novel observation can possibly augment strategies for early diagnosis of PDAC but needs further study.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.10.002" class="uri">https://doi.org/10.1016/j.pan.2019.10.002</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Accuracy of Fukuoka and American Gastroenterological Association Guidelines for Predicting Advanced Neoplasia in Pancreatic Cyst Neoplasm: A Meta-Analysis</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(13):4522-4536</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31617119" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31617119</a></p>
<p>BACKGROUND: A differential diagnosis of advanced pancreatic cystic neoplasms (PCNs) is critical to determine optimal treatment. The Fukuoka and American Gastroenterological Association (AGA) guidelines are the most widely accepted criteria for the management of PCNs. OBJECTIVE: This study aimed to evaluate the diagnostic value of these guidelines in predicting advanced neoplasia (AN). METHODS: A comprehensive electronic search of the PubMed, EMBASE, Web of Science, Cochrane Library, and Scopus databases was conducted to identify all relevant studies evaluating the Fukuoka and AGA guidelines in surgically resected and histologically confirmed PCNs. Pooled sensitivity, specificity, and diagnostic odds ratios (DORs) were calculated as compound measures of diagnostic accuracy using the random-effects model. Summary of receiver operating characteristic (SROC) curves and the area under the curve (AUC) were also performed. RESULTS: A total of 21 studies with 3723 patients were included in this meta-analysis. Of these studies, 15, 4, and 2 evaluated the Fukuoka guidelines, the AGA guidelines, and both guidelines, respectively. For AN prediction, the Fukuoka guidelines had a pooled sensitivity of 0.67 (95% confidence interval [CI] 0.64-0.70), pooled specificity of 0.64 (95% CI 0.62-0.66), and pooled DOR of 6.28 (95% CI 4.38-9.01), with an AUC of the SROC of 0.78. AGA guidelines showed a pooled sensitivity of 0.59 (95% CI 0.52-0.65), pooled specificity of 0.77 (95% CI 0.74-0.80), and pooled DOR of 5.84 (95% CI 2.60-13.15), with an AUC of 0.79 (95% CI 0.70-0.88). CONCLUSION: When used alone, the Fukuoka and AGA guidelines showed similar but unsatisfactory diagnostic accuracy in the risk stratification of malignant potential of PCN. Thus, we recommend that they be applied only as a broad framework in clinical practice.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07921-8" class="uri">https://doi.org/10.1245/s10434-019-07921-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Malignant biliary obstruction due to unresectable pancreatic cancer: Is the irradiation stent the most effective palliation?</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Dec;19(8):1081-1082</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31611132" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31611132</a></p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.10.001" class="uri">https://doi.org/10.1016/j.pan.2019.10.001</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cystic fibrosis transmembrane conductance regulator modulators reduce the risk of recurrent acute pancreatitis among adult patients with pancreas sufficient cystic fibrosis</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Dec;19(8):1023-1026</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31611131" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31611131</a></p>
<p>BACKGROUND: Approximately 1 in 5 patients with pancreas sufficient cystic fibrosis (PS-CF) will develop acute pancreatitis (AP). It is not known whether ivacaftor alone or in combination with other CFTR (cystic transmembrane regulator) modulators (tezacaftor or lumacaftor) can reduce the risk of AP in patients with PS-CF and AP history. METHODS: We retrospectively queried the CF registry at our institution for adult patients with PS-CF, a documented history of AP and initiation of CFTR modulators for pulmonary indications. Patient characteristics including demographics, CFTR genotype, pancreatitis risk factors, pancreatic exocrine function and other relevant laboratory, imaging parameters were obtained from the time of the sentinel AP episode through the follow-up period. RESULTS: A total of 15 adult CF patients were identified with mean age of 44.1 years (SD13.8). In the 24 months preceding CFTR modulator initiation, six of these patients had at least 1 episode of AP with median of 2 episodes [1.75, 2.5]. None of the patients had evidence of pancreatic calcifications or exocrine pancreas insufficiency at the time of CFTR modulator initiation. The mean duration of follow-up after CFTR modulator initiation was 36.7 months (SD21.5). None of the patients who remained on CFTR modulators developed an episode of AP or required hospitalization for AP related abdominal pain during follow-up. CONCLUSIONS: CFTR modulators, alone or in combination, substantially reduce the risk of recurrent AP over a mean follow-up period of 3 years in adult patients with PS-CF and a history of prior AP. These data suggest that any augmentation of CFTR function can reduce the risk of pancreatitis.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.09.014" class="uri">https://doi.org/10.1016/j.pan.2019.09.014</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Main duct and mixed type intraductal papillary mucinous neoplasms without enhancing mural nodules: Duct diameter of less than 10mm and segmental dilatation of main pancreatic duct are findings support surveillance rather than immediate surgery</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Dec;19(8):1054-1060</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31611130" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31611130</a></p>
<p>OBJECTIVE: The guidelines for pancreatic intraductal papillary mucinous neoplasms (IPMNs) recommend surgical resection of all main-duct (MD) and mixed-type IPMNs in surgically fit patients. We conducted this study to identify the rates of high-grade dysplasia (HGD) and invasive carcinoma according to the morphological features of the main pancreatic duct (MPD) in patients with MD and mixed IPMN. METHODS: We performed a retrospective study of 259 patients with histologically proven MD and mixed-type IPMNs who underwent surgery at six academic institutions. RESULTS: The rate of HGD and invasive carcinoma was 11.1% (24/216) in patients without enhancing mural nodules (MNs) and 69.8% (30/43) in patients with MNs. Multivariate analysis showed that MPD diameter of 10mm [odds ratio (OR), 2.5; 95% confidence interval (CI), 1.155-5.505; P=0.02], diffuse MPD dilatation (OR, 3.2; 95% CI, 1.152-8.998; P=0.02), and presence of enhancing MNs in MPD (OR, 9.6; 95% CI, 3.928-23.833, P&lt;0.0001) were significant predictors of HGD and invasive carcinoma. Of the 216 patients without enhancing MNs, 79 patients (36.6%) having both segmental MPD dilatation and MPD diameter of &lt;10mm showed significantly lower rates of HGD and invasive carcinoma (3/79, 3.8%) than patients having both diffuse MPD dilatation and MPD diameter 10mm (9/36, 25%, P=0.001). CONCLUSIONS: MD and mixed-type IPMNs having segmental MPD dilatation with MPD dilation &lt;10mm and no enhancing MNs on imaging showed a significantly lower rate of HGD and invasive carcinoma, and watchful follow-up instead of immediate surgical resection might be possible in these patients.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.09.010" class="uri">https://doi.org/10.1016/j.pan.2019.09.010</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Radiotherapy as an Adjunct to Surgery for Pancreatic Cancer: Where Are We After More Than 30 Years of Research and Trials?</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(13):4166-4167</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31605341" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31605341</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07787-w" class="uri">https://doi.org/10.1245/s10434-019-07787-w</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Outcomes of Lymph Node Dissection for Nonmetastatic Pancreatic Neuroendocrine Tumors: To Dissect or Not To Dissect</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 12;26(Suppl 3):872-873</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31605334" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31605334</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07925-4" class="uri">https://doi.org/10.1245/s10434-019-07925-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: Clinical Significance of Further Subdivision of N Staging in Pancreatic Cancer</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(Suppl 3):766-767</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31602575" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31602575</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07918-3" class="uri">https://doi.org/10.1245/s10434-019-07918-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Primary signet ring cell carcinoma of the pancreas: Cytopathology review of a rare entity</strong> </summary></p>
<p><em>Diagnostic cytopathology 2019 Dec;47(12):1314-1320</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31599130" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31599130</a></p>
<p>Primary signet ring cell carcinoma of the pancreas (PSRCCP) is an extremely rare diagnosis that has not been extensively studied in literature. Primary and metastatic neoplasms to the pancreas may exhibit cytomorphological similarities to signet ring cells, posing diagnostic challenges. In this article, we review PSRCCP and provide a study of several primary pancreatic neoplasms that may mimic the appearance of PSRCCP upon cytopathology evaluation, shedding light on the existence of this dilemma, and helping cytopathologists in navigating similar scenarios in their practice.</p>
<p>doi: <a href="https://doi.org/10.1002/dc.24324" class="uri">https://doi.org/10.1002/dc.24324</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Significance of MUC2 gene methylation detection in pancreatic cancer diagnosis</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Dec;19(8):1049-1053</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31590960" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31590960</a></p>
<p>PURPOSE: This study was conducted to explore the diagnostic value of MUC2 gene methylation in pancreatic cancer. METHODS: Methylation restriction enzyme digestion (Msp I/Hap II) and polymerase chain reaction (PCR) were performed to detect methylation of the MUC2 gene in fecal and blood specimens from seven study subjects with pancreatic cancer (PC), chronic pancreatitis (CP), or normal controls (CON). Simultaneously, blood CA 19-9 levels were detected as a positive indicator of PC. RESULTS: MUC2 methylation was detected in 50% of PC cell lines. In fecal samples, the MUC2 methylation rate in PC (n=30) was 43.3%, which was significantly higher than those in CP (n=8, 0%, P&lt;0.05) and CON (n=20, 5.0%, P&lt;0.05). In blood samples, the MUC2 methylation rate in PC (n=40) was 52.5%, which was significantly higher than those in CP (n=15, 0%, P&lt;0.01) and CON (n=25, 4.0%, P&lt;0.01). For PC diagnosis, MUC2 gene methylation in blood samples showed higher specificity and positive predictive value than CA 19-9. The combined detection in the feces and blood showed a 60% MUC2 methylation rate in PC (n=10), which was higher than those in the CP (n=5, 0%, P&lt;0.01) and CON (n=12, 0%, P&lt;0.01). CONCLUSIONS: The study can clearly indicate that combined detection of MUC2 gene methylation in the peripheral blood and feces could be used as a new screening and early diagnosis method for pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.09.012" class="uri">https://doi.org/10.1016/j.pan.2019.09.012</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Dec;19(8):1067-1073</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31587962" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31587962</a></p>
<p>BACKGROUND: Although prognosis of NENs is affected by several features including tumour burden, the specific role of this factor in pancreatic NENs (PanNENs) and gastrointestinal NENs (GI NENs) is not well established. AIM: To compare the prognostic role of tumour burden in PanNENs and GI NENs. PATIENTS AND METHODS: This study was a retrospective analysis of stage IV PanNENs and GI NENs. Tumours were classified based on liver tumour volume (&lt;25% or &gt;25%). Overall survival as assessed by Kaplan-Meier curves, and Cox proportional hazards method was used to perform risk factor analysis. RESULTS: The analysis included 300 patients, including 166 panNENs (55.3%) and 134 GI NENs (44.7%). A total of 158 patients (52.7%) had G2 tumours, 107 had G1 tumours (35.7%), and 35 had G3 tumours (11.6%). Tumour liver involvement &gt;25% was observed in 187 patients (62.3%): 106 PanNENs (56.7%), and 81 GI NENs (43.3%) (p=0.551). Bone metastases were present in 45 patients (15%): 22 PanNENs (13.2%) and 23 GI NENs (17.1%) (p=0.416). Characteristics of the PanNENs, including: grading (G2 vs G1, HR=3.7; G3 vs G1, HR=16.40), liver involvement&gt;25% (HR=3.09), and bone metastases (HR=2.27) were independent predictors for poor survival, whereas the only significant risk factor in GI NENs was grading (G2 vs G1, HR=4.36; G3 vs G1, HR=8.60). CONCLUSIONS: PanNENs and GI NENs have different risk profiles. Liver tumour volume and the presence of bone metastases significantly affect survival in patients with PanNENs but has no impact on the clinical outcomes of GI NENs.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.09.015" class="uri">https://doi.org/10.1016/j.pan.2019.09.015</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer</strong> </summary></p>
<p><em>Pathology, research and practice 2019 Dec;215(12):152650</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31585811" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31585811</a></p>
<p>BACKGROUND: (Interleukin 17 Receptor Beta) IL17RB has been implicated in several malignancies. However, its role in the progression of and chemosensitivity in pancreatic cancer remains unknown. We aimed to determine the clinical significance of IL17RB expression in the prognosis of resectable pancreatic cancer and in the benefits from gemcitabine treatment. MATERIALS AND METHODS: We used microarray and immunohistochemical staining techniques to evaluate IL17RB expression in 91 resectable pancreatic cancer tissues and their respective matched adjacent non-cancerous tissues. Quantitative real-time PCR and Western blotting were used to evaluate IL17RB in human pancreatic cancer cell lines after gemcitabine treatment. The correlation between IL17RB expression and overall survival and disease-free survival times were analyzed. RESULTS: IL17RB expression correlated with lymph node metastasis and (Vascular endothelial growth factor) VEGF expression. Cox proportional model showed that high IL17RB expression is a significant negative prognostic factor for both (overall survival) OS and (disease-free survival) DFS. Kaplan-Meier survival curves confirmed significantly reduced median overall and DFS time in high IL17RB patients as compared with low IL17RB patients. Furthermore, Cox proportional model confirmed a correlation between adjuvant treatment with gemcitabine-based chemotherapy and IL17RB expression. Kaplan-Meier survival curves showed that low IL17RB expression was associated with longer OS and DFS in patients than high IL17RB expression and gemcitabine-based adjuvant chemotherapy. In human pancreatic cancer cell lines, the messenger RNA and protein levels of IL17RB were signicantly enhanced after gemcitabine treatment. CONCLUSIONS: IL17RB predicts the prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1016/j.prp.2019.152650" class="uri">https://doi.org/10.1016/j.prp.2019.152650</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Vimentin Expression in Tumor Microenvironment Predicts Survival in Pancreatic Ductal Adenocarcinoma: Heterogeneity in Fibroblast Population</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(13):4791-4804</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31583548" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31583548</a></p>
<p>BACKGROUND: The tumor microenvironment, including cancer-associated fibroblasts (CAFs), plays various clinical roles in cancer growth. CAFs are a heterogeneous population and express a variety of mesenchymal markers. However, the clinical roles for CAFs expressing different markers in pancreatic ductal adenocarcinoma (PDAC) remain unknown. METHODS: We reviewed 67 resected PDAC patients who had not received preoperative therapy. Each primary tumor was analyzed for vimentin and -smooth muscle actin (-SMA) expression by immunohistochemical and dual immunofluorescence staining. RESULTS: There was no correlation between the percentage of cells expressing vimentin and -SMA in the tumor stroma (Pearsons correlation coefficient: r=0.171). Higher vimentin expression (p=0.018) was associated with significantly shorter overall survival in PDAC patients. Using dual immunofluorescence staining, vimentin-positive CAFs were divided into two subpopulations: co-expression of -SMA, and no co-expression of -SMA. In PDAC, the level of co-expression had no effect on survival using univariate analysis (median survival time, 33.3months for low co-expression vs.18.2months for high co-expression; log-rank, p=0.143). However, multivariate analysis clarified that CAFs expressing vimentin alone was an independent predictor of poor survival (p=0.014; hazard ratio, 2.305; 95% confidence interval, 1.181-4.497). CONCLUSIONS: Vimentin-positive CAFs without co-expression of -SMA were associated with poor survival in PDAC, and CAFs possessed molecular and functional heterogeneity in this disease.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07891-x" class="uri">https://doi.org/10.1245/s10434-019-07891-x</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreatic cyst surveillance imposes low psychological burden</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Dec;19(8):1061-1066</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31582346" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31582346</a></p>
<p>BACKGROUND/OBJECTIVES: For the currently recommended pancreatic cyst surveillance to be feasible, participant adherence is a prerequisite. Our objective was to evaluate the psychological burden of pancreatic cyst surveillance from a participants perspective. METHODS: The present participant survey is part of an international cohort study (PACYFIC study, www.pacyfic.net), which prospectively records the outcome of surveillance of asymptomatic pancreatic cysts. Participants are invited to complete questionnaires before and during cyst surveillance. RESULTS: 109 participants, 31 enrolled before and 78 during surveillance (median time since cyst diagnosis 16.5 (IQR 36) months), returned a total of 179 questionnaires. The majority indicated that surveillance reduces concerns of developing pancreatic cancer (82%), gives a sense of certainty (81%) and is a good method to detect cancer (91%). Participants already undergoing surveillance reported more negative aspects than those still to commence, like sleeping worse (30% vs 13%, P=0.035), postponing plans (32% vs 13%, P=0.031), and finding the follow-up burdensome (33% vs 13%, P=0.044). Overall, the vast majority (94%) deemed advantages to outweigh disadvantages. Anxiety and depression scores were low (median Hospital Anxiety and Depression Scale 4 for anxiety (IQR 6), 2 for depression (IQR 5)). CONCLUSION: The psychological burden of pancreatic cyst surveillance is low. Therefore, participant adherence is expected to be high and annual surveillance seems feasible.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.08.011" class="uri">https://doi.org/10.1016/j.pan.2019.08.011</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Perioperative Clinical Trials for Pancreatic Cancer in the National Clinical Trials Network</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(13):4173-4174</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31552616" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31552616</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07767-0" class="uri">https://doi.org/10.1245/s10434-019-07767-0</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Dec;25(23):7014-7023</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31540979" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31540979</a></p>
<p>PURPOSE: In patients with cancer who have an abnormal biomarker finding, the source of the biomarker in the bloodstream must be located for confirmation of diagnosis, staging, and therapy planning. We evaluated if immuno-PET with the radiolabeled high-affinity antibody HuMab-5B1 (MVT-2163), binding to the cancer antigen CA19-9, can identify the source of elevated biomarkers in patients with pancreatic cancer. PATIENTS AND METHODS: In this phase I dose-escalating study, 12 patients with CA19-9-positive metastatic malignancies were injected with MVT-2163. Within 7 days, all patients underwent a total of four whole-body PET/CT scans. A diagnostic CT scan was performed prior to injection of MVT-2163 to correlate findings on MVT-2163 PET/CT. RESULTS: Immuno-PET with MVT-2163 was safe and visualized known primary tumors and metastases with high contrast. In addition, radiotracer uptake was not only observed in metastases known from conventional CT, but also seen in subcentimeter lymph nodes located in typical metastatic sites of pancreatic cancer, which were not abnormal on routine clinical imaging studies. A significant fraction of the patients demonstrated very high and, over time, increased uptake of MVT-2163 in tumor tissue, suggesting that HuMab-5B1 labeled with beta-emitting radioisotopes may have the potential to deliver therapeutic doses of radiation to cancer cells. CONCLUSIONS: Our study shows that the tumor antigen CA19-9 secreted to the circulation can be used for sensitive detection of primary tumors and metastatic disease by immuno-PET. This significantly broadens the number of molecular targets that can be used for PET imaging and offers new opportunities for noninvasive characterization of tumors in patients.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-18-3667" class="uri">https://doi.org/10.1158/1078-0432.CCR-18-3667</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer on Surgical Outcomes</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(Suppl 3):739-740</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31538287" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31538287</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07857-z" class="uri">https://doi.org/10.1245/s10434-019-07857-z</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Economic Analysis of Adjuvant Chemoradiotherapy Compared with Chemotherapy in Resected Pancreas Cancer</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(13):4193-4203</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31535303" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31535303</a></p>
<p>BACKGROUND: Population-based survival and costs of pancreas adenocarcinoma patients receiving adjuvant chemoradiation and chemotherapy following pancreaticoduodenectomyare poorly understood. METHODS: This retrospective cohort study used linked administrative and pathological datasets to identify all patients diagnosed with pancreas adenocarcinoma and undergoing pancreaticoduodenectomy in Ontario between April 2004 and March 2014, who received postoperative chemoradiation or chemotherapy. Stage and margin status were defined by using pathology reports. Kaplan-Meier and Cox proportional hazards regression survival analyses were used to determine associations between adjuvant treatment approach and survival, while stratifying by margin status. Median overall health system costs were calculated at 1 and 3years for chemoradiation and chemotherapy, and differences were tested using the Kruskal-Wallis test. RESULTS: Among 709 patients undergoing pancreaticoduodenectomy for pancreas cancer during the study period, the median survival was 21months. Median survival was 19months for chemoradiation and 22months for chemotherapy. Patients receiving chemoradiation were more likely to have positive margins: 47.7% compared with 19.2% in chemotherapy. After stratifying by margin status and controlling for confounders, adjusted hazard ratio of death were not statistically different between chemotherapy and chemoradiation [margin positive, hazard ratio (HR)=0.99, 95% confidence interval (CI)=0.88-1.27; margin negative, HR 0.95, 95% CI 0.91-1.18]. Overall 1-year health system costs were significantly higher for chemoradiation (USD $70,047) than chemotherapy (USD $54,005) (p0.001). CONCLUSIONS: Chemotherapy and chemoradiation yielded similar survival, but chemoradiation resulted in higher costs. To create more sustainable healthcare systems, both the efficacy and costs of therapies should be considered.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07808-8" class="uri">https://doi.org/10.1245/s10434-019-07808-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Bioactivation of Napabucasin Triggers Reactive Oxygen Species-Mediated Cancer Cell Death</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Dec;25(23):7162-7174</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31527169" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31527169</a></p>
<p>PURPOSE: Napabucasin (2-acetylfuro-1,4-naphthoquinone or BBI-608) is a small molecule currently being clinically evaluated in various cancer types. It has mostly been recognized for its ability to inhibit STAT3 signaling. However, based on its chemical structure, we hypothesized that napabucasin is a substrate for intracellular oxidoreductases and therefore may exert its anticancer effect through redox cycling, resulting in reactive oxygen species (ROS) production and cell death. EXPERIMENTAL DESIGN: Binding of napabucasin to NAD(P)H:quinone oxidoreductase-1 (NQO1), and other oxidoreductases, was measured. Pancreatic cancer cell lines were treated with napabucasin, and cell survival, ROS generation, DNA damage, transcriptomic changes, and alterations in STAT3 activation were assayed in vitro and in vivo. Genetic knockout or pharmacologic inhibition with dicoumarol was used to evaluate the dependency on NQO1. RESULTS: Napabucasin was found to bind with high affinity to NQO1 and to a lesser degree to cytochrome P450 oxidoreductase (POR). Treatment resulted in marked induction of ROS and DNA damage with an NQO1- and ROS-dependent decrease in STAT3 phosphorylation. Differential cytotoxic effects were observed, where NQO1-expressing cells generating cytotoxic levels of ROS at low napabucasin concentrations were more sensitive. Cells with low or no baseline NQO1 expression also produced ROS in response to napabucasin, albeit to a lesser extent, through the one-electron reductase POR. CONCLUSIONS: Napabucasin is bioactivated by NQO1, and to a lesser degree by POR, resulting in futile redox cycling and ROS generation. The increased ROS levels result in DNA damage and multiple intracellular changes, one of which is a reduction in STAT3 phosphorylation.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-0302" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-0302</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Laparoscopic Distal Pancreatectomy for Left-Sided Pancreatic Cancer Using the Caudo-Dorsal Artery First Approach</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(13):4464-4465</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31502021" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31502021</a></p>
<p>BACKGROUND: Pancreatic cancer (PC) has serious malignant potential, thus requiring complete resection and adequate regional lymphadenectomy with tumor-free margins.1,2 A standard laparoscopic distal pancreatectomy (LDP) procedure for PC is not yet established due to lack of supportive evidence.3-6 METHODS: In our hospital, we first administered neoadjuvant chemoradiotherapy for resectable PC. Considering the benefits offered by a laparoscopic magnified caudo-dorsal view, we devised and standardized an LDP procedure for PC, which we employed in five patients with left-sided resectable tumors. First, the retroperitoneum was incised between the proximal jejunum and the inferior mesenteric vein with the transverse colon pushed up ventrally and cranially and with the proximal jejunum moved to the right. Then, the left renal vein (LRV) could be easily identified at this site. The retroperitoneal tissue was dissected along the LRV, and the origin of the superior mesenteric artery (SMA) also was identified just above the LRV easily. The left adrenal gland was removed to secure the dorsal margin, if needed. The retroperitoneal dissection was continued along the major anatomical landmarks, including the LRV, the left renal artery, the left kidney, and the crus of the diaphragm beside the origin of the SMA. Using the same operative field, lymphadenectomy around the SMA was performed before dividing the pancreas. We could safely and easily expose the left aspect of the SMA after dissecting the ligament of Treitz. The dissection around the SMA was performed toward the side of the arterial root that had already been exposed above the LRV. Thus, the most important difficult steps of LDP for PC, such as retroperitoneal dissection and lymphadenectomy around the SMA, were safely performed early in the operation with a good laparoscopic view. RESULTS: The median operative time was 341 (range 288-354) minutes, and median blood loss was 150 (range 50-150) ml. An intraoperative transfusion was not required for any patient. Severe postoperative complications or mortality were absent. An R0 resection was achieved in all patients. CONCLUSIONS: LDP using the caudo-dorsal artery first approach is safe and useful for performing a minimally invasive, curative resection for left-sided PC.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07789-8" class="uri">https://doi.org/10.1245/s10434-019-07789-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Loss of ATRX expression predicts worse prognosis in pulmonary carcinoid tumors</strong> </summary></p>
<p><em>Human pathology 2019 Dec;94():78-85</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31499081" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31499081</a></p>
<p>Loss of alpha thalassemia/mental retardation syndrome X-linked (ATRX), a chromatin regulator, is associated with worse prognosis in pancreatic neuroendocrine tumors. We investigated ATRX expression in pulmonary carcinoid tumors (PCT) and its diagnostic and prognostic role in these patients. Resected PCTs (1997-2017) were reviewed. Tumors were staged according to 8th UICC/AJCC system. ATRX nuclear expression was recorded independently by 2 reviewers. A cutoff of 5% of nuclear ATRX expression was statistically established as loss of expression. One-hundred-fifteen patients (72 women [63%]; median age of 60.5 years [interquartile range, 50.8-71.5]) harbored 69 (60%) typical and 46 (40%) atypical PCTs. Median tumor size was 2.3 cm (interquartile range, 1.6-3.8 cm). Loss of ATRX expression was associated with atypical PCTs (OR 7.4 [95% CI, 2.6-23, P&lt;.001]), when adjusted for lymphovascular invasion and perineural invasion. ATRX expression predicted atypical PCT with sensitivity of 37% (95% CI, 24%-52%), specificity of 92% (95% CI, 86%-98%), AUC of 0.62 (95% CI, 0.52-0.72). Loss of ATRX expression was associated with shorter disease-specific survival (HR=11, 95% CI, 1.8-68, P=.01), after adjusting for lymphovascular invasion and presence of metastatic disease at time of diagnosis. Interobserver agreement on ATRX expression by two reviewers was substantial (=0.72 [95% CI, 0.60-0.80]). ATRX expression is more commonly lost in atypical than in typical PCT, and is associated with more aggressive tumor characteristics and shorter disease-specific survival.</p>
<p>doi: <a href="https://doi.org/10.1016/j.humpath.2019.08.022" class="uri">https://doi.org/10.1016/j.humpath.2019.08.022</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Ca2+ Influx Channel Inhibitor SARAF Protects Mice From Acute Pancreatitis</strong> </summary></p>
<p><em>Gastroenterology 2019 12;157(6):1660-1672.e2</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31493399" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31493399</a></p>
<p>BACKGROUND &amp; AIMS: Pancreatitis is characterized by increased influx of Ca2+ into acinar cells, by unknown mechanisms. Inhibitors of Ca2+ influx channels could be effective in treating acute pancreatitis, but these have deleterious side effects that can result in death. We investigated the expression patterns and functions of acinar cell Ca2+ channels and factors that regulate them during development of acute pancreatitis, along with changes in the channel inactivator store-operated calcium entry-associated regulatory factor (SARAF). We investigated whether SARAF is a target for treatment of acute pancreatitis and its status in human with pancreatitis. METHODS: We generated mice that expressed SARAF tagged with hemagglutinin, using CRISPR/Cas9 gene editing, and isolated acinar cells. We also performed studies with Saraf-/- mice, Sarafzf/zf mice, mice without disruption of Saraf (control mice), and mice that overexpress fluorescently labeled SARAF in acinar cells. We analyzed interactions between stromal interaction molecule 1 (STIM1) and SARAF in HEK cells stimulated with carbachol using fluorescence resonance energy transfer microscopy and immunoprecipitation. Mice were given injections of caerulein or L-arginine to induce pancreatitis. Pancreatic tissues and blood samples were collected and levels of serum amylase, trypsin, tissue damage, inflammatory mediators, and inflammatory cells were measured. We performed quantitative polymerase chain reaction analyses of pancreatic tissues from 6 organ donors without pancreatic disease (controls) and 8 patients with alcohol-associated pancreatitis. RESULTS: Pancreatic levels of Ca2+ influx channels or STIM1 did not differ significantly between acinar cells from mice with vs.without pancreatitis. By contrast, pancreatic levels of Saraf messenger RNA and SARAF protein initially markedly increased but then decreased during cell stimulation or injection of mice with caerulein, resulting in excessive Ca2+ influx. STIM1 interacted stably with SARAF following stimulation of HEK or mouse acinar cells with physiologic levels of carbachol, but only transiently following stimulation with pathologic levels of carbachol, leading to excessive Ca2+ influx. We observed reduced levels of SARAF messenger RNA in pancreatic tissues from patients with pancreatitis, compared with controls. SARAF knockout mice developed more severe pancreatitis than control mice after administration of caerulein or L-arginine, and pancreatic acinar cells from these mice had significant increases in Ca2+ influx. Conversely, overexpression of SARAF in acini reduced Ca2+ influx, eliminated inflammation, and reduced severity of acute pancreatitis. CONCLUSIONS: In mice with pancreatitis, SARAF initially increases but is then degraded, resulting in excessive, pathological Ca2+ influx by acinar cells. SARAF knockout mice develop more severe pancreatitis than control mice, whereas mice that express SARAF from a transgene in acinar cells develop less-severe pancreatitis. SARAF therefore appears to prevent pancreatic damage during development of acute pancreatitis. Strategies to stabilize or restore SARAF to acinar cells might be developed for treatment of pancreatitis.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.08.042" class="uri">https://doi.org/10.1053/j.gastro.2019.08.042</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>MiR-194-5p in Pancreatic Ductal Adenocarcinoma Peritoneal Washings is Associated with Peritoneal Recurrence and Overall Survival in Peritoneal Cytology-Negative Patients</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(13):4506-4514</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31489551" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31489551</a></p>
<p>BACKGROUND: Peritoneal dissemination is one of the major recurrence patterns in patients with pancreatic ductal adenocarcinoma (PDAC) and is associated with poor prognosis. Here, we assessed the diagnostic potential of microRNA (miRNA) profiles in peritoneal washings for prediction of peritoneal dissemination in PDAC. PATIENTS AND METHODS: From January 2016 to July 2017, peritoneal washings were obtained prospectively from 59 patients with PDAC undergoing surgery the Yokohama City University Hospital. MiRNA expression was evaluated by Agilent human miRNA microarray and quantitative reverse-transcription polymerase chain reaction. RESULTS: Microarray analysis identified upregulated and downregulated miRNAs in peritoneal washings of patients with peritoneal dissemination. We validated four miRNAs (miR-141-3p, miR-194-3p, miR-194-5p, and miR-200c-3p) with high expression in peritoneal washings. The cumulative incidence rate of peritoneal recurrence in peritoneal cytology-negative patients in the miR-194-5p high group was significantly higher than that in the miR-194-5p low group (p=0.002). Univariate and multivariate analyses revealed that high miR-194-5p was associated with overall survival (OS). CONCLUSIONS: High expression of miR-194-5p in peritoneal washings is associated with peritoneal recurrence and poor OS in patients with peritoneal cytology-negative PDAC.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07793-y" class="uri">https://doi.org/10.1245/s10434-019-07793-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The differential distributions of ASPM isoforms and their roles in Wnt signaling, cell cycle progression, and pancreatic cancer prognosis</strong> </summary></p>
<p><em>The Journal of pathology 2019 Dec;249(4):498-508</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31465125" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31465125</a></p>
<p>Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and treatment-resistant malignancy. The lack of pathway-informed biomarkers hampers the development of rational diagnostics or therapies. Recently, the protein abnormal spindle-like microcephaly-associated (ASPM) was identified as a novel Wnt and stemness regulator in PDAC, while the pathogenic roles of its protein isoforms remain unclarified. We developed novel isoform-specific antibodies and genetic knockdown (KD) of putative ASPM isoforms, whereby we uncovered that the levels of ASPM isoform 1 (iI) and ASPM-iII are variably upregulated in PDAC cells. ASPM isoforms show remarkably different subcellular locations; specifically, ASPM-iI is exclusively localized to the cortical cytoplasm of PDAC cells, while ASPM-iII is predominantly expressed in cell nuclei. Mechanistically, ASPM-iI co-localizes with disheveled-2 and active -catenin as well as the stemness marker aldehyde dehydrogenase-1 (ALDH-1), and its expression is indispensable for the Wnt activity, stemness, and the tumorigenicity of PDAC cells. By contrast, ASPM-iII selectively regulates the expression level of cyclin E and cell cycle progression in PDAC cells. The expression of ASPM-iI and ASPM-iII displays considerable intratumoral heterogeneity in PDAC tissues and only that of ASPM-iI was prognostically significant; it outperformed ALDH-1 staining and clinico-pathological variables in a multivariant analysis. Collectively, the distinct expression patterns and biological functions of ASPM isoforms may illuminate novel molecular mechanisms and prognosticators in PDAC and may pave the way for the development of therapies targeting this novel oncoprotein.  2019 The Authors. The Journal of Pathology published by John Wiley &amp; Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.</p>
<p>doi: <a href="https://doi.org/10.1002/path.5341" class="uri">https://doi.org/10.1002/path.5341</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Deficits in the Palliative Care Process Measures in Patients with Advanced Pancreatic Cancer Undergoing Operative and Invasive Nonoperative Palliative Procedures</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(13):4204-4212</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31463695" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31463695</a></p>
<p>BACKGROUND: Given survival measured in months, metrics, such as 30-day mortality, are poorly suited to measure the quality of palliative procedures for patients with advanced cancer. Nationally endorsed process measures associated with high-quality PC include code-status clarification, goals-of-care discussions, palliative-care referral, and hospice assessment. The impact of the performance of these process measures on subsequent healthcare utilization is unknown. METHODS: Administrative data and manual review were used to identify hospital admissions with performance of palliative procedures for advanced pancreatic cancer at two tertiary care hospitals from 2011 to 2016. Natural language processing, a form of computer-assisted abstraction, identified process measures in associated free-text notes. Healthcare utilization was compared using a Cox proportional hazard model. RESULTS: We identified 823 hospital admissions with performance of a palliative procedure. PC process measures were identified in 68% of admissions. Patients with documented process measures were older (66 vs.63; p=0.04) and had a longer length of stay (9 vs.6days; p&lt;0.001). In multivariate analysis, patients treated by surgeons were less likely to have PC process measures performed (odds ratio 0.19; 95% confidence interval 0.10-0.37). Performance of PC process measures was associated with decreased healthcare utilization in a Cox proportional hazard model. CONCLUSIONS: PC process measures were not performed in almost one-third of hospital admissions for palliative procedures in patients with advanced pancreatic cancer. Performance of established high-quality process measures for seriously ill patients undergoing palliative procedures may help patients to avoid burdensome, high-intensity care at the end-of-life.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07757-2" class="uri">https://doi.org/10.1245/s10434-019-07757-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: Formalization of Robotic Central Pancreatectomy Focusing on the Reconstruction of Pancreatic Digestive Continuity</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(Suppl 3):707-708</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31463694" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31463694</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07774-1" class="uri">https://doi.org/10.1245/s10434-019-07774-1</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 and Promotes Tumorigenesis in Mice</strong> </summary></p>
<p><em>Gastroenterology 2019 12;157(6):1646-1659.e11</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31442435" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31442435</a></p>
<p>BACKGROUND &amp; AIMS: The histone lysine demethylase 3A (KDM3A) demethylates H3K9me1 and H3K9Me2 to increase gene transcription and is upregulated in tumors, including pancreatic tumors. We investigated its activities in pancreatic cancer cell lines and its regulation of the gene encoding doublecortin calmodulin-like kinase 1 (DCLK1), a marker of cancer stem cells. METHODS: We knocked down KDM3A in MiaPaCa-2 and S2-007 pancreatic cancer cell lines and overexpressed KDM3A in HPNE cells (human noncancerous pancreatic ductal cell line); we evaluated cell migration, invasion, and spheroid formation under hypoxic and normoxic conditions. Nude mice were given orthotopic injections of S2-007 cells, with or without (control) knockdown of KDM3A, and HPNE cells, with or without (control) overexpression of KDM3A; tumor growth was assessed. We analyzed pancreatic tumor tissues from mice and pancreatic cancer cell lines by immunohistochemistry and immunoblotting. We performed RNA-sequencing analysis of MiaPaCa-2 and S2-007 cells with knockdown of KDM3A and evaluated localization of DCLK1 and KDM3A by immunofluorescence. We analyzed the cancer genome atlas for levels of KDM3A and DCLK1 messenger RNA in human pancreatic ductal adenocarcinoma (PDAC) tissues and association with patient survival time. RESULTS: Levels of KDM3A were increased in human pancreatic tumor tissues and cell lines, compared with adjacent nontumor pancreatic tissues, such as islet and acinar cells. Knockdown of KDM3A in S2-007 cells significantly reduced colony formation, invasion, migration, and spheroid formation, compared with control cells, and slowed growth of orthotopic tumors in mice. We identified KDM3A-binding sites in the DCLK1 promoter; S2-007 cells with knockdown of KDM3A had reduced levels of DCLK1. HPNE cells that overexpressed KDM3A formed foci and spheres in culture and formed tumors and metastases in mice, whereas control HPNE cells did not. Hypoxia induced sphere formation and increased levels of KDM3A in S2-007 cells and in HPNE cells that overexpressed DCLK1, but not control HPNE cells. Levels of KDM3A and DCLK1 messenger RNA were higher in human PDAC than nontumor pancreatic tissues and correlated with shorter survival times of patients. CONCLUSIONS: We found human PDAC samples and pancreatic cancer cell lines to overexpress KDM3A. KDM3A increases expression of DCLK1, and levels of both proteins are increased in human PDAC samples. Knockdown of KDM3A in pancreatic cancer cell lines reduced their invasive and sphere-forming activities in culture and formation of orthotopic tumors in mice. Hypoxia increased expression of KDM3A in pancreatic cancer cells. Strategies to disrupt this pathway might be developed for treatment of pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.08.018" class="uri">https://doi.org/10.1053/j.gastro.2019.08.018</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(13):4498-4505</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31440928" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31440928</a></p>
<p>BACKGROUND: Neoadjuvant therapy reportedly shows only marginal clinical benefit in pancreatic ductal adenocarcinoma (PDAC), especially in resectable cases. However, with more effective regimens, neoadjuvant therapy may become a standard of care for resectable cases. A prospective, open-label, multicenter phases 1 and 2 trial of neoadjuvant therapy was conducted using full-dose gemcitabine and S-1 concurrently with 50.4Gy of radiation therapy (GSRT) for resectable PDAC. This report describes the phase 2 results. METHODS: The phase 2 part of this study enrolled 57 patients with cytologically or histologically proven PDAC deemed resectable based on imaging before neoadjuvant therapy. These patients received GSRT. After reevaluation by computed tomography scan, surgical exploration was performed, followed by adjuvant therapy. According to the prescribed protocol of the clinical trial, statistical analyses included 57 phase 2 patients and 6 phase 1 patients who received the same dosage as in phase 2. RESULTS: This trial enrolled 63 patients (42 men and 21 women) with a median age of 70years. Leukopenia or neutropenia of grade 3 or higher occurred for 79% of the patients, but no other severe adverse events were observed. Among the 63 patients, 54 underwent surgical resection. Intention-to-treat analysis of the 63 patients showed an excellent median survival time lasting as long as 55.3months. The patients who completed neoadjuvant therapy, surgery, and adjuvant therapy had a 5-year survival rate of 56.6%. CONCLUSIONS: This regimen showed outstanding clinical efficacy with acceptable tolerability for patients with resectable PDAC.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07735-8" class="uri">https://doi.org/10.1245/s10434-019-07735-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: Lymph Node Metastasis and the Role for Lymphadenectomy During Surgery for Nonfunctional Pancreatic Neuroendocrine Tumors</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(Suppl 3):700-701</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31440924" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31440924</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07746-5" class="uri">https://doi.org/10.1245/s10434-019-07746-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Editorial About: A Prospective, Open-Label, Multicenter Phase II Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(13):4175-4177</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31440923" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31440923</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07737-6" class="uri">https://doi.org/10.1245/s10434-019-07737-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Dec;25(23):6939-6947</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31439583" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31439583</a></p>
<p>PURPOSE: Radiolabeled somatostatin receptor 2 (SSTR2) antagonists have shown higher tumor uptake and tumor-to-organ ratios than somatostatin agonists in preclinical models of neuroendocrine tumors (NETs). We performed a phase I study to evaluate the safety and efficacy of SSTR2 antagonist 177Lu-satoreotide tetraxetan. PATIENTS AND METHODS: Twenty patients with advanced SSTR2-positive NETs were treated with 177Lu-satoreotide tetraxetan. Patients first underwent a dosimetry study with 177Lu-satoreotide tetraxetan to determine the therapeutic activity that could be safely administered. This activity was split into two equal cycles to be delivered 3 months apart. The maximum activity was 7.4 GBq per cycle. RESULTS: Of 20 patients with NETs (one lung, seven small bowel, nine pancreatic, one gastric, one rectal, one kidney; mean prior treatments: three), six received one cycle of 177Lu- satoreotide tetraxetan and 14 received two cycles. Hematologic toxicity after cycle 1 was mild-moderate and reversed before cycle 2. However, grade 4 hematologic toxicity occurred in four of seven (57%) patients after cycle 2 of 177Lu-satoreotide tetraxetan. The study was suspended, and the protocol modified to limit the cumulative absorbed bone marrow dose to 1 Gy and to reduce prescribed activity for cycle 2 by 50%. The best overall response rate was 45% [5% complete response (1/20), 40% partial response (8/20)]; with 40% stable disease (8/20) and 15% progression of disease (3/20). Median progression-free survival (PFS) was 21.0 months (95% CI, 13.6-NR). CONCLUSIONS: In this trial of heavily treated NETs, preliminary data are promising for the use of 177Lu-satoreotide tetraxetan. Additional studies are ongoing to determine optimal therapeutic dose/schedule.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-1026" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-1026</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: Resection for Metastasis to the Pancreas-Worthwhile for Selected Patients</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(Suppl 3):696-697</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31429018" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31429018</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07621-3" class="uri">https://doi.org/10.1245/s10434-019-07621-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Perioperative Gemcitabine+Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(13):4489-4497</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31418130" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31418130</a></p>
<p>BACKGROUND: There is considerable interest in a neoadjuvant approach for resectable pancreatic ductal adenocarcinoma (PDAC). This study evaluated perioperative gemcitabine+erlotinib (G+E) for resectable PDAC. METHODS: A multicenter, cooperative group, single-arm, phase II trial was conducted between April 2009 and November 2013 (ACOSOG Z5041). Patients with biopsy-confirmed PDAC in the pancreatic head without evidence of involvement of major mesenteric vessels (resectable) were eligible. Patients (n=123) received an 8-week cycle of G+E before and after surgery. The primary endpoint was 2-year overall survival (OS), and secondary endpoints included toxicity, response, resection rate, and time to progression. Resectability was assessed retrospectively by central review. The study closed early due to slow accrual, and no formal hypothesis testing was performed. RESULTS: Overall, 114 patients were eligible, consented, and initiated protocol treatment. By central radiologic review, 97 (85%) of the 114 patients met the protocol-defined resectability criteria. Grade 3+ toxicity was reported in 60% and 79% of patients during the neoadjuvant phase and overall, respectively. Twenty-two of 114 (19%) patients did not proceed to surgery; 83 patients (73%) were successfully resected. R0 and R1 margins were obtained in 67 (81%) and 16 (19%) resected patients, respectively, and 54 patients completed postoperative G+E (65%). The 2-year OS rate for the entire cohort (n=114) was 40% (95% confidence interval [CI] 31-50), with a median OS of 21.3 months (95% CI 17.2-25.9). The2-year OS rate for resected patients (n=83) was 52% (95% CI 41-63), with a median OS of 25.4 months (95% CI 21.8-29.6). CONCLUSIONS: For resectable PDAC, perioperative G+E is feasible. Further evaluation of neoadjuvant strategies in resectable PDAC is warranted with more active systemic regimens.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07685-1" class="uri">https://doi.org/10.1245/s10434-019-07685-1</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia</strong> </summary></p>
<p><em>Cancer 2019 Dec;125(23):4294-4302</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31415709" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31415709</a></p>
<p>BACKGROUND: Cancer cachexia is characterized by weight loss and is associated with increased morbidity and mortality in patients with cancer. Anamorelin (ONO-7643; ANAM) is a novel and selective ghrelin receptor agonist that improves appetite, lean body mass (LBM), body weight, and anorexia. METHODS: This multicenter, open-label, single-arm study investigated the efficacy and safety of 100mg anamorelin in 50 Japanese patients with advanced and unresectable gastrointestinal (colorectal, gastric, or pancreatic) cancer. ANAM was administered once daily over 12weeks. The primary endpoint was the proportion of patients that maintained or gained LBM over the course of the study. Secondary endpoints included changes in LBM, body weight, quality of life (QoL), and nutritional status biomarkers. RESULTS: The proportion of patients who responded to treatment was 63.3% (95% CI, 48.3%-76.6%), with a least square meanSE change in LBM and body weight from baseline of 1.890.36kg and 1.410.61kg, respectively. Appetite-related questions on the QoL questionnaire showed that ANAM improved appetite. Adverse events occurred in 79.6% of patients, and the most common treatment-related adverse events were increased -glutamyl transpeptidase (8.2%), diabetes mellitus (6.1%), hyperglycemia (6.1%), and prolonged QRS complex (6.1%). CONCLUSIONS: ANAM improved anorexia and patients nutritional status, resulting in rapid increases in LBM and body weight in patients with advanced gastrointestinal cancer who had cancer cachexia. ANAM treatment was well tolerated over 12weeks. ANAM is a potential clinically beneficial pharmacotherapeutic option for patients with advanced gastrointestinal cancer who have cancer cachexia.</p>
<p>doi: <a href="https://doi.org/10.1002/cncr.32406" class="uri">https://doi.org/10.1002/cncr.32406</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Rosai-Dorfman Disease of the Digestive System-Beware Vasculopathy: A Clinicopathologic Analysis</strong> </summary></p>
<p><em>The American journal of surgical pathology 2019 Dec;43(12):1644-1652</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31414989" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31414989</a></p>
<p>Rosai-Dorfman disease (RDD) is a rare non-Langerhans cell histiocytic proliferation that occurs in nodal and extranodal sites. Rare examples of the disease involving the digestive system have been described. To characterize the digestive tract manifestations of this disease, 12 specimens from 11 patients with extranodal RDD affecting the digestive organs were analyzed. Hematoxylin and eosin sections and available immunohistochemical stains were reviewed, and the clinical information was obtained from patients electronic or submitted records. Eight patients were female and 3 male (median age, 65y; range, 17 to 76y). Abdominal pain was the most frequent symptom. Six patients had an associated immunologic or malignant disease. Nine lesions arose in the gastrointestinal tract (1 involving the appendix, 2 right colon, 6 left colon), 2 in the pancreas, and 1 in the liver. Two patients had the coexistent nodal disease, and 1 had bone and soft-tissue involvement. The lesions were generally composed of polygonal to spindle-shaped histiocytes with eosinophilic to clear cytoplasm admixed with lymphoplasmacytic cells. The inflammatory cells formed lymphoid aggregates in 7 cases and included focally scattered or small collections of neutrophils in 6 cases. Fibrosis was variable, and 4 cases had a storiform pattern. Vasculopathy in the form of a thickened capillary wall, medium-sized arterial wall infiltration by lesional and inflammatory cells and phlebitis was seen in 10, 5, and 2 cases, respectively. All cases were reactive for S100-protein. Of the 5 patients with follow-up, 1 developed immunoglobulin A nephropathy and died of renal failure.</p>
<p>doi: <a href="https://doi.org/10.1097/PAS.0000000000001343" class="uri">https://doi.org/10.1097/PAS.0000000000001343</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Lipid droplet velocity is a microenvironmental sensor of aggressive tumors regulated by V-ATPase and PEDF</strong> </summary></p>
<p><em>Laboratory investigation; a journal of technical methods and pathology 2019 Dec;99(12):1822-1834</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31409893" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31409893</a></p>
<p>Lipid droplets (LDs) utilize microtubules (MTs) to participate in intracellular trafficking of cargo proteins. Cancer cells accumulate LDs and acidify their tumor microenvironment (TME) by increasing the proton pump V-ATPase. However, it is not known whether these two metabolic changes are mechanistically related or influence LD movement. We postulated that LD density and velocity are progressively increased with tumor aggressiveness and are dependent on V-ATPase and the lipolysis regulator pigment epithelium-derived factor (PEDF). LD density was assessed in human prostate cancer (PCa) specimens across Gleason scores (GS) 6-8. LD distribution and velocity were analyzed in low and highly aggressive tumors using live-cell imaging and in cells exposed to low pH and/or treated with V-ATPase inhibitors. The MT network was disrupted and analyzed by -tubulin staining. LD density positively correlated with advancing GS in human tumors. Acidification promoted peripheral localization and clustering of LDs. Highly aggressive prostate, breast, and pancreatic cell lines had significantly higher maximum LD velocity (LDVmax) than less aggressive and benign cells. LDVmax was MT-dependent and suppressed by blocking V-ATPase directly or indirectly with PEDF. Upon lowering pH, LDs moved to thecell periphery and carried metalloproteinases. These results suggest that acidification of the TME can alter intracellular LD movement and augment velocity in cancer. Restoration of PEDF or blockade of V-ATPase can normalize LD distribution and decrease velocity. This study identifies V-ATPase and PEDF as new modulators of LD trafficking in the cancer microenvironment.</p>
<p>doi: <a href="https://doi.org/10.1038/s41374-019-0296-8" class="uri">https://doi.org/10.1038/s41374-019-0296-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Dissecting the presence of malignant squamous cells in pancreatic cytopathology: A case series</strong> </summary></p>
<p><em>Diagnostic cytopathology 2019 Dec;47(12):1287-1292</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31407529" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31407529</a></p>
<p>The presence of malignant squamous cells in pancreatic cytopathology is a rare phenomenon that results either from a primary or a metastatic process. Pancreatic adenosquamous carcinoma (PASC) represents the most common variant of pancreatic ductal adenocarcinoma and is associated with a dismal prognosis. Within the period of 2013-2018, the archives of Hygeia and Mitera Hospital were searched for pancreatic cytopathology-related diagnoses that included the interpretation of malignant squamous cells present. All fine needle aspirations (FNAs) of pancreatic lesions, including liver metastases in patients with known pancreatic primaries, were retrieved along with their relevant clinical information. Five pancreatic and two liver FNAs acquired from a total of six patients were reexamined. None of these patients had any documented history of primary squamous malignancy elsewhere. All pancreatic and one of the two liver FNAs showed malignant squamous cells, identified based on either morphology or immunochemistry. The other liver FNA represented a metastatic deposit which comprised of only a glandular component, whereas the associated pancreatic FNA exhibited both squamous and glandular counterparts. Most cases characteristically showed necrosis and keratinization. Of interest, two cases revealed the presence of tumor-associated giant cells. In conclusion, the presence of malignant squamous cells in pancreatic FNAs could mean the presence of PASC, especially when there is no documented history of a primary malignancy and a complete clinical and imaging workup has been performed. Immunochemistry on cell block material could help to confirm squamous differentiation in the absence of overt keratinization.</p>
<p>doi: <a href="https://doi.org/10.1002/dc.24302" class="uri">https://doi.org/10.1002/dc.24302</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comment on Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer</strong> </summary></p>
<p><em>Annals of surgery 2019 Dec;270(6):e138-e139</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31356282" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31356282</a></p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003422" class="uri">https://doi.org/10.1097/SLA.0000000000003422</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Acinar cell carcinoma of the pancreas with thyroid-like follicular features: first description of a new diagnostic challenging subtype</strong> </summary></p>
<p><em>Virchows Archiv : an international journal of pathology 2019 Dec;475(6):789-794</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31338587" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31338587</a></p>
<p>Acinar cell carcinomas (ACCs) of the pancreas are a heterogeneous group of neoplasms showing a wide spectrum of morphological features including acinar, solid, glandular, and trabecular architecture. In addition, uncommon cytological aspects have recently been described and include oncocytic, spindle, clear, and pleomorphic cell types. This wide histological spectrum represents a challenge in the diagnostic task for pathologists. Molecular mechanisms involved in the onset and progression of ACCs are not completely known, but, in general, they differ from those observed in ductal adenocarcinomas or neuroendocrine neoplasms of the pancreas and frequently include alterations in the APC/-catenin pathway. In the present paper, we describe a new variant of ACC showing thyroid-like follicular features and CTNNB1 mutation. This phenotype needs to be included in the spectrum of morphological presentation of ACC.</p>
<p>doi: <a href="https://doi.org/10.1007/s00428-019-02628-3" class="uri">https://doi.org/10.1007/s00428-019-02628-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Clonal evolution of chronic lymphocytic leukemia to Langerhans cell histiocytosis: a case report</strong> </summary></p>
<p><em>Virchows Archiv : an international journal of pathology 2019 Dec;475(6):795-798</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31317311" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31317311</a></p>
<p>The traditional concept of unidirectional maturation of hematopoietic cells has been called into question due to the recognition of lineage plasticity, which is increasingly found also in the clonal evolution of hematopoietic and lymphoid malignancies. Here we present an unusual case of a patient with TP53-mutated chronic lymphocytic leukemia (CLL) treated with a PI3K inhibitor evolving to clonally related Langerhans cell histiocytosis (LCH) with acquired BRAF V600E and STK11 mutations and loss of expression of PAX-5 and other examined B cell markers. In indolent B cell lymphoma, transformation to a more aggressive high-grade lymphoma occurs frequently during the course of disease and is thought to be caused by clonal evolution. Our case further supports the concept of significant lineage plasticity in lymphomas and raises the question of a potential role of novel pharmacologic agents in clonal evolution.</p>
<p>doi: <a href="https://doi.org/10.1007/s00428-019-02608-7" class="uri">https://doi.org/10.1007/s00428-019-02608-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Histomorphology of pancreatic cancer in patients with inherited ATM serine/threonine kinase pathogenic variants</strong> </summary></p>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019 Dec;32(12):1806-1813</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31285527" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31285527</a></p>
<p>Germline pathogenic variants in the ATM serine/threonine kinase (ATM) gene are associated with an increased risk of pancreatic ductal adenocarcinoma. It is important to identify germline ATM pathogenic variants in pancreatic cancer patients because these alterations are potentially targetable with chemotherapeutic drugs and/or radiation and have implications for other family members. As germline pathogenic variants in other genes have been associated with distinct histologic subtypes of pancreatic cancer, we studied the histomorphology of pancreatic cancer in 23 patients with germline ATM pathogenic variants. The histologic subtype was ductal adenocarcinoma in 19/23 (83%) of the patients, adenosquamous carcinoma in 1/23 (4%), and colloid (mucinous non-cystic) carcinoma in 3/23 (13%). The percentage of colloid (mucinous non-cystic) carcinomas is higher than we have previously observed in patients with familial and sporadic pancreatic cancer (1 and 2% in prior reports, p&lt;0.01 and p&lt;0.01, respectively). Three carcinomas (2 colloid carcinomas, 1 ductal adenocarcinoma) arose in association with intraductal papillary mucinous neoplasms. Among the resected pancreata, non-invasive precursor lesions, including pancreatic intraepithelial neoplasia and incipient intraductal papillary mucinous neoplasms, were identified in 83%. We conclude that pancreatic cancers in patients with germline ATM pathogenic variants are more frequently of colloid (mucinous non-cystic) morphology but are overall morphologically diverse supporting the utility of universal germline genetic testing for patients with pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-019-0317-6" class="uri">https://doi.org/10.1038/s41379-019-0317-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comment on Main Duct Dilatation Is the Best Predictor of High-grade Dysplasia or Invasion in Intraductal Papillary Mucinous Neoplasms of the Pancreas</strong> </summary></p>
<p><em>Annals of surgery 2019 Dec;270(6):e108-e109</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31232787" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31232787</a></p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003260" class="uri">https://doi.org/10.1097/SLA.0000000000003260</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: Optimal Technical Management of Pancreatic Transection During Distal Pancreatectomy</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(Suppl 3):643-644</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31222682" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31222682</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07486-6" class="uri">https://doi.org/10.1245/s10434-019-07486-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comment on The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Annals of surgery 2019 Dec;270(6):e129-e130</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31188217" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31188217</a></p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003372" class="uri">https://doi.org/10.1097/SLA.0000000000003372</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Response to Comment on The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma by Niccolo Petrucciani, MD, PhD, FACS, Laura Antolino, MD, Giovanni Moschetta, MD, Giovanni Ramacciato, MD, FACS</strong> </summary></p>
<p><em>Annals of surgery 2019 Dec;270(6):e130-e131</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31090562" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31090562</a></p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003371" class="uri">https://doi.org/10.1097/SLA.0000000000003371</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: Irreversible Electroporation for Locally Advanced Pancreatic Cancer</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(Suppl 3):610-611</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31087182" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31087182</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07436-2" class="uri">https://doi.org/10.1245/s10434-019-07436-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: Dissecting the Risk and Impact of Venous Thromboembolism During Neoadjuvant Treatment and the Subsequent Perioperative Period for Patients With Pancreatic Adenocarcinoma</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(Suppl 3):590-591</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31016487" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31016487</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07396-7" class="uri">https://doi.org/10.1245/s10434-019-07396-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Enrichment of oral microbiota in early cystic precursors to invasive pancreatic cancer</strong> </summary></p>
<p><em>Gut 2019 12;68(12):2186-2194</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30872392" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30872392</a></p>
<p>OBJECTIVES: Intraductal papillary mucinous neoplasms (IPMNs) are pancreatic cysts that can progress to invasive pancreatic cancer. Associations between oncogenesis and oral microbiome alterations have been reported. This study aims to investigate a potential intracystic pancreatic microbiome in a pancreatic cystic neoplasm (PCN) surgery patient cohort. DESIGN: Paired cyst fluid and plasma were collected at pancreatic surgery from patients with suspected PCN (n=105). Quantitative and qualitative assessment of bacterial DNA by qPCR, PacBio sequencing (n=35), and interleukin (IL)-1 quantification was performed. The data were correlated to diagnosis, lesion severity and clinical and laboratory profile, including proton-pump inhibitor (PPI) usage and history of invasive endoscopy procedures. RESULTS: Intracystic bacterial 16S DNA copy number and IL-1 protein quantity were significantly higher in IPMN with high-grade dysplasia and IPMN with cancer compared with non-IPMN PCNs. Despite high interpersonal variation of intracystic microbiota composition, bacterial network and linear discriminant analysis effect size analyses demonstrated co-occurrence and enrichment of oral bacterial taxa including Fusobacterium nucleatum and Granulicatella adiacens in cyst fluid from IPMN with high-grade dysplasia. The elevated intracystic bacterial DNA is associated with, but not limited to, prior exposure to invasive endoscopic procedures, and is independent from use of PPI and antibiotics. CONCLUSIONS: Collectively, these findings warrant further investigation into the role of oral bacteria in cystic precursors to pancreatic cancer and have added values on the aetiopathology as well as the management of pancreatic cysts.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2018-317458" class="uri">https://doi.org/10.1136/gutjnl-2018-317458</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: Temporary Mesocaval Shunt: Indications and Technique for Safe Resection of Pancreatic Tumors With Mesenteric Venous Occlusion</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(Suppl 3):579-580</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30859352" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30859352</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07290-2" class="uri">https://doi.org/10.1245/s10434-019-07290-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer</strong> </summary></p>
<p><em>Medical molecular morphology 2019 Dec;52(4):198-208</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30805710" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30805710</a></p>
<p>Cancer cells surviving in ascites exhibit cancer stem cell (CSC)-like features. This study analyzed the expression of the CSC marker CD133 in the ascites-derived exosomes obtained from patients with unresectable pancreatic cancer. In addition, inverse correlation of CD133 expression with prognosis was examined. Of the 133 consecutive patients, 19 patients were enrolled in the study. Exosomes derived from the malignant ascites demonstrated higher density and wider variation in size than those from non-malignant ascites. Western blot revealed enhanced expression of CD133 in exosomes obtained from patients with pancreatic cancer compared to those obtained from patients with gastric cancer or liver cirrhosis. A xenograft mouse model with malignant ascites was established by intraperitoneal inoculation of human pancreatic cancer cells in nude mice. Results obtained from the human study were reproduced in the mouse model. Statistically significant equilateral correlation was identified between the band intensity of CD133 in western blot and overall survival of patients. Lectin microarray analyses revealed glycosylation of CD133 by sialic acids as the major glycosylation among diverse others responsible for the glycosylation of exosomal CD133. These findings suggest that highly glycosylated CD133 in ascites-derived exosomes as a potential biomarker for better prognosis of patients with advanced pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1007/s00795-019-00218-5" class="uri">https://doi.org/10.1007/s00795-019-00218-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: Tumor-Infiltrating NETs are New Biomarkers to Predict Postsurgical Survival for Patients with Pancreatic Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(Suppl 3):571-572</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30710182" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30710182</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07169-2" class="uri">https://doi.org/10.1245/s10434-019-07169-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: Role of SOX9 Transcription Factor in Pancreatic Neoplasms</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(Suppl 3):567-568</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30680476" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30680476</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07154-9" class="uri">https://doi.org/10.1245/s10434-019-07154-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: Pancreatic Neuroendocrine Tumor Recurrence and Survival Predicted by Ki67</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(Suppl 3):531-532</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30519760" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30519760</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-018-7019-z" class="uri">https://doi.org/10.1245/s10434-018-7019-z</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Lumen-apposing metal stent acted as an interim role in walled-off necrosis drainage</strong> </summary></p>
<p><em>Gut 2019 12;68(12):2255-2256</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30368455" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30368455</a></p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2018-317494" class="uri">https://doi.org/10.1136/gutjnl-2018-317494</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comparing Short-term and Oncologic Outcomes of Minimally Invasive Versus Open Pancreaticoduodenectomy Across Low and High Volume Centers</strong> </summary></p>
<p><em>Annals of surgery 2019 Dec;270(6):1147-1155</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=29771723" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=29771723</a></p>
<p>OBJECTIVE: To compare short-term and oncologic outcomes of patients with cancer who underwent open pancreaticoduodenectomy (OPD) versus minimally invasive pancreaticoduodenectomy (MIPD) using the National Cancer Database. SUMMARY BACKGROUND DATA: MIPD, including laparoscopic and robotic approaches, has continued to gain acceptance despite prior reports of increased short-term mortality when compared with OPD. METHODS: Patients with pancreatic cancer diagnosed from 2010 to 2015 undergoing curative intent resection were selected from the National Cancer Database. Patients submitted to OPD were compared with those submitted to MIPD. Laparoscopic and robotic approaches were included in the MIPD cohort. The primary outcome was 90-day mortality; secondary outcomes included 30-day mortality, hospital length of stay, unplanned 30-day readmission, surgical margins, number of lymph nodes harvested, and receipt of adjuvant chemotherapy. Propensity score-weighted random effects logistic regression models were used to examine the adjusted association between surgical approach and the specified outcomes. RESULTS: Between 2010 and 2015, 22,013 patients underwent OPD or MIPD for pancreatic cancer and 3754 (17.1%) were performed minimally invasively. On multivariable analysis, there was no difference in 90-day mortality between MIPD and OPD (OR, 0.92; 95% CI, 0.75-1.14). Patients undergoing MIPD were less likely to stay in the hospital for a prolonged time (OR, 0.75; 95% CI, 0.68-0.82). 30-day mortality, unplanned readmissions, margins, lymph nodes harvested, and receipt of adjuvant chemotherapy were equivalent between groups. Regardless of surgical approach, patients operated on at high volume centers had reduced 90-day mortality. CONCLUSION: Patients selected to receive MIPD for cancer have equivalent short-term and oncologic outcomes, when compared with patients who undergo OPD.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000002810" class="uri">https://doi.org/10.1097/SLA.0000000000002810</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Number of Examined Lymph Nodes and Nodal Status Assessment in Distal Pancreatectomy for Body/Tail Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Annals of surgery 2019 Dec;270(6):1138-1146</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=29672406" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=29672406</a></p>
<p>OBJECTIVE: First, to assess the impact of the number of examined lymph nodes (ELNs) on staging and survival after distal pancreatectomy (DP) for pancreatic adenocarcinoma (PDAC). Second, to identify the minimum number of ELNs (MNELNs) ensuring an accurate detection of nodal involvement. Third, to reappraise the role of lymph node (LN) parameters, including N-status and lymph node ratio (LNR). BACKGROUND: In contrast with pancreatoduodenectomy, information on LN staging and the MNELN required in DP is lacking. METHODS: Patients undergoing DP for PDAC at 2 academic hospitals from 2000 through 2013 were retrospectively analyzed. The eighth edition of the American Joint Committee on Cancer staging system was used. The MNELN was estimated using the binomial probability law. Survival analyses were performed separately for node-negative and node-positive patients using univariable and multivariable models. RESULTS: The study population consisted of 240 patients. The median number of ELN was 21, significantly lower in node-negative patients as compared with node-positive patients (18.5 vs 24.0; P = 0.001). The proportion of node-positive patients increased with increasing numbers of ELNs, whereas LNR showed an inverse trend. The estimated MNELN was 20. The number of ELN ( or &lt;20) was an independent prognostic factor only in node-negative patients [odds ratio (OR) 3.23 for ELN &lt;20), suggesting a stage migration effect. In node-positive patients, N2-class, but not LNR, was a significant predictor of survival at multivariable analysis (OR 1.68). CONCLUSION: The number of ELN affects nodal staging in body/tail PDAC. At least 20 LNs are required for correct staging. N-status is superior to LNR in predicting survival of node-positive patients.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000002781" class="uri">https://doi.org/10.1097/SLA.0000000000002781</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Characterization of 22 Canine Pancreatic Carcinomas and Review of Literature</strong> </summary></p>
<p><em>Journal of comparative pathology 2019 Nov;173():71-82</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31812175" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31812175</a></p>
<p>Pancreatic carcinomas are rare in dogs and clinical signs are mostly non-specific. The literature on clinically and pathologically characterized canine exocrine pancreatic tumours is limited to 76 cases reported since 1963. This retrospective study analysed formalin-fixed samples of pancreatic carcinomas from 22 dogs, obtained during elective exploratory surgery (n=16) or if the dog was humanely destroyed (n=6). Tumours were diagnosed according to the World Health Organization classification of tumours of the pancreas of domestic animals. In seven cases, blood samples taken during or shortly before surgery were analysed for concentrations of alpha-amylase, 1,2-o-dilauryl-rac-glycero-3-glutaric acid-(6-methylresorufin) ester lipase (DGGR lipase), C-reactive protein (CRP), alanine aminotransferase, glutamate dehydrogenase, alkaline phosphatase (ALP), canine trypsin-like immunoreactivity (cTLI) and canine pancreatic lipase immunoreactivity (cPLI). Neutrophil and lymphocyte numbers were determined as part of a complete blood count. Clinical signs were non-specific and included vomiting, inappetence and diarrhoea. Acinar carcinomas were most common (19/22) and observed growth patterns included: solid (n=14), acinar (n=5), clear cell (n=3), mucinous (n=2), trabecular (n=1) or rosette-like (n=1), occurring as a single pattern or in combination. Ductal carcinomas were identified in three cases. Pancreatitis was a common additional histological finding; five dogs had mild and nine dogs had severe pancreatitis. cPLI, DGGR lipase, cTLI and CRP were elevated in 5/5 acinar carcinomas. All liver enzymes were elevated in three of these five animals and ALP was increased in 4/5 dogs. Two dogs with ductal pancreatic carcinomas showed normal cPLI concentrations. One had increased CRP, liver enzymes and leucocytosis with neutrophilia, the other had elevated DGGR lipase and cTLI concentrations. Clinical findings in canine pancreatic carcinomas were non-specific and simultaneous inflammation can mask the detection of the underlying neoplasm in clinical examination and laboratory testing.</p>
<p>doi: <a href="https://doi.org/10.1016/j.jcpa.2019.10.008" class="uri">https://doi.org/10.1016/j.jcpa.2019.10.008</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Relationship between SDC1 and cadherin signalling activation in cancer</strong> </summary></p>
<p><em>Pathology, research and practice 2019 Nov;():152756</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31810587" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31810587</a></p>
<p>E-cadherin and SDC1 are markers of epithelial-to-mesenchymal transition (EMT) that can be used to assess tumour prognosis. SDC1 has different effects in various types of cancers. On the one hand, reduced expression of SDC1 can leads to advantage stages of some cancers, such as gastric and colorectal cancer. On the other hand, SDC1 overexpression can also promote the growth and proliferation of cancer cells in pancreatic and breast cancer. However, the function of SDC1 is influenced and regulated by many factors. Exfoliated extracellular domain HS chain can mediate the function of SDC1 and play an important role in the occurrence and development of cancer. SDC1 binds to various ligands and influences the growth and reproduction of cancer cells via the activation of Wnt, the long isoform of FLICE-inhibitory protein (FLIP long), vascular endothelial growth factor receptor (VEGFR), mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) and MAPK/c-Jun N-terminal kinase (JNK) and other pathways. Cadherins occur in several types, but this review focuses on classical cadherins. N-cadherin and P-cadherin are activated during tumour development, whereas E-cadherin is a tumour suppressor. The cellular signalling pathways involved in classical cadherins, such as Wnt and VEGFR pathways, are also related to SDC1. The activation of E-cadherin caused by SDC1 knockdown has also been observed. Despite this evidence, no articles regarding the relationship of SDC1 and cadherin activation have been published. This review summarises the expressions of these two molecules in different cancers and analyses their possible relationship to provide insights into future cancer research and clinical treatment.</p>
<p>doi: <a href="https://doi.org/10.1016/j.prp.2019.152756" class="uri">https://doi.org/10.1016/j.prp.2019.152756</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Is There a Role for Liver Transplantation in the Treatment of Patients With Metastatic Colorectal Cancer?</strong> </summary></p>
<p><em>Annals of surgery 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31804393" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31804393</a></p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003713" class="uri">https://doi.org/10.1097/SLA.0000000000003713</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial</strong> </summary></p>
<p><em>Gut 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31801872" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31801872</a></p>
<p>OBJECTIVE: This trial compared the efficacy and safety of transarterial chemoembolisation (TACE) plus sorafenib with TACE alone using a newly established TACE-specific endpoint and pre-treatment of sorafenib before initial TACE. DESIGN: Patients with unresectable hepatocellular carcinoma (HCC) were randomised to TACE plus sorafenib (n=80) or TACE alone (n=76). Patients in the combination group received sorafenib 400mg once daily for 2-3 weeks before TACE, followed by 800mg once daily during on-demand conventional TACE sessions until time to untreatable (unTACEable) progression (TTUP), defined as untreatable tumour progression, transient deterioration to Child-Pugh C or appearance of vascular invasion/extrahepatic spread. Co-primary endpoints were progression-free survival (PFS), which is not a conventional one but defined as TTUP, or time to any cause of death plus overall survival (OS). Multiplicity was adjusted by gatekeeping hierarchical testing. RESULTS: Median PFS was significantly longer in the TACE plus sorafenib than in the TACE alone group (25.2 vs 13.5 months; p=0.006). OS was not analysed because only 73.6% of OS events were reached. Median TTUP (26.7 vs 20.6 months; p=0.02) was also significantly longer in the TACE plus sorafenib group. OS at 1 year and 2years in TACE plus sorafenib group and TACE alone group were 96.2% and 82.7% and 77.2% and 64.6%, respectively. There were no unexpected toxicities. CONCLUSION: TACE plus sorafenib significantly improved PFS over TACE alone in patients with unresectable HCC. Adverse events were consistent with those of previous TACE combination trials. TRIAL REGISTRATION NUMBER: NCT01217034.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2019-318934" class="uri">https://doi.org/10.1136/gutjnl-2019-318934</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comment on Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy Versus Portal Vein Embolization for Hepatitis-related Hepatocellular Carcinoma. A Changing Paradigm in Modulation of Future Liver Remnant Before Major Hepatectomy by A. Chan, et al: Adapt the Means to the Objectives Not the Other Way Round</strong> </summary></p>
<p><em>Annals of surgery 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31800494" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31800494</a></p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003687" class="uri">https://doi.org/10.1097/SLA.0000000000003687</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A clinically feasible method for the assessment and characterization of pain in patients with chronic pancreatitis</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31787527" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31787527</a></p>
<p>BACKGROUND AND AIMS: Pain is the primary symptom of chronic pancreatitis (CP), but methods for sensory testing and pain characterization have not previously been validated for clinical use. We present a clinically feasible method for the assessment and characterization of pain mechanisms in patients with CP based on quantitative sensory testing (QST). METHODS: This was a cross-sectional, multicenter study of 122 control subjects without pancreatic disease and another 60 patients with painful CP. All subjects underwent standardized QST assessments including a cold pressor test, a conditioned pain modulation paradigm, repetitive pin-prick stimuli (temporal summation) and pressure stimulation of the upper abdominal (pancreatic) and control dermatomes. The effects of age and gender on QST assessment parameters were investigated and normative reference values based on quartile regression were derived and implemented in algorithms to categorize patients according to their patterns of central pain processing (normal vs.segmental sensitization vs.widespread sensitization). RESULTS: Absolute pressure thresholds were subject to clinically relevant gender effects (all p&lt;0.001), while the remainder of QST parameters were unaffected by age and gender. The algorithm with the best discriminatory capacity showed good separation between patients and controls (p&lt;0.001); 50% of patients had normal central pain processing, 23% had evidence of segmental sensitization and 27% had evidence of widespread sensitization. CONCLUSION: We show normative reference values for a clinically feasible method for assessment and characterization of pain mechanisms in patients with CP. Application of this method streamlines the evaluation of pancreatic pain and may be used to inform treatment. CLINICALTRIALS. GOV ID: NCT03434392.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.11.007" class="uri">https://doi.org/10.1016/j.pan.2019.11.007</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31787526" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31787526</a></p>
<p>BACKGROUND/OBJECTIVES: Interplay between the Hedgehog (HH) and epidermal growth factor receptor (EGFR) pathways modulating the outcome of their signaling activity have been reported in various cancers including pancreatic ductal adenocarcinoma (PDAC). Therefore, simultaneous targeting of these pathways may be clinically beneficial. This Phase I study combined HH and EGFR inhibition in metastatic PDAC patients. METHODS: Combined effects of HH and EGFR inhibition using Vismodegib and Erlotinib with or without gemcitabine in metastatic solid tumors were assessed by CT. Another cohort of patients with metastatic PDAC was evaluated by FDG-PET and tumor biopsies-derived biomarkers. RESULTS: Treatment was well tolerated with the maximum tolerated dose cohort experiencing no grade 4 toxicities though 25% experienced grade 3 adverse effects. Recommended phase II dose of Vismodegib and Erlotinib were each 150mg daily. No tumor responses were observed although 16 patients achieved stable disease for 2-7 cycles. Paired biopsy analysis before and after first cycle of therapy in PDAC patients showed reduced GLI1 mRNA, phospho-GLI1 and associated HH target genes in all cases. However, only half of the cases showed reduced levels of desmoplasia or changes in fibroblast markers. Most patients had decreased phospho-EGFR levels. CONCLUSIONS: Vismodegib and Erlotinib combination was well-tolerated although overall outcome in patients with metastatic PDAC was not significantly impacted by combination treatment. Biomarker analysis suggests direct targets inhibition without significantly affecting the stromal compartment. These findings conflict with pre-clinical mouse models, and thus warrant further investigation into how upstream inhibition of these pathways is circumvented in PDAC.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.11.011" class="uri">https://doi.org/10.1016/j.pan.2019.11.011</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Differences between KC and KPC pancreatic ductal adenocarcinoma mice models, in terms of their modeling biology and their clinical relevance</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31780287" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31780287</a></p>
<p>Pancreatic ductal adenocarcinoma (PDAC) is among the dangerous human cancers, is the 10th highly prevalent cancer, and the fourth sole cause of cancer-related mortality in the United States of America. Notwithstanding the significant commitment, the forecast for people with this burden continues to have a five-year survival rate of just 4-6%. The most critical altered genes within PDAC consist of K-ras the proto-oncogene which is usually mutationally activated above 90% cases and tumor suppressors likeTrp53 are altered at 55%. To face the burden of pancreatic ductal adenocarcinoma, a variety of genetically engineered pancreatic cancer mice models have been created over the last past years. These models have distinctive features and are not all appropriate for preclinical studies. In this review, we focus on differences between two mice models K-rasLSL.G12D/+;Pdx-1-Cre(KC) and K-rasLSL.G12D/+; Trp53R172H/+; Pdx-1-Cre(KPC) in terms of their modeling biology and their clinical relevance.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.11.006" class="uri">https://doi.org/10.1016/j.pan.2019.11.006</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Site and size of extrapancreatic necrosis are associated with clinical outcomes in patients with acute necrotizing pancreatitis</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31780286" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31780286</a></p>
<p>BACKGROUND: The site and size of extrapancreatic necrosis (EPN) as assessed on computed tomography may influence the severity of acute necrotizing pancreatitis (ANP). The objective of the study was to evaluate the impact of site and size of EPN on the clinical outcomes in patients with acute necrotizing pancreatitis (ANP). METHOD AND MATERIALS: This retrospective study comprised of consecutive patients with ANP who were admitted between January 2017 and March 2019. Patients in whom the initial contrast enhanced CT showed EPN were eligible for inclusion. The site, volume and maximum dimension of EPN were recorded. The severity of AP and modified CT severity index (MCTSI) was calculated. Clinical outcomes were recorded. RESULTS: A total of 119 patients (mean age, 37.56 years, 91 males) were included. There was a significant association between the location of EPN and the outcome parameters. The left posterior pararenal collections were significantly associated with mortality (P=0.041), left paracolic gutter collections with the length of hospitalisation (LOH) (P=0.014), and right paracolic gutter and mesenteric collections with the intensive care unit (ICU) stay (P=0.024, and P=0.021, respectively). There was a significant correlation between the volume and the maximum dimension of collection with LOH and ICU stay. The area under the receiver operating characteristic curve for volume, maximum dimension and MCTSI for predicting death was 0.724 (95% CI, 0.612-0.837), 0.644 (95% CI, 0.516-0.772) and 0.574 (95% CI, 0.452-0.696), respectively. CONCLUSION: The site and size of EPN provide reliable and objective information for assessing clinical outcomes in patients with ANP.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.11.010" class="uri">https://doi.org/10.1016/j.pan.2019.11.010</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>USP22 promotes hypoxia-induced hepatocellular carcinoma stemness by a HIF1/USP22 positive feedback loop upon TP53 inactivation</strong> </summary></p>
<p><em>Gut 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31776228" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31776228</a></p>
<p>OBJECTIVE: We aimed to elucidate the mutual regulation mechanism of ubiquitin-specific protease 22 (USP22) and hypoxia inducible factor-1 (HIF1), and the mechanism they promote the stemness of hepatocellular carcinoma (HCC) cells under hypoxic conditions. DESIGN: Cell counting, migration, self-renewal ability, chemoresistance and expression of stemness genes were established to detect the stemness of HCC cells. Immunoprecipitation, ubiquitination assay and chromatin immunoprecipitation assay were used to elucidate the mutual regulation mechanism of USP22 and HIF1. HCC patient samples and The Cancer Genome Atlas data were used to demonstrate the clinical significance. In vivo USP22-targeting experiment was performed in mice bearing HCC. RESULTS: USP22 promotes hypoxia-induced HCC stemness and glycolysis by deubiquitinating and stabilising HIF1. As direct target genes of HIF1, USP22 and TP53 can be transcriptionally upregulated by HIF1 under hypoxic conditions. In TP53 wild-type HCC cells, HIF1 induced TP53-mediated inhibition of HIF1-induced USP22 upregulation. In TP53-mutant HCC cells, USP22 and HIF1 formed a positive feedback loop and promote the stemness of HCC. HCC patients with a loss-of-function mutation at TP53 and high USP22 and/or HIF1 expression tend to have a worse prognosis. The USP22-targeting lipopolyplexes caused high tumour inhibition and high sorafenib sensitivity in mice bearing HCC. CONCLUSION: USP22 promotes hypoxia-induced HCC stemness by a HIF1/USP22 positive feedback loop on TP53 inactivation. USP22 is a promising target for the HCC therapy.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2019-319616" class="uri">https://doi.org/10.1136/gutjnl-2019-319616</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The expression of versican and its role in pancreatic neuroendocrine tumors</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31771905" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31771905</a></p>
<p>BACKGROUND: Pancreatic neuroendocrine tumors (pNET) are rare and heterogeneous. New biomarkers are needed for better predicting the prognosis and for providing individualized treatment. Versican (VCAN) plays an important role in tumorigenesis. Therefore, we plan to investigate the role of VCAN in pNET prognosis. METHOD: The clinical and pathological data of pNET patients who underwent surgery between 2005 and 2010 were collected and evaluated. Radiologic tumor assessments with contrast computed tomography or magnetic resonance imaging were performed at baseline and follow up. The radiologic response was classified according to the RECIST 1.1 criteria. VCAN expression was assessed by immunohistochemical staining (IHC). RESULT: Among 155 pNET patients, 112 (72.3%) pNET patients were VCAN positive, and 43 (27.7%) were negative. Positive expression of VCAN in pNET was significantly associated with a longer disease-free survival (DFS) compared with VCAN negative pNET (p=0.038, HR 0.462, 95% CI 0.218-0.978). Subgroup analysis showed that VCAN positive expression was associated with a longer DFS in the G1 subgroup (p=0.031, HR 0.124, 95% CI 0.013-1.193), the tumor size&gt;2cm subgroup (p=0.047, HR 0.458, 95% CI 0.207-1.012) and the NF-pNET subgroup (p=0.003, HR 0.274, 95% CI 0.112-0.673). Multivariable analysis showed that VCAN negative expression, G2 and tumor size&gt;2cm were independent factors of poor prognosis of pNET (p=0.041, p&lt;0.001, p=0.008, respectively). CONCLUSION: Our data indicate that VCAN positive expression may serve as an independent factor of predicting DFS in pNET; its expression in pNET tissues was correlated with a longer DFS.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.11.009" class="uri">https://doi.org/10.1016/j.pan.2019.11.009</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Chronic Pancreatitis: Managing a Difficult Disease</strong> </summary></p>
<p><em>The American journal of gastroenterology 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31764092" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31764092</a></p>
<p>Chronic pancreatitis is characterized by progressive, irreversible morphologic and functional changes that are most commonly attributed to environmental insults, particularly when there is a genetic or anatomic predisposition. Heavy alcohol use and cigarette smoking are the most common environmental risk factors, but both may be absent. Antecedent episodes of acute pancreatitis occur in about half of patients. Abdominal pain is the most common symptom and requires a tailored approach depending on the anatomic changes in the pancreas. Other clinical manifestations include diabetes mellitus, exocrine pancreatic insufficiency, metabolic bone disease, pancreatic cancer, and anatomic complications. Current disease management is centered on risk factor reduction and screening for and treating disease complications. There are no current therapies to delay or retard disease progression, but there are ongoing efforts to more fully understand the natural history of chronic pancreatitis and underlying mechanisms of disease. These studies are expected to provide insights that will transform our approach to disease management and provide increased hope to patients.</p>
<p>doi: <a href="https://doi.org/10.14309/ajg.0000000000000421" class="uri">https://doi.org/10.14309/ajg.0000000000000421</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Clinical impact of celiac ganglia metastasis upon pancreatic ductal adenocarcinoma</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31759906" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31759906</a></p>
<p>BACKGROUND: Pre-operative staging of pancreatic adenocarcinoma guides clinical decision making. Limited data indicate that metastasis to celiac ganglia (CG) correlates with poor prognosis. We investigated feasibility and safety of endoscopic ultrasound fine needle aspiration (EUS-FNA) detection of CG metastasis and its impact upon tumor stage, resectability, and survival in pancreatic ductal adenocarcinoma (PDAC). PATIENTS: We reviewed our prospectively maintained EUS and cytopathology databases to identify patients with FNA proven CG metastasis in patients with PDAC from 2004 to 2017. Clinical demographics, EUS, CT, MRI, cytopathology, cancer stage, and resectability data were analyzed. Survival of PDAC patients with CG metastasis was compared to the expected survival of PDAC patients of similar stage as reported by the United States National Cancer Database. RESULTS: Twenty-one patients with PDAC [median age 73 (IQR63-78); 14 (67%) female)], had CG metastasis confirmed by cytopathologic assessment. CG metastasis resulted in tumor upstaging relative to other EUS findings and cross sectional imaging findings in 12 (57%) and 15 (71%) patients, and converted cancers from resectable to unresectable relative to EUS and cross sectional imaging in 7 (37%) and 7 (37%) patients, respectively. In patients with PDAC, the survival of patients with CG metastasis was not significantly different from the overall survival (hazard ratio 0.71; 95% confidence interval 0.44, 1.13; p=0.15). CONCLUSIONS: EUS-FNA may safely identify CG metastases. While CG metastasis upstaged and altered the resectability status among this cohort of patients with PDAC, the survival data with regard to PDAC suggest that this may be misguided.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.11.003" class="uri">https://doi.org/10.1016/j.pan.2019.11.003</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Opioid use disorder in admissions for acute exacerbations of chronic pancreatitis and 30-day readmission risk: A nationwide matched analysis</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31759905" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31759905</a></p>
<p>BACKGROUND: The opioid epidemic in the United States has been on the rise. Acute exacerbations of chronic pancreatitis (AECP) patients are at higher risk for Opioid Use Disorder (OUD). Evidence on OUDs impact on healthcare utilization, especially hospital re-admissions is scarce. We measured the impact of OUD on 30-day readmissions, in patients admitted with AECP from 2010 to 2014. METHODS: This is a retrospective cohort study which included patients with concurrently documented CP and acute pancreatitis as first two diagnoses, from the National Readmissions Database (NRD). Pancreatic cancer patients and those who left against medical advice were excluded. We compared the 30-day readmission risk between OUD-vs.-non-OUD, while adjusting for other confounders, using multivariable exact-matched [(EM); 18 confounders; n=28,389] and non-EM regression/time-to-event analyses. RESULTS: 189,585 patients were identified. 6589 (3.5%) had OUD. Mean age was 48.7 years and 57.5% were men. Length-of-stay (4.4 vs 3.9 days) and mean index hospitalization costs ($10,251 vs.$9174) were significantly higher in OUD-compared to non-OUD-patients (p&lt;0.001). The overall mean 30-day readmission rate was 27.3% (n=51,806; 35.3% in OUD vs.27.0% in non-OUD; p&lt;0.001). OUD patients were 25% more likely to be re-admitted during a 30-day period (EM-HR: 1.25; 95%CI: 1.16-1.36; p&lt;0.001), Majority of readmissions were pancreas-related (60%), especially AP. OUD cases aggregate readmissions costs were $23.31.5 million USD (n=2289). CONCLUSION: OUD contributes significantly to increased readmission risk in patients with AECP, with significant downstream healthcare costs. Measures against OUD in these patients, such as alternative pain-control therapies, may potentially alleviate such increase in health-care resource utilization.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.11.004" class="uri">https://doi.org/10.1016/j.pan.2019.11.004</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31758284" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31758284</a></p>
<p>OBJECTIVE: To define short-term and long-term outcomes of IORT for the management of BR/LA PDAC in the era of modern neoadjuvant therapy (NAT). BACKGROUND: In the era of neoadjuvant FOLFIRINOX, many patients with borderline resectable/locally advanced (BR/LA) pancreatic ductal adenocarcinoma (PDAC) become candidates for surgical exploration with curative intent. IORT may be used to consolidate treatment for successfully resected patients with close or positive margins or administered in unresectable patients without distant metastases. METHODS: A retrospective review of 158 patients who received IORT in the setting of biopsy-proven BR/LA PDAC following NAT between 2008 and 2017 was performed. The Kaplan-Meier method was used to analyze progression-free survival (PFS) and overall survival (OS) of FOLFIRINOX treated patients. RESULTS: Most patients (83%) received FOLFIRINOX, and 95% underwent consolidative chemoradiation therapy (50.4-58.8Gy). Among FOLFIRINOX-treated patients, 86 underwent combined surgical resection with IORT (10Gy) while 46 received IORT alone (15-20Gy). The median PFS and OS were 21.5 and 46.7months for patients who underwent resection with IORT and 14.7 and 23months in the IORT alone group. Local progression occurred in 12.7% of patients after resection with IORT, and in 15% of patients who received IORT alone. Major complications occurred in 13% of patients following resection, and 5% of patients after IORT alone, including one death. CONCLUSION: IORT combined with surgical resection appears to be associated with improved survival and minimal morbidity in patients with positive or close margins. IORT is also associated with improved survival in patients with unresectable, non-metastatic disease.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-08084-2" class="uri">https://doi.org/10.1245/s10434-019-08084-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: Clinical Significance of Large Tenascin C Splice Variants and Annexin A2 for Pancreatic Cancer</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31758283" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31758283</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-08009-z" class="uri">https://doi.org/10.1245/s10434-019-08009-z</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Corrigendum to Recommendations from the United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis [Pancreatology 18(8) (2018) 847-854]</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31757740" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31757740</a></p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.10.005" class="uri">https://doi.org/10.1016/j.pan.2019.10.005</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Clinicopathologic and Prognostic Significance of Gallbladder and Cystic Duct Invasion in Distal Bile Duct Carcinoma</strong> </summary></p>
<p><em>Archives of pathology &amp; laboratory medicine 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31755778" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31755778</a></p>
<p>CONTEXT.: The roles of the gallbladder and cystic duct (CD) invasions in distal bile duct carcinoma (DBDC) have not been well elucidated. OBJECTIVE.: To define the characteristics and prognostic significance of gallbladder or CD invasions in patients with DBDC. DESIGN.: Organ invasion patterns with clinicopathologic features were assessed in 258 resected DBDCs. RESULTS.: CD invasions (N = 31) were associated with frequent concomitant pancreatic and/or duodenal invasions (23 of 31, 74%) and showed stromal infiltration (16 of 31, 52%) and intraductal cancerization (15 of 31, 48%) patterns. In only 2 cases, invasions with intraductal cancerization were observed in the gallbladder neck. Conversely, all pancreatic (N = 175) and duodenal (83) invasions developed through stromal infiltration. CD invasions were associated with larger tumor size (P = .001), bile duct margin positivity (P = .001), perineural invasions (P = .04), and higher N categories (P = .007). Patients with pancreatic or duodenal invasions had significantly lower survival rates than those without pancreatic (median, 31.0 versus 93.9 months) or duodenal (27.5 versus 56.8 months, P &lt; .001, both) invasions. However, those with gallbladder or CD invasions did not have different survival times (P = .13). Patients with concomitant gallbladder/CD and pancreatic/duodenal invasions demonstrated significantly lower survival rates than those without organ invasions (P &lt; .001). CONCLUSIONS.: Gallbladder invasions were rare in DBDCs as neck invasions with intraductal cancerization. CD invasions occurred by stromal infiltrations and intraductal cancerization, whereas all pancreatic and duodenal invasions had stromal infiltration patterns. Gallbladder and/or CD invasions did not affect survival rates of patients with DBDC, while pancreatic and duodenal invasions affected survival rates. Therefore, these differences in survival rates may originate from the different invasive patterns of DBDCs.</p>
<p>doi: <a href="https://doi.org/10.5858/arpa.2019-0218-OA" class="uri">https://doi.org/10.5858/arpa.2019-0218-OA</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31754050" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31754050</a></p>
<p>PURPOSE: Molecular subtyping for pancreatic cancer has made substantial progress in recent years, facilitating the optimization of existing therapeutic approaches to improve clinical outcomes in pancreatic cancer. With advances in treatment combinations and choices, it is becoming increasingly important to determine ways to place patients on the best therapies upfront. Although various molecular subtyping systems for pancreatic cancer have been proposed, consensus regarding proposed subtypes, as well as their relative clinical utility, remains largely unknown and presents a natural barrier to wider clinical adoption. METHODS: We assess three major subtype classification schemas in the context of results from two clinical trials and by meta-analysis of publicly available expression data to assess statistical criteria of subtype robustness and overall clinical relevance. We then developed a single-sample classifier (SSC) using penalized logistic regression based on the most robust and replicable schema. RESULTS: We demonstrate that a tumor-intrinsic two-subtype schema is most robust, replicable, and clinically relevant. We developed Purity Independent Subtyping of Tumors (PurIST), a SSC with robust and highly replicable performance on a wide range of platforms and sample types. We show that PurIST subtypes have meaningful associations with patient prognosis and have significant implications for treatment response to FOLIFIRNOX. CONCLUSIONS: The flexibility and utility of PurIST on low-input samples such as tumor biopsies allows it to be used at the time of diagnosis to facilitate the choice of effective therapies for patients with pancreatic ductal adenocarcinoma and should be considered in the context of future clinical trials.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-1467" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-1467</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>MicroRNAs in Pancreatic Cancer: biomarkers, prognostic, and therapeutic modulators</strong> </summary></p>
<p><em>BMC cancer 2019 Nov;19(1):1130</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31752758" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31752758</a></p>
<p>A severe lack of early diagnosis coupled with resistance to most available therapeutic options renders pancreatic cancer as a major clinical concern. The limited efficacy of current treatments necessitates the development of novel therapeutic strategies that are based on an understanding of the molecular mechanisms involved in pancreatic cancer progression. MicroRNAs (miRNAs) are non-coding small RNAs that regulate the expression of multiple proteins in the post-translation process and thus have promise as biomarkers, prognostic agents, and as advanced pancreatic therapies. Profiling of deregulated miRNAs in pancreatic cancer cancorrelate to diagnosis, indicate optimal treatment and predictresponse to therapy. Furthermore, understanding the main effector genes in pancreatic cancer along with downstream pathwayscan identify possible miRNAs as therapeutic candidates. Additionally, obstacles to the translation of miRNAs into the clinic arealso considered. Distinct miRNA expression profiles can correlate to stages of malignant pancreatic disease, and hold potential as biomarkers, prognostic markers and clinical targets. However, a limited understanding and validation of the specific role of such miRNAs stunts clinical application. Target prediction using algorithms provides a wide range of possible targets, but these miRNAs still require validation through pre-clinical studies to determine the knock-on genetic effects.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6284-y" class="uri">https://doi.org/10.1186/s12885-019-6284-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Preoperative risk stratification for early recurrence of HBV-related hepatocellular carcinoma after deceased donor liver transplantation: a five-eight model development and validation</strong> </summary></p>
<p><em>BMC cancer 2019 Nov;19(1):1136</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31752756" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31752756</a></p>
<p>BACKGROUND: Early recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is associated with poor surgical outcomes. This study aims to construct a preoperative model to predict individual risk of post-LT HCC recurrence. METHODS: Data of 748 adult patients who underwent deceased donor LT for HCC between January 2015, and February 2019 were collected retrospectively from the China Liver Transplant Registry database and randomly divided into training (n=486) and validation(n=262) cohorts. A multivariate analysis was performed and the five-eight model was developed. RESULTS: A total of 748 patients were included in the study; of them, 96% had hepatitis B virus (HBV) and 84% had cirrhosis. Pre-LT serum alpha-fetoprotein (AFP), tumor number and largest tumor diameter were incorporated to construct the 5-8 model which can stratify patients accurately according to their risk of recurrence into three prognostic subgroups; low-(0-5 points), medium-(6-8 points) and high-risk (&gt;8 points) with 2-year post-LT recurrence rate of (5,20 and 51%,p&lt;0.001) respectively. The 5-8 model was better than Milan, Hangzhou, and AFP-model for prediction of HCC early recurrence. These findings were confirmed by the results of the validation cohort. CONCLUSIONS: The 5-8 model is a simple validated and accurate tool for preoperative stratification of early recurrence of HCC after LT.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6343-4" class="uri">https://doi.org/10.1186/s12885-019-6343-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Laennecs approach for laparoscopic anatomic hepatectomy based on Laennecs capsule</strong> </summary></p>
<p><em>BMC gastroenterology 2019 Nov;19(1):194</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31752706" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31752706</a></p>
<p>BACKGROUND: Although isolating Glissonean pedicles and hepatic veins are critical procedures during anatomical hepatectomy, there is no standardized approach. We propose the novel Laennecs approach for laparoscopic anatomic hepatectomy (LAH) based on Laennecs capsule, which serves as the anatomic landmark for LAH. The aim of this study was to elucidate that the natural gap between Laennecs capsule and the adjacent tissues contributes to standardization of the surgical technique for LAH. METHODS: Eighty-four cases were enrolled in this observable clinical trial. They underwent LAH for liver diseases. Laennecs approach was proposed for LAH based on Laennecs capsule. The liver tissues close to Glissonean pedicle, hepatic veins, naked area, and inferior vena cava were collected for hematoxylin and eosin, resorcinol-fuchsin staining, and immunohistochemistry. RESULTS: The staining revealed capsule packaging of the whole liver independent of the adjacent tissues and intrahepatic vessels. A natural gap was found between Laennecs capsule and the adjacent tissues at different sites. Laennecs capsule served as the landmark for isolating Glissonean pedicle and hepatic veins, mobilizing the liver, and performing Hanging maneuver. Eighty-four cases underwent LAH for liver diseases using this strategy. The operation time was 277.23min. The mean of hospital days was 9.8. CONCLUSIONS: Laennecs approach based on Laennecs capsule contributes to standardization of the surgical technique for LAH, and brings innovations that facilitates safe and effective liver resection under laparoscopy.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-019-1107-9" class="uri">https://doi.org/10.1186/s12876-019-1107-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Mutation That Promotes Activation of Trypsinogen Increases Severity of Secretagogue-Induced Pancreatitis in Mice</strong> </summary></p>
<p><em>Gastroenterology 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31751559" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31751559</a></p>
<p>Mutations in the human serine protease 1 gene (PRSS1), which encodes cationic trypsinogen, can accelerate its autoactivation and cause hereditary or sporadic chronic pancreatitis. Disruption of the locus that encodes cationic trypsinogen in mice (T7) causes loss of expression of the protein, but only partially decreases the severity of secretagogue-induced acute pancreatitis and has no effect on chronic pancreatitis. We investigated whether trypsinogen becomes pathogenic only when it is activated by mutation METHODS: We generated mice with knock-in of the p.K24R mutation (called T7K24R mice), which is analogous to human PRSS1 mutation p.K23R. We gave T7K24R and C57BL/6N (control) mice repeated injections of cerulein to induce pancreatitis. Plasma amylase activity, pancreatic edema, and myeloperoxidase content in pancreas and lungs and were quantified. We expressed mutant and full-length forms of PRSS1 in Escherichia coli and compared their autoactivation RESULTS: The p.K24R mutation increased autoactivation of T7 5-fold. T7K24R mice developed no spontaneous pancreatitis. T7K24R mice given cerulein injections had increased pancreatic activation of trypsinogen and edema, infiltration of lung and pancreas by inflammatory cells, and plasma amylase activity compared with control mice given cerulein injections. Injection of cerulein for 2 days induced progressive pancreatitis in T7K24R mice, but not in control mice, with typical features of chronic pancreatitis CONCLUSIONS: Introduction of a mutation into mice that is analogous to the p.K23R mutation in PRSS1 increases pancreatic activation of trypsinogen during secretagogue-induced pancreatitis. Higher pancreatic activity of trypsin increases the severity of pancreatitis even though loss of trypsin activity does not prevent pancreatitis in mice.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.11.020" class="uri">https://doi.org/10.1053/j.gastro.2019.11.020</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Chest wall lymph node metastasis from follicular thyroid carcinoma: a rare case report</strong> </summary></p>
<p><em>Diagnostic pathology 2019 Nov;14(1):130</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31747942" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31747942</a></p>
<p>BACKGROUND: Distant metastases from follicular thyroid carcinoma are mainly hematogenous and are commonly observed in the lungs and bones. Other rare sites are the parotid gland, skin, brain, ovary, adrenal gland, kidney, pancreas and breast, with chest wall lymph node metastasis being even more rare. CASE PRESENTATION: Over the past 10years, three surgeries were performed on a 69-year-old women with a history of follicular thyroid cancer and its metastatic lesions. The patient presented with a 3-month history of masses in the left chest. She underwent detailed examination of the chest wall tumors, and surgery was then performed to resect all of the tumors. Based on the histopathology, these lymph nodes were confirmed to harbor metastatic follicular thyroid carcinoma. CONCLUSION: This study reports the first case of follicular thyroidcarcinoma metastasis to the chest wall lymph node.</p>
<p>doi: <a href="https://doi.org/10.1186/s13000-019-0907-0" class="uri">https://doi.org/10.1186/s13000-019-0907-0</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Does Pancreatic Cyst Stability Justify Stopping Intraductal Papillary Mucinous Neoplasm Surveillance?</strong> </summary></p>
<p><em>Gastroenterology 2020 Jan;158(1):44-46</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31738923" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31738923</a></p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.11.014" class="uri">https://doi.org/10.1053/j.gastro.2019.11.014</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Clinical Utility of Endoscopic Ultrasound-Guided Fine Needle Biopsy in Providing a Histologic Diagnosis of Pancreatic Cystic Lesions</strong> </summary></p>
<p><em>Gastroenterology 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31738913" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31738913</a></p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.10.048" class="uri">https://doi.org/10.1053/j.gastro.2019.10.048</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer</strong> </summary></p>
<p><em>Cell 2019 Nov;179(5):1239</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31730860" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31730860</a></p>
<p>doi: <a href="https://doi.org/10.1016/j.cell.2019.10.037" class="uri">https://doi.org/10.1016/j.cell.2019.10.037</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Platinum exposure and cause-specific mortality among patients with testicular cancer</strong> </summary></p>
<p><em>Cancer 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31730712" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31730712</a></p>
<p>BACKGROUND: Although testicular cancer (TC) treatment has been associated with severe late morbidities, including second malignant neoplasms (SMNs) and ischemic heart disease (IHD), cause-specific excess mortality has been rarely studied among patients treated in the platinum era. METHODS: In a large, multicenter cohort including 6042 patients with TC treated between 1976 and 2006, cause-specific mortality was compared with general population mortality rates. Associations with treatment were assessed with proportional hazards analysis. RESULTS: With a median follow-up of 17.6years, 800 patients died; 40.3% of these patients died because of TC. The cumulative mortality was 9.6% (95% confidence interval [CI], 8.5%-10.7%) 25years after TC treatment. In comparison with general population mortality rates, patients with nonseminoma experienced 2.0 to 11.6 times elevated mortality from lung, stomach, pancreatic, rectal, and kidney cancers, soft-tissue sarcomas, and leukemia; 1.9-fold increased mortality (95% CI, 1.3-2.8) from IHD; and 3.9-fold increased mortality (95% CI, 1.5-8.4) from pneumonia. Seminoma patients experienced 2.5 to 4.6 times increased mortality from stomach, pancreatic, bladder cancer and leukemia. Radiotherapy and chemotherapy were associated with 2.1 (95% CI, 1.8-2.5) and 2.5 times higher SMN mortality (95% CI, 2.0-3.1), respectively, in comparison with the general population. In a multivariable analysis, patients treated with platinum-containing chemotherapy had a 2.5-fold increased hazard ratio (HR; 95% CI, 1.8-3.5) for SMN mortality in comparison with patients without platinum-containing chemotherapy. The HR for SMN mortality increased 0.29 (95% CI, 0.19-0.39) per 100mg/m2 platinum dose administered (Ptrend &lt;.001). IHD mortality was increased 2.1-fold (95% CI, 1.5-4.2) after platinum-containing chemotherapy in comparison with patients without platinum exposure. CONCLUSIONS: Platinum-containing chemotherapy is associated with a dose-dependent increase in the risk of SMN mortality.</p>
<p>doi: <a href="https://doi.org/10.1002/cncr.32538" class="uri">https://doi.org/10.1002/cncr.32538</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Atypical ovarian carcinoid tumor with widespread skeletal metastases: a case report of multiple endocrine neoplasia type 1 in a young woman</strong> </summary></p>
<p><em>BMC cancer 2019 Nov;19(1):1107</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31727021" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31727021</a></p>
<p>BACKGROUND: Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant inherited condition affecting multiple endocrine organs, resulting in significant morbidity and decreased life expectancy. Early tumor identification allows for timely patient management, reduces morbidity, and improves disease outcomes. Patients with MEN1 typically present with primary hyperparathyroidism caused by multiple parathyroid tumors, however, thymic and bronchial carcinoid tumors are also less common manifestations. MEN1-related neuroendocrine tumors often show hematogenous metastasis, with the liver being the most common metastatic site. Skeletal metastases from neuroendocrine tumors are extremely rare. As few as 50 case reports were identified in a recently published literature review on skeletal metastases from carcinoid tumors. To our knowledge, studies related to MEN1 have not been previously conducted. CASE PRESENTATION: We present a case of MEN1-related atypical ovarian carcinoid presenting as the first disease manifestation in a 30-year old woman. After two years, another atypical carcinoid was incidentally diagnosed in the contralateral ovary during a caesarean section. Syndromic MEN1 was not diagnosed clinically despite her young age and bilateral involvement. The patient remained disease-free for two years without further adjuvant treatment prior to clinic presentation with complaints of chest discomfort and body pain. Radiologic and pathologic investigations identified multifocal simultaneous neuroendocrine tumors involving the parathyroid, thymus, pancreas, and adrenal glands, in addition to multiple other metastatic sites. The findings ultimately resulted in the patient being diagnosed with MEN1. CONCLUSIONS: This extremely rare case emphasizes that ovarian carcinoids, especially when bilateral, could be the initial manifestation of MEN1. The significance of this differential diagnosis was highlighted by the subsequent detection of widespread skeletal metastasis resulting from the carcinoid tumors. A low threshold of suspicion, systemic diagnostic work-up, and regular follow-up are of utmost importance to timely diagnosis of MEN1.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6332-7" class="uri">https://doi.org/10.1186/s12885-019-6332-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Metachronous intraductal papillary mucinous neoplasms disseminate via the pancreatic duct following resection</strong> </summary></p>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31723240" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31723240</a></p>
<p>Metachronous development of intraductal papillary mucinous neoplasms in the remnant pancreas following resection is a significant clinical burden. Our aim was to characterize the clinicopathological and molecular features of the patients with metachronous tumor development to identify predictive factors and the possible route(s) of dissemination. Seventy-four patients who underwent resection of intraductal papillary mucinous neoplasms with no invasive compartment or associated carcinoma were retrospectively analyzed. In patients with metachronous tumor development, targeted sequencing of 18 genes associated with pancreatic tumorigenesis and immunohistochemical detection of four proteins (p53, SMAD4, p16, and -catenin) were performed on both primary and metachronous tumors. The distributions of microscopic neoplastic lesions were examined at surgical margins and in apparently normal tissue apart from the primary tumor. During the median follow-up period of 52 months, 9 patients (12%) developed metachronous tumors in the remnant pancreas. Primary tumors located in the body/tail of the pancreas (odds ratio, 15; 95% confidence interval, 1.6-131) and of the pancreatobiliary type (odds ratio, 6.1; 95% confidence interval, 1.1-35.7) were identified as significant risk factors for subsequent metachronous tumor development. Eight of the nine patients shared molecular aberrations between their primary and metachronous tumors, suggesting migrations from the primary tumor to the pancreatic duct as the cause of metachronous tumor development. Our data suggest that these post-resection metachronous tumors develop by skip dissemination of the primary tumor, potentially via the pancreatic duct. The development of strategies to better predict and prevent this form of tumor progression is necessary.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-019-0405-7" class="uri">https://doi.org/10.1038/s41379-019-0405-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Update on risk stratification in the Papanicolaou Society of Cytopathology System for Reporting Pancreaticobiliary Cytology categories: 3-year, prospective, single-institution experience</strong> </summary></p>
<p><em>Cancer cytopathology 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31722125" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31722125</a></p>
<p>BACKGROUND: Risk stratification is a critical element for the successful implementation of cytopathology reporting systems. To the authors knowledge, there are limited prior studies regarding risk stratification for The Papanicolaou Society of Cytopathology System for Reporting Pancreaticobiliary Cytology (PSCPC). In the current study, the authors reported on a single-institution experience on 3-year prospective PSCPC regarding risk of malignancy (ROM) and the overall risk of malignancy (OROM). METHODS: A computerized search was performed from August 2014 to December 2017 for all pancreatic fine-needle aspiration (FNA) samples. Pathology from surgical resections and biopsies and relevant radiologic and clinical follow-up data were collected. The ROM and the OROM were calculated. The OROM was based on the total number of FNA samples in each category. RESULTS: A total of 1017 pancreatic FNA cases were identified, with surgical and/or clinical follow-up data available for 548 cases. The cytopathologic diagnoses included 242 nondiagnostic (category I), 162 benign (category II), 142 atypical (category III), 20 neoplastic-benign (categoryIV:benign), 133 neoplastic-other (category IV:other), 28 suspicious (category V), and 290 malignant (category VI) cases. A total of 364 malignancies were documented in 11 cases, 4 cases, 36 cases, 0 cases, 36 cases, 21 cases, and 255 cases, respectively, from categories I, II, III, IV:benign, IV:other, V, and VI. The ROM was 25%, 17.4%, 41.8%, 0%, 34.3% (95.2%), 95.5%, and 99.6%, respectively, and the OROM was 4.5%, 2.5%, 25.3%, 0%, 27.1% (83.3%), 75%, and 87.9%, respectively, for categories I, II, III, IV:benign, IV:other (with high-grade dysplasia), V, and VI. CONCLUSIONS: The true ROM for PSCPC is likely between the ROM and OROM for the benign and indeterminate categories. In the neoplastic-other category (category IV: other), identifying high-grade dysplasia is important for its association with malignancy and a higher ROM.</p>
<p>doi: <a href="https://doi.org/10.1002/cncy.22199" class="uri">https://doi.org/10.1002/cncy.22199</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Main Pancreatic Duct to Parenchymal Thickness Ratio at Preoperative Imaging is Associated with Overall Survival in Upfront Resected Pancreatic Cancer</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31722071" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31722071</a></p>
<p>BACKGROUND: Pancreatic cancer induces parenchymal atrophy and duct dilation. The aim of this study was to evaluate whether these radiologic modifications are associated with outcomes. METHODS: Upfront pancreaticoduodenectomy patients with available preoperative contrast enhanced CT scan imaging were retrospectively analyzed. Thickness of the pancreas, size of the main pancreatic duct (MPD), and distance of the tumor from the ampulla were assessed. A training cohort was selected, including short- (3-12months following surgery) and long-term (36months) survivors. Identified survival determinants were validated in the overall cohort. RESULTS: Two-hundred-sixteen patients were analyzed. In the training cohort (N=118), 68 patients (57.6%) were in the short-term and 50 (42.4%) in the long-term survival group. The short-term survival group had significantly higher CA 19-9 levels (p=0.027), larger tumors (32.612.1mm vs.26.511.6mm, p=0.007), poorer differentiation (p=0.003), higher rate of R&lt;1mm resections (54% vs.32%, p=0.008), and reduced receipt of adjuvant chemotherapy (p=0.020). The MPD-to-pancreatic thickness ratio was significantly lower in the short-term survivors (3.66.2 vs.8.212.0, p=0.016). In the entire cohort, an MPD-to-pancreatic thickness ratio 3.5 was associated with improved OS [median 33.0months IQR (19.7-48.1) versus 17months IQR (14.8-19.2), p=0.004], and confirmed by a Cox-proportional hazards model independently associated with OS (HR=0.58; p=0.009), together with tumor size (HR=1.02; p=0.012), R1/R2 status (HR=1.53; p=0.029), and receipt of adjuvant treatment (HR=0.61; p=0.021). CONCLUSIONS: High MPD-to-pancreatic thickness ratio was associated with improved long-term survival in pancreaticoduodenectomy for cancer. Whether these features are related to tumor chronicity, indolent biology, or local growth over metastasis remains to be determined.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-08040-0" class="uri">https://doi.org/10.1245/s10434-019-08040-0</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31720931" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31720931</a></p>
<p>BACKGROUND: While platinum-based chemotherapy represents the standard treatment for advanced grade 3 (G3) neuroendocrine neoplasms (NENs) according to the European Neuroendocrine Tumor Society guidelines, the role of radical-intended surgery in these patients, as well as the use of adjuvant chemotherapy, are still controversial. The aim of the present work is to describe, in a retrospective series of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) G3, the overall survival (OS) rate and risk factors for death after radical surgery. Secondary aims are the description of median recurrence-free survival (RFS) and of the role of adjuvant chemotherapy. PATIENTS AND METHODS: Multicenter analysis of a series of stage I-III GEP-NEN G3 patients receiving radical surgery (R0/R1) with/without adjuvant chemotherapy was performed. RESULTS: Sixty patients from eight neuroendocrine tumor (NET) referral centers, with median follow-up of 23months (5-187months) were evaluated. While 28.6% of cases had NET G3, 71.4% had neuroendocrine carcinoma G3 (NEC G3). The 2-year OS rate after radical surgery was 64.5%, with a statistically significant difference in terms of Ki67 threshold (cut-off 55%, P=0.03) and tumor differentiation (NEC G3 vs.NET G3, P=0.03). Median RFS after radical surgery was 14months, and 2-year RFS rate was 44.9%. Use of adjuvant chemotherapy provided no benefit in terms of either OS or RFS in this series. CONCLUSIONS: Surgery with radical intent might represent a valid option for GEP-NEN G3 patients with locoregional disease, especially with Ki67 value55%.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-08049-5" class="uri">https://doi.org/10.1245/s10434-019-08049-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Surgery for elderly patients with resectable pancreatic cancer, a comparison with non-surgical treatments: a retrospective study outcomes of resectable pancreatic cancer</strong> </summary></p>
<p><em>BMC cancer 2019 Nov;19(1):1090</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31718565" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31718565</a></p>
<p>BACKGROUND: We designed a retrospective study to compare prognostic outcomes based on whether or not surgical resection was performed in elderly patients aged(75years) with resectable pancreatic cancer. METHODS: We retrospectively analyzed 49 patients with resectable pancreatic cancer (surgery group, resection was performed for 38 cases; no surgery group, resection was not performed for 11 cases) diagnosed from January 2003 to December 2014 at the National Cancer Center, Korea. RESULTS: There was no significant difference in demographics between the two groups. The surgery group showed significantly better overall survival after diagnosis than the no surgery group (2-year survival rate, 40.7% vs.0%; log-rank test, p=0.015). Multivariate analysis revealed that not having undergone surgical resection [hazard ratio (HR) 2.412, P=0.022] and a high Charlson comorbidity index (HR 5.252, P=0.014) were independent prognostic factors for poor overall survival in elderly patients with early stage pancreatic cancer. CONCLUSIONS: In the present study, surgical resection resulted in better prognosis than non-surgical resection for elderly patients with resectable pancreatic cancer. Except for patients with a high Charlson comorbidity index, an aggressive surgical approach seems to be beneficial for elderly patients with resectable pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6255-3" class="uri">https://doi.org/10.1186/s12885-019-6255-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>MRTFB suppresses colorectal cancer development through regulating SPDL1 and MCAM</strong> </summary></p>
<p><em>Proceedings of the National Academy of Sciences of the United States of America 2019 Nov;116(47):23625-23635</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31690663" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31690663</a></p>
<p>Myocardin-related transcription factor B (MRTFB) is a candidate tumor-suppressor gene identified in transposon mutagenesis screens of the intestine, liver, and pancreas. Using a combination of cell-based assays, in vivo tumor xenograft assays, and Mrtfb knockout mice, we demonstrate here that MRTFB is a human and mouse colorectal cancer (CRC) tumor suppressor that functions in part by inhibiting cell invasion and migration. To identify possible MRTFB transcriptional targets, we performed whole transcriptome RNA sequencing in MRTFB siRNA knockdown primary human colon cells and identified 15 differentially expressed genes. Among the top candidate tumor-suppressor targets were melanoma cell adhesion molecule (MCAM), a known tumor suppressor, and spindle apparatus coiled-coil protein 1 (SPDL1), which has no confirmed role in cancer. To determine whether these genes play a role in CRC, we knocked down the expression of MCAM and SPDL1 in human CRC cells and showed significantly increased invasion and migration of tumor cells. We also showed that Spdl1 expression is significantly down-regulated in Mrtfb knockout mouse intestine, while lower SPDL1 expression levels are significantly associated with reduced survival in CRC patients. Finally, we show that depletion of MCAM and SPDL1 in human CRC cells significantly increases tumor development in xenograft assays, further confirming their tumor-suppressive roles in CRC. Collectively, our findings demonstrate the tumor-suppressive role of MRTFB in CRC and identify several genes, including 2 tumor suppressors, that act downstream of MRTFB to regulate tumor growth and survival in CRC patients.</p>
<p>doi: <a href="https://doi.org/10.1073/pnas.1910413116" class="uri">https://doi.org/10.1073/pnas.1910413116</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma</strong> </summary></p>
<p><em>Proceedings of the National Academy of Sciences of the United States of America 2019 Nov;116(46):23264-23273</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31662475" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31662475</a></p>
<p>Glycolytic enzyme phosphoglycerate mutase 1 (PGAM1) plays a critical role in cancer metabolism by coordinating glycolysis and biosynthesis. A well-validated PGAM1 inhibitor, however, has not been reported for treating pancreatic ductal adenocarcinoma (PDAC), which is one of the deadliest malignancies worldwide. By uncovering the elevated PGAM1 expressions were statistically related to worse prognosis of PDAC in a cohort of 50 patients, we developed a series of allosteric PGAM1 inhibitors by structure-guided optimization. The compound KH3 significantly suppressed proliferation of various PDAC cells by down-regulating the levels of glycolysis and mitochondrial respiration in correlation with PGAM1 expression. Similar to PGAM1 depletion, KH3 dramatically hampered the canonic pathways highly involved in cancer metabolism and development. Additionally, we observed the shared expression profiles of several signature pathways at 12 h after treatment in multiple PDAC primary cells of which the matched patient-derived xenograft (PDX) models responded similarly to KH3 in the 2 wk treatment. The better responses to KH3 in PDXs were associated with higher expression of PGAM1 and longer/stronger suppressions of cancer metabolic pathways. Taken together, our findings demonstrate a strategy of targeting cancer metabolism by PGAM1 inhibition in PDAC. Also, this work provided proof of concept for the potential application of metabolic treatment in clinical practice.</p>
<p>doi: <a href="https://doi.org/10.1073/pnas.1914557116" class="uri">https://doi.org/10.1073/pnas.1914557116</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Achievement of a Sustained Virological Response Either Before or After Hepatectomy Improves the Prognosis of Patients with Primary Hepatitis C Virus-Related Hepatocellular Carcinoma</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(13):4566-4575</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31602577" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31602577</a></p>
<p>BACKGROUND: Hepatitis C virus (HCV) infection is a major cause of hepatocellular carcinoma (HCC). Achieving a sustained virological response (SVR) is associated with a reduced risk of recurrence. The recent introduction of direct acting antivirals (DAAs) has resulted in SVR rates of nearly 100% in treated patients. The purpose of the present study was to clarify the outcomes in patients who underwent antiviral therapy and patients without antiviral therapy. METHODS: This retrospective study included 220 patients with primary HCV-related HCC who underwent hepatectomy. An SVR was defined as a serum HCV-RNA titer below the detection sensitivity limit at 6months after the termination of antiviral therapy. Postoperative antiviral therapy was introduced after confirming that there was no early recurrence. RESULTS: Eighty-eight patients received antiviral therapy. Among these, 58 patients (66%) obtained an SVR. With the exception of one patient, all patients who received DAAs obtained an SVR. The overall survival rate of the pre-operative SVR group was significantly better than that of the preoperative untreated group (P=0.045). Moreover, there was no recurrence at 3years after surgery in the pre-operative SVR group. The achievement of an SVR was an independent predictor of overall survival [hazard ratio (HR) 0.75, 95% confidence interval (CI) 0.59-0.94, P=0.011] and recurrence (HR 0.61, 95% CI 0.40-0.94, P=0.024). CONCLUSIONS: Obtaining an SVR either before or after surgery was associated with the suppression of HCC recurrence after hepatectomy in patients with primary HCV-related HCC.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07911-w" class="uri">https://doi.org/10.1245/s10434-019-07911-w</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cancer biology as revealed by the research autopsy</strong> </summary></p>
<p><em>Nature reviews. Cancer 2019 12;19(12):686-697</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31519982" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31519982</a></p>
<p>A research autopsy is a post-mortem medical procedure performed on a deceased individual with the primary goal of collecting tissue to support basic and translational research. This approach has increasingly been used to investigate the pathophysiological mechanisms of cancer evolution, metastasis and treatment resistance. In this Review, we discuss the rationale for the use of research autopsies in cancer research and provide an evidence-based discussion of the quality of post-mortem tissues compared with other types of biospecimens. We also discuss the advantages of using post-mortem tissues over other types of biospecimens, including the large amounts of tissue that can be obtained and the extent of multiregion sampling that is achievable, which is not otherwise possible in living patients. We highlight how the research autopsy has supported the identification of the clonal origins and modes of spread among metastases, the extent that selective pressures imposed by treatments cause bottlenecks leading to parallel and convergent tumour evolution, and the creation of rare tissue banks and patient-derived model systems. Finally, we comment on the future of the research autopsy as an integral component of precision medicine strategies.</p>
<p>doi: <a href="https://doi.org/10.1038/s41568-019-0199-4" class="uri">https://doi.org/10.1038/s41568-019-0199-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Nov;25(22):6742-6755</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31492749" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31492749</a></p>
<p>PURPOSE: KRAS is mutated in the majority of pancreatic ductal adenocarcinoma. MAPK and PI3K-AKT are primary KRAS effector pathways, but combined MAPK and PI3K inhibition has not been demonstrated to be clinically effective to date. We explore the resistance mechanisms uniquely employed by malignant cells. EXPERIMENTAL DESIGN: We evaluated the expression and activation of receptor tyrosine kinases in response to combined MEK and AKT inhibition in KPC mice and pancreatic ductal organoids. In addition, we sought to determine the therapeutic efficacy of targeting resistance pathways induced by MEK and AKT inhibition in order to identify malignant-specific vulnerabilities. RESULTS: Combined MEK and AKT inhibition modestly extended the survival of KPC mice and increased Egfr and ErbB2 phosphorylation levels. Tumor organoids, but not their normal counterparts, exhibited elevated phosphorylation of ERBB2 and ERBB3 after MEK and AKT blockade. A pan-ERBB inhibitor synergized with MEK and AKT blockade in human PDA organoids, whereas this was not observed for the EGFR inhibitor erlotinib. Combined MEK and ERBB inhibitor treatment of human organoid orthotopic xenografts was sufficient to cause tumor regression in short-term intervention studies. CONCLUSIONS: Analyses of normal and tumor pancreatic organoids revealed the importance of ERBB activation during MEK and AKT blockade primarily in the malignant cultures. The lack of ERBB hyperactivation in normal organoids suggests a larger therapeutic index. In our models, pan-ERBB inhibition was synergistic with dual inhibition of MEK and AKT, and the combination of a pan-ERBB inhibitor with MEK antagonists showed the highest activity both in vitro and in vivo.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-1398" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-1398</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Nov;25(22):6614-6622</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31455681" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31455681</a></p>
<p>PURPOSE: Regulatory T cells (Tregs) expressing CC chemokine receptor 4 (CCR4) can suppress antitumor immune responses and are associated with poor prognoses in several cancers. We assessed the safety and efficacy of combined mogamulizumab (anti-CCR4 antibody) and nivolumab [anti-programmed death-1 (PD-1) antibody] in immunotherapy-nave patients with advanced/metastatic solid tumors. PATIENTS AND METHODS: This study (NCT02476123) comprised dose-escalation (3+3 design) and expansion parts. Patients received nivolumab (3.0 mg/kg) every 2 weeks, with mogamulizumab (0.3 or 1.0 mg/kg in dose escalation, 1.0 mg/kg in expansion) once weekly for 4 weeks, then every 2 weeks, until progression or unacceptable toxicity. Primary objective was safety; secondary objectives were antitumor effects, pharmacokinetics, and immunogenicity. Exploratory biomarker analyses were conducted. RESULTS: Ninety-six patients were enrolled (July 2015-November 2016): six patients in the dose-escalation part and 90 in the expansion part. No dose-limiting toxicities were observed in the dose-escalation part. Grade 3/4 treatment-related adverse events (TRAEs) occurred in 29% of patients in the expansion part (no grade 5 TRAEs). The most frequent TRAEs were rash (39%), rash maculopapular (20%), diarrhea (13%), stomatitis (12%), and pruritus (11%). There were four (27%) confirmed tumor responses among 15 patients with hepatocellular carcinoma, and one confirmed and two unconfirmed responses among 15 patients with pancreatic adenocarcinoma. During treatment, populations of effector Tregs (CD4+CD45RA-FoxP3high) decreased and CD8+ T cells in tumor-infiltrating lymphocytes increased. CONCLUSIONS: Combining an anti-PD-1 antibody, nivolumab, with a Treg-depleting anti-CCR4 antibody, mogamulizumab, provides an acceptable safety profile, antitumor activity, and a potentially effective option in cancer immunotherapy.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-1090" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-1090</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>New High-Throughput Screening Identifies Compounds That Reduce Viability Specifically in Liver Cancer Cells That Express High Levels of SALL4 by Inhibiting Oxidative Phosphorylation</strong> </summary></p>
<p><em>Gastroenterology 2019 12;157(6):1615-1629.e17</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31446059" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31446059</a></p>
<p>BACKGROUND &amp; AIMS: Some oncogenes encode transcription factors, but few drugs have been successfully developed to block their activity specifically in cancer cells. The transcription factor SALL4 is aberrantly expressed in solid tumor and leukemia cells. We developed a screen to identify compounds that reduce the viability of liver cancer cells that express high levels of SALL4, and we investigated their mechanisms. METHODS: We developed a stringent high-throughput screening platform comprising unmodified SNU-387 and SNU-398 liver cancer cell lines and SNU-387 cell lines engineered to express low and high levels of SALL4. We screened 1597 pharmacologically active small molecules and 21,575 natural product extracts from plant, bacteria, and fungal sources for those that selectively reduce the viability of cells with high levels of SALL4 (SALL4hi cells). We compared gene expression patterns of SALL4hi cells vs SALL4-knockdown cells using RNA sequencing and real-time polymerase chain reaction analyses. Xenograft tumors were grown in NOD/SCID gamma mice from SALL4hi SNU-398 or HCC26.1 cells or from SALL4lo patient-derived xenograft (PDX) cells; mice were given injections of identified compounds or sorafenib, and the effects on tumor growth were measured. RESULTS: Our screening identified 1 small molecule (PI-103) and 4 natural compound analogues (oligomycin, efrapeptin, antimycin, and leucinostatin) that selectively reduced viability of SALL4hi cells. We performed validation studies, and 4 of these compounds were found to inhibit oxidative phosphorylation. The adenosine triphosphate (ATP) synthase inhibitor oligomycin reduced the viability of SALL4hi hepatocellular carcinoma and non-small-cell lung cancer cell lines with minimal effects on SALL4lo cells. Oligomycin also reduced the growth of xenograft tumors grown from SALL4hi SNU-398 or HCC26.1 cells to a greater extent than sorafenib, but oligomycin had little effect on tumors grown from SALL4lo PDX cells. Oligomycin was not toxic to mice. Analyses of chromatin immunoprecipitation sequencing data showed that SALL4 binds approximately 50% of mitochondrial genes, including many oxidative phosphorylation genes, to activate their transcription. In comparing SALL4hi and SALL4-knockdown cells, we found SALL4 to increase oxidative phosphorylation, oxygen consumption rate, mitochondrial membrane potential, and use of oxidative phosphorylation-related metabolites to generate ATP. CONCLUSIONS: In a screening for compounds that reduce the viability of cells that express high levels of the transcription factor SALL4, we identified inhibitors of oxidative phosphorylation, which slowed the growth of xenograft tumors from SALL4hi cells in mice. SALL4 activates the transcription of genes that regulate oxidative phosphorylation to increase oxygen consumption, mitochondrial membrane potential, and ATP generation in cancer cells. Inhibitors of oxidative phosphorylation might be used for the treatment of liver tumors with high levels of SALL4.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.08.022" class="uri">https://doi.org/10.1053/j.gastro.2019.08.022</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comparison of Tissue and Blood Concentrations of Oxaliplatin Administrated by Different Modalities of Intraperitoneal Chemotherapy</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(13):4445-4451</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31399820" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31399820</a></p>
<p>BACKGROUND: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new technology for delivering intraperitoneal chemotherapy. It is generally assumed that with PIPAC, the ratio of peritoneal to systemic drug concentration is superior to liquid hyperthermic intraperitoneal chemotherapy (HIPEC). To date, no direct comparative data are available supporting such an assumption. MATERIALS AND METHODS: Twelve 65-day-old pigs were randomly separated into three groups of four pigs each, all of which received intraperitoneal chemotherapy using the following administration methods: PIPAC with oxaliplatin 92mg in 150ml dextrose 5% (Group 1); PIPAC with electrostatic aerosol precipitation (ePIPAC; Group 2); or laparoscopic HIPEC (L-HIPEC) with oxaliplatin 400mg in 4L dextrose 5% at 42C (Group 3). Serial blood and peritoneal tissue concentrations of oxaliplatin were determined by spectrometry. RESULTS: In all three groups, the maximum concentration of oxaliplatin in blood was detected 50-60min after onset of the chemotherapy experiments, with no significant differences among the three groups (p=0.7994). Blood oxaliplatin concentrations (0-30min) were significantly higher in the L-HIPEC group compared with the ePIPAC group (p&lt;0.05). No difference was found for the overall systemic oxaliplatin absorption (area under the curve). Overall concentrations in the peritoneum were not different among the three groups (p=0.4725), but were significantly higher in the visceral peritoneum in the PIPAC group (p=0.0242). CONCLUSIONS: Blood and tissue concentrations were comparable between all groups; however, depending on the intraperitoneal area examined and the time points of drug delivery, the concentrations differed significantly between the three groups.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07695-z" class="uri">https://doi.org/10.1245/s10434-019-07695-z</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreatic cancer-A disease in need: Optimizing and integrating supportive care</strong> </summary></p>
<p><em>Cancer 2019 Nov;125(22):3927-3935</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31381149" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31381149</a></p>
<p>Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that continues to be challenging to treat. PDAC has the lowest 5-year relative survival rate compared with all other solid tumor malignancies and is expected to become the second-leading cause of cancer-related death in the United States by 2030. Given the high mortality, there is an increasing role for concurrent anticancer and supportive care in the management of patients with PDAC with the aims of maximizing length of life, quality of life, and symptom control. Emerging trends in supportive care that can be integrated into the clinical management of patients with PDAC include standardized supportive care screening, early integration of supportive care into routine cancer care, early implementation of outpatient-based advance care planning, and utilization of electronic patient-reported outcomes for improved symptom management and quality of life. The most common symptoms experienced are nausea, constipation, weight loss, diarrhea, anorexia, and abdominal and back pain. This review article includes current supportive management strategies for these and others. Common disease-related complications include biliary and duodenal obstruction requiring endoscopic procedures and venous thromboembolic events. Patients with PDAC continue to have a poor prognosis. Systemic therapy options are able to palliate the high symptom burden but have a modest impact on overall survival. Early integration of supportive care can lead to improved outcomes.</p>
<p>doi: <a href="https://doi.org/10.1002/cncr.32423" class="uri">https://doi.org/10.1002/cncr.32423</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Nov;25(22):6692-6699</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31375514" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31375514</a></p>
<p>PURPOSE: Tumor growth rate (TGR) represents the percentage change in tumor volume per month (%/m). Previous results from the GREPONET study showed that TGR measured after 3 months (TGR3m) of starting systemic treatment (ST) or watch and wait (WW) was an early biomarker predicting progression-free survival (PFS) in neuroendocrine tumors (NET). EXPERIMENTAL DESIGN: Patients from 7 centers with advanced grade (G) 1/2 NETs from the pancreas (P)/small bowel (SB) initiating ST/WW were eligible. Computed tomography (CT)/MRI performed at prebaseline, baseline, and 3(1) months of study entry were retrospectively reviewed. Aim-1: explore treatment-induced changes in TGR (TGR3m-BL; paired T test), and Aim-2: validate TGR3m (&lt;0.8%/m vs.0.8%/m) as an early biomarker in an independent cohort (Kaplan-Meier/Cox regression). RESULTS: Of 785 patients screened, 127 were eligible. Mean (SD) TGR0 and TGR3m were 5.4%/m (14.9) and -1.4%/m (11.8), respectively. Mean (SD) TGR3m-BL paired-difference was -6.8%/m (19.3; P &lt; 0.001). Most marked TGR3m-BL [mean (SD)] were identified with targeted therapies [-11.3%/m (4.7); P = 0.0237] and chemotherapy [-7.9%/m (3.4); P = 0.0261]. Multivariable analysis confirmed the absence of previous treatment (OR = 4.65; 95% CI, 1.31-16.52; P = 0.018) and low TGR3m (continuous variable; OR 1.09; 95% CI, 1.01-1.19; P = 0.042) to be independent predictors of radiologic objective response. When the multivariable survival analysis for PFS (Cox regression) was adjusted to grade (P = 0.004) and stage (P = 0.017), TGR3m  0.8 (vs.&lt;0.8) maintained its significance as a prognostic factor (P &lt; 0.001), whereas TGR0 and TGR3m-BL did not. TGR3m  0.8%/m was confirmed as an independent prognostic factor for PFS [external validation; Aim-2; multivariable HR 2.21 (95% CI, 1.21-3.70; P = 0.003)]. CONCLUSIONS: TGR has a role as a biomarker for monitoring response to therapy for early identification of treatment-induced changes and for early prediction of PFS and radiologic objective response.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-0963" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-0963</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ZEB1 promotes inflammation and progression towards inflammation-driven carcinoma through repression of the DNA repair glycosylase MPG in epithelial cells</strong> </summary></p>
<p><em>Gut 2019 12;68(12):2129-2141</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31366457" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31366457</a></p>
<p>OBJECTIVE: Chronic inflammation is a risk factor in colorectal cancer (CRC) and reactive oxygen species (ROS) released by the inflamed stroma elicit DNA damage in epithelial cells. We sought to identify new drivers of ulcerative colitis (UC) and inflammatory CRC. DESIGN: The study uses samples from patients with UC, mouse models of colitis and CRC and mice deficient for the epithelial-to-mesenchymal transition factor ZEB1 and the DNA repair glycosylase N-methyl-purine glycosylase (MPG). Samples were analysed by immunostaining, qRT-PCR, chromatin immunoprecipitation assays, microbiota next-generation sequencing and ROS determination. RESULTS: ZEB1 was induced in the colonic epithelium of UC and of mouse models of colitis. Compared with wild-type counterparts, Zeb1-deficient mice were partially protected from experimental colitis and, in a model of inflammatory CRC, they developed fewer tumours and exhibited lower levels of DNA damage (8-oxo-dG) and higher expression of MPG. Knockdown of ZEB1 in CRC cells inhibited 8-oxo-dG induction by oxidative stress (H2O2) and inflammatory cytokines (interleukin (IL)1). ZEB1 bound directly to the MPG promoter whose expression inhibited. This molecular mechanism was validated at the genetic level and the crossing of Zeb1-deficient and Mpg-deficient mice reverted the reduced inflammation and tumourigenesis in the former. ZEB1 expression in CRC cells induced ROS and IL1 production by macrophages that, in turn, lowered MPG in CRC cells thus amplifying a positive loop between both cells to promote DNA damage and inhibit DNA repair. CONCLUSIONS: ZEB1 promotes colitis and inflammatory CRC through the inhibition of MPG in epithelial cells, thus offering new therapeutic strategies to modulate inflammation and inflammatory cancer.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2018-317294" class="uri">https://doi.org/10.1136/gutjnl-2018-317294</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Impact of Postoperative Complications on Survival and Recurrence After Resection of Colorectal Liver Metastases: Systematic Review and Meta-analysis</strong> </summary></p>
<p><em>Annals of surgery 2019 Dec;270(6):1018-1027</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30829704" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30829704</a></p>
<p>OBJECTIVE: To study the effect of postoperative complications (POC) on overall survival (OS) and disease-free survival (DFS) after surgical resection of colorectal liver metastases (CRLM). SUMMARY BACKGROUND DATA: Morbidity rates after liver resection can reach 45%. The negative impact of POC on oncologic outcomes has been reported in various types of cancer, especially colorectal. However, data on the consequences of POC after CRLM resection on long-term survival are scarce. METHODS: Eligible studies examining the association between POC after CRLM resection and OS/DFS were sought using the PubMed and Web of Science databases. A random-effects model was used to calculate pooled effect estimate for OS and DFS hazard ratios (HR), estimating between-study variance with restricted maximum likelihood estimator with Hartung-Knapp adjustment. Subgroup analysis was used to control the effect of POC on OS and DFS for: 1) Method used to define postoperative complications, 2) Exclusion of early postoperative death from survival analysis, 3) Method of data extraction used, and 4) Tumor and treatment characteristics. RESULTS: Forty-one studies were deemed eligible, including 12,817 patients. POC patients had a significant risk of reduced OS compared with no POC group (HR 1.43 [95% CI: 1.3, 1.57], P &lt; 0.0001). POC had also a negative impact on DFS. The HR for reduced DFS was 1.38 [95% CI 1.27, 1.49], P &lt; 0.0001. The negative impact of POC on survival and recurrence was confirmed in subgroup analysis. CONCLUSIONS: Our findings evidence the negative impact of POC on survival and recurrence after CRLM resection.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003254" class="uri">https://doi.org/10.1097/SLA.0000000000003254</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG Unresponsive Trials</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31712383" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31712383</a></p>
<p>PURPOSE: To characterize immune cell expression among patients with Non-Muscle Invasive Bladder Cancer (NMIBC) treated with BCG. EXPERIMENTAL DESIGN: Patients with NMIBC treated with intravesical BCG (2008-2015) were identified, and a TMA was constructed using paired pre and post-BCG bladder samples. Immunohistochemistry was performed for CD8, CD4, FoxP3, PD-L1 (SP-142 and 22C3) and PD-1. A full slide review of PD-L1+ staining tumors was performed to characterize PD-L1 and CD8 co-localization. RNAseq was performed on cored tumors from available specimens. We compared immune cell populations between BCG responders and nonresponders, and between pretreatment and postreatment tumor samples. Baseline PD-L1 staining in the BCG naive population was then validated in a separate cohort. RESULTS: The final cohort contained 63 pretreatment NMIBC cases, including 31 BCG responders and 32 BCG non-responders. No differences in CD4, CD8, or FoxP3 expression were identified between responders and non-responders. Baseline PD-L1 expression (22C3 and SP-142) was observed in 25-28% of nonresponders and 0-4% of responders (P&lt;0.01). PD-L1+ cells in BCG nonresponders co-localized with CD8+ T-cells. Additionally BCG therapy did not increase PD-L1 gene expression (RNAseq) or protein levels (IHC). The number of pre-treatment CD4+ T-cells was very low among PD-L1+ non-responders (12%) and high among PD-L1- non-responders (50%, p&lt;0.01). In a separate cohort of 57 NMIBC patients undergoing BCG, baseline PD-L1 staining was similar (26%). CONCLUSIONS: One mechanism of BCG failure may be adaptive immune resistance. Baseline tumor PD-L1 expression predicts an unfavorable response to BCG and if validated, could be used to guide therapeutic decisions.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-1920" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-1920</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer</strong> </summary></p>
<p><em>Trends in cancer 2019 Nov;5(11):724-741</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31735290" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31735290</a></p>
<p>Cancer-associated fibroblasts (CAFs) are one of the most significant components in the tumour microenvironment (TME), where they can perform several protumourigenic functions. Several studies have recently reported that CAFs are more heterogenous and plastic than was previously thought. As such, there has been a shift in the field to study CAF subpopulations and the emergent functions of these subsets in tumourigenesis. In this review, we explore how different aspects of CAF heterogeneity are defined and how these manifest in multiple cancers, with a focus on pancreatic ductal adenocarcinoma (PDAC). We also discuss therapeutic approaches to selectively target protumourigenic CAF functions, while avoiding normal fibroblasts, providing insight into the future of stromal targeting for the treatment of PDAC and other solid tumours.</p>
<p>doi: <a href="https://doi.org/10.1016/j.trecan.2019.09.010" class="uri">https://doi.org/10.1016/j.trecan.2019.09.010</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Harnessing the Microbiome for Pancreatic Cancer Immunotherapy</strong> </summary></p>
<p><em>Trends in cancer 2019 Nov;5(11):670-676</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31735286" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31735286</a></p>
<p>Late-stage pancreatic cancer harbors a fibrotic and immune-excluded tumor microenvironment that impedes immunotherapy success. A key to unlocking pancreatic cancer immunotherapy may be treating early-stage pancreatic cancer, when peripancreatic inflammation promoted by the microbiome potentiates oncogenic signaling and suppresses innate and adaptive immunity. Hence, understanding the role of microbiota in pancreatic cancer initiation, progression, and immunosuppression is crucial. We propose that not only are microbiota targets for immunomodulation in this disease, but also that microbiome profiling has a potential role in pancreatic cancer screening. Furthermore, combining microbiome profiling with liquid and tissue biopsy may validate the early pancreatic cancer treatment approach of microbiome modulation and immunotherapy.</p>
<p>doi: <a href="https://doi.org/10.1016/j.trecan.2019.10.005" class="uri">https://doi.org/10.1016/j.trecan.2019.10.005</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin 31 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells</strong> </summary></p>
<p><em>Gastroenterology 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31711924" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31711924</a></p>
<p>BACKGROUND &amp; AIMS: Pancreatic tumors undergo rapid growth and progression, become resistant to chemotherapy, and recur after surgery. We studied the functions of the solute carrier family 39 member 4 (SLC39A4, also called ZIP4), which regulates concentrations of intracellular zinc and is increased in pancreatic cancer cells, in cell lines and mice. METHODS: We obtained 93 pancreatic cancer specimens (tumor and adjacent non-tumor tissues) from patients who underwent surgery and gemcitabine chemotherapy and analyzed them by immunohistochemistry. ZIP4 and/or ITGA3 or ITGB1 were overexpressed or knocked down with small hairpin RNAs in AsPC-1 and MIA PaCa-2 pancreatic cancer cells lines, and in pancreatic cells from KPC and KPC-ZEB1 knockout mice, and pancreatic spheroids were established; cells and spheroids were analyzed by immunoblots, reverse transcription PCR, and liquid chromatography tandem mass spectrometry. We studied transcriptional regulation of ZEB1, ITGA3, ITGB1, JNK, and ENT1 by ZIP4 using chromatin precipitation and luciferase reporter assays. Nude mice were given injections of genetically manipulated AsPC-1 and MIA PaCa-2 cells and growth of xenograft tumors and metastases was measured. RESULTS: In pancreatic cancer specimens from patients, increased levels of ZIP4 associated with shorter survival times. MIA PaCa-2 cells that overexpressed ZIP4 had increased resistance to gemcitabine, 5-FU, and cisplatin, whereas AsPC-1 cells with ZIP4 knockdown had increased sensitivity to these drugs. In mice, xenograft tumors grown from AsPC-1 cells with ZIP4 knockdown were smaller and more sensitive to gemcitabine. ZIP4 overexpression significantly reduced accumulation of gemcitabine in pancreatic cancer cells, increased growth of xenograft tumors in mice, and increased expression of the integrin subunits ITGA3 and ITGB1; expression of ITGA3 and ITGB1 was reduced in cells with ZIP4 knockdown. Pancreatic cancer cells with ITGA3 or ITGB1 knockdown had reduced proliferation and formed smaller tumors in mice, despite overexpression of ZIP4; spheroids established from these cells had increased sensitivity to gemcitabine. We found ZIP4 to activate STAT3 to induce expression of ZEB1, which induced expression of ITGA3 and ITGB1 in KPC cells. Increased ITGA3 and ITGB1 expression and subsequent integrin 31 signaling, via JNK, inhibited expression of the gemcitabine transporter ENT1, which reduced gemcitabine uptake by pancreatic cancer cells. ZEB1-knockdown cells had increased sensitivity to gemcitabine. CONCLUSIONS: In studies of pancreatic cancer cell lines and mice, we found that ZIP4 increases expression of the transcription factor ZEB1, which activates expression of ITGA3 and ITGB1. The subsequent increase in integrin 31 signaling, via JNK, inhibits expression of the gemcitabine transporter ENT1, so that cells take up smaller amounts of the drug. Activation of this pathway might help mediate resistance of pancreatic tumors to chemotherapeutic agents.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.10.038" class="uri">https://doi.org/10.1053/j.gastro.2019.10.038</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>External validation of the Besanon nomogram in Asian patients with advanced pancreatic cancer receiving second-line chemotherapy: A multi-institute experience in Taiwan</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31711795" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31711795</a></p>
<p>BACKGROUND: Determining survival outcome in advanced pancreatic ductal adenocarcinoma (aPDAC) patients receiving second-line (L2) chemotherapy is important for clinical decision-making. The Besanon group from France recently proposed a prognostic nomogram to predict overall survival (OS) for aPDAC patients receiving L2 chemotherapy. The present study aimed to externally validate the performance of the Besanon nomogram in predicting OS in an Asian cohort. METHODS: We retrospectively enrolled 349 patients who received L2 chemotherapy for aPDAC between 2010 and 2016at four institutes in Taiwan. The performance of the Besanon model in this cohort was evaluated with C-index and calibration plots. RESULTS: The median OS time in our patient cohort was 4.5 months (95% confidence interval [CI], 3.0-5.0). Using the Besanon nomogram-predicted risk groups, the median OS times in the low, intermediate, and high-risk groups were 6.7 (95% CI, 5.3-8.2), 3.2 (95% CI, 2.4-3.9), and 1.7 months (95% CI, 0.6-2.7), respectively. The C-index of the predicted six- and 12-month survival probabilities for the Besanon nomogram were 0.766 (95% CI, 0.715-0.816) and 0.698 (95% CI, 0.641-0.754), respectively. The calibration plot showed that the observed six-month survival probability was close to the diagonal line, while that for 12-month survival deviated below the diagonal line compared to the survival probability predicted by the Besanon nomogram. CONCLUSIONS: Although the Besanon nomogram tended to over-estimate the 12-month survival probability, our study demonstrated that the nomogram is a reliable and readily applicable model to estimate survival outcomes of aPDAC patients receiving L2 chemotherapy.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.11.001" class="uri">https://doi.org/10.1016/j.pan.2019.11.001</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Relationship of pancreas volume to tobacco smoking and alcohol consumption following pancreatitis</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31708473" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31708473</a></p>
<p>BACKGROUND: Tobacco smoking and alcohol consumption are established risk factors for diseases of the pancreas. With the recent advances in imaging modalities (such as magnetic resonance (MR) imaging), opportunities have arisen to study pancreas size, in both health and disease. Studies investigating the relationship between tobacco smoking, alcohol consumption, and total pancreas volume (TPV) - a holistic measure of pancreatic exocrine reserve - are lacking. The aim of the present study was to investigate the associations between MR-derived TPV and tobacco smoking/alcohol consumption. METHODS: This cross-sectional study recruited individuals with a history of pancreatitis and healthy controls. A validated questionnaire was used to ascertain current and lifetime tobacco smoking and alcohol consumption. TPV was quantified using MR images by two independent raters. Generalized additive models and linear regression analyses were conducted and adjusted for demographic, metabolic, and pancreatitis-related factors. RESULTS: A total of 107 individuals following pancreatitis and 38 healthy controls were included. There was no statistically significant difference in TPV between any of the tobacco smoking/alcohol consumption categories of individuals following pancreatitis and healthy controls, in both unadjusted and adjusted analyses. In individuals following pancreatitis, multivariate linear regression found no association between TPV and 7 smoking- and alcohol-related variables. Sensitivity analyses constrained to individuals who did not abstain from either smoking or drinking following their first attack of pancreatitis did not yield statistical significance with TPV. In post-hoc analysis, age was significantly inversely associated with TPV in the most adjusted model (p=0.016). CONCLUSIONS: This is the first study to investigate the association between tobacco smoking, alcohol consumption, and MR-derived TPV following pancreatitis. It appears that age, but not tobacco smoking or alcohol consumption, is associated with a significantly reduced TPV.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.10.009" class="uri">https://doi.org/10.1016/j.pan.2019.10.009</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Diabetes mellitus is associated with unfavorable pathologic features, increased postoperative mortality, and worse long-term survival in resected pancreatic cancer</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31706821" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31706821</a></p>
<p>BACKGROUND: The risk of pancreatic ductal adenocarcinoma (PDAC) is increased in patients with diabetes mellitus (DM), particularly in those with new-onset DM. However, the impact of DM on outcomes following pancreatic surgery is not fully understood. We sought to explore the effects of DM on post-resection outcomes in patients undergoing either upfront resection or following neoadjuvant treatment (NAT). METHODS: Resections for PDAC between 2007 and 2016 were identified from a prospectively-maintained database. Data on demographics, pathology, and perioperative outcomes were compared between patients with or without DM. Survival analysis was performed using Kaplan-Meier curves and adjusted for confounders by a Cox-proportional hazards model. RESULTS: 662 patients were identified, of whom 277 (41.8%) had DM. Diabetics were more likely to be male, had higher BMI, and higher ASA-scores. At pathology, DM was associated with larger tumors (30 vs.26mm; p=0.041), higher rates of lymph-node involvement (69% vs.59%; p=0.031) and perineural invasion (88% vs.82%; p=0.026). Despite having similar rates of complications, diabetics experienced higher 30-day mortality (3.2% vs.0.8%; p=0.019). Median overall survival was worse in diabetic patients (18 vs.34 months; p&lt;0.001); this effect was more pronounced in patients with NAT (18 vs.54 months; p&lt;0.001). At multivariate analysis, DM was confirmed as an independent predictor of post-resection survival. CONCLUSION: DM is a common comorbidity in PDAC and is associated with unfavorable pathology, as well as worse postoperative and oncologic outcomes. The blunted effect on survival is more pronounced in patients who undergo resection following NAT.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.10.007" class="uri">https://doi.org/10.1016/j.pan.2019.10.007</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Childhood pancreatic trauma: Clinical presentation, natural history and outcome</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31706820" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31706820</a></p>
<p>OBJECTIVES: To study the presentation, management strategies and long-term natural history of children with pancreatic trauma. METHODS: Children admitted with pancreatic trauma were analyzed for their presentation, management and outcome. Management included nasojejunal feeds, total parenteral nutrition (TPN), octreotide, drainage (radiological and endoscopic), endoscopic retrograde cholangiopancreatography (ERCP) and surgery. Patients were assessed in follow-up for development of chronic pancreatitis (CP). RESULTS: 36 children [29 boys, age 144 (13-194) months] presented at 30 (3-210) days after trauma. Most common cause of trauma was bicycle handle bar injury [n=18,50%]. Presenting features were abdominal pain [n=26,72%], lump [n=16, 44.4%], ascites [n=13,36%], pleural effusion [n=9,25%] and anasarca [n=3,8.3%]. All presented with sequelae of ductal disruption with pseudocyst, ascites or pleural effusion. Fifteen (41.6%) patients each had Grade III and IV injury, 4 (11%) had grade V, and grading was unavailable in 2. Other organs were injured in 4 (11%) cases. Management consisted of various combinations of nasojejunal feeds [n=17,47.2%], TPN [n=5,13.8%], octreotide [n=13,36%], pseudocyst drainage [radiological (n=18,50%), endoscopic (n=3,8.3%)] and ERCP [n=12,33.3%]. Surgical intervention was done in 2 (5.5%) cases [cystojejunostomy and peritoneal lavage in 1 each]. Two (5.5%) patients died due to sepsis. Of the 32 cases in follow-up, 19 (59.3%) recovered and 13 (40.6%) developed CP, with half (6/13) of them being symptomatic with recurrent pain. CONCLUSION: Multi-disciplinary non-operative management is effective for managing pancreatic trauma in 94.4% of children, with 75% requiring radiological or endoscopic intervention. 40% developed structural changes later but only half were symptomatic.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.10.008" class="uri">https://doi.org/10.1016/j.pan.2019.10.008</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Endoscopic and surgical drainage for pancreatic fluid collections are better than percutaneous drainage: Meta-analysis</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31706819" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31706819</a></p>
<p>BACKGROUND: Pancreatic pseudocyst (PP) and walled-off necrosis can be managed endoscopically, percutaneously or surgically, but with diverse efficacy. AIMS &amp; METHODS: A comprehensive literature search was carried out from inception to December 2018, to identify articles which compared at least two of the three kinds of treatment modalities, regarding the mortality, clinical success, recurrence, complications, cost and length of hospitalisation (LOH). RESULTS: The outcomes of endoscopic (ED) and percutaneous drainage (PD) were comparable in six articles. The clinical success of endoscopic intervention was better considering any types of fluid collections (OR=3.36; 95% confidence interval (CI) 1.48, 7.63; p=0.004). ED was preferable regarding recurrence of PP (OR=0.23; 95% CI 0.08, 0.66; p=0.006). Fifteen articles compared surgical intervention with ED. Significant difference was found in postoperative LOH (WMD (days)=-4.61; 95%CI -7.89,-1.33; p=0.006) and total LOH (WMD (days)=-3.67; 95%CI -5.00,-2.34; p&lt;0.001) which favored endoscopy, but ED had lower rate of clinical success (OR=0.54; 95% CI 0.35, 0.85; p=0.007) and higher rate of recurrence (OR=1.80; 95% CI 1.16, 2.79; p=0.009) in the treatment of PP. Eleven studies compared surgical and percutaneous intervention. PD resulted in higher rate of recurrence (OR=4.91; 95% CI 1.82, 13.22; p=0.002) and lower rate of clinical success (OR=0.13; 95% CI 0.07, 0.22, p&lt;0.001). CONCLUSION: Both endoscopy and surgery are preferable over percutaneous intervention, furthermore endoscopic treatment is associated with shorter hospitalisation than surgery.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.10.006" class="uri">https://doi.org/10.1016/j.pan.2019.10.006</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Can Prognosis Be Modified in Pancreatic Cancer?</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31701297" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31701297</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-08052-w" class="uri">https://doi.org/10.1245/s10434-019-08052-w</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Three-dimensional visualization of cleared human pancreas cancer reveals that sustained epithelial-to-mesenchymal transition is not required for venous invasion</strong> </summary></p>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31700162" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31700162</a></p>
<p>Venous invasion is three times more common in pancreatic cancer than it is in other major cancers of the gastrointestinal tract, and venous invasion may explain why pancreatic cancer is so deadly. To characterize the patterns of venous invasion in pancreatic cancer, 52 thick slabs (up to 5mm) of tissue were harvested from 52 surgically resected human ductal adenocarcinomas, cleared with a modified iDISCO method, and labeled with fluorescent-conjugated antibodies to cytokeratin 19, desmin, CD31, p53 and/or e-cadherin. Labeled three-dimensional (3D) pancreas cancer tissues were visualized with confocal laser scanning or light sheet microscopy. Multiple foci of venous and even arterial invasion were visualized. Venous invasion was detected more often in 3D (88%, 30/34 cases) than in conventional 2D slide evaluation (75%, 25/34 cases, P&lt;0.001). 3D visualization revealed pancreatic cancer cells crossing the walls of veins at multiple points, often at points where preexisting capillary structures bridge the blood vessels. The neoplastic cells often retained a ductal morphology (cohesive cells forming tubes) as they progressed from a stromal to intravenous location. Although immunolabeling with antibodies to e-cadherin revealed focal loss of expression at the leading edges of the cancers, the neoplastic cells within veins expressed e-cadherin and formed well-oriented glands. We conclude that venous invasion is almost universal in pancreatic cancer, suggesting that even surgically resectable PDAC has access to the venous spaces and thus the ability to disseminate widely. Furthermore, we observe that sustained epithelial-mesenchymal transition is not required for venous invasion in pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-019-0409-3" class="uri">https://doi.org/10.1038/s41379-019-0409-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Neuroendocrine carcinoma diagnosis from bile duct cytological specimens: A retrospective single-center study</strong> </summary></p>
<p><em>Diagnostic cytopathology 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31697402" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31697402</a></p>
<p>Neuroendocrine carcinoma (NEC) in the extrahepatic bile duct is extremely rare and clinically aggressive. Cytological examination of bile and/or bile duct brushing specimens plays an important role in the diagnosis of carcinoma of the extrahepatic bile duct, but only a few articles have described the cytological features of NEC in this area. Thus, we retrospectively analyzed the cytological features of NEC in bile and/or bile duct brushing specimens. Patients with a histopathological diagnosis of NEC who underwent bile and/or bile duct brush cytological examination were enrolled in this study. The cytological features, including the background, arrangement, and shape of the neoplastic cells, and nuclear and cytoplasmic features were reviewed. Six patients with small cell NEC were enrolled, and two of them had pancreatic tumors directly invading the bile duct wall. The cytological specimens showed small and/or large neoplastic cell clusters with occasional single cells in all cases. The neoplastic cells had a high nuclear/cytoplasmic ratio and round-to-oval nuclei with powdery chromatin, inconspicuous nucleoli, and scant cytoplasm. Nuclear molding was a characteristic finding in all cases. One case had an adenocarcinoma component, which was also present in the cytological specimen. Cytological examination of bile and/or bile duct brushing specimens can be useful for the diagnosis of small cell NEC. This is an extremely rare but aggressive carcinoma, and its diagnosis by identifying characteristic cytological features may facilitate early detection and treatment.</p>
<p>doi: <a href="https://doi.org/10.1002/dc.24334" class="uri">https://doi.org/10.1002/dc.24334</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Lipid signalling drives proteolytic rewiring of mitochondria by YME1L</strong> </summary></p>
<p><em>Nature 2019 11;575(7782):361-365</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31695197" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31695197</a></p>
<p>Reprogramming of mitochondria provides cells with the metabolic flexibility required to adapt to various developmental transitions such as stem cell activation or immune cell reprogramming, and to respond to environmental challenges such as those encountered under hypoxic conditions or during tumorigenesis1-3. Here we show that the i-AAA protease YME1L rewires the proteome of pre-existing mitochondria in response to hypoxia or nutrient starvation. Inhibition of mTORC1 induces a lipid signalling cascade via the phosphatidic acid phosphatase LIPIN1, which decreases phosphatidylethanolamine levels in mitochondrial membranes and promotes proteolysis. YME1L degrades mitochondrial protein translocases, lipid transfer proteins and metabolic enzymes to acutely limit mitochondrial biogenesis and support cell growth. YME1L-mediated mitochondrial reshaping supports the growth of pancreatic ductal adenocarcinoma (PDAC) cells as spheroids or xenografts. Similar changes to the mitochondrial proteome occur in the tumour tissues of patients with PDAC, suggesting that YME1L is relevant to the pathophysiology of these tumours. Our results identify the mTORC1-LIPIN1-YME1L axis as a post-translational regulator of mitochondrial proteostasis at the interface between metabolism and mitochondrial dynamics.</p>
<p>doi: <a href="https://doi.org/10.1038/s41586-019-1738-6" class="uri">https://doi.org/10.1038/s41586-019-1738-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31694832" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31694832</a></p>
<p>BACKGROUND: Pelareorep is an intravenously delivered oncolytic reovirus that can induce a T-cell-inflamed phenotype in pancreatic ductal adenocarcinoma (PDAC). Tumor tissues from patients treated with pelareorep have shown reovirus replication, T-cell infiltration, and upregulation of PD-L1. We hypothesized that pelareorep in combination with pembrolizumab and chemotherapy in patients with PDAC would be safe and effective. METHODS: A phase Ib single-arm study enrolled patients with PDAC who progressed after first-line treatment. Patients received pelareorep, pembrolizumab, and either 5-fluorouracil, gemcitabine, or irinotecan until disease progression or unacceptable toxicity. Study objectives included safety and dose-limiting toxicities, tumor response, evaluation for reovirus replication, and immune analysis in peripheral blood and tumor biopsies. RESULTS: Eleven patients were enrolled. Disease control was achieved in three of the 10 efficacy-evaluable patients. One patient achieved partial response for 17.4 months. Two additional patients achieved stable disease, lasting 9 and 4 months, respectively. Treatment was well tolerated, with mostly grade 1 or 2 treatment-related adverse events, including flu-like symptoms. Viral replication was observed in on-treatment tumor biopsies. T-cell receptor sequencing from peripheral blood revealed the creation of new T-cell clones during treatment. High peripheral clonality and changes in the expression of immune genes were observed in patients with clinical benefit. CONCLUSIONS: Pelareorep and pembrolizumab added to chemotherapy did not add significant toxicity and showed encouraging efficacy. Further evaluation of pelareorep and anti-PD-1 therapy is ongoing in follow-up studies. This research highlights the potential utility of several pretreatment and on-treatment biomarkers for pelareorep therapy warranting further investigation.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-2078" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-2078</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>IFN- down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer</strong> </summary></p>
<p><em>BMC cancer 2019 Nov;19(1):1053</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31694582" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31694582</a></p>
<p>BACKGROUND: Pancreatic cancer is characterized by a highly immunosuppressive tumor microenvironment and evasion of immune surveillance. Although programmed cell death 1 receptor (PD-1) blockade has achieved certain success in immunogenic cancers, the responses to the PD-1 antibody are not effective or sustained in patients with pancreatic cancer. METHODS: Firstly, PD-1 expressions on peripheral CD8+ T-lymphocytes of patients with pancreatic cancer and healthy donors were measured. In in vitro study, peripheral T-lymphocytes were isolated and treated with nivolumab and/or interferon-, and next, PD-1-blockade effects, proliferations, cytokine secretions and cytotoxic activities were tested after different treatments. In in vivo study, mice bearing subcutaneous pancreatic cancer cell lines were treated with induced T-lymphocytes and tumor sizes were measured. RESULTS: PD-1 protein expression is increased on peripheral CD8+ T cells in patients with pancreatic ductal adenocarcinoma compared with that in health donor. PD-1 expression on CD8+ T-lymphocytes was decreased by nivolumab in a concentration-dependent manner in vitro. IFN- could directly down-regulate expression of PD-1 in vitro. Furthermore, the combination therapy of nivolumab and IFN- resulted in greatest effect of PD-1-blockde (1.730.78), compared with IFN- along (18.630.82) and nivolumab along (13.651.22). Moreover, the effects of nivolumab plus IFN- largest promoted the T-lymphocytes function of proliferations, cytokine secretions and cytotoxic activities. Most importantly, T-lymphocytes induced by nivolumab plus IFN- presented the best repression of tumor growth. CONCLUSIONS: IFN- plus a PD-1-blockading agent could enhance the immunologic function and might play a crucial role in effective adoptive transfer treatments of pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6145-8" class="uri">https://doi.org/10.1186/s12885-019-6145-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Risk factors of lymph node metastasis or lymphovascular invasion for early gastric cancer: a practical and effective predictive model based on international multicenter data</strong> </summary></p>
<p><em>BMC cancer 2019 Nov;19(1):1048</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31694573" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31694573</a></p>
<p>BACKGROUND: Most lymph node metastasis (LNM) models for early gastric cancer (EGC) include lymphovascular invasion (LVI) as a predictor. However, LVI must be confirmed by postoperative pathology. In this study, we aimed to develop a model for predicting the risk of LNM/LVI in EGC using preoperative factors. METHODS: EGC patients who underwent radical gastrectomy at Fujian Medical University Union Hospital and Sun Yat-sen University Cancer Center (n=1460) were selected as the training set. The risk factors of LNM/LVI were investigated. Data from the International study group on Minimally Invasive surgery for GASTRIc Cancer trial (n=172) were selected as the validation set. RESULTS: In the training set, the incidence of LNM/LVI was 21.6%. The 5-year cancer-specific survival rates of patients with and without LNM/LVI were 92.4 and 95.0%, respectively, with significant difference (P=0.030). Multivariable logistic regression analysis showed that the four independent risk factors for LNM/LVI were female, tumor larger than 20mm, submucosal invasion and undifferentiated tumor histological type (all P&lt;0.05); the area under the curve (AUC) was 0.694 (95% confidence interval [CI]: 0.659-0.730). Patients were divided into low-risk, intermediate-risk, high-risk and extremely high-risk groups by recursive partitioning analysis; the incidences of LNM/LVI were 5.4, 12.6, 24.2 and 37.8%, respectively (P&lt;0.001). The AUC of the validation set was 0.796 (95%CI, 0.662-0.851) and the predictive performance of the LNM/LVI risk in the validation set was consistent with that in the training set. CONCLUSIONS: The risk of LNM/LVI in differentiated mucosal EGC is low, which indicated that endoscopic resection is a treatment option. The risk of LNM/LVI in undifferentiated mucosal EGC and submucosa EGC are high and gastrectomy with lymph node dissection is suggested.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6147-6" class="uri">https://doi.org/10.1186/s12885-019-6147-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pitfalls of histopathological evaluation of EUS guided microbiopsies from pancreatic cystic neoplasms</strong> </summary></p>
<p><em>Histopathology 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31693198" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31693198</a></p>
<p>The incidence of cystic lesions of the pancreas is increasing [1]. A proportion of these harbor malignant potential such as Intraductal Papillary Mucinous Neoplasms (IPMNs), where up to one third at our institution is associated with pancreatic ductal adenocarcinoma and/or have areas of microinvasion observed in surgical specimens. Other types of cysts such as Serous Cystic Neoplasms (SCNs) are considered benign and do not require surgery [2].</p>
<p>doi: <a href="https://doi.org/10.1111/his.14030" class="uri">https://doi.org/10.1111/his.14030</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>National Use of Chemotherapy in Initial Management of Stage I Pancreatic Cancer and Failure to Perform Subsequent Resection</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31691112" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31691112</a></p>
<p>INTRODUCTION: Chemotherapy is increasingly administered prior to resection in patients with early-stage pancreatic adenocarcinoma, but the national prevalence of this practice is poorly understood. Our objectives were to (1) describe the utilization of upfront chemotherapy management of stage I pancreatic cancer; (2) define factors associated with the use of upfront chemotherapy and subsequent resection; and (3) assess hospital-level variability in upfront chemotherapy and subsequent resection. METHODS: The National Cancer Database was used to identify patients treated for clinical stage I pancreatic adenocarcinoma. Outcomes were receipt of upfront chemotherapy and surgical resection after upfront chemotherapy. Associations between patient/hospital factors and both initial management and subsequent resection were assessed by multivariable logistic regression. RESULTS: A total of 17,495 patients were included, with 26.6% receiving upfront chemotherapy. Upfront chemotherapy was more likely in patients who were80years of age (odds ratio [OR] 1.64, 95% confidence interval [CI] 1.39-1.93), had T2 tumors (OR 2.56, 95% CI 2.36-2.78), or were treated at a low-volume center (OR 2.10, 95% CI 1.63-2.71). Among patients receiving upfront chemotherapy, only 33.5% underwent subsequent resection. Resection was more likely in patients with T1 tumors (OR 1.22, 95% CI 1.04-1.43) and in those treated at high-volume centers (OR 4.03, 95% CI 2.90-5.60). Only 20.4% of hospitals performed resection in&gt;50% of patients after upfront chemotherapy. CONCLUSION: Rates of surgical resection after upfront chemotherapy are relatively low, and the proportion of patients who eventually undergo resection varies considerably between hospitals. The use of surgery after upfront chemotherapy in resectable pancreatic cancer should be considered as an internal quality-of-cancer-care measure.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-08023-1" class="uri">https://doi.org/10.1245/s10434-019-08023-1</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Defining the Safety Profile for Performing Pancreatoduodenectomy in the Setting of Hyperbilirubinemia</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31691110" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31691110</a></p>
<p>BACKGROUND: Hyperbilirubinemia is commonly observed in patients requiring pancreatoduodenectomy (PD). Thus far, literature regarding the danger of operating in the setting of hyperbilirubinemia is equivocal. What remains undefined is at what specific level of bilirubin there is an adverse safety profile for undergoing PD. The aim of this study is to identify the optimal safety profile of patients with hyperbilirubinemia undergoing PD. PATIENTS AND METHODS: The present work analyzed 803 PDs from 2004 to 2018. A generalized additive model was used to determine cutoff values of total serum bilirubin (TB) that were associated with increases in adverse outcomes, including 90-day mortality. Subgroup comparisons and biliary stent-specific analyses were performed for patients with TB below and above the cutoff. RESULTS: TB of 13mg/dL was associated with an increase in 90-day mortality (P=0.043) and was the dominant risk factor on multivariate logistic regression [odds ratio (OR) 8.193, P=0.001]. Increased TB levels were also associated with reoperations, number of complications per patient, and length of stay. Patients with TB greater than or equal to 13mg/dL (TB13) who received successful biliary decompression through stenting had less combined death and serious morbidity (P=0.048). CONCLUSIONS: Preoperative TB13mg/dL was associated with increased 90-day mortality after PD. Reducing a TB13 is generally recommended before proceeding to surgery.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-08044-w" class="uri">https://doi.org/10.1245/s10434-019-08044-w</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Prognostic Implication of pN Stage Subdivision Using Metastatic Lymph Node Ratio in Resected Pancreatic Ductal Adenocarcinoma</strong> </summary></p>
<p><em>International journal of surgical pathology 2019 Nov;():1066896919886057</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31690145" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31690145</a></p>
<p>In this meta-analysis, we aimed to evaluate the prognostic implication of the metastatic lymph node ratio (mLNR) and its optimal criterion in pancreatic ductal adenocarcinoma (PDAC) with lymph node metastasis (LNM). The present study included 3735 patients with PDAC who had LNM, from 11 eligible studies. We carried out a meta-analysis to determine the correlation between a high mLNR and PDAC prognosis. The estimated mean numbers of examined and metastatic lymph nodes were 22.396 (95% confidence interval [CI] = 19.681-25.111) and 6.496 (95% CI = 4.646-8.345), respectively. A high mLNR was significantly correlated with worse overall survival (hazard ratio = 1.344, 95% CI = 1.276-1.416). In 3 subgroups based on high mLNR criteria (&gt;0 and &lt;0.2, 0.2 and &lt;0.4, and 0.4), there were significant correlations between a high mLNR and worse survival. A cutoff of 0.200 showed the highest hazard ratio (1.391, 95% CI = 1.268-1.525), which was statistically significant. Our results showed that mLNR is a useful prognostic factor for PDAC with LNM. Although the optimal criterion of high mLNR may be 0.200, further cumulative studies are required before this can be applied in daily practice.</p>
<p>doi: <a href="https://doi.org/10.1177/1066896919886057" class="uri">https://doi.org/10.1177/1066896919886057</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Ewings sarcoma of the cervix: A case report and review of literature</strong> </summary></p>
<p><em>Histology and histopathology 2019 Nov;():18181</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688946" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688946</a></p>
<p>Ewings sarcoma (ES) is a small cell malignant tumor that occurs in the bone of children or adolescents. ES can also occur in extraskeletal organs, such as the pancreas, thyroid, liver, proximal phalanx, and, rarely, cervix. Only 15 published case reports have discussed ES arising in the cervix. We report a 76-year-old woman who had groin mass. ES was diagnosed in accordance with morphological and immunohistochemical maps. Fluorescence in situ hybridization and RT-PCR (reverse transcription PCR) revealed ESWR1 gene rearrangement and fusion gene formation (EWS-FLI-1), both of which confirmed the diagnosis of ES. Although the patient underwent surgical resection, the patient died without chemotherapy and radiotherapy. This case is the first one to involve a patient aged over 70 years and the fifth one to show metastasis occurrence.</p>
<p>doi: <a href="https://doi.org/10.14670/HH-18-181" class="uri">https://doi.org/10.14670/HH-18-181</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - **** </summary></p>
<ul>
<li>;():*</li>
</ul>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=</a></p>
<p>doi: <a href="https://doi.org/" class="uri">https://doi.org/</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - **** </summary></p>
<ul>
<li>;():*</li>
</ul>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=</a></p>
<p>doi: <a href="https://doi.org/" class="uri">https://doi.org/</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Are Opioid-Naive Patients With Acute Pancreatitis Given Opioid Prescriptions at Discharge?</strong> </summary></p>
<p><em>Pancreas 2019 11;48(10):1397-1399</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688608" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688608</a></p>
<p>OBJECTIVES: Opioids are commonly used in the management of acute pancreatitis (AP). Inpatient opioid exposure is known to increase the risk of chronic opioid use after discharge. Prescription patterns for opioids at discharge for AP are unknown. METHODS: Medical records of adult AP patients who presented to the emergency department from September 1, 2013, to August 31, 2016, were reviewed. Opioid prescription at discharge was defined as a prescription for opioids in a patient who was opioid naive at admission. Multivariable logistic regression was performed to identify predictors of opioid prescription at discharge. RESULTS: A total of 259 opioid-naive AP patients were identified. Of these, 108 (41.6%) of 259 were discharged with an opioid prescription and 61 (56.5%) of 108 had discharge pain scores of 3 or lower. Two hundred twenty-two (85.7%) received opioids during admission and 105 (47.3%) of 222 were discharged with an opioid prescription. On multivariable analysis, predictors of discharge opioid prescription included inpatient use of opioids, female sex, and discharge pain score greater than 3. CONCLUSIONS: In opioid-naive AP patients, 41.6% were discharged from the hospital with a new prescription for opioids, even though a significant proportion had pain scores of 3 or lower. Guidelines are needed for opioid prescriptions at discharge for AP.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001436" class="uri">https://doi.org/10.1097/MPA.0000000000001436</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Prognostic Factors of Acinar Cell Carcinomas: A Study of 44 Patients</strong> </summary></p>
<p><em>Pancreas 2019 11;48(10):1393-1396</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688607" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688607</a></p>
<p>OBJECTIVES: Acinar cell carcinoma is a rare tumor of the pancreas. Our current series aimed to assess the clinical and morphological features of pancreatic acinar cell carcinoma and to evaluate the treatment strategies and prognosis. METHODS: This retrospective study was conducted in 3 French referral centers. Clinical data were obtained from medical records, and data about survival were then calculated and compared using statistical analysis. RESULTS: Forty-four patients were included (men, 81.8%; median age, 65.5 years; range, 21-85). Tumors were localized, locally advanced, or metastatic in 48.8%, 14.0%, and 37.2% of cases, respectively. Twenty-nine patients (65.9%) underwent a curative-intent resection (R0, 79.2%). First-line chemotherapy in metastatic patients was heterogeneous but mainly consisted in 5-fluorouracil-based or gemcitabine plus oxaliplatin combinations. Median disease-free survival was 12 months (range, 0-82 months). Median overall survival was 55.5 months; it was 40 months in patients with metastatic tumor compared with 106.5 months (P = 0.1058) in those with a nonmetastatic one. Age older than 60 years and a proliferation index greater than 30% were poor prognostic factors. CONCLUSIONS: In this large series of patients with pancreatic acinar cell carcinoma, the rate of R0 resection and the prognosis of patients appeared to be much better than that of classic ductal adenocarcinomas.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001440" class="uri">https://doi.org/10.1097/MPA.0000000000001440</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Rising Prevalence of Opioid Use Disorder and Predictors for Opioid Use Disorder Among Hospitalized Patients With Chronic Pancreatitis</strong> </summary></p>
<p><em>Pancreas 2019 11;48(10):1386-1392</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688606" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688606</a></p>
<p>OBJECTIVES: We aimed to evaluate the prevalence, impact, and predictors of opioid use disorder (OUD) in hospitalized chronic pancreatitis (CP) patients. METHODS: A retrospective cohort study was performed using the National Inpatient Sample database from 2005 to 2014. Patients with a primary diagnosis of CP and OUD were included. The primary outcome was evaluating the prevalence and trend of OUD in patients hospitalized with CP. Secondary outcomes were to (1) assess the impact of OUD on health care resource utilization and (2) identify predictors of OUD in hospitalized CP patients. RESULTS: A total of 176,857 CP patients were included, and OUD was present in 3.8% of patients. The prevalence of OUD in CP doubled between 2005 and 2014. Patients with CP who had OUD were found to have higher mean length of stay (adjusted mean difference, 1.2 days; P &lt; 0.001) and hospitalization costs (adjusted mean difference, US $1936; P &lt; 0.001). Independent predictors of OUD in CP patients were obesity, presence of depression, and increased severity of illness. CONCLUSIONS: Opioid use disorder-related diagnoses are increasing among CP patients and are associated with increased health care resource utilization. Our study identifies patients at high-risk for OUD whose pain should be carefully managed.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001430" class="uri">https://doi.org/10.1097/MPA.0000000000001430</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Activation of the Nuclear Factor-kappa B Signaling Pathway Damages the Epithelial Barrier in the Human Pancreatic Ductal Adenocarcinoma Cell Line HPAF-II</strong> </summary></p>
<p><em>Pancreas 2019 11;48(10):1380-1385</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688605" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688605</a></p>
<p>OBJECTIVES: Injury of the pancreatic duct epithelial barrier plays a critical role in the development of acute pancreatitis. The activity of the nuclear factor-kappa B (NF-B) pathway is involved in the disruption of the pancreatic duct epithelial barrier. This study investigated how NF-B impacts the dysfunction of the pancreatic duct epithelial barrier. METHODS: A human pancreatic ductal adenocarcinoma cell line was treated with tumor necrosis factor-alpha (TNF-) and pyrrolidine dithiocarbamate. The expression levels of p65 and p-p65 were detected to evaluate NF-B activity. Tricellulin (TRIC) expression levels were measured to assess the change in tight junction (TJ)-related proteins. The expression and localization of myosin light chain kinase (MLCK) were investigated. The structure of TJs and monolayer permeability were also examined. RESULTS: NF-B was activated by TNF- and suppressed by pyrrolidine dithiocarbamate. Activation of NF-B upregulated the expression levels of TRIC and MLCK. Broadened TJs were observed after NF-B was activated. Lower monolayer permeability was observed when NF-B was suppressed. CONCLUSIONS: Activation of the NF-B pathway induced by TNF- leads to increased TRIC and MLCK expression, resulting in broadened TJs and high permeability, which contribute to damage to the pancreatic duct epithelial barrier.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001441" class="uri">https://doi.org/10.1097/MPA.0000000000001441</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Racial Differences in the Incidence and Survival of Patients With Neuroendocrine Tumors</strong> </summary></p>
<p><em>Pancreas 2019 11;48(10):1373-1379</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688604" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688604</a></p>
<p>OBJECTIVES: The incidence of neuroendocrine tumors (NETs) has been steadily increasing. Racial differences in the incidence and survival are mostly unknown. This study examines the racial differences and the underlying causes. METHODS: We conducted a retrospective, population-based study using datasets from Surveillance, Epidemiology, and End Results (SEER) cancer registry and SEER data linked with Medicare claims (SEER-Medicare). We examined the incidence rates and the effects of patient demographics, clinical characteristics, and socioeconomic factors on survival. RESULTS: Of the 15,786 and 1731 cases from SEER and SEER-Medicare, 1991 and 163 were blacks, respectively. We found that blacks had higher NET incidence for all stages, with the largest difference noted in the local stage (4.3 vs 2.6 per 100,000 in whites). We found worse survival for distant-stage black patients, although they more often had clinical factors typically associated with better prognosis in NETs. However, they were also found to have significant unfavorable differences in socioeconomic and sociodemographic factors. CONCLUSIONS: Blacks have higher incidence of NETs and worse survival compared with other races, especially whites. The influences of neighborhood socioeconomic, sociodemographic, and marital status suggest that social determinants, support mechanisms, and access to health care may be contributing factors.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001431" class="uri">https://doi.org/10.1097/MPA.0000000000001431</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Expression of Epithelial-Mesenchymal Transition Markers in Treated Pancreatic Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Pancreas 2019 11;48(10):1367-1372</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688603" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688603</a></p>
<p>OBJECTIVES: Epithelial-mesenchymal transition (EMT) plays an important role in the progression, metastasis, and chemoresistance of pancreatic duct adenocarcinoma (PDAC); however, the expression of EMT markers and their clinical significance in PDAC patients who received neoadjuvant therapy (NAT) are unclear. METHODS: We examined the expression of EMT markers, including Zeb-1 (zinc finger E-box-binding homeobox 1), E-cadherin, and vimentin by immunohistochemistry in 120 PDAC patients who received NAT and pancreatectomy from 1999 to 2007. The results were correlated with clinicopathologic parameters and survival. RESULTS: Among 120 cases, 45 (37.5%) and 14 (11.7%) were positive for Zeb-1 and vimentin, respectively, and 25 (20.8%) were E-cadherin-low. The median overall survival and disease-free survival were 35.3 (standard deviation [SD], 2.8) and 15.9 (SD, 3.6) months, respectively, in vimentin-negative group compared with 16.1 (SD, 1.1) (P = 0.03) and 7.0 (SD, 1.1) months (P = 0.02) in the vimentin-positive group. In multivariate analysis, vimentin expression was an independent predictor of shorter disease-free survival (hazard ratio, 2.50; 95% confidence interval, 1.31-4.78; P = 0.016) and overall survival (hazard ratio, 2.55; 95% confidence interval, 1.33-4.89; P = 0.01). CONCLUSIONS: Epithelial-mesenchymal transition markers are frequently expressed in treated PDAC. Vimentin expression is a prognostic biomarker for survival in PDAC patients who received NAT.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001432" class="uri">https://doi.org/10.1097/MPA.0000000000001432</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Estimation of Extracellular Volume Fraction With Routine Multiphasic Pancreatic Computed Tomography to Predict the Survival of Patients With Stage IV Pancreatic Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Pancreas 2019 11;48(10):1360-1366</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688602" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688602</a></p>
<p>OBJECTIVE: This study aimed to determine whether extracellular volume (ECV) fraction with routine equilibrium contrast-enhanced computed tomography (CT) can predict outcomes in patients with stage IV pancreatic ductal adenocarcinoma (PDAC) treated with chemotherapy. METHODS: This is a retrospective cohort study of 128 patients with stage IV PDAC who underwent multiphasic pancreatic CT before systemic chemotherapy. Contrast enhancement and ECV fraction of the primary lesion were calculated using region-of-interest measurement within the PDAC and aorta on unenhanced and equilibrium phase-enhanced CT. The effects of clinical prognostic factors and ECV fractions on progression-free survival (PFS) and overall survival (OS) were assessed by univariate and multivariate analyses using Cox proportional hazards models. RESULTS: The number of metastatic organs and tumor ECV fraction were significant for PFS (P = 0.005 and 0.001, respectively) and OS (P = 0.012 and 0.007, respectively). On the multivariate analysis, multiple metastatic organs (PFS, P = 0.046; OS, P = 0.047) and lower tumor ECV fraction (PFS, P = 0.010; OS, P = 0.026) were identified as independent predictors of poor PFS and OS. CONCLUSION: Extracellular volume fraction with routine equilibrium contrast-enhanced CT may potentially predict survival in patients with stage IV PDAC treated with chemotherapy.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001427" class="uri">https://doi.org/10.1097/MPA.0000000000001427</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A Clinical Feasible Method for Computed Tomography-Based Assessment of Sarcopenia in Patients With Chronic Pancreatitis</strong> </summary></p>
<p><em>Pancreas 2019 11;48(10):1354-1359</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688601" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688601</a></p>
<p>OBJECTIVES: Sarcopenia is a serious but often overlooked complication of chronic pancreatitis (CP). We investigated the prevalence and risk factors for sarcopenia in patients with CP and determined the utility of a computed tomography (CT)-based method, based on psoas muscle measurements, for easy and clinical feasible diagnosis of sarcopenia. METHODS: This was a retrospective multicenter study of 265 patients with CP. We used segmentation of CT images to quantify skeletal muscle mass and diagnose sarcopenia. On the same CT image as used for muscle segmentation, psoas muscle thickness and cross-sectional area were measured and receiver operating characteristic analyses defined age and sex-specific cutoffs for diagnosing sarcopenia. RESULTS: The prevalence of sarcopenia was 20.4%. The optimal height-adjusted psoas muscle cross-sectional area cutoff for diagnosing sarcopenia was 3.3 cm/m in males and 2.5 cm/m in females. The corresponding area under the receiver operating characteristic curves were 0.8 and 0.9, with sensitivities of 84% and 81% and specificities of 62% and 81%, respectively. Comparable diagnostic performance characteristics were observed for psoas muscle thickness. CONCLUSIONS: Sarcopenia is present in 1 of 5 patients with CP. Assessment of psoas muscle parameters provides a clinical feasible method to diagnose sarcopenia.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001439" class="uri">https://doi.org/10.1097/MPA.0000000000001439</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Prevalence and Associated Factors of Abdominal Pain and Disability at 1-Year Follow-up After an Attack of Acute Pancreatitis</strong> </summary></p>
<p><em>Pancreas 2020 11;48(10):1348-1353</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688600" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688600</a></p>
<p>OBJECTIVE: The aim of the study was to report the prevalence and predictors of abdominal pain and disability 1 year after an acute pancreatitis (AP) attack. METHODS: Patients were prospectively enrolled between December 2012 and April 2016. Enrolled subjects were contacted at a median of 13 months after enrollment. Multivariable regression models were used to determine factors independently associated with abdominal pain at follow-up. RESULTS: Response rate was 71% (110/155). Of respondents, median age was 51 years, 58% were female, and 14% had severe AP. At follow-up, 24% of patients reported abdominal pain (65% intermittent, 35% constant), 10% used analgesics regularly, and 6% had regular opioids use. Furthermore, 41% of patients experienced pain-related interference with work or daily activities, and 8% developed disability. On regression analysis, idiopathic etiology (odds ratio [OR], 3.8; 95% confidence interval [CI], 1.1-13.6) failure (OR, 3.3; 95% CI, 1.1-7.9), and recurrent AP (OR, 2.9; 95% CI, 1.1-10.6) were independently associated with abdominal pain at follow-up. Disability at follow-up was associated with younger age, current smoking, and intensive care unit admission (all P &lt; 0.05). CONCLUSIONS: Abdominal pain and disability are potential long-term sequelae of AP. Certain pre-existing factors and pancreatitis features are associated with these outcomes at one-year follow-up of AP.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001434" class="uri">https://doi.org/10.1097/MPA.0000000000001434</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Performance Characteristics of Magnetic Resonance Imaging in Patients With Pancreas Divisum</strong> </summary></p>
<p><em>Pancreas 2019 11;48(10):1343-1347</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688599" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688599</a></p>
<p>OBJECTIVE: This study was designed to assess the diagnostic accuracy of standard nonsecretin-enhanced preprocedural magnetic resonance imaging/cholangiopancreatography (MRI/MRCP) in patients with and without pancreas divisum. METHODS: Patients undergoing MRI/MRCP followed by endoscopic retrograde cholangiopancreatography with between 2009 and 2016 were reviewed. The diagnostic accuracy of the MRI/MRCP was evaluated against the pancreatography. A subsequent independent blinded re-review performed by an expert abdominal radiologist was also evaluated. Multivariate binary logistic regression was performed to assess the impact of clinicopathologic factors on the diagnostic accuracy. RESULTS: A total of 189 patients were included in analysis. The sensitivity, specificity, positive predictive value, and negative predictive value of MRI/MRCP for pancreas divisum were 63%, 97%, 94%, and 82% initially and 81%, 91%, 91%, and 82% on the expert review. Motion artifact, the presence of pancreatic tumor, and pancreatic necrosis were not found to significantly impact the accuracy. A normal diameter pancreatic duct (P = 0.04) and complete divisum anatomy were correlated with improved accuracy (P = 0.001). CONCLUSIONS: Although expert review, normal duct diameter, and complete divisum are associated with increased sensitivity, pancreas divisum may be uncharacterized by preprocedural MRI in 19% to 37% of patients before the index endoscopic retrograde cholangiopancreatography.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001437" class="uri">https://doi.org/10.1097/MPA.0000000000001437</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Systematic Review and Meta-analysis of Minimally Invasive Pancreatectomies for Solid Pseudopapillary Neoplasms of the Pancreas</strong> </summary></p>
<p><em>Pancreas 2019 11;48(10):1334-1342</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688598" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688598</a></p>
<p>OBJECTIVES: We report the first systematic review and meta-analysis on minimally invasive pancreatectomy (MIP) for solid pseudopapillary neoplasms (SPPN) of the pancreas. METHODS: A systematic review of all studies reporting patient characteristics and outcomes of MIP for SPPN was conducted. RESULTS: We reviewed 27 studies comprising 149 patients with SPPN managed via MIP. Five were comparative retrospective cohort studies, comprising 46 and 60 patients in the minimally-invasive and open groups, respectively. Tumor size was smaller in the minimally-invasive group (mean difference, -2.20; 95% confidence interval (CI), -3.09 to -1.32; P &lt; 0.001). The MI group had lower intraoperative blood loss (mean difference, -180.19; 95% CI, -344.28 to -16.09; P = 0.03) and transfusion requirement (relative risk, 0.24; 95% CI, 0.06-0.94; P = 0.04), and a shorter time to diet (mean difference, -2.99; 95% CI, -3.96 to -2.03; P &lt; 0.001) and length of stay (mean difference, -3.61; 95% CI, -6.98 to -0.24; P = 0.04). There was no significant difference in operating time, margin positivity, postoperative morbidity, and postoperative pancreatic fistula rates. CONCLUSIONS: Minimally invasive pancreatectomy for SPPN is associated with decreased intraoperative blood loss and transfusion requirements and a shorter postoperative time to diet and hospital stay.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001426" class="uri">https://doi.org/10.1097/MPA.0000000000001426</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Portal Vein Thrombosis After Total Pancreatectomy and Islet Autotransplant: Prophylaxis and Graft Impact</strong> </summary></p>
<p><em>Pancreas 2019 11;48(10):1329-1333</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688597" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688597</a></p>
<p>OBJECTIVES: To determine the rate of portal vein thrombosis (PVT) based on pharmacologic prophylaxis protocol and the impact of PVT on islet graft function after total pancreatectomy with islet autotransplantation (TPIAT). METHODS: We compared the incidence of PVT, postsurgical bleeding, and thrombotic complications in patients undergoing TPIAT between 2001 and 2018 at the University of Minnesota who received either unfractionated heparin (UFH) or enoxaparin for postoperative PVT prophylaxis. Six-month and 1-year graft function was compared between patients who developed PVT and those who did not. RESULTS: Twelve patients (6.6%) developed a PVT, which resolved by 6 months after TPIAT in 10 patients. There was no statistically significant difference in PVT rate between patients who received UFH or enoxaparin for prophylaxis (P = 0.54). Patients who received enoxaparin developed other thrombotic complications more often (6% vs 0%, P = 0.02). Islet graft function did not differ in patients who developed PVT versus those who did not. CONCLUSIONS: There was no difference between enoxaparin or UFH prophylaxis in preventing PVT, but there may be a higher incidence of other thrombotic complications with enoxaparin. In the setting of routine screening and anticoagulation therapy, PVT is a self-limited process.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001421" class="uri">https://doi.org/10.1097/MPA.0000000000001421</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Severe Acute Pancreatitis in Autopsies Associated With Surgeries and Severe Inflammatory Diseases</strong> </summary></p>
<p><em>Pancreas 2019 11;48(10):1321-1328</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688596" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688596</a></p>
<p>OBJECTIVE: We clarified clinicopathological characteristics of acute pancreatitis in terminal patients. METHODS: Pathological changes in the entire pancreas from serial autopsies (N = 183) classified lesions into the following 3 categories: focal neutrophil infiltration, focal necrotizing pancreatitis, and diffuse necrotizing pancreatitis. The former two are possible precursors of diffuse necrotizing pancreatitis. Immunohistochemical staining was performed to analyze pancreatic stellate cells and inflammatory cells. RESULTS: There were pathologically acute pancreatitis in 45 patients (24.6%), and no patients were diagnosed with it before autopsy. Focal neutrophil infiltration was present in 22 cases, focal necrotizing pancreatitis in 18 cases, and diffuse necrotizing pancreatitis in 5 cases. Severe inflammatory disease and surgery were associated with acute pancreatitis. Sepsis due to viral or bacterial infection was the most common cause of acute pancreatitis. Patients with diffuse necrotizing pancreatitis showed low white blood cell counts, while amylase levels were not increased. Increase in -smooth muscle actin and nestin-positive stellate cell numbers in acute pancreatitis was correlated to increase in numbers of CD34-positive vascular endothelium, CD68- or CD163-positive macrophages, CD138-positive plasmacytes, CD3-positive T lymphocytes, and myeloperoxidase-positive leucocytes. CONCLUSIONS: Necrotizing pancreatitis without typical clinical signs was frequently detected in autopsy samples. Clinicians must be mindful of necrotizing pancreatitis in terminal patients.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001423" class="uri">https://doi.org/10.1097/MPA.0000000000001423</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Investigation of Fluorodeoxyglucose Positron Emission Tomography for the Diagnosis of Solid Pseudopapillary Neoplasm of the Pancreas: A Study Associated With a National Survey of Solid Pseudopapillary Neoplasms</strong> </summary></p>
<p><em>Pancreas 2019 11;48(10):1312-1320</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688595" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688595</a></p>
<p>OBJECTIVES: This study aimed to investigate the utility of fluorodeoxyglucose (FDG) positron emission tomography for solid pseudopapillary neoplasm (SPN) diagnosis. METHODS: The subjects included 53 cases of SPN. We compared the maximal standardized uptake volume (SUVmax) with those of 25 cases of pancreatic duct cancer and 18 cases of pancreatic neuroendocrine neoplasm. In addition, immunopathological testing for SPN with regard to FDG uptake was undertaken. RESULTS: An increase in SUVmax was observed in all tumors with increased tumor diameter. Among tumors of 20 mm or smaller, the SUVmax of SPN was significantly higher than those of pancreatic duct cancer and pancreatic neuroendocrine neoplasm. The results of a pathological study of FDG uptake in SPN revealed increased glucose transporter protein type 1 expression with tumor enlargement. Furthermore, increased hypoxia-inducible factor-1 and vascular endothelial growth factor expression under hypoxic conditions were observed in the areas of necrosis. CONCLUSIONS: In cases in which high FDG uptake is observed in small pancreatic tumors, FDG positron emission tomography is potentially useful for SPN differentiation. The factors involved in FDG uptake in SPN include cell density and glucose transporter protein expression, as well as hypoxia-inducible factor and vascular endothelia growth factor expression in the hypoxic environment of necrotic areas.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001424" class="uri">https://doi.org/10.1097/MPA.0000000000001424</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>FGD4 (Frabin) Overexpression in Pancreatic Neuroendocrine Neoplasms</strong> </summary></p>
<p><em>Pancreas 2019 11;48(10):1307-1311</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688594" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688594</a></p>
<p>OBJECTIVE: The pathogenesis of pancreatic neuroendocrine tumors (PNETs) is still unclear. We propose Frabin as a new molecular alteration in PNETs. Frabin is a guanine nucleotide exchange factor playing a role in mediating actin cytoskeleton changes during cell migration, morphogenesis, polarization, and division. METHODS: Patients with PNETs of different grades were assessed for Frabin expression using immunohistochemistry and tissue microarray. The tissue microarray included 12 grade 1 and 3 grade 2 PNETs and 14 grade 3 pancreatic neuroendocrine carcinomas (PECAs). Frabin immunostain was scored with Allred system. Statistical analysis used SAS and R software. Immunohistochemistry scores were correlated with tumor grade and stage. The Spearman correlation coefficient was calculated with P values. RESULTS: Pancreatic neuroendocrine tumors were graded according to the World Health Organization 2017 guidelines. Frabin was expressed by 24 (82.7%) of the PNET/PECA studied. Only 5 (17.2%) of the 29 PNETs/PECA evaluated were Frabin negative. Frabin expression was cytoplasmic in all cases. We found a significant positive correlation ( = 0.47) between Frabin immunohistochemistry score and tumor grade (P = 0.01). No correlation was found between Frabin expression and tumor stage (P = 0.91). CONCLUSIONS: We report Frabin overexpression as a novel molecular alteration occurring in PNETs/PECAs.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001422" class="uri">https://doi.org/10.1097/MPA.0000000000001422</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Systemic Chemotherapy in Metastasis-Induced Acute Pancreatitis Patients With Small Cell Lung Cancer</strong> </summary></p>
<p><em>Pancreas 2019 11;48(10):1303-1306</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688593" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688593</a></p>
<p>OBJECTIVES: Small cell lung carcinoma (SCLC) is a highly malignant tumor characterized by early metastasis even at the time of diagnosis. Although pancreatic metastasis occurring in SCLC is a common observation in the literatures, there is currently very limited experience with the metastasis-induced acute pancreatitis in SCLC patients. METHODS: Here we retrospectively analyzed patients with metastasis-induced acute pancreatitis and SCLC in West China Hospital between 2009 and 2017. The patients were diagnosed as having SCLC by bronchoscopic biopsy or computed tomography-guided percutaneous biopsy. Metastasis-induced pancreatitis was established by clinical symptoms, radiologic surveillance, serum amylase, and lipase level. The series included 14 patients, 4 women and 10 men, with a mean age of 54 years (range, 29-76 years). The patients underwent chemotherapy plus palliative treatment (n = 8) or palliative care alone (n = 6). RESULTS: Compared with patients receiving palliative treatment alone, a trend toward improved survival was observed in patients who underwent chemotherapy. CONCLUSION: Our personal experience indicated that chemotherapy might provide a survival benefit in SCLC patients with metastasis-induced pancreatitis, especially those with good performance status.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001442" class="uri">https://doi.org/10.1097/MPA.0000000000001442</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Xenografts Derived From Patients Ascites Recapitulate the Gemcitabine Resistance Observed in Pancreatic Cancer Patients</strong> </summary></p>
<p><em>Pancreas 2019 11;48(10):1294-1302</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688592" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688592</a></p>
<p>OBJECTIVES: Most patient-derived pancreatic ductal adenocarcinoma (PDAC) xenografts have been established from surgical specimens of patients who have not received chemotherapy. However, xenografts have rarely been established from chemotherapy-resistant, advanced PDACs, because such cases are usually inoperable. The purpose of this study is to establish patient-derived xenografts using PDAC cells refractory to chemotherapy. METHODS: Clinical PDAC cells obtained from ascites of patients who had received continuous chemotherapy were implanted into the flanks of immunocompromised mice. Growth and histological features of the xenografts with and without gemcitabine treatment were then analyzed. RESULTS: Ascites-derived PDAC cells were successfully expanded through serial xenograft passage without changes in histological appearance. While treatment with gemcitabine substantially inhibited the growth of all PDAC xenografts tested, the tumor volume gradually increased, and the tumors showed marked regrowth even under continued gemcitabine treatment. These findings are consistent with the actual clinical course of the corresponding patients for each xenograft. CONCLUSIONS: Ascites-derived xenograft models represent a valuable experimental system for testing the efficacy of currently available therapeutic compounds on chemotherapy-resistant PDAC cells and for elucidation of the mechanisms underlying chemotherapy resistance.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001438" class="uri">https://doi.org/10.1097/MPA.0000000000001438</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Establishment and Characterization of 10 Human Pancreatic Cancer Cell Lines Including a HER2 Overexpressed Cell Line</strong> </summary></p>
<p><em>Pancreas 2019 11;48(10):1285-1293</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688591" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688591</a></p>
<p>OBJECTIVE: The incidence of pancreatic adenocarcinoma (PA) approximates its prevalence, as the malignancy is almost consistently fatal within a year. Although the currently available adjuvant therapy seems to provide survival benefit, it is only moderate, and the standard regimen has not yet been established. Therefore, more biological resources to investigate the PA are needed. METHODS: Here, we established and characterized 10 human pancreatic cancer cell lines derived from primary tumor mass. Whole exome sequencing technique was used to identify driver mutations and aberrant pathways in each cell line. RESULTS: Five anticancer drugs were treated to find half maximal effective concentration (EC50), and the response was analyzed in reference to mutational status. Frame shift mutations in ARID1A gene and HER2 amplification were mutually related to better response to the anticancer drugs. In contrast, frame shift mutation in MSH6 gene was associated with resistance to anticancer drugs. CONCLUSIONS: In summary, we established 10 pancreatic cancer cell lines and integrated various molecular aberrations and features of pancreatic cancer cells. Our biological resources are expected to contribute to facilitating research on PA.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001420" class="uri">https://doi.org/10.1097/MPA.0000000000001420</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Evaluation of Phase II Trial Design in Advanced Pancreatic Cancer</strong> </summary></p>
<p><em>Pancreas 2019 11;48(10):1274-1284</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688590" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688590</a></p>
<p>OBJECTIVES: We evaluated how well phase II trials in locally advanced and metastatic pancreatic cancer (LAMPC) meet current recommendations for trial design. METHODS: We conducted a systematic review of phase II first-line treatment trial for LAMPC. We assessed baseline characteristics, type of comparison, and primary end point to examine adherence to the National Cancer Institute recommendations for trial design. RESULTS: We identified 148 studies (180 treatment arms, 7505 participants). Forty-seven (32%) studies adhered to none of the 5 evaluated National Cancer Institute recommendations, 62 (42%) followed 1, 31 (21%) followed 2, and 8 (5%) followed 3 recommendations. Studies varied with respect to the proportion of patients with good performance status (range, 0%-80%) and locally advanced disease (range, 14%-100%). Eighty-two (55%) studies concluded that investigational agents should progress to phase III testing; of these, 24 (16%) had documented phase III trials. Three (8%) phase III trials demonstrated clinically meaningful improvements for investigational agents. One of 38 phase II trials that investigated biological investigational agents was enriched for a biomarker. CONCLUSIONS: Phase II trials do not conform well to current recommendations for trial design in LAMPC.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001429" class="uri">https://doi.org/10.1097/MPA.0000000000001429</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Drug-Induced Acute Pancreatitis in Adults: An Update</strong> </summary></p>
<p><em>Pancreas 2019 11;48(10):1263-1273</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688589" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688589</a></p>
<p>Drug-induced acute pancreatitis (DIAP) is a rare entity that is often challenging for clinicians. The aim of our study was to provide updated DIAP classes considering the updated definition of acute pancreatitis (AP) and in light of new medications and new case reports. A MEDLINE search (1950-2018) of the English language literature was performed looking for all adult (17 years old) human case reports with medication/drug induced as the cause of AP. The included case reports were required to provide the name of the drug, and diagnosis of AP must have been strictly established based on the revised Atlanta Classification criteria. A total of 183 medications were found to be implicated in 577 DIAP cases. A total of 78 cases were excluded because of minimal details or lack of definite diagnosis of AP. Drug-induced AP is rare, and most drugs cause mild DIAP. Only 2 drugs are well described in the literature to explain causation rather than association (azathioprine and didanosine). Larger case-control studies and a formal standardized DIAP reporting system are essential to study the true potential of the DIAP-implicated drugs described in this review.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001428" class="uri">https://doi.org/10.1097/MPA.0000000000001428</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Reducing Pancreatic Fibrosis Using Antioxidant Therapy Targeting Nrf2 Antioxidant Pathway: A Possible Treatment for Chronic Pancreatitis</strong> </summary></p>
<p><em>Pancreas 2019 11;48(10):1259-1262</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688588" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688588</a></p>
<p>Chronic pancreatitis is the progressive inflammation of the pancreas resulting in the irreversible damage of pancreatic structure and function by means of fibrosis. Chronic pancreatitis is most commonly caused by alcohol consumption, although the direct molecular etiology is unknown. Recent studies suggest oxidative stress as a catalyst for pancreatic stellate cell activation leading to the deposition of collagenous extracellular matrix causing pancreatic fibrosis. We review the effect of oxidative stress on pancreatic fibrogenesis and indicate the molecular pathways involved in preventing oxidant-related cell damage. Likewise, we summarize existing antioxidative therapies for chronic pancreatitis and discuss a novel nuclear factor erythroid 2-related factor 2 activator, dimethyl fumarate, and its potential to reduce fibrogenesis by downregulating pancreatic stellate cell activation.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001433" class="uri">https://doi.org/10.1097/MPA.0000000000001433</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Precision Medicine in Pancreatic Disease-Knowledge Gaps and Research Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop</strong> </summary></p>
<p><em>Pancreas 2019 11;48(10):1250-1258</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688587" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688587</a></p>
<p>A workshop on research gaps and opportunities for Precision Medicine in Pancreatic Disease was sponsored by the National Institute of Diabetes and Digestive Kidney Diseases on July 24, 2019, in Pittsburgh. The workshop included an overview lecture on precision medicine in cancer and 4 sessions: (1) general considerations for the application of bioinformatics and artificial intelligence; (2) omics, the combination of risk factors and biomarkers; (3) precision imaging; and (4) gaps, barriers, and needs to move from precision to personalized medicine for pancreatic disease. Current precision medicine approaches and tools were reviewed, and participants identified knowledge gaps and research needs that hinder bringing precision medicine to pancreatic diseases. Most critical were (a) multicenter efforts to collect large-scale patient data sets from multiple data streams in the context of environmental and social factors; (b) new information systems that can collect, annotate, and quantify data to inform disease mechanisms; (c) novel prospective clinical trial designs to test and improve therapies; and (d) a framework for measuring and assessing the value of proposed approaches to the health care system. With these advances, precision medicine can identify patients early in the course of their pancreatic disease and prevent progression to chronic or fatal illness.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001412" class="uri">https://doi.org/10.1097/MPA.0000000000001412</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Barriers and Research Priorities for Implementing Precision Medicine</strong> </summary></p>
<p><em>Pancreas 2020 11;48(10):1246-1249</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688586" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688586</a></p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001415" class="uri">https://doi.org/10.1097/MPA.0000000000001415</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The 50th Anniversary of the American Pancreatic Association and Japan Pancreas Society: The Vay Liang and Frisca Go Award for Lifetime Achievement and the Distinguished Service Award</strong> </summary></p>
<p><em>Pancreas 2019 11;48(10):1242-1245</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688585" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688585</a></p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001418" class="uri">https://doi.org/10.1097/MPA.0000000000001418</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>2019 Japan Pancreas Society Presidential Address: The American Pancreatic Association/Japan Pancreas Society Joint Meeting on Maui Island - The Third American Pancreatic Association/Japan Pancreas Society Joint Meeting</strong> </summary></p>
<p><em>Pancreas 2019 11;48(10):1240-1241</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688584" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688584</a></p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001387" class="uri">https://doi.org/10.1097/MPA.0000000000001387</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>2019 American Pancreatic Association Presidential Address: On Our Golden Jubilee</strong> </summary></p>
<p><em>Pancreas 2019 11;48(10):1238-1239</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688583" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688583</a></p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001413" class="uri">https://doi.org/10.1097/MPA.0000000000001413</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Congratulations on the Golden Anniversaries of the American Pancreatic Association and Japan Pancreas Society</strong> </summary></p>
<p><em>Pancreas 2019 11;48(10):1237</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31688582" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31688582</a></p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001411" class="uri">https://doi.org/10.1097/MPA.0000000000001411</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>SMAD4 Y353C promotes the progression of PDAC</strong> </summary></p>
<p><em>BMC cancer 2019 Nov;19(1):1037</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31684910" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31684910</a></p>
<p>BACKGROUND: SMAD4 is frequently inactivated and associated with a poor prognosis in pancreatic ductal adenocarcinoma (PDAC). Abnormal SMAD4 expression also plays an important role in the malignant progression of PDAC. METHODS: We investigated SMAD4 status in PDAC by immunohistochemical methods to explore the relationships between SMAD4 expression and clinicopathological features and then detected SMAD4 mutations by Sanger sequencing in 95 patients with PDAC to identify new mutation sites in PDAC. We further evaluated the effects of a missense mutation, Y353C, in the SMAD4 MH2 domain, on cell proliferation and migration in vitro. RESULTS: Immunohistochemistry showed that the expression of SMAD4 in PDAC carcinoma tissue was significantly lower than that in normal pancreatic tissue, and negative SMAD4 expression was closely related to tumour diameter, staging, lymph node metastasis and differentiation. Sanger sequencing analysis showed that the rate of SMAD4 mutation was 11.8% in 85 PDAC cases, and the novel SMAD4 Y353C missense mutation identified in this study promoted cell migration and invasion without affecting cell proliferation in vitro. Furthermore, SMAD4 Y353C resulted in reduced expression of E-cadherin and increased expression of Vimentin compared with wild-type SMAD4 overexpression. CONCLUSION: This study supports the key role of SMAD4 as a tumour suppressor gene in PDAC and shows that SMAD4 Y353C is associated with poor progression of PDAC.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6251-7" class="uri">https://doi.org/10.1186/s12885-019-6251-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Recurrent Rearrangements in PRKACA and PRKACB in Intraductal Oncocytic Papillary Neoplasms of the Pancreas and Bile Duct</strong> </summary></p>
<p><em>Gastroenterology 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31678302" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31678302</a></p>
<p>BACKGROUND &amp; AIMS: Intraductal oncocytic papillary neoplasms (IOPNs) of the pancreas and bile duct contain epithelial cells with numerous, large mitochondria and are cystic precursors to pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CCA), respectively. However, IOPNs do not have the genomic alterations found in other pancreatobiliary neoplasms. In fact, no recurrent genomic alterations have been described in IOPNs. PDACs without activating mutations in KRAS contain gene rearrangements, so we investigated whether IOPNs have recurrent fusions in genes. METHODS: We analyzed 20 resected pancreatic IOPNs and 3 resected biliary IOPNs using a broad RNA-based targeted sequencing panel to detect cancer-related fusion genes. Four invasive PDACs and 2 intrahepatic cholangiocarcinomas from the same patients as the IOPNs, were also available for analysis. Samples of pancreatic cyst fluid (n=5, collected before surgery) and bile duct brushings (n=2) were analyzed for translocations. For comparison, we analyzed pancreatobiliary lesions from 126 patients without IOPN (controls). RESULTS: All IOPNs evaluated were found to have recurring fusions of ATP1B1-PRKACB (n = 13), DNAJB1-PRKACA (n = 6), or ATP1B1-PRKACA (n = 4). These fusions were also found in corresponding invasive PDACs and intrahepatic cholangiocarcinomas, as well as in matched pancreatic cyst fluid and bile duct brushings. These gene rearrangements were absent from all 126 control pancreatobiliary lesions. CONCLUSIONS: We identified fusions in PRKACA and PRKACB genes in pancreatic and biliary IOPNs, as well as in PDACs and pancreatic cyst fluid and bile duct cells from the same patients. We did not identify these gene fusions in 126 control pancreatobiliary lesions. These fusions might be used to identify patients at risk for IOPNs and their associated invasive carcinomas.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.10.028" class="uri">https://doi.org/10.1053/j.gastro.2019.10.028</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma</strong> </summary></p>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31676785" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31676785</a></p>
<p>Recently discovered DNAJB1-PRKACA oncogenic fusions have been considered diagnostic for fibrolamellar hepatocellular carcinoma. In this study, we describe six pancreatobiliary neoplasms with PRKACA fusions, five of which harbor the DNAJB1-PRKACA fusion. All neoplasms were subjected to a hybridization capture-based next-generation sequencing assay (MSK-IMPACT), which enables the identification of sequence mutations, copy number alterations, and selected structural rearrangements involving 410 genes (n=6) and/or to a custom targeted, RNA-based panel (MSK-Fusion) that utilizes Archer Anchored Multiplex PCR technology and next-generation sequencing to detect gene fusions in 62 genes (n=2). Selected neoplasms also underwent FISH analysis, albumin mRNA in-situ hybridization, and arginase-1 immunohistochemical labeling (n=3). Five neoplasms were pancreatic, and one arose in the intrahepatic bile ducts. All revealed at least focal oncocytic morphology: three cases were diagnosed as intraductal oncocytic papillary neoplasms, and three as intraductal papillary mucinous neoplasms with mixed oncocytic and pancreatobiliary or gastric features. Four cases had an invasive carcinoma component composed of oncocytic cells. Five cases revealed DNAJB1-PRKACA fusions and one revealed an ATP1B1-PRKACA fusion. None of the cases tested were positive for albumin or arginase-1. Our data prove that DNAJB1-PRKACA fusion is neither exclusive nor diagnostic for fibrolamellar hepatocellular carcinoma, and caution should be exercised in diagnosing liver tumors with DNAJB1-PRKACA fusions as fibrolamellar hepatocellular carcinoma, particularly if a pancreatic lesion is present. Moreover, considering DNAJB1-PRKACA fusions lead to upregulated protein kinase activity and that this upregulated protein kinase activity has a significant role in tumorigenesis of fibrolamellar hepatocellular carcinoma, protein kinase inhibition could have therapeutic potential in the treatment of these pancreatobiliary neoplasms as well, once a suitable drug is developed.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-019-0398-2" class="uri">https://doi.org/10.1038/s41379-019-0398-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A novel approach with holmium laser ablation for endoscopic management of intrahepatic biliary stricture</strong> </summary></p>
<p><em>BMC gastroenterology 2019 Nov;19(1):172</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31675911" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31675911</a></p>
<p>BACKGROUND: Hepatolithiasis, featuring high incidence, severe symptoms, and common recurrence, poses a heavy disease burden. Endoscopic management provides an opportunity to cure hepatolithiasis, but fails to properly resolve biliary stricture without additional interventional techniques. An innovative approach towards endoscopic management of biliary stricture is required. METHODS: Holmium laser ablation was applied to biliary strictures via endoscopic access. Patients demographic, operative, and follow-up data after receiving holmium laser ablation were retrospectively collected for analysis. RESULTS: A total of 15 patients (4 males and 11 females) underwent stricture ablation by holmium laser via cholangioscopy. All the patients successfully received holmium laser ablation, indicating a technical success rate of 100%. No postoperative mortality or no major perioperative complication was observed. During the follow-up period, the recurrence-free rate was 73% at 2years and 67% at 5years. CONCLUSIONS: We successfully developed a novel technique of biliary stricture removal by cholangioscopic holmium laser ablation with satisfying clinical outcomes.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-019-1093-y" class="uri">https://doi.org/10.1186/s12876-019-1093-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Oncologic Outcomes After Robotic Pancreatic Resections Are Not Inferior to Open Surgery</strong> </summary></p>
<p><em>Annals of surgery 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31663967" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31663967</a></p>
<p>OBJECTIVE: Compare oncologic outcomes after open and robotic pancreatic resections for pancreatic adenocarcinoma (PDAC). SUMMARY OF BACKGROUND DATA: Receipt of adjuvant chemotherapy improves survival after resected PDAC. Complications after pancreatectomy have been shown to prohibit the administration of adjuvant chemotherapy and survival. We examined the effect of surgical approach on receipt of adjuvant chemotherapy, complications, and overall survival after pancreatectomy. METHODS: A single-institution retrospective review of all patients with PDAC who underwent robotic or open pancreatectomy from 2011 to 2016 with 24-month follow-up. RESULTS: Four hundred fifty-six patients underwent resection: 226 robotic and 230 open. No significant difference was identified in major complications or receipt of adjuvant chemotherapy between robotic and open pancreatectomy, nor was approach an independent predictor of these outcomes. Robotic pancreatectomy patients had a shorter length of stay than patients who underwent open pancreatectomy (7 days vs 9 days; P &lt; 0.001). Additionally, wound infection rate (32.3% vs 12.4%, P &lt; 0.0001) and transfusion (39.6% vs 12.4%, P &lt; 0.0001) was improved in robotic pancreatectomy group with no differences in perioperative mortality. Improved median overall survival approached statistical significance for the robotic cohort (25.6 months vs 23.9 months; P = 0.055); however, on multivariable analysis the robotic approach predicted overall survival, (hazard ratio 0.77, P = 0.041). Robotic approach was an independent predictor of decreased blood loss and less transfusions than the open approach. CONCLUSIONS: Robotic pancreatectomy was not inferior compared to open pancreatectomy in a high-volume experienced center for oncologic outcomes and due to decreased blood loss and transfusion may have improved survival.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003615" class="uri">https://doi.org/10.1097/SLA.0000000000003615</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: Regulation of Chemoresistance in Pancreatic Ductal Adenocarcinoma by Scavenger Receptor CD36</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31659646" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31659646</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-08022-2" class="uri">https://doi.org/10.1245/s10434-019-08022-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Gastrocolic Fistula Involving the Pancreas in a Patient With Crohns Disease</strong> </summary></p>
<p><em>The American journal of gastroenterology 2019 Nov;114(11):1823-1824</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31658126" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31658126</a></p>
<p>doi: <a href="https://doi.org/10.14309/ajg.0000000000000418" class="uri">https://doi.org/10.14309/ajg.0000000000000418</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>[IgG4-related disease : Microscopic diagnosis and differential diagnosis]</strong> </summary></p>
<p><em>Der Pathologe 2019 Nov;40(6):619-626</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31641859" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31641859</a></p>
<p>IgG4-related disease (IgG4-RD) is apotentially systemic inflammatory and fibrosing disease. Independent of the affected organ, the main histological features are adense lymphoplasmacytic infiltrate, storiform fibrosis, and obliterative phlebitis. These features are weighted slightly different, dependent on the respective organ. If several of these features are present and changes inconsistent with IgG4-RD are absent, the diagnosis is further supported by the immunohistochemical demonstration of increased IgG4-positive plasma cells and an elevated IgG4-IgG ratio, as well as serologically by elevated IgG4 levels. Atissue biopsy is often mandatory for the diagnosis, as IgG4-RD clinically and radiologically can imitate amalignant tumor.</p>
<p>doi: <a href="https://doi.org/10.1007/s00292-019-00685-8" class="uri">https://doi.org/10.1007/s00292-019-00685-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes</strong> </summary></p>
<p><em>The New England journal of medicine 2019 10;381(18):1707-1717</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31618560" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31618560</a></p>
<p>BACKGROUND: Closed-loop systems that automate insulin delivery may improve glycemic outcomes in patients with type 1 diabetes. METHODS: In this 6-month randomized, multicenter trial, patients with type 1 diabetes were assigned in a 2:1 ratio to receive treatment with a closed-loop system (closed-loop group) or a sensor-augmented pump (control group). The primary outcome was the percentage of time that the blood glucose level was within the target range of 70 to 180 mg per deciliter (3.9 to 10.0 mmol per liter), as measured by continuous glucose monitoring. RESULTS: A total of 168 patients underwent randomization; 112 were assigned to the closed-loop group, and 56 were assigned to the control group. The age range of the patients was 14 to 71 years, and the glycated hemoglobin level ranged from 5.4 to 10.6%. All 168 patients completed the trial. The mean (SD) percentage of time that the glucose level was within the target range increased in the closed-loop group from 6117% at baseline to 7112% during the 6 months and remained unchanged at 5914% in the control group (mean adjusted difference, 11 percentage points; 95% confidence interval [CI], 9 to 14; P&lt;0.001). The results with regard to the main secondary outcomes (percentage of time that the glucose level was &gt;180 mg per deciliter, mean glucose level, glycated hemoglobin level, and percentage of time that the glucose level was &lt;70 mg per deciliter or &lt;54 mg per deciliter [3.0 mmol per liter]) all met the prespecified hierarchical criterion for significance, favoring the closed-loop system. The mean difference (closed loop minus control) in the percentage of time that the blood glucose level was lower than 70 mg per deciliter was -0.88 percentage points (95% CI, -1.19 to -0.57; P&lt;0.001). The mean adjusted difference in glycated hemoglobin level after 6 months was -0.33 percentage points (95% CI, -0.53 to -0.13; P=0.001). In the closed-loop group, the median percentage of time that the system was in closed-loop mode was 90% over 6 months. No serious hypoglycemic events occurred in either group; one episode of diabetic ketoacidosis occurred in the closed-loop group. CONCLUSIONS: In this 6-month trial involving patients with type 1 diabetes, the use of a closed-loop system was associated with a greater percentage of time spent in a target glycemic range than the use of a sensor-augmented insulin pump. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases; iDCL ClinicalTrials.gov number, NCT03563313.).</p>
<p>doi: <a href="https://doi.org/10.1056/NEJMoa1907863" class="uri">https://doi.org/10.1056/NEJMoa1907863</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Toward Automated Insulin Delivery</strong> </summary></p>
<p><em>The New England journal of medicine 2019 10;381(18):1774-1775</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31618534" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31618534</a></p>
<p>doi: <a href="https://doi.org/10.1056/NEJMe1912822" class="uri">https://doi.org/10.1056/NEJMe1912822</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Multiple functions of S100A10, an important cancer promoter</strong> </summary></p>
<p><em>Pathology international 2019 Nov;69(11):629-636</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31612598" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31612598</a></p>
<p>The S100 group of calcium binding proteins is composed of 21 members that exhibit tissue/cell specific expressions. These S100 proteins bind a diverse range of targets and regulate multiple cellular processes, including proliferation, migration and differentiation. S100A10, also known as p11, binds mainly to annexin A2 and mediates the conversion of plasminogen to an active protease, plasmin. Higher S100A10 expression has been reported to link to worse outcome and/or chemoresistance in a number of cancer types in lung, breast, ovary, pancreas, gall bladder and colorectum and leukemia although some discrepancy was reported. In this review, we focused on the roles of the S100A10 in cancer. We summarized its biological functions, role in cancer progression, prognostic value and targeting of S100A10 for cancer therapy.</p>
<p>doi: <a href="https://doi.org/10.1111/pin.12861" class="uri">https://doi.org/10.1111/pin.12861</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The RNA m6A methyltransferase METTL3 promotes pancreatic cancer cell proliferation and invasion</strong> </summary></p>
<p><em>Pathology, research and practice 2019 Nov;215(11):152666</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31606241" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31606241</a></p>
<p>Epigenetic modifications are involved in carcinogenesis and METTL3 is involved in RNA methylation. This study aimed to explore the role of the RNA m6A methyltransferase METTL3 in pancreatic cancer cells. The m6A modification was analyzed in human pancreatic cancer and paracancerous specimens, as well as in the normal HPDE6-C7 pancreatic cell line and the MIA-PaCa-2 and BxPC-3 pancreatic cancer cell lines. Immunohistochemistry (IHC), western blotting, and RT-qPCR were used to detect the expression of METTL3. Cell lines were transfected with siRNAs against METLL3. Proliferation, invasion, and migration were examined. The functions of METTL3 were predicted by bioinformatics analysis. In the 40 patients included, high METTL3 expression was associated with high pathological stage (P=0.02) and high N stage (P=0.02). Survival was better in patients with low METTL3 expression compared with those with high MTTL3 expression (P&lt;0.01). METTL3 and CIITA expression levels were inversely correlated (r=-0.71, P&lt;0.01). RNA m6A content in tumor specimens was significantly higher than that in paracancerous specimens. METTL3 protein and mRNA levels were significantly higher in tumor specimens compared with paracancerous specimens, as well as in cancerous cell lines vs.normal cells. METTL3 knockdown in MIA PaCa-2 and BxPC-3 cells decreased RNA m6A modifications. Cell proliferation, invasion, and migration were decreased by METTL3 knockdown in cancerous cell lines. A total of 673 differentially expressed genes were identified by bioinformatics: 659 were upregulated and 14 were downregulated. In conclusion, METTL3 is probably involved in pancreatic carcinogenesis. It could eventually be a prognostic marker or a treatment target.</p>
<p>doi: <a href="https://doi.org/10.1016/j.prp.2019.152666" class="uri">https://doi.org/10.1016/j.prp.2019.152666</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Defining Global Benchmarks in Bariatric Surgery: A Retrospective Multicenter Analysis of Minimally Invasive Roux-en-Y Gastric Bypass and Sleeve Gastrectomy</strong> </summary></p>
<p><em>Annals of surgery 2019 Nov;270(5):859-867</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31592894" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31592894</a></p>
<p>OBJECTIVE: To define best possible outcomes for bariatric surgery (BS)(Roux-en-Y gastric bypass [RYGB] and sleeve gastrectomy [SG]). BACKGROUND: Reference values for optimal surgical outcomes in well-defined low-risk bariatric patients have not been established so far. Consequently, outcome comparison across centers and over time is impeded by heterogeneity in case-mix. METHODS: Out of 39,424 elective BS performed in 19 high-volume academic centers from 3 continents between June 2012 and May 2017, we identified 4120 RYGB and 1457 SG low-risk cases defined by absence of previous abdominal surgery, concomitant procedures, diabetes mellitus, sleep apnea, cardiopathy, renal insufficiency, inflammatory bowel disease, immunosuppression, anticoagulation, BMI&gt;50kg/m and age&gt;65 years. We chose clinically relevant endpoints covering the intra- and postoperative course. Complications were graded by severity using the comprehensive complication index. Benchmark values were defined as the 75th percentile of the participating centers median values for respective quality indicators. RESULTS: Patients were mainly females (78%), aged 3811 years, with a baseline BMI 40.85.8kg/m. Over 90 days, 7.2% of RYGB and 6.2% of SG patients presented at least 1 complication and no patients died (mortality in nonbenchmark cases: 0.06%). The most frequent reasons for readmission after 90-days following both procedures were symptomatic cholelithiasis and abdominal pain of unknown origin. Benchmark values for both RYGB and SG at 90-days postoperatively were 5.5% Clavien-Dindo grade IIIa complication rate, 5.5% readmission rate, and comprehensive complication index 33.73 in the subgroup of patients presenting at least 1 grade II complication. CONCLUSION: Benchmark cutoffs targeting perioperative outcomes in BS offer a new tool in surgical quality-metrics and may be implemented in quality-improvement cycle.ClinicalTrials.gov Identifier NCT03440138.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003512" class="uri">https://doi.org/10.1097/SLA.0000000000003512</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Perioperative Interstitial Fluid Expansion Predicts Major Morbidity Following Pancreatic Surgery: Appraisal by Bioimpedance Vector Analysis</strong> </summary></p>
<p><em>Annals of surgery 2019 Nov;270(5):923-929</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31592889" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31592889</a></p>
<p>OBJECTIVE: To evaluate whether perioperative bioimpedance vector analysis (BIVA) predicts the occurrence of surgery-related morbidity. SUMMARY BACKGROUND DATA: BIVA is a reliable tool to assess hydration status and compartimentalized fluid distribution. METHODS: The BIVA of patients undergoing resection for pancreatic malignancies was prospectively measured on the day prior to surgery and on postoperative day (POD)1. Postoperative morbidity was scored per the Clavien-Dindo classification (CDC), and the Comprehensive Complication Index (CCI). RESULTS: Out of 249 patients, the overall and major complication rates were 61% and 16.5% respectively. The median CCI was 24 (IQR 0.0-24.2), and 24 patients (9.6%) had a complication burden with CCI40. At baseline the impedance vectors of severe complicated patients were shorter compared to the vectors of uncomplicated patients only for the female subgroup (P=0.016). The preoperative extracellular water (ECW) was significantly higher in patients who experienced severe morbidity according to the CDC or not [19.4L (17.5-22.0) vs.18.2L (15.6-20.6), P=0.009, respectively] and CCI40, or not [20.3L (18.5-22.7) vs.18.3L (15.6-20.6), P=0.002, respectively]. The hydration index on POD1 was significantly higher in patients who experienced major complications than in uncomplicated patients (P=0.020 and P=0.025 for CDC and CCI, respectively).At a linear regression model, age (=0.14, P=0.035), sex female (=0.40, P&lt;0.001), BMI (=0.30, P&lt;0.001), and malnutrition (=0.14, P=0.037) were independent predictors of postoperative ECW. CONCLUSION: The amount of extracellular fluid accumulation predicts major morbidity after pancreatic surgery. Female, obese and malnourished patients were at high risk of extracellular fluid accumulation.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003536" class="uri">https://doi.org/10.1097/SLA.0000000000003536</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The usefulness of lymphoid enhancer-binding factor 1 and androgen receptor in diagnosing solid pseudopapillary neoplasm of the pancreas on cytopathology</strong> </summary></p>
<p><em>Cancer cytopathology 2019 Nov;127(11):700-707</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31584754" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31584754</a></p>
<p>BACKGROUND: Solid pseudopapillary neoplasm (SPN) is an uncommon tumor that is challenging to diagnose on cytology due to morphologic overlap with other pancreatic neoplasms. Recently, putative diagnostic markers for SPN have been reported in the surgical pathology literature, with nuclear positivity for lymphoid enhancer-binding factor 1 (LEF1) and androgen receptor (AR) identified in &gt;90% and &gt;80% of cases, respectively. In the current study, the authors sought to evaluate the sensitivity and specificity of LEF1 and AR on SPN cytology specimens and available corresponding surgical resection specimens. METHODS: Immunohistochemistry was performed using monoclonal antibodies against LEF1 and AR on 19 SPN cytology cases and 15 corresponding follow-up surgical resection specimens from 2 institutions. To evaluate specificity, the authors stained 23 non-SPN tumors diagnosed on cytology with corresponding surgical specimens (4 acinar cell carcinomas, 9 pancreatic neuroendocrine tumors, and 10 ductal adenocarcinomas). Positivity for LEF1 and AR was defined as any nuclear staining within neoplastic nuclei. RESULTS: LEF1 was found to be positive in 18 of 19 cytology cases (94.7%) and 15 of 15 corresponding surgical resection specimens (100%). AR was positive in 4 of 16 cytology cases (25.0%) and 4 of 15 corresponding surgical resection specimens (26.7%). Among non-SPN tumors, LEF1 demonstrated a specificity of 87% whereas the specificity for AR was 100%. CONCLUSIONS: LEF1 for SPN on cytology material was found to demonstrate a sensitivity of 94.7% and a specificity of 87%. Although AR was found to have a specificity of 100%, its sensitivity was lower (25%). LEF1 could be a valuable immunostain on cytology cell block material for the diagnosis of SPN. However, the same may not hold true for AR.</p>
<p>doi: <a href="https://doi.org/10.1002/cncy.22186" class="uri">https://doi.org/10.1002/cncy.22186</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreatoblastoma: Cytologic and histologic analysis of 12 adultcases reveals helpful criteria in their diagnosis and distinction from common mimics</strong> </summary></p>
<p><em>Cancer cytopathology 2019 Nov;127(11):708-719</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31581358" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31581358</a></p>
<p>BACKGROUND: Pancreatoblastoma (PBL) is a rare malignant pancreatic tumor seen predominantly in childhood, and its cytologic diagnosis remains challenging. METHODS: Twelve fine-needle-aspirations from 11 adults were analyzed. RESULTS: In total, 6 men and 5 women (median age, 45years; age range, 32-60years) had tumors measuring a median 5.6cm (range, 2.5-12cm) located in the pancreatic head (n=7) or tail (n=4), including 3 with familial adenomatous polyposis (FAP)/FAP-related syndromes and 4 with metastasis at diagnosis. The median follow-up was 39.8months (range, 0.8-348months), and 5 patients died of disease. The original cytology diagnoses were: PBL (n=2), neuroendocrine neoplasm (n=2), poorly differentiated neuroendocrine carcinoma (n=2), well differentiated neuroendocrine tumor (n=1), poorly differentiated carcinoma (n=2), positive for malignancy (n=1), acinar cell carcinoma (n=1), and epithelioid neoplasm with endocrine and acinar differentiation versus PBL (n=1). Universal cytopathologic findings included hypercellularity; 3-dimensional clusters; and single, monotonous, blast-like cells that were from 1.5 to 2.0 times the size of red blood cells with high nuclear-to-cytoplasmic ratio, fine chromatin, small, distinct nucleoli, and a resemblance to well differentiated neuroendocrine tumor and poorly differentiated neuroendocrine carcinoma. Branching pseudopapillae (n=7) and grooved nuclei (n=3) raised the differential diagnosis of solid-pseudopapillary neoplasm, but with more atypia. Uncommon features included pleomorphism (n=4) and numerous mitoses (n=1). Squamoid morules were seen on smears (n=5) or cell blocks (n=6) in 70% of patients and were characterized by epithelioid cells with elongated, streaming nuclei, fine chromatin, absent nucleoli, and positive nuclear -catenin (n=6 of 8). The median Ki-67 index was 21% (range, 2%-70%), and neuroendocrine marker expression was common (100%), but acinar markers were variable (63%). CONCLUSIONS: A combination of cytologic findings in PBL, including a predominant population of primitive blast-like cells, subtle squamoid morules, frequent neuroendocrine and variable acinar phenotype, should facilitate accurate cytologic diagnosis and distinction from common mimics.</p>
<p>doi: <a href="https://doi.org/10.1002/cncy.22187" class="uri">https://doi.org/10.1002/cncy.22187</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Permanent Pancreatic Duct Occlusion With Neoprene-based Glue Injection After Pancreatoduodenectomy at High Risk of Pancreatic Fistula: A Prospective Clinical Study</strong> </summary></p>
<p><em>Annals of surgery 2019 Nov;270(5):791-798</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31567180" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31567180</a></p>
<p>OBJECTIVE: The aim of this study was to assess safety and efficacy of pancreatic duct occlusion (PDO) with neoprene-based glue in selected patients undergoing pancreatoduodenectomy (PD) at high risk of postoperative pancreatic fistula (POPF). BACKGROUND DATA: PD is the reference standard approach for tumors of the pancreaticoduodenal region. POPF is the most relevant complication after PD. PDO has been proposed as an alternative to anastomosis to manage the pancreatic stump. METHODS: A single-center, prospective, nonrandomized trial enrolled 100 consecutive PD for cancer. Patients at high risk for POPF according to Fistula Risk Score (FRS) &gt;15% (6 points) were treated with PDO using neoprene glue (study cohort); patients with FRS 15% (5 points) received pancreaticojejunal anastomosis (PJA: control cohort). Primary endpoint was complication rate grade 3 according to Dindo-Clavien Classification (DCC). Other postoperative outcomes were monitored (ClinicalTrials.gov NCT03738787). RESULTS: Fifty-one patients underwent PDO and 49 PJA. DCC 3, postoperative mortality, and POPF grade B-C were 25.5% versus 24.5% (P = 0.91), 5.9% versus 2% (P = 0.62), and 11.8% versus 16.3% (P = 0.51) in the study versus control cohort, respectively. At 1 and 3 years, new-onset diabetes was diagnosed in 13.7% and 36.7% of the study cohort versu 4.2% and 12.2% in controls (P = 0.007). CONCLUSIONS: PDO with neoprene-based glue is a safe technique that equalizes early outcome of selected patients at high risk of POPF to those at low risk undergoing PJA. Neoprene-based PDO, however, triples the risk of diabetes at 1 and 3 years.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003514" class="uri">https://doi.org/10.1097/SLA.0000000000003514</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Stress-induced phosphoprotein 1 promotes pancreatic cancer progression through activation of the FAK/AKT/MMP signaling axis</strong> </summary></p>
<p><em>Pathology, research and practice 2019 Nov;215(11):152564</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31547977" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31547977</a></p>
<p>BACKGROUND: Dependent on the extent of adenosine triphosphate (ATP) hydrolysis and/or ATP/ADP exchange, the stress-induced phosphoprotein 1 (STIP1) mediates molecular interaction and complex formation between the molecular chaperones heat shock protein (Hsp)70 and Hsp90. The overexpression of STIP1 is increasingly being documented in various human malignancies, including ovarian, cholangiocellular, renal and gastric cancers. However, the role of STIP1 in pancreatic cancer (PANC) and probable molecular mechanism remains largely unexplored. METHODS &amp; RESULTS: In the present study, using clinical samples (n=88) and human PANC cell lines PANC-1, Capan-2, SW1990, and BxPC-3, we demonstrated that STIP1 is aberrantly expressed in human PANC tissues or cell lines compared to adjacent non-tumor pancreas samples or human pancreatic duct epithelial cells (HPDEC), respectively. Clinicopathological correlation studies revealed significant positive correlation between high STIP1 expression and lymph node involvement (p=0.001), cancer metastasis (p=0.002), microvascular invasion (p=0.002), advance TNM stage (p=0.024), perineural invasion (PNI; p=0.013), and cancer-related death (p=0.002) among patients with PANC. Univariate and multivariate analyses indicate that STIP1overexpression is an independent prognostic factor of PANC. Furthermore, STIP1 knockdown significantly inhibit the migration and invasive ability of PANC-1 and SW1990 cells, while downregulating N-cadherin and Vimentin, but upregulating E-cadherin mRNA expression levels, concurrently. We also demonstrated that STIP1 knockdown suppressed p-FAK, p-AKT, MMP2, MMP9, and Slug protein and mRNA expression levels, thus, indicating, at least in part, a role for STIP1 in the activation of FAK/AKT/MMP signaling. CONCLUSION: Taken together, our results demonstrate a critical role for STIP1 in cancer metastasis, disease progression and poor prognosis, as well as, provide evidence suggestive of the therapeutic efficacy of STIP1-mediated targeting of the FAK/AKT/MMP signaling axis in patients with PANC.</p>
<p>doi: <a href="https://doi.org/10.1016/j.prp.2019.152564" class="uri">https://doi.org/10.1016/j.prp.2019.152564</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Correlation of clinicopathological features and leucine-rich repeat-containing G-protein-coupled receptor 5 expression in pancreatic ductal adenocarcinoma</strong> </summary></p>
<p><em>Pathology, research and practice 2019 Nov;215(11):152623</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31543221" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31543221</a></p>
<p>Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer. Previous studies have established leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) as a cancer stem cell marker in gastrointestinal cancers. However, few reports have examined LGR5 in PDAC. Here we examined LGR5 expression and its clinicopathological significance in PDAC. We evaluated LGR5 expression in 78 PDAC patients who underwent surgical resection in our institution using RNAscope, a newly described RNA in situ hybridization technique. All 78 PDAC cases expressed LGR5 in cancer tissues, and LGR5 expression was prominent in the gland-forming part. LGR5 expression was significantly higher in patients with low histological grade (G1-G2) (p&lt; 0.001) and early clinical stage (p= 0.004). Univariate analysis showed that low LGR5 expression (p= 0.034) was significantly associated with worse overall survival. However, LGR5 expression did not remain a predictor of prognosis in multivariate analysis (p= 0.639). All PDAC cases showed LGR5 expression to varying degrees, indicating LGR5 might be a cancer stem cell marker of PDAC, as in gastrointestinal cancer. Reduced LGR5 expression in tumor cells was associated with worse prognosis in PDAC. Further studies are required to elucidate the relationship between tumor progression and LGR5 expression in PDAC.</p>
<p>doi: <a href="https://doi.org/10.1016/j.prp.2019.152623" class="uri">https://doi.org/10.1016/j.prp.2019.152623</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Nov;25(21):6452-6462</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31533931" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31533931</a></p>
<p>PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is a predominantly fatal common malignancy with inadequate treatment options. Glycogen synthase kinase 3 (GSK-3) is an emerging target in human malignancies including PDAC.Experimental Design: Pancreatic cancer cell lines and patient-derived xenografts were treated with a novel GSK-3 inhibitor 9-ING-41 alone or in combination with chemotherapy. Activation of the DNA damage response pathway and S-phase arrest induced by gemcitabine were assessed in pancreatic tumor cells with pharmacologic inhibition or siRNA depletion of GSK-3 kinases by immunoblotting, flow cytometry, and immunofluorescence. RESULTS: 9-ING-41 treatment significantly increased pancreatic tumor cell killing when combined with chemotherapy. Inhibition of GSK-3 by 9-ING-41 prevented gemcitabine-induced S-phase arrest suggesting an impact on the ATR-mediated DNA damage response. Both 9-ING-41 and siRNA depletion of GSK-3 kinases impaired the activation of ATR leading to the phosphorylation and activation of Chk1. Mechanistically, depletion or knockdown of GSK-3 kinases resulted in the degradation of the ATR-interacting protein TopBP1, thus limiting the activation of ATR in response to single-strand DNA damage. CONCLUSIONS: These data identify a previously unknown role for GSK-3 kinases in the regulation of the TopBP1/ATR/Chk1 DNA damage response pathway. The data also support the inclusion of patients with PDAC in clinical studies of 9-ING-41 alone and in combination with gemcitabine.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-0799" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-0799</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study</strong> </summary></p>
<p><em>The Lancet. Oncology 2019 Nov;20(11):1493-1505</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31521509" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31521509</a></p>
<p>BACKGROUND: Population-based cancer survival estimates provide valuable insights into the effectiveness of cancer services and can reflect the prospects of cure. As part of the second phase of the International Cancer Benchmarking Partnership (ICBP), the Cancer Survival in High-Income Countries (SURVMARK-2) project aims to provide a comprehensive overview of cancer survival across seven high-income countries and a comparative assessment of corresponding incidence and mortality trends. METHODS: In this longitudinal, population-based study, we collected patient-level data on 39 million patients with cancer from population-based cancer registries in 21 jurisdictions in seven countries (Australia, Canada, Denmark, Ireland, New Zealand, Norway, and the UK) for seven sites of cancer (oesophagus, stomach, colon, rectum, pancreas, lung, and ovary) diagnosed between 1995 and 2014, and followed up until Dec 31, 2015. We calculated age-standardised net survival at 1 year and 5 years after diagnosis by site, age group, and period of diagnosis. We mapped changes in incidence and mortality to changes in survival to assess progress in cancer control. FINDINGS: In 19 eligible jurisdictions, 3764543 cases of cancer were eligible for inclusion in the study. In the 19 included jurisdictions, over 1995-2014, 1-year and 5-year net survival increased in each country across almost all cancer types, with, for example, 5-year rectal cancer survival increasing more than 13 percentage points in Denmark, Ireland, and the UK. For 2010-14, survival was generally higher in Australia, Canada, and Norway than in New Zealand, Denmark, Ireland, and the UK. Over the study period, larger survival improvements were observed for patients younger than 75 years at diagnosis than those aged 75 years and older, and notably for cancers with a poor prognosis (ie, oesophagus, stomach, pancreas, and lung). Progress in cancer control (ie, increased survival, decreased mortality and incidence) over the study period was evident for stomach, colon, lung (in males), and ovarian cancer. INTERPRETATION: The joint evaluation of trends in incidence, mortality, and survival indicated progress in four of the seven studied cancers. Cancer survival continues to increase across high-income countries; however, international disparities persist. While truly valid comparisons require differences in registration practice, classification, and coding to be minimal, stage of disease at diagnosis, timely access to effective treatment, and the extent of comorbidity are likely the main determinants of patient outcomes. Future studies are needed to assess the impact of these factors to further our understanding of international disparities in cancer survival. FUNDING: Canadian Partnership Against Cancer; Cancer Council Victoria; Cancer Institute New South Wales; Cancer Research UK; Danish Cancer Society; National Cancer Registry Ireland; The Cancer Society of New Zealand; National Health Service England; Norwegian Cancer Society; Public Health Agency Northern Ireland, on behalf of the Northern Ireland Cancer Registry; The Scottish Government; Western Australia Department of Health; and Wales Cancer Network.</p>
<p>doi: <a href="https://doi.org/10.1016/S1470-2045(19)30456-5" class="uri">https://doi.org/10.1016/S1470-2045(19)30456-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A Clinicopathologic and Molecular Update of Pancreatic Neuroendocrine Neoplasms With a Focus on the New World Health Organization Classification</strong> </summary></p>
<p><em>Archives of pathology &amp; laboratory medicine 2019 Nov;143(11):1317-1326</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31509453" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31509453</a></p>
<p>CONTEXT.: According to the 2017 World Health Organization classification, pancreatic neuroendocrine neoplasms (PanNENs) include a new category of pancreatic neuroendocrine tumor, grade 3, which is often difficult to differentiate from pancreatic neuroendocrine carcinoma. However, pancreatic neuroendocrine tumor grade 3 and pancreatic neuroendocrine carcinoma are distinct entities with very different clinical presentation, prognosis, and therapeutic strategies. Recent discoveries on the molecular characteristics of pancreatic neuroendocrine tumors also play an essential role in the pathologic differential diagnosis of PanNENs. In addition, the histopathologic varieties of PanNENs bring in many differential diagnoses with other pancreatic neoplasms, especially acinar cell carcinoma, solid pseudopapillary neoplasm, and ductal adenocarcinoma. OBJECTIVE.: To provide a brief update of the World Health Organization classification; the clinical, histopathologic, immunohistochemical, and molecular characteristics; and the differential diagnoses and biological behavior of PanNENs. DATA SOURCES.: Analysis of the pertinent literature (PubMed) and authors clinical practice experience based on institutional and consultation materials. CONCLUSIONS.: The evolving clinical, histopathologic, immunohistochemical, and molecular features of PanNENs are reviewed. Important differential diagnoses with other neoplasms of the pancreas are discussed.</p>
<p>doi: <a href="https://doi.org/10.5858/arpa.2019-0338-RA" class="uri">https://doi.org/10.5858/arpa.2019-0338-RA</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Does the Artery-first Approach Improve the Rate of R0 Resection in Pancreatoduodenectomy?: A Multicenter, Randomized, Controlled Trial</strong> </summary></p>
<p><em>Annals of surgery 2019 Nov;270(5):738-746</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31498183" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31498183</a></p>
<p>OBJECTIVE: To compare the rates of R0 resection in pancreatoduodenectomy (PD) for pancreatic and periampullary malignant tumors by means of standard (ST-PD) versus artery-first approach (AFA-PD). BACKGROUND: Standardized histological examination of PD specimens has shown that most pancreatic resections thought to be R0 resections are R1. Artery-first approach is a surgical technique characterized by meticulous dissection of arterial planes and clearing of retropancreatic tissue in an attempt to achieve a higher rate of R0. To date, studies comparing AFA-PD versus ST-PD are retrospective cohort or case-control studies. METHODS: A multicenter, randomized, controlled trial was conducted in 10 University Hospitals (NCT02803814, ClinicalTrials.gov). Eligible patients were those who presented with pancreatic head adenocarcinoma and periampullary tumors (ampulloma, distal cholangiocarcinoma, duodenal adenocarcinoma). Assignment to each group (ST-PD or AFA-PD) was randomized by blocks and stratified by centers. The primary end-point was the rate of tumor-free resection margins (R0); secondary end-points were postoperative complications and mortality. RESULTS: One hundred seventy-nine patients were assessed for eligibility and 176 randomized. After exclusions, the final analysis included 75 ST-PD and 78 AFA-PD. R0 resection rates were 77.3% (95% CI: 68.4-87.4) with ST-PD and 67.9% (95% CI: 58.3-79.1) with AFA-PD, P=0.194. There were no significant differences in postoperative complication rates, overall 73.3% versus 67.9%, and perioperative mortality 4% versus 6.4%. CONCLUSIONS: Despite theoretical oncological advantages associated with AFA-PD and evidence coming from low-level studies, this multicenter, randomized, controlled trial has found no difference neither in R0 resection rates nor in postoperative complications in patients undergoing ST-PD versus AFA-PD for pancreatic head adenocarcinoma and other periampullary tumors.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003535" class="uri">https://doi.org/10.1097/SLA.0000000000003535</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Goals of Treatment Sequencing for Localized Pancreatic Cancer</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Nov;26(12):3815-3819</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31493126" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31493126</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07738-5" class="uri">https://doi.org/10.1245/s10434-019-07738-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>An analysis of genetic heterogeneity in untreated cancers</strong> </summary></p>
<p><em>Nature reviews. Cancer 2019 11;19(11):639-650</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31455892" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31455892</a></p>
<p>Genetic intratumoural heterogeneity is a natural consequence of imperfect DNA replication. Any two randomly selected cells, whether normal or cancerous, are therefore genetically different. Here, we review the different forms of genetic heterogeneity in cancer and re-analyse the extent of genetic heterogeneity within seven types of untreated epithelial cancers, with particular regard to its clinical relevance. We find that the homogeneity of predicted functional mutations indriver genes is the rule rather than the exception. In primary tumours with multiple samples, 97% of driver-gene mutations in 38 patients were homogeneous. Moreover, among metastases from the same primary tumour, 100% of the driver mutations in 17 patients were homogeneous. With a single biopsy of a primary tumour in 14 patients, the likelihood of missing a functional driver-gene mutation that was present in all metastases was 2.6%. Furthermore, all functional driver-gene mutations detected in these 14 primary tumours were present among all their metastases. Finally, we found that individual metastatic lesions responded concordantly to targeted therapies in 91% of 44patients. These analyses indicate that the cells within the primary tumours that gave rise to metastases are genetically homogeneous with respect to functional driver-gene mutations, and we suggest that future efforts to develop combination therapies have the potential to be curative.</p>
<p>doi: <a href="https://doi.org/10.1038/s41568-019-0185-x" class="uri">https://doi.org/10.1038/s41568-019-0185-x</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Dynamic Changes in Normal Liver Parenchymal Volume During Chemotherapy for Colorectal Cancer: Liver Atrophy as an Alternate Marker of Chemotherapy-Associated Liver Injury</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Nov;26(12):4100-4107</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31440929" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31440929</a></p>
<p>BACKGROUND: The purpose of this study was to investigate the incidence, origin, and clinical significance of liver atrophy during chemotherapy for colorectal cancer. METHODS: This study included 103 patients who underwent chemotherapy before resection for colorectal liver metastases (training set) and 171 patients who underwent adjuvant or first-line chemotherapy without liver resection (validation set). A greater than 10% decrease (atrophy) or increase (hypertrophy) of the liver volume from the baseline was defined as a significant change. RESULTS: In the training set, the numbers of patients who developed atrophy, no change of volume, and hypertrophy of the liver after chemotherapy were 15 (14.6%), 73 (70.9%), and 15 (14.6%), respectively. Liver atrophy was associated with impaired hepatic function, and the postoperative morbidity rate and refractory ascites/pleural effusion were higher in the patients with liver atrophy than those without (60.0% vs.31.8%, P=0.045 and 46.7% vs.8.0%, P&lt;0.001, respectively). Histopathological examination revealed a strong association between sinusoidal injury and liver atrophy (P&lt;0.001). The cumulative incidence of liver atrophy increased with increasing duration of chemotherapy, whereas the incidence of liver atrophy was less frequent in patients who had received bevacizumab than those who had not in both the training set (odds ratio [OR], 0.13; P=0.001) and the validation set (OR, 0.31; P=0.007). CONCLUSIONS: Liver atrophy is associated with impaired hepatic functional reserve and observed at an increasing frequency as the duration of chemotherapy increases with frequent histopathological evidence of sinusoidal injury in the liver. Bevacizumab may protect against the development of liver atrophy.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07740-x" class="uri">https://doi.org/10.1245/s10434-019-07740-x</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A New Role for the Spleen: Aggravation of the Systemic Inflammatory Response in Rats with Severe Acute Pancreatitis</strong> </summary></p>
<p><em>The American journal of pathology 2019 Nov;189(11):2233-2245</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31430464" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31430464</a></p>
<p>Little is known about the role of the spleen in mediating systemic inflammatory responses in severe acute pancreatitis (SAP). We investigated the role played by the spleen in rats after SAP induction. Splenectomy was performed at designated time points after SAP induction. Pancreatic tissue and serum samples were collected and subjected to histologic, immunohistochemical, and immunologic analyses. After SAP induction, the splenic immune response was enhanced during SAP progression, as shown by the increased diameter of the splenic periarterial lymphatic sheath and the thickness of the splenic marginal zone. Rats with splenectomy developed acute pancreatitis more slowly than rats without splenectomy. In addition, pancreatic tissues of rats with splenectomy contained lower levels of serum amylase, tumor necrosis factor-, and IL-6 and exhibited less acinar cell death, leukocyte infiltration, and interstitial edema than those of rats without splenectomy. Compared with splenectomy alone, cotreatment with splenectomy and the administration of splenic cells originating from a rat with SAP 12 hours after induction increased systemic inflammation in SAP rats. Splenic factors exacerbated SAP-associated liver and lung injury and accentuated intestinal mucosal barrier dysfunction. Splenectomy altered the serum cytokine profile in rats with SAP. In a rat model of SAP, the spleen exacerbated the systematic inflammatory responses and injury to multiple organs, indicating a new role for the spleen in SAP.</p>
<p>doi: <a href="https://doi.org/10.1016/j.ajpath.2019.07.008" class="uri">https://doi.org/10.1016/j.ajpath.2019.07.008</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Nov;25(21):6309-6319</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31420359" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31420359</a></p>
<p>PURPOSE: Bromodomain and extraterminal (BET) proteins play important roles in transcriptional regulation relevant to cancer pathogenesis, and therapeutic targeting/inhibition of BET causes apoptosis of cancer cells in vitro. In this first-in-human study of the pan-BET inhibitor mivebresib (ABBV-075), the safety profile, MTD, and recommended phase II dose (RP2D) were determined in patients with advanced solid tumors. PATIENTS AND METHODS: A 3 + 3 dose escalation for different mivebresib dosing schedules [daily, Monday/Wednesday/Friday (M-W-F), 4 days on/3 off (4/7)] was followed by dose expansion in patients with prostate cancer. Endpoints were safety, tolerability, pharmacokinetics, and preliminary antitumor activity. RESULTS: Seventy-two patients with solid tumors (14% uveal melanoma; 11% colorectal; 11% breast; 8% pancreatic; 7% head/neck; 49% others) were treated with mivebresib during dose escalation, and 12 additional patients with prostate cancer in expansion cohort. Most common treatment-emergent adverse events (TEAE) related to mivebresib were dysgeusia (49%), thrombocytopenia (48%), fatigue (26%), and nausea (25%). Most common grade 3/4 TEAEs related to mivebresib were thrombocytopenia (35%) and anemia (6%). Dose-limiting toxicities included thrombocytopenia (2 mg daily; 4.5 mg M-W-F), gastrointestinal bleed (2 mg daily), hypertension (2-3 mg 4/7), fatigue, decreased appetite, and aspartate aminotransferase elevation (4 mg M-W-F). Of 61 evaluable patients from dose escalation, 26 (43%) had stable disease and 35 (57%) had progressive disease. Median progression-free survival was 1.8 months (95% confidence interval, 1.8-1.9). CONCLUSIONS: On the basis of safety and tolerability, mivebresib RP2D is 1.5 mg for the daily schedule, 2.5 mg for 4/7, and 3 mg for M-W-F. Mivebresib has a tolerable safety profile, and stable disease was observed in some patients with malignant solid tumors.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-0578" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-0578</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Robotic Extended Right Hemicolectomy with Complete Mesocolic Excision and D3 Lymph Node Dissection</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Nov;26(12):3990-3991</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31407176" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31407176</a></p>
<p>BACKGROUND: Recent studies have shown the benefits of complete mesocolic excision and extended lymphadenectomy (D3 lymph node dissection) in patients with colon cancer.1-3 METHODS: We present the case of a 62-year-old male with hepatic flexure adenocarcinoma. No metastatic disease was identified by computed tomography. A robot-assisted extended right hemicolectomy with complete mesocolic excision, D3 lymph node dissection, and resection of the mesentery with intact visceral peritoneum was performed. RESULTS: The trocars are placed in the right lower (8mm), lower midline (8mm), and left upper (12mm) quadrants. The camera port is placed superior to the umbilicus, and the assistant port is placed in the left lower quadrant. The robotic right lower port is used to place the cecum on tension in order to outline the ileocolic pedicle. The assistant retracts the transverse colon cephalad to outline the superior mesenteric artery and vein. Using two robotic arms, the surgeon begins dissection over the superior mesenteric vein inferior to the ileocolic pedicle. Cephalad dissection along the superior mesenteric vein proceeds with reflection of the mesentery and D3 lymph nodes laterally to allow en bloc resection. The ileocolic and middle colic vessels are identified, ligated and divided at their origins. The plane is then developed between the right colon mesentery and the retroperitoneum, including Gerotas fascia, duodenum, and head of the pancreas, in a medial-to-lateral fashion, with care taken to ensure an intact visceral peritoneum is maintained. The proximal transverse colon, hepatic flexure, and ascending colon are mobilized by taking down lateral attachments. The intervening mesentery is transected, and perfusion is assessed with indocyanine green fluorescence imaging. An intracorporeal, isoperistaltic, side-to-side anastomosis is performed using the 45-mm robotic stapler. The common enterotomy is sewn closed in two layers. Pathology showed T3N0 adenocarcinoma with all negative margins. CONCLUSION: Extended right hemicolectomy with complete mesocolic excision and D3 lymph node dissection is facilitated by a robotic approach, which improves visualization and instrument dexterity.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07692-2" class="uri">https://doi.org/10.1245/s10434-019-07692-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Impact of Dedicated Cancer Centers on Outcomes Among Medicare Beneficiaries Undergoing Liver and Pancreatic Cancer Surgery</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Nov;26(12):4083-4090</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31376033" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31376033</a></p>
<p>BACKGROUND: The Alliance of Dedicated Cancer Centers (DCCs) is comprised of 11 institutions that are exempt from the prospective payment system utilized by Medicare for hospital reimbursement. OBJECTIVE: The aim of this study was to compare short- and long-term outcomes of patients undergoing liver and pancreatic surgery for cancer at DCCs versus non-DCCs. METHODS: Patients who underwent a liver or pancreatic operation for a malignant indication between 2013 and 2015 were identified using the Medicare Inpatient Standard Analytic Files. Regression analyses and the Kaplan-Meier method were used to assess short- and long-term outcomes of patients at DCCs versus non-DCCs. RESULTS: Among 13,256 patients, 7.0% of patients were treated at a DCC. Median patient age and complexity of surgical procedures were comparable among DCCs and non-DCCs (all p&gt;0.05). Overall complications (16.5% vs.23.6%), 90-day readmission (26.2% vs.30.2%), and 90-day mortality (3.0% vs.8.7%) were lower at DCCs compared with non-DCCs (all p&lt;0.001). In addition, long-term hazards of death among patients undergoing hepatectomy [hazard ratio (HR) 0.64, 95% confidence interval (CI) 0.54-0.75] and pancreatectomy (HR 0.66, 95% CI 0.56-0.78) were lower among patients treated at DCCs (both p&lt;0.05). While Medicare payments for patients undergoing pancreatic surgery (DCC: $22,200 vs.non-DCC: $22,100; p=0.772) were comparable among DCC and non-DCC hospitals, Medicare payments for liver resection at DCCs were 13.9% lower than non-DCCs (DCC: $16,700 vs.non-DCC: $19,400; p&lt;0.001). CONCLUSIONS: Patients undergoing hepatopancreatic surgery at DCCs had better short- and long-term outcomes for the same/lower level of Medicare expenditure as non-DCC hospitals. DCCs provide higher-value surgical care for patients undergoing liver and pancreatic cancer operations.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07677-1" class="uri">https://doi.org/10.1245/s10434-019-07677-1</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Facility Type is Another Factor in the Volume-Outcome Relationship for Complex Hepatopancreatobiliary Procedures</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Nov;26(12):3811-3812</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31372869" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31372869</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07668-2" class="uri">https://doi.org/10.1245/s10434-019-07668-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Rosai-Dorfman Disease of the Pancreas Shows Significant Histologic Overlap With IgG4-related Disease</strong> </summary></p>
<p><em>The American journal of surgical pathology 2019 Nov;43(11):1536-1546</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31368911" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31368911</a></p>
<p>Rosai-Dorfman disease (RDD) is a rare entity characterized by proliferating S100-positive histiocytes. Originally described in lymph nodes, it can involve extranodal sites. Pancreatic involvement is rare, with &lt;10 cases previously reported. Recent studies demonstrate a possible overlap between RDD and the more common IgG4-related disease (IRD), which could further complicate pathologic diagnosis. We describe distinct morphologic characteristics as well as overlapping histologic features of IRD in 5 cases of pancreatic RDD at our institution and compare these to a cohort of nonpancreatic extranodal RDD cases. All pancreatic cases were mass forming and had spindled patterns of elongated histiocytes with smaller areas of more classical appearing RDD; all cases had areas of storiform fibrosis and dense lymphoplasmacytic infiltrates with no increase in IgG4-positive plasma cells, and all cases had some degree of vasculitis (4 cases had obliterative vasculitis). Thirteen nonpancreatic extranodal RDD cases had dense lymphoplasmacytic infiltrates; most (85%) had some fibrosis with 46% showing storiform fibrosis, 85% had vasculitis with 31% demonstrating obliterative vasculitis and 2 cases had increased IgG4 staining. Extranodal (pancreatic and nonpancreatic) RDD often shows overlapping morphologic features with IRD, including lymphoplasmacytic inflammation, storiform fibrosis with elongated histiocytes and vasculitis. This can create a diagnostic challenge in the pancreas where IRD is more commonly encountered. Pathologists need to be aware that RDD can occur in the pancreas and should include RDD in the differential of any mass forming pancreatic lesion in which morphologic features of IRD are present.</p>
<p>doi: <a href="https://doi.org/10.1097/PAS.0000000000001334" class="uri">https://doi.org/10.1097/PAS.0000000000001334</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Actual 10-Year Survival After Surgical Microwave Ablation for Hepatocellular Carcinoma: A Single-Center Experience in Japan</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Nov;26(12):4126-4133</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31359277" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31359277</a></p>
<p>BACKGROUND: Little evidence exists regarding long-term survival after microwave ablation for hepatocellular carcinoma (HCC). The aim of this study is to determine actual 10-year survival and clarify the clinicopathological features of patients surviving10years after surgical microwave ablation. PATIENTS AND METHODS: This retrospective study identified 459 patients who underwent surgical microwave ablation for HCC with curative intent between 2001 and 2008. We compared 100 patients who survived10years with 321 patients who died within 10years. RESULTS: Median overall survival and recurrence-free survival rates were 5.5 and 2.4years, respectively. The actual 10-year overall survival rate was 23.8%, and the actual 10-year recurrence-free survival rate was 8.1%. Multivariate analysis showed that age&gt;70years [odds ratio 1.87, P=0.029], hepatitis C virus positivity (OR 2.30, P=0.004), Child-Pugh class B (OR 3.28, P=0.003), and platelet count&lt;10104 /L (OR 1.93, P=0.033) were independent risk factors for actual 10-year survival. During 10-year follow-up, 66% of the10-year survivors developed recurrence, and 91% of these patients underwent further curative treatment, including hepatic resection or local ablation, for HCC recurrence. CONCLUSION: Ten-year survival after surgical microwave ablation for HCC can be expected in approximately 24% of patients, even though nearly 2/3 of our 10-year survival patients experienced recurrence. Close postoperative follow-up and further curative treatment for recurrence are important for improving long-term survival.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07646-8" class="uri">https://doi.org/10.1245/s10434-019-07646-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Characterization and Comparison of GITR Expression in Solid Tumors</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Nov;25(21):6501-6510</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31358539" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31358539</a></p>
<p>PURPOSE: Determine the differential effect of a FcR-binding, mIgG2a anti-GITR antibody in mouse tumor models, and characterize the tumor microenvironment for the frequency of GITR expression in T-cell subsets from seven different human solid tumors.Experimental Design: For mouse experiments, wild-type C57BL/6 mice were subcutaneously injected with MC38 cells or B16 cells, and BALB/c mice were injected with CT26 cells. Mice were treated with the anti-mouse GITR agonist antibody 21B6, and tumor burden and survival were monitored. GITR expression was evaluated at the single-cell level using flow cytometry (FC). A total of 213 samples were evaluated for GITR expression by IHC, 63 by FC, and 170 by both in seven human solid tumors: advanced hepatocellular carcinoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, pancreatic carcinoma, head and neck carcinoma, melanoma, and ovarian carcinoma. RESULTS: The therapeutic benefit of 21B6 was greatest in CT26 followed by MC38, and was least in the B16 tumor model. The frequency of CD8 T cells and effector CD4 T cells within the immune infiltrate correlated with response to treatment with GITR antibody. Analysis of clinical tumor samples showed that NSCLC, renal cell carcinoma, and melanoma had the highest proportions of GITR-expressing cells and highest per-cell density of GITR expression on CD4+ Foxp3+ T regulatory cells. IHC and FC data showed similar trends with a good correlation between both techniques. CONCLUSIONS: Human tumor data suggest that NSCLC, renal cell carcinoma, and melanoma should be the tumor subtypes prioritized for anti-GITR therapy development.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-0289" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-0289</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cytology with rapid on-site examination (ROSE) does not improve diagnostic yield of EUS-FNA of pancreatic cystic lesions</strong> </summary></p>
<p><em>Diagnostic cytopathology 2019 Nov;47(11):1184-1189</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31356003" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31356003</a></p>
<p>BACKGROUND: Cytology with rapid on-site evaluation (ROSE) has been shown to increase the diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for solid pancreatic lesions. No data exists on the need for rapid onsite cytology in the evaluation of pancreatic cystic lesions (PCLs). The purpose of this study is to determine whether onsite cytology impacts the diagnostic yield of EUS-FNA of PCLs. METHODS: We prospectively examined all patients with PCLs who underwent EUS-FNA without onsite cytology over a 6-month period and compared this to a historical cohort of patients with PCLs who underwent EUS-FNA with ROSE in the previous 6 months. Comparison was made between the two groups based upon patient demographics, EUS cyst characteristics, and FNA fluid &amp; cytopathology results. RESULTS: A total of 100 EUS-FNA exams for PCLs were identified: 46 with ROSE and 54 without onsite cytology. The majority of cytology findings were negative or nondiagnostic, 87.0% in the ROSE group, 77.8% in the group without onsite cytology. There was no difference using EUS-FNA without onsite cytology compared to ROSE when measuring total diagnostic yield (22.2% vs 13.0%, P = .30), number of nondiagnostic specimens (50% vs 54%, P = .69), and number of needle passes (1.51 vs 1.57, P = .68). CONCLUSIONS: (a) The majority of cytology results from EUS-FNA of cystic lesions are negative or nondiagnostic. (b) Having rapid onsite cytology evaluation of cystic lesions does not affect the number of needle passes nor diagnostic yield and is thus not recommended.</p>
<p>doi: <a href="https://doi.org/10.1002/dc.24291" class="uri">https://doi.org/10.1002/dc.24291</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet</strong> </summary></p>
<p><em>Gastroenterology 2019 11;157(5):1413-1428.e11</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31352001" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31352001</a></p>
<p>BACKGROUND &amp; AIMS: Obesity is a risk factor for pancreatic cancer. In mice, a high-fat diet (HFD) and expression of oncogenic KRAS lead to development of invasive pancreatic ductal adenocarcinoma (PDAC) by unknown mechanisms. We investigated how oncogenic KRAS regulates the expression of fibroblast growth factor 21, FGF21, a metabolic regulator that prevents obesity, and the effects of recombinant human FGF21 (rhFGF21) on pancreatic tumorigenesis. METHODS: We performed immunohistochemical analyses of FGF21 levels in human pancreatic tissue arrays, comprising 59 PDAC specimens and 45 nontumor tissues. We also studied mice with tamoxifen-inducible expression of oncogenic KRAS in acinar cells (KrasG12D/+ mice) and fElasCreERT mice (controls). KrasG12D/+ mice were placed on an HFD or regular chow diet (control) and given injections of rhFGF21 or vehicle; pancreata were collected and analyzed by histology, immunoblots, quantitative polymerase chain reaction, and immunohistochemistry. We measured markers of inflammation in the pancreas, liver, and adipose tissue. Activity of RAS was measured based on the amount of bound guanosine triphosphate. RESULTS: Pancreatic tissues of mice expressed high levels of FGF21 compared with liver tissues. FGF21 and its receptor proteins were expressed by acinar cells. Acinar cells that expressed KrasG12D/+ had significantly lower expression of Fgf21 messenger RNA compared with acinar cells from control mice, partly due to down-regulation of PPARG expression-a transcription factor that activates Fgf21 transcription. Pancreata from KrasG12D/+ mice on a control diet and given injections of rhFGF21 had reduced pancreatic inflammation, infiltration by immune cells, and acinar-to-ductal metaplasia compared with mice given injections of vehicle. HFD-fed KrasG12D/+ mice given injections of vehicle accumulated abdominal fat, developed extensive inflammation, pancreatic cysts, and high-grade pancreatic intraepithelial neoplasias (PanINs); half the mice developed PDAC with liver metastases. HFD-fed KrasG12D/+ mice given injections of rhFGF21 had reduced accumulation of abdominal fat and pancreatic triglycerides, fewer pancreatic cysts, reduced systemic and pancreatic markers of inflammation, fewer PanINs, and longer survival-only approximately 12% of the mice developed PDACs, and none of the mice had metastases. Pancreata from HFD-fed KrasG12D/+ mice given injections of rhFGF21 had lower levels of active RAS than from mice given vehicle. CONCLUSIONS: Normal acinar cells from mice and humans express high levels of FGF21. In mice, acinar expression of oncogenic KRAS significantly reduces FGF21 expression. When these mice are placed on an HFD, they develop extensive inflammation, pancreatic cysts, PanINs, and PDACs, which are reduced by injection of FGF21. FGF21 also reduces the guanosine triphosphate binding capacity of RAS. FGF21 might be used in the prevention or treatment of pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.07.030" class="uri">https://doi.org/10.1053/j.gastro.2019.07.030</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Nov;25(21):6417-6428</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31332047" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31332047</a></p>
<p>PURPOSE: Recent studies demonstrate the role of the tumor microenvironment in tumor progression. However, strategies used to overcome the malignant phenotypes of cancer cells modulated by the microenvironment have not been thoroughly explored. In this study, we evaluated the therapeutic efficacy of a newly developed mAb targeting microfibril-associated protein 5 (MFAP5), which is secreted predominately by cancer-associated fibroblast (CAF), in ovarian and pancreatic cancer models.Experimental Design: MAbs were developed using human MFAP5 recombinant protein as an antigen in mice, and antibodies from hybridoma clones were evaluated for their specificity to human and murine MFAP5. An Octet RED384 system was used to determine the kinetics of binding affinity and the specificity of the antibody clones, which were followed by epitope mapping and functional characterization by in vitro assays. The therapeutic efficacy of a lead anti-MFAP5 antibody clone 130A in tumor suppression was evaluated by ovarian tumor- and pancreatic tumor-bearing mouse models. RESULTS: Three hybridoma clones, which produced antibodies with high affinity and specificity to MFAP5, were selected for functional studies. Antibody clone 130A, which recognizes a common epitope shared between human and murine MFAP5 protein, was further selected for in vivo studies. Results showed that clone 130A downregulated MFAP5-induced collagen production in CAFs, suppressed intratumoral microvessel leakiness, and enhanced paclitaxel bioavailability in both ovarian and pancreatic cancer mouse models. CONCLUSIONS: These data suggest that MFAP5 blockade using an immunologic approach inhibits fibrosis, induces tumor vessel normalization, and enhances chemosensitivity in ovarian and pancreatic cancer, and can be used as a novel therapeutic agent.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-0187" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-0187</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Endoscopic ultrasound guided fine-needle aspiration vs core needle biopsy for solid pancreatic lesions: Comparison of diagnostic accuracy and procedural efficiency</strong> </summary></p>
<p><em>Diagnostic cytopathology 2019 Nov;47(11):1138-1144</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31313531" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31313531</a></p>
<p>BACKGROUND: Endoscopic ultrasound (EUS) guided core needle biopsies (CNB) are increasingly being performed to diagnose solid pancreatic lesions. However, studies have been conflicting in terms of CNB improving diagnostic accuracy and procedural efficiency vs fine-needle aspiration (FNA), which this study aims to elucidate. METHODS: Data were prospectively collected on consecutive patients with solid pancreatic or peripancreatic lesions at a single tertiary care center from November 2015 to November 2016 that underwent either FNA or CNB. Patient demographics, characteristics of lesions, diagnostic accuracy, final and follow-up pathology, use of rapid on-site evaluation (ROSE), complications, and procedure variables were obtained. RESULTS: A total of 75 FNA and 48 CNB were performed; of these, 13 patients had both. Mean passes were lower with CNB compared to FNA (2.4 vs 2.9, P = .02). Use of ROSE was higher for FNA (97.3% vs 68.1%, P = .001). Mean procedure time was shorter with CNB (34.1minutes vs 51.2minutes, P = .02) and diagnostic accuracy was similar (89.2% vs 89.4%, P = .98). There was no difference in diagnostic accuracy when ROSE was performed for CNB vs not performed (93.5% vs 85.7%, P = .58). Additionally, diagnostic accuracy of combined FNA and CNB procedures was 92.3%, which was comparable to FNA (P = .73) or CNB (P = .52) alone. CONCLUSION: FNA and CNB had comparable safety and diagnostic accuracy. Use of CNB resulted in less number of passes and shorter procedure time as compared to FNA. Moreover, diagnostic accuracy for CNB with or without ROSE was similar.</p>
<p>doi: <a href="https://doi.org/10.1002/dc.24277" class="uri">https://doi.org/10.1002/dc.24277</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Completion of Adjuvant Chemotherapy After Upfront Surgical Resection for Pancreatic Cancer Is Uncommon Yet Associated With Improved Survival</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Nov;26(12):4108-4116</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31313044" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31313044</a></p>
<p>BACKGROUND: Multiple trials have demonstrated a survival benefit for adjuvant chemotherapy after resection of pancreatic adenocarcinoma. This study aimed to identify the rate for completion of adjuvant chemotherapy, factors associated with completion, and its impact on survival after surgical resection. METHODS: The Surveillance Epidemiology and End Results Medicare-linked data was used to identify patients who underwent upfront resection for pancreatic adenocarcinoma from 2004 to 2013. Billing codes were used to quantify receipt and completion of chemotherapy. Factors associated with completion of chemotherapy were identified using multivariable regression. Kaplan-Meier and Cox proportional-hazards modeling were used to examine survival. RESULTS: The inclusion criteria were met by 2440 patients. Of these patients, 65% received no adjuvant chemotherapy, 28% received incomplete therapy, and 7% completed chemotherapy. The factors associated with chemotherapy completion were nodal metastases and treatment at a National Cancer Institute-designated cancer center (p0.05). Comorbidities decreased the odds of completion (p0.05). The median overall survival (OS) was 14months for the patients who received no adjuvant chemotherapy, 17months for those who received incomplete adjuvant chemotherapy, and 22months for those who completed adjuvant chemotherapy (p0.05). More recent diagnosis, comorbidities, T stage, nodal metastases, and no adjuvant chemotherapy were associated with an increased hazard ratio for death (p0.05). Evaluation of 15 or more nodes and completion of chemotherapy decreased the hazard ratio for death (p0.05). CONCLUSIONS: Only 7% of the Medicare patients who underwent upfront resection for pancreatic cancer completed adjuvant chemotherapy, yet completion of adjuvant chemotherapy was associated with improved OS. Completion of adjuvant chemotherapy should be the goal after upfront resection, but neoadjuvant chemotherapy may ensure that patients receive systemic chemotherapy.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07602-6" class="uri">https://doi.org/10.1245/s10434-019-07602-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Next-generation sequencing of endoscopic ultrasound guided microbiopsies from pancreatic cystic neoplasms</strong> </summary></p>
<p><em>Histopathology 2019 Nov;75(5):767-771</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31278869" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31278869</a></p>
<p>AIMS: Interpretation of cytology samples from pancreatic cysts is challenging. A novel microbiopsy forceps used during endoscopic ultrasound examinations offers new opportunities for histological examination of tissue from pancreatic cysts as well as next-generation sequencing. The aim of this study was to analyse the results of next-generation sequencing of microbiopsies from pancreatic cysts. METHODS AND RESULTS: Microbiopsies from 27 patients were obtained, 23 of which were subjected to next-generation sequencing. Sixteen intraductal papillary mucinous neoplasms harboured mutations in genes regulating cell cycle and repair, and three were without mutations. Most frequent mutations were found in the KRAS and GNAS genes, and these were often concomitant. Three serous cystic neoplasms were without mutations, while with regard to histology, a non-diagnostic microbiopsy harboured a KRAS and a TP53 mutation and was deemed malignant after clinical follow-up. Three patients underwent surgery, and the point mutations detected in the microbiopsies were confirmed in the resected specimens. We identified one resected sample with an additional GNAS mutation which was not identified in the microbiopsy. CONCLUSIONS: Next-generation sequencing of microbiopsies may have the potential to improve diagnostic decision-making.</p>
<p>doi: <a href="https://doi.org/10.1111/his.13949" class="uri">https://doi.org/10.1111/his.13949</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Incidental splenic findings in pancreatosplenectomy specimens resected for primary pancreatic lesions</strong> </summary></p>
<p><em>Histopathology 2019 Nov;75(5):746-754</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31269535" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31269535</a></p>
<p>AIMS: Little has been written on the frequency and nature of incidental splenic lesions diagnosed on histopathological examination of pancreatosplenectomy specimens. METHODS AND RESULTS: For 191 such specimens, incidental histological findings after haematopathologist re-review were tabulated. Cases suspicious for lymphoid malignancy underwent molecular analysis for immunoglobulin heavy and kappa light chain rearrangement. Follow-up was obtained on selected cases. In five cases (3%), the spleen was sampled but not mentioned in the original microscopic report; all were normal on re-review. Otherwise, most (171 of 186, 92%) were initially diagnosed as normal, with 160 (94%) remaining so on re-review. Findings on re-review not initially described (n=11, 6%) included four cases with splenic morphology suspicious for possible leukaemia/lymphoma involvement. Additional findings included abscess formation, foamy macrophages, necrotising granulomas and simple cysts. Fifteen spleens were initially diagnosed as abnormal; the histopathological process was confirmed in all, including non-necrotising granulomas, cysts, Gamna-Gandy bodies, foamy macrophages, involvement by pancreatic neoplasm and involvement by known chronic lymphocytic leukaemia (CLL). Molecular analysis was performed on the five cases of known/suspected lymphoma and two were positive for monoclonal gene rearrangement, including the known CLL and a previously undiagnosed case with similar immunophenotype. CONCLUSIONS: Incidental splenic findings are not uncommon in pancreatosplenectomy specimens. While most are of limited clinical significance, low-grade lymphoproliferative disorders may go undetected if the spleen is overlooked. We recommend careful observation of splenic findings in these specimens, with a low threshold for haematopathological consultation when in doubt.</p>
<p>doi: <a href="https://doi.org/10.1111/his.13948" class="uri">https://doi.org/10.1111/his.13948</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The integrin v6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy</strong> </summary></p>
<p><em>The Journal of pathology 2019 Nov;249(3):332-342</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31259422" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31259422</a></p>
<p>Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of less than 4% and desperately needs novel effective therapeutics. Integrin v6 has been linked with poor prognosis in cancer but its potential as a target in PDAC remains unclear. We report that transcriptional expression analysis revealed that high levels of 6 mRNA correlated strongly with significantly poorer survival (n=491 cases, p=3.17  10-8 ). In two separate cohorts, we showed that over 80% of PDACs expressed v6 protein and that paired metastases retained v6 expression. In vitro, integrin v6 promoted PDAC cell growth, survival, migration, and invasion. Treatment of both v6-positive human PDAC xenografts and transgenic mice bearing v6-positive PDAC with the v6 blocking antibody 264RAD, combined with gemcitabine, significantly reduced tumour growth (p&lt;0.0001) and increased survival (log-rank test, p&lt;0.05). Antibody therapy was associated with suppression of tumour cell activity (suppression of pErk growth signals, increased apoptosis seen as activated caspase-3) and suppression of the pro-tumourigenic microenvironment (suppression of TGF signalling, fewer SMA-positive myofibroblasts, decreased blood vessel density). These data show that v6 promotes PDAC growth through both tumour cell and tumour microenvironment mechanisms and represents a valuable target for PDAC therapy.  2019 The Authors. The Journal of Pathology published by John Wiley &amp; Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.</p>
<p>doi: <a href="https://doi.org/10.1002/path.5320" class="uri">https://doi.org/10.1002/path.5320</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Mutational profiling and immunohistochemical analysis of a surgical series of ampullary carcinomas</strong> </summary></p>
<p><em>Journal of clinical pathology 2019 Nov;72(11):762-770</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31256008" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31256008</a></p>
<p>AIMS: Knowledge regarding the genetic features of ampullary carcinoma (AC) in European patients is limited. The utility of tumour markers for the establishment of a malignant diagnosis in biopsies from the ampullary region has not been fully elucidated. We aimed to describe the clinical, pathological, immunohistochemical (IHC) and genetic features of a Danish series of surgically resected ACs. METHODS: Surgically resected ACs (n=59) were examined regarding (1) clinicopathological features, (2) histological subtypes, (3) expression of IMP3, maspin, MUC5AC and S100P and (4) next-generation sequencing using a hybrid capture-based platform (Illumina HiSeq2500), including 315 cancer-related genes plus introns from 28 genes often rearranged or altered in cancer. Tumour mutational burden (TMB) and microsatellite instability (MSI) were also evaluated. RESULTS: Pancreatobiliary adenocarcinomas (PB-AC), intestinal adenocarcinomas (INT-AC), other ampullary tumours and mixed adenocarcinomas represented 45.8%, 23.7%, 16.9% and 13.6%. The proportion of IHC-positive ACs (score 2) was: Maspin (94.9%), IMP3 (67.8%), S100P (39.0%) and MUC5AC (18.6%). Most frequently altered genes were TP53 (59.3%), KRAS (40.7%), APC (27.8%), SMAD4 (20.4%), CDKN2A (16.7%) and ARID2/PIK3CA (each 11.1%). MUC5AC and S100P were frequently expressed in PB-AC, APC alterations frequent in INT-AC, SOX9 alterations were exclusive in INT-AC and MDM2 and FRS2 alterations in PB-AC. Four of 49 ACs (8.2%) were TMB-high/MSI-high and showed loss of MLH1 and PMS2. CONCLUSIONS: PB-AC was the most frequent histological subtype of AC. Maspin and IMP3 were the IHC tumour markers with the highest sensitivity. Adenocarcinoma subtypes differed regarding several genetic alterations, whose predictive value remains to be evaluated.</p>
<p>doi: <a href="https://doi.org/10.1136/jclinpath-2019-205912" class="uri">https://doi.org/10.1136/jclinpath-2019-205912</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma</strong> </summary></p>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019 Nov;32(11):1646-1656</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31231126" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31231126</a></p>
<p>Programmed death ligand 1 (PD-L1) protein expression by immunohistochemistry is a promising biomarker for PD-1/PD-L1 blockade in hepatocellular carcinoma. There are a number of commercially available PD-L1 assays. Our study aimed to compare the analytical performance of different PD-L1 assays and evaluate the reliability of pathologists in PD-L1 scoring. Consecutive sections from tumor samples from 55 patients with surgically resected primary hepatocellular carcinoma were stained with four standardized PD-L1 assays (22C3, 28-8, SP142, and SP263). We also correlated the PD-L1 protein level by immunohistochemistry with the mRNA level of those genes associated with tumor immune microenvironment by the NanoString platform. Five pathologists independently assessed PD-L1 expression on tumor cells [tumor proportion score] together with tumor-infiltrating immune cells (combined positive score). The 22C3, 28-8, and SP263 assays had comparable sensitivity in detecting PD-L1 expression, whereas the SP142 assay was the least sensitive assay. The inter-assay agreement measured by intraclass correlation coefficients for the tumor proportion score and combined positive score were 0.646 and 0.780, respectively. The inter-rater agreement was good to excellent (the overall intraclass correlation coefficient for the tumor proportion score and combined positive score was 0.946 and 0.809, respectively). Pathologists were less reliable in scoring combined positive score than tumor proportion score, particularly when using the SP142 assay. Up to 18% of samples were misclassified by individual pathologists in comparison to the consensus score at the cutoff of combined positive score1. The combined positive score by the 22C3 assay demonstrated the strongest correlation with immune-related gene mRNA signatures, closely followed by combined positive scores by the 28-8 and SP263 assays. In conclusion, the 22C3, 28-8, and SP263 assays are highly concordant in PD-L1 scoring and suggest the interchangeability of these three assays. Further improvement of the accuracy in assessing PD-L1 expression at a low cutoff is still necessary.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-019-0307-8" class="uri">https://doi.org/10.1038/s41379-019-0307-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Targeted next-generation sequencing identifies distinct clinicopathologic and molecular entities of intraductal papillary neoplasms of the bile duct</strong> </summary></p>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019 Nov;32(11):1637-1645</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31231124" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31231124</a></p>
<p>Intraductal papillary neoplasm of the bile duct (IPNB) is a mass-forming neoplasm in the bile duct considered to be the biliary counterpart of pancreatic intraductal papillary mucinous neoplasm (IPMN). By its cell lineage, IPNB can be classified into gastric, intestinal, pancreatobiliary, and oncocytic types. Recently, a group of Japanese and Korean pathologists proposed that IPNB be classified into two types, with type 1, being the histological counterpart of IPMN and type 2, having a more complex histological architecture. We used targeted next-generation sequencing to study the molecular change of 37 IPNBs and identified frequent mutations of KRAS (49%), GNAS (32%), RNF43 (24%), APC (24%), TP53 (24%), and CTNNB1 (11%) in IPNBs. Intestinal-type IPNB was associated with KRAS, GNAS, and RNF43 mutations. Japan-Korea consensus type 1 was associated with KRAS and GNAS mutations. All four IPNBs with CTNNB1 mutations were of pancreatobiliary type and located in the extrahepatic bile duct. A hierarchical analysis identified three distinct groups within IPNB: group 1 was Japan-Korea consensus type 1 tumors with macroscopic mucin, old age, and frequent KRAS, GNAS, and RNF43 mutations. Group 2 was Japan-Korea consensus type 2 with intestinal differentiation and frequent KRAS mutation but rare GNAS mutation, MUC2 expression, and macroscopic mucin. Group 3 was characterized by CTNNB1 mutation, extrahepatic location, lack of expression of intestinal markers, Japan-Korea consensus type 2, and lack of mutations in KRAS, APC, RNF43, and GNAS. Our results indicated that IPNB is a heterogeneous disease and that the activation of Ras-mitogen-activated protein kinase (MAPK), Wnt/-catenin, and G-protein-coupled receptor (GPCR)-cAMP signaling is the main oncogenic mechanism of IPNB.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-019-0306-9" class="uri">https://doi.org/10.1038/s41379-019-0306-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas</strong> </summary></p>
<p><em>Gut 2019 11;68(11):2019-2031</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31227589" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31227589</a></p>
<p>OBJECTIVE: Hepatocellular carcinoma (HCC) is heterogeneous, especially in multifocal tumours, which decreases the efficacy of clinical treatments. Understanding tumour heterogeneity is critical when developing novel treatment strategies. However, a comprehensive investigation of tumour heterogeneity in HCC is lacking, and the available evidence regarding tumour heterogeneity has not led to improvements in clinical practice. DESIGN: We harvested 42 samples from eight HCC patients and evaluated tumour heterogeneity using whole-exome sequencing, RNA sequencing, mass spectrometry-based proteomics and metabolomics, cytometry by time-of-flight, and single-cell analysis. Immunohistochemistry and quantitative polymerase chain reactions were performed to confirm the expression levels of genes. Three independent cohorts were further used to validate the findings. RESULTS: Tumour heterogeneity is considerable with regard to the genomes, transcriptomes, proteomes, and metabolomes of lesions and tumours. The immune status of the HCC microenvironment was relatively less heterogenous. Targeting local immunity could be a suitable intervention with balanced precision and practicability. By clustering immune cells in the HCC microenvironment, we identified three distinctive HCC subtypes with immunocompetent, immunodeficient, and immunosuppressive features. We further revealed the specific metabolic features and cytokine/chemokine expression levels of the different subtypes. Determining the expression levels of CD45 and Foxp3 using immunohistochemistry facilitated the correct classification of HCC patients and the prediction of their prognosis. CONCLUSION: There is comprehensive intratumoral and intertumoral heterogeneity in all dimensions of HCC. Based on the results, we propose a novel immunophenotypic classification of HCCs that facilitates prognostic prediction and may support decision making with regard to the choice of therapy.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2019-318912" class="uri">https://doi.org/10.1136/gutjnl-2019-318912</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreatic Steatosis: An Emerging Clinical Entity</strong> </summary></p>
<p><em>The American journal of gastroenterology 2019 Nov;114(11):1726-1734</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31185002" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31185002</a></p>
<p>Pancreatic steatosis is an emerging clinical entity whose pathophysiology, natural history, and long-term complications are poorly characterized in the current literature. Epidemiological and prospective studies have described prevalence rates between 16% and 35%. Although the natural history is not well known, there are strong associations with obesity, metabolic syndrome, type 2 diabetes mellitus, and nonalcoholic fatty liver disease. Ectopic fat accumulation of the pancreas can cause chronic, low-grade inflammation from adipocytokine imbalances that involve beta cells and acinar cells. This mechanism can lead to pancreatic endocrine and exocrine dysfunction and initiate carcinogenesis. Although it is associated with morbid conditions, pancreatic steatosis may be amendable to treatment with a healthy diet, less meat consumption, exercise, and smoking cessation. Pancreatic steatosis should factor into clinical decision-making and prognostication of patients with pancreatic and systemic disease. This review seeks to describe the pathophysiology, natural history, diagnosis, and complications of this emerging clinically relevant entity.</p>
<p>doi: <a href="https://doi.org/10.14309/ajg.0000000000000262" class="uri">https://doi.org/10.14309/ajg.0000000000000262</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Familial Adenomatous Polyposis Syndrome: An Update and Review of Extraintestinal Manifestations</strong> </summary></p>
<p><em>Archives of pathology &amp; laboratory medicine 2019 Nov;143(11):1382-1398</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31070935" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31070935</a></p>
<p>CONTEXT.: Familial adenomatous polyposis (FAP) is a rare genetic disorder with autosomal dominant inheritance, defined by numerous adenomatous polyps, which inevitably progress to colorectal carcinoma unless detected and managed early. Greater than 70% of patients with this syndrome also develop extraintestinal manifestations, such as multiple osteomas, dental abnormalities, and a variety of other lesions located throughout the body. These manifestations have historically been subcategorized as Gardner syndrome, Turcot syndrome, or gastric adenocarcinoma and proximal polyposis of the stomach. Recent studies, however, correlate the severity of gastrointestinal disease and the prominence of extraintestinal findings to specific mutations within the adenomatous polyposis coli gene (APC), supporting a spectrum of disease as opposed to subcategorization. Advances in immunohistochemical and molecular techniques shed new light on the origin, classification, and progression risk of different entities associated with FAP. OBJECTIVE.: To provide a comprehensive clinicopathologic review of neoplastic and nonneoplastic entities associated with FAP syndrome, with emphasis on recent developments in immunohistochemical and molecular profiles of extraintestinal manifestations in the thyroid, skin, soft tissue, bone, central nervous system, liver, and pancreas, and the subsequent changes in classification schemes and risk stratification. DATA SOURCES.: This review will be based on peer-reviewed literature and the authors experiences. CONCLUSIONS.: In this review we will provide an update on the clinicopathologic manifestations, immunohistochemical profiles, molecular features, and prognosis of entities seen in FAP, with a focus on routine recognition and appropriate workup of extraintestinal manifestations.</p>
<p>doi: <a href="https://doi.org/10.5858/arpa.2018-0570-RA" class="uri">https://doi.org/10.5858/arpa.2018-0570-RA</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Ring1b-dependent epigenetic remodelling is an essential prerequisite for pancreatic carcinogenesis</strong> </summary></p>
<p><em>Gut 2019 11;68(11):2007-2018</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30954952" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30954952</a></p>
<p>BACKGROUND AND AIMS: Besides well-defined genetic alterations, the dedifferentiation of mature acinar cells is an important prerequisite for pancreatic carcinogenesis. Acinar-specific genes controlling cell homeostasis are extensively downregulated during cancer development; however, the underlying mechanisms are poorly understood. Now, we devised a novel in vitro strategy to determine genome-wide dynamics in the epigenetic landscape in pancreatic carcinogenesis. DESIGN: With our in vitro carcinogenic sequence, we performed global gene expression analysis and ChIP sequencing for the histone modifications H3K4me3, H3K27me3 and H2AK119ub. Followed by a comprehensive bioinformatic approach, we captured gene clusters with extensive epigenetic and transcriptional remodelling. Relevance of Ring1b-catalysed H2AK119ub in acinar cell reprogramming was studied in an inducible Ring1b knockout mouse model. CRISPR/Cas9-mediated Ring1b ablation as well as drug-induced Ring1b inhibition were functionally characterised in pancreatic cancer cells. RESULTS: The epigenome is vigorously modified during pancreatic carcinogenesis, defining cellular identity. Particularly, regulatory acinar cell transcription factors are epigenetically silenced by the Ring1b-catalysed histone modification H2AK119ub in acinar-to-ductal metaplasia and pancreatic cancer cells. Ring1b knockout mice showed greatly impaired acinar cell dedifferentiation and pancreatic tumour formation due to a retained expression of acinar differentiation genes. Depletion or drug-induced inhibition of Ring1b promoted tumour cell reprogramming towards a less aggressive phenotype. CONCLUSIONS: Our data provide substantial evidence that the epigenetic silencing of acinar cell fate genes is a mandatory event in the development and progression of pancreatic cancer. Targeting the epigenetic repressor Ring1b could offer new therapeutic options.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2018-317208" class="uri">https://doi.org/10.1136/gutjnl-2018-317208</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca2+ signalling in a GABA-independent manner</strong> </summary></p>
<p><em>Gut 2019 11;68(11):1994-2006</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30826748" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30826748</a></p>
<p>BACKGROUND AND AIMS: Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related death worldwide. Neurotransmitter-initiated signalling pathway is profoundly implicated in tumour initiation and progression. Here, we investigated whether dysregulated neurotransmitter receptors play a role during pancreatic tumourigenesis. METHODS: The Cancer Genome Atlas and Gene Expression Omnibus datasets were used to identify differentially expressed neurotransmitter receptors. The expression pattern of gamma-aminobutyric acid type A receptor pi subunit (GABRP) in human and mouse PDAC tissues and cells was studied by immunohistochemistry and western blot analysis. The in vivo implications of GABRP in PDAC were tested by subcutaneous xenograft model and lung metastasis model. Bioinformatics analysis, transwell experiment and orthotopic xenograft model were used to identify the in vitro and in vivo effects of GABRP on macrophages in PDAC. ELISA, co-immunoprecipitation, proximity ligation assay, electrophysiology, promoter luciferase activity and quantitative real-time PCR analyses were used to identify molecular mechanism. RESULTS: GABRP expression was remarkably increased in PDAC tissues and associated with poor prognosis, contributed to tumour growth and metastasis. GABRP was correlated with macrophage infiltration in PDAC and pharmacological deletion of macrophages largely abrogated the oncogenic functions of GABRP in PDAC. Mechanistically, GABRP interacted with KCNN4 to induce Ca2+ entry, which leads to activation of nuclear factor B signalling and ultimately facilitates macrophage infiltration by inducing CXCL5 and CCL20 expression. CONCLUSIONS: Overexpressed GABRP exhibits an immunomodulatory role in PDAC in a neurotransmitter-independent manner. Targeting GABRP or its interaction partner KCNN4 may be an effective therapeutic strategy for PDAC.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2018-317479" class="uri">https://doi.org/10.1136/gutjnl-2018-317479</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Isolated peripancreatic necrosis (PPN) is associated with better clinical outcomes compared with combined pancreatic and peripancreatic involvement (CPN)- a systematic review and meta-analysis</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31678043" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31678043</a></p>
<p>BACKGROUND AND AIMS: Peripancreatic necrosis (PPN) is considered as a distinct entity with a better outcome when compared with combined pancreatic and peripancreatic necrosis (CPN), but there is no systematic review to summarize the evidence. Our study aimed to perform a meta-analysis of existing observational studies comparing the outcomes of PPN with CPN. METHODS: Studies in adult patients comparing the outcomes of PPN and CPN from PubMed, Medline, and Scopus databases from inception to November 2018 were systematically searched. The primary outcome was mortality, and secondary outcomes included multi-organ failure, persistent organ failure, infected necrosis, need for interventions including open necrosectomy. Pooled adjusted odds ratios, and 95% confidence intervals (CI) were obtained by the random-effects model. Forrest plots were constructed to show the summary pooled estimate. Heterogeneity was assessed by using I2 measure of inconsistency. RESULTS: A total of 6 studies involving 1851 patients (1295 (70%) with CPN and 556 (30%) with PPN) were included. Patients with CPN had a significantly higher mortality (OR 2.49, 95% CI: 1.61-3.87), risk for multi-organ failure (OR 3.24, 95% CI: 2.38-4.43), persistent organ failure (OR 2.79, 95% CI: 1.53-5.08), and infected necrosis (OR 6.21, 95% CI: 3.85-10.03). They underwent more interventions (OR 5.86, 95% CI: 3.69-9.32), including open necrosectomy (OR 5.04, 95% CI: 3.33-7.63). Heterogeneity was low (I2=18.1, p=0.296), and there was no publication bias. CONCLUSION: Isolated peripancreatic necrosis portends an overall better prognosis when compared to necrosis involves pancreatic parenchyma. Clinicians should recognize this distinction for management decisions.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.10.004" class="uri">https://doi.org/10.1016/j.pan.2019.10.004</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: Acceptable Impact of Endocrine and Exocrine Insufficiency on Quality of Life After Total Pancreatectomy</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31654166" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31654166</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-08008-0" class="uri">https://doi.org/10.1245/s10434-019-08008-0</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: 10-Year Survival After Surgical Microwave Ablation for Hepatocellular Carcinoma</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(Suppl 3):808-809</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31654158" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31654158</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07987-4" class="uri">https://doi.org/10.1245/s10434-019-07987-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Prophylaxis of Wound Infections-antibiotics in Renal Donation (POWAR): A UK Multicentre Double blind Placebo Controlled Randomised Trial</strong> </summary></p>
<p><em>Annals of surgery 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31714309" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31714309</a></p>
<p>BACKGROUND: Postoperative infection after hand-assisted laparoscopic donor nephrectomy (HALDN) confers significant morbidity to a healthy patient group. Current UK guidelines cite a lack of evidence for routine antibiotic prophylaxis. This trial assessed if a single preoperative antibiotic dose could reduce post HALDN infections. METHODS: Eligible donors were randomly and blindly allocated to preoperative single-dose intravenous co-amoxiclav or saline. The primary composite endpoint was clinical evidence of any postoperative infection at 30 days, including surgical site infection (SSI), urinary tract infection (UTI), and lower respiratory tract infection (LRTI). FINDINGS: In all, 293 participants underwent HALDN (148 antibiotic arm and 145 placebo arm). Among them, 99% (291/293) completed follow-up. The total infection rate was 40.7% (59/145) in the placebo group and 23% (34 of 148) in the antibiotic group (P = 0.001). Superficial SSIs were 20.7% (30/145 patients) in the placebo group versus 10.1% (15/148 patients) in the antibiotic group (P = 0.012). LRTIs were 9% (13/145) in the placebo group and 3.4% (5/148) in the antibiotic group (P = 0.046). UTIs were 4.1% (6/145) in the placebo group and 3.4% (5/148) in the antibiotic group (P = 0.72).Antibiotic prophylaxis conferred a 17.7% (95% confidence interval 7.2%-28.1%), absolute risk reduction in developing postoperative infection, with 6 donors requiring treatment to prevent 1 infection. INTERPRETATION: Single-dose preoperative antibiotic prophylaxis dramatically reduces post-HALDN infection rates, mainly impacting SSIs and LRTIs.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003666" class="uri">https://doi.org/10.1097/SLA.0000000000003666</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Keratin 17 is a negative prognostic biomarker in high-grade endometrial carcinomas</strong> </summary></p>
<p><em>Human pathology 2019 Dec;94():40-50</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31655172" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31655172</a></p>
<p>Keratin 17 (K17) has been established as a negative prognostic biomarker in cervical and ovarian cancers but has not previously been evaluated as a prognostic biomarker in endometrial adenocarcinoma. The association of K17 with decreased patient survival may be explained in part by the discovery that K17 drives tumor aggression by serving as a nuclear shuttle of p27, leading to cell cycle progression and tumor growth. The current study tests the hypothesis that K17 mRNA and protein levels correlate with decreased survival of patients with high-grade endometrial cancer. Gene expression data (mRNA) from The Cancer Genome Atlas were analyzed for 271 high-grade endometrial carcinomas and K17 immunohistochemistry (IHC) was performed on a separate cohort of 119 high-grade endometrial cancer cases from two academic medical centers. Survival analyses were determined by Cox proportional hazards regression. High K17 mRNA and IHC correlated with decreased overall survival (HR: 1.8, P=.0101, HR: 1.8, P=.0488, respectively). K17 was positive in malignant glandular cells of the endometrium but not in other tissues, including endometrial stroma, myometrium and uterine sarcoma. These results support the conclusion that K17 is a negative prognostic biomarker in high-grade endometrial carcinoma and that K17 IHC test results could be used to inform decisions related to therapeutic intervention.</p>
<p>doi: <a href="https://doi.org/10.1016/j.humpath.2019.09.005" class="uri">https://doi.org/10.1016/j.humpath.2019.09.005</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Response: Comment on Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer What Is Good for the Surgeon Is Just as Good for the Patient? The Case of Unresectable Pancreatic Cancer After Neoadjuvant Treatment</strong> </summary></p>
<p><em>Annals of surgery 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31651537" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31651537</a></p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003652" class="uri">https://doi.org/10.1097/SLA.0000000000003652</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Learning Curve From 450 Cases of Robot-Assisted Pancreaticoduocectomy in a High-Volume Pancreatic Center: Optimization of Operative Procedure and a Retrospective Study</strong> </summary></p>
<p><em>Annals of surgery 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31651533" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31651533</a></p>
<p>OBJECTIVE: We aimed to describe our experience and the learning curve of 450 cases of robot-assisted pancreaticoduodenectomy (RPD) and optimize the surgical process so that our findings can be useful for surgeons starting to perform RPD. SUMMARY BACKGROUND DATA: Robotic surgical systems were first introduced 20 years ago. Pancreaticoduodenectomy (PD) is a challenging surgery because of its technical difficulty. RPD may overcome some of these difficulties. METHODS: The medical records of 450 patients who underwent RPD between May 2010 and December 2018 at the Shanghai Ruijin Hospital were retrospectively analyzed. Operative times and estimated blood loss (EBL) were analyzed and the learning curve was determined. A cumulative sum (CUSUM) analysis was used to identify the inflexion points. Other postoperative outcomes, postoperative complications, and long-term follow-up were also analyzed. RESULTS: Operative time improved gradually over time from 405.4112.9minutes (case 1-50) to 273.670minutes (case 301-350) (P &lt; 0.001). EBL improved from 410563.5mL (case 1-50) to 149.0103.3mL (case 351-400) (P &lt; 0.001). According to the CUSUM curve, there were 3 phases in the RPD learning curve. The inflexion points were around cases 100 and 250. The incidence of pancreatic leak in the last 350 cases was significantly lower than that in the first 100 cases (30.0% vs 15.1%, P = 0.003). CONCLUSIONS: RPD is safe and feasible for selected patients. Operative and oncologic outcomes were much improved after experience of 250 cases. Our optimization of the surgical process may have also contributed to this. Future prospective and randomized studies are needed to confirm our results.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003664" class="uri">https://doi.org/10.1097/SLA.0000000000003664</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Proceedings of the 2019 National Toxicology Program Satellite Symposium</strong> </summary></p>
<p><em>Toxicologic pathology 2019 Dec;47(8):913-953</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31645210" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31645210</a></p>
<p>The 2019 annual National Toxicology Program Satellite Symposium, entitled Pathology Potpourri, was held in Raleigh, North Carolina, at the Society of Toxicologic Pathologys 38th annual meeting. The goal of this symposium was to present and discuss challenging diagnostic pathology and/or nomenclature issues. This article presents summaries of the speakers talks along with select images that were used by the audience for voting and discussion. Various lesions and topics covered during the symposium included aging mouse lesions from various strains, as well as the following lesions from various rat strains: rete testis sperm granuloma/fibrosis, ovarian cystadenocarcinoma, retro-orbital schwannoma, periductal cholangiofibrosis of the liver and pancreas, pars distalis hypertrophy, chronic progressive nephropathy, and renal tubule regeneration. Other cases included polyovular follicles in young beagle dogs and a fungal blood smear contaminant. One series of cases challenged the audience to consider how immunohistochemistry may improve the diagnosis of some tumors. Interesting retinal lesions from a rhesus macaque emphasized the difficulty in determining the etiology of any particular retinal lesion due to the retinas similar response to vascular injury. Finally, a series of lesions from the International Harmonization of Nomenclature and Diagnostic Criteria Non-Rodent Fish Working Group were presented.</p>
<p>doi: <a href="https://doi.org/10.1177/0192623319876929" class="uri">https://doi.org/10.1177/0192623319876929</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreatic Intraepithelial Neoplasia (PanIN) as a Morphologic Marker of Pancreatobiliary Type of Ampullary Carcinoma</strong> </summary></p>
<p><em>Pathology oncology research : POR 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31642034" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31642034</a></p>
<p>The classification of ampullary adenocarcinoma into intestinal and pancreatobiliary sub-types has been found to be important in predicting prognosis and determining therapeutic strategy. Due to considerable inter-observer variability in sub-typing based solely on morphology, higher frequency of poorly differentiated cancers and low incidence of the disease, the histomorphologic classification of ampullary adenocarcinoma remains one of the grey zones in surgical pathology. Pan-IN is a well recognized precursor to pancreatic adenocarcinoma. Three studies have shown concurrent Pan-IN in patients with ampullary carcinoma, but their association with the two sub-types has not yet been reported. Fourteen cases of surgical resection for ampullary adenocarcinoma were retrieved from the archives. The cases were classified into two groups based on the presence or absence of concomitant Pan-IN. All the cases were stained for CK7, CK 20, Villin and CDX 2 and were classified as intestinal or pancreatobiliary types based on the staining pattern. All the 10 cases with Pan-IN stained negative for CDX2 and were classified as pancreatobiliary type (p=0.01). Of the cases without Pan-IN, 3 were classified as intestinal sub-type based on morphology and CDX2 positivity and 1 was classified as pancreatobiliary type. Concomitant Pan-IN was present in 91% of pancreatobiliary type of ampullary adenocarcinoma. The grade of Pan-IN did not influence the grade or stage of the adenocarcinoma (p&gt;0.05). The co-occurrence of Pan-IN in a high percentage of the pancreatobiliary sub-type and its complete absence in the intestinal sub-type may serve as a strong differentiator between the two sub-types.</p>
<p>doi: <a href="https://doi.org/10.1007/s12253-019-00754-6" class="uri">https://doi.org/10.1007/s12253-019-00754-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein (HIP/PAP) confers protection against hepatic fibrosis through downregulation of transforming growth factor  receptor II</strong> </summary></p>
<p><em>Laboratory investigation; a journal of technical methods and pathology 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31641222" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31641222</a></p>
<p>Hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein (HIP/PAP) has antimicrobial, antioxidant, anti-inflammatory, mitogenic, and antiapoptotic effects and thus exerts important functions in the maintenance of integrity and homeostasis of several organs, such as the gastrointestinal tract, pancreas, and liver. Although the potent hepatoprotective effect of HIP/PAP has been validated, its impact on liver fibrosis has not been reported. In this study, we evaluated the role of HIP/PAP on hepatic fibrosis and explored the possible underlying mechanisms. We found that the expression of HIP/PAP and its mouse counterpart, Reg3B, was markedly upregulated in fibrotic human or mouse livers. Intraperitoneal (i.p.) interleukin (IL)-10, IL-6, and TNF- but not TGF-1 significantly induced hepatic overexpression of Reg3B in mice. In both CCl4 and BDL liver fibrosis models, adenovirus-mediated ectopic expression of HIP/PAP markedly alleviated liver injury, inflammation, collagen deposition, hepatic stellate cell activation, and the overexpression of profibrotic cytokines, including transforming growth factor 1 (TGF-1), platelet-derived growth factor (PDGF)-A, B, connective tissue growth factor (CTGF), and plasminogen activator inhibitor-1 (PAI-1), in mice. In vitro experiments demonstrated that, in addition to suppressing hepatic stellate cell proliferation and accelerating hepatocyte proliferation, HIP/PAP mitigated TGF-1-induced hepatic stellate cell activation, hepatocyte epithelial-mesenchymal transition (EMT) and upregulated expression of profibrotic cytokines in both hepatic stellate cells and hepatocytes. Moreover, HIP/PAP attenuated the overexpression of TGF- receptor II (TGF-RII) in fibrotic mouse livers and decreased the basal expression of TGF-RII in nonfibrotic mouse livers as well as in cultured hepatocytes and hepatic stellate cells, which is at least partly attributable to the TGF-1-antagonizing function of HIP/PAP. This study indicates that increased expression of hepatic HIP/PAP serves as a countermeasure against liver injury and fibrosis. Exogenous supplementation of HIP/PAP might be a promising therapeutic agent for hepatic fibrosis as well as liver injury.</p>
<p>doi: <a href="https://doi.org/10.1038/s41374-019-0314-x" class="uri">https://doi.org/10.1038/s41374-019-0314-x</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial</strong> </summary></p>
<p><em>BMC cancer 2019 Oct;19(1):979</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31640628" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31640628</a></p>
<p>BACKGROUND: One critical step in the therapy of patients with localized pancreatic cancer is the determination of local resectability. The decision between primary surgery versus upfront local or systemic cancer therapy seems especially to differ between pancreatic cancer centers. In our cohort study, we analyzed the independent judgement of resectability of five experienced high volume pancreatic surgeons in 200 consecutive patients with borderline resectable or locally advanced pancreatic cancer. METHODS: Pretherapeutic CT or MRI scans of 200 consecutive patients with borderline resectable or locally advanced pancreatic cancer were evaluated by 5 independent pancreatic surgeons. Resectability and the degree of abutment of the tumor to the venous and arterial structures adjacent to the pancreas were reported. Interrater reliability and dispersion indices were compared. RESULTS: One hundred ninety-four CT scans and 6 MRI scans were evaluated and all parameters were evaluated by all surgeons in 133 (66.5%) cases. Low agreement was observed for tumor infiltration of venous structures (=0.265 and =0.285) while good agreement was achieved for the abutment of the tumor to arterial structures (interrater reliability celiac trunk =0.708 P&lt;0.001). In patients with vascular tumor contact indicating locally advanced disease, surgeons highly agreed on unresectability, but in patients with vascular tumor abutment consistent with borderline resectable disease, the judgement of resectability was less uniform (dispersion index locally advanced vs.borderline resectable p&lt;0.05). CONCLUSION: Excellent agreement between surgeons exists in determining the presence of arterial abutment and locally advanced pancreatic cancer. The determination of resectability in borderline resectable patients is influenced by additional subjective factors. TRIAL REGISTRATION: EudraCT:2009-014476-21 (2013-02-22) and NCT01827553 (2013-04-09).</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6148-5" class="uri">https://doi.org/10.1186/s12885-019-6148-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The diversity between curatively resected pancreatic head and body-tail cancers based on the 8th edition of AJCC staging system: a multicenter cohort study</strong> </summary></p>
<p><em>BMC cancer 2019 Oct;19(1):981</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31640615" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31640615</a></p>
<p>BACKGROUND: To our knowledge, there are no studies to systematically compare the detailed clinical significance between curatively resected pancreatic head (ph) and body-tail (pbt) ductal adenocarcinoma based on the new 8th edition of AJCC staging system (8th AJCC stage) that was just applied in clinical practice in 2018. METHODS: Three hundred fifty-one patients with curatively resected pancreatic adenocarcinoma (PC) from three center hospitals were entered into this multicenter cohort study. RESULTS: Increasing tumor size (P&lt;0.001), T stage (T1+T2 vs T3+T4, P=0.003), frequent postoperative liver metastasis (PLM) (P=0.002) and 8th AJCC stage (IA to VI, P&lt;0.001; I+II vs III+IV, P=0.002) were closely associated with the progression of pbt cancers compared with that in ph cancer patients. Moreover, tumor size3cm (P=0.012), 8th AJCC stage (III+IV) (P=0.025) and PLM (P=0.010) were identified as independent risk factors in pbt cancers in logistic analysis. Patients with pbt cancers had a significantly worse overall survival compared with ph cancer patients (P=0.003). Moreover, pbt was an independent unfavorable factor in multivariate analysis (P=0.011). In addition to lymph nodes metastasis,8th AJCC stage, vascular invasion and PLM, increasing tumor size and advanced T stage were also closely associated with the poor prognosis in 131 cases of pbt cancer patients compared with Ph cancer patients. CONCLUSION: Pbt, as an independent unfavorable factor for the prognosis of PC patients, are much more aggressive than that in ph cancers according to 8th AJCC staging system. 8th AJCC staging system are more comprehensive and sensitive to reflect the malignant biology of pbt cancers.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6178-z" class="uri">https://doi.org/10.1186/s12885-019-6178-z</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer</strong> </summary></p>
<p><em>BMC cancer 2019 Oct;19(1):977</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31640607" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31640607</a></p>
<p>BACKGROUND: Conventionally fractionated (CF) radiation therapy (RT) has been associated with lymphopenia, leading to compromised overall survival (OS) in cancer patients. It currently remains unknown if stereotactic body (SB) RT induces lymphopenia to the same degree. The aim of this study is to determine if SBRT with either chemotherapy (CMT) (Fluorouracil (5FU) or capecitabine) or Nelfinavir (NFV) to pancreatic adenocarcinoma induces lymphopenia to the same degree as CFRT with 5FU or capecitabine and how any associated difference affects patient survival outcomes. METHODS: Medical records of pancreatic adenocarcinoma patients treated with induction CMT followed by RT with concurrent CMT or NFVwere reviewed. Patients with total lymphocyte counts (TLCs) available both prior to and following initiation of RT were included. Three groups were identified: CFRT/CMT, SBRT/CMT, and SBRT/NFV. Median delivered RT doses for CFRT and SBRT were 50.4Gy in 1.8Gy fractions and 35Gy in 7Gy fractions, respectively. TLCs from day 0 (the first day of RT) to 40 were recorded and analyzed using the Kruskal-Wallis test with p-values adjusted with Bonferronis method. Linear regressions were utilized to estimate the slope of TLCs as it changes with time and survival analysis was performed via Kaplan-Meier plots. RESULTS: One hundred patients were identified (28 CFRT/CMT, 27 SBRT/CMT, 45 SBRT/NFV). Median pre-RT TLCs were not different among groups. Median lowest TLCs were significantly lower (p&lt;0.0001) and median TLCs reduction over time were significantly greater (p&lt;0.0001) in the CFRT group than SBRT groups. There was no difference in lowest TLCs or TLCs reduction over time between SBRT groups. Across all groups, the median time to lowest TLCs was similar. Survival analysis revealed no significant difference in median OS between SBRT and CFRT groups. However, in patients with surgery, Median OS for patients with SBRT/CMT was significantly higher than in those with SBRT/NFV (p=0.03). CONCLUSIONS: Compared to CFRT, SBRT is associated with less lymphopenia. Further study of the effect of radiation technique on immune status is warranted.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6220-1" class="uri">https://doi.org/10.1186/s12885-019-6220-1</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Metastatic pheochromocytoma to the pancreas diagnosed by endoscopic ultrasound-guided fine needle aspiration: A case report and review of literature</strong> </summary></p>
<p><em>Diagnostic cytopathology 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31639290" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31639290</a></p>
<p>Pancreatic pheochromocytomas are rare and typically diagnosed by local resection. We present the first reported case of metastatic pheochromocytoma to the pancreas diagnosed by endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) and cytology. A 67-year-old female presented with 2 to 3months of abdominal pain. A CT scan showed a large mass in the head of the pancreas engulfing the superior mesentery artery and vein, along with a large mass in the left adrenal gland. An EUS-FNA was performed on the pancreatic mass with a 22-gauge needle, yielding an adequate sample. Papanicolaou stain, Diff-Quik, and cell block showed loosely cohesive clustered tumor cells and singly dispersed pleomorphic naked tumor nuclei with anisonucleosis and cytoplasmic vacuolization. Tumor cells stained positive for synaptophysin, chromogranin A, and CD56 and negative for CK AE1/3 and CK AE1/3-CAM5.2 cytokeratin cocktail. Because of cytokeratin negativity, diffusely positive neuroendocrine markers, and the presence of an adrenal mass, a metastatic malignant pheochromocytoma was suspected. Additional testing showed elevations in plasma metanephrines and normetanephrines, urine metanephrine-to-creatinine and normetanephrine-to-creatinine ratios, and serum chromogranin A. An iodine123 -metaiodobenzylguanidine (MIBG) scan was obtained, which showed significantly increased MIBG uptake in the left adrenal lesion. A diagnosis of metastatic malignant pheochromocytoma was made. Surgical oncology was consulted, who recommended against resection of the adrenal mass in favor of outpatient management. Metastatic pheochromocytoma to the pancreas are rare tumors that may yield diagnostic material by EUS-FNA with a 22-gauge needle.</p>
<p>doi: <a href="https://doi.org/10.1002/dc.24326" class="uri">https://doi.org/10.1002/dc.24326</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Minimally invasive drainage versus open surgical debridement in SAP/SMAP - a network meta-analysis</strong> </summary></p>
<p><em>BMC gastroenterology 2019 Oct;19(1):168</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31638914" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31638914</a></p>
<p>BACKGROUND: The efficacy of some therapeutic methods (open surgical debridement (OSD), conservative treatment (CST) and minimally invasive drainage (MID)) for severe acute pancreatitis (SAP) and moderately severe acute pancreatitis (MSAP) has been widely evaluated. However, the results remained controversial. We performed this study to illuminate whether any difference in incidence exists on patients with SAP/MSAP treated with OSD and MID. METHODS: Eligible articles were collected base of a comprehensive review of PUBMED, EMBASE, COCHRANE, CKNI and WANGFANG for published randomized controlled trials. Two steps of meta-analysis were performed, routine pair-wise meta-analysis and network meta-analysis. RESULTS: Thirteen studies were included in this study. Participants were classed as 5 groups, CST, early MID (EMID), late MID (LMID), early OSD (EOSD) and late OSD (LOSD). And MID contains endoscopic drainage (ESD), percutaneous catheter drainage (PCD) and minimally invasive surgery (MIS). Compared with CST, MID could decrease both mortality and multiple organ dysfunction syndrome (MODS) rate but OSD couldnt. Both EMID and MID can significantly decrease the mortality and MODS rate compared to CST. PCD might be most likely to have a benefit compared to CST. CONCLUSION: Existing evidence for the use of MID in SAP/MSAP is reliable and it can be used as early treatment. OSD, if necessary, should be avoided or delayed as long as possible.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-019-1078-x" class="uri">https://doi.org/10.1186/s12876-019-1078-x</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Metabolic Subtyping for Novel Personalized Therapies Against Pancreatic Cancer</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31628144" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31628144</a></p>
<p>Through metabolic subtyping, metabolic vulnerabilities can be exploited for developing efficacious treatments. A glycolytic subtype indicates poor survival in patients with pancreatic cancer, whereas a cholesterogenic subtype correlates with better outcomes potentially due to more energy expenditure. Personalized medicine holds great promise for improving therapy outcomes by optimally targeting metabolic pathways.See related article by Karasinska et al., p.xxx.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-2926" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-2926</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Case report of oxalate nephropathy in a patient with pancreatic metastases from renal carcinoma</strong> </summary></p>
<p><em>BMC cancer 2019 Oct;19(1):967</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31623580" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31623580</a></p>
<p>BACKGROUND: Patients with metastatic renal carcinoma frequently have pre-existing renal impairment and not infrequently develop worsening renal function as a complication of their treatment. The presence of pancreatic metastases in patients with metastatic renal carcinoma, often confers a more favourable prognosis and as a consequence this patient group may be exposed to such treatments for more prolonged periods of time. However, the development of renal failure may also be a consequence of the cancer itself rather than its treatment. CASE PRESENTATION: We present an 84-year-old patient receiving the tyrosine kinase inhibitor (TKI) pazopanib for metastatic renal carcinoma who developed oxalate nephropathy as a consequence of pancreatic exocrine insufficiency resulting from pancreatic metastases. CONCLUSIONS: This case demonstrates the importance of investigating unexpected toxicities and highlights the potential consequences of pancreatic insufficiency and its sequelae in patients with pancreatic metastases.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6215-y" class="uri">https://doi.org/10.1186/s12885-019-6215-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Recurrent Leg Ulcer, Underweight, Short Stature, and Exocrine Pancreatic Insufficiency</strong> </summary></p>
<p><em>The American journal of gastroenterology 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31634262" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31634262</a></p>
<p>doi: <a href="https://doi.org/10.14309/ajg.0000000000000420" class="uri">https://doi.org/10.14309/ajg.0000000000000420</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Habenular TCF7L2 links nicotine addiction to diabetes</strong> </summary></p>
<p><em>Nature 2019 10;574(7778):372-377</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31619789" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31619789</a></p>
<p>Diabetes is far more prevalent in smokers than non-smokers, but the underlying mechanisms of vulnerability are unknown. Here we show that the diabetes-associated gene Tcf7l2 is densely expressed in the medial habenula (mHb) region of the rodent brain, where it regulates the function of nicotinic acetylcholine receptors. Inhibition of TCF7L2 signalling in the mHb increases nicotine intake in mice and rats. Nicotine increases levels of blood glucose by TCF7L2-dependent stimulation of the mHb. Virus-tracing experiments identify a polysynaptic connection from the mHb to the pancreas, and wild-type rats with a history of nicotine consumption show increased circulating levels of glucagon and insulin, and diabetes-like dysregulation of blood glucose homeostasis. By contrast, mutant Tcf7l2 rats are resistant to these actions of nicotine. Our findings suggest that TCF7L2 regulates the stimulatory actions of nicotine on a habenula-pancreas axis that links the addictive properties of nicotine to its diabetes-promoting actions.</p>
<p>doi: <a href="https://doi.org/10.1038/s41586-019-1653-x" class="uri">https://doi.org/10.1038/s41586-019-1653-x</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial</strong> </summary></p>
<p><em>BMC cancer 2019 Oct;19(1):954</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31615466" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31615466</a></p>
<p>BACKGROUND: The efficacy of hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma (HCC) remains unclear. We conducted a multi-center randomized phase II study comparing a sequential HAIC-sorafenib regimen versus sorafenib alone as an initial therapy for HCC. METHODS: Patients were randomly assigned (ratio, 1:1) to receive sequential HAIC with cisplatin followed by sorafenib (HAIC group, n=35) or sorafenib alone (sorafenib group, n=33) as an initial therapy. The primary endpoint was the one-year survival rate. Secondary endpoint included overall survival (OS), the 2-year survival rate, the time-to-progression (TTP), the objective response rate (ORR), the disease control rate (DCR), and safety. RESULTS: For the primary endpoint, the one-year survival rates were 46% in the HAIC group and 58% in the sorafenib group. The median OS period was 10.0months (95% CI, 7.0-18.8) in the HAIC group and 15.2months (95% CI, 8.2-19.7) in the sorafenib group (hazard ratio [HR], 1.08; 95% CI, 0.63 to 1.86, P=0.78). The median TTP, ORR and DCR in the HAIC group were 2.8months (95% CI, 1.7-5.5), 14.3, and 45.7%, respectively, while those in the sorafenib group were 3.9months (95% CI, 2.3-6.8), 9.1, and 45.5%, respectively. No unexpected adverse events related to HAIC or sorafenib were observed in either group. CONCLUSIONS: Sequential HAIC with cisplatin and sorafenib does not improve the survival benefit, compared with sorafenib alone, when used as an initial therapy for advanced HCC. However, this study was underpowered in regard to its primary and secondary endpoints, so the results should be interpreted with caution. TRIAL REGISTRATION: UMIN ID 000006147 , registration data: August 11, 2011.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6198-8" class="uri">https://doi.org/10.1186/s12885-019-6198-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Lymph node ratio as valuable predictor in pancreatic cancer treated with R0 resection and adjuvant treatment</strong> </summary></p>
<p><em>BMC cancer 2019 Oct;19(1):952</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31615457" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31615457</a></p>
<p>BACKGROUND: Lymph-node (LN) metastasis is an important prognostic factor in resected pancreatic cancer. In this study, the prognostic value of American Joint Committee on Cancer (AJCC) 8th edition N stage, lymph-node ratio (LNR), and log odds of positive lymph nodes (LODDS) in resected pancreatic cancer was investigated. METHODS: Between January 2005 and December 2017, there were 351 patients with pancreatic cancer treated with R0 resection and adjuvant therapy at Seoul National University Hospital. Relationships between the three LN parameters and overall survival (OS) and recurrence-free survival (RFS) were evaluated using a log-rank test and Cox proportional hazard regression model. Each multivariate-adjusted LN parameter was internally validated by bootstrap-corrected Harrells C-index. RESULTS: The mean duration from surgery to adjuvant therapy was 47.617.4days. In total, the median OS and RFS was 31.7 (95% CI, 27.2-37.2) and 15.4 (95% CI, 13.5-17.7) months. The three LN classification systems were significantly correlated with OS and RFS in log-rank tests and multivariate-adjusted models (all p&lt;0.05). When internally validated, LNR showed the highest discrimination ability in predicting OS and RFS (each C-index=0.65). LNR also showed the highest C-index in subgroup analysis, classified by adjuvant therapy modality. LNR and the AJCC 8th edition LN classification system were significantly associated with loco-regional recurrence (p=0.026 and p=0.027, respectively). CONCLUSIONS: LNR, which showed the best prognostic performance and significant relationship with loco-regional recurrence, can help further stratify the patients and establish an active treatment plan.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6193-0" class="uri">https://doi.org/10.1186/s12885-019-6193-0</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer</strong> </summary></p>
<p><em>Gut 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31611300" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31611300</a></p>
<p>OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) is the most aggressive type of GI tumour, and it possesses deregulated cellular energetics. Although recent advances in PDAC biology have led to the discovery of recurrent genetic mutations in Kras, TP53 and SMAD4, which are related to this disease, clinical application of the molecular phenotype of PDAC remains challenging. DESIGN: We combined molecular imaging technology (positron emission tomography/CT) and immunohistochemistry to evaluate the correlation between the maximum standardised uptake value and SMAD4 expression and examined the effect of SMAD4 on glycolysis through in vitro and in vivo experiments. Furthermore, we identified the effect of SMAD4 on metabolic reprogramming by metabolomics and glucose metabolism gene expression analyses. Dual luciferase reporter assays and chromatin immunoprecipitation were performed to identify whether SMAD4 functioned as a transcription factor for phosphoglycerate kinase 1 (PGK1) in PDAC cells. Proliferative and metastatic assays were performed to examine the effect of PGK1 on the malignant behaviour of PDAC. RESULTS: We provide compelling evidence that the glycolytic enzyme PGK1 is repressed by transforming growth factor-/SMAD4. Loss of SMAD4 induces PGK1 upregulation in PDAC, which enhances glycolysis and aggressive tumour behaviour. Notably, in SMAD4-negative PDAC, nuclear PGK1 preferentially drives cell metastasis via mitochondrial oxidative phosphorylation induction, whereas cytoplasmic PGK1 preferentially supports proliferation by functioning as a glycolytic enzyme. The PDAC progression pattern and distinct PGK1 localisation combine to predict overall survival and disease-free survival. CONCLUSION: PGK1 is a decisive oncogene in patients with SMAD4-negative PDAC and can be a target for the development of a therapeutic strategy for SMAD4-negative PDAC.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2018-317163" class="uri">https://doi.org/10.1136/gutjnl-2018-317163</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Size and Importance of Socioeconomic Status-Based Disparities in Use of Surgery in Nonadvanced Stage Gastrointestinal Cancers</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31605347" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31605347</a></p>
<p>BACKGROUND: The size and importance of socioeconomic status (SES)-based disparities in use of surgery for non-advanced stage gastrointestinal (GI) cancers have not been quantified. METHODS: The exposure in this study of patients age 18-80 with one of nine non-advanced stage GI cancers in the 2007-2015 SEER database was a census tract-level SES composite. Multivariable models assessed associations of SES with use of surgery. Causal mediation analysis was used to estimate the proportion of survival disparities in SES quintiles 1 versus 5 that were mediated by disparities in use of surgery. RESULTS: Lowest SES quintile patients underwent surgery at significantly lower rates than highest quintile patients in each cancer. SES-based disparities in use of surgery were large and graded in esophagus adenocarcinoma, intrahepatic and extrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma. Smaller but clinically relevant disparities were present in stomach, ampulla, and small bowel adenocarcinoma, whereas disparities were small in colorectal adenocarcinoma. Five-year all-stage overall survival (OS) was correlated with the size of disparities in use of surgery in SES quintiles 1 versus 5 (r=-0.87; p=0.003). Mean OS was significantly longer (range 3.5-8.9months) in SES quintile 5 versus 1. Approximately one third of SES-based survival disparities in poor prognosis GI cancers were mediated by disparities in use of surgery. The size of disparities in use of surgery in SES quintiles 1 versus 5 was correlated with the proportion mediated (r=0.98; p&lt;0.001). CONCLUSIONS: Low SES patients with poor prognosis GI cancers are at substantial risk of undertreatment. Disparities in use of surgery contribute to diminished survival.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07922-7" class="uri">https://doi.org/10.1245/s10434-019-07922-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31605325" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31605325</a></p>
<p>BACKGROUND: CD36, a multi-ligand scavenger receptor, has been associated with several cancers. Many studies have revealed that CD36 contributed to cancer malignancy. This study aimed to reveal the function of CD36 expression in pancreatic ductal adenocarcinoma (PDAC). METHODS: CD36 expression was characterized using immunohistochemistry in 95 clinical specimens resected from patients with PDAC. We divided patients into two groups, with different CD36 expression levels, and analyzed and compared their prognoses. CD36 expression was also assessed in PDAC cell lines. Gemcitabine-resistant (GR) PDAC cell lines were transfected with small interfering RNA (siRNA) that specifically targeted CD36 to evaluate chemoresistance and apoptosis. RESULTS: In resected PDAC samples, CD36 expression was significantly correlated with microinvasion into the venous system (p=0.0284). Patients with high CD36 expression had significantly lower overall survival (OS) and recurrence-free survival (RFS) rates than patients with low expression; thus, CD36 was an independent prognostic factor for OS and RFS. In subgroup analyses, CD36 was an independent risk factor for OS and RFS in 59 patients treated with gemcitabine adjuvant chemotherapy. CD36 expression was upregulated in PDAC-GR cell lines compared with the PDAC parent cell line. Transduction with siRNA downregulated CD36, which reduced PDAC cell resistance to gemcitabine and inhibited anti-apoptosis proteins. CONCLUSION: CD36 expression influenced gemcitabine resistance by regulating anti-apoptosis proteins. High CD36 expression was a significant, unfavorable prognostic factor in PDAC. Anti-CD36 treatment might serve as an optional treatment for lowering resistance to gemcitabine.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07927-2" class="uri">https://doi.org/10.1245/s10434-019-07927-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Preoperative Risk Score for Predicting Incomplete Cytoreduction: A 12-Institution Study from the US HIPEC Collaborative</strong> </summary></p>
<p><em>Annals of surgical oncology 2020 Jan;27(1):156-164</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31602579" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31602579</a></p>
<p>BACKGROUND: For patients with peritoneal carcinomatosis undergoing cytoreductive surgery with heated intraperitoneal chemotherapy (CRS/HIPEC), incomplete cytoreduction (CCR2/3) confers morbidity without survival benefit. The aim of this study is to identify preoperative factors which predict CCR2/3. METHODS: All patients who underwent curative-intent CRS/HIPEC of low/high-grade appendiceal, colorectal, or peritoneal mesothelioma cancers in the 12-institution US HIPEC Collaborative from 2000 to 2017 were included (n=2027). The primary aim is to create an incomplete-cytoreduction risk score (ICRS) to predict CCR2/3 CRS utilizing preoperative data. ICRS was created from a randomly selected cohort of 50% of patients (derivation cohort) and verified on the remaining patients (validation cohort). RESULTS: Within our derivation cohort (n=998), histology was low-grade appendiceal neoplasms in 30%, high-grade appendiceal tumor in 41%, colorectal tumor in 22%, and peritoneal mesothelioma in 8%. CCR0/1 was achieved in 816 patients and CCR 2/3 in 116 patients. On multivariable analysis, preoperative factors associated with incomplete cytoreduction were male gender [odds ratio (OR) 3.4, p=0.007], presence of ascites (OR 2.8, p=0.028), cancer antigen (CA)-12540U/mL (OR 3.4, p=0.012), and carcinoembryonic antigen (CEA)4.2ng/mL (OR 3.2, p=0.029). Each preoperative factor was assigned a score of 0 or 1 to form an ICRS from 0 to 4. Scores were grouped as zero (0), low (1-2), or high (3-4). Incidence of CCR2/3 progressively increased by risk group from 1.6% in zero to 13% in low and 39% in high. When ICRS was applied to the validation cohort (n=1029), this relationship was maintained. CONCLUSION: The incomplete cytoreduction risk score incorporates preoperative factors to accurately stratify the risk of CCR2/3 resection in CRS/HIPEC. This score should not be used in isolation, however, to exclude patients from surgery.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07626-y" class="uri">https://doi.org/10.1245/s10434-019-07626-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Mycobacterium Spindle Cell Pseudotumor Caused by Mycobacterium xenopi: A First Described Association of a Rare Entity Presenting in the Lung</strong> </summary></p>
<p><em>International journal of surgical pathology 2019 Oct;():1066896919879745</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31601138" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31601138</a></p>
<p>Mycobacterial spindle cell pseudotumor (MSP) is a rare benign lesion characterized by a proliferation of bland spindle-shaped histiocytes with vague granulomatous formation, positive for acid-fast bacilli staining. This lesion is usually reported in the lymph nodes and skin of immunocompromised patients; only 6 cases primary in the lung have been reported in the English literature to this date. In this article, we present the case of a 42-year-old female status post failed kidney-pancreas transplant with subsequent multiple kidney transplants, on chronic immunosuppression, who developed a mass in the left lower lobe consistent with MSP. Mycobacterium xenopi was identified in lung tissue culture, an association never previously described in literature. This case report alerts for the possible association of this rare form of non-tuberculous mycobacteria in the pathogenesis of MSP and highlights the importance of this differential diagnosis in lung masses of immunocompromised patients.</p>
<p>doi: <a href="https://doi.org/10.1177/1066896919879745" class="uri">https://doi.org/10.1177/1066896919879745</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Maintenance Olaparib for Metastatic Pancreatic Cancer. Reply</strong> </summary></p>
<p><em>The New England journal of medicine 2019 10;381(15):1492-1493</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31597029" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31597029</a></p>
<p>doi: <a href="https://doi.org/10.1056/NEJMc1911185" class="uri">https://doi.org/10.1056/NEJMc1911185</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Maintenance Olaparib for Metastatic Pancreatic Cancer</strong> </summary></p>
<p><em>The New England journal of medicine 2019 10;381(15):1491-1492</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31597028" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31597028</a></p>
<p>doi: <a href="https://doi.org/10.1056/NEJMc1911185" class="uri">https://doi.org/10.1056/NEJMc1911185</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Maintenance Olaparib for Metastatic Pancreatic Cancer</strong> </summary></p>
<p><em>The New England journal of medicine 2019 10;381(15):1491</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31597027" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31597027</a></p>
<p>doi: <a href="https://doi.org/10.1056/NEJMc1911185" class="uri">https://doi.org/10.1056/NEJMc1911185</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors</strong> </summary></p>
<p><em>Annals of surgery 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31599805" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31599805</a></p>
<p>OBJECTIVE: The goal of this retrospective study was to clarify the clinical implications of immunohistochemically detected protein expression for genes that are frequently mutated in pancreatic neuroendocrine tumors (PNETs). BACKGROUND: The clinical management of PNETs is hindered by their heterogenous biological behavior. Whole-exome sequencing recently showed that 5 genes (DAXX/ATRX, MEN1, TSC2, and PTEN) are frequently mutated in PNETs. However, the clinical implications of the associated alterations in protein expression remain unclear. METHODS: We collected Grade 1 and 2 (World Health Organization 2017 Classification) primary PNETs samples from 100 patients who underwent surgical resection. ATRX, DAXX, MEN1, TSC2, and PTEN expression were determined immunohistochemically to clarify their relationships with prognosis and clinicopathological findings. RESULTS: Kaplan-Meier analysis indicated that loss of TSC2 (n = 58) or PTEN (n = 37) was associated with significantly shorter overall survival, and that loss of TSC2 or ATRX (n = 41) was associated with significantly shorter recurrence-free survival. Additionally, loss of ATRX or TSC2 was significantly associated with nodal metastasis. In a multivariate analysis, combined loss of TSC2 and ATRX (n = 31) was an independent prognostic factor for shorter recurrence-free survival (hazard ratio 10.1, 95% confidence interval 2.1-66.9, P = 0.003) in G2 PNETs. CONCLUSIONS: Loss of ATRX, TSC2, and PTEN expression might be useful as a method of clarifying the behavior and clinical outcomes of Grade 1 and 2 PNETs in routine clinical practice. Combined loss of TSC2 and ATRX had an especially strong, independent association with shorter recurrence-free survival in patients with G2 PNETs. Loss of pairs in ATRX, TSC2, or PTEN would be useful for selecting the candidate for postoperative adjuvant therapy.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003624" class="uri">https://doi.org/10.1097/SLA.0000000000003624</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Elucidating the roles of ASPM isoforms reveals a novel prognostic marker for pancreatic cancer</strong> </summary></p>
<p><em>The Journal of pathology 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31595972" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31595972</a></p>
<p>Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers worldwide. Late diagnosis, desmoplastic tissue and intrinsic resistance to therapy are among the main reasons for its aggressive phenotype. In addition, it is now appreciated that cancer stem cells-a rare subpopulation of tumor cells highly resistant to therapy-are crucial players in PDAC initiation, progression and resistance to therapy. In a recent article in The Journal of Pathology, Hsu et al elucidated the specific roles of abnormal spindle-like, microcephaly-associated protein (ASPM) isoforms in PDAC. The authors reported that ASPM isoform I (ASPM-iI) is mainly expressed in the cytoplasm of PDAC cells. Its expression is associated with the Wnt signaling pathway, which promotes stemness and maintains the cancer stem cell niche. Clinically, expression of ASPM-iI correlates with poor survival in PDAC patients. Thus, this study revealed a novel prognostic marker as well as a potential therapeutic target for PDAC.  2019 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</p>
<p>doi: <a href="https://doi.org/10.1002/path.5355" class="uri">https://doi.org/10.1002/path.5355</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>SATB2 Protein Expression by Immunohistochemistry is a Sensitive and Specific Marker of Appendiceal and Rectosigmoid Well Differentiated Neuroendocrine Tumors</strong> </summary></p>
<p><em>Histopathology 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31595536" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31595536</a></p>
<p>AIMS: Neuroendocrineneoplasms (NN)s range from well to poorly differentiated and indolent to highly aggressive.The site of origin in metastatic NNs has therapeutic and prognostic implications. SATB2 is a transcriptional regulator involved in osteoblastic and neuronal differentiation and a sensitive and specific marker of colorectal epithelium.This study aimed to evaluate the expression of SATB2 in NNs from various primary sitesand its utility as a marker in determining the site of origin of these neoplasms. METHODS AND RESULTS: SATB2 immunohistochemistrywas performed on 266 NNs, including lung small cell carcinomas (N=39) and carcinoids(N=30); bladder (N=21) and prostate (N=31) small cell carcinomas; and gastrointestinal (GI)/pancreatic NNs of various primary sites (N=145) consisting of well differentiated neuroendocrine tumors (WDNET)s (N=124) and poorly differentiated neuroendocrine carcinomas (PDNEC)s (N=21). SATB2 was expressed in prostatic (10/31, 32%) and bladder (8/21, 38%) small carcinomas, and lung carcinoid tumors (1/30, 3%) and small cell carcinomas (8/39, 21%). Among primary GI NNs, SATB2 was expressed in 37/124 (30%) WDNETs and 4/21 (19%) PDNECs. Of the former, 15/15 (100%) rectal/rectosigmoid and 22/22 (100%) appendiceal neoplasms expressed SATB2. By receiver operator characteristic analysis, SATB2 was a sensitive and specific marker for rectal (100.0%; 80.0%) and appendiceal (100.0%; 84.5%) WDNETs, respectively. CONCLUSIONS: In summary, SATB2 is a sensitive and specific marker for rectal/rectosigmoid and appendiceal WDNETs and may represent a useful diagnostic tool when these sites of origin are considered in the differential diagnosis.</p>
<p>doi: <a href="https://doi.org/10.1111/his.14012" class="uri">https://doi.org/10.1111/his.14012</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Current progress in the clinical use of circulating tumor cells as prognostic biomarkers</strong> </summary></p>
<p><em>Cancer cytopathology 2019 Dec;127(12):739-749</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31589381" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31589381</a></p>
<p>The process of metastasis is characterized by the shedding of tumor cells into the bloodstream, where they are transported to other parts of the body to seed new tumors. These cells, known as circulating tumor cells (CTCs), have the potential to reveal much about an individual cancer case, and theoretically can aid in the prediction of outcomes and design of precision treatments. Recent advances in technology now allow for the robust and reproducible characterization of CTCs from a simple blood draw. Both the number of circulating cells and important molecular characteristics correlated with clinical phenotypes such as drug resistance can be obtained and used for real-time prognostic analysis. Molecular characterization can provide a snapshot of the activity of the main tumor (serving as a liquid biopsy) and early warnings concerning changes such as the development of resistance, and aid in predicting the efficacy of different therapeutic approaches for treatment optimization. Herein, the authors review the current clinical use of CTCs as prognostic biomarkers for several different cancers. The quantification of CTCs can lead to more accurate staging and decision making regarding options such as adjuvant chemotherapy.</p>
<p>doi: <a href="https://doi.org/10.1002/cncy.22189" class="uri">https://doi.org/10.1002/cncy.22189</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Metastatic pancreatic adenosquamous carcinoma to the scalp: A case report and review of the literature</strong> </summary></p>
<p><em>Journal of cutaneous pathology 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31587324" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31587324</a></p>
<p>Metastatic carcinoma to the skin occurs in only a minority of patients with a visceral or internal malignancy, with breast, lung, and colorectum accounting for the majority of cases. We present the case of a 66-year-old man with a recent violaceous nodule of the left scalp (1.2 1.0 0.2 cm) that was a metastatic pancreatic adenosquamous carcinoma, representing a seemingly rare event. Two months prior, after complaining of right hip pain, an image revealed a right femoral lesion. A biopsy of that lesion showed moderately differentiated adenocarcinoma. Subsequent imaging showed a mass in the pancreatic tail and also markedly elevated serum tumor markers, CA 19-9 and carcinoembryonic antigen (5325 and 111.5 U/mL, respectively). Before the appearance of the scalp nodule, the patient received radiotherapy and was started on chemotherapy, which was continued after diagnosis and resection of the nodule. Subsequent metastases developed in the liver, lung and additional cutaneous lesions. He died 11months after initial presentation with right hip pain. As this case shows, cutaneous metastases confer a poor prognosis, often with less than a year survival following their appearance.</p>
<p>doi: <a href="https://doi.org/10.1111/cup.13582" class="uri">https://doi.org/10.1111/cup.13582</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Aldh1b1 expression defines progenitor cells in the adult pancreas and is required for Kras-induced pancreatic cancer</strong> </summary></p>
<p><em>Proceedings of the National Academy of Sciences of the United States of America 2019 Oct;116(41):20679-20688</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31548432" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31548432</a></p>
<p>The presence of progenitor or stem cells in the adult pancreas and their potential involvement in homeostasis and cancer development remain unresolved issues. Here, we show that mouse centroacinar cells can be identified and isolated by virtue of the mitochondrial enzyme Aldh1b1 that they uniquely express. These cells are necessary and sufficient for the formation of self-renewing adult pancreatic organoids in an Aldh1b1-dependent manner. Aldh1b1-expressing centroacinar cells are largely quiescent, self-renew, and, as shown by genetic lineage tracing, contribute to all 3 pancreatic lineages in the adult organ under homeostatic conditions. Single-cell RNA sequencing analysis of these cells identified a progenitor cell population, established its molecular signature, and determined distinct differentiation pathways to early progenitors. A distinct feature of these progenitor cells is the preferential expression of small GTPases, including Kras, suggesting that they might be susceptible to Kras-driven oncogenic transformation. This finding and the overexpression of Aldh1b1 in human and mouse pancreatic cancers, driven by activated Kras, prompted us to examine the involvement of Aldh1b1 in oncogenesis. We demonstrated genetically that ablation of Aldh1b1 completely abrogates tumor development in a mouse model of KrasG12D-induced pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1073/pnas.1901075116" class="uri">https://doi.org/10.1073/pnas.1901075116</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cell division rates decrease with age, providing a potential explanation for the age-dependent deceleration in cancer incidence</strong> </summary></p>
<p><em>Proceedings of the National Academy of Sciences of the United States of America 2019 Oct;116(41):20482-20488</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31548407" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31548407</a></p>
<p>A new evaluation of previously published data suggested to us that the accumulation of mutations might slow, rather than increase, as individuals age. To explain this unexpected finding, we hypothesized that normal stem cell division rates might decrease as we age. To test this hypothesis, we evaluated cell division rates in the epithelium of human colonic, duodenal, esophageal, and posterior ethmoid sinonasal tissues. In all 4 tissues, there was a significant decrease in cell division rates with age. In contrast, cell division rates did not decrease in the colon of aged mice, and only small decreases were observed in their small intestine or esophagus. These results have important implications for understanding the relationship between normal stem cells, aging, and cancer. Moreover, they provide a plausible explanation for the enigmatic age-dependent deceleration in cancer incidence in very old humans but not in mice.</p>
<p>doi: <a href="https://doi.org/10.1073/pnas.1905722116" class="uri">https://doi.org/10.1073/pnas.1905722116</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Application of Artificial Intelligence to Gastroenterology and Hepatology</strong> </summary></p>
<p><em>Gastroenterology 2020 Jan;158(1):76-94.e2</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31593701" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31593701</a></p>
<p>Since 2010, substantial progress has been made in artificial intelligence (AI) and its application to medicine. AI is explored in gastroenterology for endoscopic analysis of lesions, in detection of cancer, and to facilitate the analysis of inflammatory lesions or gastrointestinal bleeding during wireless capsule endoscopy. AI is also tested to assess liver fibrosis and to differentiate patients with pancreatic cancer from those with pancreatitis. AI might also be used to establish prognoses of patients or predict their response to treatments, based on multiple factors. We review the ways in which AI may help physicians make a diagnosis or establish a prognosis and discuss its limitations, knowing that further randomized controlled studies will be required before the approval of AI techniques by the health authorities.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.08.058" class="uri">https://doi.org/10.1053/j.gastro.2019.08.058</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>NLRP3 Inflammasome Regulates Development of Systemic Inflammatory Response and Compensatory Anti-Inflammatory Response Syndromes in Mice With Acute Pancreatitis</strong> </summary></p>
<p><em>Gastroenterology 2020 Jan;158(1):253-269.e14</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31593700" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31593700</a></p>
<p>BACKGROUND &amp; AIMS: Pancreatitis starts with primarily sterile local inflammation that induces systemic inflammatory response syndrome, followed by compensatory anti-inflammatory response syndrome (CARS). We investigated the mechanisms of these processes in mice and human serum. METHODS: We induced severe acute pancreatitis by partial duct ligation with caerulein stimulation or intraperitoneal injection of l-arginine in mice with deletion of interleukin (IL)12B,NLRP3, or IL18 and in mice given MCC950, a small molecule inhibitor of the NLRP3-inflammasome. Pancreata were collected from mice and analyzed by histology, and cytokine levels were measured in serum samples. We measured activation of adaptive immune responses in mice with pancreatitis by flow cytometry analysis of T cells (CD25 and CD69) isolated from the spleen. Differentiation of T-helper (Th1) cells, Th2 cells, and T-regulatory cells was determined by nuclear staining for TBET, GATA3, and FOXP3. We performed transcriptome analysis of mouse lymph nodes and bone marrow-derived macrophages after incubation with acini. We measured levels of cytokines in serum samples from patients with mild and severe acute pancreatitis. RESULTS: Activation of the adaptive immune response in mice was initiated by macrophage-derived, caspase 1-processed cytokines and required activation of NLRP3 (confirmed in serum samples from patients with pancreatitis). Spleen cells from mice with pancreatitis had increases in Th2 cells but not in Th1 cells. Bone marrow-derived macrophages secreted IL1B and IL18, but not IL12, after co-incubation with pancreatic acini. T-cell activation and severity of acute pancreatitis did not differ significantly between IL12B-deficient and control mice. In contrast, NLRP3- or IL18-deficient mice had reduced activation of T cells and no increase in Th2 cell-mediated responses compared with control mice. The systemic type 2 immune response was mediated by macrophage-derived cytokines of the IL1 family. Specifically, IL18 induced a Th2 cell-mediated response in the absence of IL12. MCC950 significantly reduced neutrophil infiltration, T-cell activation, and disease severity in mice. CONCLUSIONS: In mice with severe pancreatitis, we found systemic inflammatory response syndrome andcompensatory anti-inflammatory response syndrome developed in parallel. Infiltrating macrophages promote inflammation and simultaneously induce a Th2 cell-mediated response via IL18. Inhibition of NLRP3 reduces systemic inflammatory response syndrome and compensatory anti-inflammatory response syndrome and might be used to treat patients with severe pancreatitis.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.09.040" class="uri">https://doi.org/10.1053/j.gastro.2019.09.040</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31585935" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31585935</a></p>
<p>PURPOSE: Neoadjuvant therapy (neoTx) has dramatically improved the prognosis of patients with locally advanced and borderline resectable pancreatic ductal adenocarcinoma, yet its mechanisms of action on tumor cells and the tumor microenvironment are still unknown. Here, we aimed to characterize the multiple facets of neoTx-induced alterations in the pancreatic cancer microenvironment. EXPERIMENTAL DESIGN: We performed the currently most comprehensive histopathologic analysis of desmoplasia, angiogenesis, neural invasion, and immune cell infiltration at the tumor-host interface of pancreatic cancer after neoTx (n = 37) versus after primary resection (n = 37) through quantitative IHC and double immunofluorescence using automated and software-based quantification algorithms. RESULTS: We demonstrate that, independently of the applied pretreatment, neoadjuvant regimes are able to reverse the immunosuppressive behavior of malignant cells on pancreatic cancer microenvironment. Here, neoTx-driven selective depletion of regulatory T cells and myeloid-derived suppressor cells was associated with enrichment of antitumor immune cells in the peritumoral niche, decreased stromal activation, and less neural invasion. Importantly, the degree of this antitumor immune remodeling correlates to the degree of histopathologic response to neoTx. Survival analysis revealed that the tumor proliferation rate together with the activation of the stroma and the intratumoral infiltration with CD4+ T cells and natural killer cells constitute as independent prognostic factors for neoadjuvantly treated pancreatic cancer. CONCLUSIONS: NeoTx is not only cytotoxic but has pleiotropic, beneficial effects on all cellular and noncellular components of pancreatic cancer. Combinational approaches including immunotherapy may unleash long-term and more effective antitumor responses and improve prognosis of pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-1864" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-1864</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Advances in -cell replacement therapy for the treatment of type 1 diabetes</strong> </summary></p>
<p><em>Lancet (London, England) 2019 10;394(10205):1274-1285</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31533905" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31533905</a></p>
<p>The main goal of treatment for type 1 diabetes is to control glycaemia with insulin therapy to reduce disease complications. For some patients, technological approaches to insulin delivery are inadequate, and allogeneic islet transplantation is a safe alternative for those patients who have had severe hypoglycaemia complicated by impaired hypoglycaemia awareness or glycaemic lability, or who already receive immunosuppressive drugs for a kidney transplant. Since 2000, intrahepatic islet transplantation has proven efficacious in alleviating the burden of labile diabetes and preventing complications related to diabetes, whether or not a previous kidney transplant is present. Age, body-mass index, renal status, and cardiopulmonary status affect the choice between pancreas or islet transplantation. Access to transplantation is limited by the number of deceased donors and the necessity of immunosuppression. Future approaches might include alternative sources of islets (eg, xenogeneic tissue or human stem cells), extrahepatic sites of implantation (eg, omental, subcutaneous, or intramuscular), and induction of immune tolerance or encapsulation of islets.</p>
<p>doi: <a href="https://doi.org/10.1016/S0140-6736(19)31334-0" class="uri">https://doi.org/10.1016/S0140-6736(19)31334-0</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Solid pseudopapillary neoplasm of pancreas metastasizing to spleen in a post menopausal female</strong> </summary></p>
<p><em>Indian journal of pathology &amp; microbiology 2019 10;62(4):624-626</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31611457" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31611457</a></p>
<p>doi: <a href="https://doi.org/10.4103/IJPM.IJPM_43_19" class="uri">https://doi.org/10.4103/IJPM.IJPM_43_19</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Factors Affecting Nonalcoholic Fatty Liver Disease After Pancreatic Head Resection</strong> </summary></p>
<p><em>Pancreas 2019 Oct;48(9):e75-e77</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31609939" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31609939</a></p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001407" class="uri">https://doi.org/10.1097/MPA.0000000000001407</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Fate of Autophagic Vacuoles in Acinar Cells During Pancreatitis</strong> </summary></p>
<p><em>Pancreas 2019 Oct;48(9):e71-e75</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31609938" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31609938</a></p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001389" class="uri">https://doi.org/10.1097/MPA.0000000000001389</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A Better Way to Predict the Severity of Acute Pancreatitis?</strong> </summary></p>
<p><em>Pancreas 2019 Oct;48(9):e70-e71</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31609937" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31609937</a></p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001406" class="uri">https://doi.org/10.1097/MPA.0000000000001406</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Modified Marshall Score Predicts Mortality in Patients With Walled-off Pancreatic Necrosis Treated in an Intensive Care Unit</strong> </summary></p>
<p><em>Pancreas 2019 Oct;48(9):e68-e70</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31609936" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31609936</a></p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001409" class="uri">https://doi.org/10.1097/MPA.0000000000001409</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>African Americans With Acute Pancreatitis Present With Worsened Kidney Injury and Have Inadequate Access to Care</strong> </summary></p>
<p><em>Pancreas 2019 Oct;48(9):e66-e68</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31609935" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31609935</a></p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001400" class="uri">https://doi.org/10.1097/MPA.0000000000001400</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ABO Blood Group and the Risk of Pancreatic Neoplasms in Chinese Han Population: A Study at Shanghai Pancreatic Cancer Institute</strong> </summary></p>
<p><em>Pancreas 2019 Oct;48(9):e65-e66</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31609934" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31609934</a></p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001408" class="uri">https://doi.org/10.1097/MPA.0000000000001408</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Combined Antiangiogenic Therapy and Immunotherapy Is Effective for Pancreatic Cancer With Mismatch Repair Proficiency but High Tumor Mutation Burden: A Case Report</strong> </summary></p>
<p><em>Pancreas 2019 Oct;48(9):1232-1236</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31609933" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31609933</a></p>
<p>Immunotherapy has been recommended as a second-line treatment only for high microsatellite instability or DNA mismatch repair deficiency advanced pancreatic cancer in National Comprehensive Cancer Network guidelines. Here, we report a case with a good response to immunotherapy in pancreatic cancer with mismatch repair proficiency. A 55-year-old woman diagnosed with pancreatic cancer cT4N1M1 (liver, lung) who harbored ERBB2 mutations with high tumor mutation burden (TMB) underwent multiple therapies and survived 19 months. A partial response in pancreatic cancer was observed when the patient was treated with combined antiangiogenic therapy and immunotherapy after a series of ineffective treatments. Neutrophil-to-lymphocyte ratio (NLR), a predictive marker of efficacy of immunotherapy, confirmed that immunotherapy resulted in the partial response in pancreatic cancer. To our knowledge, this is the first to report advanced pancreatic cancer with mismatch repair proficiency had a good response to immunotherapy, and this is the first to report an association between high blood-based TMB or NLR and improved clinical outcomes in pancreatic cancer. Therefore, TMB may also be a biomarker for immunotherapy of pancreatic cancer, and NLR may be a prospective predictive marker for efficacy of immunotherapy in pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001398" class="uri">https://doi.org/10.1097/MPA.0000000000001398</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Vasoactive Intestinal Peptide-Secreting Tumors: A Review</strong> </summary></p>
<p><em>Pancreas 2019 Oct;48(9):1119-1125</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31609932" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31609932</a></p>
<p>Vasoactive intestinal peptide-secreting tumors (VIPomas) are a group of rare neuroendocrine tumors, which cause a typical syndrome of watery diarrhea. Most of these tumors are found in the pancreas and are usually detected at a later stage. Although curative resection is not possible in most of these tumors, both symptom and tumor control can be achieved by a multidimensional approach, to enable a long survival of most patients. There are no clear-cut guidelines for the management of VIPomas because of the rarity of this neoplasm and lack of prospective data. In this review, we discuss the available evidence on the clinical features and management of these rare tumors.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001402" class="uri">https://doi.org/10.1097/MPA.0000000000001402</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Current Practices and Novel Techniques in the Diagnosis and Management of Neuroendocrine Tumors of Unknown Primary</strong> </summary></p>
<p><em>Pancreas 2019 Oct;48(9):1111-1118</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31609931" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31609931</a></p>
<p>Neuroendocrine tumors (NETs) comprise a heterogeneous group of neoplasms in which tumor staging/prognosis and response to treatments depend heavily on accurate and timely identification of the anatomic primary site or NET subtype. Despite recent technological advancements and use of multiple diagnostic modalities, 10% to 14% of newly diagnosed NETs are not fully characterized based on subtype or anatomic primary site. Inability to fully characterize NETs of unknown primary may cause delays in surgical intervention and limit potential treatment options. To address this unmet need, clinical validity and utility are being demonstrated for novel approaches that improve NET subtype or anatomic primary site identification. Functional imaging using Ga-radiolabeled DOTATATE positron emission tomography/computed tomography has been shown to overcome some false-positive and resolution issues associated with octreotide scanning and computed tomography/magnetic resonance imaging. Using a genomic approach, molecular tumor classification based on differential gene expression has demonstrated high diagnostic accuracy in blinded validation studies of different NET types and subtypes. Given the widespread availability of these technologies, we propose an algorithm for the workup of NETs of unknown primary that integrates these approaches. Including these technologies in the standard workup will lead to better NET subtype identification and improved treatment optimization for patients.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001391" class="uri">https://doi.org/10.1097/MPA.0000000000001391</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Analysis of Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs Between Octreotide and Lanreotide Among Patients With Neuroendocrine Tumors</strong> </summary></p>
<p><em>Pancreas 2019 Oct;48(9):1126-1135</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31593022" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31593022</a></p>
<p>OBJECTIVE: The aim of the study was to assess treatment patterns, healthcare resource utilization, and healthcare costs among patients with neuroendocrine tumors (NETs) receiving long-acting octreotide versus lanreotide, overall and in patients with carcinoid syndrome (CS). METHODS: A provider-based claims database was used to identify NET patients who first initiated long-acting octreotide or lanreotide (index date) from January 2015 to November 2017. Propensity-score matching 1:1 was used. Patients with CS were identified from the previously mentioned matched cohorts. Time-to-treatment discontinuation (TTD) was estimated using Kaplan-Meier analyses. Per-patient-per-month rates of healthcare resource utilization were compared using rate ratios from multivariable Poisson regression models. Multivariable linear regression models were used to compare mean monthly cost differences. RESULTS: The median TTD was similar between the 2 matched cohorts (N = 543 each; long-acting octreotide = 19.2 months, lanreotide = 17.5 months, P = 0.58). Significantly fewer NET-related outpatient visits (rate ratio = 0.95, P = 0.005) and significantly lower total healthcare costs (mean monthly cost difference: all-cause = US -$3701, NET-related = US -$3752, Ps &lt; 0.001) were observed in the long-acting octreotide cohort than lanreotide. Similar results were found in CS patients. CONCLUSIONS: Patients on first-line long-acting octreotide and lanreotide had similar TTD. Long-acting octreotide was associated with significantly lower total healthcare costs than lanreotide.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001403" class="uri">https://doi.org/10.1097/MPA.0000000000001403</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Relationship Between Radiomics and Risk of Lymph Node Metastasis in Pancreatic Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Pancreas 2019 Oct;48(9):1195-1203</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31593021" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31593021</a></p>
<p>OBJECTIVE: The objective of this study was to explore the exact relationship between the arterial radiomics score (rad-score) and lymph node (LN) metastasis in pancreatic ductal adenocarcinoma (PDAC). METHODS: A total of 225 patients with pathologically confirmed PDAC who underwent multislice computed tomography within 1 month of resection from December 2016 to August 2017 were retrospectively studied. For each patient, 1029 radiomics features of arterial phase were extracted, which were reduced using the least absolute shrinkage and selection operator logistic regression algorithm. Multivariate logistic regression models were used to analyze the association between the arterial rad-score and LN metastasis. RESULTS: Lymph node-negative and LN-positive patients accounted for 107 (47.56%) and 118 (52.44%) of the cohort, respectively. The rad-score, which consisted of 12 selected features of the arterial phase, was significantly associated with LN status (P &lt; 0.05). Univariate analysis revealed that the arterial rad-score and T stage were independently and positively associated with risk of LN metastasis (P &lt; 0.05). Multivariate analyses revealed a significant association between the arterial rad-score and the LN metastasis (P &lt; 0.0001). Higher arterial rad-score was associated with LN metastasis (P for trend &lt;0.0001). CONCLUSIONS: The arterial rad-score is independently and positively associated with the risk of LN metastasis in PDAC.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001404" class="uri">https://doi.org/10.1097/MPA.0000000000001404</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A Study on the Effect of Patient Characteristics, Geographical Utilization, and Patient Outcomes for Total Pancreatectomy Alone and Total Pancreatectomy With Islet Autotransplantation in Patients With Pancreatitis in the United States</strong> </summary></p>
<p><em>Pancreas 2019 Oct;48(9):1204-1211</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31593020" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31593020</a></p>
<p>OBJECTIVES: A selective therapy for pancreatitis is total pancreatectomy and islet autotransplantation. Outcomes and geographical variability of patients who had total pancreatectomy (TP) alone or total pancreatectomy with islet autotransplantation (TPIAT) were assessed. METHODS: Data were obtained from the Healthcare Cost and Utilization Project National Inpatient Sample database. Weighed univariate and multivariate analyses were performed to determine the effect of measured variables on outcomes. RESULTS: Between 2002 and 2013, there were 1006 TP and 825 TPIAT in patients with a diagnosis of chronic pancreatitis, and 1705 TP and 830 TPIAT for any diagnosis of pancreatitis. The majority of the TP and TPIAT were performed in larger urban hospitals. Costs were similar for TP and TPIAT for chronic pancreatitis but were lower for TPIAT compared with TP for any type of pancreatitis. The trend for TP and TPIAT was significant in all geographical areas during the study period. CONCLUSIONS: There is an increasing trend of both TP and TPIAT. Certain groups are more likely to be offered TPIAT compared with TP alone. More data are needed to understand disparities and barriers to TPIAT, and long-term outcomes of TPIAT such as pain control and glucose intolerance need further study.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001405" class="uri">https://doi.org/10.1097/MPA.0000000000001405</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Secondhand Smoke Exposure and Serum Trypsinogen in Cystic Fibrosis Carriers</strong> </summary></p>
<p><em>Pancreas 2019 Oct;48(9):1155-1159</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31593019" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31593019</a></p>
<p>OBJECTIVE: The objective of this study was to determine if infants carrying 1 cystic fibrosis transmembrane receptor (CFTR) mutation demonstrate pancreatic inflammation in response to tobacco exposure. METHODS: Cystic fibrosis carrier infants aged 4 to 16 weeks were prospectively enrolled. Tobacco exposure was assessed by survey and maternal hair nicotine analysis. Serum immunoreactive trypsinogen (IRT) levels at birth and at the time of recruitment were analyzed relative to the presence or absence of tobacco exposure. The effect of the severity of the CFTR mutation carried by the infant on the tobacco-IRT relationship was also analyzed. RESULTS: Forty-eight infants completed the study. Newborn screen and follow-up IRT levels were not different between exposed infants (19 by hair analysis) and nonexposed infants (29 by hair analysis). Follow-up IRT levels were lower in infants with more severe CFTR mutations (P = 0.005). There was no difference in follow-up IRT based on CFTR mutation severity in exposed infants. Nonexposed infants with milder CFTR mutations had higher median IRT values on follow-up testing than those with more severe CFTR mutations (P &lt; 0.05). CONCLUSIONS: The pancreas of cystic fibrosis carrier infants is affected by tobacco exposure, and those carrying less severe CFTR mutations may be more susceptible to tobacco effects.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001401" class="uri">https://doi.org/10.1097/MPA.0000000000001401</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Is Centralization Needed for Patients Undergoing Distal Pancreatectomy?: A Nationwide Study of 3314 Patients</strong> </summary></p>
<p><em>Pancreas 2019 Oct;48(9):1188-1194</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31593018" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31593018</a></p>
<p>OBJECTIVE: The centralization of complex surgical procedures is associated with better postoperative outcomes. However, little is known about the impact of hospital volume on the outcome after distal pancreatectomy. METHODS: Using the French national hospital discharge database, we identified all patients having undergone distal pancreatectomy in France between 2012 and 2015. A spline model was applied to determine the caseload cut-off in annual distal pancreatectomy that influenced 90-day postoperative mortality. RESULTS: A total of 3314 patients were identified. Use of a spline model did not reveal a cut-off in the annual distal pancreatectomy caseload. By taking the median number of distal pancreatectomy (n = 5) and the third quartile (n = 15), we stratified centers into low, intermediate, and high hospital volume groups. The overall postoperative mortality rate was 3.0% and did not differ significantly between these groups. In a multivariable analysis, age, Charlson comorbidity score, septic complications, hemorrhage, shock, and reoperation were independently associated with a greater overall risk of death. However, hospital volume had no impact on mortality after distal pancreatectomy (odds ratio, 0.954; 95% confidence interval, 0.552-1.651, P = 0.867). CONCLUSIONS: Hospital volume does not seem to influence mortality after distal pancreatectomy in France, and centralization may not necessarily improve outcomes.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001410" class="uri">https://doi.org/10.1097/MPA.0000000000001410</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Acupuncture for Acute Pancreatitis: A Systematic Review and Meta-analysis</strong> </summary></p>
<p><em>Pancreas 2019 Oct;48(9):1136-1147</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31593017" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31593017</a></p>
<p>OBJECTIVE: The objective of this study was to assess the efficacy and safety of acupuncture plus routine treatment (RT) for acute pancreatitis (AP). METHODS: Literature searches were performed in 8 databases up to October 31, 2018. Randomized controlled trials comparing acupuncture plus RT with RT alone for AP were included. RESULTS: Twelve eligible studies were included finally. The meta-analysis showed that acupuncture plus RT compared with RT alone could significantly improve the total effective rate and gastrointestinal function and reduce the Acute Physiology, Age, Chronic Health Evaluation II score, tumor necrosis factor  count, the time of resuming to diets, and the length of hospital stay. Only 3 of the studies reported adverse events or reactions. CONCLUSIONS: This study suggested that acupuncture combined with RT may be effective for AP. However, more rigorously designed randomized controlled trials are warranted to confirm the current findings.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001399" class="uri">https://doi.org/10.1097/MPA.0000000000001399</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Predrainage and Postdrainage Prognostic Nomograms to Predict Outcome of Percutaneous Drainage for Infected Pancreatic and Peripancreatic Necrotic Collections</strong> </summary></p>
<p><em>Pancreas 2019 Oct;48(9):1212-1219</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31593016" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31593016</a></p>
<p>OBJECTIVES: This study aimed to identify factors affecting outcome of percutaneous catheter drainage (PCD) in management of infected pancreatic necrosis treated with step-up approach. METHODS: This was a single-center retrospective cohort study that included patients with infected necrosis undergoing PCD as initial intervention. Patients who did not respond underwent necrosectomy. Predictors of PCD failure (ie, mortality or need for necrosectomy) were analyzed. Models were constructed for predrainage and postdrainage use and were internally validated. RESULTS: Of 304 patients included, catheter drainage was successful in 59.8%, with overall mortality of 22%. Predrainage model consisted of Acute Physiologic and Chronic Health Evaluation II score at admission, early organ failure, and pancreatic necrosis of greater than 50%. Postdrainage model consisted of Acute Physiologic and Chronic Health Evaluation II at first PCD, early organ failure, pancreatic necrosis of greater than 50%, sepsis reversal within 1 week of PCD and Escherichia coli in PCD culture. Both models were internally validated with area under receiver operating characteristics curve of 71.2% for pre-PCD and 81.2% for post-PCD model. Prognostic nomograms were constructed using the models. CONCLUSIONS: Percutaneous catheter drainage alone was successful in 59.8% with mortality of 22%. The nomograms can help in guiding treatment strategy and referral of high-risk cases.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001395" class="uri">https://doi.org/10.1097/MPA.0000000000001395</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Lowest Case Fatality Rate for Patients With Acute Pancreatitis Admitted in Gastroenterology Units in Veneto Region, Italy</strong> </summary></p>
<p><em>Pancreas 2019 Oct;48(9):1175-1181</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31593015" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31593015</a></p>
<p>OBJECTIVES: This study aimed to evaluate trends in hospitalizations and outcomes of acute pancreatitis (AP) according to first admitting hospital unit and hospital volumes. METHODS: Hospital discharge records of patients with AP admitted in the Veneto Region (Northeast Italy) during the period 2001-2015 were examined. RESULTS: A total of 23,389 patients (54% males; mean age, 62.2 years; standard deviation, 19.3 years) were admitted for AP. Both hospitalization (32.4 to 29.5/100,000 inhabitants per year; P &lt; 0.05) and in-hospital mortality (1.41 to 0.79/100,000 inhabitants per year; P &lt; 0.05) decreased over the study period. Case fatality rate was altogether 3.2%. The percentages of patients admitted in surgery, nongastroenterology medical units, gastroenterology, and intensive care were 52%, 30%, 16%, and 2%, respectively. Fewer fatalities were observed in gastroenterology units (1.7%) compared with nongastroenterology medical units (4.3%; odds ratio, 0.37; 95% confidence interval, 0.28-0.49) and surgical units (2.7%; odds ratio, 0.61; 95% confidence interval, 0.47-0.80). Fatalities decreased progressively with increasing hospital volumes from 3.7% to 2.9% (P &lt; 0.05). CONCLUSION: In the Veneto Region, both hospitalizations and in-hospital mortality for AP significantly decreased over the last 15 years. Case fatality rate was lowest for patients admitted in gastroenterology units.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001397" class="uri">https://doi.org/10.1097/MPA.0000000000001397</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Parecoxib Improves the Outcomes of Acute Mild and Moderate Pancreatitis: A 3-Year Matched Cohort Study Based on a Prospective Database</strong> </summary></p>
<p><em>Pancreas 2019 Oct;48(9):1148-1154</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31593014" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31593014</a></p>
<p>OBJECTIVES: The aim of this study was to evaluate the role of parecoxib in patients with different severities of acute pancreatitis (AP). METHODS: A total of 772 eligible patients with AP were divided into 4 groups: mild and moderately AP (MAP) treated with parecoxib (group A, n = 236), MAP without parecoxib treatment (group B, n = 453), severe AP (SAP) treated with parecoxib (group C, n = 28), and SAP without parecoxib treatment (group D, n = 55). Patients in group A were exactly matched with patients in group B by propensity score matching, similar to the matching between group C and group D. RESULTS: The morbidity of abdominal infection in group A was significantly lower as compared with that in group B (P &lt; 0.050). The progression of MAP to SAP significantly decreased in group A than group B (P &lt; 0.050). No significant differences were observed between group C and group D. The risk factors independently related to the progression of MAP included alcoholic/high-fat dietary (P = 0.028) and parecoxib administration (P = 0.011). CONCLUSIONS: Early administration of parecoxib could reduce the morbidity of complications among patients with MAP. Parecoxib may prevent the progression of MAP to SAP and improve its outcomes.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001393" class="uri">https://doi.org/10.1097/MPA.0000000000001393</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Risk Factors Associated With Progression Toward Endocrine Insufficiency in Chronic Pancreatitis</strong> </summary></p>
<p><em>Pancreas 2019 Oct;48(9):1160-1166</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31593013" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31593013</a></p>
<p>OBJECTIVE: Little data exist describing the change over time in islet function and glycemic control in patients with chronic pancreatitis (CP). METHODS: In 325 CP patients who underwent 2 mixed meal tolerance tests and/or glycated hemoglobin (HbA1c) levels, we estimated the rate of change in metabolic measures per 6 months and assessed the association between potential risk factors for diabetes and rate of change using multivariate regression models. RESULTS: Per 6-month time, HbA1c increased by 0.062% with a standard error of 0.029% (P = 0.037) and the ratio (area under the curve (AUC) C-peptide to AUC glucose from mixed meal tolerance testing) decreased by 0.0028 with a standard error of 0.0011 (P = 0.014). We observed more rapid decline in smokers (AUC C-peptide, P = 0.043) and patients with surgical drainage (AUC glucose, P = 0.001; ratio, P = 0.03) or with calcific pancreatitis (HbA1c, P = 0.003). In multivariate models, AUC C-peptide and ratio declined at a greater rate in smokers and HbA1c in those with pancreatic calcifications (both P &lt; 0.05). CONCLUSIONS: We observed a measurable decline in -cell function and glycemic control in patients with CP. Patients with a history of tobacco smoking, surgical drainage, or pancreatic calcification may be at highest risk.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001394" class="uri">https://doi.org/10.1097/MPA.0000000000001394</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Prevalence of Nonalcoholic Fatty Pancreas by Endoscopic Ultrasonography</strong> </summary></p>
<p><em>Pancreas 2019 Oct;48(9):1220-1224</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31593012" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31593012</a></p>
<p>OBJECTIVES: Pancreatic steatosis or fatty pancreas refers to the fat accumulation in the pancreas, which can lead to inflammation and fibrosis, -cell dysfunction, fibrosis, and, possibly, pancreatic cancer. This study aimed to study the prevalence of fatty pancreas and its risk factors in patients referred to an endosonography center. METHODS: During 18 months, 228 patients who were referred to our endosonography center for various reasons were evaluated for fatty pancreas. Fatty pancreas was defined as hyperechoic pancreas echotexture compared with spleen echotexture. Demographic characteristics, past medical history, and laboratory measurements were compared between groups with and without fatty pancreas to determine the risk factors for fatty pancreas. RESULTS: The prevalence of fatty pancreas was 25.9%. Patients with fatty pancreas had a significantly higher mean level of uric acid (P = 0.04), frequency of ischemic heart disease (P = 0.03), hyperlipidemia (P = 0.04), frequency of fatty liver (P &lt; 0.001), and aortic intima thickness (P = 0.01). There was no significant difference in age, sex, body mass index, smoking status, substance abuse, and use of oral contraceptives in the 2 groups. CONCLUSIONS: Fatty pancreas is a common disorder. There are meaningful relationships between coronary artery disease, nonalcoholic fatty liver, and atherosclerosis with fatty pancreas.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001396" class="uri">https://doi.org/10.1097/MPA.0000000000001396</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Long-Term Functional Outcome After Pancreatoduodenectomy for Periampullary Carcinoma With Morphological Correlation</strong> </summary></p>
<p><em>Pancreas 2019 Oct;48(9):1182-1187</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31593011" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31593011</a></p>
<p>OBJECTIVE: The aim of the study was to evaluate the long-term functional outcome (exocrine and endocrine) and morphological changes in remnant pancreas after pancreatoduodenectomy and its clinical impact. METHODS: Periampullary carcinoma patients with minimum follow-up of 2 years and without recurrence were included (N = 102). Exocrine insufficiency includes clinical steatorrhea and fecal elastase-1 (FE-1) levels; endocrine insufficiency, glucose levels and glycated hemoglobin; and morphological changes, main pancreatic duct (MPD) diameter and thickness of remnant pancreas. RESULTS: The mean (standard deviation) follow-up period was 59 (26) months. Of the 102 patients, 81 (80%) had severely deficient FE-1 (0-100 g/g). The preoperative MPD was significantly more and thickness of remnant pancreas was significantly less in patients with severely deficient FE-1. Overall, 15.6% (16/102) developed steatorrhea and improved on enzyme replacement therapy. The presence of MPD stricture (P = 0.008) and weight loss (P = 0.001) were significantly associated with steatorrhea. New-onset diabetes was seen in 17% (15/90) patients, of whom 3 of 5 developed it after 4 years (range, 4-7 years). The blood glucose was controlled on oral hypoglycemics in 2 (10/15) of 3 patients. CONCLUSIONS: The assessment by FE-1 indicates loss of exocrine function in more than 90%, whereas only 1 of 6 developed steatorrhea and new-onset diabetes. Morphological changes especially MPD stricture affect the functional status of remnant pancreas.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001392" class="uri">https://doi.org/10.1097/MPA.0000000000001392</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Biphenotypic Differentiation of Pancreatic Cancer in 3-Dimensional Culture</strong> </summary></p>
<p><em>Pancreas 2019 Oct;48(9):1225-1231</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31593010" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31593010</a></p>
<p>OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) is the third most common cause of cancer death in the United States. Improved characterized models of PDAC are needed for drug screening. METHODS: We grew 4 established pancreatic cancer cell lines in hanging drop cultures to produce spheroids. We also grew organoids from explanted xenografted PDAC and surgically resected primary PDAC. We performed transmission and scanning electron microscopy and compared findings with those of the normal pancreatic duct. We also performed single-cell cloning to determine the potential options for differentiation. RESULTS: Spheroids contained tight junctions and desmosomes but lacked zymogen granules, as expected. The former features were present in normal pancreatic duct but absent from PDAC cell lines grown in standard 2-dimensional culture. Spheroids functionally excluded macromolecules in whole mounts. Cells on the surface of PDAC spheroids were carpeted by microvilli except for rare cells with prominent stereocilia. Carpets of microvilli were also seen in low passage organoids produced from xenografts and surgically resected human PDAC, in addition to normal human pancreatic duct. We performed single-cell cloning and resulting spheroids produced both cell phenotypes at the same approximate ratios as those from bulk cultures. CONCLUSIONS: Pancreatic cancer spheroids/organoids are capable of biphenotypic differentiation.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001390" class="uri">https://doi.org/10.1097/MPA.0000000000001390</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>What is the Outcome of Patients Affected by Intraductal Papillary Mucinous Neoplasms Without High-Risk Stigmata?: A Single-Center Retrospective Study</strong> </summary></p>
<p><em>Pancreas 2019 Oct;48(9):1167-1174</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31593009" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31593009</a></p>
<p>OBJECTIVES: The objectives of the study were to define the natural history of intraductal papillary mucinous neoplasms (IPMNs) without high-risk stigmata (HRS) and to identify factors capable of influencing outcome and management. METHODS: This is a retrospective study of patients affected by IPMNs without HRS. Survival analyses included overall survival, disease-specific survival, and years of life lost. Uni- and multivariate analyses were carried out to identify factors capable of predicting years of life lost. RESULTS: Three hundred fifty-six patients were analyzed. Fifty-three patients (14.9%) died: no postoperative mortality, 6 (1.7%) patients from pancreatic cancer and 47 (13.2%) from reasons not related to the disease. Mean overall survival and disease-specific survival were 199.4 (SD, 16.6) and 281 months (SD, 6.9), respectively. The years of life lost of the sample observed with respect to the general population were 2 years and 3 months (15 years and 3 months vs 17 years and 6 months). Younger age, length of follow-up more than 3 years, and surgery significantly increased the years of life lost. CONCLUSIONS: The patients affected by IPMNs without HRS rarely died from the disease. Young age (&lt;65 years) and follow-up more than 3 years seemed to be the only factors capable of influencing the outcome and management.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001388" class="uri">https://doi.org/10.1097/MPA.0000000000001388</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Fungi accelerate pancreatic cancer</strong> </summary></p>
<p><em>Nature 2019 10;574(7777):184-185</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31591542" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31591542</a></p>
<p>doi: <a href="https://doi.org/10.1038/d41586-019-02892-y" class="uri">https://doi.org/10.1038/d41586-019-02892-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cell Type Purification by Single-Cell Transcriptome-Trained Sorting</strong> </summary></p>
<p><em>Cell 2019 Oct;179(2):527-542.e19</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31585086" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31585086</a></p>
<p>Much of current molecular and cell biology research relies on the ability to purify cell types by fluorescence-activated cell sorting (FACS). FACS typically relies on the ability to label cell types of interest with antibodies or fluorescent transgenic constructs. However, antibody availability is often limited, and genetic manipulation is labor intensive or impossible in the case of primary human tissue. To date, no systematic method exists to enrich for cell types without a priori knowledge of cell-type markers. Here, we propose GateID, a computational method that combines single-cell transcriptomics with FACS index sorting to purify cell types of choice using only native cellular properties such as cell size, granularity, and mitochondrial content. We validate GateID by purifying various cell types from zebrafish kidney marrow and the human pancreas to high purity without resorting to specific antibodies or transgenes.</p>
<p>doi: <a href="https://doi.org/10.1016/j.cell.2019.08.006" class="uri">https://doi.org/10.1016/j.cell.2019.08.006</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Targeting tumour microenvironment, a FAKtual challenge in pancreatic cancer</strong> </summary></p>
<p><em>Gut 2020 01;69(1):1-2</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31582402" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31582402</a></p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2019-318962" class="uri">https://doi.org/10.1136/gutjnl-2019-318962</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cathepsin E expression and activity: Role in the detection and treatment of pancreatic cancer</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Oct;19(7):951-956</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31582345" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31582345</a></p>
<p>Cathepsin E (CTSE) is an intracellular, hydrolytic aspartic protease found to be expressed in cells of the immune and gastrointestinal systems, lymphoid tissues, erythrocytes, and cancer cells. The precise functions are not fully understood; however, various studies have investigated its numerous cell-type specific roles. CTSE expression has been shown to be a potential early biomarker for pancreatic ductal adenocarcinoma (PDAC). PDAC patients have low survival rates mostly due to the lack of early detection methods. CTSE-specific activity probes have been developed and tested to assist in tumor imaging and functional studies investigating the role of CTSE expression in PDAC tumors. Furthermore, a CTSE protease-specific, photodynamic therapy pro-drug was developed to explore its potential use to treat tumors that express CTSE. Since CTSE is expressed in pancreatic diseases that are risk factors for PDAC, such as pancreatic cysts and chronic pancreatitis, learning about its function in these disease types could assist in early PDAC detection and in understanding the biology of PDAC progression. Overall, CTSE expression and activity shows potential to detect PDAC and other pancreatic diseases. Further research is needed to fully understand its functions and potential translational applicability.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.09.009" class="uri">https://doi.org/10.1016/j.pan.2019.09.009</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL</strong> </summary></p>
<p><em>Nature 2019 10;574(7777):264-267</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31578522" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31578522</a></p>
<p>Bacterial dysbiosis accompanies carcinogenesis in malignancies such as colon and liver cancer, and has recently been implicated in the pathogenesis of pancreatic ductal adenocarcinoma (PDA)1. However, the mycobiome has not been clearly implicated in tumorigenesis. Here we show that fungi migrate from the gut lumen to the pancreas, and that this is implicated in the pathogenesis of PDA. PDA tumours in humansand mouse models of this cancerdisplayed an increase in fungi of about 3,000-fold compared to normal pancreatic tissue. The composition of the mycobiome of PDA tumours was distinct from that of the gut or normal pancreas on the basis of alpha- and beta-diversity indices. Specifically, the fungal community that infiltrated PDA tumours was markedly enriched for Malassezia spp. in both mice and humans. Ablation of the mycobiome was protective against tumour growth in slowly progressive and invasive models of PDA, and repopulation with a Malassezia species-but not species in the genera Candida, Saccharomyces or Aspergillus-accelerated oncogenesis. We also discovered that ligation of mannose-binding lectin (MBL), which binds to glycans of the fungal wall to activate the complement cascade, was required for oncogenic progression, whereas deletion of MBL or C3 in the extratumoral compartment-or knockdown of C3aR in tumour cells-were both protective against tumour growth. In addition, reprogramming of the mycobiome did not alter the progression of PDA in Mbl- (also known as Mbl2) or C3-deficient mice. Collectively, our work shows that pathogenic fungi promote PDA by driving the complement cascade through the activation of MBL.</p>
<p>doi: <a href="https://doi.org/10.1038/s41586-019-1608-2" class="uri">https://doi.org/10.1038/s41586-019-1608-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Prognostic Significance of Stromal and Intraepithelial Tumor-Infiltrating Lymphocytes in Small Intestinal Adenocarcinoma</strong> </summary></p>
<p><em>American journal of clinical pathology 2020 Jan;153(1):105-118</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31576398" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31576398</a></p>
<p>OBJECTIVES: Assessment of tumor-infiltrating lymphocytes (TILs) may predict the prognosis and therapeutic benefit of immunotherapy in small intestinal adenocarcinoma (SIAC) patients. METHODS: TILs were evaluated in 231 surgically resected SIACs and compared with microsatellite instability (MSI) and clinicopathologic variables. The average number of intraepithelial TILs (iTILs) and the average density of stromal TILs (sTILs) were calculated separately. RESULTS: High iTIL count (2 per high-power field) was associated with MSI-high, whereas high sTIL density (20% on 200 magnification) was not. High iTIL count and high sTIL density were related to distal tumor location, medullary carcinoma, high Crohn-like lymphoid reaction counts, and fewer pancreatic invasions. SIAC patients with high iTIL count or high sTIL density had better survival than those with low values. On multivariate analysis, MSI, high sTIL density, proximal locations, lower N category, and absence of lymphovascular invasions and retroperitoneal seeding were the best independent prognostic predictors. CONCLUSIONS: High sTIL density can be used as a prognostic indicator and high iTIL count may provide a basis for the clinical use of targeted immunotherapy in SIAC patients.</p>
<p>doi: <a href="https://doi.org/10.1093/ajcp/aqz136" class="uri">https://doi.org/10.1093/ajcp/aqz136</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Identification of FES as a Novel Radiosensitizing Target in Human Cancers</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31573955" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31573955</a></p>
<p>PURPOSE: The identification of novel targets for developing synergistic drug-radiation combinations would pave the way to overcome tumor radioresistance. We conducted cell-based screening of a human kinome siRNA library to identify a radiation-specific kinase that has a synergistic toxic effect with radiation upon inhibition and is not essential for cell survival in the absence of radiation. EXPERIMENTAL DESIGN: Unbiased RNAi screening was performed by transfecting A549 cells with a human kinome siRNA library followed by irradiation. Radiosensitizing effects of a target gene and involved mechanisms were examined. RESULTS: We identified the nonreceptor protein tyrosine kinase FES (FEline Sarcoma oncogene) as a radiosensitizing target. The expression of FES was increased in response to irradiation. Cell viability and clonogenic survival after irradiation were significantly decreased by FES knockdown in lung and pancreatic cancer cell lines. In contrast, FES depletion alone did not significantly affect cell proliferation without irradiation. An inducible RNAi mouse xenograft model verified in vivo radiosensitizing effects. FES-depleted cells showed increased apoptosis, DNA damage, G2-M phase arrest, and mitotic catastrophe after irradiation. FES depletion promoted radiation-induced reactive oxygen species formation, which resulted in phosphorylation of S6K and MDM2. The radiosensitizing effect of FES knockdown was partially reversed by inhibition of S6K activity. Consistent with the increase in phosphorylated MDM2, an increase in nuclear p53 levels was observed, which appears to contribute increased radiosensitivity of FES-depleted cells. CONCLUSIONS: We uncovered that inhibition of FES could be a potential strategy for inducing radiosensitization in cancer. Our results provide the basis for developing novel radiosensitizers.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-0610" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-0610</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The future of cystic fibrosis care: a global perspective</strong> </summary></p>
<p><em>The Lancet. Respiratory medicine 2019 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31570318" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31570318</a></p>
<p>The past six decades have seen remarkable improvements in health outcomes for people with cystic fibrosis, which was once a fatal disease of infants and young children. However, although life expectancy for people with cystic fibrosis has increased substantially, the disease continues to limit survival and quality of life, and results in a large burden of care for people with cystic fibrosis and their families. Furthermore, epidemiological studies in the past two decades have shown that cystic fibrosis occurs and is more frequent than was previously thought in populations of non-European descent, and the disease is now recognised in many regions of the world. The Lancet Respiratory Medicine Commission on the future of cystic fibrosis care was established at a time of great change in the clinical care of people with the disease, with a growing population of adult patients, widespread genetic testing supporting the diagnosis of cystic fibrosis, and the development of therapies targeting defects in the cystic fibrosis transmembrane conductance regulator (CFTR), which are likely to affect the natural trajectory of the disease. The aim of the Commission was to bring to the attention of patients, health-care professionals, researchers, funders, service providers, and policy makers the various challenges associated with the changing landscape of cystic fibrosis care and the opportunities available for progress, providing a blueprint for the future of cystic fibrosis care. The discovery of the CFTR gene in the late 1980s triggered a surge of basic research that enhanced understanding of the pathophysiology and the genotype-phenotype relationships of this clinically variable disease. Until recently, available treatments could only control symptoms and restrict the complications of cystic fibrosis, but advances in CFTR modulator therapies to address the basic defect of cystic fibrosis have been remarkable and the field is evolving rapidly. However, CFTR modulators approved for use to date are highly expensive, which has prompted questions about the affordability of new treatments and served to emphasise the considerable gap in health outcomes for patients with cystic fibrosis between high-income countries, and low-income and middle-income countries (LMICs). Advances in clinical care have been multifaceted and include earlier diagnosis through the implementation of newborn screening programmes, formalised airway clearance therapy, and reduced malnutrition through the use of effective pancreatic enzyme replacement and a high-energy, high-protein diet. Centre-based care has become the norm in high-income countries, allowing patients to benefit from the skills of expert members of multidisciplinary teams. Pharmacological interventions to address respiratory manifestations now include drugs that target airway mucus and airway surface liquid hydration, and antimicrobial therapies such as antibiotic eradication treatment in early-stage infections and protocols for maintenance therapy of chronic infections. Despite the recent breakthrough with CFTR modulators for cystic fibrosis, the development of novel mucolytic, anti-inflammatory, and anti-infective therapies is likely to remain important, especially for patients with more advanced stages of lung disease. As the median age of patients with cystic fibrosis increases, with a rapid increase in the population of adults living with the disease, complications of cystic fibrosis are becoming increasingly common. Steps need to be taken to ensure that enough highly qualified professionals are present in cystic fibrosis centres to meet the needs of ageing patients, and new technologies need to be adopted to support communication between patients and health-care providers. In considering the future of cystic fibrosis care, the Commission focused on five key areas, which are discussed in this report: the changing epidemiology of cystic fibrosis (section 1); future challenges of clinical care and its delivery (section 2); the building of cystic fibrosis care globally (section 3); novel therapeutics (section 4); and patient engagement (section 5). In panel 1, we summarise key messages of the Commission. The challenges faced by all stakeholders in building and developing cystic fibrosis care globally are substantial, but many opportunities exist for improved care and health outcomes for patients in countries with established cystic fibrosis care programmes, and in LMICs where integrated multidisciplinary care is not available and resources are lacking at present. A concerted effort is needed to ensure that all patients with cystic fibrosis have access to high-quality health care in the future.</p>
<p>doi: <a href="https://doi.org/10.1016/S2213-2600(19)30337-6" class="uri">https://doi.org/10.1016/S2213-2600(19)30337-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Miami International Evidence-based Guidelines on Minimally Invasive Pancreas Resection</strong> </summary></p>
<p><em>Annals of surgery 2020 Jan;271(1):1-14</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31567509" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31567509</a></p>
<p>OBJECTIVE: The aim of this study was to develop and externally validate the first evidence-based guidelines on minimally invasive pancreas resection (MIPR) before and during the International Evidence-based Guidelines on Minimally Invasive Pancreas Resection (IG-MIPR) meeting in Miami (March 2019). SUMMARY BACKGROUND DATA: MIPR has seen rapid development in the past decade. Promising outcomes have been reported by early adopters from high-volume centers. Subsequently, multicenter series as well as randomized controlled trials were reported; however, guidelines for clinical practice were lacking. METHODS: The Scottisch Intercollegiate Guidelines Network (SIGN) methodology was used, incorporating these 4 items: systematic reviews using PubMed, Embase, and Cochrane databases to answer clinical questions, whenever possible in PICO style, the GRADE approach for assessment of the quality of evidence, the Delphi method for establishing consensus on the developed recommendations, and the AGREE-II instrument for the assessment of guideline quality and external validation. The current guidelines are cosponsored by the International Hepato-Pancreato-Biliary Association, the Americas Hepato-Pancreato-Biliary Association, the Asian-Pacific Hepato-Pancreato-Biliary Association, the European-African Hepato-Pancreato-Biliary Association, the European Association for Endoscopic Surgery, Pancreas Club, the Society of American Gastrointestinal and Endoscopic Surgery, the Society for Surgery of the Alimentary Tract, and the Society of Surgical Oncology. RESULTS: After screening 16,069 titles, 694 studies were reviewed, and 291 were included. The final 28 recommendations covered 6 topics; laparoscopic and robotic distal pancreatectomy, central pancreatectomy, pancreatoduodenectomy, as well as patient selection, training, learning curve, and minimal annual center volume required to obtain optimal outcomes and patient safety. CONCLUSION: The IG-MIPR using SIGN methodology give guidance to surgeons, hospital administrators, patients, and medical societies on the use and outcome of MIPR as well as the approach to be taken regarding this challenging type of surgery.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003590" class="uri">https://doi.org/10.1097/SLA.0000000000003590</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Multi-institutional Development and External Validation of a Nomogram to Predict Recurrence After Curative Resection of Pancreatic Neuroendocrine Tumors</strong> </summary></p>
<p><em>Annals of surgery 2019 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31567347" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31567347</a></p>
<p>OBJECTIVE: To develop a nomogram estimating the probability of recurrence free at 5 years after resection for localized grade 1 (G1)/ grade 2 (G2) pancreatic neuroendocrine tumors (PanNETs). BACKGROUND: Among patients undergoing resection of PanNETs, approximately 17% experience recurrence. It is not established which patients are at risk, with no consensus on optimal follow-up. METHOD: A multi-institutional database of patients with G1/G2 PanNETs treated at 2 institutions was used to develop a nomogram estimating the rate of freedom from recurrence at 5 years after curative resection. A second cohort of patients from 3 additional institutions was used to validate the nomogram. Prognostic factors were assessed by univariate analysis using Cox regression model. The nomogram was internally validated using bootstrap resampling method and on the external cohort. Performance was assessed by concordance index (c-index) and a calibration curve. RESULTS: The nomogram was constructed using a cohort of 632 patients. Overall, 68% of PanNETs were G1, the median follow-up was 51 months, and we observed 74 recurrences. Variables included in the nomogram were the number of positive nodes, tumor diameter, Ki-67, and vascular/perineural invasion. The model bias-corrected c-index from the internal validation was 0.85, which was higher than European Neuroendocrine Tumors Society/American Joint Committee on Cancer 8th staging scheme (c-index 0.76, P=&lt;0.001). On the external cohort of 328 patients, the nomogram c-index was 0.84 (95% confidence interval 0.79-0.88). CONCLUSION: Our externally validated nomogram predicts the probability of recurrence-free survival at 5 years after PanNETs curative resection, with improved accuracy over current staging systems. Estimating individual recurrence risk will guide the development of personalized surveillance programs after surgery.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003579" class="uri">https://doi.org/10.1097/SLA.0000000000003579</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The impact of preoperative biliary stenting in pancreatic cancer: A case-matched study from the German nationwide pancreatic surgery registry (DGAV StuDoQ|Pancreas)</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Oct;19(7):985-993</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31563328" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31563328</a></p>
<p>BACKGROUND/OBJECTIVE: The impact of preoperative biliary stenting (PBS) before pancreatoduodenectomy (PD) for pancreatic ductal adenocarcinoma (PDAC) is controversial. METHODS: Patients undergoing PD with or without PBS for PDAC were identified from the German DGAV-StuDoQlPancreas registry. The impact of PBS on perioperative complications was analyzed. RESULTS: 1133 patients undergoing PD for PDAC were identified from the registry. After matching, 480 PBS patients vs.480 patients without PBS were analyzed. Postoperative complications Clavien-Dindo classification (CDC) grade IIIa-IVb were higher in PBS patients (PBS 27% vs.no PBS 22%, p=0.027). 320 PBS patients (66%) had no history of jaundice. In these patients, PBS was associated with higher morbidity. In contrast, PBS was not associated with higher complication rates in patients with history of jaundice. Serum bilirubin levels of 15mg/dl and higher lead to more CDC IIIa-IVb (24% vs.28%, p=0.053) and higher mortality (3% vs.7%, p&lt;0.001). PBS in patients with serum bilirubin levels of &gt;15mg/dl increased CDC IIa-IVb complications (21% vs.50%, p=0.001), mortality was equivalent. CONCLUSION: Most PBS procedures were performed in patients with no history of jaundice and increased morbidity. Serum bilirubin levels &gt;15mg/dl lead to higher morbidity and mortality. PBS correlated with higher complication rates in these patients.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.09.007" class="uri">https://doi.org/10.1016/j.pan.2019.09.007</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Impact of Endocrine and Exocrine Insufficiency on Quality of Life After Total Pancreatectomy</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31562603" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31562603</a></p>
<p>BACKGROUND: Total pancreatectomy (TP) is rarely performed due to concerns for endocrine and exocrine insufficiency and decreased quality of life (QoL). Renewed interest is seen in recent years, but large cohort studies remain scarce. This study was designed to evaluate endocrine and exocrine insufficiency after TP and its impact on QoL. METHODS: Adult patients (age18years) who underwent TP between 2008 and 2017 at Karolinska University Hospital with at least 6months follow-up were included. Endocrine and exocrine insufficiency and QoL were assessed using validated questionnaires (EORTC QLQ-C30, QLQ-PAN26, PAID20, and DTSQs). Both pre- and postoperative questionnaires were available in a subgroup. RESULTS: Of 145 TP, 60 patients were eligible of whom 53 (88.3%) with a median of 21months (interquartile range [IQR] 13-54) follow-up were included. Symptomatic hypoglycemia occurred in 90.6% (48/53) of patients, and 25% (12/48) experienced 1 episodes of loss of consciousness. The PAID20 revealed emotional burnout in seven patients (13.2%), whereas a high satisfaction score of diabetes treatment (median 28, IQR 24-32) was measured according to the DTSQs. Overall, 27 patients (50.9%) reported to have steatorrhea during a median of 2days (IQR 0-4) in the past week. Overall QoL was reduced compared with a general population (66.7% vs.76.4%; 9.7%) but did not differ with preoperative outcomes (n=39, 66.7%; IQR 41.7-83.3 vs.66.7%, IQR 50.0-83.3; P=0.553) according to the EORTC QLQ-C30. CONCLUSIONS: Although the impact of endocrine and exocrine insufficiency on QoL after TP seems acceptable, the management of both insufficiencies should be further improved.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07853-3" class="uri">https://doi.org/10.1245/s10434-019-07853-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma</strong> </summary></p>
<p><em>Gut 2019 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31562239" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31562239</a></p>
<p>OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) is difficult to diagnose at resectable stage. Recent studies have suggested that extracellular vesicles (EVs) contain long RNAs. The aim of this study was to develop a diagnostic (d-)signature for the detection of PDAC based on EV long RNA (exLR) profiling. DESIGN: We conducted a case-control study with 501 participants, including 284 patients with PDAC, 100 patients with chronic pancreatitis (CP) and 117 healthy subjects. The exLR profile of plasma samples was analysed by exLR sequencing. The d-signature was identified using a support vector machine algorithm and a training cohort (n=188) and was validated using an internal validation cohort (n=135) and an external validation cohort (n=178). RESULTS: We developed a d-signature that comprised eight exLRs, including FGA, KRT19, HIST1H2BK, ITIH2, MARCH2, CLDN1, MAL2 and TIMP1, for PDAC detection. The d-signature showed high accuracy, with an area under the receiver operating characteristic curve (AUC) of 0.960, 0.950 and 0.936 in the training, internal validation and external validation cohort, respectively. The d-signature was able to identify resectable stage I/II cancer with an AUC of 0.949 in the combined three cohorts. In addition, the d-signature showed superior performance to carbohydrate antigen 19-9 in distinguishing PDAC from CP (AUC 0.931 vs 0.873, p=0.028). CONCLUSION: This study is the first to characterise the plasma exLR profile in PDAC and to report an exLR signature for the detection of pancreatic cancer. This signature may improve the prognosis of patients who would have otherwise missed the curative treatment window.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2019-318860" class="uri">https://doi.org/10.1136/gutjnl-2019-318860</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Unilateral Scrotal Swelling after Acute Pancreatitis of Pancreas Transplant Graft</strong> </summary></p>
<p><em>Gastroenterology 2019 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31560896" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31560896</a></p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.09.014" class="uri">https://doi.org/10.1053/j.gastro.2019.09.014</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>RET gene rearrangements occur in a subset of pancreatic acinar cell carcinomas</strong> </summary></p>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31558784" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31558784</a></p>
<p>Pancreatic acinar cell carcinoma is relatively rare (1 to 2% of pancreatic malignancies) but may be under-recognized. In contrast to pancreatic ductal adenocarcinoma, most acinar cell carcinomas lack mutations in KRAS, DPC, CDKN2A or TP53, but appear to have a high incidence of gene rearrangements, with up to 20% reported to be driven by BRAF fusions. With the development of a new class of RET-specific tyrosine kinase inhibitors, which appear to have particularly strong activity against RET gene rearranged tumours, there is now considerable interest in identifying RET gene rearrangements across a wide range of cancers. RET rearrangements have been reported to occur at a very low incidence (&lt;1%) in all pancreatic carcinomas. We postulated that given its unique molecular profile, RET gene rearrangements may be common in acinar cell carcinomas. We performed fluorescent in-situ hybridization (FISH) studies on a cohort of 40 acinar cell spectrum tumours comprising 36 pure acinar cell carcinomas, three pancreatoblastomas and one mixed acinar-pancreatic neuroendocrine tumour. RET gene rearrangements were identified in 3 (7.5%) cases and BRAF gene rearrangements in 5 (12.5%). All gene rearranged tumours were pure acinar cell carcinomas. Our findings indicate that amongst all pancreatic carcinomas, acinar carcinomas are highly enriched for potentially actionable gene rearrangements in RET or BRAF. FISH testing is inexpensive and readily available in the routine clinical setting and may have a role in the assessment of all acinar cell carcinomas-at this stage to recruit patients for clinical trials of new targeted therapies, but perhaps in the near future as part of routine care.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-019-0373-y" class="uri">https://doi.org/10.1038/s41379-019-0373-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31558477" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31558477</a></p>
<p>PURPOSE: 5-Fluorouracil (5-FU)/leucovorin, irinotecan, and nab-paclitaxel are all active agents in gastrointestinal cancers; the combination, FOLFIRABRAX, has not been previously evaluated. UDP Glucuronosyltransferase 1A1 (UGT1A1) clears SN-38, the active metabolite of irinotecan. UGT1A1<em>28 polymorphism reduces UGT1A1 enzymatic activity and predisposes to toxicity. We performed a trial to assess the safety and tolerability of FOLFIRABRAX with UGT1A1 genotype-guided dosing of irinotecan. EXPERIMENTAL DESIGN: Patients with previously untreated, advanced gastrointestinal cancers received FOLFIRABRAX with prophylactic pegfilgrastim every 14 days. UGT1A1 </em>1/<em>1, </em>1/<em>28, and </em>28/<em>28 patients received initial irinotecan doses of 180, 135, and 90 mg/m2, respectively. 5-FU 2,400 mg/m2 over 46 hours, leucovorin 400 mg/m2, and nab-paclitaxel 125 mg/m2 were administered. Doses were deemed tolerable if the dose-limiting toxicity (DLT) rate during cycle 1 was 35% in each genotype group. DLTs were monitored using a sequential procedure. RESULTS: Fifty patients enrolled, 30 pancreatic, 9 biliary tract, 6 gastroesophageal, and 5 others. DLTs occurred in 5 of 23 (22%) </em>1/<em>1 patients, 1 of 19 (5%) </em>1/<em>28 patients, and 0 of 7 </em>28/<em>28 patients. DLTs were all grade 3: diarrhea (3 patients), nausea (2 patients), and febrile neutropenia (1 patient). The overall response rate was 31%. Response rates in pancreatic, gastroesophageal, and biliary tract cancers were 34%, 50%, and 11%, respectively. Eighteen patients (36%) received therapy for at least 24 weeks. CONCLUSIONS: FOLFIRABRAX with genotype-guided dosing of irinotecan is tolerable in patients with advanced gastrointestinal cancer and UGT1A1</em>1<em>1 or UGT1A1</em>1<em>28 genotypes. Too few </em>28/*28 patients were enrolled to provide conclusive results. Responses occurred across multiple tumor types.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-1483" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-1483</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Adverse clinical outcomes associated with multidrug-resistant organisms in patients with infected pancreatic necrosis</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Oct;19(7):935-940</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31558390" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31558390</a></p>
<p>BACKGROUND: Multidrug-resistant organisms (MDROs) is becoming a serious worldwide threat to public health. However, the impact of MDROs on the outcomes of the patients with infected pancreatic necrosis (IPN) remains unclear. This study aims to evaluate the roles of MDROs in IPN. METHODS: A prospectively maintained database of 188 patients with IPN between January 2010 and May 2019 was analyzed. The microbiology profile of organisms isolated from wall-off necrosis (WON) was specifically investigated to correlate with the outcomes of the patients. RESULTS: Of the 188 patients with IPN, 108 patients (57.4%) had MDROs detected in aspirates from WON. Carbapenem-resistant Klebsiella pneumoniae (CRKP) accounted for 43.5% of the MDROs isolated (60/138), followed by Carbapenem-resistant Acinetobacter baumanii (CRAB) (34.8%, 48/138) and Escherichia coli producing an extended-spectrum beta-lactamase (ESBLp) (6.5%, 9/138). MDROs infection was associated with higher mortality (35.2% vs 11.3%, P&lt;0.001), higher rate of hemorrhage (36.1% vs 11.3%, P&lt;0.001), longer intensive care unit (ICU) stay (23 vs 12 days, P&lt;0.001), longer hospital stay (68 vs 51 days, P=0.001) and more hospitalization expenses (45,19031,680 vs 26,96517,167 $, P&lt;0.001). Multivariate analysis of predictors of mortality indicated that MDROs infection (OR=2.6; 95% confidence interval [CI], 1.0-6.5; P=0.042), age50 years (OR=2.6; 95% CI, 1.2-5.8; P=0.016), severe category (OR=2.9; 95% CI, 1.1-8.0; P=0.035), bloodstream infection (OR=3.4; 95% CI, 1.5-7.6; P=0.049), step-down surgical approach (OR=2.7; 95% CI, 1.1-6.2; P=0.023) were significant factors. CONCLUSIONS: MDROs infection was prevalent among patients with IPN and associated with adverse clinical outcomes and increased mortality.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.09.008" class="uri">https://doi.org/10.1016/j.pan.2019.09.008</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Modelling human hepato-biliary-pancreatic organogenesis from the foregut-midgut boundary</strong> </summary></p>
<p><em>Nature 2019 10;574(7776):112-116</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31554966" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31554966</a></p>
<p>Organogenesis is a complex and interconnected process that is orchestrated by multiple boundary tissue interactions1-7. However, it remains unclear how individual, neighbouring components coordinate to establish an integral multi-organ structure. Here we report the continuous patterning and dynamic morphogenesis of hepatic, biliary and pancreatic structures, invaginating from a three-dimensional culture of human pluripotent stem cells. The boundary interactions between anterior and posterior gut spheroids differentiated from human pluripotent stem cells enables retinoic acid-dependent emergence of hepato-biliary-pancreatic organ domains specified at the foregut-midgut boundary organoids in the absence of extrinsic factors. Whereas transplant-derived tissues are dominated by midgut derivatives, long-term-cultured microdissected hepato-biliary-pancreatic organoids develop into segregated multi-organ anlages, which then recapitulate early morphogenetic events including the invagination and branching of three different and interconnected organ structures, reminiscent of tissues derived from mouse explanted foregut-midgut culture. Mis-segregation of multi-organ domains caused by a genetic mutation in HES1 abolishes the biliary specification potential in culture, as seen in vivo8,9. In sum, we demonstrate that the experimental multi-organ integrated model can be established by the juxtapositioning of foregut and midgut tissues, and potentially serves as a tractable, manipulatable and easilyaccessible model for the study of complex human endoderm organogenesis.</p>
<p>doi: <a href="https://doi.org/10.1038/s41586-019-1598-0" class="uri">https://doi.org/10.1038/s41586-019-1598-0</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: What Will Be the Future of IPMN Management?</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(Suppl 3):743-744</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31552617" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31552617</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07858-y" class="uri">https://doi.org/10.1245/s10434-019-07858-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Percutaneous stenting and chemotherapy for unresectable pancreatic cancer: Comparison of irradiation stents vs conventional metal stents</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Oct;19(7):957-962</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31551162" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31551162</a></p>
<p>OBJECTIVES: Percutaneous stenting is a palliative method to relieve obstructive jaundice caused by unresectable pancreatic carcinoma. In this study, we aimed to compare the safety and efficacy of irradiation stents and conventional metal stents. METHODS: A total of 32 patients who received irradiation stents or conventional metal stents to treat obstructive jaundice caused by locally advanced pancreatic cancer were included in this retrospective study. Chemotherapy using gemcitabine was performed after jaundice subsided. Stent patency, technical success, survival, and complications were compared between groups. RESULTS: Seventeen patients were enrolled in the irradiation stent group (ISG), and 15 patients were enrolled in the uncovered stent group (USG). Median and mean stent patency time were 9.8 months (95% CI, 7.682-11.981) and 9.506 months (95% CI, 8.0-11.012) in the ISG, respectively, vs 8.8 months (95% CI, 6.528-11.072) and 7.62 months (95% CI, 5.917-9.323) in the USG, respectively (P=0.019). Median and mean overall survival were 10.4 months (95% CI, 8.383-12.417) and 9.953 months (95% CI, 8.408-11.498), respectively, in the ISG vs 9.7 months (95% CI, 7.901-11.499) and 8.14 months (95% CI, 6.44-9.84), respectively, in the USG (P=0.027). CONCLUSIONS: Irradiation stents extend stent patency and overall survival compared with conventional biliary stents for the treatment of pancreatic carcinoma complicated by obstructive jaundice. Irradiation stents combined with chemotherapy may be a better choice for the treatment of obstructive jaundice caused by unresectable pancreatic carcinoma.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.09.006" class="uri">https://doi.org/10.1016/j.pan.2019.09.006</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Brush Cytology Performance for the Assessment of Biliopancreatic Strictures</strong> </summary></p>
<p><em>Acta cytologica 2019 Sep;():1-8</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31550713" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31550713</a></p>
<p>INTRODUCTION: Brush cytology is commonly used during endoscopic retrograde cholangiopancreatography for the diagnostic evaluation of biliopancreatic strictures. However, since the overall sensitivity of brush cytology is poor, the exclusion of malignancy is difficult. Recognition of factors related to the patient, technique or lesion may help improve the diagnostic yield of brush cytology. The objective of this study was to evaluate the diagnostic yield of brush cytology in the assessment of biliopancreatic strictures and identify predictive factors associated with a positive diagnosis of malignancy. METHODS: Retrospective study that evaluated all consecutive patients that underwent brush cytology for the investigation of biliopancreatic strictures in a tertiary center, between January 2012 and January 2018. RESULTS: One hundred and sixty-five patients that underwent 182 procedures were included. A diagnosis of malignancy was confirmed in 110 patients (66.7%), of whom 62 had positive brush cytology (sensitivity 53.7%, specificity 98.5%, accuracy 69.8%). On the multivariate analysis, age 68 years (OR 4.83, 95% CI 1.04-22.37) and lesions suspicious of metastasis on cross-sectional imaging (OR 8.58, 95% CI 1.70-43.38) were independently associated with a positive result. Subanalysis of the patients presenting with these two factors (n = 26) revealed an increase in the diagnostic yield (sensitivity 80.8%). CONCLUSION: Age 68 years and lesions suspicious of metastasis on cross-sectional imaging are independent factors associated with a positive result. Patient selection taking these factors into account may increase the diagnostic yield of brush cytology.</p>
<p>doi: <a href="https://doi.org/10.1159/000502791" class="uri">https://doi.org/10.1159/000502791</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cystic Lesions of the Pancreas: Differential Diagnosis and Cytologic-Histologic Correlation</strong> </summary></p>
<p><em>Archives of pathology &amp; laboratory medicine 2019 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31538798" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31538798</a></p>
<p>CONTEXT.: Pancreatic cystic lesions (PCLs) are very common, and their detection is increasing with the advances in imaging techniques. Because of the major implications for management, distinguishing between neoplastic and nonneoplastic PCLs is critical. Neoplastic cysts with potential to progress into cancer include mucinous PCLs (intraductal papillary mucinous neoplasms and mucinous cystic neoplasms) and nonmucinous cysts (solid pseudopapillary tumors, serous cystic neoplasms, and neuroendocrine tumors with cystic degeneration). Nonneoplastic cysts with no risk of malignant transformation include pseudocysts, retention cysts, lymphoepithelial cysts, cystic pancreatic lymphangioma, and duplication cyst/ciliated foregut cysts. The role of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) cytology with cyst fluid analysis in the diagnosis of PCLs has evolved during the last decade; however, a definitive diagnosis on cytologic specimens is hampered by the sparse cellularity and can be challenging. EUS-FNA can play an important role to differentiate low-risk from high-risk pancreatic cysts and to distinguish between patients with cysts that need clinical follow-up versus those that require surgery. OBJECTIVE.: To provide an integrative approach to diagnose pancreatic cystic lesions, using EUS-FNA cytology and cyst fluid analysis, along with clinical, radiologic, histologic, genetic, and molecular characteristics. DATA SOURCES.: The review and analysis of the latest literature describing pancreatic cystic lesions. CONCLUSIONS.: Accurate diagnosis of PCLs requires a multidisciplinary and multimodal team approach, including the integration of clinical findings, imaging, cytology, cyst fluid analysis, and molecular testing.</p>
<p>doi: <a href="https://doi.org/10.5858/arpa.2019-0308-RA" class="uri">https://doi.org/10.5858/arpa.2019-0308-RA</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>-Ketoglutarate links p53 to cell fate during tumour suppression</strong> </summary></p>
<p><em>Nature 2019 Sep;573(7775):595-599</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31534224" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31534224</a></p>
<p>The tumour suppressor TP53 is mutated in the majority of human cancers, and in over 70% of pancreatic ductal adenocarcinoma (PDAC)1,2. Wild-type p53 accumulates in response to cellular stress, and regulates gene expression to alter cell fate and prevent tumour development2. Wild-type p53 is also known to modulate cellular metabolic pathways3, although p53-dependent metabolic alterations that constrain cancer progression remain poorly understood. Here we find that p53 remodels cancer-cell metabolism to enforce changes in chromatin and gene expression that favour a premalignant cell fate. Restoring p53 function in cancer cells derived from KRAS-mutant mouse models of PDAC leads to the accumulation of -ketoglutarate (KG, also known as 2-oxoglutarate), a metabolite that also serves as an obligate substrate for a subset of chromatin-modifying enzymes. p53 induces transcriptional programs that are characteristic of premalignant differentiation, and this effect can be partially recapitulated by the addition of cell-permeable KG. Increased levels of the KG-dependent chromatin modification 5-hydroxymethylcytosine (5hmC) accompany the tumour-cell differentiation that is triggered by p53, whereas decreased 5hmC characterizes the transition from premalignant to de-differentiated malignant lesions that is associated with mutations in Trp53. Enforcing the accumulation of KG in p53-deficient PDAC cells through the inhibition of oxoglutarate dehydrogenase-an enzyme of the tricarboxylic acid cycle-specifically results in increased 5hmC, tumour-cell differentiation and decreased tumour-cell fitness. Conversely, increasing the intracellular levels of succinate (a competitive inhibitor of KG-dependent dioxygenases) blunts p53-driventumour suppression. These data suggest that KG is an effector of p53-mediated tumour suppression, and that the accumulation of KG in p53-deficient tumours can drive tumour-cell differentiation and antagonize malignant progression.</p>
<p>doi: <a href="https://doi.org/10.1038/s41586-019-1577-5" class="uri">https://doi.org/10.1038/s41586-019-1577-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Akt1 signalling supports acinar proliferation and limits acinar-to-ductal metaplasia formation upon induction of acute pancreatitis</strong> </summary></p>
<p><em>The Journal of pathology 2020 Jan;250(1):42-54</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31531867" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31531867</a></p>
<p>Molecular signalling mediated by the phosphatidylinositol-3-kinase (PI3K)-Akt axis is a key regulator of cellular functions. Importantly, alteration of the PI3K-Akt signalling underlies the development of different human diseases, thus prompting the investigation of the pathway as a molecular target for pharmacologic intervention. In this regard, recent studies showed that small molecule inhibitors of PI3K, the upstream regulator of the pathway, reduced the development of inflammation during acute pancreatitis, a highly debilitating and potentially lethal disease. Here we investigated whether a specific reduction of Akt activity, by using either pharmacologic Akt inhibition, or genetic inactivation of the Akt1 isoform selectively in pancreatic acinar cells, is effective in ameliorating the onset and progression of the disease. We discovered that systemic reduction of Akt activity did not protect the pancreas from initial damage and only transiently delayed leukocyte recruitment. However, reduction of Akt activity decreased acinar proliferation and exacerbated acinar-to-ductal metaplasia (ADM) formation, two critical events in the progression of pancreatitis. These phenotypes were recapitulated upon conditional inactivation of Akt1 in acinar cells, which resulted in reduced expression of 4E-BP1, a multifunctional protein of key importance in cell proliferation and metaplasia formation. Collectively, our results highlight the critical role played by Akt1 during the development of acute pancreatitis in the control of acinar cell proliferation and ADM formation. In addition, these results harbour important translational implications as they raise the concern that inhibitors of PI3K-Akt signalling pathways may negatively affect the regeneration of the pancreas. Finally, this work provides the basis for further investigating the potential of Akt1 activators to boost pancreatic regeneration following inflammatory insults.  2019 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</p>
<p>doi: <a href="https://doi.org/10.1002/path.5348" class="uri">https://doi.org/10.1002/path.5348</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Atp6ap2 deletion causes extensive vacuolation that consumes the insulin content of pancreatic  cells</strong> </summary></p>
<p><em>Proceedings of the National Academy of Sciences of the United States of America 2019 Oct;116(40):19983-19988</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31527264" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31527264</a></p>
<p>Pancreatic  cells store insulin within secretory granules which undergo exocytosis upon elevation of blood glucose levels. Crinophagy and autophagy are instead responsible to deliver damaged or old granules to acidic lysosomes for intracellular degradation. However, excessive consumption of insulin granules can impair  cell function and cause diabetes. Atp6ap2 is an essential accessory component of the vacuolar ATPase required for lysosomal degradative functions and autophagy. Here, we show that Cre recombinase-mediated conditional deletion of Atp6ap2 in mouse  cells causes a dramatic accumulation of large, multigranular vacuoles in the cytoplasm, with reduction of insulin content and compromised glucose homeostasis. Loss of insulin stores and gigantic vacuoles were also observed in cultured insulinoma INS-1 cells upon CRISPR/Cas9-mediated removal of Atp6ap2. Remarkably, these phenotypic alterations could not be attributed to a deficiency in autophagy or acidification of lysosomes. Together, these data indicate that Atp6ap2 is critical for regulating the stored insulin pool and that a balanced regulation of granule turnover is key to maintaining  cell function and diabetes prevention.</p>
<p>doi: <a href="https://doi.org/10.1073/pnas.1903678116" class="uri">https://doi.org/10.1073/pnas.1903678116</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Precision medicine in pancreatic cancer: treating every patient as an exception</strong> </summary></p>
<p><em>The lancet. Gastroenterology &amp; hepatology 2019 Oct;4(10):805-810</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31511204" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31511204</a></p>
<p>Patients with pancreatic cancer have not benefited from recent improvements in overall survival brought about by precision medicine in other malignancies. This failure is not due to a dearth of precision-medicine research in pancreatic ductal adenocarcinoma (PDAC), the main type of pancreatic cancer. In fact, the stalled progress in precision therapies for this type of cancer is due to the absence of agents that are able to target the common genetic alterations in PDAC. Several studies have attempted to phenotypically stratify PDAC at the transcriptional level. However, the value of such classifications will only be revealed through prospective studies and, crucially, only after development of new treatment options for this disease. Therefore, it is essential to learn from breakthrough discoveries in other cancer types that could benefit subpopulations of patients with PDAC and convert them from ordinary to exceptional responders. Identifying these exceptional patients will help to bring PDAC in line with other cancer types in terms of availability of precision therapies. Thus, the true challenge to precision medicine for PDAC might be the poor consensus on which genetic and phenotypic alterations across the spectrum of this disease are actionable; not the absence of actionable variables themselves. To reach consensus, knowledge and tools must be developed and disseminated for individuals who provide pancreatic cancer care, to enable the real-time identification of exceptional patients, more precise subgroup classifications, and effective disease management strategies; all informed by immediate feedback from clinical outcome data.</p>
<p>doi: <a href="https://doi.org/10.1016/S2468-1253(19)30175-X" class="uri">https://doi.org/10.1016/S2468-1253(19)30175-X</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells</strong> </summary></p>
<p><em>Proceedings of the National Academy of Sciences of the United States of America 2019 Sep;116(39):19609-19618</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31484774" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31484774</a></p>
<p>Pancreatic ductal adenocarcinoma (PDAC) has prominent extracellular matrix (ECM) that compromises treatments yet cannot be nonselectively disrupted without adverse consequences. ECM of PDAC, despite the recognition of its importance, has not been comprehensively studied in patients. In this study, we used quantitative mass spectrometry (MS)-based proteomics to characterize ECM proteins in normal pancreas and pancreatic intraepithelial neoplasia (PanIN)- and PDAC-bearing pancreas from both human patients and mouse genetic models, as well as chronic pancreatitis patient samples. We describe detailed changes in both abundance and complexity of matrisome proteins in the course of PDAC progression. We reveal an early up-regulated group of matrisome proteins in PanIN, which are further up-regulated in PDAC, and we uncover notable similarities in matrix changes between pancreatitis and PDAC. We further assigned cellular origins to matrisome proteins by performing MS on multiple lines of human-to-mouse xenograft tumors. We found that, although stromal cells produce over 90% of the ECM mass, elevated levels of ECM proteins derived from the tumor cells, but not those produced exclusively by stromal cells, tend to correlate with poor patient survival. Furthermore, distinct pathways were implicated in regulating expression of matrisome proteins in cancer cells and stromal cells. We suggest that, rather than global suppression of ECM production, more precise ECM manipulations, such as targeting tumor-promoting ECM proteins and their regulators in cancer cells, could be more effective therapeutically.</p>
<p>doi: <a href="https://doi.org/10.1073/pnas.1908626116" class="uri">https://doi.org/10.1073/pnas.1908626116</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Higher IL-6 peri-tumoural expression is associated with gastro-intestinal neuroendocrine tumour progression</strong> </summary></p>
<p><em>Pathology 2019 Oct;51(6):593-599</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31466863" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31466863</a></p>
<p>An association of well-differentiated gastroenteropancreatic neuroendocrine tumours (WD GEP NETs) with metabolic syndrome (MetS) was recently described. Yet no molecular mechanisms linking the two conditions are known. This studys aim was to identify putative molecular signatures linking WD GEP NETs and MetS to gain further insight into potential mechanisms for this association. Patients with WD GEP NETs (n=39), pancreatic (panNET) and gastro-intestinal (GI-NET), were clinically evaluated for presence of MetS. WD GEP NETs immunohistochemistry staining for Forkhead box protein M1 (FOXM1), insulin growth factor 1 receptor (IGF1R), Ki-67 and interleukin 6 (IL-6) was performed and quantified by computerised morphometric analysis. FOXM1, Ki-67, IGF1R or IL-6 expression in WD GEP NETs was not influenced by the presence of MetS. IL-6 peritumoural expression was higher in GI-NETs of patients with low HDL cholesterol (0.0180.005% vs 0.0300.005%, p=0.02). In GI-NETs, a higher IL-6 expression was also associated with disease progression (0.0260.004% vs 0.0160.002%, p=0.03). In WD GEP-NETs, MetS did not influence FOXM1, IGF1R and IL-6 expression. In GI-NETs, IL-6 expression was influenced by the MetS feature low HDL, and positively associated with disease progression. These data suggest that local and systemic inflammatory status can potentially modulate GI-NET behaviour.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pathol.2019.07.001" class="uri">https://doi.org/10.1016/j.pathol.2019.07.001</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Trivial Cysts Redefine the Risk of Cancer in Presumed Branch-Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Potential Target for Follow-Up Discontinuation?</strong> </summary></p>
<p><em>The American journal of gastroenterology 2019 Oct;114(10):1678-1684</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31449158" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31449158</a></p>
<p>OBJECTIVES: The management of small and incidental branch duct intraductal papillary mucinous neoplasms (BD-IPMNs) still is of concern. The aim is assessing the safety of a surveillance protocol through the evaluation of their progression to malignancy. METHODS: All presumed BD-IPMNs observed from 2000 to 2016 were included. Only patients presenting without worrisome features (WFs) and high-risk stigmata (HRS) at diagnosis were included. Development of WF, HRS, pancreatic cancer (PC), and survival were analyzed. BD-IPMNs were defined as trivial in the continuing absence of WF/HRS after 5 years of surveillance. The age-specific standardized incidence ratio of PC in the general population was used for comparison. RESULTS: A total of 1,036 BD-IPMNs without WF/HRS at diagnosis were included, 4.2% developed WF or HRS, and 1.1% developed PC after a median of 62 months. The median cyst growth rate was 0 mm/yr. A growth rate 2.5 mm/yr and the development of WF resulted independent predictors of PC. The standardized incidence ratio of PC for trivial BD-IPMN (n = 378) was 22.45 (95% confidence interval 8.19-48.86), but considering only patients aged &gt;65 years (n = 198), it decreased to 3.84 (95% confidence interval 0.77-11.20). DISCUSSION: Surveillance of the vast majority of presumed BD-IPMNs is safe, as the risk of PC is comparable to postoperative mortality of pancreatic surgery. A growth rate 2.5 mm/yr is the main predictor of PC, reinforcing the role of repeated observations. A trivial BD-IPMN in patients aged &gt;65 years might not increase the risk of developing PC compared with general population, identifying potential targets for follow-up discontinuation.</p>
<p>doi: <a href="https://doi.org/10.14309/ajg.0000000000000378" class="uri">https://doi.org/10.14309/ajg.0000000000000378</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases</strong> </summary></p>
<p><em>Lancet (London, England) 2019 09;394(10203):1041-1054</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31443926" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31443926</a></p>
<p>BACKGROUND: The past few decades have seen substantial improvements in cancer survival, but concerns exist about long-term cardiovascular disease risk in survivors. Evidence is scarce on the risks of specific cardiovascular diseases in survivors of a wide range of cancers to inform prevention and management. In this study, we used large-scale electronic health records data from multiple linked UK databases to address these evidence gaps. METHODS: For this population-based cohort study, we used linked primary care, hospital, and cancer registry data from the UK Clinical Practice Research Datalink to identify cohorts of survivors of the 20 most common cancers who were 18 years or older and alive 12 months after diagnosis and controls without history of cancer, matched for age, sex, and general practice. We compared risks for a range of cardiovascular disease outcomes using crude and adjusted Cox models. We fitted interactions to investigate effect modification, and flexible parametric survival models to estimate absolute excess risks over time. FINDINGS: Between Jan 1, 1990, and Dec 31, 2015, 126120 individuals with a diagnosis of a cancer of interest still being followed up at least 1 year later were identified and matched to 630144 controls. After exclusions, 108215 cancer survivors and 523541 controls were included in the main analyses. Venous thromboembolism risk was elevated in survivors of 18 of 20 site-specific cancers compared with that of controls; adjusted hazard ratios (HRs) ranged from 172 (95% CI 157-189) in patients after prostate cancer to 972 (550-1718) after pancreatic cancer. HRs decreased over time, but remained elevated more than 5 years after diagnosis. We observed increased risks of heart failure or cardiomyopathy in patients after ten of 20 cancers, including haematological (adjusted HR 194, 166-225, with non-Hodgkin lymphoma; 177, 150-209, with leukaemia; and 329, 259-418, with multiple myeloma), oesophageal (196, 146-264), lung (182, 152-217) kidney (173, 138-217) and ovarian (159, 119-212). Elevated risks of arrhythmia, pericarditis, coronary artery disease, stroke, and valvular heart disease were also observed for multiple cancers, including haematological malignancies. HRs for heart failure or cardiomyopathy and venous thromboembolism were greater in patients without previous cardiovascular disease and in younger patients. However, absolute excess risks were generally greater with increasing age. Increased risks of these outcomes seemed most pronounced in patients who had received chemotherapy. INTERPRETATION: Survivors of most site-specific cancers had increased medium-term to long-term risk for one or more cardiovascular diseases compared with that for the general population, with substantial variations between cancer sites. FUNDING: Wellcome Trust and Royal Society.</p>
<p>doi: <a href="https://doi.org/10.1016/S0140-6736(19)31674-5" class="uri">https://doi.org/10.1016/S0140-6736(19)31674-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials</strong> </summary></p>
<p><em>The lancet. Diabetes &amp; endocrinology 2019 Oct;7(10):776-785</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31422062" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31422062</a></p>
<p>BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their structure and duration of action and have been studied in trials of varying sizes and with different patient populations, with inconsistent effects on cardiovascular outcomes reported. We aimed to synthesise the available evidence by doing a systematic review and meta-analysis of cardiovascular outcome trials of these drugs. METHODS: We searched MEDLINE (via PubMed) and the Cochrane Central Register of Controlled Trials for eligible placebo-controlled trials reporting major adverse cardiovascular events (MACE; ie, cardiovascular death, stroke, or myocardial infarction) up to June 15, 2019. We did a meta-analysis using a random-effects model to estimate overall hazard ratios (HRs) for MACE, its components, death from any cause, hospital admission for heart failure, kidney outcomes, and key safety outcomes (severe hypoglycaemia, pancreatitis, and pancreatic cancer). We also examined MACE in several subgroups based on patient characteristics (history of cardiovascular disease, BMI, age, baseline HbA1c, and baseline estimated glomerular filtration rate), trial duration, treatment dosing interval, and structural homology. FINDINGS: Of 27 publications screened, seven trials, with a combined total of 56004 participants, were included: ELIXA (lixisenatide), LEADER (liraglutide), SUSTAIN-6 (semaglutide), EXSCEL (exenatide), Harmony Outcomes (albiglutide), REWIND (dulaglutide), and PIONEER 6 (oral semaglutide). Overall, GLP-1 receptor agonist treatment reduced MACE by 12% (HR 088, 95% CI 082-094; p&lt;00001). There was no statistically significant heterogeneity across the subgroups examined. HRs were 088 (95% CI 081-096; p=0003) for death from cardiovascular causes, 084 (076-093; p&lt;00001) for fatal or non-fatal stroke, and 091 (084-100; p=0043) for fatal or non-fatal myocardial infarction. GLP-1 receptor agonist treatment reduced all-cause mortality by 12% (088, 083-095; p=0001), hospital admission for heart failure by 9% (091, 083-099; p=0028), and a broad composite kidney outcome (development of new-onset macroalbuminuria, decline in estimated glomerular filtration rate [or increase in creatinine], progression to end-stage kidney disease, or death attributable to kidney causes) by 17% (083, 078-089; p&lt;00001), mainly due to a reduction in urinary albumin excretion. There was no increase in risk of severe hypoglycaemia, pancreatitis, or pancreatic cancer. INTERPRETATION: Treatment with GLP-1 receptor agonists has beneficial effects on cardiovascular, mortality, and kidney outcomes in patients with type 2 diabetes. FUNDING: None.</p>
<p>doi: <a href="https://doi.org/10.1016/S2213-8587(19)30249-9" class="uri">https://doi.org/10.1016/S2213-8587(19)30249-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Extended Laparoscopic Central Pancreatectomy with Clamping of the Mesentericoportal Vein and Resection of the Splenic Vessels for a Large Solid Pseudopapillary Tumor</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Oct;26(11):3709-3710</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31407182" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31407182</a></p>
<p>BACKGROUND: Solid pseudopapillary tumors (SPPTs) are low malignant potential entities found mainly in young females.1,2 Pancreatectomy without tumor rupture is the treatment of choice, and the laparoscopic approach is indicated.3,4 Limited pancreatectomy is possible due to the low risk of malignancy (&lt;10%) based on the low risk of lymph node invasion or true vascular invasion.1,2 Centrally located large SPPTs can be treated by extended central pancreatectomy with or without vascular resection to avoid pancreatoduodenectomy or distal pancreatectomy. METHODS: A 24-year-old woman was admitted with abdominal pain. A 6-cm SPPT was discovered at the neck-body junction in close contact with the anterior aspect of the mesentericoportal vein (MPV) and the splenic vessels, with signs of segmental portal hypertension. To avoid an extended pancreatectomy for this young patient, an extended central pancreatectomy was performed, with resection of the splenic vessels, and the MPV was freed from the tumor under clamping for 10min, with no need for vascular reconstruction. The duration of the surgery was 260min, with 200ml of blood loss and no transfusion. RESULTS: The womans postoperative course was uneventful, with a hospital stay of 16days. Histology confirmed the diagnosis of a 6-cm SPPT tumor (R0 and N0). The patient was asymptomatic 1year later, with no tumor recurrence and no pancreatic insufficiency. Between 2011 and 2018 the authors performed 72 laparoscopic central pancreatectomies, with SPPT performed for 13 patients (18%). Laparoscopic central pancreatectomy was extended (n=5) or standard (n=8) with no conversion, no recurrence, and no pancreatic insufficiency. CONCLUSION: An SPPT tumor is a good indication for the laparoscopic approach because this entity is found in young patients with a low risk of malignancy. Large centrally located tumors can be treated by extended central pancreatectomy to avoid a large pancreatectomy with greater early and long-term disadvantages.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07689-x" class="uri">https://doi.org/10.1245/s10434-019-07689-x</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Intraductal Papillary Mucinous Neoplasms: Attack of the Clones</strong> </summary></p>
<p><em>Gastroenterology 2019 10;157(4):929-932</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31400367" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31400367</a></p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.08.007" class="uri">https://doi.org/10.1053/j.gastro.2019.08.007</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Fungal sinusitis in simultaneous pancreas-kidney transplant</strong> </summary></p>
<p><em>Journal of clinical pathology 2019 10;72(10):720</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31358535" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31358535</a></p>
<p>doi: <a href="https://doi.org/10.1136/jclinpath-2018-205258" class="uri">https://doi.org/10.1136/jclinpath-2018-205258</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Feasibility of Using Hydrogel Spacers for Borderline-Resectable and Locally Advanced Pancreatic Tumors</strong> </summary></p>
<p><em>Gastroenterology 2019 10;157(4):933-935</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31306631" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31306631</a></p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.07.012" class="uri">https://doi.org/10.1053/j.gastro.2019.07.012</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Reply to Deprescription during last year of life in patients with pancreatic cancer: Optimization or nihilism?</strong> </summary></p>
<p><em>Cancer 2019 Oct;125(19):3471-3472</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31291006" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31291006</a></p>
<p>doi: <a href="https://doi.org/10.1002/cncr.32390" class="uri">https://doi.org/10.1002/cncr.32390</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Deprescription during last year of life in patients with pancreatic cancer: Optimization or nihilism?</strong> </summary></p>
<p><em>Cancer 2019 Oct;125(19):3470-3471</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31290998" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31290998</a></p>
<p>doi: <a href="https://doi.org/10.1002/cncr.32389" class="uri">https://doi.org/10.1002/cncr.32389</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Better Defining the Role of Total Neoadjuvant Radiation: Changing Paradigms in Locally Advanced Pancreatic Cancer</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Oct;26(11):3701-3708</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31286306" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31286306</a></p>
<p>BACKGROUND: This study was designed to better define the role of radiation (Neo-Rad) in addition to neoadjuvant multiagent chemotherapy (NAT) for the treatment of locally advanced pancreatic cancer. METHODS: Retrospective cohort study using the NCDB. Individuals with AJCC clinical T3/T4 pancreatic carcinoma who underwent resection and multiagent chemotherapy were included. Kaplan-Meier, logistic-regression, and Cox proportional-hazard models were used for analysis. RESULTS: A total of 2703 patients were included; 2039 had T3 and 664 had T4 tumors, and 1092 (40.4%) received Neo-Rad. Median follow-up was 22.5months. During the study period, there was increased use of NAT and a decline in the use of Neo-Rad. Addition of Neo-Rad did not affect 30-day (2.51% vs.3.24%, p=0.272) or 90-day mortality (5.23% vs.6.38%, p=0.216). Neo-Rad was not associated with improved overall survival on univariable (25.95 vs.24.7months, p=0.202), or multivariable analyses (hazard ratio [HR] 0.94; 95% confidence interval [CI] 0.85-1.05). Time from diagnosis to definitive surgery was increased by Neo-Rad (204 vs.115days, p&lt;0.001). Neo-Rad was associated with increased pathologic downstaging in T3 (32.8% vs.14.4%) (odds ratio [OR] 2.90; 95% CI 2.30-3.66) and T4 tumors (88.9% vs.77.8%) (OR 2.29; 95% CI 1.44-3.67); complete pathologic response (5.3% vs.1.6%) (OR 2.89; 95% CI 1.73-4.83), and increased R0 resection rates (85.7% vs.76.8%) (OR 1.79; 95% CI 1.44-2.23). CONCLUSIONS: The use of neoadjuvant therapy is increasing for the treatment of locally advanced pancreatic cancer. The addition of radiation to neoadjuvant chemotherapy is associated with improved antineoplastic effectiveness (downstaging, complete pathologic response), surgical resection (R0 rates), but has no effect on overall survival.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07584-5" class="uri">https://doi.org/10.1245/s10434-019-07584-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Oct;25(19):5890-5900</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31285373" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31285373</a></p>
<p>PURPOSE: Genetically engineered T cells are powerful anticancer treatments but are limited by safety and specificity issues. We herein describe an MHC-unrestricted modular platform combining autologous T cells, transduced with a targetable synthetic agonistic receptor (SAR), with bispecific antibodies (BiAb) that specifically recruit and activate T cells for tumor killing. EXPERIMENTAL DESIGN: BiAbs of different formats were generated by recombinant expression. T cells were retrovirally transduced with SARs. T-cell activation, proliferation, differentiation, and T-cell-induced lysis were characterized in three murine and human tumor models in vitro and in vivo. RESULTS: Murine T cells transduced with SAR composed of an extracellular domain EGFRvIII fused to CD28 and CD3 signaling domains could be specifically recruited toward murine tumor cells expressing EpCAM by anti-EGFRvIII  anti-EpCAM BiAb. BiAb induced selective antigen-dependent activation, proliferation of SAR T cells, and redirected tumor cell lysis. Selectivity was dependent on the monovalency of the antibody for EGFRvIII. We identified FAS ligand as a major mediator of killing utilized by the T cells. Similarly, human SAR T cells could be specifically redirected toward mesothelin-expressing human pancreatic cancer cells. In vivo, treatment with SAR T cells and BiAb mediated antitumoral activity in three human pancreatic cancer cell xenograft models. Importantly, SAR activity, unlike CAR activity, was reversible in vitro and in vivo. CONCLUSIONS: We describe a novel ACT platform with antitumor activity in murine and human tumor models with a distinct mode of action that combines adoptive T-cell therapy with bispecific antibodies.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-18-3927" class="uri">https://doi.org/10.1158/1078-0432.CCR-18-3927</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cytologic features of pancreatobiliary neoplasm of duodenum</strong> </summary></p>
<p><em>Diagnostic cytopathology 2019 Oct;47(10):1059-1062</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31276311" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31276311</a></p>
<p>Small intestinal adenomas are uncommon. Majority of these occur in the region of the ampulla of Vater. Adenomas of the ampulla can be further subdivided into two types-intestinal and pancreatobiliary. While intestinal adenomas are more frequent, pancreatobiliary adenomas are rare. There is limited literature regarding the role of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) in the diagnosis of ampullary/peri-ampullary neoplasms. Here, we describe the cytologic features of a pancreatobiliary neoplasm of the duodenum that was sampled by EUS-FNA. The aspirate was cellular and revealed cells with moderately abundant oncocytic cytoplasm. The nuclei were round with fine chromatin and focally prominent nucleoli. Although the concurrent biopsy showed no high-grade dysplasia or invasive carcinoma, the EUS and imaging findings were highly suspicious for invasion. A broad differential diagnosis is under consideration for a duodenal mass that encompasses neoplasms of the biliary tract, pancreas, duodenum, and ampulla of Vater. To our knowledge, cytologic features of a pancreatobiliary neoplasm of the duodenum have not been previously reported. Our case highlights the features seen on cytology with histologic correlation in the hopes of elucidating features to better characterize these lesions.</p>
<p>doi: <a href="https://doi.org/10.1002/dc.24271" class="uri">https://doi.org/10.1002/dc.24271</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>miR-149-5p protects against high glucose-induced pancreatic beta cell apoptosis via targeting the BH3-only protein BIM</strong> </summary></p>
<p><em>Experimental and molecular pathology 2019 Oct;110():104279</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31260649" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31260649</a></p>
<p>Diabetes mellitus (DM) is characterized by the elevated blood glucose levels and is regarded as one of the most threatening diseases worldwide. The dysfunction of pancreatic beta cells is a key contributor for the pathophysiology of DM. There is growing evidence showing the role of microRNAs (miRNAs) in the regulation of pancreatic beta cell functions. In the present study, we determined the expression of miR-149-5p in pancreatic beta cells under high-glucose (HG) stimulation and explored the underlying mechanism of miR-149-5p-mediated functions of pancreatic beta cells. The results showed the down-regulation of miR-149-5p in the pancreatic beta cell line (MIN6 cells) under HG stimulation. Overexpression of miR-149-5p protected against HG-induced cell apoptosis and impairment of insulin secretion, and attenuated HG-induced an increase in reactive oxygen species (ROS) production in MIN6 cells; while inhibition of miR-149-5p suppressed cell viability, induced cell apoptosis, inhibited insulin secretion and enhanced ROS production in MIN6 cells. Further mechanistic studies revealed that miR-149-5p targeted the BH3-only protein BIM 3 untranslated region and suppressed BIM expression in MIN6 cells. The rescue experimental assays showed that enforced expression of BIM attenuated the miR-149-5p-mediated effects in HG-stimulated pancreatic beta cells. In conclusion, the present study for the first time elucidated the biological functions of miR-149-5p in regulating pancreatic beta cell functions. The data from the present study provided evidence showing that miR-149-5p protected against HG-induced pancreatic beta cell apoptosis partly via suppressing BIM expression. The therapeutic potential of miR-149-5p in the treatment of DM still requires further detailed investigations.</p>
<p>doi: <a href="https://doi.org/10.1016/j.yexmp.2019.104279" class="uri">https://doi.org/10.1016/j.yexmp.2019.104279</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Inpatient Opioid Use After Pancreatectomy: Opportunities for Reducing Initial Opioid Exposure in Cancer Surgery Patients</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Oct;26(11):3428-3435</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31243665" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31243665</a></p>
<p>BACKGROUND: Despite advances in enhanced surgical recovery programs, strategies limiting postoperative inpatient opioid exposure have not been optimized for pancreatic surgery. The primary aims of this study were to analyze the magnitude and variations in post-pancreatectomy opioid administration and to characterize predictors of low and high inpatient use. METHODS: Clinical characteristics and inpatient oral morphine equivalents (OMEs) were downloaded from electronic records for consecutive pancreatectomy patients at a high-volume institution between March 2016 and August 2017. Regression analyses identified predictors of total OMEs as well as highest and lowest quartiles. RESULTS: Pancreatectomy was performed for 158 patients (73% pancreaticoduodenectomy). Transversus abdominus plane (TAP) block was performed for 80% (n=127) of these patients, almost always paired with intravenous patient-controlled analgesia (IV-PCA), whereas 15% received epidural alone. All the patients received scheduled non-opioid analgesics (median, 2). The median total OME administered was 423mg (range 0-4362mg). Higher total OME was associated with preoperative opioid prescriptions (p&lt;0.001), longer hospital length of stay (LOS; p&lt;0.001), and no epidural (p=0.006). The lowest and best quartile cutoff was 180mg of OME or less, whereas the highest and worst quartile cutoff began at 892.5mg. After adjustment for inpatient team, only epidural use [odds ratio (OR) 0.3; p=0.04] predicted lowest-quartile OME. Preoperative opioid prescriptions (OR 8.1; p&lt;0.001), longer operative time (OR 3.4; p=0.05), and longer LOS (OR 1.1; p=0.007) predicted highest-quartile OME. CONCLUSIONS: Preoperative opioid prescriptions and longer LOS were associated with increased inpatient OME, whereas epidural use reduced inpatient OME. Understanding the predictors of inpatient opioid use and the variables predicting the lowest and highest quartiles can inform decision-making regarding preoperative counseling, regional anesthetic block choice, and novel inpatient opioid weaning strategies to reduce initial postoperative opioid exposure.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07528-z" class="uri">https://doi.org/10.1245/s10434-019-07528-z</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Oct;25(19):5984-5996</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31227505" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31227505</a></p>
<p>PURPOSE: Mutant KRAS is a major driver of pancreatic oncogenesis and therapy resistance, yet KRAS inhibitors are lacking in the clinic. KRAS requires farnesylation for membrane localization and cancer-causing activity prompting the development of farnesyltransferase inhibitors (FTIs) as anticancer agents. However, KRAS becomes geranylgeranylated and active when cancer cells are treated with FTIs. To overcome this geranylgeranylation-dependent resistance to FTIs, we designed FGTI-2734, a RAS C-terminal mimetic dual FT and geranylgeranyltransferase-1 inhibitor (GGTI). EXPERIMENTAL DESIGN: Immunofluorescence, cellular fractionation, and gel shift assays were used to assess RAS membrane association, Western blotting to evaluate FGTI-2734 effects on signaling, and mouse models to demonstrate its antitumor activity. RESULTS: FGTI-2734, but not the selective FTI-2148 and GGTI-2418, inhibited membrane localization of KRAS in pancreatic, lung, and colon human cancer cells. FGTI-2734 induced apoptosis and inhibited the growth in mice of mutant KRAS-dependent but not mutant KRAS-independent human tumors. Importantly, FGTI-2734 inhibited the growth of xenografts derived from four patients with pancreatic cancer with mutant KRAS (2 G12D and 2 G12V) tumors. FGTI-2734 was also highly effective at inhibiting, in three-dimensional cocultures with resistance promoting pancreatic stellate cells, the viability of primary and metastatic mutant KRAS tumor cells derived from eight patients with pancreatic cancer. Finally, FGTI-2734 suppressed oncogenic pathways mediated by AKT, mTOR, and cMYC while upregulating p53 and inducing apoptosis in patient-derived xenografts in vivo. CONCLUSIONS: The development of this novel dual FGTI overcomes a major hurdle in KRAS resistance, thwarting growth of patient-derived mutant KRAS-driven xenografts from patients with pancreatic cancer, and as such it warrants further preclinical and clinical studies.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-18-3399" class="uri">https://doi.org/10.1158/1078-0432.CCR-18-3399</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Characterization of spatial distribution of tumor-infiltrating CD8+ T cells refines their prognostic utility for pancreatic cancer survival</strong> </summary></p>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019 Oct;32(10):1495-1507</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31186528" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31186528</a></p>
<p>The abundance of cytotoxic T-cell infiltrates has important implications for patient outcome and therapeutic design for pancreatic ductal adenocarcinoma. However, intratumoral heterogeneity remains a challenge to understanding the complex immune microenvironment. We hypothesized that characterizing CD8+ cell distribution within pancreatic adenocarcinoma tissues might refine the prognostic value of tumor-infiltrating CD8+ lymphocytes. Using multiplex immunohistochemistry-based image analysis on whole-tissue sections of 214 pancreatic ductal adenocarcinomas, we measured CD8+ cell densities in the tumor center, the tumor margin, and the whole tumor, along with the proximity of CD8+ cells to carcinoma cells. Multivariable Cox regression analysis was performed to assess the associations of CD8+ cell densities with pancreatic cancer-specific survival, adjusting for clinicopathologic and immune-related features, including tumor expressions of TP53, SMAD4, and the programmed cell death 1 ligand 1 (CD274, PD-L1) and the extent of tertiary lymphoid structures. There was substantial heterogeneity in CD8+ cell density, with the mean density in the tumor center less than half that in the tumor margin. Tumor CD274 expression and extensive tertiary lymphoid structures were appeared to be associated with higher CD8+ cell density in the tumor margin (P=0.037 and P=0.005, respectively), but not with that in the tumor center (P&gt;0.50). The association of higher CD8+ cell density with prolonged survival was significant for the whole tumor (Ptrend=0.009); however, the association was stronger for the tumor center (Ptrend=0.002) and insignificant for the tumor margin (Ptrend=0.07). Tumor cell-CD8+ cell distance correlated strongly with CD8+ cell density, whereas the density of CD8+ cells proximate to cancer cells exhibited no prognostic association. In conclusion, spatial computational analysis on pancreatic ductal adenocarcinoma reveals the prognostic validity of CD8+ cell density in the tumor center, where CD8+ cell infiltration is ununiformly restricted, likely suggesting pro-tumorigenic roles of the immunosuppressive tumor microenvironment of pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-019-0291-z" class="uri">https://doi.org/10.1038/s41379-019-0291-z</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Intraductal Papillary Mucinous Neoplasms Arise From Multiple Independent Clones, Each With Distinct Mutations</strong> </summary></p>
<p><em>Gastroenterology 2019 10;157(4):1123-1137.e22</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31175866" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31175866</a></p>
<p>BACKGROUND &amp; AIMS: Intraductal papillary mucinous neoplasms (IPMNs) are lesions that can progress to invasive pancreatic cancer and constitute an important system for studies of pancreatic tumorigenesis. We performed comprehensive genomic analyses of entire IPMNs to determine the diversity of somatic mutations in genes that promote tumorigenesis. METHODS: We microdissected neoplastic tissues from 6-24 regions each of 20 resected IPMNs, resulting in 227 neoplastic samples that were analyzed by capture-based targeted sequencing. Somatic mutations in genes associated with pancreatic tumorigenesis were assessed across entire IPMN lesions, and the resulting data were supported by evolutionary modeling, whole-exome sequencing, and in situ detection of mutations. RESULTS: We found a high prevalence of heterogeneity among mutations in IPMNs. Heterogeneity in mutations in KRAS and GNAS was significantly more prevalent in IPMNs with low-grade dysplasia than in IPMNs with high-grade dysplasia (P &lt; .02). Whole-exome sequencing confirmed that IPMNs contained multiple independent clones, each with distinct mutations, as originally indicated by targeted sequencing and evolutionary modeling. We also found evidence for convergent evolution of mutations in RNF43 and TP53, which are acquired during later stages of tumorigenesis. CONCLUSIONS: In an analysis of the heterogeneity of mutations throughout IPMNs, we found that early-stage IPMNs contain multiple independent clones, each with distinct mutations, indicating their polyclonal origin. These findings challenge the model in which pancreatic neoplasms arise from a single clone. Increasing our understanding of the mechanisms of IPMN polyclonality could lead to strategies to identify patients at increased risk for pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.06.001" class="uri">https://doi.org/10.1053/j.gastro.2019.06.001</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Usefulness of immunohistochemical staining for MUC5AC in differentiating primary pancreatic cancer from pancreatic metastasis of breast cancer</strong> </summary></p>
<p><em>Diagnostic cytopathology 2019 Oct;47(10):1037-1041</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31169985" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31169985</a></p>
<p>Diagnosis of pancreatic ductal adenocarcinoma (PDAC) and its differentiation from metastases to the pancreas from other organs remains challenging. We report a case in which immunohistochemical staining for MUC5AC was useful in distinguishing primary pancreatic cancer from breast cancer metastasis. A 51-year-old Japanese woman who underwent curative resection of her breast cancer was referred to our hospital with a pancreatic head tumor. Although we surmised her pancreatic tumor to be metastatic breast cancer based on her past history and imaging studies, she was subsequently diagnosed with PDAC on the basis of immunohistochemical staining for MUC5AC using specimens obtained by endoscopic ultrasound-fine-needle aspiration. Thus, MUC5AC may be a useful diagnostic marker for discriminating PDAC from a secondary malignancy.</p>
<p>doi: <a href="https://doi.org/10.1002/dc.24249" class="uri">https://doi.org/10.1002/dc.24249</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Genomic landscape of lymphoepithelioma-like hepatocellular carcinoma</strong> </summary></p>
<p><em>The Journal of pathology 2019 Oct;249(2):166-172</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31168847" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31168847</a></p>
<p>Lymphoepithelioma-like hepatocellular carcinoma (LEL-HCC) is a distinct variant of HCC that is characterized by dense tumor-infiltrating lymphocytes (TILs). Patients with LEL-HCC also show better clinical outcomes compared to conventional HCC (c-HCC), which is commonly presented with low TIL. Emerging evidence has begun to highlight tumor-intrinsic genetic abnormalities in the tumor-host immune interfaces. However, genome-wide characterization of LEL-HCC remains largely unexplored. Here, we defined the genomic landscape of 12 LEL-HCC using whole-exome sequencing, and further underpinned those genetic alterations related to an immune active microenvironment by comparing findings to 15 c-HCC that were sequenced in parallel. Overall, the mutational load between LEL-HCC and c-HCC was similar. Interestingly, SNV incidences of specific genes (CTNNB1, AXIN1, NOTCH1, and NOTCH2) were significantly higher in c-HCC than LEL-HCC, suggesting a plausible link between activated Wnt/-catenin and Notch signaling pathways and immune avoidance. Marked focal amplification of chromosome 11q13.3 was prevalent in LEL-HCC. Using The Cancer Genome Atlas dataset, we further established oncogenes expressed from chromosome 11q13.3 (CCND1, FGF19, and FGF4) to be strongly associated with the immune checkpoint signature (CD274, PDCD1, BTLA, CTLA4, HAVCR2, IDO1, and LAG3). Our results have illustrated for the first time the somatic landscape of LEL-HCC, and highlighted molecular alterations that could be exploited in combinatory therapy with checkpoint inhibitors in targeting HCC.  2019 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</p>
<p>doi: <a href="https://doi.org/10.1002/path.5313" class="uri">https://doi.org/10.1002/path.5313</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Multiple KRAS mutations in the non-mucinous epithelial lining in the majority of mucinous cystic neoplasms of the pancreas</strong> </summary></p>
<p><em>Histopathology 2019 Oct;75(4):559-567</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31077597" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31077597</a></p>
<p>AIMS: Mucinous cystic neoplasms (MCNs) of the pancreas are cystic neoplasms lined by mucinous lining epithelium (MLE) with associated ovarian-type stroma. Although a non-MLE (NMLE) can be observed in some MCNs, whether cystic neoplasms with ovarian-type stroma and NMLE should be classified as MCNs or separately designated is debated. METHODS AND RESULTS: To test this, NMLEs were defined as flat or cuboidal epithelial cells without intracytoplasmic mucin. A total of 112 MCNs were reviewed, and the epithelium was classified as NMLE or MLE. A total of 110 females and two males with a mean age of 46.512.3years were included in this study. At least focal NMLE was noted in 76.8% (86/112) of MCNs. The mean percentage of the neoplastic epithelium that was NMLE in these 86 cases was 46%. NMLE was predominant (&gt;50%) in 38.4% (43/112) of cases. MCNs with NMLE were smaller (4221mm) than those with MLE (6036mm, P&lt;0.001), and all NMLEs had low-grade dysplasia. Twelve MCNs with NMLE or MLE were selected for KRAS mutation analysis with droplet digital polymerase chain reaction after laser capture microdissection. All 12 MCNs showed multiple types of KRAS mutation, which were detected in 92% (11/12) of NMLE foci and 89% (8/9) of MLE foci. Predominant NMLE was common in small MCNs with low-grade dysplasia. CONCLUSIONS: Clonal KRAS mutations were observed in both NMLE and MLE, supporting the hypothesis that MCNs with NMLE should be classified as MCNs.</p>
<p>doi: <a href="https://doi.org/10.1111/his.13897" class="uri">https://doi.org/10.1111/his.13897</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Loss of SMAD4 protein expression in gastrointestinal and extra-gastrointestinal carcinomas</strong> </summary></p>
<p><em>Histopathology 2019 Oct;75(4):546-551</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31054158" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31054158</a></p>
<p>AIMS: SMAD4 (DPC4) is a tumour suppressor gene that is dysregulated in various tumour types, particularly pancreaticobiliary and gastrointestinal carcinomas. Corresponding loss of protein expression has been reported in approximately 50% of pancreatic and 25% of colonic adenocarcinomas. In the evaluation of carcinoma of unknown primary site, immunohistochemical loss of SMAD4 expression is often used to suggest pancreaticobiliary origin, but there are limited data on the spectrum of SMAD4 expression in carcinomas of other sites. This study evaluates the frequency of SMAD4 loss in a large cohort of carcinomas from diverse anatomical sites. METHODS AND RESULTS: Immunohistochemistry for SMAD4 was performed on tissue microarrays or whole tissue sections of 1210 carcinomas from various organs: gastrointestinal tract, liver, pancreas/biliary tract, lung, breast, thyroid, kidney, ovary and uterus. Expression was considered lost when there was complete absence of staining in tumour cell nuclei, in the presence of intact staining in non-neoplastic cells. SMAD4 loss was seen in 58% of pancreatic adenocarcinomas, 27% of appendiceal adenocarcinomas, 19% of colorectal adenocarcinomas, 16% of cholangiocarcinomas, 10% of lung adenocarcinomas and &lt;5% of oesophageal, breast, gastric and mucinous ovarian adenocarcinomas. All papillary thyroid, hepatocellular, non-mucinous ovarian, endometrial and renal cell carcinomas showed intact SMAD4 nuclear expression. CONCLUSION: In addition to pancreaticobiliary, appendiceal and colonic tumours, SMAD4 loss is also seen in a small subset of other carcinomas, specifically breast, lung, oesophageal and gastric adenocarcinomas, all of which are typically CK7-positive, similar to pancreaticobiliary carcinoma. Awareness of SMAD4 loss in these other carcinoma types is helpful in the evaluation of carcinomas of unknownor uncertain primary site.</p>
<p>doi: <a href="https://doi.org/10.1111/his.13894" class="uri">https://doi.org/10.1111/his.13894</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>STING signalling protects against chronic pancreatitis by modulating Th17 response</strong> </summary></p>
<p><em>Gut 2019 10;68(10):1827-1837</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30705050" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30705050</a></p>
<p>OBJECTIVE: Chronic pancreatitis (CP) is an inflammatory disease with progressive fibrosis leading to exocrine and endocrine dysfunction. Currently, there are no approved effective therapies for CP. Stimulator of interferon genes (STING) signalling is a key innate immune sensor of DNA. In this study, we evaluated the role of STING signalling in CP. DESIGN: We used an experimental model of CP to test the effect of STING signalling in STING wild-type and knockout mice as well as bone marrow chimaeras (BMCs). STING was activated using a pharmacological agent. Since we found changes in Th17 cells, we used neutralising and control antibodies to determine the role of IL-17A. The effect of STING signalling was further explored in IL-17A generation and we examined the effect of IL-17A on pancreatic stellate cells (PSCs). Human pancreas from patients with CP and without CP were also stained for IL-17A. RESULTS: STING activation decreased CP-associated pancreatic inflammation and fibrosis, whereas absence of STING led to worsening of the disease. BMCs showed that leucocytes play an important role in STING signalling-mediated amelioration of experimental CP. STING deletion was associated with increased Th17 cell infiltration in the pancreas, whereas STING agonist limited this Th17 response. Importantly, anti-IL-17A antibody treatment mitigated the severity of CP in the absence of STING signalling. STING deficiency promoted Th17 polarisation and PSCs express functional IL-17 receptor by upregulating fibrosis genes. Compared with tumour margins, pancreas from patients with CP had significant increase in IL-17A+ cells. CONCLUSION: Unlike acute pancreatitis, STING activation is protective in CP. STING signalling is important in regulating adaptive immune responses by diminishing generation of IL-17A during CP and presents a novel therapeutic target for CP.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2018-317098" class="uri">https://doi.org/10.1136/gutjnl-2018-317098</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Towards optimal pancreatic cyst fluid management: the need for standardisation</strong> </summary></p>
<p><em>Gut 2019 10;68(10):1906</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30301772" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30301772</a></p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2018-317156" class="uri">https://doi.org/10.1136/gutjnl-2018-317156</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Single LAMS versus multigate plastic stent drainage of WON; fair comparison or apples versus oranges?</strong> </summary></p>
<p><em>Gut 2019 10;68(10):1904-1905</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30301769" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30301769</a></p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2018-317387" class="uri">https://doi.org/10.1136/gutjnl-2018-317387</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Immunohistochemical profiling of liver metastases and matched-pair analysis in patients with metastatic pancreatic ductal adenocarcinoma</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Oct;19(7):963-970</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31542399" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31542399</a></p>
<p>BACKGROUND: The purpose of the current study was to investigate the immunohistochemical (IHC) profile of liver metastases (LM) in patients with pancreatic ductal adenocarcinoma (PDAC). METHODS: Expression of 15 IHC markers in liver biopsies from 77 patients with PDAC, who were diagnosed between 2010 and 2014, were evaluated. In a separate subgroup analysis (n=12), paired samples (LM and primary tumor) from the same patient were investigated for IHC profile differences. RESULTS: LM samples were classified as pancreatobiliary-type (PB-type) in 72 patients (93.5%), intestinal-type (INT-type) in four patients (5.2%), and squamous in one patient (1.3%). There was no significant difference in overall survival (OS) between LM of the PB-type or INT-type (p=0.097). In a multivariate analysis, age &lt;70 years (p=0.047), absence of SMAD4 mutation (p=0.026), absence of CDX2 expression (p=0.003), and well to moderate differentiation were significant prognostic factors for better OS in patients with LM (p=0.031). Analysis of paired tissue samples from LM and the primary tumor revealed a difference in CDX2 (50% increase, p=0.125) and SMAD4 (33% loss of SMAD4, p=0.375). CONCLUSIONS: CDX2 expression and SMAD4 mutation indicate a poor outcome in patients with LM of PDAC. Matched-pair analysis revealed differences in distinct IHC marker expression.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.09.005" class="uri">https://doi.org/10.1016/j.pan.2019.09.005</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Preoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: a prospective, phase II, multicentre, single-arm study</strong> </summary></p>
<p><em>BMC cancer 2019 Sep;19(1):922</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31521134" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31521134</a></p>
<p>BACKGROUND: Pancreatic adenocarcinoma is a high-mortality neoplasm with a documented 5-years-overall survival around 5%. In the last decades, a real breakthrough in the treatment of the disease has not been achieved. Here we propose a prospective, phase II, multicentre, single-arm study aiming to assess the efficacy and the feasibility of a therapeutic protocol combining chemotherapy, carbon ion therapy and surgery for resectable and borderline resectable pancreatic adenocarcinoma. METHOD: The purpose of this trial (PIOPPO Protocol) is to assess the efficacy and the feasibility of 3cycles of FOLFIRINOX neoadjuvant chemotherapy followed by a short-course of carbon ion radiotherapy (CIRT) for resectable or borderline resectable pancreatic adenocarcinoma patients. Primary outcome of this study is the assessment of local progression free survival (L-PFS). The calculation of sample size is based on the analysis of the primary endpoint progression free survival according to Flemings Procedure. DISCUSSION: Very preliminary results provide initial evidence of the feasibility of the combined chemotherapy and CIRT in the neoadjuvant setting for resectable or borderline resectable pancreatic cancer. Completion of the accrual and long term results are awaited to see if this combination of treatment is advisable and will provide the expected benefits. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03822936 registered on January 2019.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6108-0" class="uri">https://doi.org/10.1186/s12885-019-6108-0</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Vaccination for Pancreatic Ductal Adenocarcinoma: A Hard Nut to Crack</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Sep;25(18):5435-5437</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31315885" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31315885</a></p>
<p>No immunotherapy strategy is yet offering consistent results against pancreatic ductal adenocarcinoma. A randomized clinical trial testing repeated immunization with a Listeria monocytogenes-based vaccine encoding for mesothelin in combination with a GM-CSF-transfected allogeneic pancreatic cell vaccine reports no survival benefit for the vaccinated patients.See related article by Le et al., p.5493.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-1753" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-1753</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Effective Delivery of a Microtubule Polymerization Inhibitor Synergizes with Standard Regimens in Models of Pancreatic Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Sep;25(18):5548-5560</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31175095" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31175095</a></p>
<p>PURPOSE: Pancreatic ductal adenocarcinoma (PDA) is a deadly cancer that is broadly chemoresistant, due in part to biophysical properties of tumor stroma, which serves as a barrier to drug delivery for most classical chemotherapeutic drugs. The goal of this work is to evaluate the preclinical efficacy and mechanisms of PTC596, a novel agent with potent anticancer properties in vitro and desirable pharmacologic properties in vivo.Experimental Design: We assessed the pharmacology, mechanism, and preclinical efficacy of PTC596 in combination with standards of care, using multiple preclinical models of PDA. RESULTS: We found that PTC596 has pharmacologic properties that overcome the barrier to drug delivery in PDA, including a long circulating half-life, lack of P-glycoprotein substrate activity, and high systemic tolerability. We also found that PTC596 combined synergistically with standard clinical regimens to improve efficacy in multiple model systems, including the chemoresistant genetically engineered KPC model of PDA. Through mechanistic studies, we learned that PTC596 functions as a direct microtubule polymerization inhibitor, yet a prior clinical trial found that it lacks peripheral neurotoxicity, in contrast to other such agents. Strikingly, we found that PTC596 synergized with the standard clinical backbone regimen gemcitabine/nab-paclitaxel, yielding potent, durable regressions in a PDX model. Moreover, similar efficacy was achieved in combination with nab-paclitaxel alone, highlighting a specific synergistic interaction between two different microtubule-targeted agents in the setting of pancreatic ductal adenocarcinoma. CONCLUSIONS: These data demonstrate clear rationale for the development of PTC596 in combination with standard-of-care chemotherapy for PDA.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-18-3281" class="uri">https://doi.org/10.1158/1078-0432.CCR-18-3281</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Sep;25(18):5493-5502</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31126960" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31126960</a></p>
<p>PURPOSE: Limited options exist for patients with advanced pancreatic cancer progressing after 1 or more lines of therapy. A phase II study in patients with previously treated metastatic pancreatic cancer showed that combining GVAX pancreas (granulocyte-macrophage colony-stimulating factor-secreting allogeneic pancreatic tumor cells) with cyclophosphamide (Cy) and CRS-207 (live, attenuated Listeria monocytogenes expressing mesothelin) resulted in median overall survival (OS) of 6.1 months, which compares favorably with historical OS achieved with chemotherapy. In the current study, we compared Cy/GVAX + CRS-207, CRS-207 alone, and standard chemotherapy in a three-arm, randomized, controlled phase IIb trial. PATIENTS AND METHODS: Patients with previously treated metastatic pancreatic adenocarcinoma were randomized 1:1:1 to receive Cy/GVAX + CRS-207 (arm A), CRS-207 (arm B), or physicians choice of single-agent chemotherapy (arm C). The primary cohort included patients who had failed 2 prior lines of therapy, including gemcitabine. The primary objective compared OS between arms A and C in the primary cohort. The second-line cohort included patients who had received 1 prior line of therapy. Additional objectives included OS between all treatment arms, safety, and tumor responses. RESULTS: The study did not meet its primary efficacy endpoint. At the final study analysis, median OS [95% confidence interval (CI)] in the primary cohort (N = 213) was 3.7 (2.9-5.3), 5.4 (4.2-6.4), and 4.6 (4.2-5.7) months in arms A, B, and C, respectively, showing no significant difference between arm A and arm C [P = not significant (NS), HR = 1.17; 95% CI, 0.84-1.64]. The most frequently reported adverse events in all treatment groups were chills, pyrexia, fatigue, and nausea. No treatment-related deaths occurred. CONCLUSIONS: The combination of Cy/GVAX + CRS-207 did not improve survival over chemotherapy. (ClinicalTrials.gov ID: NCT02004262)See related commentary by Salas-Benito et al., p.5435.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-18-2992" class="uri">https://doi.org/10.1158/1078-0432.CCR-18-2992</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A Semicentennial of Pancreatic Pathology: The Genetic Revolution Is Here, But Dont Throw the Baby Out With The Bath Water!</strong> </summary></p>
<p><em>Human pathology 2019 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31521627" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31521627</a></p>
<p>The last fifty years have witnessed an explosion in our understanding of the pathology of pancreatic diseases. Entities known to exist 50 years ago have been defined more precisely and are now better classified. New entities, previously not recognized, have been discovered and can now be treated. Importantly, new tools have been developed that have unraveled the fundamental biological drivers of a number of pancreatic diseases. Many of these same tools have also been applied clinically, supplementing the tried and true hematoxylin and eosin stained slide with a plethora of new, highly sensitive and specific tests that improve diagnostic accuracy and delineate best treatments. As exciting as these many advances are, our knowledge of pancreatic pathology remains incomplete, and there is much to be learned.</p>
<p>doi: <a href="https://doi.org/10.1016/j.humpath.2019.08.024" class="uri">https://doi.org/10.1016/j.humpath.2019.08.024</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>An Unusual Lung Mass of Heterotopic Pancreatic Tissue in a Neonate With an Elevated Immunoreactive Trypsinogen on Newborn Screen</strong> </summary></p>
<p><em>Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 2019 Sep;():1093526619876820</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31514577" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31514577</a></p>
<p>We present a case of a neonate with tracheoesophageal fistula and esophageal atresia along with a suspicious lung mass who had a false-positive newborn screen for cystic fibrosis due to an elevated serum immunoreactive trypsinogen with an additionally elevated serum lipase. The infants lung mass was found to contain heterotopic pancreatic tissue consisting of acini, ducts, and islet cells, without an associated gastrointestinal duplication cyst. This constellation of congenital abnormalities has not been described in previous literature. Also, this is the first reported case of a neonate with elevated serum pancreatic enzymes in which the underlying etiology was discovered to be heterotopic pancreas.</p>
<p>doi: <a href="https://doi.org/10.1177/1093526619876820" class="uri">https://doi.org/10.1177/1093526619876820</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Two cases of lung neuroendocrine carcinoma with carcinoid morphology</strong> </summary></p>
<p><em>Diagnostic pathology 2019 Sep;14(1):104</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31511024" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31511024</a></p>
<p>BACKGROUND: The category of grade 3 neuroendocrine tumor (NET G3) was newly introduced in the 2017 World Health Organization (WHO 2017) classification of neuroendocrine neoplasms of the pancreas. Pancreatic NET G3 shows a carcinoid-like morphology with high proliferative activity and the prognosis is intermediate between NET G2 and neuroendocrine carcinoma. There is no category corresponding to NET G3 in the current WHO 2015 classification of lung tumors. Herein, we report two cases of lung neuroendocrine carcinoma with carcinoid morphology that correspond to NET G3. CASE PRESENTATION: Case 1: An abnormal chest shadow was detected in a 78-year-old female never-smoker during a routine medical examination. She was asymptomatic. The radiological assessment revealed a mass in the peripheral S4 segment of the right lung. She underwent right middle lobectomy for the mass preoperatively diagnosed as non-small cell lung carcinoma. Postoperative histological examination revealed a neuroendocrine tumor with carcinoid morphology and a mitotic count of 15/2mm2. Case 2: An abnormal chest shadow was detected in a 74-year-old female never-smoker undergoing follow-up for another disease. She was asymptomatic. The radiological assessment revealed a mass in the peripheral S3 segment of the right lung. She underwent right upper lobectomy for the mass suspected to be lung carcinoma. Postoperative histological examination revealed a neuroendocrine tumor with carcinoid morphology with mitotic count of 13/2mm2. Both of these tumors showed carcinoid morphology but with a mitotic count exceeding 10/2mm2; thus, we diagnosed them as small cell lung carcinomas according to the current WHO 2015 classification. CONCLUSIONS: Our tumors occurred in female never-smokers and their histology showed carcinoid morphology without extensive necrosis. Moreover, proliferative abilities of them were extremely low compared to small cell lung carcinoma. The clinical and pathological features of our tumors appeared to be different from those of small cell lung carcinoma. Although there is no category corresponding to NET G3 in the current classification of lung tumors, we consider that our tumors may correspond to NET G3 and identification of this subset is relevant for therapeutic management.</p>
<p>doi: <a href="https://doi.org/10.1186/s13000-019-0886-1" class="uri">https://doi.org/10.1186/s13000-019-0886-1</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Risk evaluation of splenic hilar or splenic artery lymph node metastasis and survival analysis for patients with proximal gastric cancer after curative gastrectomy: a retrospective study</strong> </summary></p>
<p><em>BMC cancer 2019 Sep;19(1):905</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31510966" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31510966</a></p>
<p>BACKGROUND: As splenectomy and spleen-preserving lymphadenectomy are performed only in some proximal gastric cancer patients, it is difficult to identify patients who have undergone radical gastrectomy with or without splenic hilar (No.10) or splenic artery (No.11) lymph node metastases. We aimed to determine the risk factors for No.10 and No.11 lymph node metastases and evaluate the survival significance of No.10 and No.11 lymph node dissection in advanced proximal gastric cancer patients. METHODS: A total of 873 advanced proximal gastric cancer patients who underwent curative gastrectomy with or without splenectomy or pancreaticosplenectomy were analyzed retrospectively. The clinicopathological characteristics of 152 patients who underwent splenectomy or pancreaticosplenectomy were analyzed to determine the risk factors for No.10 and No.11 lymph node metastases. The survival difference between patients with No.10 and No.11 lymph node dissections and those who did not undergo these dissections were compared. RESULTS: Patients with No.10 and No.11 lymph node metastases had very poor prognoses. Tumor invasion of the greater curvature and No.2 and No.4 lymph node metastases were independent risk factors for No.10 and No.11 lymph node metastases. No survival differences were evident between patients with No.10 and No.11 lymph node metastases who underwent No.10 and No.11 lymph node dissections and those who did not undergo these dissections but were at high risks of No.10 and No.11 lymph node metastases. CONCLUSIONS: Splenic hilar or splenic artery lymph node dissection was not associated with increased survival, in proximal gastric cancer patients without direct cancer invasion of the spleen and pancreas, regardless of whether splenectomy, pancreaticosplenectomy, or spleen-preserving lymphadenectomy was performed.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6112-4" class="uri">https://doi.org/10.1186/s12885-019-6112-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Role of Ancillary Testing on Endoscopic US-Guided Fine Needle Aspiration Samples from Cystic Pancreatic Neoplasms</strong> </summary></p>
<p><em>Acta cytologica 2019 Sep;64(1-2):1-12</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31509835" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31509835</a></p>
<p>Pancreatic cysts are increasingly detected on imaging studies. Accurate determination of the cyst type is important to provide appropriate care for the patients. It is also very clear that not one single modality can provide adequate diagnostic information. A multidisciplinary approach is the key to the diagnosis of pancreatic cysts. In this setting, the role of ancillary testing, which includes biochemical testing (carcinoembryonic antigen and amylase levels in the cyst), molecular testing (e.g., KRAS, GNAS, VHL, and CTNB1), and/or immunohistochemical tests are very important to obtain an accurate diagnosis. This review will discuss helpful ancillary tests in common pancreatic cyst neoplasms and how to approach the diagnosis of pancreatic cysts.</p>
<p>doi: <a href="https://doi.org/10.1159/000502372" class="uri">https://doi.org/10.1159/000502372</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Risk and subtypes of secondary primary malignancies in diffuse large B-cell lymphoma survivors change over time based on stage at diagnosis</strong> </summary></p>
<p><em>Cancer 2020 Jan;126(1):189-201</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31509235" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31509235</a></p>
<p>BACKGROUND: Previous studies have shown an increased risk of secondary primary malignancies (SPMs) after diffuse large B-cell lymphoma (DLBCL) treatment. Whether stage of DLBCL at diagnosis affects the subtypes of SPMs that occur has not been previously described. METHODS: The Surveillance, Epidemiology, and End Results database was queried for patients aged &gt;18years diagnosed with primary DLBCL from 1973 to 2010 and categorized by early stage (ES) (stage I-II) or advanced stage (AS) (stage III-IV) disease. Differences in overall and location-specific SPM incidence by stage and time since diagnosis were assessed in 5-year intervals using a Fine-Gray hazards model. Overall survival was compared using the log-rank test. A Cox proportional hazards model was used to assess differences in survival. RESULTS: In total, 26,038 patients with DLBCL were identified, including 14,724 with ES and 11,314 with AS disease. The median follow-up was 13.3years. Overall, 13.0% of patients developed SPM, with a higher but nonsignificantly increased risk of SPM development in those who had ES disease compared with those who had AS disease (14% vs 11.6%; P=.14). During the first 5years after diagnosis, patients who had ES disease had a higher risk of SPM than those who had AS disease, specifically colorectal, pancreas, breast, and prostate SPMs. During the period from 10 to 15years after diagnosis, patients who had AS disease had a higher risk of SPM than those who had ES disease, specifically hematologic SPMs. Development of SPM was found to significantly increase the risk of death regardless of stage at diagnosis. CONCLUSIONS: In this large, population-based study, distinctly different subtypes and temporal patterns of SPM development were identified based on stage of DLBCL at diagnosis. The current study merits consideration of tailored site-specific and time-specific surveillance for patients with DLBCL according to stage and time interval since diagnosis.</p>
<p>doi: <a href="https://doi.org/10.1002/cncr.32513" class="uri">https://doi.org/10.1002/cncr.32513</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Alcohol-dependent effect of PRSS1-PRSS2 haplotype in chronic pancreatitis</strong> </summary></p>
<p><em>Gut 2019 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31506327" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31506327</a></p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2019-319729" class="uri">https://doi.org/10.1136/gutjnl-2019-319729</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cytological appearance of pancreatic cystosis on fine-needle aspiration</strong> </summary></p>
<p><em>Diagnostic cytopathology 2020 Jan;48(1):82-85</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31503419" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31503419</a></p>
<p>A 22-year-old Caucasian male with cystic fibrosis and recently diagnosed insulin-dependent diabetes mellitus underwent magnetic resonance imaging (MRI) and was found to have multiple cystic lesions in the pancreas. Endoscopic ultrasound evaluation revealed multiple macro- and microcystic components without mural nodules. One of the cysts in the body of the pancreas was in clear direct communication with the nondilated main pancreatic duct. Fine-needle aspiration (FNA) of two cysts was performed and showed foamy macrophages and rare ductal as well as acinar cells. Cell blocks showed nonpolarizable pink crystalloid material and small nonlaminated concretions consistent with inspissated secretions. Special stains for chymotrypsin and trypsin highlighted the acinar cells. Periodic acid Schiff, with and without diastase, was negative. Biopsy of the cyst wall showed ductal epithelial cells with underlying fibrotic stroma. This is the first description of the FNA appearance of pancreatic cystosis. We discuss the cytological differential diagnosis of cystic lesions of the pancreas and the biochemical as well as imaging findings used to arrive at the diagnosis.</p>
<p>doi: <a href="https://doi.org/10.1002/dc.24313" class="uri">https://doi.org/10.1002/dc.24313</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Allosteric modulation of -cell M3 muscarinic acetylcholine receptors greatly improves glucose homeostasis in lean and obese mice</strong> </summary></p>
<p><em>Proceedings of the National Academy of Sciences of the United States of America 2019 Sep;116(37):18684-18690</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31451647" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31451647</a></p>
<p>Given the global epidemic in type 2 diabetes, novel antidiabetic drugs with increased efficacy and reduced side effects are urgently needed. Previous work has shown that M3 muscarinic acetylcholine (ACh) receptors (M3Rs) expressed by pancreatic  cells play key roles in stimulating insulin secretion and maintaining physiological blood glucose levels. In the present study, we tested the hypothesis that a positive allosteric modulator (PAM) of M3R function can improve glucose homeostasis in mice by promoting insulin release. One major advantage of this approach is that allosteric agents respect the ACh-dependent spatiotemporal control of M3R activity. In this study, we first demonstrated that VU0119498, a drug known to act as a PAM at M3Rs, significantly augmented ACh-induced insulin release from cultured  cells and mouse and human pancreatic islets. This stimulatory effect was absent in islets prepared from mice lacking M3Rs, indicative of the involvement of M3Rs. VU0119498 treatment of wild-type mice caused a significant increase in plasma insulin levels, accompanied by a striking improvement in glucose tolerance. These effects were mediated by -cell M3Rs, since they were absent in mutant mice selectively lacking M3Rs in  cells. Moreover, acute VU0119498 treatment of obese, glucose-intolerant mice triggered enhanced insulin release and restored normal glucose tolerance. Interestingly, doses of VU0119498 that led to pronounced improvements in glucose homeostasis did not cause any significant side effects due to activation of M3Rs expressed by other peripheral cell types. Taken together, the data from this proof-of-concept study strongly suggest that M3R PAMs may become clinically useful as novel antidiabetic agents.</p>
<p>doi: <a href="https://doi.org/10.1073/pnas.1904943116" class="uri">https://doi.org/10.1073/pnas.1904943116</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Incidental pulmonary embolism in pancreatic ductal adenocarcinoma: Impact of tumor and AJCC stages at initial staging CT</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Oct;19(7):979-984</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31522961" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31522961</a></p>
<p>BACKGROUND/OBJECTIVES: To determine the prevalence of incidental pulmonary embolism (PE) detected during initial staging CT among patients with newly diagnosed pancreatic ductal adenocarcinoma (PDAC) and assess their association with underlying tumor burden. MATERIALS AND METHODS: This retrospective cohort study evaluated staging chest CT scans (2013-2017) to identify PE among patients with treatment nave, biopsy-proven PDAC. Data included age, sex, T stage, AJCC stage, presence/absence of metastases and their location at diagnosis. The association of PE with tumor (T1-T4) and AJCC stage were assessed using Pearson Chi-square and Fischers exact test. A threshold p-value of &lt;0.05 indicated statistical significance. RESULTS: A total of 174 patients (90 female, mean age, 68 years; range: 34-93) were identified, of which 10 patients harbored incidental PE (prevalence, 5.7%). In the PE group, two patients presented with distant metastasis (liver, 20%), while eight patients had T4 tumors (80%). No statistical association was detected between PE and age, sex, and the presence/absence or location of distant metastasis (p=0.065, p=0.59, p=0.687 and p=0.933, respectively). Patients with T4 tumors and higher AJCC stages (stage III/IV) were significantly more likely to present with PE than those with lower T stage (p=0.045) and AJCC stage (stage I/II; p=0.017). CONCLUSION: The prevalence of incidental PE among PDAC patients undergoing initial CT staging is 5.7%. Patients with T4 and AJCC stages III/IV are at higher risk of PE. Caution should be exercised during radiographic interpretation of initial staging chest CTs, as incidental PE may be lurking and require treatment.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.09.002" class="uri">https://doi.org/10.1016/j.pan.2019.09.002</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Lavage through percutaneous catheter drains in severe acute pancreatitis: Does it help?A randomized control trial</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Oct;19(7):929-934</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31521496" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31521496</a></p>
<p>AIMS: There is no study comparing large volume lavage through image guided percutaneously placed drains in severe acute pancreatitis. METHODS: Of the 114 randomized patients, 60 eligible candidates were randomly allocated to - Lavage Treatment (LT) group (28 patients) and Dependent Drainage (DD) group (32 patients). Primary end point was reversal of pre-existing organ failure, development of new onset organ failure, need for surgery, mortality and hospital stay. RESULTS: Both the groups were comparable in terms of demographic data, onset and severity of pancreatitis. LT group had higher infected pancreatic necrosis (75% vs 50%,p=0.047). On intention to treat analysis, lavage treatment group showed a significant reversal of persistent organ failure (84% vs 50%, p=0.23), reduction in APACHEII scores (3.53.405 vs 1.163.811 p=0.012), as measured at the time of placement of PCD to cessation of intervention. There was no difference in development of new onset organ failure in the two groups (25% vs37.5% p=.290). 75% in LT group and 69% in DD group improved with PCD alone. There was no difference in the catheter related complications and number of catheters used. The need for surgical intervention was comparable in two groups (18.8% vs 14.3% p=.737). There was a trend toward decreased mortality in group A (18.8% vs 28.8% p=.370). CONCLUSION: Large volume lavage trough PCD improves organ failure and this translates into trend towards reduced mortality.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.09.003" class="uri">https://doi.org/10.1016/j.pan.2019.09.003</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Psychometric performance of the PAncreatic CAncer disease impact (PACADI) score</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Oct;19(7):971-978</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31530448" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31530448</a></p>
<p>BACKGROUND/OBJECTIVE: Pancreatic Cancer Disease Impact (PACADI) score measures the impact of pancreatic cancer (PC) on important health dimensions, selected by patients. The aim of this single center study was to test the psychometric performance of the Pancreatic Cancer Disease Impact (PACADI) score. METHODS: Patients with suspected pancreatic cancer (PC) completed PACADI, the EuroQol-5D (EQ-5D index) and Edmonton Symptom Assessment System (ESAS) in this longitudinal observational study. Measures were compared across patients with PC (n=210), other malignant lesions (OML) (n=109) and non-malignant lesions (NML) (n=41). Associations, test-retest and internal consistency reliability, longitudinal changes, sensitivity to change and prediction of mortality during the first year were examined in patients with PC. RESULTS: The three measures discriminated between PC and OML. The PACADI score correlated strongly at baseline (n=199)/after three months (n=85) with the EQ-5D index and ESAS sense of well-being (0.64 and 0.66/0.73 and 0.69, p&lt;0.001, respectively), showed high test-retest reliability (ICC 0.84) and very good internal consistency reliability (Cronbachs alpha 0.81-0.85) across all visits. Scores improved over time at 3, 6, 9 and 12 months for survivors, and standardized response mean (SRM) for improvement between 2 and 3 months (n=44) was 0.80 (PACADI),-0.59 (EQ-5D index) and 0.69 (ESAS sense of well-being). The PACADI score significantly predicted mortality within the first year (p=0.02) in contrast to the EQ-5D index and ESAS sense of well-being. CONCLUSION: This study showed satisfactory psychometric performance of the PACADI score. The results support its use in clinical practice and intervention trials.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.09.001" class="uri">https://doi.org/10.1016/j.pan.2019.09.001</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel</strong> </summary></p>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31485011" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31485011</a></p>
<p>Localized malignant mesotheliomas (LMM) is an uncommon and poorly recognized neoplasm. Its pathologic diagnosis is often surprising in patients with serosal/subserosal based localized tumors that are clinically suspicious for metastatic lesions or primary sarcomas. Once a tumor is diagnosed as mesothelioma, LMM is often mistaken for diffuse malignant mesothelioma (DMM). Best currently available evidence about LMM was collected from the literature and cases diagnosed by members of the International Mesothelioma Panel (IMP). One hundred and one (101) LMM have been reported in the English literature. Patients had localized tumors with identical histopathologic features to DMM. Patients ranged in age from 6 to 82 years; 75% were men. Most (82%) of the tumors were intrathoracic. Others presented as intrahepatic, mesenteric, gastric, pancreatic, umbilical, splenic, and abdominal wall lesions. Tumors varied in size from 0.6 to 15cm. Most patients underwent surgical resection and/or chemotherapy or radiation therapy. Median survival in a subset of patients was 29 months. Seventy two additional LMM from IMP institutions ranged in age from 28 to 95 years; 58.3% were men. Sixty tumors (83.3%) were intrathoracic, others presented in intraabdominal sites. Tumors varied in size from 1.2 to 19cm. Median survival for 51 cases was 134 months. Best evidence was used to formulate guidelines for the diagnosis of LMM. It is important to distinguish LMM from DMM as their treatment and prognosis is different. A multidisciplinary approach is needed for the diagnosis of LMM as it shows identical histopathology and immunophenotype to DMM.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-019-0352-3" class="uri">https://doi.org/10.1038/s41379-019-0352-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Altered Gene Expression along the Glycolysis-Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31481506" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31481506</a></p>
<p>PURPOSE: Identification of clinically actionable molecular subtypes of pancreatic ductal adenocarcinoma (PDAC) is key to improving patient outcome. Intertumoral metabolic heterogeneity contributes to cancer survival and the balance between distinct metabolic pathways may influence PDAC outcome. We hypothesized that PDAC can be stratified into prognostic metabolic subgroups based on alterations in the expression of genes involved in glycolysis and cholesterol synthesis. EXPERIMENTAL DESIGN: We performed bioinformatics analysis of genomic, transcriptomic, and clinical data in an integrated cohort of 325 resectable and nonresectable PDAC. The resectable datasets included retrospective The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) cohorts. The nonresectable PDAC cohort studies included prospective COMPASS, PanGen, and BC Cancer Personalized OncoGenomics program (POG). RESULTS: On the basis of the median normalized expression of glycolytic and cholesterogenic genes, four subgroups were identified: quiescent, glycolytic, cholesterogenic, and mixed. Glycolytic tumors were associated with the shortest median survival in resectable (log-rank test P = 0.018) and metastatic settings (log-rank test P = 0.027). Patients with cholesterogenic tumors had the longest median survival. KRAS and MYC-amplified tumors had higher expression of glycolytic genes than tumors with normal or lost copies of the oncogenes (Wilcoxon rank sum test P = 0.015). Glycolytic tumors had the lowest expression of mitochondrial pyruvate carriers MPC1 and MPC2. Glycolytic and cholesterogenic gene expression correlated with the expression of prognostic PDAC subtype classifier genes. CONCLUSIONS: Metabolic classification specific to glycolytic and cholesterogenic pathways provides novel biological insight into previously established PDAC subtypes and may help develop personalized therapies targeting unique tumor metabolic profiles.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-1543" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-1543</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comparison of the clinicopathological features of pancreatic solid pseudopapillary neoplasms between males and females: gender does matter</strong> </summary></p>
<p><em>Histology and histopathology 2019 Sep;():18156</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31478554" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31478554</a></p>
<p>BACKGROUND: Solid pseudopapillary neoplasms (SPN) of the pancreas are a rare and low-grade malignant entity with a female predominance. However, it also occurs in males, but the rarity and lack of concern makes its clinicopathological features unclarified. METHODS: The morphological, immunohistochemical, prognostic features and CTNNB1 exon 3 mutation status of SPN were compared semi-quantitively between 9 male and 21 female patients. RESULTS: SPN in males grew in a distinctive solid pattern, with abundant fibrotic stroma and clear cells. Collagen tended to be the main component of tumor stroma in males, while hyaluronan composed a considerable proportion in females. A much stronger expression of androgen receptor (AR) was found in males, and CD56 and/or synaptophysin (Syn) was expressed frequently in both genders. All patients survived. One male patient had post-operational liver nodules and accepted interventional therapy without biopsy. Mutations of CTNNB1 exon 3 were observed in all cases, distributed at codon 32, 33 and 37 in both genders, as well as 34, 41 and 62 in females. CONCLUSION: SPN in males presented with significantly different morphological features from that in females, which might be helpful in differential diagnosis, especially when with extensive positivity for CD56 and/or Syn. The stronger expression of AR in males might be a clue to explore the underlying mechanism of the gender difference.</p>
<p>doi: <a href="https://doi.org/10.14670/HH-18-156" class="uri">https://doi.org/10.14670/HH-18-156</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers</strong> </summary></p>
<p><em>Pathology oncology research : POR 2019 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31478179" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31478179</a></p>
<p>In preclinical studies serotonin stimulates and dopamine inhibits tumour growth and angiogenesis. Information regarding serotonin and dopamine receptor (5-HTR and DRD) expression in human cancers is limited. Therefore, we screened a large tumour set for receptor mRNA overexpression using functional genomic mRNA (FGmRNA) profiling, and we analysed protein expression and location of 5-HTR1B, 5-HTR2B, DRD1, and DRD2 with immunohistochemistry in different tumour types. With FGmRNA profiling 11,756 samples representing 43 tumour types were compared to 3,520 normal tissue samples to analyse receptor overexpression. 5-HTR2B overexpression was present in many tumour types, most frequently in uveal melanomas (56%). Receptor overexpression in rare cancers included 5-HTR1B in nasopharyngeal carcinoma (17%), DRD1 in ependymoma (30%) and synovial sarcoma (21%), and DRD2 in astrocytoma (13%). Immunohistochemistry demonstrated high 5-HTR2B protein expression on melanoma and gastro-intestinal stromal tumour cells and endothelial cells of colon, ovarian, breast, renal and pancreatic tumours. 5-HTR1B expression was predominantly low. High DRD2 protein expression on tumour cells was observed in 48% of pheochromocytomas, and DRD1 expression ranged from 14% in melanoma to 57% in renal cell carcinoma. In conclusion, 5-HTR1B, 5-HTR2B, DRD1, and DRD2 show mRNA overexpression in a broad spectrum of common and rare cancers. 5-HTR2B protein is frequently highly expressed in human cancers, especially on endothelial cells. These findings support further investigation of especially 5HTR2B as a potential treatment target.</p>
<p>doi: <a href="https://doi.org/10.1007/s12253-019-00734-w" class="uri">https://doi.org/10.1007/s12253-019-00734-w</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Design of an immunohistochemistry biomarker panel for diagnosis of pancreatic adenocarcinoma</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Sep;19(6):842-849</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31445888" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31445888</a></p>
<p>BACKGROUND: Challenges still exist in differentiating pancreatic adenocarcinoma from benign disease. The use of adjuvant testing of tissue biopsies has demonstrated potential diagnostic value. We designed a proof of concept study to first validate four individual immunohistochemistry biomarkers and then combine them into a panel to boost overall diagnostic sensitivity. METHODS: Malignant and benign pancreas from 27 pancreaticoduodenectomy specimens underwent immunohistochemistry staining with VHL, IMP3, S100A4, S100P. Using ROC curve analysis, threshold criteria for number of cells staining were chosen for each biomarker. Biomarkers were then evaluated as a panel for their ability to discriminate malignant from benign specimens. RESULTS: Diagnostic sensitivity of VHL, IMP3, S100A4, and S100P were 75.0%, 79.2%, 45.8%, and 0%. When VHL, IMP3, and S100A4 were grouped into a panel, they were able to distinguish cancer from normal tissue with a sensitivity of 100% and a specificity of 96%. CONCLUSIONS: The high diagnostic value of an IHC panel consisting of VHL, IMP3, and S100A4 on surgical specimens suggests the need for future prospective studies of these biomarkers on biopsy specimens.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.08.007" class="uri">https://doi.org/10.1016/j.pan.2019.08.007</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma</strong> </summary></p>
<p><em>Proceedings of the National Academy of Sciences of the United States of America 2019 Sep;116(36):17990-18000</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31439820" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31439820</a></p>
<p>Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are an established treatment in estrogen receptor-positive breast cancer and are currently in clinical development in melanoma, a tumor that exhibits high rates of CDK4 activation. We analyzed melanoma cells with acquired resistance to the CDK4/6 inhibitor palbociclib and demonstrate that the activity of PRMT5, a protein arginine methyltransferase and indirect target of CDK4, is essential for CDK4/6 inhibitor sensitivity. By indirectly suppressing PRMT5 activity, palbociclib alters the pre-mRNA splicing of MDM4, a negative regulator of p53, leading to decreased MDM4 protein expression and subsequent p53 activation. In turn, p53 induces p21, leading to inhibition of CDK2, the main kinase substituting for CDK4/6 and a key driver of resistance to palbociclib. Loss of the ability of palbociclib to regulate the PRMT5-MDM4 axis leads to resistance. Importantly, combining palbociclib with the PRMT5 inhibitor GSK3326595 enhances the efficacy of palbociclib in treating naive and resistant models and also delays the emergence of resistance. Our studies have uncovered a mechanism of action of CDK4/6 inhibitors in regulating the MDM4 oncogene and the tumor suppressor, p53. Furthermore, we have established that palbociclib inhibition of the PRMT5-MDM4 axis is essential for robust melanoma cell sensitivity and provide preclinical evidence that coinhibition of CDK4/6 and PRMT5 is an effective and well-tolerated therapeutic strategy. Overall, our data provide a strong rationale for further investigation of novel combinations of CDK4/6 and PRMT5 inhibitors, not only in melanoma but other tumor types, including breast, pancreatic, and esophageal carcinoma.</p>
<p>doi: <a href="https://doi.org/10.1073/pnas.1901323116" class="uri">https://doi.org/10.1073/pnas.1901323116</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>AZD1775 plus chemoradiotherapy for pancreatic cancer</strong> </summary></p>
<p><em>The Lancet. Oncology 2019 Sep;20(9):e472</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31427207" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31427207</a></p>
<p>doi: <a href="https://doi.org/10.1016/S1470-2045(19)30537-6" class="uri">https://doi.org/10.1016/S1470-2045(19)30537-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Acute Pancreatitis Associated With Myotonic Dystrophy Type I</strong> </summary></p>
<p><em>Pancreas 2019 Sep;48(8):e63-e64</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31425487" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31425487</a></p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001366" class="uri">https://doi.org/10.1097/MPA.0000000000001366</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Minimally Invasive Treatment for Severe Acute Pancreatitis With Superior Mesenteric Vein and Common Bile Duct Stenosis: A Case Report and Review of the Literature</strong> </summary></p>
<p><em>Pancreas 2019 Sep;48(8):e61-e63</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31425486" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31425486</a></p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001379" class="uri">https://doi.org/10.1097/MPA.0000000000001379</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Clinical Utility of Cytokine Biomarker Analysis of Pancreatic Cyst Fluid Obtained by Endoscopic Ultrasound Fine Needle Aspiration: A Pilot Study</strong> </summary></p>
<p><em>Pancreas 2019 Sep;48(8):e60-e61</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31425485" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31425485</a></p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001365" class="uri">https://doi.org/10.1097/MPA.0000000000001365</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cigarette Smoking and Mortality in Patients With Pancreatic Cancer: A Systematic Review and Meta-analysis</strong> </summary></p>
<p><em>Pancreas 2019 Sep;48(8):985-995</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31425484" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31425484</a></p>
<p>Current evidence on cigarette smoking associated with pancreatic cancer mortality is limited. We searched MEDLINE, Web of Science, and Embase databases to identify relevant studies published through January 31, 2018. A random-effects model was used to estimate summary hazard ratios (HRs) and 95% confidence intervals (CIs). A total of 20 studies were retrieved, involving 2,517,623 participants. Of these, more than 15,341 patients with pancreatic cancer died. Compared with never smokers, current (summary HR, 1.56; 95% CI, 1.34-1.83) and former (summary HR, 1.15; 95% CI, 1.06-1.26) smokers had elevated risk of total mortality in patients diagnosed with pancreatic cancer. This effect of cigarette smoking is observed both in the Western regions and the Asia-Pacific regions. This effect of smoking is independent of alcohol use, body mass index, and history of diabetes but is modified by tumor stage and study settings. Dose-response associations between smoking and pancreatic cancer mortality were revealed for smoking intensity, cumulative amount of cigarettes smoked, and duration of smoking. Cigarette smoking was associated with an increase in total mortality for patients with pancreatic cancer. Future studies should further clarify the role of smoking as an effect modifier in treatment trials of pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001383" class="uri">https://doi.org/10.1097/MPA.0000000000001383</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A Qualitative Review of Neoadjuvant Chemotherapy in Resectable Pancreatic Adenocarcinoma</strong> </summary></p>
<p><em>Pancreas 2019 Sep;48(8):973-984</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31425483" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31425483</a></p>
<p>The aim of this study was to evaluate outcomes of patients with resectable pancreatic adenocarcinoma (PDAC) who underwent neoadjuvant chemotherapy. The MEDLINE and PubMed databases were searched to identify relevant original articles investigating neoadjuvant therapy in resectable PDAC. Qualitative analyses were performed to investigate patient selection, disease stage, impact on perioperative outcomes, and cost-effectiveness. Forty-three studies met inclusion criteria for this review. Neoadjuvant chemotherapy for upfront resectable PDAC is cost-effective, safe, may result in lower stage disease and has potential survival advantages. With proper patient selection, neoadjuvant chemotherapy is an appropriate approach for upfront resectable PDAC. Nevertheless, the risk for disease progression and losing a curative surgical window highlights the need for appropriate patient identification, further discovery of superior biomarkers or molecular profiles representative of positive treatment response, and additional prospective comparative study.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001376" class="uri">https://doi.org/10.1097/MPA.0000000000001376</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Management of Diarrhea in Patients With Carcinoid Syndrome</strong> </summary></p>
<p><em>Pancreas 2019 Sep;48(8):961-972</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31425482" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31425482</a></p>
<p>Neuroendocrine tumors (NETs) arise from enterochromaffin cells found in neuroendocrine tissues, with most occurring in the gastrointestinal tract. The global incidence of NETs has increased in the past 15 years, likely due to better diagnostic methods. Small-bowel NETs are frequently associated with carcinoid syndrome (CS). Carcinoid syndrome diarrhea occurs in 80% of CS patients and poses a substantial symptomatic and economic burden. Patients with CS diarrhea frequently suffer from diarrhea and flushing and report corresponding impairment in quality of life, requiring substantial changes in daily activities and lifestyle. Treatment paradigms range from surgical debulking to liver-directed therapies to treatment with somatostatin analogs, nonspecific anti-diarrheal agents, and a tryptophan hydroxylase inhibitor. Other causes of diarrhea, including steatorrhea, short bowel syndrome, and bile acid malabsorption, should be considered in NET patients with refractory diarrhea. More therapeutic options are needed for symptomatic management of patients with NETs, and better understanding of the pathophysiology can empower clinicians with improved patient care.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001384" class="uri">https://doi.org/10.1097/MPA.0000000000001384</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Long-term outcomes of therapeutic ERCP in pediatric patients with pancreas divisum presenting with acute recurrent or chronic pancreatitis</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Sep;19(6):834-841</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31421974" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31421974</a></p>
<p>OBJECTIVES: The aim of this study was to evaluate the long-term outcomes of therapeutic endoscopic retrograde cholangiopancreatography (ERCP) for pediatric patients with pancreas divisum (PD) presenting with acute recurrent pancreatitis (ARP) or chronic pancreatitis (CP). METHODS: Between May 2008 and August 2017, pediatric patients with PD who received endotherapy at Ruijin Hospital were identified and grouped according to clinical presentation, namely ARP and CP. Primary success was defined as patients improvement in symptoms after index ERCPs, without further intervention or any analgesic. RESULTS: A total of 74 ERCPs were performed in 38 pediatric patients. The frequency of at least 1 genetic mutation identified in patients with ARP and CP was 44.4% and 68.4%, respectively. Patients with CP required more ERCPs than those with ARP (2.41.7 vs.1.10.4, P=0.005). The incidence of post-ERCP complications was 14.9%, including pancreatitis of 13.5% and hemorrhage of 1.4%. During a median follow-up duration of 41 months (range, 12-123 months), the frequency of pancreatitis episodes decreased significantly from 2.31 to 0.45 (P&lt;0.0001). The 25% recurrence and reintervention rates were estimated at 25 and 48 months, respectively, without significant difference between patients with ARP or CP. There was a nonsignificant trend towards a higher rate of primary success in patients with ARP than those with CP (92.9% vs.69.6%, P=0.123). After further endotherapy, 91.3% patients with CP improved clinically. CONCLUSIONS: Therapeutic ERCP is an effective and safe intervention for pediatric patients with symptomatic PD. Patients presenting with CP seem to achieve improvement after additional ERCPs.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.08.004" class="uri">https://doi.org/10.1016/j.pan.2019.08.004</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cell phenotypic plasticity requires autophagic flux driven by YAP/TAZ mechanotransduction</strong> </summary></p>
<p><em>Proceedings of the National Academy of Sciences of the United States of America 2019 Sep;116(36):17848-17857</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31416916" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31416916</a></p>
<p>Autophagy, besides ensuring energy metabolism and organelle renewal, is crucial for the biology of adult normal and cancer stem cells. However, it remains incompletely understood how autophagy connects to stemness factors and the nature of the microenvironmental signals that pattern autophagy in different cell types. Here we advance in these directions by reporting that YAP/TAZ transcriptionally control autophagy, being critical for autophagosomal degradation into autolysosomes. YAP/TAZ are downstream effectors of cellular mechanotransduction and indeed we found that cell mechanics, dictated by the physical property of the ECM and cytoskeletal tension, profoundly impact on autophagic flux in a YAP/TAZ-mediated manner. Functionally, by using pancreatic and mammary organoid cultures, we found that YAP/TAZ-regulated autophagy is essential in normal cells for YAP/TAZ-mediated dedifferentiation and acquisition of self-renewing properties. In tumor cells, the YAP/TAZ-autophagy connection is key to sustain transformed traits and for acquisition of a cancer stem cell state by otherwise more benign cells. Mechanistically, YAP/TAZ promote autophagic flux by directly promoting the expression of Armus, a RAB7-GAP required for autophagosome turnover and whose add-back rescues autophagy in YAP/TAZ-depleted cells. These findings expand the influence of YAP/TAZ mechanotransduction to the control of autophagy and, vice versa, the role of autophagy in YAP/TAZ biology, and suggest a mechanism to coordinate transcriptional rewiring with cytoplasmic restructuring during cell reprogramming.</p>
<p>doi: <a href="https://doi.org/10.1073/pnas.1908228116" class="uri">https://doi.org/10.1073/pnas.1908228116</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The applications of metabolomics in the molecular diagnostics of cancer</strong> </summary></p>
<p><em>Expert review of molecular diagnostics 2019 Sep;19(9):785-793</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31414918" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31414918</a></p>
<p>Introduction: Metabolomics, the study of metabolites, is a promising research field for cancers. The metabolic pathway in a tumor cell is different from a normal tissue cell. There are two approaches to study the metabolism, targeted and untargeted. The general approach is that metabolomic data are interpreted by bioinformatics tools correlating with metabolomic databases to obtain significant findings. With the use of specific analysis tools, such as nuclear magnetic resonance (NMR) and mass spectrometer (MS) combined with chromatography, metabolic profile or metabolic fingerprint of various biological specimens could be obtained. The applications of metabolomics are used to discover potential cancer biomarkers and monitor the metastatic state, therapeutic and drug response for better patient management. Areas covered: In this review, the author introduce metabolomics and discuss the use of metabolomics approaches in different cancers, including the study of colorectal cancer, prostate cancer, liver cancer, pancreatic cancer and breast cancer using NMR and MS. Expert opinion: Knowledge on the molecular basis of cancer metabolism and its potential clinical applications has been improving recently. However, there are still many challenges for the technological development and integration of metabolomics with other omics spaces such as genomics. In the near future, it is expected that metabolomics will play an important role in cancer molecular diagnostics.</p>
<p>doi: <a href="https://doi.org/10.1080/14737159.2019.1656530" class="uri">https://doi.org/10.1080/14737159.2019.1656530</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Prognostic significance of neutrophil-lymphocyte ratio in resectablepancreatic neuroendocrine tumors with special referenceto tumor-associated macrophages</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Sep;19(6):897-902</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31409525" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31409525</a></p>
<p>BACKGROUND: Recent studies have shown that the systemic inflammatory response induced by cancer leads to cancer progression. Neutrophil-to-lymphocyte ratio (NLR) is the most reliable marker to detect systemic inflammation. In this study, we investigated the significance of NLR in patients with well-differentiated pancreatic neuroendocrine tumors (PanNETs) according to the World Health Organization 2017 classification. METHODS: We retrospectively collected data for patients with PanNET who underwent pancreatic resection with curative intent between January 2008 and December 2017at six institutions. Clinicopathological factors, recurrence, and immunohistochemical staining of tumor-associated macrophages (TAMs) were analyzed in a total of 55 patients in this study. RESULTS: High NLR (&gt;3.41) in patients was significantly associated with higher white blood cell count, higher Ki-67 index, higher mitotic count, higher grade, higher incidence of lymph node metastasis, higher incidence of lymphatic and neural invasion, massive blood loss, and a large number of CD163-expressing TAMs. Recurrence-free survival of patients with high NLR was significantly poorer than that of patients with low NLR. Multivariate analysis identified high NLR, NET Grade 2 (G2) or Grade 3 (G3), and synchronous hepatic resection as independent risk factors for recurrence after curative resection. CONCLUSIONS: NLR is a promising predictor of recurrence after pancreatectomy that needs to be further investigated and that accumulation of TAMs in the tumor could be one of the causes of NLR elevation.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.08.003" class="uri">https://doi.org/10.1016/j.pan.2019.08.003</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Inflammation Promotes Progression of Pancreatic Cancer Through WNT/-Catenin Pathway-Dependent Manner</strong> </summary></p>
<p><em>Pancreas 2019 Sep;48(8):1003-1014</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404031" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404031</a></p>
<p>OBJECTIVE: Identify the molecular mechanism of inflammatory stimuli induced pancreatic cancer progression. METHODS: RNA-seq, microarray assay and bioinformatics analyses were used to identify differentially expressed genes. Immunohistochemical staining was performed to evaluate CD68, CD163, -catenin, CD103, CCL3 markers. Quantitative real-time polymerase chain reaction (qRT-PCR), luciferase reporter assay, apoptosis assay, wound healing assay and immunofluorescence were performed to study the relationship of inflammatory stimuli and WNT/-catenin pathway. RESULTS: Differentially expressed genes of macrophage-conditioned medium-treated pancreatic cancer cells were related with WNT/-catenin pathway. Inflammatory stimuli could activate WNT/-catenin signaling pathway. In 106 pancreatic cancer patients, nuclear -catenin expression of CD68-high group was much higher than CD68-low group (P &lt; 0.05), as same as CD163 (P &lt; 0.05). Inflammatory stimuli downregulated the expression of CCL3 via WNT/-catenin pathway and inhibited the chemotaxis of CD103 dendritic cells. Six pancreatic cancer prognosis associating genes were upregulated by inflammatory stimuli via WNT/-catenin pathway. Transforming growth factor- promoted malignant biological behavior of pancreatic cancer cells through WNT/-catenin pathway-dependent mechanism. CONCLUSIONS: Our present study provided a novel mechanism involved in the inflammation-driven cancer progression through tumor immune escape and downstream gene regulation of WNT/-catenin pathway-dependent manner.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001386" class="uri">https://doi.org/10.1097/MPA.0000000000001386</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Detection of Reg3 by Immunohistochemistry in Cerulein-Induced Model of Acute Pancreatic Injury in Mice and Rats</strong> </summary></p>
<p><em>Pancreas 2019 Sep;48(8):1015-1025</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404030" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404030</a></p>
<p>OBJECTIVE: In a continuation of previous work, Reg3 protein was further evaluated as a biomarker of pancreatic injury using immunohistochemistry in an additional species. METHODS: Mice and rats were treated with intraperitoneal cerulein injections, creating acute pancreatic injury. Mice received 2, 4, or 6 doses, and rats received 1, 2, or 3 doses of cerulein creating low, medium, and high treatment groups. Control animals were dosed with phosphate-buffered saline at corresponding volumes and intervals. Groups of 6 animals were killed 1, 3, 6, 24, and 48 hours after final treatments. Reg3 immunohistochemical staining and image analysis were performed on pancreatic tissue obtained 6, 24, or 48 hours after control or cerulein treatment. Staining was quantified using image analysis software to calculate area of positivity as a percentage of total tissue area. RESULTS: Percent positivity of Reg3 in both species rose by 6 hours, peaked by 24 hours across all 3 cerulein doses, and dropped significantly by 48 hours. In high-dose rats with accompanying gene expression data, Reg3 gene expression corresponded temporally with quantitative staining data. CONCLUSIONS: Reg3 staining quantified through image analysis showed a time- and dose-response in cerulein-treated mice and rats.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001382" class="uri">https://doi.org/10.1097/MPA.0000000000001382</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreatic Function in Chronic Pancreatitis: A Cohort Study Comparing 3 Methods of Detecting Fat Malabsorption and the Impact of Short-term Pancreatic Enzyme Replacement Therapy</strong> </summary></p>
<p><em>Pancreas 2019 Sep;48(8):1068-1078</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404029" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404029</a></p>
<p>OBJECTIVES: Reliable pancreatic function tests in patients with chronic pancreatitis (CP) are needed. This cohort study identified malabsorption in people with CP compared with healthy people and then investigated short-term pancreatic enzyme replacement therapy (PERT) and fat malabsorption, nutritional status, and quality of life (QOL). METHODS: Subjects with CP were evaluated before and after PERT and compared with the healthy cohort using coefficient of fat absorption (CFA), stool bomb calorimetry, and the malabsorption blood test (MBT). Anthropometrics, micronutrients, and QOL data were collected. Group means at baseline and after PERT were analyzed. RESULTS: The 24 subjects with CP had greater stool energy loss (5668 cal/g [standard deviation {SD}, 753] vs 5152 cal/g [SD, 418], P &lt; 0.01), reduced triglyceride absorption (MBT, 8.3 mgh/dL [SD, 4.3] vs 17.7 mgh/dL [SD, 10.3], P &lt; 0.001), lower fat intake, and poorer QOL. Differences in CFA were not significant (90.9% [SD, 12.8] vs 95.4% [SD, 9.3]). After PERT, triglyceride absorption ( = 1.7 [SD, 3], P &lt; 0.05) and QOL increased. CONCLUSIONS: The MBT detected changes in triglyceride absorption in the absence of CFA changes. The MBT may be helpful in guiding PERT initiation in patients with CP before significant morbidity.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001381" class="uri">https://doi.org/10.1097/MPA.0000000000001381</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Risk and Outcomes of Clostridium difficile Infection With Chronic Pancreatitis</strong> </summary></p>
<p><em>Pancreas 2019 Sep;48(8):1041-1049</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404028" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404028</a></p>
<p>OBJECTIVES: Chronic pancreatitis (CP) is associated with high rates of recurrent hospitalizations, which predisposes to Clostridium difficile infection (CDI). We investigate the burden of CDI in CP. METHODS: We identified records of patients with CP from the Nationwide Inpatient Sample (NIS) 2012-2014 and estimated the impact of CDI on their outcomes. We calculated the adjusted odds ratio (AOR) of CP on having CDI (NIS 2014). From NIS 2007-2014, we plotted the trends of CDI and its interaction with CP. RESULTS: From 2012 to 2014, 886 (2.72%) of the 32,614 CP patients had concomitant CDI, which was associated with poorer outcomes: acute kidney injury (AOR, 2.57 [95% confidence interval {CI}, 2.11-3.13]), length of stay (13.3 vs 7.4 days), and charges (US $127,496 vs US $72,767), but not mortality (AOR, 0.93 [95% CI, 0.28-3.05]). In 2014, CP was associated with an increased risk of CDI (crude odds ratio, 2.10 [95% CI, 1.95-2.26]), which persisted after multivariate adjustment (AOR, 2.03 [95% CI, 1.87-2.19]). From 2007 to 2014, the annual prevalence of CDI was 106.4 cases per 10,000 hospitalizations, increasing from 2007 (95.5/10,000) to 2014 (118.4/10,000), with a 3.7 times higher annual rate of increase among CP versus no-CP patients (13.4/10,000 vs 3.7/10,000 population/year). CONCLUSIONS: Chronic pancreatitis patients have high burden of CDI and may benefit from CDI prophylaxis.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001380" class="uri">https://doi.org/10.1097/MPA.0000000000001380</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Microbial Contamination, Infection, and Antimicrobial Use During Total Pancreatectomy With Islet Autotransplantation</strong> </summary></p>
<p><em>Pancreas 2019 Sep;48(8):1050-1055</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404027" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404027</a></p>
<p>OBJECTIVES: Total pancreatectomy with islet autotransplantation can relieve pain associated with chronic pancreatitis while preserving islet function. Islet preparations are often contaminated by enteric flora. We assessed the impact of contaminated islet preparations on the prevalence of postoperative infection. METHODS: Electronic health records for patients who underwent total pancreatectomy with islet autotransplantation from August 1, 2011, to November 15, 2017 were retrospectively reviewed to compare the prevalence of postoperative infection in patients with a positive islet culture and islet culture negative patients. RESULTS: Sixty-one patients were included. Twenty-nine patients (47.5%) had a positive islet culture, and 23 (79.3%) of these patients received antimicrobial prophylaxis. The prevalence of postoperative infection did not differ between the islet culture positive and islet culture negative groups (41% vs 34%, P = 0.57). No infections occurred in the 6 islet culture positive patients who did not receive prophylaxis. No difference in intensive care unit or hospital length of stay or in 30-day or 90-day readmission rates were observed. CONCLUSIONS: Despite the common use of postoperative systemic antimicrobials, we observed no difference in the prevalence of postoperative infection, length of stay, or hospital readmission in patients receiving a contaminated islet preparation. If prophylactic antimicrobials are used, the duration should be minimized.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001378" class="uri">https://doi.org/10.1097/MPA.0000000000001378</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Association Between Pancreatic Cystic Lesions and High-grade Intraepithelial Neoplasia and Aging: An Autopsy Study</strong> </summary></p>
<p><em>Pancreas 2019 Sep;48(8):1079-1085</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404026" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404026</a></p>
<p>OBJECTIVES: This study aimed to clarify clinicopathological features of pancreatic cysts. METHODS: Pancreata from 280 autopsies (median, 83 years; male, 146; female, 134) were sectioned every 5 mm. Cysts (&lt;10 mm) were diagnosed as a simple cyst or low-grade, intermediate-grade, or high-grade dysplasia. RESULTS: We found 236 cysts in 93 patients (33.2%). The number and diameter of cysts increased according to the age. Of the 236 cysts, 9 (3.8%) were with high-grade dysplasia. Cysts with high-grade dysplasia arose in the pancreata of older patients with larger numbers of cysts. In contrast, 15 noncystic lesions with high-grade dysplasia were also detected. Hence, in total, 24 high-grade dysplastic lesions in 15 patients (5.4%) were noted. Of the 15 patients with high-grade dysplastic lesions, in 10 patients, the condition was accompanied by pancreatic cysts, whereas 5 patients did not have any cysts in the pancreas; therefore, patients with cyst showed higher incidence of high-grade dysplasia (10.8%; P = 0.0047) than patients without cyst (2.7%). All cysts with high-grade dysplasia were located in the branch duct of the pancreatic head/body, whereas 20% of noncystic lesions with high-grade dysplasia were located in the main pancreatic duct. CONCLUSIONS: Cystic lesions with high-grade dysplasia may have different characteristics compared with noncystic high-grade dysplasia.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001374" class="uri">https://doi.org/10.1097/MPA.0000000000001374</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Treatment Efficacy and Clinical Outcome for Patients With Pancreatic Carcinoma: A Meta-analysis</strong> </summary></p>
<p><em>Pancreas 2019 Sep;48(8):996-1002</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404025" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404025</a></p>
<p>OBJECTIVES: F-Fluorodeoxyglucose positron emission tomography (FDG-PET) has been an important modality for detecting malignancies. Recently, an increasing number of studies reported the utility of FDG-PET parameters in predicting clinical outcomes and treatment assessment in variety of cancers. We aimed at clarifying both the prognostic role and assessment value of FDG-PET in pancreatic carcinoma. METHODS: We systematically searched electronic databases of PubMed, Embase, Cochrane Library, and Web of Science to identify relevant studies to conduct this meta-analysis. Comparative analyses of the pooled hazard ratio (HR) for overall survival were performed to assess the utility of FDG-PET parameters in prognosis evaluation and treatment assessment by random-effect model. RESULTS: Twenty-three studies with 1762 patients met the inclusion criteria of this meta-analysis. The pooled results revealed that greater maximum standardized uptake value of the primary tumor was significantly correlated with poorer overall survival (HR, 1.31; 95% confidence interval, 1.15-1.50; P &lt; 0.001). Besides, greater reduction of maximum standardized uptake value after treatments indicated significant better overall survival (HR, 0.68; 95% confidence interval, 0.47-0.98; P = 0.037). CONCLUSIONS: F-Fluorodeoxyglucose positron emission tomography parameters might be helpful not only for predicting survival outcome but also for selecting potentially efficacious treatments in patients with pancreatic carcinoma.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001375" class="uri">https://doi.org/10.1097/MPA.0000000000001375</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Time to Adjuvant Systemic Therapy Following Pancreatic Cancer Resection and Effect on Outcome</strong> </summary></p>
<p><em>Pancreas 2019 Sep;48(8):1086-1091</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404024" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404024</a></p>
<p>OBJECTIVES: The appropriate timing of chemotherapy following surgery for resectable pancreatic adenocarcinoma is controversial. Using the National Cancer Database we evaluated time to initiation of chemotherapy postresection and correlated with outcome. METHODS: We identified stage I-III pancreatic adenocarcinoma treated surgically with adjuvant chemoradiotherapy. Receiver operator curve analysis identified an interval of 66 days as the a priori value for largest discrepancy in outcome. Multivariable logistic regression analysis identified variables associated with increased time to chemotherapy postoperatively (&gt;66 days). Propensity matching was performed to account for indication bias. RESULTS: In total, 6873 and 3348 patients received chemotherapy before and after the 66-day cutoff, respectively. Predictors of expedited chemotherapy included lower comorbidity, treatment outside a community program in an urban location, having insurance, white race, and treatment after 2009. Propensity-matched median survival was 21.8 months for all patients, and of these, 6462 were stage 1. Five-year survival was 20% in patients receiving chemotherapy within 66 days and 18% in those not (P = 0.0266). In stage 1 patients, 5-year survival was 23% versus 21% (P = 0.0116) in favor of expedited chemotherapy. CONCLUSIONS: The present propensity-matched analysis showed a significant association with survival for earlier delivery of chemotherapy in the adjuvant setting.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001373" class="uri">https://doi.org/10.1097/MPA.0000000000001373</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreatic Fluid Interleukin-1 Complements Prostaglandin E2 and Serum Carbohydrate Antigen 19-9 in Prediction of Intraductal Papillary Mucinous Neoplasm Dysplasia</strong> </summary></p>
<p><em>Pancreas 2019 Sep;48(8):1026-1031</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404023" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404023</a></p>
<p>OBJECTIVES: We sought to determine if interleukin (IL)-1 and prostaglandin E2 (PGE2) (inflammatory mediators in pancreatic fluid) together with serum carbohydrate antigen (CA) 19-9 could better predict intraductal papillary mucinous neoplasm (IPMN) dysplasia than individual biomarkers alone. METHODS: Pancreatic cyst fluid (n = 92) collected via endoscopy or surgery (2003-2016) was analyzed for PGE2 and IL-1 (enzyme-linked immunosorbent assay). Patients had surgical pathology-proven IPMN. Threshold values (PGE2 [&gt;1100 pg/mL], IL-1 [&gt;20 pg/mL], and serum CA 19-9 [&gt;36 U/mL]) were determined. RESULTS: Levels of IL-1 were higher in high-grade dysplasia (HGD)/invasive-IPMN (n = 42) compared with low/moderate IPMN (n = 37) (median [range], 54.6 [0-2671] vs 5.9 [0-797] pg/mL; P &lt; 0.001; area under curve [AUC], 0.766). Similarly, PGE2 was higher in HGD/invasive IPMN (n = 45) compared with low/moderate IPMN (n = 47) (median [range], 1790 [20-15,180] vs.140 [10-14,630] pg/mL; P &lt; 0.001; AUC, 0.748). Presence of elevated PGE2 and IL-1 (AUC, 0.789) provided 89% specificity and 82% positive predictive value (PPV) for HGD/invasive IPMN. Elevated levels of all 3 provided 100% specificity and PPV for HGD/invasive IPMN. CONCLUSIONS: Cyst fluid PGE2, IL-1, and serum CA 19-9 in combination optimize specificity and PPV for HGD/invasive IPMN and may help build a panel of markers to predict IPMN dysplasia.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001377" class="uri">https://doi.org/10.1097/MPA.0000000000001377</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Etiologic Distribution of Pancreatic Cystic Lesions Identified on Computed Tomography/Magnetic Resonance Imaging</strong> </summary></p>
<p><em>Pancreas 2019 Sep;48(8):1092-1097</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404022" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404022</a></p>
<p>OBJECTIVES: This study aimed to determine the distribution of etiology of pancreatic cysts using established criteria/markers from cyst fluid analysis and cytology that have been reported to have high specificity in published literature. METHODS: A retrospective study of pancreatic cysts using an endoscopic database from March 2002 and May 2013 was conducted. Pancreatic cysts &lt;10 mm and cysts with a history of pancreatic cancer were excluded. RESULTS: In our cohort of 758 patients with pancreatic cyst(s), the cyst etiology was as follows: mucinous cyst/side-branch intraductal papillary mucinous neoplasms (SB-IPMNs)/mucinous cystic neoplasms (MCN; 48.2%), pseudocyst (27.6%), serous cystadenoma (11%), simple cysts (6.4%), mucinous cystadenocarcinoma (5.1%), and other (1%). Approximately 41% (n = 310) of the cysts were 3 cm in size and included the following: pseudocyst (39.7%), mucinous cysts/SB-IPMN/MCN (28.1%), serous cystadenoma (16.7%), mucinous cyst adenocarcinoma (9.7%), and simple cyst (4.8%). In 118 patients with a known history of acute pancreatitis, the cyst diagnoses included pseudocyst (68.7%), mucinous cyst/SB-IPMN/MCN (18.6%), benign/simple cyst (7.6%), and mucinous cystadenocarcinoma (2.5%). CONCLUSIONS: In patients with cystic pancreatic lesion noted on cross-sectional imaging, approximately half of the patients have lesions without malignancy or malignant potential and therefore not requiring surveillance. Endoscopic ultrasound/endoscopic ultrasound-guided fine-needle aspiration evaluation of the pancreatic cysts can help optimize their further management.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001372" class="uri">https://doi.org/10.1097/MPA.0000000000001372</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Mutational Patterns in Pancreatic Juice of Intraductal Papillary Mucinous Neoplasms and Concomitant Pancreatic Cancer</strong> </summary></p>
<p><em>Pancreas 2019 Sep;48(8):1032-1040</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404021" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404021</a></p>
<p>OBJECTIVES: The aims of this study were to identify genetic characteristics of intraductal papillary mucinous neoplasm (IPMN)-associated pancreatic ductal carcinoma (PDC) and to detect these markers using pancreatic juice. METHODS: From 76 cases, 102 tissues were obtained: 29 cases were noninvasive IPMN, 18 were PDC derived from IPMN (D-PDC; noninvasive part, n = 16; invasive part, n = 18), and 29 were PDC concomitant with IPMN (C-PDC; IPMN part, n = 10; PDC part, n = 29). Moreover, pancreatic juice samples from 28 cases were obtained (noninvasive IPMN, n = 13; D-PDC, n = 7; C-PDC, n = 8). Fifty-one cancer-related genes were analyzed by next-generation sequencing. RESULTS: TP53 mutation rates in D-PDC, C-PDC, and noninvasive IPMN were 67%, 66%, and 10%, respectively. Moreover, KRAS mutational patterns between 2 simultaneous tumors differed in 1 (6.3%) of the 16 D-PDC cases and in 8 (80%) of the 10 C-PDC cases (P = 0.0006). TP53 or multiple KRAS mutations were detected using pancreatic juice more frequently in C-PDC cases than in noninvasive IPMN cases (75% and 23%, respectively, P = 0.03). CONCLUSIONS: Multiple KRAS mutations along with TP53 mutation are genetic markers for C-PDC, which could be detected using pancreatic juice preoperatively.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001371" class="uri">https://doi.org/10.1097/MPA.0000000000001371</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>SpHincterotomy for Acute Recurrent Pancreatitis Randomized Trial: Rationale, Methodology, and Potential Implications</strong> </summary></p>
<p><em>Pancreas 2019 Sep;48(8):1061-1067</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404020" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404020</a></p>
<p>OBJECTIVES: In patients with acute recurrent pancreatitis (ARP), pancreas divisum, and no other etiologic factors, endoscopic retrograde cholangiopancreatography (ERCP) with minor papilla endoscopic sphincterotomy (miES) is often performed to enlarge the minor papillary orifice, based on limited data. The aims of this study are to describe the rationale and methodology of a sham-controlled clinical trial designed to test the hypothesis that miES reduces the risk of acute pancreatitis. METHODS: The SpHincterotomy for Acute Recurrent Pancreatitis (SHARP) trial is a multicenter, international, sham-controlled, randomized trial comparing endoscopic ultrasound + ERCP with miES versus endoscopic ultrasound + sham for the management of ARP. A total of 234 consented patients having 2 or more discrete episodes of acute pancreatitis, pancreas divisum confirmed by magnetic resonance cholangiopancreatography, and no other clear etiology for acute pancreatitis will be randomized. Both cohorts will be followed for a minimum of 6 months and a maximum of 48 months. RESULTS: The trial is powered to detect a 33% risk reduction of acute pancreatitis frequency. CONCLUSIONS: The SHARP trial will determine whether ERCP with miES benefits patients with idiopathic ARP and pancreas divisum. Trial planning has informed the importance of blinded outcome assessors and long-term follow-up.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001370" class="uri">https://doi.org/10.1097/MPA.0000000000001370</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Expression of Monocarboxylate Transporter 1 Is Associated With Better Prognosis and Reduced Nodal Metastasis in Pancreatic Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Pancreas 2019 Sep;48(8):1102-1110</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404019" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404019</a></p>
<p>OBJECTIVES: Because lactate is believed to support tumor growth, monocarboxylate transporters (MCTs), which transport lactate, have been investigated in multiple tumors. However, the significance of MCTs in pancreatic cancer is unclear. METHODS: A retrospective survey was conducted on 240 patients who underwent surgical resection for pancreatic ductal adenocarcinoma without preoperative treatment. The expression of MCT1, MCT2, MCT3, MCT4, and the glucose transporter 1 (GLUT1) was assessed in tumor cells and cancer-associated fibroblasts (CAFs) by tissue microarrays and immunohistochemistry. The impact of their expression on patient outcome and clinicopathological characteristics was also analyzed. RESULTS: In tumor cells, MCT1, MCT2, MCT3, MCT4, and GLUT1 were detected in 52 (22%), 31 (13%), 149 (62%), 204 (85%), and 235 (98%) cases, respectively. In CAFs, MCT2, MCT4, and GLUT1 were detected in 9 (3.8%), 178 (74%), and 36 (15%) cases, respectively. In tumor cells, MCT1 expression was associated with extended overall and progression-free survival and decreased nodal metastasis. Conversely, MCT4 expression in CAFs was associated with shortened survival. CONCLUSIONS: In tumor cells, MCT1 expression is associated with better prognosis and reduced nodal metastasis in pancreatic cancer, contrary to findings of past in vitro studies. Conversely, MCT4 expression in CAFs is indicative of worse prognosis.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001369" class="uri">https://doi.org/10.1097/MPA.0000000000001369</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Prevention of Infectious Complications in Acute Pancreatitis: Results of a Single-Center, Randomized, Controlled Trial</strong> </summary></p>
<p><em>Pancreas 2019 Sep;48(8):1056-1060</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404018" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404018</a></p>
<p>OBJECTIVES: This study aimed to investigate the efficiency of imipenem to prevent infectious complications in predicted severe acute pancreatitis (AP). METHODS: Consecutive AP patients were randomized to imipenem 3  500 mg intravenously daily or an identical placebo. Exclusion criteria were prior AP, chronic pancreatitis, active malignancy, immune deficiency, active infection, concomitant antibiotic treatment, pregnancy, and patients younger than 18 years. Infectious complications including infected pancreatic necrosis, pneumonia, urinary tract infection, positive blood cultures, sepsis, and other infections were assessed as the primary outcome. Secondary outcomes included mortality, persistent organ failure, systemic inflammatory response syndrome, local complications, serious adverse events, and need for surgical intervention. RESULTS: Forty-nine patients were randomized to each group. Infectious complications were present in 10 versus 12 of 49 patients (relative risk [RR], 0.833; 95% confidence interval [CI], 0.398-1.747). There were no significant differences in infected pancreatic necrosis (RR, 1.5; 95% CI, 0.262-8.588), pneumonia (RR, 1.5; 95% CI, 0.262-8.588), urinary tract infection (RR, 0.6; 95% CI, 0.152-2.374), positive blood cultures (RR, 0.5; 95% CI, 0.047-5.336), sepsis (RR, 0.333; 95% CI, 0.036-3.095), and other (RR, 1.333; 95% CI, 0.315-5.648). We found no significant differences in secondary outcomes. CONCLUSIONS: Concordantly to available evidence, there is currently no ground to support prophylactic use of antibiotics in predicted severe AP.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001368" class="uri">https://doi.org/10.1097/MPA.0000000000001368</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Defining Pancreatitis as a Risk Factor for Pancreatic Cancer: The Role, Incidence, and Timeline of Development</strong> </summary></p>
<p><em>Pancreas 2019 Sep;48(8):1098-1101</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31404017" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31404017</a></p>
<p>OBJECTIVES: Acute and/or chronic pancreatitis has been implicated as an important risk factor for pancreatic cancer; however, the incidence and temporal relationship of pancreatitis before pancreatic cancer diagnosis are unclear. We aim to understand the role and incidence of pancreatitis temporally with the development of pancreatic cancer. METHODS: A population-based study was used to investigate a temporal relationship between pancreatitis and pancreatic cancer diagnoses. Intervals of 3, 6, 12, 24, and 36 months were developed. Demographical data including age, sex, and race were also recorded and analyzed. RESULTS: A total of 50,080 patients were found to have a diagnosis of pancreatic cancer, of which 7420 (14.8%) had prior diagnoses of pancreatitis. Of those, 92% were between the ages of 40 and 89 years. African Americans had a higher rate of pancreatitis before cancer diagnosis when compared with whites (21.2% vs 14.8%, P &lt; 0.0001). Further analysis revealed that pancreatitis occurred in 81.3% of patients 3 months before a diagnosis of pancreas cancer and 98.9% had established diagnoses of pancreatic cancer within 3 years. CONCLUSIONS: Screening of patients older than 40 years who have pancreatitis and unclear etiology of pancreatitis may be warranted, especially in African Americans and male individuals.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001367" class="uri">https://doi.org/10.1097/MPA.0000000000001367</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Variation in use of open and laparoscopic distal pancreatectomy and associated outcome metrics in a universal health care system</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Sep;19(6):880-887</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31395453" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31395453</a></p>
<p>BACKGROUND: Universal health care (UHC) should ensure equal access to and use of surgery, but few studies have explored variation in UHC systems. The objective was to describe practice of distal pancreatectomy in Norway covered exclusively by an UHC. METHODS: Data on all patients undergoing distal pancreatectomy from the Norwegian Patient Register over a 5-year period. Age- and gender-adjusted population-based resection rates (adj. per million/yr) for distal pancreatectomy were analysed across 4 regions and outcomes related to splenic salvage rate, hospital stay, reoperation, readmissions and 90-day mortality risk between regions. Risk is reported as odds ratio (OR) with 95% confidence interval (c.i.). RESULTS: Regional difference exist in terms of absolute numbers, with the majority of procedures done in one region (n=331; 59.7%). Regional variation persisted for age- and gender-adjusted population-rates, with highest rate at 23.8/million/yr and lowest rate at 13.5/mill/yr (for a 176% relative difference; or an absolute difference of+10.3 resections/million/yr). Overall, a lapDP instead of an open DP was 3.5 times more likely in SouthEast compared to all other regions combined (lapDP rate: 83% vrs 24%, respectively; OR 15.4, 95% c.i. 10.1-23.5; P&lt;0.001). The splenic salvage rate was lower in SouthEast (19.9%) compared to all other regions (average 26.5%; highest in Central-region at 37.0%; P=0.010 for trend). Controlled for other factors in multivariate regression, region of surgery remained significantly associated with laparoscopic access. CONCLUSION: Despite a universal health care system, considerable variation exists in resection rates, use of laparoscopy and splenic salvage rates across regions.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.07.047" class="uri">https://doi.org/10.1016/j.pan.2019.07.047</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Corrigendum to Cystic pancreatic neuroendocrine tumors: A more favorable lesion? [Pancreatology 19 (2) (March 2019) 372-376]</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Sep;19(6):903</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31387834" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31387834</a></p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.07.043" class="uri">https://doi.org/10.1016/j.pan.2019.07.043</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The harms of early cessation of trials on systematic reviews - Authors reply</strong> </summary></p>
<p><em>The lancet. Gastroenterology &amp; hepatology 2019 Sep;4(9):667-668</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31387729" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31387729</a></p>
<p>doi: <a href="https://doi.org/10.1016/S2468-1253(19)30228-6" class="uri">https://doi.org/10.1016/S2468-1253(19)30228-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The cost of endoscopic treatment for walled-off pancreatic necrosis</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Sep;19(6):828-833</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31383574" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31383574</a></p>
<p>BACKGROUND: Use of minimally invasive techniques has reduced mortality in walled-off pancreatic necrosis (WON) but may be costly. The aim of this study was to evaluate the actual costs associated with the endoscopic management of patients with WON. METHODS: We included a retrospective cohort of WON patients treated with endoscopic, transgastric drainage and necrosectomy (ETDN) during 2013-2014. Costs were calculated for six sub-areas based on a micro-costing model. Students T-test and non-parametric analysis of variance were performed to evaluate costs in relation to disease etiology and outcome. RESULTS: We included 58 patients (50% men, median age 57 years). The most common etiologies were gallstones (57%) and alcohol (19%). Nine patients (16%) died during admission. The median length of stay was 50 days (IQR 31 days). Eighteen patients (31%) needed treatment in our intensive care unit with a median length of stay of 16 days (IQR 31 days). The mean costs and standard deviation of costs (SD) per patient were: diagnostic imaging $2,431 ($2,301), laboratory tests $3,579 ($2,477), blood products $982 ($1,734), endoscopic treatment $3,794 ($1,777), medicine $5,440 ($6,656), and ward cost $41,260 ($35,854). The mean total cost was $57,486 ($46,739). Post-ERCP pancreatitis and mortality predicted higher costs. CONCLUSIONS: This study sheds light on the different costs associated with endoscopic treatment of WON. As nearly three quarters of the costs are related to ward care, initiatives aimed at reducing the length of hospital stay may have a great impact on making endoscopic treatment more cost effective.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.07.042" class="uri">https://doi.org/10.1016/j.pan.2019.07.042</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The role of abdominal drainage in pancreatic resection - A multicenter validation study for early drain removal</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Sep;19(6):888-896</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31378583" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31378583</a></p>
<p>BACKGROUND: Abdominal drainage and the timing of drain removal in patients undergoing pancreatic resection are under debate. Early drain removal after pancreatic resection has been reported to be safe with a low risk for clinical relevant postoperative pancreatic fistula (CR-POPF) when drain amylase on POD1 is&lt;5000U/L. The aim of this study was to validate this algorithm in a large national cohort. METHODS: Patients registered in the Dutch Pancreatic Cancer Audit (2014-2016) who underwent pancreatoduodenectomy, distal pancreatectomy or enucleation were analysed. Data on post-operative drain amylase levels, drain removal, postoperative pancreatic fistulae were collected. Univariate and multivariate analysis using a logistic regression model were performed. The primary outcome measure was grade B/C pancreatic fistula (CR-POPF). RESULTS: Among 1402 included patients, 433 patients with a drain fluid amylase level of &lt;5000U/L on POD1, 7% developed a CR-POPF. For patients with an amylase level &gt;5000U/L the CR-POPF rate was 28%. When using a cut-off point of 2000U/L or 1000U/L during POD1-3, the CR-POPF rates were 6% and 5% respectively. For patients with an amylase level of &gt;2000U/L and &gt;1000UL during POD 1-3 the CR-POPF rates were 26% and 22% respectively (n=223). Drain removal on POD4 or thereafter was associated with more complications (p=0.004). Drain amylase level was shown to be the most statistically significant predicting factor for CR-POPF (Wald=49.7; p&lt;0.001). CONCLUSION: Our data support early drain removal after pancreatic resection. However, a cut-off of 5000U/L drain amylase on POD1 was associated with a relatively high CR-POPF rate of 7%. A cut-off point of 1000U/L during POD1-3 resulted in 5% CR-POPF and might be a safer alternative.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.07.041" class="uri">https://doi.org/10.1016/j.pan.2019.07.041</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Factors predicting readmission within 30 days of acute pancreatitis attack: A prospective study</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Sep;19(6):805-806</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31378581" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31378581</a></p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.07.044" class="uri">https://doi.org/10.1016/j.pan.2019.07.044</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Intraductal oncocytic papillary neoplasm of the pancreas: A systematic review</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Sep;19(6):858-865</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31375434" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31375434</a></p>
<p>BACKGROUND: Intraductal oncocytic papillary neoplasm of the pancreas (IOPN-P) is a rare subtype of intraductal papillary mucinous neoplasm (IPMN). This study was performed to summarize the clinicopathological features and management of IOPN-P. METHODS: English-language articles were searched from MEDLINE and EMBASE from the first report of IOPN-P in 1996 until 1 May 2019 following the methodology in the PRISMA guidelines. RESULTS: In total, 66 patients from 24 full articles were included in the final data analysis. The patients average age was 61 years, and the male/female ratio was 1. Most lesions were large (average size, 5.50cm), located in the pancreatic head, and found either incidentally or by uncharacteristic abdominal symptoms. IOPN-P was usually a cystic and solid lesion with or without mural nodules on radiological examination. A definitive diagnosis was often acquired from fine needle aspiration biopsy or postoperative pathology. All tumors were diagnosed as carcinoma in situ or minimally invasive carcinoma, necessitating surgical resection. The prognosis of IOPN-P was better than that of other IPMN subtypes, even when metastasis occurred. Recurrence after surgical resection of IOPN-P was rare. CONCLUSIONS: IOPN-P is rare among IPMN subtypes with unique pathological characteristics. Because of the nontypical symptoms and radiological findings, a definitive preoperative diagnosis usually depends on multimodal examinations. Management and surveillance of IOPN-P after surgical resection should be differentiated from those of other pancreatic benign cystic lesions because of its relative malignancy, but IOPN-P should also be differentiated from other IPMN subtypes and malignant cystic tumors because of its favorable prognosis.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.07.040" class="uri">https://doi.org/10.1016/j.pan.2019.07.040</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Response to repeat echoendoscopic celiac plexus neurolysis in pancreatic cancer patients: A machine learning approach</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Sep;19(6):866-872</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31375433" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31375433</a></p>
<p>BACKGROUND: /Objectives: Efficacy of repeat echoendoscopic celiac plexus neurolysis is still unclear. Aim of the study was to assess the efficacy of repeat celiac plexus neurolysis and to build an artificial neural network model able to predict pain response. METHODS: Data regarding 156 patients treated with repeat celiac plexus neurolysis between 2004 and 2019 were reviewed. Artificial neural network and logistic regression models were built to predict pain response after treatment. Performance of the models was expressed in terms of accuracy, positive predictive value, and positive likelihood ratio. RESULTS: Median age was 62 years (range 39-86) and most patients were male (66%) with pre-procedural visual analogue score 7. Fifty-one patients (32.6%) experienced treatment response, of which 6 (3.8%) complete pain suppression. Median duration of pain relief was 6 (2-8) weeks. Tumoral stage, interval from initial to repeat treatment, response to initial neurolysis, and tumor progression between the two treatments resulted as significant predictors of pain response. The performance of the artificial neural network in predicting treatment response was higher than regression model (area under the curve: 0.94, 0.89-0.97 versus 0.85, 0.78-0.89; p&lt;0.001). Positive predictive value and positive likelihood ratio resulted 90.3% and 19.35, respectively. Classification error rate was 5.7% with the artificial neural network compared to 14.7% of regression model (p&lt;0.001). These findings were confirmed through ten-fold cross validation. CONCLUSIONS: Pain response following repeat neurolysis is generally less pronounced than after initial treatment. Artificial neural network may help to identify those subjects likely to benefit from repeat neurolysis.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.07.038" class="uri">https://doi.org/10.1016/j.pan.2019.07.038</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Characterising the impact of body composition change during neoadjuvant chemotherapy for pancreatic cancer</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Sep;19(6):850-857</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31362865" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31362865</a></p>
<p>BACKGROUND: Pancreatic Cancer remains a lethal disease for the majority of patients. New chemotherapy agents such as Folfirinox offer therapeutic potential for patients who present with Borderline Resectable disease (BRPC). However, results to date are inconsistent, with factors such as malnutrition limiting successful drug delivery. We sought to determine the prevalence of sarcopenia in BRPC patients at diagnosis, and to quantify body composition change during chemotherapy. METHODS: The diagnostic/restaging CT scans of BRPC patients were analysed. Body composition was measured at L3 using Tomovision Slice-O-Matic. Total muscle and adipose tissue mass were estimated using validated regression equations. Sarcopenia was defined as per gender- and body mass index (BMI)-specific lumbar skeletal muscle index (LSMI) and muscle attenuation reference values. RESULTS: Seventy-eight patients received neo-adjuvant chemotherapy, and 67 patients underwent restaging CT, at which point a third were deemed resectable. Half were sarcopenic at diagnosis, and sarcopenia was equally prevalent across all BMI categories.. Skeletal muscle and adipose tissue (intra-muscular, visceral and sub-cutaneous) area decreased during chemotherapy (p&lt;0.0001). Low muscle attenuation was observed in half of patients at diagnosis, and was associated with increased mortality risk. Loss of lean tissue parameters during chemotherapy was associated with an increased mortality risk; specifically fat-free mass, HR 1.1 (95% CI 1.03-1.17, p=0.003) and skeletal muscle mass, HR 1.21 (95%CI 1.08-1.35, p=0.001). CONCLUSIONS: Sarcopenia was prevalent in half of patients at the time of diagnosis with BRPC. Low muscle attenuation at diagnosis, coupled with lean tissue loss during chemotherapy, independently increased mortality risk.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.07.039" class="uri">https://doi.org/10.1016/j.pan.2019.07.039</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Silibinin inhibited autophagy and mitochondrial apoptosis in pancreatic carcinoma by activating JNK/SAPK signaling</strong> </summary></p>
<p><em>Pathology, research and practice 2019 Sep;215(9):152530</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31351801" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31351801</a></p>
<p>BACKGROUND: Previous investigation have indicated Silibinin induces apoptosis and JNK/SAPK in human pancreatic cancer cells. This study aims to evaluate the further mechanism of Silibinin in pancreatic cancer treatment. MATERIALS AND METHODS: Human pancreatic cancer cell lines SW1990 was treated with Silibinin and/or JNK/SAPK inhibitor SP600125 followed by measurement of cell viability, apoptosis, autophagy, ROS and ATP, and western blotting. RESULTS: Silibinin promoted cell viability and promoted cell apoptosis. The expression of ROS and ATP associated with mitochondrial function was also promoted by the treatment of silibinin. Silibinin also promoted autophagy in pancreatic cancer cells. All these biological effects of Silibinin can be reversed by JNK/SAPK inhibitor. CONCLUSIONS: The biological effects regulated by Silibinin can be mediated by JNK/SAPK signaling. This provides a solid theoretical basis for the role of Silibinin in the treatment of pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1016/j.prp.2019.152530" class="uri">https://doi.org/10.1016/j.prp.2019.152530</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Period prevalence of chronic pancreatitis diagnosis from 2001-2013 in the commercially insured population of the United States</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Sep;19(6):813-818</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31350077" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31350077</a></p>
<p>BACKGROUND: Prevalence estimates of chronic pancreatitis (CP) in the US are scarce. We aimed to determine the prevalence of CP in the commercially insured population of the US. METHODS: We analyzed the IQVIA Legacy PharMetrics database to calculate the period prevalence of CP from 2001 to 2013 among individuals with 1 year of enrollment. CP was defined as 1 healthcare contacts associated with a non-ancillary claim for a primary diagnosis of CP (ICD-9-CM 577.1). Prevalence estimates were age- and sex- adjusted to the 2010 US population. Sensitivity analysis was performed by using more stringent criteria: a) 1 claim of CP+[1 claims of acute pancreatitis (AP), CP or pancreatic cyst/pseudocyst]; b) 1 claim of CP+[1 claims for AP, CP or pancreatic cyst/pseudocyst in 3 months before or after the index CP claim]; c) 2 claims for CP; and d) 2 claims for CP separated by6 months. RESULTS: Of 48.67 million eligible enrollees, 37,061 received the diagnosis of CP (mean age, 51.215.2 years; 49% male). The age- and sex- adjusted period prevalence of CP per 100,000 was 73.4 (95% CI, 72.6-74.1), 98.7 (95% CI, 97.7-99.7) for adults and 8.3 (95% CI, 7.8-8.8) for children. Prevalence of CP was slightly higher in males (sex ratio, 1.05) and highest in the age group of 46-55 years (135/100,000). On sensitivity analysis, the prevalence of CP per 100,000 decreased to 60.2, 39.7, 38.8, and 18.8 with each of the alternative definitions. CONCLUSION: Prevalence estimates reported in our study provide an insight into the population burden of CP in the US.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.07.003" class="uri">https://doi.org/10.1016/j.pan.2019.07.003</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Tumor Budding in Intrahepatic Cholangiocarcinoma: A Predictor of Postsurgery Outcomes</strong> </summary></p>
<p><em>The American journal of surgical pathology 2019 Sep;43(9):1180-1190</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31335353" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31335353</a></p>
<p>Intrahepatic cholangiocarcinoma (ICC) is an extremely aggressive carcinoma. Useful predictors for the patients prognosis after surgery have not been fully established. From the University of Tokyo Hospital pathology archives, we reviewed 107 cases of ICC, 54 cases of perihilar cholangiocarcinoma, and 40 cases of extrahepatic cholangiocarcinoma (ECC); we also investigated the significance of tumor budding in ICC, in comparison with perihilar cholangiocarcinoma and ECC. The tumor-budding frequencies were different by tumor location: 40.2% (43/107) in ICC, 70.4% (38/54) in perihilar cholangiocarcinoma, and 60.0% (24/40) in ECC. Tumor budding in ICC was associated with many pathologic indicators associated with invasion, such as major vascular invasion (P=0.012) and Union for International Cancer Control stage (P=0.007). Univariate and multivariate Cox regression analyses revealed tumor budding as a powerful prognostic factor for both recurrence-free survival (RFS) and overall survival (OS) in ICC by univariate (RFS: hazard ratio [HR]: 2.666; 95% confidence interval [CI]: 1.517-4.683, OS: HR: 4.206; 95% CI: 2.447-7.230) and by multivariate analyses (RFS: HR: 3.038; 95% CI: 1.591-5.973, OS: HR: 4.547, 95% CI: 2.348-8.805). Tumor budding was also a significant prognostic factor of perihilar cholangiocarcinoma, but not of ECC. When ICC was divided into 2 subtypes, type 1 (hilar) and type 2 (peripheral), tumor budding was the strong prognostic factor in type 2 ICC, but not in type 1 ICC, suggesting that some differences in biological behavior exist between type 1 ICC and perihilar cholangiocarcinoma. Tumor budding is prognostically important in ICC, and its pathogenetic role in biliary tract carcinomas might be different by anatomic location.</p>
<p>doi: <a href="https://doi.org/10.1097/PAS.0000000000001332" class="uri">https://doi.org/10.1097/PAS.0000000000001332</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Novel Methylated DNA Markers Discriminate Advanced Neoplasia in Pancreatic Cysts: Marker Discovery, Tissue Validation, and Cyst Fluid Testing</strong> </summary></p>
<p><em>The American journal of gastroenterology 2019 Sep;114(9):1539-1549</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31306149" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31306149</a></p>
<p>OBJECTIVES: Pancreatic cystic lesions (PCLs) may be precancerous. Those likely to harbor high-grade dysplasia (HGD) or pancreatic cancer (PC) are targets for surgical resection. Current algorithms to predict advanced neoplasia (HGD/PC) in PCLs lack diagnostic accuracy. In pancreatic tissue and cyst fluid (CF) from PCLs, we sought to identify and validate novel methylated DNA markers (MDMs) that discriminate HGD/PC from low-grade dysplasia (LGD) or no dysplasia (ND). METHODS: From an unbiased whole-methylome discovery approach using predefined selection criteria followed by multistep validation on case (HGD or PC) and control (ND or LGD) tissues, we identified discriminant MDMs. Top candidate MDMs were then assayed by quantitative methylation-specific polymerase chain reaction on archival CF from surgically resected PCLs. RESULTS: Of 25 discriminant MDMs identified in tissue, 13 were selected for validation in 134 CF samples (21 cases [8 HGD, 13 PC], 113 controls [45 ND, 68 LGD]). A tree-based algorithm using 2 CF-MDMs (TBX15, BMP3) achieved sensitivity and specificity above 90%. Discrimination was significantly better by this CF-MDM panel than by mutant KRAS or carcinoembryonic antigen, with areas under the receiver operating characteristic curve of 0.93 (95% confidence interval: 0.86-0.99), 0.71 (0.57-0.85), and 0.72 (0.60-0.84), respectively. Cutoffs for the MDM panel applied to an independent CF validation set (31 cases, 56 controls) yielded similarly high discrimination, areas under the receiver operating characteristic curve = 0.86 (95% confidence interval: 0.77-0.94, P = 0.2). DISCUSSION: Novel MDMs discovered and validated in tissue accurately identify PCLs harboring HGD/PC. A panel of 2 MDMs assayed in CF yielded results with potential to enhance current risk prediction algorithms. Prospective studies are indicated to optimize and further evaluate CF-MDMs for clinical use.</p>
<p>doi: <a href="https://doi.org/10.14309/ajg.0000000000000284" class="uri">https://doi.org/10.14309/ajg.0000000000000284</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer</strong> </summary></p>
<p><em>Annals of surgery 2019 Sep;270(3):400-413</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31283563" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31283563</a></p>
<p>OBJECTIVE: To compare the survival outcomes associated with clinical and pathological response in pancreatic ductal adenocarcinoma (PDAC) patients receiving neoadjuvant chemotherapy (NAC) with FOLFIRINOX (FLX) or gemcitabine/nab-paclitaxel (GNP) followed by curative-intent pancreatectomy. BACKGROUND: Newer multiagent NAC regimens have resulted in improved clinical and pathological responses in PDAC; however, the effects of these responses on survival outcomes remain unknown. METHODS: Clinicopathological and survival data of PDAC patients treated at 7 academic medical centers were analyzed. Primary outcomes were overall survival (OS), local recurrence-free survival (L-RFS), and metastasis-free survival (MFS) associated with biochemical (CA 19-9 decrease 50% vs &lt;50%) and pathological response (complete, pCR; partial, pPR or limited, pLR) following NAC. RESULTS: Of 274 included patients, 46.4% were borderline resectable, 25.5% locally advanced, and 83.2% had pancreatic head/neck tumors. Vein resection was performed in 34.7% and 30-day mortality was 2.2%. R0 and pCR rates were 82.5% and 6%, respectively. Median, 3-year, and 5-year OS were 32 months, 46.3%, and 30.3%, respectively. OS, L-RFS, and MFS were superior in patients with marked biochemical response (CA 19-9 decrease 50% vs &lt;50%; OS: 42.3 vs 24.3 months, P &lt; 0.001; L-RFS-27.3 vs 14.1 months, P = 0.042; MFS-29.3 vs 13 months, P = 0.047) and pathological response [pCR vs pPR vs pLR: OS- not reached (NR) vs 40.3 vs 26.1 months, P &lt; 0.001; L-RFS-NR vs 24.5 vs 21.4 months, P = 0.044; MFS-NR vs 23.7 vs 20.2 months, P = 0.017]. There was no difference in L-RFS, MFS, or OS between patients who received FLX or GNP. CONCLUSION: This large, multicenter study shows that improved biochemical, pathological, and clinical responses associated with NAC FLX or GNP result in improved OS, L-RFS, and MFS in PDAC. NAC with FLX or GNP has similar survival outcomes.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003468" class="uri">https://doi.org/10.1097/SLA.0000000000003468</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients</strong> </summary></p>
<p><em>Annals of surgery 2019 Sep;270(3):422-433</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31283562" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31283562</a></p>
<p>OBJECTIVE: Despite heterogeneous biology, similar surveillance schemas are utilized after resection of all pancreatic neuroendocrine tumors (PanNETs). Given concerns regarding excess radiation exposure and financial burden, our aim was to develop a prognostic score for disease recurrence to guide individually tailored surveillance strategies. METHODS: All patients with primary nonfunctioning, nonmetastatic well/moderately differentiated PanNETs who underwent curative-intent resection at 9-institutions from 2000 to 2016 were included (n = 1006). A Recurrence Risk Score (RRS) was developed from a randomly selected derivation cohort comprised of 67% of patients and verified on the validation-cohort comprised of the remaining 33%. RESULTS: On multivariable analysis, patients within the derivation cohort (n = 681) with symptomatic tumors (jaundice, pain, bleeding), tumors &gt;2cm, Ki67 &gt;3%, and lymph node (LN) (+) disease had increased recurrence. Each factor was assigned a score based on their weighted odds ratio that formed a RRS of 0 to 10: symptomatic = 1, tumor &gt;2cm = 2, Ki67 3% to 20% = 1, Ki67 &gt;20% = 6, LN (+) = 1. Patients were grouped into low- (RRS = 0-2; n = 247), intermediate-(RRS = 3-5; n = 204), or high (RRS = 6-10; n = 9)-risk groups. At 24 months, 33% of high RRS recurred, whereas only 2% of low and 14% of intermediate RRS recurred. This persisted in the validation cohort (n = 325). CONCLUSIONS: This international, novel, internally validated RRS accurately stratifies recurrence-free survival for patients with resected PanNETs. Given their unique recurrence patterns, surveillance intervals of 12, 6, and 3 months are proposed for low, intermediate, and high RRS patients, respectively, to minimize radiation exposure and optimize cost/resource utilization.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003461" class="uri">https://doi.org/10.1097/SLA.0000000000003461</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Well-differentiated Pancreatic Neuroendocrine Tumor in a Patient With Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM)</strong> </summary></p>
<p><em>The American journal of surgical pathology 2019 Sep;43(9):1297-1302</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31261289" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31261289</a></p>
<p>Germline mutations in CDKN2A result in Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM), which is associated with an increased risk for pancreatic ductal adenocarcinoma and melanoma. CDKN2A is somatically inactivated in multiple neoplasms, raising the possibility that, although the data are not conclusive, germline CDKN2A mutation may also impose an increased risk for other neoplasms. We present a patient with a CDKN2A germline mutation (p16-Leiden mutation) and mosaicism for neurofibromatosis type 2, who presented with a small asymptomatic pancreatic lesion, detected during endoscopic ultrasound screening of the pancreas. After resection, the lesion was found to be a well-differentiated pancreatic neuroendocrine tumor (PanNET). Molecular analysis of the tumor showed somatic loss of the second allele, supporting a causal relation of the PanNET to the underlying FAMMM syndrome. Recent data, showing the association between certain single-nucleotide polymorphisms in the CDKN2A gene and an increased incidence for PanNET, further support a role for germline CDKN2A alterations in PanNET risk. We conclude that PanNETs can be a phenotypic expression of FAMMM syndrome. This can have implications for screening and for the diagnosis of pancreatic neoplasms in carriers of germline CDKN2A mutations.</p>
<p>doi: <a href="https://doi.org/10.1097/PAS.0000000000001314" class="uri">https://doi.org/10.1097/PAS.0000000000001314</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>miR-199a-3p targets ETNK1 to promote invasion and migration in gastric cancer cells and is associated with poor prognosis</strong> </summary></p>
<p><em>Pathology, research and practice 2019 Sep;215(9):152511</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31255331" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31255331</a></p>
<p>PURPOSE: To investigate the prognostic significance of miR-199a-3p and its role in invasion and metastasis in gastric cancer. METHODS: miR-199a-3p expression in 436 formalin-fixed and 39 frozen gastric cancer tissues was investigated by in situ hybridization and RT-PCR, respectively. The role of miR-199a-3p in the migration and invasion of gastric cancer cells was determined in overexpression and inhibitor studies using transwell assays and the SGC-7901, BGC-823 and MGC-803 gastric cancer cells lines. The effect of miR-199a-3p expression on ethanolamine kinase 1 (ETNK1) levels was determined by western botting. RESULTS: miR-199a-3p was significantly up-regulated in AGS, SGC-7901, BGC-823 and MGC-803 gastric cancer cells, when compared with GES-1 non-malignant gastric epithelial cells. In situ hybridization studies revealed that human non-tumor gastric mucosa samples were negative for miR-199a-3p expression, while 162 of 436 (37.16%) cases of gastric cancer demonstrated positive expression. miR-199a-3p overexpression was associated with tumor size, Lauren classification, depth of invasion, lymph node and distant metastasis, TNM stage and prognosis. In patients with I, II and III stage tumors, high miR-199a-3p expression was associated with a significantly lower 5-year survival rate. miR-199a-3p overexpression was associated with increased cell migration and invasion. ETNK1 expression was inhibited following miR-199a-3p overexpression in BGC-823 and SGC-7901 cells, and elevated following miR-199a-3p suppression in MGC-803 cells. CONCLUSION: miR-199a-3p is highly expressed in gastric cancer, and correlates with invasion, metastasis and prognosis. miR-199a-3p regulates the invasion and migration of gastric cancer cells by targeting ETNK1. Consequently, miR-199a-3p may serve as a prognostic indicator in gastric cancer.</p>
<p>doi: <a href="https://doi.org/10.1016/j.prp.2019.152511" class="uri">https://doi.org/10.1016/j.prp.2019.152511</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cytopathology of anaplastic carcinoma of the pancreas: Review of a rare entity and description of a variant with signet ring cell features</strong> </summary></p>
<p><em>Diagnostic cytopathology 2019 Sep;47(9):956-960</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31254330" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31254330</a></p>
<p>Anaplastic carcinoma of the pancreas (ACP) is a rare and aggressive variant of pancreatic ductal adenocarcinoma (PDAC). Several studies have attempted to characterize this subtype through case series or single case reports; however, ACP remains underrecognized by cytopathologists in particular, and often lumped under the umbrella of classic PDAC. Here, we review the most up to date data that literature provides about ACP, to bring familiarity with this entity to the cytopathology practice, and to elucidate the role cytopathologists can play in recognizing and diagnosing this subtype on pancreatic aspiration biopsy, before surgical resection. We also describe a rare case of ACP, demonstrating signet ring cell features, that was diagnosed on fine needle aspiration of a pancreatic mass.</p>
<p>doi: <a href="https://doi.org/10.1002/dc.24263" class="uri">https://doi.org/10.1002/dc.24263</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Of scientists and tweets</strong> </summary></p>
<p><em>Nature reviews. Cancer 2019 09;19(9):479-480</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31253855" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31253855</a></p>
<p>doi: <a href="https://doi.org/10.1038/s41568-019-0170-4" class="uri">https://doi.org/10.1038/s41568-019-0170-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cytohistological diagnosis of pancreatic serous cystadenoma: a multimodal approach</strong> </summary></p>
<p><em>Journal of clinical pathology 2019 Sep;72(9):615-621</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31235542" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31235542</a></p>
<p>AIMS: Serous cystadenomata (SCAs) are benign pancreatic cystic neoplasms that present a diagnostic challenge despite many investigational approaches. Notwithstanding the promise of molecular diagnostics, these tests have limited accessibility in day-to-day surgical pathology practices. We aim to corroborate and build on recent evidence which suggests that positive -inhibin immunohistochemistry (IHC) is a helpful adjunct in the biopsy confirmation of pancreatic SCA. METHODS: We retrospectively reviewed 22 fine-needle aspirates/biopsies from 14 patients (mean age 65 years, 47-83 years) with pancreatic multicystic lesions radiologically suspicious for SCA (location: 6 body, 2 head, 4 tail, 1 neck, 1 uncinate; cyst size: mean 3.7 cm, 2.0-7.6 cm), as well as an additional 10 pancreatic resection specimens with confirmed SCA; -inhibin IHC was performed on all cell blocks, biopsy slides and representative resection specimen sections. Where available, associated cyst fluid was analysed for correlative vascular endothelial growth factor A (VEGF-A) and carcinoembryonic antigen levels. RESULTS: An -inhibin IHC sensitivity of 80% was observed in the cases with resection confirmed SCA. Of the fine-needle aspirate/biopsy specimens, 59% (13/22) contained epithelial cells strongly positive for -inhibin. When selecting for specimens that exhibited distinct strips of epithelium, the -inhibin strong positivity rate increased to 73% (8/11). VEGF-A values were supportive of false-negative -inhibin IHC in three cases and true-negative -inhibin IHC in one case. CONCLUSION: This study postulates a diagnostic algorithm to confirm pancreatic SCA which may help to decrease unnecessary follow-up endoscopy/surgical resection and would decrease the associated morbidity, mortality and financial costs in patients with this otherwise benign condition.</p>
<p>doi: <a href="https://doi.org/10.1136/jclinpath-2019-205872" class="uri">https://doi.org/10.1136/jclinpath-2019-205872</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Accurate and Dynamic Monitoring of Pancreatic Endocrine Function Is Required in Discharged Patients With Necrotizing Pancreatitis</strong> </summary></p>
<p><em>Gastroenterology 2019 09;157(3):892</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31228436" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31228436</a></p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2018.12.052" class="uri">https://doi.org/10.1053/j.gastro.2018.12.052</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Quality of Life Following Major Laparoscopic or Open Pancreatic Resection</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Sep;26(9):2985-2993</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31228131" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31228131</a></p>
<p>PURPOSE: This study was designed to compare quality of life (QoL) among patients who underwent open versus laparoscopic pancreatic resection, including distal pancreatectomy and pancreaticoduodenectomy, and to identify clinical characteristics that are associated with changes in QoL. METHODS: Quality of life (QoL) was assessed in patients undergoing pancreatic resection with the Functional Assessment of Cancer Therapy-Hepatobiliary questionnaire preoperatively and 2weeks, 1, 3, and 6months postoperatively. Multilevel regression modeling was used to determine the variability in each QoL domain within the first 2weeks (postoperative period) and thereafter (recovery period). RESULTS: Among 159 patients, 60.4% underwent open and 39.6% underwent laparoscopic surgery. Physical, functional, hepatobiliary, and total QoL scores decreased in the postoperative period but returned to baseline levels by 6months postoperatively. Emotional QoL improved from baseline by 2weeks after surgery (p&lt;0.001) and social QoL improved from baseline by 3months after surgery (p&lt;0.001). Emotional QoL was the only domain where significant differences were observed in QoL in the postoperative and recovery periods between patients who underwent open and laparoscopic pancreatic resection. Controlling for surgical approach, patients who experienced a grade III or IV complication experienced greater declines in physical, functional, hepatobiliary, and total QoL in the postoperative period. The negative impact of complications on QoL resolved by 6months postoperatively. CONCLUSIONS: The impact of pancreatic resection on QoL was comparable between patients who underwent laparoscopic versus open pancreatic resection. Complications were strongly associated with changes in postoperative QoL, suggesting that performing a safe operation is the best approach for optimizing patient reported QoL.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07449-x" class="uri">https://doi.org/10.1245/s10434-019-07449-x</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Outcomes of Lymph Node Dissection for Non-metastatic Pancreatic Neuroendocrine Tumors: A Propensity Score-Weighted Analysis of the National Cancer Database</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Sep;26(9):2722-2729</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31209670" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31209670</a></p>
<p>BACKGROUND: Although the National Comprehensive Cancer Network (NCCN) guidelines recommend use of lymph node dissection (LND) in patients with pancreatic neuroendocrine tumors (pNETs) &gt;2cm, there is limited evidence to support the association between use of LND and overall survival (OS). METHODS: Patients with resected pNETs were identified in the National Cancer Database (2004-2014). The inverse probability of treatment weighting (IPTW) method was used to reduce the selection bias. IPTW-adjusted Kaplan-Meier curves and Cox proportional hazards models were used to compare OS of patients in different treatment groups. RESULTS: A total of 2664 patients diagnosed met the study entry criteria. Of these, 2132 patients (80.6%) received LND, with a median of nine nodes removed. Positive nodes were identified in 28.0% of patients who underwent LND. IPTW-adjusted Kaplan-Meier analysis showed that median OS was similar between the LND and LND-omitted groups (152.8 vs.147.3months; p=0.61). In IPTW-adjusted Cox proportional hazards regression analysis, LND was not associated with an OS benefit (hazard ratio [HR] 1.15, 95% confidence interval [CI] 0.94-1.42; p=0.18). The results were consistent across subgroups stratified by clinical T and N stages. Among patients with lymph node metastasis, the number of removed nodes (NRN) above the median was not associated with an improved OS (HR 0.82, 95% CI 0.60-1.13; p=0.22). CONCLUSIONS: LND had no additional therapeutic benefit among patients undergoing resection for pNETs. The present findings should be considered when managing patients with resectable pNETs.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07506-5" class="uri">https://doi.org/10.1245/s10434-019-07506-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Sep;25(17):5351-5363</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31186314" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31186314</a></p>
<p>PURPOSE: Myeloid cells are a prominent immunosuppressive component within the stroma of pancreatic ductal adenocarcinoma (PDAC). Previously, targeting myeloid cells has had limited success. Here, we sought to target the myeloid cells through modifying a specific stromal component. EXPERIMENTAL DESIGN: A murine model of metastatic PDAC treated with an irradiated whole-cell PDAC vaccine and PDAC specimens from patients treated with the same type of vaccine were used to assess the immune-modulating effect of stromal hyaluronan (HA) degradation by PEGPH20. RESULTS: Targeting stroma by degrading HA with PEGPH20 in combination with vaccine decreases CXCL12/CXCR4/CCR7 immunosuppressive signaling axis expression in cancer-associated fibroblasts, myeloid, and CD8+ T cells, respectively. This corresponds with increased CCR7- effector memory T-cell infiltration, an increase in tumor-specific IFN, and improved survival. In the stroma of human PDACs treated with the same vaccine, decreased stromal CXCR4 expression significantly correlated with decreased HA and increased cytotoxic activities, suggesting CXCR4 is an important therapeutic target. CONCLUSIONS: This study represents the first to dissect signaling cascades following PDAC stroma remodeling via HA depletion, suggesting this not only overcomes a physical barrier for immune cell trafficking, but alters myeloid function leading to downstream selective increases in effector memory T-cell infiltration and antitumor activity.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-18-4192" class="uri">https://doi.org/10.1158/1078-0432.CCR-18-4192</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreatobiliary-type intraductal papillary mucinous neoplasm of the pancreas may have 2 subtypes with distinct clinicopathologic and genetic features</strong> </summary></p>
<p><em>Human pathology 2019 Sep;91():26-35</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31175918" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31175918</a></p>
<p>We recently experienced cases of pancreatobiliary-type intraductal papillary mucinous neoplasms (PB-IPMNs) with imaging features resembling pancreatic ductal adenocarcinomas (PDACs), and histologic appearance of purely pancreatobiliary morphology and highly distorted papillary growth, which led to the present study aiming to systematically investigate PB-IPMNs in comparison with PDACs. Surgical cases of PB-IPMNs (n=31) and PDACs (n=24) were examined. PB-IPMNs were classified into monotypic tumors (n=12; 39%) consisting of entirely high-grade pancreatobiliary-type neoplastic cells and polytypic cases (n=19; 61%) associated with components of low-grade dysplasia and/or other histologic types (eg, gastric, intestinal, or oncocytic types). Clinically, monotypic PB-IPMNs less commonly had dilatation of the ampullary orifice (0% versus 74%) and mucin hypersecretion (17% versus 89%) than did polytypic cases. In most cases of monotypic PB-IPMNs, cystic dilatation of the lesional ducts was less obvious on imaging; therefore, 33% were radiologically diagnosed as PDACs. Histologically, intraductal tumors in monotypic cases showed a highly complex papillary architecture with tubular/cribriform glands and irregular branching, and all these cases were associated with invasive malignancy. GNAS mutations were detected in polytypic PB-IPMNs (6/19; 32%), but there were no GNAS mutations in monotypic cases. The recurrence-free survival of patients with monotypic PB-IPMN or PDAC was similar and significantly worse than that of patients with polytypic PB-IPMN. In conclusion, some cases of monotypic PB-IPMNs lacked the classic characteristics of IPMNs and shared features with PDACs, raising the possibility that these cases may be better classified as a papillary variant of PDACs rather than IPMNs.</p>
<p>doi: <a href="https://doi.org/10.1016/j.humpath.2019.05.010" class="uri">https://doi.org/10.1016/j.humpath.2019.05.010</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cross Validation of the Monoclonal Antibody Das-1 in Identification of High-Risk Mucinous Pancreatic Cystic Lesions</strong> </summary></p>
<p><em>Gastroenterology 2019 09;157(3):720-730.e2</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31175863" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31175863</a></p>
<p>BACKGROUND &amp; AIMS: Although pancreatic cystic lesions (PCLs) are frequently and incidentally detected, it is a challenge to determine their risk of malignancy. In immunohistochemical and enzyme-linked immunosorbent assay (ELISA) analyses of tissue and cyst fluid from pancreatic intraductal papillary mucinous neoplasms, the monoclonal antibody Das-1 identifies those at risk for malignancy with high levels of specificity and sensitivity. We aimed to validate the ability of Das-1 to identify high-risk PCLs in comparison to clinical guidelines and clinical features, using samples from a multicenter cohort. METHODS: We obtained cyst fluid samples of 169 PCLs (90 intraductal papillary mucinous neoplasms, 43 mucinous cystic neoplasms, and 36 non-mucinous cysts) from patients undergoing surgery at 4 tertiary referral centers (January 2010 through June 2017). Histology findings from surgical samples, analyzed independently and centrally re-reviewed in a blinded manner, were used as the reference standard. High-risk PCLs were those with invasive carcinomas, high-grade dysplasia, or intestinal-type intraductal papillary mucinous neoplasms with intermediate-grade dysplasia. An ELISA with Das-1 was performed in parallel using banked cyst fluid samples. We evaluated the biomarkers performance, generated area under the curve values, and conducted multivariate logistic regression using clinical and pathology features. RESULTS: The ELISA for Das-1 identified high-risk PCLs with 88% sensitivity, 99% specificity, and 95% accuracy, at a cutoff optical density value of 0.104. In 10-fold cross-validation analysis with 100 replications, Das-1 identified high-risk PCLs with 88% sensitivity and 98% specificity. The Sendai, Fukuoka, and American Gastroenterological Association guideline criteria identified high-risk PCLs with 46%, 52%, and 74% accuracy (P for comparison to Das-1 ELISA &lt;.001). When we controlled for Das-1 in multivariate regression, main pancreatic duct dilation &gt;5 mm (odds ratio, 14.98; 95% confidence interval, 2.63-108; P &lt; .0012), main pancreatic duct dilation 1 cm (odds ratio, 47.9; 95% confidence interval, 6.39-490; P &lt; .0001), and jaundice (odds ratio, 6.16; 95% confidence interval, 1.08-36.7; P= .0397) were significantly associated with high-risk PCLs. CONCLUSIONS: We validated the ability of an ELISA with the monoclonal antibody Das-1 to detect PCLs at risk for malignancy with high levels of sensitivity and specificity. This biomarker might be used in conjunction with clinical guidelines to identify patients at risk for malignancy.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.05.014" class="uri">https://doi.org/10.1053/j.gastro.2019.05.014</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A Novel Oxoglutarate Dehydrogenase-Like Mediated miR-214/TWIST1 Negative Feedback Loop Inhibits Pancreatic Cancer Growth and Metastasis</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Sep;25(17):5407-5421</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31175094" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31175094</a></p>
<p>PURPOSE: As a main rate-limiting subunit of the 2-oxoglutarate dehydrogenase multienzyme complex, oxoglutarate dehydrogenase like (OGDHL) is involved in the tricarboxylic acid cycle, and frequently downregulated in human carcinoma and suppresses tumor growth. However, little is known about the role of OGDHL in human cancer, especially pancreatic cancer. Our goal is to study the underlying mechanism and define a novel signaling pathway controlled by OGDHL modulating pancreatic cancer progression. EXPERIMENTAL DESIGN: The expression and functional analysis of OGDHL, miR-214, and TWIST1 in human pancreatic cancer tissues, cell lines, and xenograft tumor model were investigated. The correlations between OGDHL and those markers were analyzed. RESULTS: OGDHL was downregulated in human pancreatic cancer and predicted poor prognosis. OGDHL overexpression inhibited migration and invasion of pancreatic cancer cells and suppressed pancreatic cancer tumor growth. OGDHL was shown to be negatively regulated by miR-214. TWIST1 upregulation induced miR-214 expression in pancreatic cancer. OGDHL suppressed TWIST1 expression through promoting ubiquitin-mediated proteasomal degradation of HIF1 and regulating AKT pathways. A combination of OGDHL downregulation and TWIST1 and miR-214 overexpression predicted worse prognosis in patients with pancreatic cancer. CONCLUSIONS: We demonstrated the prognostic value of OGDHL, miR-214, and TWIST1 in pancreatic cancer, and elucidated a novel pathway in OGDHL-regulated inhibition of pancreatic cancer tumorigenesis and metastasis. These findings may lead to new targeted therapy for pancreatic cancer through regulating OGDHL, miR-214, and TWIST1.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-18-4113" class="uri">https://doi.org/10.1158/1078-0432.CCR-18-4113</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Pathologic and Genetic Characteristics of the Intestinal Subtype of Intraductal Papillary Neoplasms of the Bile Duct</strong> </summary></p>
<p><em>The American journal of surgical pathology 2019 Sep;43(9):1212-1220</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31166202" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31166202</a></p>
<p>The present study aimed to identify the pathologic and genetic characteristics of intestinal subtype of intraductal papillary neoplasm of the bile duct (iIPNB) showing columnar cells with pseudostratified, cigar-shaped nuclei, and basophilic or amphophilic cytoplasm with the diffuse immunohistochemical expression of CK20 and/or CDX2. A total of 34 cases of iIPNB were pathologically examined according to their anatomic location (the bile duct) and were then compared with the intestinal subtype of intraductal papillary mucinous neoplasm (iIPMN) of the pancreas (n=22). Mutations of 26 somatic genes were examined in formalin-fixed paraffin-embedded tissue specimens from 21 cases of iIPNB using the TruSight Tumor 26 gene panel and next-generation sequencing. iIPNB cases were divided into intrahepatic (n=6) and extrahepatic (n=28) categories. Intrahepatic IPNBs showed a less-complicated villous-papillary pattern, while extrahepatic IPNBs showed a papillary pattern with tubular and/or villous components and predominant high-grade dysplasia with complicated architectures. MUC5AC was frequently and extensively expressed in intrahepatic iIPNBs and iIPMNs but not in extrahepatic iIPNBs. CD10 was frequently expressed in extrahepatic IPNBs but not in intrahepatic iIPNBs or iIPMN. Genetic mutations of TP53 and PIK3CA, which were infrequent or absent in iIPMNs, were frequently detected in extrahepatic iIPNBs, while KRAS and GNAS, which were commonly observed in iIPMNs, were frequently detected in intrahepatic iIPNBs. Intrahepatic iIPNBs showed villous-papillary growth with features reminiscent of iIPMNs, while extrahepatic iIPNBs showed papillary growth with tubular and/or villous components, complicated histology and variable differences from iIPMNs, suggesting differences in the tumorigenesis of iIPNBs along the biliary tree.</p>
<p>doi: <a href="https://doi.org/10.1097/PAS.0000000000001295" class="uri">https://doi.org/10.1097/PAS.0000000000001295</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Axon Guidance Molecules Promote Perineural Invasion and Metastasis of Orthotopic Pancreatic Tumors in Mice</strong> </summary></p>
<p><em>Gastroenterology 2019 09;157(3):838-850.e6</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31163177" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31163177</a></p>
<p>BACKGROUND &amp; AIMS: Little is known about mechanisms of perineural invasion (PNI) by pancreatic ductal adenocarcinomas (PDAs) or other tumors. Annexin A2 (ANXA2) regulates secretion of SEMA3D, an axon guidance molecule, which binds and activates the receptor PLXND1 to promote PDA invasion and metastasis. We investigated whether axon guidance molecules promote PNI and metastasis by PDA cells in mice. METHODS: We performed studies in a dorsal root ganglion (DRG) invasion system, wild-type C57BL/6 mice (controls), mice with peripheral sensory neuron-specific disruption of PlxnD1 (PLAC mice), LSL-KRASG12D/+;LSL-TP53R172H/+;PDX-1-CRE+/+ (KPC) mice, and KPC mice crossed with ANXA2-knockout mice (KPCA mice). PDA cells were isolated from KPC mice and DRG cells were isolated from control mice. Levels of SEMA3D or ANXA2 were knocked down in PDA cells with small hairpin and interfering RNAs and cells were analyzed by immunoblots in migration assays, with DRGs and with or without antibodies against PLXND1. PDA cells were injected into the pancreas of control and PLAC mice, growth of tumors was assessed, and tumor samples were analyzed by histology. DRG cells were incubated with SEMA3D and analyzed by live imaging. We measured levels of SEMA3D and PLXND1 in PDA specimens from patients with PNI and calculated distances between tumor cells and nerves. RESULTS: DRG cells increase the migration of PDC cells in invasion assays; knockdown of SEMA3D in PDA cells or antibody blockade of PLXND1 on DRG cells reduced this invasive activity. In mice, orthotopic tumors grown from PDA cells with knockdown of SEMA3D, and in PLAC mice, orthotopic tumors grown from PDA cells, had reduced innervation and formed fewer metastases than orthotopic tumors grown from PDA cells in control mice. Increased levels of SEMA3D and PLXND1 in human PDA specimens associated with PNI. CONCLUSIONS: DRG cells increase the migratory and invasive activities of pancreatic cancer cells, via secretion of SEMA3D by pancreatic cells and activation of PLXND1 on DRGs. Knockdown ofSEMA3D and loss of neural PLXND1 reduces innervation of orthotopic PDAs and metastasis in mice. Increased levels of SEMA3D and PLXND1 in human PDA specimens associated with PNI. Strategies to disrupt the axon guidance pathway mediated by SEMA3D and PLXND1 might be developed to slow progression of PDA.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.05.065" class="uri">https://doi.org/10.1053/j.gastro.2019.05.065</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cholangiographic Tumor Classification for Simple Patient Selection Prior to Hepatopancreatoduodenectomy for Cholangiocarcinoma</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Sep;26(9):2971-2979</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31102092" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31102092</a></p>
<p>BACKGROUND: Hepatopancreatoduodenectomy (HPD) is employed for patients with laterally advanced cholangiocarcinoma. However, the survival benefit of this extended approach remains controversial. The aim of this study is to identify a tumor feature benefiting from HPD from the standpoint of long-term survival. PATIENTS AND METHODS: Patients with cholangiocarcinoma who underwent HPD with curative intent between 2001 and 2017 were retrospectively analyzed. Tumors were radiologically classified by preoperative cholangiogram. Diffuse type was defined as significant tumor/stricture located from the hilar to intrapancreatic duct; localized type was defined as tumor otherwise. Univariable and multivariable analyses were performed to identify prognostic indicators. RESULTS: Of 100 study patients, 28 (28%) patients had diffuse tumor type, while the remaining 72 (72%) patients had localized tumors. The former group showed significantly longer lateral length (43 versus 22mm, P&lt;0.001) and more frequent pancreatic invasion (50% versus 32%, P=0.110), advanced T classification (64% versus 49%, P=0.185), and nodal metastasis (57% versus 47%, P=0.504), compared with the latter group. The survival for patients with diffuse tumor type was significantly worse than that for patients with localized tumor type, with 5-year survival rates of 59.0% versus 26.3%, respectively (P=0.003). Multivariable analysis identified four independent factors deteriorating long-term survival: cholangiographic diffuse tumor (P=0.021), higher age (P=0.020), percutaneous biliary drainage (P=0.007), and portal vein resection (P=0.007). CONCLUSIONS: Presurgical cholangiographic classification, diffuse or localized type, is a tumor-related factor closely associated with survival probability; therefore, it may be a useful feature for patient selection prior to HPD for cholangiocarcinoma.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07457-x" class="uri">https://doi.org/10.1245/s10434-019-07457-x</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Understanding the mechanisms of reversal of type 2 diabetes</strong> </summary></p>
<p><em>The lancet. Diabetes &amp; endocrinology 2019 Sep;7(9):726-736</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31097391" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31097391</a></p>
<p>Clinical and pathophysiological studies have shown type 2 diabetes to be a condition mainly caused by excess, yet reversible, fat accumulation in the liver and pancreas. Within the liver, excess fat worsens hepatic responsiveness to insulin, leading to increased glucose production. Within the pancreas, the  cell seems to enter a survival mode and fails to function because of the fat-induced metabolic stress. Removal of excess fat from these organs via substantial weight loss can normalise hepatic insulin responsiveness and, in the early years post-diagnosis, is associated with -cell recovery of acute insulin secretion in many individuals, possibly by redifferentiation. Collectively, these changes can normalise blood glucose levels. Importantly, the primary care-based Diabetes Remission Clinical Trial (DiRECT) showed that 46% of people with type 2 diabetes could achieve remission at 12 months, and 36% at 24 months, mediated by weight loss. This major change in our understanding of the underlying mechanisms of disease permits a reassessment of advice for people with type 2 diabetes.</p>
<p>doi: <a href="https://doi.org/10.1016/S2213-8587(19)30076-2" class="uri">https://doi.org/10.1016/S2213-8587(19)30076-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Rapid research autopsy is a stealthy but growing contributor to cancer research</strong> </summary></p>
<p><em>Cancer 2019 Sep;125(17):2915-2919</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31090935" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31090935</a></p>
<p>doi: <a href="https://doi.org/10.1002/cncr.32184" class="uri">https://doi.org/10.1002/cncr.32184</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Biomarkers to diagnose metastatic breast carcinoma to the pancreas: A case report and update</strong> </summary></p>
<p><em>Diagnostic cytopathology 2019 Sep;47(9):912-917</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31087784" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31087784</a></p>
<p>The patient is a 72-year-old female who presents with new onset jaundice. The patient has a past medical history significant for right-sided estrogen receptor (ER)-positive and left-sided ER-negative breast cancers in 2005 and 2009, respectively, and recent 1-year history of ER-positive right-sided breast cancer with bone and brain metastases. CT scan and endoscopic ultrasound (EUS) revealed a new 2cm mass in the head of the pancreas, leading to EUS-guided fine-needle aspiration of the lesion. Pathologic workup revealed adenocarcinoma with signet-ring cells, representing either metastatic breast or primary pancreatic cancer. Immunohistochemistry and molecular diagnostic workup identified positive GATA-binding protein 3 (GATA3) immunoreactivity and a mutation in Erb-B2 receptor tyrosine kinase 2 (ERBB2), also known as human epidermal growth factor receptor 2 (HER2). Here, we review the diagnostic markers commonly used to differentiate metastatic breast vs primary pancreatic adenocarcinoma, and discuss the challenges of utilizing GATA3 immunoreactivity and ERBB2 mutations for diagnosis.</p>
<p>doi: <a href="https://doi.org/10.1002/dc.24210" class="uri">https://doi.org/10.1002/dc.24210</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreatic panniculitis in active systemic lupus erythematosus</strong> </summary></p>
<p><em>Journal of cutaneous pathology 2019 Sep;46(9):688-690</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31081550" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31081550</a></p>
<p>This report documents the case of a 64-year-old African-American female with new end-stage renal disease (ESRD), diagnosed with systemic lupus erythematosus (SLE) on renal biopsy and serologies including a positive ANA (&gt;1:2560), positive anti-Sm antibodies, low titer anti-RNP antibodies, high titer anti-Ro antibodies, anti-dsDNA antibodies, lupus anticoagulant, and hypocomplementemia. She was also noted to have tender nodules on the bilateral shins. Excisional biopsy of one of the nodules showed marked fat necrosis with ghost cells and patchy basophilic granular debris consistent with pancreatic panniculitis. Further examination for pancreatic pathology showed an elevated lipase of 585U/L (reference range 8-78U/L) and amylase of 214U/L (reference range 25-125U/L). However, computed tomography imaging showed no evidence of pancreatitis or pancreatic tumors. This is very similar to another case recently reported in the literature. Similarities of these two cases (African-American females with lupus nephritis on dialysis) may represent a particular subset of SLE patients at increased risk for pancreatic panniculitis.</p>
<p>doi: <a href="https://doi.org/10.1111/cup.13493" class="uri">https://doi.org/10.1111/cup.13493</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia</strong> </summary></p>
<p><em>Gastroenterology 2019 09;157(3):823-837</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31078621" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31078621</a></p>
<p>BACKGROUND &amp; AIMS: Most pancreatic ductal adenocarcinomas (PDACs) express an activated form of KRAS, become hypoxic and dysplastic, and are refractory to chemo and radiation therapies. To survive in the hypoxic environment, PDAC cells upregulate enzymes and transporters involved in pH regulation, including the extracellular facing carbonic anhydrase 9 (CA9). We evaluated the effect of blocking CA9, in combination with administration of gemcitabine, in mouse models of pancreatic cancer. METHODS: We knocked down expression of KRAS in human (PK-8 and PK-1) PDAC cells with small hairpin RNAs. Human and mouse (KrasG12D/Pdx1-Cre/Tp53/RosaYFP) PDAC cells were incubated with inhibitors of MEK (trametinib) or extracellular signal-regulated kinase (ERK), and some cells were cultured under hypoxic conditions. We measured levels and stability of the hypoxia-inducible factor 1 subunit alpha (HIF1A), endothelial PAS domain 1 protein (EPAS1, also called HIF2A), CA9, solute carrier family 16 member 4 (SLC16A4, also called MCT4), and SLC2A1 (also called GLUT1) by immunoblot analyses. We analyzed intracellular pH (pHi) and extracellular metabolic flux. We knocked down expression of CA9 in PDAC cells, or inhibited CA9 with SLC-0111, incubated them with gemcitabine, and assessed pHi, metabolic flux, and cytotoxicity under normoxic and hypoxic conditions. Cells were also injected into either immune-compromised or immune-competent mice and growth of xenograft tumors was assessed. Tumor fragments derived from patients with PDAC were surgically ligated to the pancreas of mice and the growth of tumors was assessed. We performed tissue microarray analyses of 205 human PDAC samples to measure levels of CA9 and associated expression of genes that regulate hypoxia with outcomes of patients using the Cancer Genome Atlas database. RESULTS: Under hypoxic conditions, PDAC cells had increased levels of HIF1A and HIF2A, upregulated expression of CA9, and activated glycolysis. Knockdown of KRAS in PDAC cells, or incubation with trametinib, reduced the posttranscriptional stabilization of HIF1A and HIF2A, upregulation of CA9, pHi, and glycolysis in response to hypoxia. CA9 was expressed by 66% of PDAC samples analyzed; high expression of genes associated with metabolic adaptation to hypoxia, including CA9, correlated with significantly reduced survival times of patients. Knockdown or pharmacologic inhibition of CA9 in PDAC cells significantly reduced pHi in cells under hypoxic conditions, decreased gemcitabine-induced glycolysis, and increased their sensitivity to gemcitabine. PDAC cells with knockdown of CA9 formed smaller xenograft tumors in mice, and injection of gemcitabine inhibited tumor growth and significantly increased survival times of mice. In mice with xenograft tumors grown from human PDAC cells, oral administration of SLC-0111 and injection of gemcitabine increased intratumor acidosis and increased cell death. These tumors, and tumors grown from PDAC patient-derived tumor fragments, grew more slowly than xenograft tumors in mice given control agents, resulting in longer survival times. In KrasG12D/Pdx1-Cre/Tp53/RosaYFP genetically modified mice, oral administration of SLC-0111 and injection of gemcitabine reduced numbers of B cells in tumors. CONCLUSIONS: In response to hypoxia, PDAC cells that express activated KRAS increase expression of CA9, via stabilization of HIF1A and HIF2A, to regulate pH and glycolysis. Disruption of this pathway slows growth of PDAC xenograft tumors in mice and might be developed for treatment of pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.05.004" class="uri">https://doi.org/10.1053/j.gastro.2019.05.004</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>In Patients with Localized and Resectable Gastric Cancer, What is the Optimal Extent of Lymph Node Dissection-D1 Versus D2 Versus D3?</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Sep;26(9):2912-2932</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31076930" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31076930</a></p>
<p>BACKGROUND: Despite advances in the treatment of patients with gastric cancer, the debate over the optimal extent of lymphadenectomy continues. METHOD: A review of the classification, rationale for, and boundaries of lymphadenectomy is presented. A review of the available literature comparing D1 versus D2 versus D3 lymphadenectomy was performed and included randomized controlled trials, and prospective and retrospective comparative and non-comparative studies. RESULTS: Earlier studies demonstrated increased morbidity with D2 compared with D1 lymphadenectomy, with no significant survival benefit. More recent studies have demonstrated survival benefit of a pancreas and spleen-sparing D2 lymphadenectomy in patients with advanced, node-positive tumors. Para-aortic/D3 dissections contribute to increased morbidity, with no survival benefit. CONCLUSIONS: In patients with resectable gastric adenocarcinoma, a D2 lymph node dissection preserving the pancreas and spleen should be considered standard for optimal staging and treatment, provided it is performed by surgeons with sufficient expertise. Extended lymph node dissections beyond D2 should not be routinely performed as it has been shown to have increased morbidity, with no improvement in outcomes. While systemic chemotherapy should be considered standard in patients undergoing D2 lymphadenectomy, the role of adjuvant radiation continues to evolve.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07417-5" class="uri">https://doi.org/10.1245/s10434-019-07417-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Gastroparesis Mimicry: Thinking Beyond the Pylorus</strong> </summary></p>
<p><em>Gastroenterology 2019 09;157(3):610-611</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31063781" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31063781</a></p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.04.045" class="uri">https://doi.org/10.1053/j.gastro.2019.04.045</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The role of rapid on-site evaluation on diagnostic accuracy of endoscopic ultrasound fine needle aspiration for pancreatic, submucosal upper gastrointestinal tract and adjacent lesions</strong> </summary></p>
<p><em>Cytopathology : official journal of the British Society for Clinical Cytology 2019 Sep;30(5):499-503</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31034112" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31034112</a></p>
<p>BACKGROUND AND AIM: Our aim was to assess adequacy and diagnostic accuracy of endoscopic ultrasound-fine needle aspiration (EUS-FNA) specimens with or without rapid on-site evaluation (ROSE) from pancreatic, upper gastrointestinal tract (UGIT) and adjacent masses. METHOD: A retrospective cohort study based on patients files who underwent EUS-FNA in Galilee Medical Center in a 4years period. Number of needle passes, repeated EUS and ROSE effect on tissue adequacy and diagnostic accuracy were reported. RESULTS: One-hundred sixty-one patients were included. Ninety-three patients (57.7%) underwent EUS-FNA without ROSE (group A) compared to 68 patients (42.3%) with ROSE (group B). The most common location was in the pancreas (55% in group A vs 81% in group B). Addition of ROSE yielded a significantly higher specimen adequacy (65% in group A vs 92.6% in group B (Chi-Square&lt;0.0001, OR 6.72, 95% CI 2.45-18.38). The matching rate (accuracy) between ROSE diagnosis and final histopathological diagnosis was noticed in 61 out of 68 patients (89.7%, 95% CI 0.7993-0.9576). The Kappa coefficient correlations of matching rate between ROSE and final histopathological diagnosis of all lesion and in pancreatic lesions were 0.7558, (95% CI 0.625-0.887) and 0.7814, (95% CI 0.639-0.924), respectively. CONCLUSIONS: EUS-FNA with ROSE significantly improve specimen adequacy and was associated with high diagnostic accuracy.</p>
<p>doi: <a href="https://doi.org/10.1111/cyt.12712" class="uri">https://doi.org/10.1111/cyt.12712</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Acute Methamphetamine-Induced Hepatic and Pancreatic Ischemia</strong> </summary></p>
<p><em>The American journal of forensic medicine and pathology 2019 Sep;40(3):285-288</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31033491" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31033491</a></p>
<p>Methamphetamine is a central nervous system stimulant that induces arousal, a positive mood, cardiac stimulation, and an acute improvement in cognitive domains. Its illicit exploitation is rapidly growing in North America. Typically, extended use of the drug induces organ damage via vasoconstriction and subsequent ischemia. This case specifically discusses hepatic and pancreatic pathology resulting from methamphetamine overdose alongside an unusual discovery of globally necrotic von Meyenburg complexes.</p>
<p>doi: <a href="https://doi.org/10.1097/PAF.0000000000000486" class="uri">https://doi.org/10.1097/PAF.0000000000000486</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreatic islet (of Langerhans) revisited</strong> </summary></p>
<p><em>Histology and histopathology 2019 Sep;34(9):985-993</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31020988" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31020988</a></p>
<p>One hundred and fifty years ago, Paul Langerhans described what would come to be known as pancreatic islet of Langerhans. Since then, we have accumulated knowledge about the pancreatic islet, the cells that exist there and the hormones secreted by these cells. The increasing prevalence of obesity, diabetes and Alzheimers disease in the population (three conditions that are linked to pancreatic islet function), the islet has been playing a significant role in endocrinological and metabolic studies searching how we can protect the pancreatic islet and its cell content, or how we can regenerate it. This review will be interested in the most recent and relevant aspects of knowledge regarding the pancreatic islet, always mentioning the evolution of knowledge and future perspectives for the treatment of diabetes and Alzheimers disease. The most recent research with microRNAs and islet culture and pseudoislet culture (organoids) allows predicting advances in knowledge with new drugs to act on the islet/cells (such as the hormone glucagon-like peptide (GLP) -1) as well as induction of other islet cells like alpha-cells and delta-cells to transform into beta-cells.</p>
<p>doi: <a href="https://doi.org/10.14670/HH-18-118" class="uri">https://doi.org/10.14670/HH-18-118</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Keratin 19-expressing hepatocellular carcinoma and small-duct type intrahepatic cholangiocarcinoma show a similar postoperative clinical course but have distinct genetic features</strong> </summary></p>
<p><em>Histopathology 2019 Sep;75(3):385-393</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31017316" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31017316</a></p>
<p>AIMS: The present study aimed to systematically compare clinicopathological and genetic features between keratin 19 (K19)-expressing hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA). METHODS AND RESULTS: Consecutive cases of HCC (n=430) were classified into K19+ and K19- using immunohistochemistry. ICCA cases were also separated into small-(S-iCCA; n=36) and large-duct types (n=22) based on recently proposed criteria, with the former being used in the present study. Mutational hot-spots in TERT, CTNNB1, KRAS and IDH1 were sequenced. Twenty-six cases (6%) of HCC expressed K19. K19+ HCC was more strongly associated with chronic hepatitis B than K19- HCC and S-iCCA (46% versus 17% and 6%; both P&lt;0.001). Lymph node metastasis was observed in K19+ HCC (8%) and S-iCCA (22%), but was exceptional in K19- HCC (1%). K19+ HCC had TERT promoter mutations less frequently than K19- HCC (31% versus 59%; P=0.022), and lacked alterations in KRAS and IDH1. CTNNB1 mutations were similarly observed in K19+ and K19- HCC (23% and 19%, respectively), but rare in S-iCCA (3%). The postoperative survival curve of K19+ HCC was almost identical to that of S-iCCA in the first 5years (approximately 50% at 5years), and significantly worse than that of K19- HCC (P=0.040). Extrahepatic recurrence was more common in K19+ HCC (50%) and S-iCCA (35%) than in K19- HCC (15%) (P=0.001). CONCLUSIONS: Although K19+ HCC and S-iCCA showed similar biological behaviours, they did not share any driver gene mutations, suggesting the possible involvement of epigenetic alterations in the iCCA-like features of K19+ HCC.</p>
<p>doi: <a href="https://doi.org/10.1111/his.13884" class="uri">https://doi.org/10.1111/his.13884</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Addition of analysis of KRAS mutation or immunohistochemistry with MUC1 and carcinoembryonic antigen improves the diagnostic performance of fine needle aspiration cytology for the diagnosis of pancreatic carcinoma</strong> </summary></p>
<p><em>Cytopathology : official journal of the British Society for Clinical Cytology 2019 Sep;30(5):485-491</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30929285" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30929285</a></p>
<p>BACKGROUND: Pancreatic adenocarcinoma (PAC) is a health problem because of high lethality, increasing incidence and the absence of an early diagnosis. Biopsy by fine needle aspiration guided by endoscopic ultrasound has allowed obtaining tissue for cytopathological analysis, but there are several problems with their interpretation. We aimed to compare the diagnostic performance of the cytopathological analysis with the addition of either an immunohistochemical (IHC) panel or the KRAS mutation for the diagnosis of PAC. METHODS: We evaluated 62 pancreatic lesions by fine needle aspiration guided by endoscopic ultrasound, applying an IHC panel with mucin (MUC)-1, MUC4, carcinoembryonic antigen (CEA) and p53. All cases also had a KRAS mutation determination. Three cytopathologists blinded to clinical data and the KRAS status reviewed the cytology independently. We calculated diagnostic performances for the cytology alone, cytology+IHC and cytology+KRAS to show the best method to diagnose PAC. RESULTS: From 62 samples, 50 (80.6%) were PAC and 12 benign lesions. The cytopathological analysis correctly interpreted 26 malignant and 12 non-neoplastic cases (sensitivity 52%, specificity 100% and diagnostic accuracy 61.3%). The KRAS mutation was present in 88% of PAC. The cytology+ KRAS mutation increased the sensitivity by 10% and the diagnostic accuracy by 8%. The sensitivity increased by 2% adding either MUC1 or CEA to the cytology, and the diagnostic accuracy by 10 or 18%, respectively. CONCLUSION: The addition of IHC either with CEA or MUC1 improved the diagnostic performance of the cytology alone to diagnose PAC. The cytology + IHC evaluation was superior to the cytology + KRAS mutation to diagnose PAC.</p>
<p>doi: <a href="https://doi.org/10.1111/cyt.12697" class="uri">https://doi.org/10.1111/cyt.12697</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>IL-33 overexpression in gallbladder cancers associated with pancreatobiliary maljunction</strong> </summary></p>
<p><em>Histopathology 2019 Sep;75(3):365-375</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30882917" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30882917</a></p>
<p>AIMS: To investigate whether genetic or inflammatory pro-oncogenic factors are relevant to the increased risk of gallbladder cancers in patients with pancreaticobiliary maljunction (PBM). METHODS AND RESULTS: Mutations in KRAS exon 2 were examined by a highly sensitive, droplet digital PCR platform using surgically resected specimens of PBM-associated (n=31) and non-associated gallbladder cancers (n=49). The tissue expression of IL-6 and IL-33, which are suspected to promote biliary carcinogenesis, was analysed by quantitative real-time PCR and in-situ hybridisation. The incidence of KRAS mutations was similarly low in PBM-associated (five of 32 cases; 16%) and non-associated cancers (four of 49 cases; 8%) (P=0.272). The tissue expression of IL-33 mRNA, but not IL-6 mRNA, was significantly higher in PBM-associated gallbladder cancers than in gallbladder cancers without PBM (P=0.004). A similar degree of IL-33 overexpression was also observed in the background non-cancerous mucosa in cases of PBM-associated gallbladder cancers, and was significantly greater than that in PBM cases with cholecystitis alone (P&lt;0.001). The results of in-situ hybridisation indicated that the source of IL-33 production in PBM-associated carcinomas was the endothelium, cancer cells and non-neoplastic biliary epithelium. In a combined PBM-associated and non-associated cohort, IL-33 overexpression in gallbladder cancers correlated with less aggressive features (e.g.a lower pT stage and longer overall survival), similar to recently reported findings on large-duct cholangiocarcinomas. CONCLUSIONS: KRAS mutations do not appear to be associated with a high risk of malignancy in PBM, while IL-33 overexpression may provide a pro-oncogenic microenvironment in the gallbladder mucosa of patients with PBM.</p>
<p>doi: <a href="https://doi.org/10.1111/his.13863" class="uri">https://doi.org/10.1111/his.13863</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Updated Alternative Fistula Risk Score (ua-FRS) to Include Minimally Invasive Pancreatoduodenectomy: Pan-European Validation</strong> </summary></p>
<p><em>Annals of surgery 2019 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30829699" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30829699</a></p>
<p>OBJECTIVE: The aim of the study was to validate and optimize the alternative Fistula Risk Score (a-FRS) for patients undergoing minimally invasive pancreatoduodenectomy (MIPD) in a large pan-European cohort. BACKGROUND: MIPD may be associated with an increased risk of postoperative pancreatic fistula (POPF). The a-FRS could allow for risk-adjusted comparisons in research and improve preventive strategies for high-risk patients. The a-FRS, however, has not yet been validated specifically for laparoscopic, robot-assisted, and hybrid MIPD. METHODS: A validation study was performed in a pan-European cohort of 952 consecutive patients undergoing MIPD (543 laparoscopic, 258 robot-assisted, 151 hybrid) in 26 centers from 7 countries between 2007 and 2017. The primary outcome was POPF (International Study Group on Pancreatic Surgery grade B/C). Model performance was assessed using the area under the receiver operating curve (AUC; discrimination) and calibration plots. Validation included univariable screening for clinical variables that could improve performance. RESULTS: Overall, 202 of 952 patients (21%) developed POPF after MIPD. Before adjustment, the original a-FRS performed moderately (AUC 0.68) and calibration was inadequate with systematic underestimation of the POPF risk. Single-row pancreatojejunostomy (odds ratio 4.6, 95 confidence interval [CI] 2.8-7.6) and male sex (odds ratio 1.9, 95 CI 1.4-2.7) were identified as important risk factors for POPF in MIPD. The updated a-FRS, consisting of body mass index, pancreatic texture, duct size, and male sex, showed good discrimination (AUC 0.75, 95 CI 0.71-0.79) and adequate calibration. Performance was adequate for laparoscopic, robot-assisted, and hybrid MIPD and open pancreatoduodenectomy. CONCLUSIONS: The updated a-FRS (www.pancreascalculator.com) now includes male sex as a risk factor and is validated for both MIPD and open pancreatoduodenectomy. The increased risk of POPF in laparoscopic MIPD was associated with single-row pancreatojejunostomy, which should therefore be discouraged.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003234" class="uri">https://doi.org/10.1097/SLA.0000000000003234</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Neuroendocrine Neoplasms Associated with Germline Pathogenic Variants in the Homologous Recombination Pathway</strong> </summary></p>
<p><em>Endocrine pathology 2019 Sep;30(3):237-245</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30772928" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30772928</a></p>
<p>Neuroendocrine neoplasms (NENs) have been primarily associated with germline pathogenic variants in genes involved in chromatin remodeling (MEN1), cell cycle control (CDKN1B), PI3K/mTOR signaling (TSC1/2, PTEN) as well as pseudohypoxia (VHL, SDHx). Recent work has implicated various genes involved in DNA repair pathways in the pathophysiology of a subset of pancreatic neuroendocrine neoplasms, including BRCA2, via the homologous recombination pathway (HRD). To date, germline variants in other HRD pathway genes have not been described to contribute to NEN. PALB2, RAD51C, and BARD1 are additional tumor suppressor genes which also mediate repair of double stranded DNA breaks through the HRD pathway and are implicated in hereditary breast (PALB2; BARD1) and ovarian (RAD51C) cancer. Here we report three cases of NEN associated with germline pathogenic variants in PALB2 (pancreatic NEN), RAD51C (thymic NEN), and BARD1 (pancreaticoduodenal NEN) respectively, further linking the DNA repair pathway to NENs.</p>
<p>doi: <a href="https://doi.org/10.1007/s12022-019-9569-4" class="uri">https://doi.org/10.1007/s12022-019-9569-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>What Is the Peri-Pancreas Cystic Lesion?</strong> </summary></p>
<p><em>Gastroenterology 2019 09;157(3):622-623</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30615877" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30615877</a></p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2018.12.029" class="uri">https://doi.org/10.1053/j.gastro.2018.12.029</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>An Unusual Cause of Acute Pancreatitis in a Young Woman</strong> </summary></p>
<p><em>Gastroenterology 2019 09;157(3):619-621</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30615872" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30615872</a></p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2018.11.080" class="uri">https://doi.org/10.1053/j.gastro.2018.11.080</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Acute Pancreatitis Caused by Isolated Pancreatic Metastasis From Uterine Choriocarcinoma</strong> </summary></p>
<p><em>International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2019 Sep;38(5):430-434</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30028356" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30028356</a></p>
<p>Choriocarcinoma is an aggressive gestational trophoblastic neoplasia known for its widely metastatic potential. However, isolated pancreatic metastasis is an extremely rare occurrence and has not been documented in the English literature to the best of our knowledge. The metastatic deposits in the index case led to widespread hemorrhage and necrosis of the pancreatic parenchyma, causing severe acute pancreatitis. The patient succumbed to her illness before chemotherapy was administered. Thus, we present an autopsy case of a uterine choriocarcinoma with isolated pancreatic metastasis presenting as severe acute pancreatitis in a 27-yr-old woman following a molar pregnancy.</p>
<p>doi: <a href="https://doi.org/10.1097/PGP.0000000000000532" class="uri">https://doi.org/10.1097/PGP.0000000000000532</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>American Gastroenterological Association Clinical Practice Update: Management of Pancreatic Necrosis</strong> </summary></p>
<p><em>Gastroenterology 2020 Jan;158(1):67-75.e1</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31479658" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31479658</a></p>
<p>DESCRIPTION: The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update is to review the available evidence and expert recommendations regarding the clinical care of patients with pancreatic necrosis and to offer concise best practice advice for the optimal management of patients with this highly morbid condition. METHODS: This expert review was commissioned and approved by the AGA Institute Clinical Practice Updates Committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the Clinical Practice Updates Committee and external peer review through standard procedures of Gastroenterology. This review is framed around the 15 best practice advice points agreed upon by the authors, which reflect landmark and recent published articles in this field. This expert review also reflects the experiences of the authors, who are advanced endoscopists or hepatopancreatobiliary surgeons with extensive experience in managing and teaching others to care for patients with pancreatic necrosis. BEST PRACTICE ADVICE 1: Pancreatic necrosis is associated with substantial morbidity and mortality and optimal management requires a multidisciplinary approach, including gastroenterologists, surgeons, interventional radiologists, and specialists in critical care medicine, infectious disease, and nutrition. In situations where clinical expertise may be limited, consideration should be given to transferring patients with significant pancreatic necrosis to an appropriate tertiary-care center. BEST PRACTICE ADVICE 2: Antimicrobial therapy is best indicated for culture-proven infection in pancreatic necrosis or when infection is strongly suspected (ie, gas in the collection, bacteremia, sepsis, or clinical deterioration). Routine use of prophylactic antibiotics to prevent infection of sterile necrosis is not recommended. BEST PRACTICE ADVICE 3: When infected necrosis is suspected, broad-spectrum intravenous antibiotics with ability to penetrate pancreatic necrosis should be favored (eg, carbapenems, quinolones, and metronidazole). Routine use of antifungal agents is not recommended. Computed tomography-guided fine-needle aspiration for Gram stain and cultures is unnecessary in the majority of cases. BEST PRACTICE ADVICE 4: In patients with pancreatic necrosis, enteral feeding should be initiated early to decrease the risk of infected necrosis. A trial of oral nutrition is recommended immediately in patients in whom there is absence of nausea and vomiting and no signs of severe ileus or gastrointestinal luminal obstruction. When oral nutrition is not feasible, enteral nutrition by either nasogastric/duodenal or nasojejunal tube should be initiated as soon as possible. Total parenteral nutrition should be considered only in cases where oral or enteral feeds are not feasible or tolerated. BEST PRACTICE ADVICE 5: Drainage and/or debridement of pancreatic necrosis is indicated in patients with infected necrosis. Drainage and/or debridement may be required in patients with sterile pancreatic necrosis and persistent unwellness marked by abdominal pain, nausea, vomiting, and nutritional failure or with associated complications, including gastrointestinal luminal obstruction; biliary obstruction; recurrent acute pancreatitis; fistulas; or persistent systemic inflammatory response syndrome. BEST PRACTICE ADVICE 6: Pancreatic debridement should be avoided in the early, acute period (first 2 weeks), as it has been associated with increased morbidity and mortality. Debridement should be optimally delayed for 4 weeks and performed earlier only when there is an organized collection and a strong indication. BEST PRACTICE ADVICE 7: Percutaneous drainage and transmural endoscopic drainage are both appropriate first-line, nonsurgical approaches in managing patients with walled-off pancreatic necrosis (WON). Endoscopic therapy through transmural drainage of WON may be preferred, as it avoids the risk of forming a pancreatocutaneous fistula. BEST PRACTICE ADVICE 8: Percutaneous drainage of pancreatic necrosis should be considered in patients with infected or symptomatic necrotic collections in the early, acute period (&lt;2 weeks), and in those with WON who are too ill to undergo endoscopic or surgical intervention. Percutaneous drainage should be strongly considered as an adjunct to endoscopic drainage for WON with deep extension into the paracolic gutters and pelvis or for salvage therapy after endoscopic or surgical debridement with residual necrosis burden. BEST PRACTICE ADVICE 9: Self-expanding metal stents in the form of lumen-apposing metal stents appear to be superior to plastic stents for endoscopic transmural drainage of necrosis. BEST PRACTICE ADVICE 10: The use of direct endoscopic necrosectomy should be reserved for those patients with limited necrosis who do not adequately respond to endoscopic transmural drainage using large-bore, self-expanding metal stents/lumen-apposing metal stents alone or plastic stents combined with irrigation. Direct endoscopic necrosectomy is a therapeutic option in patients with large amounts of infected necrosis, but should be performed at referral centers with the necessary endoscopic expertise and interventional radiology and surgical backup. BEST PRACTICE ADVICE 11: Minimally invasive operative approaches to the debridement of acute necrotizing pancreatitis are preferred to open surgical necrosectomy when possible, given lower morbidity. BEST PRACTICE ADVICE 12: Multiple minimally invasive surgical techniques are feasible and effective, including videoscopic-assisted retroperitoneal debridement, laparoscopic transgastric debridement, and open transgastric debridement. Selection of approach is best determined by pattern of disease, physiology of the patient, experience and expertise of the multidisciplinary team, and available resources. BEST PRACTICE ADVICE 13: Open operative debridement maintains a role in the modern management of acute necrotizing pancreatitis in cases not amenable to less invasive endoscopic and/or surgical procedures. BEST PRACTICE ADVICE 14: For patients with disconnected left pancreatic remnant after acute necrotizing mid-body necrosis, definitive surgical management with distal pancreatectomy should be undertaken in patients with reasonable operative candidacy. Insufficient evidence exists to support the management of the disconnected left pancreatic remnant with long-term transenteric endoscopic stenting. BEST PRACTICE ADVICE 15: A step-up approach consisting of percutaneous drainage or endoscopic transmural drainage using either plastic stents and irrigation or self-expanding metal stents/lumen-apposing metal stents alone, followed by direct endoscopic necrosectomy, and then surgical debridement is reasonable, although approaches may vary based on the available clinical expertise.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.07.064" class="uri">https://doi.org/10.1053/j.gastro.2019.07.064</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comment on Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases</strong> </summary></p>
<p><em>Annals of surgery 2019 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31478983" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31478983</a></p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003600" class="uri">https://doi.org/10.1097/SLA.0000000000003600</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms</strong> </summary></p>
<p><em>Gastroenterology 2020 Jan;158(1):226-237.e5</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31473224" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31473224</a></p>
<p>BACKGROUND &amp; AIMS: Long-term outcomes of patients with branch-duct intraductal papillary mucinous neoplasms (IPMNs), particularly those after 5 years of surveillance, have not been fully evaluated in large studies. We analyzed incidences of IPMN-derived carcinoma and concomitant ductal adenocarcinoma (pancreatic ductal adenocarcinoma [PDAC]) over 20 years in a large population of patients. METHODS: We identified 1404 consecutive patients (52% women; mean age, 67.5 years) with a diagnosis of branch-duct IPMN, from 1994 through 2017, at the University of Tokyo in Japan. Using a competing risk analysis, we estimated cumulative incidence of pancreatic carcinoma, overall and by carcinoma type. We used competing risks proportional hazards models to estimate subdistribution hazard ratios (SHRs) for incidences of carcinomas. To differentiate IPMN-derived and concomitant carcinomas, we collected genomic DNA from available paired samples of IPMNs and carcinomas and detected mutations in GNAS and KRAS by polymerase chain reaction and pyrosequencing. RESULTS: During 9231 person-years of follow-up, we identified 68 patients with pancreatic carcinomas (38 patients with IPMN-derived carcinomas and 30 patients with concomitant PDACs); the overall incidence rates were 3.3%, 6.6%, and 15.0% at 5, 10, and 15 years, respectively. Among 804 patients followed more than 5 years, overall cumulative incidence rates of pancreatic carcinoma were 3.5% at 10 years and 12.0% at 15 years from the initial diagnosis. The size of the IPMN and the diameter of the main pancreatic duct associated with incidence of IPMN-derived carcinoma (SHR 1.85; 95% confidence interval 1.38-2.48 for a 10-mm increase in the IPMN size and SHR 1.56; 95% confidence interval 1.33-1.83 for a 1-mm increase in the main pancreatic duct diameter) but not with incidence of concomitant PDAC. CONCLUSIONS: In a large long-term study of patients with branch-duct IPMNs, we found the 5-year incidence rate of pancreatic malignancy to be 3.3%, reaching 15.0% at 15 years after IPMN diagnosis. We observed heterogeneous risk factor profiles between IPMN-derived and concomitant carcinomas.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.08.032" class="uri">https://doi.org/10.1053/j.gastro.2019.08.032</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Modulation of all-trans retinoic acid-induced MiRNA expression in neoplastic cell lines: a systematic review</strong> </summary></p>
<p><em>BMC cancer 2019 Aug;19(1):866</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31470825" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31470825</a></p>
<p>BACKGROUND: Cancer is a genetic and epigenetic disease that involves inactivation of tumor suppressor genes and activation of proto-oncogenes. All-trans retinoic acid (ATRA) is an isomer of retinoic acid involved in the onset of differentiation and apoptosis of a number of normal and cancer cells, functioning as an anti-cancer agent in several neoplasms. Ectopic changes in the expression of certain microRNAs (miRNAs) occur in response to ATRA, leading to phenotypic alterations in neoplastic cell lines. Moreover, the modulation of miRNA patterns upon ATRA-treatment may represent an effective chemopreventive and anti-cancer therapy strategy. The present systematic review was performed to provide an overview of the modulation of ATRA-induced miRNA expression in different types of neoplastic cells and identify the efficacy of intervention factors (i.e., concentration and duration of treatment) and how they influence expression profiles of oncogenesis-targeting miRNAs. METHODS: A systematic search was conducted according to the PRISMA statement via the US National Library of Medicine MEDLINE/PubMed bibliographic search engine. RESULTS: The search identified 31 experimental studies involving human cell lines from nine different cancer types (neuroblastoma, acute myeloid leukemia, breast cancer, lung cancer, pancreatic cancer, glioma, glioblastoma, embryonal carcinoma, and colorectal cancer) treated with ATRA at concentrations ranging from 10-3mol/L to 102molmol/L for 24h to 21days. CONCLUSION: The concentrations used and the duration of treatment of cancer cells with ATRA varied widely. The presence of ATRA in the culture medium of cancer cells was able to modulate the expression of more than 300 miRNAs, and inhibit invasive behavior and deregulated growth of cancer cells, resulting in total tumor remission in some cases. ATRA may thus be broadly effective for neoplasm treatment and prevention, although these studies may not accurately represent in vivo conditions. Additional studies are required to elucidate ATRA-induced miRNA modulation during neoplasm treatment.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6081-7" class="uri">https://doi.org/10.1186/s12885-019-6081-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>CA19-9 decrease and survival according to platelet level in patients with advanced pancreatic cancer</strong> </summary></p>
<p><em>BMC cancer 2019 Aug;19(1):860</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31470818" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31470818</a></p>
<p>BACKGROUND: CA19-9 decrease during treatment has been associated with superior survival of pancreatic cancer in several studies. The evidence to show the correlation of high platelet level with inferior survival is insufficient in pancreatic cancer. It also remains unclear whether the association between CA19-9 decrease and survival was corresponded to different levels of platelet in metastatic pancreatic cancer. METHODS: We measured CA19-9 serum concentration and platelet level at baseline and after thesecond cycle of chemotherapy for 200 advanced pancreatic cancer patients. A Cox proportional hazards model was used to compute mortality hazard ratios (HRs) for CA19-9 decrease, adjusting for potential confounders, including age, sex, KPS, prediagnosis body mass index, Diabetes Mellitus, tumor location, first-line chemotherapy regimen, and radiotherapy. RESULTS: We found that the association of CA19-9 decrease with superior overall survival was stronger in advanced pancreatic cancer with a low level of platelet (Pinteraction&lt;0.001) compared with intermediate and high level of platelet. Multivariable-adjusted hazard ratios per unit decrease of CA19-9 change was 0.45 [95% confidence interval (CI), 0.33 to 0.62] in cases withlow platelet level, 0.74 (95% CI, 0.50 to 1.09) in cases withintermediate platelet level, and 0.94 (95% CI, 0.74 to 1.10) in cases withhigh platelet level. A similar differential association was found between CA19-9 decrease and progression-free survival in strata of platelet level (Pinteraction=0.034). CONCLUSION: The association of CA19-9 decrease with superior pancreatic cancer survival appeared to be pronounced in patients with a low platelet level. This finding could provide supports for the underlying mechanisms of CA19-9 involved in platelet / tumor cell interaction.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6078-2" class="uri">https://doi.org/10.1186/s12885-019-6078-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study</strong> </summary></p>
<p><em>BMC cancer 2019 Aug;19(1):858</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31464604" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31464604</a></p>
<p>BACKGROUND: Nested case-control studies examining the association between serum markers of chronic inflammation, focused on three specific biomarkers (CRP, IL-8 and TNF-), and risk of pancreatic cancer have reported no associations. In this study, we evaluated associations between standard pre-diagnostic serum markers of chronic inflammation (CRP, albumin, haptoglobin and leukocytes) and pancreatic cancer risk in the Swedish Apolipoprotein-related MORtality RISk (AMORIS) prospective cohort study. METHODS: We selected all participants (20years old) with baseline measurements of CRP, albumin, haptoglobin and leukocytes between 1985 and 1996 (n=61,597). Participants were excluded if they had a history of chronic pancreatitis and all individuals were free from pancreatic cancer at baseline. Cox proportional multivariable hazards regression analysis was carried out for medical cut-offs of CRP, albumin, haptoglobin and leukocytes. RESULTS: We observed an increased risk of pancreatic cancer for those individuals with higher levels of serum haptoglobin (1.4g/L), CRP (10mg/L) and leukocytes (10109 cells/L) compared to those with haptoglobin levels &lt;1.4g/L, CRP levels &lt;10mg/L and Leukocyte levels &lt;10109 cells/L [haptoglobin HR: 2.23 (95% CI 1.72-2.88), CRP HR: 1.32 (95% CI 1.00-1.74), leukocytes HR: 2.20 (95% CI 1.52-3.18)]. No associations were noted for serum albumin. CONCLUSIONS: We found an increased risk of pancreatic cancer associated with pre-diagnostic serum levels of haptoglobin, CRP and leukocytes. Our finding suggests a possible role of chronic inflammation in the aetiology of pancreatic cancer and highlight the need to further investigate this association.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6082-6" class="uri">https://doi.org/10.1186/s12885-019-6082-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>High Co-expression of Large Tenascin C Splice Variants in Stromal Tissue and Annexin A2 in Cancer Cell Membranes is Associated with Poor Prognosis in Pancreatic Cancer</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31463696" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31463696</a></p>
<p>BACKGROUND: Pancreatic cancer tissue contains abundant stromal components, including extracellular matrix proteins such as tenascin C (TNC), which exists as large (TNC-L) and non-large splice variants. Here, we examined human pancreatic cancer specimens for the expression of total TNC (TNC-ALL) and TNC-L in the stroma and annexin A2 (ANXA2), a cell surface receptor for TNC, and evaluated their significance as prognostic markers for pancreatic cancer. METHODS: Expression of ANXA2, TNC-ALL, and TNC-L was examined in 106 pancreatic cancer tissues from patients who underwent curative resection and who had not received prior therapy or surgery. Protein expression was measured by immunohistochemistry and scored on a semi-quantitative scale. The relationships between protein expression, clinicopathological factors, and prognosis were evaluated by Cox proportional hazards analysis. RESULTS: TNC-ALL and TNC-L were detected mainly in the stroma, whereas ANXA2 was predominantly expressed in cancer cell membranes. TNC-ALL was also expressed in non-tumor pancreatic tissue. High levels of stromal TNC-L and membranous ANXA2, but not stromal TNC-ALL, were independently associated with cancer progression and poor prognosis. Moreover, high co-expression of stromal TNC-L and membranous ANXA2 was a superior indicator of poor prognosis compared with detection of TNC-ALL, TNC-L, or ANXA2 alone. CONCLUSIONS: Our data suggest that co-expression of stromal TNC-L and membranous ANXA2 is a poor prognostic marker compared with detection of TNC-L or ANXA2 alone for pancreatic cancer patients. Additionally, targeting of crosstalk between stromal TNC and cancer cell ANXA2 could be a promising therapeutic strategy to overcome refractory pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07708-x" class="uri">https://doi.org/10.1245/s10434-019-07708-x</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system</strong> </summary></p>
<p><em>Gut 2019 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31462556" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31462556</a></p>
<p>OBJECTIVE: Insulinomas and non-functional pancreatic neuroendocrine tumours (NF-PanNETs) have distinctive clinical presentations but share similar pathological features. Their genetic bases have not been comprehensively compared. Herein, we used whole-genome/whole-exome sequencing (WGS/WES) to identify genetic differences between insulinomas and NF-PanNETs. DESIGN: The mutational profiles and copy-number variation (CNV) patterns of 211 PanNETs, including 84 insulinomas and 127 NF-PanNETs, were obtained from WGS/WES data provided by Peking Union Medical College Hospital and the International Cancer Genome Consortium. Insulinoma RNA sequencing and immunohistochemistry data were assayed. RESULTS: PanNETs were categorised based on CNV patterns: amplification, copy neutral and deletion. Insulinomas had CNV amplifications and copy neutral and lacked CNV deletions. CNV-neutral insulinomas exhibited an elevated rate of YY1 mutations. In contrast, NF-PanNETs had all three CNV patterns, and NF-PanNETs with CNV deletions had a high rate of loss-of-function mutations of tumour suppressor genes. NF-PanNETs with CNV alterations (amplification and deletion) had an elevated risk of relapse, and additional DAXX/ATRX mutations could predict an increased relapse risk in the first 2-year period. CONCLUSION: These WGS/WES data allowed a comprehensive assessment of genetic differences between insulinomas and NF-PanNETs, reclassifying these tumours into novel molecular subtypes. We also proposed a novel relapse risk stratification system using CNV patterns and DAXX/ATRX mutations.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2018-317233" class="uri">https://doi.org/10.1136/gutjnl-2018-317233</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cell block processing is optimal for assessing endoscopic ultrasound fine needle aspiration specimens of pancreatic mucinous cysts</strong> </summary></p>
<p><em>Journal of clinical pathology 2019 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31462450" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31462450</a></p>
<p>AIMS: The cell block technique for assessing endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) specimens from pancreatic mucinous cystic lesions (MCLs) was systematically evaluated for the first time, including comparisons with three traditional methods of assessing such specimens. METHODS: The prospective arm comprised EUS-FNA specimens from EUS-suspected pancreatic MCLs. The retrospective arm comprised EUS-FNA specimens from pancreatic MCLs surgically resected before the study start. For each specimen, these data points were collected: macroscopic likelihood of mucin, cyst fluid carcinoembryonic antigen (CEA) level and presence of mucin in air-dried, direct smears and in cell block preparations. RESULTS: The prospective and retrospective arms of the study comprised 80 and 30 EUS-FNA specimens, respectively. Seven prospective cases led to surgical resections during the study, and therefore, 37 EUS-FNA specimens were confirmed to have originated from MCLs. In the prospective arm, macroscopic mucin was suspected, cyst fluid CEA level exceeded 192ng/mL, mucin was detected in direct smears and cell block preparations in 78%, 30%, 39% and 73% of cases, respectively. Of the 37 specimens confirmed to originate from MCLs, macroscopic mucin assessment, cyst fluid CEA level, direct smear mucin assessment and cell block mucin assessment had sensitivities for diagnosing MCL of 87%, 45%, 45% and 81%, respectively. CONCLUSIONS: Cell block preparations are as likely to identify mucin from pancreatic MCLs as macroscopic assessment but are twice as likely to diagnose MCL than direct smears and fluid CEA biochemistry. The cell block technique is easy for sample collection and processing especially because these are identical for solid and cystic pancreatic lesions.</p>
<p>doi: <a href="https://doi.org/10.1136/jclinpath-2019-206079" class="uri">https://doi.org/10.1136/jclinpath-2019-206079</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis</strong> </summary></p>
<p><em>BMC cancer 2019 Aug;19(1):849</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31462241" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31462241</a></p>
<p>BACKGROUND: Recent years have witnessed the rapid evolution of therapies in chronic-phase chronic myeloid leukemia (CP-CML). To assess the efficacy and tolerability of all reported front-line treatments for patients with newly diagnosed CML, a multiple-treatments meta-analysis was performed, which accounted for both direct and indirect comparisons among those treatments. METHODS: Primary outcomes were the percentage of patients achieving major molecular response (MMR) and complete cytogenetic response (CCyR) within 12months. Secondary outcomes included the percentage of progression to accelerated phase (AP), serious adverse effects (AEs), overall discontinuation and discontinuation for drug-related AEs. Direct pairwise meta-analysis and indirect multi-comparison meta-analysis among those treatments in each outcome were both conducted. The surface under the cumulative ranking curve (SUCRA) was calculated for all treatments in each outcome. Cluster analysis demonstrated the division of treatments into distinct groupings according to efficacy and tolerability profiles. RESULTS: A total of 21 randomizedcontrolled trials(RCTs,including10,187 patients) comparing 15 different interventions for CP-CMLpatients were included in this study. SUCRA analysis suggested that all tyrosine kinase inhibitors (TKIs) are highly effective in newly diagnosed CP-CML when compared to traditional drugs. Newer TKIs and higher-dose imatinib generally resulted in faster cytogenetic and molecular responses when compared with standard-dose imatinib and traditional drugs. Furthermore, traditional drugs, higher-dose imatinib and newer TKIs demonstrated lower acceptability than standard-dose imatinib. One cluster of interventions, which included nilotinib (300/400mg BID), dasatinib (100mg QD) and radotinib (300mg BID), demonstrated higher efficacy and tolerability than other treatments. CONCLUSIONS: Nilotinib (300/400mg BID), dasatinib (100mg QD) and radotinib (300mg BID) prove to be the most recommended front-line treatments of the greatest efficacy and tolerability for CP-CML patients. High-dose therapies are recommended only for patients in accelerated phase/blast phase or with suboptimal CML-CP response, and management of adverse events should be carried out to avoid compromising the clinical efficacy.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6039-9" class="uri">https://doi.org/10.1186/s12885-019-6039-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Risk analysis of extended pancreas donor selection criteria</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Oct;19(7):994-999</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31495709" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31495709</a></p>
<p>INTRODUCTION: The success of pancreas transplantation, in combination with a stable number of available allografts has resulted in an increasing waiting list. This study investigated donor potential by expanding age and Body Mass Index (BMI) criteria. METHODS: All reported donors in the Netherlands between 2013 and 2017 were analysed. Risk assessment of extended criteria donors was done by in-depth analysis of donor reports and calculation of the Pancreas Donor Risk Index (PDRI). The PDRI of these extended criteria donors was compared to standard criteria donors to evaluate the increased risk on graft failure. RESULTS: A total of 1273 donors were reported. Of these donors, 405 donors were reported as pancreas donor, of which 93 (23%) pancreata were transplanted. Extending age criterion with 5 years could result in additional 40 Donation after Brain Death donors and 37 Donation after Circulatory Death donors reported. In 24 (31%) extended age criteria donors the PDRI was below the upper limit of currently transplanted pancreata. Extending BMI criteria to 35kg/m2 could result in an additional 19 (6%) donors reported. CONCLUSIONS: Extending BMI criteria could result in a slight increase of reported donors. Extending age criteria increased significantly the number of reported donors. In 24 (31%) of the older donors the PDRI showed a reduced risk compared to currently transplanted pancreata. This study suggest that, if other risk factors are absent, pancreata of extended age and/or BMI criteria donors should be considered for transplantation.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.08.010" class="uri">https://doi.org/10.1016/j.pan.2019.08.010</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreatic calcifications associate with diverse aetiological risk factors in patients with chronic pancreatitis: A multicentre study of 1500 cases</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Oct;19(7):922-928</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31462382" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31462382</a></p>
<p>BACKGROUND: Pancreatic calcifications is a common finding in patients with chronic pancreatitis (CP), but the underlying pathophysiology is incompletely understood. Past studies for risk factors of calcifications have generally been focused on single parameters or limited by small sample sizes. The aim of this study was to explore several patient and disease characteristics and their associations with pancreatic calcifications in a large cohort of CP patients with diverse aetiological risk factors. METHODS: This was a multicentre, cross-sectional study including 1509 patients with CP. Patient and disease characteristics were compared for patients with calcifications (n=912) vs.without calcifications (n=597). Multivariable logistic regression was performed to assess the parameters independently associated with calcifications. RESULTS: The mean age of patients was 53.914.5 years and 1006 (67%) were men. The prevalence of calcifications was 60.4% in the overall patient cohort, but highly variable between patients with different aetiological risk factors (range: 2-69%). On multivariate analysis, alcoholic aetiology (OR 1.76 [95% CI, 1.39-2.24]; p&lt;0.001) and smoking aetiology (OR 1.77 [95% CI, 1.39-2.26], p&lt;0.001) were positively associated with the presence of calcifications, while an autoimmune aetiology was negatively associated with calcifications (OR 0.15 [95% CI, 0.08-0.27], p&lt;0.001). Patients with pancreatic calcifications were more likely to have undergone pancreatic duct stenting (OR 1.59 [95%CI, 1.16-2.19], p=0.004). CONCLUSION: The presence of pancreatic calcifications is associated with diverse aetiological risk factors in patients with CP. This observation attest to the understanding of CP as a complex disease and may have implications for disease classification.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.08.009" class="uri">https://doi.org/10.1016/j.pan.2019.08.009</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Preoperative Risk Assessment for Loss of Independence Following Hepatic Resection in Elderly Patients: A Prospective Multicenter Study</strong> </summary></p>
<p><em>Annals of surgery 2019 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31460876" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31460876</a></p>
<p>OBJECTIVE: To establish a preoperative risk assessment method for loss of independence after hepatic resection. SUMMARY BACKGROUND DATA: Hepatic resection often results in loss of independence in preoperatively self-sufficient elderly people. Elderly patients should therefore be carefully selected for surgery. METHODS: In this prospective, multicenter study, 347 independently-living patients aged 65 years, scheduled for hepatic resection, were divided into study (n = 232) and validation (n = 115) cohorts. We investigated the risk factors for postoperative loss of independence in the study cohort and verified our findings with the validation cohort. Loss of independence was defined as transfer to a rehabilitation facility, discharge to residence with home-based healthcare, 30-day readmission for poor functionality, and 90-day mortality (except for cancer-related deaths). RESULTS: In the study cohort, univariate and multivariate analyses indicated that frailty, age  76 years, and open surgery were independent risk factors for postoperative loss of independence. Proportions of patients with postoperative loss of independence in the study and validation cohorts were respectively 3.0% and 0% among those with no applicable risk factors, 8.1% and 12.5% among those with 1 applicable risk factor, 25.5% and 25.0% among those with 2 applicable risk factors, and 56.3% and 50.0% among those with all 3 factors applicable (P &lt; 0.001 for both cohorts). Areas under the receiver operating characteristic curves for the study and validation groups were 0.777 and 0.783, respectively. CONCLUSIONS: Preoperative risk assessments using these 3 factors may be effective in predicting and planning for postoperative loss of independence after hepatic resection in elderly patients.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003585" class="uri">https://doi.org/10.1097/SLA.0000000000003585</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Management of Locally Advanced Pancreatic Cancer: Results of an International Survey of Current Practice</strong> </summary></p>
<p><em>Annals of surgery 2019 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31449138" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31449138</a></p>
<p>MINI: An international survey of high-volume pancreas cancer surgeons revealed wide variations in management preferences, attitudes regarding contraindications to surgery, and the propensity to offer exploration. When presented with 6 hypothetical clinical vignettes using details from real patients that have received R0 resection, only 14% to 53% of participating surgeons were willing to offer exploration following neoadjuvant therapy. The aim of this study was to investigate surgeon preferences for the management of patients with locally advanced pancreatic cancer (LAPC). Select patients with LAPC may become candidates for curative resection following neoadjuvant therapy, and recent reports of survival are encouraging. Yet the optimal management approach remains unclear. An extensive electronic survey was systematically distributed by email to an international cohort of pancreas surgeons. Data collected included practice characteristics, management preferences, attitudes regarding contraindications to surgery, and 6 clinical vignettes of patients that ultimately received a margin negative resection (with detailed videos of post-neoadjuvant imaging) to assess propensity for surgical exploration if resection status is not known. A total of 153 eligible responses were received from 4 continents. Median duration of practice is 12 years (interquartile range 6-20) and 77% work in a university setting. Most surgeons (86%) are considered high volume (&gt;10resections/yr), 33% offer a minimally-invasive approach, and 50% offer arterial resections in select patients. Most (72%) always recommend neoadjuvant chemotherapy, and 65% prefer FOLFIRINOX. Preferences for the duration of chemotherapy varied widely: 39% prefer 2 months, 43% prefer 4 months, and 11% prefer 6 months. Forty-one percent frequently recommend neoadjuvant radiotherapy, and 53% prefer 5 to 6 weeks of chemoradiation. The proportion of surgeons favoring exploration following neoadjuvant varied extensively across 5 vignettes of LAPC, from 14% to 53%. In a vignette of oligometastatic liver metastases, 31% would offer exploration if a favorable therapy response is observed. In an international cohort of pancreas surgeons, there is substantial variation in management preferences, perceived contraindications to surgery, and the propensity to consider exploration in LAPC. These results emphasize the importance of a robust and nuanced multidisciplinary discussion for each patient, and suggest an evolving concept of resectability.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003568" class="uri">https://doi.org/10.1097/SLA.0000000000003568</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Primary pancreatic diffuse large B-cell lymphoma diagnosed by endoscopic ultrasound guided FNAC: A rare entity</strong> </summary></p>
<p><em>Diagnostic cytopathology 2020 Jan;48(1):57-60</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31444945" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31444945</a></p>
<p>Primary pancreatic lymphoma (PPL) is an uncommon neoplasm which can clinico-radiologically mimic carcinoma. But the management of these patients differs from that of a carcinoma. Endoscopic ultrasound (EUS) guided fine-needle aspiration (FNA) serves as a potential tool to identify pancreatic lymphomas and thus prevent an invasive diagnostic test. This case report describes the presentation and diagnosis of primary pancreatic lymphoma. A 37-year-old female presented with nausea, vomiting with signs of icterus and elevated liver function test and Bilirubin. Abdominal computed tomography (CT) revealed a hypodense lesion in the head of the pancreas. EUS guided FNA was performed and cytological material was collected. The lesion was diagnosed as Non-Hodgkin Lymphoma (NHL) and subtyped as diffuse large B-cell lymphoma-germinal centre (DLBCL-GCB) base on immunohistochemistry on cell block. The patient was started on rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (RCHOP) regimen. EUS guided FNA along with ROSE, cell bock, and immunocytochemistry helps in the diagnosis of primary pancreatic lymphoma.</p>
<p>doi: <a href="https://doi.org/10.1002/dc.24307" class="uri">https://doi.org/10.1002/dc.24307</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer</strong> </summary></p>
<p><em>Proceedings of the National Academy of Sciences of the United States of America 2019 Aug;116(35):17450-17459</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31399545" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31399545</a></p>
<p>Although KRAS and TP53 mutations are major drivers of pancreatic ductal adenocarcinoma (PDAC), the incurable nature of this cancer still remains largely elusive. ARF6 and its effector AMAP1 are often overexpressed in different cancers and regulate the intracellular dynamics of integrins and E-cadherin, thus promoting tumor invasion and metastasis when ARF6 is activated. Here we show that the ARF6-AMAP1 pathway is a major target by which KRAS and TP53 cooperatively promote malignancy. KRAS was identified to promote eIF4A-dependent ARF6 mRNA translation, which contains a quadruplex structure at its 5-untranslated region, by inducing TEAD3 and ETV4 to suppress PDCD4; and also eIF4E-dependent AMAP1 mRNA translation, which contains a 5-terminal oligopyrimidine-like sequence, via up-regulating mTORC1. TP53 facilitated ARF6 activation by platelet-derived growth factor (PDGF), via its known function to promote the expression of PDGF receptor  (PDGFR) and enzymes of the mevalonate pathway (MVP). The ARF6-AMAP1 pathway was moreover essential for PDGF-driven recycling of PD-L1, in which KRAS, TP53, eIF4A/4E-dependent translation, mTOR, and MVP were all integral. We moreover demonstrated that the mouse PDAC model KPC cells, bearing KRAS/TP53 mutations, express ARF6 and AMAP1 at high levels and that the ARF6-based pathway is closely associated with immune evasion of KPC cells. Expression of ARF6 pathway components statistically correlated with poor patient outcomes. Thus, the cooperation among eIF4A/4E-dependent mRNA translation and MVP has emerged as a link by which pancreatic driver mutations may promote tumor cell motility, PD-L1 dynamics, and immune evasion, via empowering the ARF6-based pathway and its activation by external ligands.</p>
<p>doi: <a href="https://doi.org/10.1073/pnas.1901765116" class="uri">https://doi.org/10.1073/pnas.1901765116</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Second harmonic generation detection of Ras conformational changes and discovery of a small molecule binder</strong> </summary></p>
<p><em>Proceedings of the National Academy of Sciences of the United States of America 2019 Aug;116(35):17290-17297</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31399543" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31399543</a></p>
<p>Second harmonic generation (SHG) is an emergent biophysical method that sensitively measures real-time conformational change of biomolecules in the presence of biological ligands and small molecules. This study describes the successful implementation of SHG as a primary screening platform to identify fragment ligands to oncogenic Kirsten rat sarcoma (KRas). KRas is the most frequently mutated driver of pancreatic, colon, and lung cancers; however, there are few well-characterized small molecule ligands due to a lack of deep binding pockets. Using SHG, we identified a fragment binder to KRasG12D and used 1H 15N transverse relaxation optimized spectroscopy (TROSY) heteronuclear single-quantum coherence (HSQC) NMR to characterize its binding site as a pocket adjacent to the switch 2 region. The unique sensitivity of SHG furthered our study by revealing distinct conformations induced by our hit fragment compared with 4,6-dichloro-2-methyl-3-aminoethyl-indole (DCAI), a Ras ligand previously described to bind the same pocket. This study highlights SHG as a high-throughput screening platform that reveals structural insights in addition to ligand binding.</p>
<p>doi: <a href="https://doi.org/10.1073/pnas.1905516116" class="uri">https://doi.org/10.1073/pnas.1905516116</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Ovarian Steroid Cell Tumor in an Adolescent With Von Hippel-Lindau Syndrome: A Case Report and Review of the Literature</strong> </summary></p>
<p><em>International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2019 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31433374" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31433374</a></p>
<p>Von Hippel-Lindau (VHL) syndrome is an autosomal dominant genetic disorder caused by germline mutation of the VHL gene. It is associated with multiple neoplasias including hemangioblastoma, clear cell renal cell carcinoma, pheochromocytoma, and neuroendocrine tumors. Ovarian tumors are extremely rare in this syndrome. We describe the case of a 16-yr-old girl with a previous diagnosis of bilateral pheochromocytoma and several pancreatic neuroendocrine tumors in VHL syndrome context. Follow-up abdominal-pelvic magnetic resonance imaging revealed a 33mm, well-circumscribed nodule in the right ovary. The patient was submitted to laparoscopic right salpingo-oophorectomy. Microscopically, the tumor consisted of polygonal cells with abundant microvacuolized clear cytoplasm arranged in a solid pattern. The neoplastic cells were immunohistochemically positive for inhibin and calretinin. A diagnosis of ovarian steroid cell tumor was made. Only 4 cases with this association have been reported to date. Of the previously described cases, only one concerns a child; the others were all adult women. All of them had a previous diagnosis of VHL syndrome and presented with secondary amenorrhea and/or hirsutism due to testosterone-secreting ovarian steroid cell tumors. Although extremely rare, the association between VHL syndrome and ovarian steroid cell tumor has been reported, and our case suggests there is a link between the 2 entities.</p>
<p>doi: <a href="https://doi.org/10.1097/PGP.0000000000000628" class="uri">https://doi.org/10.1097/PGP.0000000000000628</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Treatment of disrupted and disconnected pancreatic duct in necrotizing pancreatitis: A systematic review and meta-analysis</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Oct;19(7):905-915</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31473083" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31473083</a></p>
<p>BACKGROUND: Necrotizing pancreatitis may lead to loss of integrity of the pancreatic duct, resulting in leakage of pancreatic fluid. Pancreatic duct disruption or disconnection is associated with a prolonged disease course and particular complications. Since a standard treatment for this condition is currently lacking, we performed a systematic review of the literature to compare outcomes of various treatment strategies. METHODS: A systematic review was performed according to the PRISMA guidelines in the PubMed, EMBASE and Cochrane databases. Included were articles considering the treatment of patients with disrupted or disconnected pancreatic duct resulting from acute necrotizing pancreatitis. RESULTS: Overall, 21 observational cohort studies were included comprising a total of 583 relevant patients. The most frequently used treatment strategies included endoscopic transpapillary drainage, endoscopic transluminal drainage, surgical drainage or resection, or combined procedures. Pooled analysis showed success rates of 81% (95%-CI: 60-92%) for transpapillary and 92% (95%-CI: 77-98%) for transluminal drainage, 80% (95%-CI: 67-89%) for distal pancreatectomy and 84% (95%-CI: 73-91%) for cyst-jejunostomy. Success rates did not differ between surgical procedures (cyst-jejunostomy and distal pancreatectomy (risk ratio=1.06, p=.26)) but distal pancreatectomy was associated with a higher incidence of endocrine pancreatic insufficiency (risk ratio=3.06, p=.01). The success rate of conservative treatment is unknown. DISCUSSION: Different treatment strategies for pancreatic duct disruption and duct disconnection after necrotizing pancreatitis show high success rates but various sources of bias in the available studies are likely. High-quality prospective, studies, including unselected patients, are needed to establish the most effective treatment in specific subgroups of patients, including timing of treatment and long-term follow-up.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.08.006" class="uri">https://doi.org/10.1016/j.pan.2019.08.006</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Obesity and pancreatic cancer: An update of epidemiological evidence and molecular mechanisms</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Oct;19(7):941-950</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31447281" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31447281</a></p>
<p>Despite advances in therapy and achievements in translational research, pancreatic cancer (PC) remains an invariably fatal malignancy. Risk factors that affect the incidence of PC include diabetes, smoking, obesity, chronic pancreatitis, and diet. The growing worldwide obesity epidemic is associated with an increased risk of the most common cancers, including PC. Chronic inflammation, hormonal effects, circulating adipokines, and adipocyte-mediated inflammatory and immunosuppressive microenvironment are involved in the association of obesity with PC. Herein, we systematically review the epidemiology of PC and the biological mechanisms that may account for this association. Included in this review is a discussion of adipokine-mediated inflammation, lipid metabolism, and the interactions of adipocytes with cancer cells. We consider the influence of bariatric surgery on the risk of PC risk as well as potential molecular targets of therapy. Our review leads us to conclude that targeting adipose tissue to achieve weight loss may represent a new therapeutic strategy for preventing and treating PC.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.08.008" class="uri">https://doi.org/10.1016/j.pan.2019.08.008</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A rational approach to postoperative surveillance for resected non-functional pancreatic neuro-endocrine tumours</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Oct;19(7):1000-1007</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31445889" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31445889</a></p>
<p>BACKGROUND: Non-functional pancreatic neuroendocrine tumours (NF-PNETs) are rare and have highly variable outcomes. Current guidelines recommend surveillance for NF-PNETs &lt;2cm. Patients who ultimately have surgical resection are at risk of disease recurrence, and data to support postoperative surveillance protocols are lacking. The aims of this study were to i) identify post-operative predictors of recurrence and ii) risk stratify patients at risk of recurrence. METHODS: Consecutive patients who underwent surgery for NF-PNETs between 2002 and 2015 were identified retrospectively. Data were collected on demographics, pre-operative laboratory results and histopathological tumour characteristics. Statistical analyses were based on penalised Cox-regression modelling and a decision-tree model. Comparison of the variables identified was performed using ROC curves to identify the most sensitive and specific variable associated with disease recurrence. RESULTS: We identified 73 patients (38 males) with a median age of 61.5 years (range: 31-79). The median period of follow-up was 49 months (5-131). During follow up, 10 deaths (13.9%) were recorded and disease recurrence occurred in 12 patients (16.4%). The Kaplan-Meier predicted 1-,3- and 5-year recurrence-free survival rates were 98.6% (95% CI=95.9, 100%), 85.4% (76.9-94.8%) and 72% (58.7-88.2%) respectively. Cox multivariate analysis identified poor tumour differentiation (WHO G3 grade) and lymph node ratio (LNR) as independent predictors for recurrence (p&lt;0.05). A simple criterion of tumour grade G3 or LNR 0.1 was found to be sensitive and specific in detecting disease recurrence. CONCLUSION: Our results have identified a simple and sensitive criterion for risk stratifying post-resection surveillance. Prospective validation in larger patient cohort is now warranted.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.08.005" class="uri">https://doi.org/10.1016/j.pan.2019.08.005</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreatic tumor in type 1 autoimmune pancreatitis: a diagnostic challenge</strong> </summary></p>
<p><em>BMC cancer 2019 Aug;19(1):814</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31419961" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31419961</a></p>
<p>BACKGROUND: The co-occurrence of type 1 autoimmune pancreatitis (AIP) and pancreatic tumor (PaT) has been previously reported. Pure AIP cases have favorable prognosis and are primarily treated with steroids, while AIP cases with PaT are associated with poor prognosis where the primary management is pancreatic resection. However, its a challenge to timely identify the concurrent PaT in AIP because of their similar clinical and radiological manifestations. METHODS: We retrospectively reviewed the data in two medical centers from January 2010 to April 2019. The inclusion criteria were as follows: 1) completion of abdominal CT imaging before invasive procedures to the pancreas, 2) a final diagnosis of type 1 AIP using the 2011 international consensus diagnostic criteria, 3) follow-up duration of at least one month unless AIP and PaT were identified simultaneously. The presence of PaT in AIP was made based on histopathological confirmation, and the absence of PaT in AIP was defined as no pathological or radiological evidence of concurrent PaT. Clinical and radiological characteristics including gender, age, surveillance period, serum IgG4 and Ca-199 levels, biopsy, extrapancreatic involvement, CT and MR (if performed) imaging characteristics were compared between AIP with and without PaT. The Fishers exact test was used for qualitative variables, and nonparametric Mann-Whitney test for quantitative variables. A p value 0.05 was considered statistically significant. RESULTS: A total of 74 patients with type 1 AIP were included, of which 5 (6.7%) had the concurrent PaT. The subtypes were pancreatic ductal adenocarcinoma (3/5), solitary extramedullary plasmacytoma in the pancreas (1/5) and cholangiocarcinoma in the pancreatic segment (1/5), respectively. Gender (p=0.044), the pattern of pancreatic enlargement (p=0.003), heterogeneity (p=0.015), low-density (p=0.004) on CT and rim enhancement on MRI (p=0.050) differed significantly between AIP with and without PaT. None of the low-density characteristics on CT or other assessed MRI characteristics could significantly differentiate the two groups (p&gt;0.05). CONCLUSIONS: Female, focal pancreatic enlargement, pancreatic heterogeneity, low-density on CT and rim enhancement on MRI are suggestive of the concurrent PaT in type 1 AIP. The characteristics of low-density on CT or other MRI characteristics did not provide further diagnostic values.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6027-0" class="uri">https://doi.org/10.1186/s12885-019-6027-0</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>African American women with gum disease and tooth loss face higher pancreatic cancer risk</strong> </summary></p>
<p><em>Cancer 2019 Aug;125(16):2719</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31355935" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31355935</a></p>
<p>doi: <a href="https://doi.org/10.1002/cncr.32413" class="uri">https://doi.org/10.1002/cncr.32413</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Aug;25(16):4973-4984</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31142500" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31142500</a></p>
<p>PURPOSE: In research settings, circulating tumor DNA (ctDNA) shows promise as a tumor-specific biomarker for pancreatic ductal adenocarcinoma (PDAC). This study aims to perform analytical and clinical validation of a KRAS ctDNA assay in a Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathology-certified clinical laboratory. EXPERIMENTAL DESIGN: Digital-droplet PCR was used to detect the major PDAC-associated somatic KRAS mutations (G12D, G12V, G12R, and Q61H) in liquid biopsies. For clinical validation, 290 preoperative and longitudinal postoperative plasma samples were collected from 59 patients with PDAC. The utility of ctDNA status to predict PDAC recurrence during follow-up was assessed. RESULTS: ctDNA was detected preoperatively in 29 (49%) patients and was an independent predictor of decreased recurrence-free survival (RFS) and overall survival (OS). Patients who had neoadjuvant chemotherapy were less likely to have preoperative ctDNA than were chemo-nave patients (21% vs.69%; P &lt; 0.001). ctDNA levels dropped significantly after tumor resection. Persistence of ctDNA in the immediate postoperative period was associated with a high rate of recurrence and poor median RFS (5 months). ctDNA detected during follow-up predicted clinical recurrence [sensitivity 90% (95% confidence interval (CI), 74%-98%), specificity 88% (95% CI, 62%-98%)] with a median lead time of 84 days (interquartile range, 25-146). Detection of ctDNA during postpancreatectomy follow-up was associated with a median OS of 17 months, while median OS was not yet reached at 30 months for patients without ctDNA (P = 0.011). CONCLUSIONS: Measurement of KRAS ctDNA in a CLIA laboratory setting can be used to predict recurrence and survival in patients with PDAC.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-0197" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-0197</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Aug;25(16):5122-5134</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31113844" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31113844</a></p>
<p>PURPOSE: The response to acute and long-term arginine starvation results in a conditional adaptive metabolic reprogramming that can be harnessed for therapeutic opportunities in ASS1-negative tumors. Here, we investigate the underlying biology of priming ASS1- tumors with arginine deiminase (ADI-PEG20) before treatment with gemcitabine (GEM) and docetaxel (DTX) in sarcoma, pancreatic cancer, and melanoma cell lines. EXPERIMENTAL DESIGN: ASS1- tumor cell lines were treated to create LTAT (long-term ADI treated) cell lines (ASS1+) and used for drug combination studies. Protein expression of ASS1, dCK, RRM2, E2F1, c-MYC, and hENT1 was measured. c-MYC activity was determined, live-cell immunofluorescent studies for hENT1, uptake assays of FITC-cytosine probe, and rescue studies with a c-MYC inhibitor were all determined in the presence or absence of the ADI-PEG20:GEM:DTX. RESULTS: In examining modulations within the pyrimidine pathway, we identified that the addition of DTX to cells treated with ADI-PEG20 resulted in translocation of stabilized c-Myc to the nucleus. This resulted in an increase of hENT1 cell-surface expression and rendered the cells susceptible to GEM. In vivo studies demonstrate that the combination of ADI-PEG20:GEM:DTX was optimal for tumor growth inhibition, providing the preclinical mechanism and justification for the ongoing clinical trial of ADI-PEG20, GEM, and DTX in sarcoma. CONCLUSIONS: The priming of tumors with ADI-PEG20 and DTX results in the stabilization of c-MYC potentiating the effect of GEM treatment via an increase in hENT1 expression. This finding is applicable to ASS1-deficient cancers that are currently treated with GEM.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-0206" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-0206</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Advanced stage at diagnosis and elevated mortality among US patients with cancer infected with HIV in the National Cancer Data Base</strong> </summary></p>
<p><em>Cancer 2019 Aug;125(16):2868-2876</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31050361" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31050361</a></p>
<p>BACKGROUND: People living with HIV (PLWH) are at an increased risk of developing several cancers, but to the authors knowledge less is known regarding how HIV impacts the rate of progression to advanced cancer or death. METHODS: The authors compared stage of disease at the time of presentation and mortality after diagnosis between 14,453 PLWH and 6,368,126 HIV-uninfected patients diagnosed with cancers of the oral cavity, stomach, colorectum, anus, liver, pancreas, lung, female breast, cervix, prostate, bladder, kidney, and thyroid and melanoma using data from the National Cancer Data Base (2004-2014). Polytomous logistic regression and Cox proportional hazards regression were used to evaluate the association between HIV, cancer stage, and stage-adjusted mortality after diagnosis, respectively. Regression models accounted for the type of health facility at which cancer treatment was administered and the type of individual health insurance. RESULTS: HIV-infected patients with cancer were found to be more likely to be uninsured (HIV-infected: 5.0% vs HIV-uninfected: 3.3%; P&lt;.0001) and were less likely to have private health insurance (25.4% vs 44.7%; P&lt;.0001). Compared with those not infected with HIV, the odds of being diagnosed at an advanced stage of disease were significantly elevated in PLWH for melanoma and cancers of the oral cavity, liver, female breast, prostate, and thyroid (odds ratio for stage IV vs stage I range, 1.24-2.06). PLWH who were diagnosed with stage I to stage III disease experienced elevated mortality after diagnosis across 13 of the 14 cancer sites evaluated, with hazard ratios ranging from 1.20 (95% CI, 1.14-1.26) for lung cancer to 1.85 (95% CI, 1.68-2.04), 1.85 (95% CI, 1.51-2.27), and 2.93 (95% CI, 2.08-4.13), respectively, for cancers of the female breast, cervix, and thyroid. CONCLUSIONS: PLWH were more likely to be diagnosed with advanced-stage cancers and to experience elevated mortality after a cancer diagnosis, even after accounting for health care-related factors.</p>
<p>doi: <a href="https://doi.org/10.1002/cncr.32158" class="uri">https://doi.org/10.1002/cncr.32158</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Detection of NRG1 Gene Fusions in Solid Tumors</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Aug;25(16):4966-4972</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30988082" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30988082</a></p>
<p>PURPOSE: NRG1 gene fusions are rare but potentially actionable oncogenic drivers that are present in some solid tumors. Details regarding the incidence of these gene rearrangements are lacking. Here, we assessed the incidence of NRG1 fusions across multiple tumor types and described fusion partners. EXPERIMENTAL DESIGN: Tumor specimens submitted for molecular profiling at a Clinical Laboratory Improvement Amendments (CLIA)-certified genomics laboratory and that underwent fusion testing by anchored multiplex PCR for targeted RNA sequencing were retrospectively identified. The overall and tumor-specific incidence was noted, as was the specific fusion partner. RESULTS: Out of 21,858 tumor specimens profiled from September 2015 to December 2018, 41 cases (0.2%) harbored an NRG1 fusion. Multiple fusion partners were identified. Fusion events were seen across tumor types. The greatest incidence was in non-small cell lung cancer (NSCLC, 25), though this represented only 0.3% of NSCLC cases tested. Other tumor types harboring an NRG1 fusion included gallbladder cancer, renal cell carcinoma, bladder cancer, ovarian cancer, pancreatic cancer, breast cancer, neuroendocrine tumor, sarcoma, and colorectal cancer. CONCLUSIONS: NRG1 fusions can be detected at a low incidence across multiple tumor types with significant heterogeneity in fusion partner.See related commentary by Dimou and Camidge, p.4865.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-0160" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-0160</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Significance of Examined Lymph Node Number in Accurate Staging and Long-term Survival in Resected Stage I-II Pancreatic Cancer-More is Better? A Large International Population-based Cohort Study</strong> </summary></p>
<p><em>Annals of surgery 2019 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31425290" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31425290</a></p>
<p>OBJECTIVE: This large international cohort study aimed to investigate the associations of examined lymph node (ELN) number with accurate staging and long-term survival in pancreatic adenocarcinoma (PaC) and to robustly determine the minimal and optimal ELN thresholds. SUMMARY BACKGROUND DATA: ELN number is an important quality metric in cancer care. The recommended minimal ELN number in PaC to accurately stage cancer varies greatly across guidelines, and the optimal number especially to adequately stratify patient survival has not yet been established. METHODS: Population-based data on patients with stage I to II PaC resected in 2003 to 2015 from the US Surveillance, Epidemiology, and End Results (SEER)-18 Program and Netherlands National Cancer Registry (NCR) were analyzed. Associations of ELN number with stage migration and survival were evaluated using multivariable-adjusted logistic and Cox regression models, respectively. The series of odds ratios (ORs) for negative-to-positive node stage migration and hazard ratios (HRs) for survival with more ELNs were fitted using a LOWESS smoother, and structural breakpoints were determined by Chow test. RESULTS: Overall 16,241 patients were analyzed. With increasing ELN number, both cohorts exhibited significant proportional increases from node-negative to node-positive disease [ORSEER-18=1.05, 95% confidence interval (CI) = 1.04-1.05; ORNCR = 1.10, 95% CI = 1.08-1.12] and serial improvements in survival (HRSEER-18 = 0.98, 95% CI = 0.98-0.99; HRNCR = 0.98, 95% CI = 0.97-0.99) per additional ELN after controlling for confounders. Associations for stage migration and survival remained significant in most stratifications by patient, tumor, and treatment factors. Cut-point analyses suggested a minimal threshold ELN number of 11 and an optimal number of 19, which were validated both internally in the derivative US cohort and externally in the Dutch cohort with the ability to well discriminate different probabilities of both survival and stage migration. CONCLUSIONS: In stage I to II PaC, more ELNs are associated with more precise nodal staging, which might largely explain the survival association. Our observational study does not suggest causality, and does not encourage more extended lymphadenectomy before further randomized evidence is obtained. Our results robustly conclude 11 ELNs as the minimal and suggest 19 ELNs as the optimal cut-points, for evaluating quality of lymph node examination and possibly for stratifying postoperative prognosis.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003558" class="uri">https://doi.org/10.1097/SLA.0000000000003558</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Transgenic Expression of PRSS1R122H Sensitizes Mice to Pancreatitis</strong> </summary></p>
<p><em>Gastroenterology 2019 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31419436" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31419436</a></p>
<p>BACKGROUND &amp; AIMS: Mutations in the trypsinogen gene (PRSS1) cause human hereditary pancreatitis. However, it is not clear how mutant forms of PRSS1 contribute to disease development. We studied the effects of expressing mutant forms of human PRSS1 in mice. METHODS: We expressed forms of PRSS1 with and without the mutation encoding R122H (PRSS1R122H) specifically in pancreatic acinar cells under control of a full-length pancreatic elastase gene promoter. Mice that did not express these transgenes were used as controls. Mice were given injections of caerulein to induce acute pancreatitis or injections of lipopolysaccharide (LPS) to induce chronic pancreatitis. Other groups of mice were fed ethanol or placed on a high-fat diet to induce pancreatitis. Pancreata were collected and analyzed by histology, immunoblots, real-time PCR, and immunohistochemistry. Trypsin enzymatic activity and chymotrypsin enzymatic activity were measured in pancreatic homogenates. Blood was collected and serum amylase activity was measured. RESULTS: Pancreata from mice expressing transgenes encoding PRSS1 or PRSS1R122H had focal areas of inflammation; these lesions were more prominent in mice that express PRSS1R122H. Pancreata from mice that express PRSS1 or PRSS1R122H had increased levels of HSP70 and NRF2 and reduced levels of chymotrypsin C (CTRC), compared with control mice. Increased expression of PRSS1 or PRSS1R122H increased focal damage in pancreatic tissues and increased the severity of acute pancreatitis after caerulein injection. Administration of LPS exacerbated inflammation in mice that express PRSS1R122H compared to mice that express PRSS1 or control mice. Mice that express PRSS1R122H developed more severe pancreatitis after ethanol feeding or a high-fat diet than mice that express PRSS1 or control mice. Pancreata from mice that express PRSS1R122H had more DNA damage, apoptosis, and collagen deposition and increased trypsin activity and infiltration by inflammatory cells than mice that express PRSS1 or control mice. CONCLUSIONS: Expression of a transgene encoding PRSS1R122H in mice promoted inflammation and increase the severity of pancreatitis, compared with mice that express PRSS1 or control mice. These mice might be used as a model for human hereditary pancreatitis and can be studied to determine mechanisms of induction of pancreatitis by LPS, ethanol, or a high-fat diet.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.08.016" class="uri">https://doi.org/10.1053/j.gastro.2019.08.016</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Grading Pancreatic Neuroendocrine Tumors by Ki-67 Index Evaluated on Fine-Needle Aspiration Cell Block Material</strong> </summary></p>
<p><em>American journal of clinical pathology 2020 Jan;153(1):74-81</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31415691" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31415691</a></p>
<p>OBJECTIVES: This study aimed to determine whether Ki-67 index evaluated on cytologic material could reliably grade pancreatic neuroendocrine tumors (PanNETs). METHODS: Cases with adequate cell block and available surgical specimens were included. Ki-67 index was calculated using eyeballing, hot spot, and complete counting methods. RESULTS: The overall concordance rates between cytology and surgical specimens were 71%, 73%, and 59%, respectively, by using eyeballing, hot spot, and complete counting approaches. All grade 1 tumors were correctly graded on cytology, but in grade 2 tumors concordance rates were only 36%, 41%, and 9%, respectively. All grade 2 tumors were undergraded when cell blocks contained fewer than 1,000 cells, while concordance rate increased to 57%, 64%, and 14%, respectively, in cases with 1,000 cells or more. CONCLUSIONS: Grade 2 PanNETs can be significantly undergraded when Ki-67 index is evaluated on cell block material. In cases with 1,000 or more cells, the hot spot counting method has better correlation with surgical specimens.</p>
<p>doi: <a href="https://doi.org/10.1093/ajcp/aqz110" class="uri">https://doi.org/10.1093/ajcp/aqz110</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Randomized Comparison of Gastric Tube Reconstruction With and Without Duodenal Diversion Plus Roux-en-Y Anastomosis After Esophagectomy</strong> </summary></p>
<p><em>Annals of surgery 2019 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31415003" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31415003</a></p>
<p>OBJECTIVE: This prospective randomized phase-II trial examined whether gastric reconstruction with duodenal diversion plus Roux-en-Y anastomosis(RY) minimized gastroduodenal reflux and delayed gastric emptying compared with standard gastric reconstruction. SUMMARY BACKGROUND DATA: There is no established standard surgical procedure to prevent both gastroduodenal reflux and delayed gastric emptying simultaneously. METHODS: Sixty patients with thoracic esophageal cancer scheduled to undergo esophagectomy with retrosternal gastric tube reconstruction were randomly allocated to standard gastric reconstruction (non-RY, n = 31) or gastric reconstruction with duodenal diversion plus RY (n = 29) groups. Primary endpoint was quality of life assessed by DAUGS-32 score 1 year after surgery. Secondary endpoints were the extent of postoperative duodenal juice reflux into the gastric tube, postoperative morbidity, endoscopic findings, body weight changes, and nutritional status. RESULTS: Preoperative clinicopathological characteristics and postoperative morbidity did not differ significantly between groups. However, operation time and blood loss volume were significantly higher in the RY group. Pancreatic amylase concentrations in the gastric conduit on postoperative days 2, 3, and 7 were higher in the non-RY group. Postoperative endoscopic examination showed residual gastric content in 7 of 17 patients in the non-RY group but in none in the RY group (P = 0.012). Quality of life was significantly favorable in the RY group with regard to reflux symptoms and food passage dysfunction. Postoperative body weight changes, serum albumin levels, and peripheral blood lymphocyte counts were not significantly different between groups. CONCLUSION: Gastric reconstruction with duodenal diversion plus RY is effective in improving both gastroduodenal reflux and delayed gastric emptying.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003557" class="uri">https://doi.org/10.1097/SLA.0000000000003557</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Mouse pancreatic ductal organoid culture as a relevant model to study exocrine pancreatic ion secretion</strong> </summary></p>
<p><em>Laboratory investigation; a journal of technical methods and pathology 2020 Jan;100(1):84-97</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31409889" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31409889</a></p>
<p>Pancreatic exocrine secretory processes are challenging to investigate on primary epithelial cells. Pancreatic organoid cultures may help to overcome shortcomings of the current models, however the ion secretory processes in pancreatic organoids-and therefore their physiological relevance or their utility in disease modeling-are not known. To answer these questions, we provide side-by-side comparison of gene expression, morphology, and function of epithelial cells in primary isolated pancreatic ducts and organoids. We used mouse pancreatic ductal fragments for experiments or were grown in Matrigel to obtain organoid cultures. Using PCR analysiswe showed that gene expression of ion channels and transporters remarkably overlap in primary ductal cells and organoids. Morphological analysis with scanning electron microscopy revealed that pancreatic organoids form polarized monolayers with brush border on the apical membrane. Whereas the expression and localization of key proteins involved in ductal secretion (cystic fibrosis transmembrane conductance regulator, Na+/H+ exchanger 1 and electrogenic Na+/HCO3- cotransporter 1) are equivalent to the primary ductal fragments. Measurements of intracellular pH and Cl- levels revealed no significant difference in the activities of the apical Cl-/HCO3- exchange, or in the basolateral Na+ dependent HCO3- uptake. In summary we found that ion transport activities in the mouse pancreatic organoids are remarkably similar to those observed in freshly isolated primary ductal fragments. These results suggest that organoids can be suitable and robust model to study pancreatic ductal epithelial ion transport in health and diseases and facilitate drug development for secretory pancreatic disorders like cystic fibrosis, or chronic pancreatitis.</p>
<p>doi: <a href="https://doi.org/10.1038/s41374-019-0300-3" class="uri">https://doi.org/10.1038/s41374-019-0300-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Laparoscopic Suprapancreatic Lymph Node Dissection Using a Systematic Mesogastric Excision Concept for Gastric Cancer</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31407184" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31407184</a></p>
<p>BACKGROUND: Gastrointestinal cancer surgery requires en bloc removal of the primary tumor and organ-specific mesentery1,2. However, this surgical concept for gastric cancer has not yet been applied because of the morphological complexity of the mesenteries of the stomach. Lymph node dissection in gastric cancer surgery can be roughly performed into three regions: lesser curvature, grater curvature, and suprapancreatic region. In this video, we introduced laparoscopic lymphadenectomy in the suprapancreatic region using a systematic mesogastric excision (SME), which has been reported as a concept to perform en bloc resection3. METHODS: This procedure was divided into three steps. First, mesenterization of the mesogastrium was performed by dissecting the embryological planes, and the mesogastrium was dissected from the retroperitoneal surface (Fig.1a). Second, soft tissue, including the lymph node, was separated from the pancreas and the splenic artery by tracing the inner dissectable layer (Fig.1b). Finally, the tumor-specific mesentery was transected according to the extent of the lymphadenectomy (Fig.1c). Fig.1 Intraoperative findings during the stepwise procedure in dissecting the lymph node in the suprapancreatic region. The red broken line indicates the surgical outline. a The mesogastrium is dissected from the retroperitoneal tissue. b The mesogastrium is separated from the pancreas and splenic artery. c The mesogastric transection line is determined on the basis of the extent of the lymphadenectomy. Inf. phrenic a. inferior phrenic artery; PGA posterior gastric artery; Post. epiploic a. posterior epiploic artery; RV renal vein; SA splenic artery; SV splenic vein RESULTS: Between January 2017 and December 2017, six patients underwent laparoscopic distal gastrectomy with D2 lymphadenectomy using SME. The median time required to complete the suprapancreatic lymphadenectomy was 48min. No patient underwent conversion to open surgery or experienced intraoperative complications. CONCLUSIONS: We believe that this laparoscopic suprapancreatic lymphadenectomy using SME takes advantage of the surgical anatomy and achieves en bloc removal of the primary tumor and gastric mesentery. This series is a proof of concept that this procedure can be performed in a timely manner and is feasible.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07700-5" class="uri">https://doi.org/10.1245/s10434-019-07700-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Short-Term Outcomes of Laparoscopic and Open Total Gastrectomy for Gastric Cancer: A Nationwide Retrospective Cohort Analysis</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31407172" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31407172</a></p>
<p>BACKGROUND: Laparoscopic total gastrectomy is gradually gaining popularity; however, previous studies have produced conflicting results regarding the safety and advantages of the procedure, partly because of small sample sizes. The purpose of this study was to compare short-term outcomes between laparoscopic and open total gastrectomy for gastric cancer. METHODS: We analyzed data for patients undergoing laparoscopic or open total gastrectomy for clinical stage I-III gastric cancer from July 2010 to March 2017, using a Japanese nationwide inpatient database. We performed propensity-matched analyses to compare in-hospital mortality, morbidity, duration of anesthesia, time to first oral intake, and length of postoperative stay between the two groups. RESULTS: Among 58,689 eligible patients, propensity-score matching created 12,229 pairs. Laparoscopic total gastrectomy was associated with higher incidences of anastomotic leakage (2.9% vs.1.7%, p&lt;0.001) and stenosis (0.9% vs.0.6%, p=0.02), lower incidences of pancreatic injury (1.4% vs.1.8%, p=0.01), endoscopic hemostasis (0.9% vs.1.7%, p&lt;0.001), blood transfusion (9.9% vs.17.7%, p&lt;0.001) and 30-day readmission, a shorter interval from surgery to first oral intake (4 vs.5days, p&lt;0.001), shorter postoperative hospital stay (14 vs.15days, p&lt;0.001), and a longer duration of anesthesia (323 vs.304min, p&lt;0.001). There was no significant difference in in-hospital mortality (0.6% vs.0.8%, p=0.58). CONCLUSIONS: Laparoscopic total gastrectomy has some advantages over open surgery for gastric cancer in terms of time to first oral intake and postoperative length of stay, but the incidence of anastomotic leakage was higher than that of open total gastrectomy.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07688-y" class="uri">https://doi.org/10.1245/s10434-019-07688-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Disruption of IRE1 through its kinase domain attenuates multiple myeloma</strong> </summary></p>
<p><em>Proceedings of the National Academy of Sciences of the United States of America 2019 Aug;116(33):16420-16429</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31371506" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31371506</a></p>
<p>Multiple myeloma (MM) arises from malignant immunoglobulin (Ig)-secreting plasma cells and remains an incurable, often lethal disease despite therapeutic advances. The unfolded-protein response sensor IRE1 supports protein secretion by deploying a kinase-endoribonuclease module to activate the transcription factor XBP1s. MM cells may co-opt the IRE1-XBP1s pathway; however, the validity of IRE1 as a potential MM therapeutic target is controversial. Genetic disruption of IRE1 or XBP1s, or pharmacologic IRE1 kinase inhibition, attenuated subcutaneous or orthometastatic growth of MM tumors in mice and augmented efficacy of two established frontline antimyeloma agents, bortezomib and lenalidomide. Mechanistically, IRE1 perturbation inhibited expression of key components of the endoplasmic reticulum-associated degradation machinery, as well as secretion of Ig light chains and of cytokines and chemokines known to promote MM growth. Selective IRE1 kinase inhibition reduced viability of CD138+ plasma cells while sparing CD138- cells derived from bone marrows of newly diagnosed or posttreatment-relapsed MM patients, in both US- and European Union-based cohorts. Effective IRE1 inhibition preserved glucose-induced insulin secretion by pancreatic microislets and viability of primary hepatocytes in vitro, as well as normal tissue homeostasis in mice. These results establish a strong rationale for developing kinase-directed inhibitors of IRE1 for MM therapy.</p>
<p>doi: <a href="https://doi.org/10.1073/pnas.1906999116" class="uri">https://doi.org/10.1073/pnas.1906999116</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Mild maternal hyperglycemia in INSC93S transgenic pigs causes impaired glucose tolerance and metabolic alterations in neonatal offspring</strong> </summary></p>
<p><em>Disease models &amp; mechanisms 2019 08;12(8):</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31308048" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31308048</a></p>
<p>Alongside the obesity epidemic, the prevalence of maternal diabetes is rising worldwide, and adverse effects on fetal development and metabolic disturbances in the offsprings later life have been described. To clarify whether metabolic programming effects are due to mild maternal hyperglycemia without confounding obesity, we investigated wild-type offspring of INSC93S transgenic pigs, which are a novel genetically modified large-animal model expressing mutant insulin (INS) C93S in pancreatic -cells. This mutation results in impaired glucose tolerance, mild fasting hyperglycemia and insulin resistance during late pregnancy. Compared with offspring from wild-type sows, piglets from hyperglycemic mothers showed impaired glucose tolerance and insulin resistance (homeostatic model assessment of insulin resistance: +3-fold in males; +4.4-fold in females) prior to colostrum uptake. Targeted metabolomics in the fasting and insulin-stimulated state revealed distinct alterations in the plasma metabolic profile of piglets from hyperglycemic mothers. They showed increased levels of acylcarnitines, gluconeogenic precursors such as alanine, phospholipids (in particular lyso-phosphatidylcholines) and -aminoadipic acid, a potential biomarker for type 2 diabetes. These observations indicate that mild gestational hyperglycemia can cause impaired glucose tolerance, insulin resistance and associated metabolic alterations in neonatal offspring of a large-animal model born at a developmental maturation status comparable to human babies.</p>
<p>doi: <a href="https://doi.org/10.1242/dmm.039156" class="uri">https://doi.org/10.1242/dmm.039156</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreas FNA</strong> </summary></p>
<p><em>Cytopathology : official journal of the British Society for Clinical Cytology 2019 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31400170" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31400170</a></p>
<p>doi: <a href="https://doi.org/10.1111/cyt.12767" class="uri">https://doi.org/10.1111/cyt.12767</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes</strong> </summary></p>
<p><em>Cell 2019 Aug;178(4):795-806.e12</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31398337" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31398337</a></p>
<p>Most patients diagnosed with resected pancreatic adenocarcinoma (PDAC) survive less than 5 years, but a minor subset survives longer. Here, we dissect the role of the tumor microbiota and the immune system in influencing long-term survival. Using 16S rRNA gene sequencing, we analyzed the tumor microbiome composition in PDAC patients with short-term survival (STS) and long-term survival (LTS). We found higher alpha-diversity in the tumor microbiome of LTS patients and identified an intra-tumoral microbiome signature (Pseudoxanthomonas-Streptomyces-Saccharopolyspora-Bacillus clausii) highly predictive of long-term survivorship in both discovery and validation cohorts. Through human-into-mice fecal microbiota transplantation (FMT) experiments from STS, LTS, or control donors, we were able to differentially modulate the tumor microbiome and affect tumor growth as well as tumor immune infiltration. Our study demonstrates that PDAC microbiome composition, which cross-talks to the gut microbiome, influences the host immune response and natural history of the disease.</p>
<p>doi: <a href="https://doi.org/10.1016/j.cell.2019.07.008" class="uri">https://doi.org/10.1016/j.cell.2019.07.008</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comparison of overall survival and perioperative outcomes of laparoscopic pancreaticoduodenectomy and open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a systematic review and meta-analysis</strong> </summary></p>
<p><em>BMC cancer 2019 Aug;19(1):781</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31391085" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31391085</a></p>
<p>BACKGROUND: The aim of this study was to compare the oncological outcomes and clinical efficacy of laparoscopic pancreaticoduodenectomy (LPD) and open pancreaticoduodenectomy (OPD) in patients with pancreatic ductal adenocarcinoma (PDAC). METHODS: We systematically searched PubMed, EMBASE, Web of Science, ClinicalTrials.gov and the Cochrane Central Register for studies published between May 1998 and May 2018. The included studies compared LPD and OPD for the treatment of PDAC. The oncological outcomes and perioperative data were analyzed. RESULTS: Eight studies involving 15,278 patients were included in our meta-analysis. No significant difference was found in the 5-year overall survival (OS) between patients undergoing the two types of surgery (HR: 0.97, 95% CI 0.82-1.15, p=0.76). LPD resulted in a higher rate of R0 resection than OPD (OR: 1.16, 95% CI 0.85-1.57, p&gt;0.05). This study showed that compared with OPD, LPD resulted in comparable rates of postoperative pancreatic fistulas (POPFs) (OR: 1.07, 95% CI: 0.68-1.68, p=0.77) and postoperative hemorrhage (OR: 1.74, 95% CI 0.96-3.71, p=0.07), more harvested lymph nodes (WMD: 1.84, 95% CI: 0.95-2.72, p&lt;0.05), shorter hospital stays (WMD: -2.45, 95% CI: -3.33- -1.56, p&lt;0.05), and less estimated blood loss (WMD: -374.30, 95% CI: -513.06- -235.54, p&lt;0.05). CONCLUSIONS: LPD is equivalent to OPD with respect to 5-year OS and results in better perioperative clinical outcomes for patients with PDAC.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6001-x" class="uri">https://doi.org/10.1186/s12885-019-6001-x</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A 12-year trend analysis of the incidence of gastrointestinal cancers in East Azerbaijan: last updated results of an ongoing population-based cancer registry</strong> </summary></p>
<p><em>BMC cancer 2019 Aug;19(1):782</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31391032" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31391032</a></p>
<p>BACKGROUND: The most recent results of Global Cancer Statistics indicated that gastrointestinal cancers, including gastric, colorectal, esophageal, and liver cancers, are among the most commonly diagnosed cancers worldwide. Previous reports from cancer registries in East Azerbaijan have shown that there is a high incidence of gastrointestinal cancer in this region, so we performed a trend analysis to determine the pattern of change over the last decade. METHODS: In total, 12years of cancer registry data were collected from different sources in East Azerbaijan, and a data quality check was performed to ensure clean data. Using the 2000 World Health Organization standard population, we then generated age-standardized incidence rates (ASRs) for different cancers, and for each year from 1383 to 1394 of the Persian calendar (i.e., 19 March 2004 to 20 March 2015). Annual percent changes (APCs) and Average annual percent changes (AAPCs) in the ASRs for esophageal, gastric, small intestine, colorectal, anal, liver, gallbladder, and pancreatic cancers were calculated using Joinpoint Software (Version 4.5.0.1, June 2017). RESULTS: An increase in most types of cancer was observed during the study period. The ASR for colorectal cancer increased from 2.9 to 13.6 per 100,000 women (APC, 9.7%) and from 2.2 to 17.8 per 100,000 men (APC, 10.2%). The ASR for gastric cancer showed a slight increasing trend from 10.5 to 13.5 per 100,000 women (APC, 1.3%) and from 3.1 to 29.9 per 100,000 men (APC, 3.2%). However, trend analysis showed a decreasing pattern for the ASR of esophageal cancer in both genders (APC,-3%), with APCs of -1.1% in females and-0.4% in males. CONCLUSIONS: The latest results of the East Azerbaijan Population-Based Cancer Registry indicate that gastrointestinal cancers remain common, with significant increasing trends in their ASRs. Improved screening and early detection are needed in this region.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6008-3" class="uri">https://doi.org/10.1186/s12885-019-6008-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The prognostic value of lncRNA SNHG1 in cancer patients: a meta-analysis</strong> </summary></p>
<p><em>BMC cancer 2019 Aug;19(1):780</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31391030" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31391030</a></p>
<p>BACKGROUND: Increasing evidence revealed that high expression level of lncRNA SNHG1 was associated with the unfavorable prognosis of cancer and maybe used as a valuable biomarker for cancer patients. The present meta-&gt;analysis is to analyze existing data to reveal potential clinical application of SNHG1 on cancer prognosis and tumor progression. All of the included studies were collected through a variety of retrieval strategies. And the articles were qualified by MOOSE and PRISMA checklists. METHODS: Up to Mar 20, 2018, literature collection was performed by comprehensive search through electronic databases, including the Cochrane library, PubMed, Embase, Web of science, Springer, Science direct, and three Chinese databases: CNKI, Weipu, and Wanfang. We analyzed 14studies that met the criteria, and concluded that the increased SHNG1 level was correlated with poor OS and tumor progression. RESULTS: The combined results indicated that elevated SNHG1 expression level was significantly associated with poor OS (HR=2.06, 95% CI: 1.69-2.52, P&lt;0.01) and PFS (HR=2.78, 95% CI: 1.69-4.55, P&lt;0.01) in various cancers. Moreover, the promoted SNHG1 expression was also associated with tumor progression ((III/IV vs.I/II: HR=1.89, 95% CI: 1.53-2.34, P&lt;0.01). In stratified analyses, a significantly unfavorable association of elevated lncRNA SNHG1 and OS was observed in both digestive system (HR=2.04, 95% CI: 1.56-2.68, P&lt;0.01) and non-digestive system (HR=2.09, 95% CI: 1.55-2.83, P&lt;0.01) cancer patients. CONCLUSIONS: The present analysis indicated that the increased SNHG1 is associated with poor OS in patients with general tumors and may be served as a useful prognostic biomarker.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-5987-4" class="uri">https://doi.org/10.1186/s12885-019-5987-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Dynamic serum alkaline phosphatase is an indicator of overall survival in pancreatic cancer</strong> </summary></p>
<p><em>BMC cancer 2019 Aug;19(1):785</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31391026" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31391026</a></p>
<p>BACKGROUND: The prognostic role of serum alkaline phosphatase (ALP) has been found in several kinds of solid malignant tumor, but has never been extensively discussed in pancreatic cancer, especially through the application of dynamic survival model which incorporates the varying nature of ALP measurements. METHODS: We conducted a retrospective study which successfully collected 551 histopathologically confirmed pancreatic ductal adenocarcinoma (PDAC) patients from a cancer specialized hospital in southwest China. The association between variant ALP which measured during the whole survival period and the overall survival (OS) of PDAC patients was evaluated by using dynamic Anderson-Gill (AG) model. Exhaustive sensitivity analysis was performed by adopting continuous cut-offs of ALP. RESULTS: After adjusted for possible confounding of serum albumin, total bilirubin and leukocyte counts, AG model revealed that, serum ALP during the survival period was nonlinearly associated with the OS of PDAC: for resected patients, compared with those whose ALP results ranged within the first quartile (&lt;P25), patients whose ALP measurements belonged to the second (P25-P50), the third (P50-P75), and the forth (&gt;P75) quartiles were observed 1.14 (95% CI: 0.29-4.56), 3.93 (95% CI: 1.23-12.60), 3.87 (95% CI: 1.32-11.36) folds of death hazard; whereas in un-resected PDAC patients, the hazard ratios (HRs) were 1.15 (95% CI: 0.79-1.68), 1.92 (95% CI: 1.32-2.78), and 1.97 (95% CI: 1.30-2.98), respectively. Sensitivity analysis revealed that, for both resected and un-resected patients, the results of AG model were robust with regard to various cut-offs of ALP, and an increased ALP was in general associated with significantly increased hazard of death. CONCLUSION: Serum ALP during the survival period was significantly associated with the OS of PDAC patients, especially for resected early stage PDAC patients. Future studies with expanded sample size and refined prospective design should be implemented to corroborate our major findings. Besides, the underlying mechanism for this possible hazardous role of ALP should also be investigated.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6004-7" class="uri">https://doi.org/10.1186/s12885-019-6004-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Sclerosing epithelioid mesenchymal neoplasm of the pancreas-a proposed new entity</strong> </summary></p>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31383964" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31383964</a></p>
<p>We have encountered pancreatic tumors with unique histologic features, which do not conform to any of the known tumors of the pancreas or other anatomical sites. We aimed to define their clinicopathologic features and whether they are characterized by recurrent molecular signatures. Eight cases were identified; studied histologically and by immunohistochemistry. Selected cases were also subjected to whole-exome sequencing (WES; n=4), RNA-sequencing (n=6), Archer FusionPlex assay (n=5), methylation profiling using the Illumina MethylationEPIC (850k) array platform (n=6), and TERT promoter sequencing (n=5). Six neoplasms occurred in females. The mean age was 43 years (range: 26-75). Five occurred in the head/neck of the pancreas. All patients were treated surgically; none received neoadjuvant/adjuvant therapy. All patients are free of disease after 53 months of median follow-up (range: 8-94). The tumors were well-circumscribed, and the median size was 1.8cm (range: 1.3-5.8). Microscopically, the unencapsulated tumors had a geographic pattern of epithelioid cell nests alternating with spindle cell fascicles. Some areas showed dense fibrosis, in which enmeshed tumor cells imparted a slit-like pattern. The predominant epithelioid cells had scant cytoplasm and round-oval nuclei with open chromatin. The spindle cells displayed irregular, hyperchromatic nuclei. Mitoses were rare. No lymph node metastases were identified. All tumors were positive for vimentin, CD99 and cytokeratin (patchy), while negative for markers of solid pseudopapillary neoplasm, neuroendocrine, acinar, myogenic/rhabdoid, vascular, melanocytic, or lymphoid differentiation, gastrointestinal stromal tumor as well as MUC4. Whole-exome sequencing revealed no recurrent somatic mutations or amplifications/homozygous deletions in any known oncogenes or tumor suppressor genes. RNA-sequencing and the Archer FusionPlex assay did not detect any recurrent likely pathogenic gene fusions. Single sample gene set enrichment analysis revealed that these tumors display a likely mesenchymal transcriptomic program. Unsupervised analysis (t-SNE) of their methylation profiles against a set of different mesenchymal neoplasms demonstrated a distinct methylation pattern. Here, we describe pancreatic neoplasms with unique morphologic/immunophenotypic features and a distinct methylation pattern, along with a lack of abnormalities in any of key genetic drivers, supporting that these neoplasms represent a novel entity with an indolent clinical course. Given their mesenchymal transcriptomic features, we propose the designation of sclerosing epithelioid mesenchymal neoplasm of the pancreas.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-019-0334-5" class="uri">https://doi.org/10.1038/s41379-019-0334-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ESWL for large pancreatic calculi: Report of over 5000 patients</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Oct;19(7):916-921</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31447280" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31447280</a></p>
<p>INTRODUCTION: The primary aim of this study was to evaluate efficacy, safety and short-term pain relief after ESWL for large pancreatic calculi in over 5000 patients at a single center. METHODS: This is a retrospective analysis of prospectively collected data. Patients with painful calculi &gt;5mm, located in the head, neck and body region in the MPD, who were not amenable for extraction by the standard procedure of endoscopic pancreatic sphincterotomy were subjected to ESWL using a third generation dual focus lithotripter. Patients were followed up at 6 months for outcome evaluation. RESULTS: A total of 5124 patients (66% males) were subjected to ESWL. Majority of stones (79.2%) were radiopaque. Single calculi were seen in 3851 (75.1%).The majority of stones were located in head region of MPD in 2824 (55.1%) patients. 4386 (85.5%) patients required 3 or less sessions for fragmentation and complete stone clearance was achieved in 3722 (72.6%). EPS was performed in 5022 (98%) while PD stenting was required in 3536 (69%) patients. Of the 4280 patients followed up for 6 months, 3529 (82.6%) patients were pain free. Another 512 (11.9%) patients had significant reduction in VAS score. In 229 (5.3%) there was no decrease in pain intensity. Minor and self-limiting complications were reported in 1153 (22.5%). DISCUSSION: Our study confirms the safety and efficacy and short-term pain relief of ESWL for large calculi in the MPD. In properly selected patients, this should be offered as the first line of therapy for all large MPD calculi not amenable to the standard techniques of stone extraction.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.08.001" class="uri">https://doi.org/10.1016/j.pan.2019.08.001</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Classification of Complication Clusters Might Vary in Different Populations With Chronic Pancreatitis</strong> </summary></p>
<p><em>The American journal of gastroenterology 2019 Aug;114(8):1351-1352</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31386633" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31386633</a></p>
<p>doi: <a href="https://doi.org/10.14309/ajg.0000000000000292" class="uri">https://doi.org/10.14309/ajg.0000000000000292</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls</strong> </summary></p>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31375766" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31375766</a></p>
<p>With the FDA approval of larotrectinib, NTRK fusion assessment has recently become a standard part of management for patients with locally advanced or metastatic cancers. Unlike somatic mutation assessment, the detection of NTRK fusions is not straightforward, and various assays exist at the DNA, RNA, and protein level. Here, we investigate the performance of immunohistochemistry and DNA-based next-generation sequencing to indirectly or directly detect NTRK fusions relative to an RNA-based next-generation sequencing approach in the largest cohort of NTRK fusion positive solid tumors to date. A retrospective analysis of 38,095 samples from 33,997 patients sequenced by a targeted DNA-based next-generation sequencing panel (MSK-IMPACT), 2189 of which were also examined by an RNA-based sequencing assay (MSK-Fusion), identified 87 patients with oncogenic NTRK1-3 fusions. All available institutional NTRK fusion positive cases were assessed by pan-Trk immunohistochemistry along with a cohort of control cases negative for NTRK fusions by next-generation sequencing. DNA-based sequencing showed an overall sensitivity and specificity of 81.1% and 99.9%, respectively, for the detection of NTRK fusions when compared to RNA-based sequencing. False negatives occurred when fusions involved breakpoints not covered by the assay. Immunohistochemistry showed overall sensitivity of 87.9% and specificity of 81.1%, with high sensitivity for NTRK1 (96%) and NTRK2 (100%) fusions and lower sensitivity for NTRK3 fusions (79%). Specificity was 100% for carcinomas of the colon, lung, thyroid, pancreas, and biliary tract. Decreased specificity was seen in breast and salivary gland carcinomas (82% and 52%, respectively), and positive staining was often seen in tumors with neural differentiation. Both sensitivity and specificity were poor in sarcomas. Selection of the appropriate assay for NTRK fusion detection therefore depends on tumor type and genes involved, as well as consideration of other factors such as available material, accessibility of various clinical assays, and whether comprehensive genomic testing is needed concurrently.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-019-0324-7" class="uri">https://doi.org/10.1038/s41379-019-0324-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comparative effectiveness of primary tumor resection in patients with stage III pancreatic adenocarcinoma</strong> </summary></p>
<p><em>BMC cancer 2019 Aug;19(1):761</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31370893" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31370893</a></p>
<p>BACKGROUND: Previous studies comparing primary tumor resection (PTR) to palliative treatment for advanced-stage pancreatic ductal adenocarcinoma (PDA) were limited by strong selection bias. We used multiple methods to control for confounding and selection bias to estimate the effect of PTR on survival for late-stage PDA. METHODS: Surveillance, Epidemiology, and End Results (SEER) 18 registry database for 2004 through 2014 was retrieved for the present study. A total of 4322 patients with stage III (AJCC, 6th) PDA were included in this study. Propensity score matching (PSM) was performed to eliminate possible bias. In addition, instrumental variable (IV) analysis was utilized to adjust for both measured and unmeasured confounders. RESULTS: A total of 4322 patients with stage III PDA including 552 (12.8%) who underwent PTR, 3770 (87.2%) without PTR, were identified. In the multivariable cohort, a clear prognostic advantage of PTR was observed in overall survival (OS) (P&lt;0.001) and disease-specific survival (DSS) (P&lt;0.001) compared to patients after non-surgery therapy. In the PSM cohort, patients in PTR group showed a better OS and DSS (both P values &lt;0.001) compared to patients in non-surgery group. The survival benefit of PTR for stage III PDA was not observed in the two-stage residual inclusion (2SRI) model. Estimates based on this instrument indicated that patients treated with PTR had similar OS (P=0.448) and DSS (P=0.719). In IV analyses stratified by chemotherapy and tumor location, patients undergoing PTR had similar OS and DSS compared to patients in non-surgery group across all subgroups. CONCLUSIONS: Survival with PTR did not differ significantly from palliative treatment in marginal patients with stage III pancreatic adenocarcinoma. High-quality randomized trials are needed to validate these results.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-5966-9" class="uri">https://doi.org/10.1186/s12885-019-5966-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Reply to Comment on Zeng et al, Spatial Distribution of Pancreatic Stones in Chronic Pancreatitis</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):e59</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31306309" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31306309</a></p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001351" class="uri">https://doi.org/10.1097/MPA.0000000000001351</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Mathematical Model and Study Design Could Be Optimized in Spatial Distribution Analysis of Pancreatic Stones</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):e58</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31306308" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31306308</a></p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001362" class="uri">https://doi.org/10.1097/MPA.0000000000001362</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Reply to: The Relationship of Acute Pancreatitis and Pancreatic Cancer</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):e57-e58</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31306307" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31306307</a></p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001358" class="uri">https://doi.org/10.1097/MPA.0000000000001358</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Relationship of Acute Pancreatitis and Pancreatic Cancer</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):e57</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31306306" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31306306</a></p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001357" class="uri">https://doi.org/10.1097/MPA.0000000000001357</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Surgical and Oncological Outcomes of Laparoscopic Versus Open Pancreaticoduodenectomy in Patients With Pancreatic Duct Adenocarcinoma</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):861-867</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31306305" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31306305</a></p>
<p>It is not clear which of the 2 principal treatments for patients with pancreatic duct adenocarcinoma (PDAC), laparoscopic pancreaticoduodenectomy (LPD) and open pancreaticoduodenectomy (OPD), has greater safety and efficacy. We performed the present meta-analysis to assess the efficacy of both treatments for PDAC patients undergoing LPD. Multiple electronic databases were systematically searched to identify studies (up to October 2018) comparing LPD with OPD for PDAC. Short- and long-term oncological outcomes were evaluated. Six studies were qualified for inclusion criteria in this meta-analysis with a total of 9144 PDAC participants. Regarding safety, there were fewer overall postoperative complications associated with LPD (P = 0.005), but the results were similar in terms of pancreatic fistula and mortality. Laparoscopic pancreaticoduodenectomy was associated with a better trend of performance both in R0 resection (relative risk, 1.03; 95% confidence interval [CI], 1.00-1.07; P = 0.07) and preserved lymph nodes (median, 2.14; 95% CI, -0.21 to 4.49; P = 0.07). Long-term overall survival was comparable between LPD and OPD (hazard ratio, 1.03; 95% CI, 0.95-1.13; P = 0.49). In conclusion, LPD was found to be a suitable alternative to OPD in selected PDAC patients with respect to both surgical and oncological outcomes.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001363" class="uri">https://doi.org/10.1097/MPA.0000000000001363</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Excess body weight at age &lt;50years is linked to pancreatic cancer mortality</strong> </summary></p>
<p><em>Cancer 2019 Aug;125(15):2527</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31298753" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31298753</a></p>
<p>doi: <a href="https://doi.org/10.1002/cncr.32394" class="uri">https://doi.org/10.1002/cncr.32394</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Trends in biomarker discoveries for the early detection and risk stratification of pancreatic cancer using omics studies</strong> </summary></p>
<p><em>Expert review of molecular diagnostics 2019 Aug;19(8):651-654</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31298060" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31298060</a></p>
<p>doi: <a href="https://doi.org/10.1080/14737159.2019.1643718" class="uri">https://doi.org/10.1080/14737159.2019.1643718</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Impact of Changes in the American Joint Committee on Cancer Staging Manual, Eighth Edition, for Pancreatic Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):876-882</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31268985" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31268985</a></p>
<p>OBJECTIVE: Consistent and reliable tumor staging is a critical factor in determining treatment strategy, selection of patients for adjuvant therapy, and for therapeutic clinical trials. The aim of this study was to evaluate the number and extent of pancreatic ductal adenocarcinoma (PDAC) cases that would have a different pT, pN, and overall stages based on the new eighth edition American Joint Committee on Cancer staging system when compared with the seventh edition. METHODS: Patients diagnosed with PDAC who underwent pancreaticoduodenectomy, total pancreatectomy, or distal pancreatectomy from 2007 to 2017 were retrospectively reviewed. A total of 340 cases were included. RESULTS: According to the seventh edition, the vast majority of tumors in our cohort were staged as pT3 tumors (88.2%). Restaging these cases with the new size-based pT system resulted in a more equal distribution among the 3 pT categories, with higher percentage of pT2 cases (55%). CONCLUSIONS: The newly adopted pT stage protocol for PDAC is clinically relevant, ensures a more equal distribution among different stages, and allows for a significant prognostic stratification. In contrast, the new pN classification (pN1 and pN2) based on the number of positive lymph nodes failed to show survival differences and remains controversial.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001349" class="uri">https://doi.org/10.1097/MPA.0000000000001349</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Surveillance Patterns of Incidentally Detected Pancreatic Cysts Vary Widely and Infrequently Adhere to Guidelines</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):883-887</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31268984" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31268984</a></p>
<p>OBJECTIVES: We aimed to determine incidental pancreatic cyst (cyst) surveillance patterns, predictors of receiving surveillance, and guideline adherence. METHODS: We performed a retrospective cohort study of all patients receiving longitudinal care at a single tertiary care center with a newly diagnosed incidental pancreatic cyst over a 2-year period (2010-2011). All follow-up care was abstracted over a 5-year period. RESULTS: Of 3241 eligible imaging studies reviewed, 100 patients with newly diagnosed incidental cysts eligible for surveillance were identified. A majority (53%) received no follow-up. We identified 4 predictors of cyst surveillance: radiology report conclusion mentioning the cyst (odds ratio [OR], 14.9; 95% confidence interval [CI], 1.9-119) and recommending follow-up (OR, 5.5; 95% CI, 2.1-13.9), pancreas main duct dilation (OR, 10.7; 95% CI, 1.3-89), and absence of multiple cysts (OR, 2.5; 95% CI, 1.1-10.0). Of the 47 patients who received surveillance, 66% met minimum surveillance imaging intervals of at least one guideline. Conversely, 21% of patients met the criteria for overutilization in at least one guideline. CONCLUSIONS: Although guidelines recommend that surgically fit patients with incidental cysts undergo surveillance, most patients receive no follow-up. When follow-up occurs, surveillance patterns vary widely and infrequently conform to guidelines. Interventions to reduce care variation require study.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001352" class="uri">https://doi.org/10.1097/MPA.0000000000001352</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Alternate Week Gemcitabine and Capecitabine: An Effective Treatment for Patients With Pancreatic Adenocarcinoma</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):927-930</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31268983" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31268983</a></p>
<p>OBJECTIVE: Determine whether a regimen of fixed dose rate gemcitabine plus capecitabine is effective and tolerable for advanced pancreatic adenocarcinoma. METHODS: We performed a retrospective analysis of 62 patients with locally advanced or metastatic pancreatic adenocarcinoma treated at the University of California San Francisco between 2008 and 2016. Treatment was an alternate week schedule of fixed dose rate 1000 mg/m gemcitabine and capecitabine 1000 mg/m (58 patients), 1200 mg/m (12 patients), or 650 mg/m (1 patient) for intended 12 cycles. We evaluated overall survival (OS), progression-free survival (PFS), radiologic response, and adverse events necessitating treatment modification. RESULTS: For metastatic patients, median OS was 10.3 months (95% confidence interval [CI], 6.7-12.1 months), and PFS was 5.6 months (95% CI, 2.6-7.7 months). In locally advanced patients, OS was 12.0 months (95% CI, 4.9-17.1 months), and PFS was 5.4 months (95% CI, 2.5-9.4 months). Radiologic response for metastatic disease (42 patients) was 19% objective response, 45% stable disease, and 36% progressive disease. Treatment required modification for 22 patients due to adverse events, most frequently hand-foot syndrome (18 patients). CONCLUSIONS: Alternate week schedule of fixed dose rate gemcitabine and capecitabine was active and tolerable for advanced pancreatic adenocarcinoma. Overall survival and PFS were comparable to first-line treatments. Importantly, adverse effects appear less severe than first-line treatments.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001354" class="uri">https://doi.org/10.1097/MPA.0000000000001354</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Induction Therapy in Localized Pancreatic Cancer</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):913-919</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31268982" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31268982</a></p>
<p>OBJECTIVES: Pancreatic cancer (PDAC) with localized stage includes resectable (RPC), borderline resectable (BRPC), or locally advanced unresectable (LAPC). Standard of care for RPC is adjuvant chemotherapy. There are no prospective randomized trials for best treatment of BRPC and LAPC. We evaluate the impact of induction chemotherapy on localized PDAC. METHODS: Charts of PDAC patients treated at Emory University between 2009 and 2016 were reviewed. The primary end point was overall survival (OS). RESULTS: A total of 409 localized PDACs were identified. Resectability was prospectively determined at a multidisciplinary tumor conference. Median age was 67 years (range, 30-92 years), 49% were male, 66% were white, 171 had RPC, 131 had BRPC, and 107 had LAPC. Median OSs for RPC, BRPC, and LAPC were 19.5, 16.1, and 12.7 months, respectively. Type of chemotherapy and age were predictors of OS. Induction chemotherapy was used in 106 with BRPC (81%) and 74 with RPC (56.5%); patients with BRPC who received combination chemotherapy and resection had a median OS of 31.5 compared with 19.5 months in patients with RPC (P = 0.0049). Patients with LAPC had a median OS of 12.7 months. CONCLUSIONS: In patients with BRPC who undergo resection after induction treatment, the OS was significantly better than in patients with RPC. Neoadjuvant treatment should be considered for all localized PDACs.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001353" class="uri">https://doi.org/10.1097/MPA.0000000000001353</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Acute Recurrent and Chronic Pancreatitis as Initial Manifestations of Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator-Related Disorders</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):888-893</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31268981" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31268981</a></p>
<p>OBJECTIVES: Recurrent pancreatitis is considered a rare manifestation of cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction; this case series highlights that pancreatitis can be a presenting symptoms of cystic fibrosis (CF) or a CFTR-related disorder (CFTR-RD). METHODS: Retrospective review of patients younger than 30 years diagnosed as having acute recurrent pancreatitis (ARP) or chronic pancreatitis (CP) and subsequently diagnosed as having CF or CFTR-RD. RESULTS: Among 18 patients, median time from diagnosis of ARP/CP to diagnosis of CF was 0.4 years (range, 0-33 years). Eight were classified as having CF by elevated sweat chloride testing (SCT). Five had intermediate SCT (30-59 mmol/L) with 2 pathogenic mutations. Five had CFTR-RD with intermediate SCT and 0 to 1 pathogenic mutations. Eight patients (44%) had exocrine pancreatic insufficiency, and pancreatic fluid collections were more common in this group. Based on the CFTR mutation, 6 patients were eligible for CFTR potentiator therapy, although none received it during the study period. Nine of the 18 had 1 other likely CF manifestations, including sinusitis (33%), nasal polyps (11%), pneumonia (22%), and gallbladder disease (22%). CONCLUSIONS: Cystic fibrosis or CFTR-RD can present as ARP/CP. Complete diagnostic testing for CFTR-RD in patients with ARP/CP will broaden treatment options and help to identify comorbid illness.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001350" class="uri">https://doi.org/10.1097/MPA.0000000000001350</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Significance of Lymph Node Metastasis in Resectable Well-differentiated Pancreatic Neuroendocrine Tumor</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):943-947</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31268980" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31268980</a></p>
<p>OBJECTIVES: Understanding the effect of lymph node metastasis (LNM) on prognosis in pancreatic neuroendocrine neoplasm is helpful for surgery and follow-up. In this study, we investigated the significance of LNM in well-differentiated pancreatic neuroendocrine tumors (PanNETs) according to the World Health Organization 2017 classification. METHODS: We retrospectively collected data for 95 consecutive patients with PanNET who underwent pancreatic resection with curative intent between January 2008 and December 2017 at 6 institutions. The clinicopathological factors were compared in patients with and without LNM, and prognostic factors were analyzed. RESULTS: Lymph node metastasis was significantly associated with malignant potential of PanNET, such as larger tumor size, higher Ki-67 index, higher tumor grade, and higher incidence of lymphatic, vessel, and neural invasion. Lymph node metastasis was also associated with disease-free but not overall survival. Multivariate analysis identified NET grade 2 (G2) and G3 as independent risk factors for recurrence after curative resection. CONCLUSIONS: World Health Organization 2017 classification was the most independent prognostic factor in patients with resectable well-differentiated PanNETs. Patients with G2 and higher-grade tumors require lymph node dissection to improve prognosis.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001355" class="uri">https://doi.org/10.1097/MPA.0000000000001355</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Gastric Emptying and Distal Gastrectomy Independently Enhance Postprandial Glucagon-Like Peptide-1 Release After a Mixed Meal and Improve Glycemic Control in Subjects Having Undergone Pancreaticoduodenectomy</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):953-957</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31268979" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31268979</a></p>
<p>OBJECTIVES: New-onset diabetes frequently resolves after pancreaticoduodenectomy (PD). Glucagon-like peptide-1 (GLP-1) conceivably is involved as its release is enhanced by rapid gastric emptying and distal bowel exposure to nutrients. We aimed at studying factors associated with GLP-1 release after PD. METHODS: Fifteen PD subjects with distal gastrectomy (Whipple) and 15 with pylorus preservation were evaluated. A test meal containing 1 g paracetamol to measure gastric emptying was ingested. Blood for the measurement of paracetamol, glucose, insulin, and GLP-1 was drawn at baseline and 10, 20, 30, 60, 90, 120, 150, and 180 minutes thereafter. The Matsuda index of insulin sensitivity was calculated. RESULTS: In univariate analysis, gastric emptying correlated with GLP-1. Glucagon-like peptide-1 responses to the modes of operation did not differ. Multiple regression analysis confirmed gastric emptying and Whipple versus pylorus-preserving pancreaticoduodenectomy as independent predictors of GLP-1 release. The Matsuda index of insulin sensitivity correlated with GLP-1 concentrations and inversely with body mass index. Patients after Whipple procedure revealed lower glycated hemoglobin as compared with pylorus-preserving pancreaticoduodenectomy. CONCLUSIONS: Following PD, the postprandial GLP-1 release seems to be enhanced by rapid gastric emptying and to improve insulin sensitivity. Partial gastrectomy versus pylorus preservation enhanced the release of GLP-1, conceivably because of greater distal bowel exposure to undigested nutrients.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001361" class="uri">https://doi.org/10.1097/MPA.0000000000001361</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Endogenous Gastrin Collaborates With Mutant KRAS in Pancreatic Carcinogenesis</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):894-903</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31268978" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31268978</a></p>
<p>OBJECTIVE: The KRAS gene is the most frequently mutated gene in pancreatic cancer, and no successful anti-Ras therapy has been developed. Gastrin has been shown to stimulate pancreatic cancer in an autocrine fashion. We hypothesized that reactivation of the peptide gastrin collaborates with KRAS during pancreatic carcinogenesis. METHODS: LSL-Kras; P48-Cre (KC) mutant KRAS transgenic mice were crossed with gastrin-KO (GKO) mice to develop GKO/KC mice. Pancreata were examined for 8 months for stage of pancreatic intraepithelial neoplasia lesions, inflammation, fibrosis, gastrin peptide, and microRNA expression. Pancreatic intraepithelial neoplasias from mice were collected by laser capture microdissection and subjected to reverse-phase protein microarray, for gastrin and protein kinases associated with signal transduction. Gastrin mRNA was measured by RNAseq in human pancreatic cancer tissues and compared to that in normal pancreas. RESULTS: In the absence of gastrin, PanIN progression, inflammation, and fibrosis were significantly decreased and signal transduction was reversed to the canonical pathway with decreased KRAS. Gastrin re-expression in the PanINs was mediated by miR-27a. Gastrin mRNA expression was significantly increased in human pancreatic cancer samples compared to normal human pancreas controls. CONCLUSIONS: This study supports the mitogenic role of gastrin in activation of KRAS during pancreatic carcinogenesis.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001360" class="uri">https://doi.org/10.1097/MPA.0000000000001360</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>New-Onset Diabetes Mellitus After Chronic Pancreatitis Diagnosis: A Systematic Review and Meta-analysis</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):868-875</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31268977" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31268977</a></p>
<p>OBJECTIVES: The aim of this study was to assess the occurrence of new-onset diabetes mellitus (DM) after chronic pancreatitis (CP) diagnosis via systematic review and meta-analysis. METHODS: A systematic review of literature and meta-analysis of relevant reports were performed. The primary outcome measures studied were newly diagnosed DM and DM treated with insulin. For the binary outcomes, pooled prevalence and 95% confidence interval (CI) were calculated. METHODS: Fifteen studies involving 8970 patients were eligible. The incidence of new-onset DM after CP diagnosis was 30% (95% CI, 27%-33%). Among all patients, 17% (95% CI, 13%-22%) developed insulin-dependent new-onset DM. The prevalence of newly diagnosed DM after CP diagnosis increased from 15% within 36 months to 33% after 60 months. The proportion of alcoholic CP, sex, age, and body mass index had minimal effect on the studied outcomes. CONCLUSIONS: This systematic review identified a clinically relevant risk of new-onset DM after CP diagnosis. Therefore, patients should be informed of the risk of DM and monitored.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001359" class="uri">https://doi.org/10.1097/MPA.0000000000001359</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Importance of a Conjoint Analysis of Tumor-Associated Macrophages and Immune Checkpoints in Pancreatic Cancer</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):904-912</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31268976" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31268976</a></p>
<p>OBJECTIVES: Tumor-associated macrophages are dominant players in establishing the inmmunosuppressive microenvironment in pancreatic ductal adenocarcinoma (PDAC). Immune checkpoint inhibitor monotherapy has achieved limited clinical effectiveness. To date, the interaction of macrophages and checkpoint regulators and their correlation with clinicopathologic characteristics in PDAC have been largely unavailable. METHODS: Macrophages and immune checkpoint expression were assessed by immunohistochemistry from 80 PDAC samples. Clinicopathologic features and the prognostic value of each marker were evaluated. In vitro changes in the expression of immune markers in cocultured macrophages and PDAC cells were detected by Western blot and immunosorbance assays. RESULTS: The macrophages marker CD163 and the checkpoint marker programmed death-ligand 1 (PD-L1) remained as the independent prognostic factors for overall survival (hazard ratio, 2.543; P = 0.017 and hazard ratio, 2.389; P = 0.021). Furthermore, integrated analysis of CD163 and PD-L1 served as more optimal indicators of survival (P = 0.000). In vitro coculture of macrophages and PDAC cells significantly increased the expression of CD163 and PD-L1, compared with monocultured counterpart (P &lt; 0.05). CONCLUSIONS: Combined analysis of CD163 and PD-L1 was enhanced indicators of survival in PDAC patients. The interaction of macrophages and immune checkpoints implied the value of the combination therapy.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001364" class="uri">https://doi.org/10.1097/MPA.0000000000001364</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Correlation of DOTATOC Uptake and Pathologic Grade in Neuroendocrine Tumors</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):948-952</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31268975" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31268975</a></p>
<p>OBJECTIVES: Gallium (Ga)-DOTATOC is a somatostatin analog used to detect neuroendocrine tumors (NETs). Ki-67 proliferation index (Ki-67 PI) has been established as a prognostic factor in NETs. We aimed to evaluate whether a correlation exists between Ki-67 PI and somatostatin receptor positron emission tomography (SSTR-PET) uptake. METHODS: We retrospectively reviewed 238 DOTATOC PET scans between 2014 and 2016. Patients were excluded if DOTATOC PET was performed more than 365 days from the date of biopsy. Maximum standardized uptake values (SUVmax) of SSTR-PET from biopsied lesions were measured and correlated with Ki-67 PI using the Pearson correlation coefficient. RESULTS: Among 110 lesions from 90 patients, DOTATOC PET had 92.7% sensitivity and 100% specificity (102 true positives, 8 false negatives) for detection of NETs. Among 63 lesions from 54 patients with Ki-67 PI available, there were 27 grade 1 lesions [median Ki-67 PI, 1.0%; interquartile range (IQR), 1.0-2.0], 30 grade 2 lesions (median, Ki-67 PI 7.5%; IQR, 5-10), and 6 grade 3 lesions (median Ki-67 PI, 30%; IQR, 26-34). There was a correlation between Ki-67 PI and SUVmax (r = -0.3, P = 0.018). CONCLUSIONS: Our analysis demonstrates an inverse correlation between Ki-67 PI and SUVmax in NETs. Somatostatin receptor-PET provides additional information that can help guide management of NETs.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001356" class="uri">https://doi.org/10.1097/MPA.0000000000001356</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Diagnostic and Management Challenges in Vasoactive Intestinal Peptide Secreting Tumors: A Series of 15 Patients</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):934-942</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31268974" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31268974</a></p>
<p>OBJECTIVES: Vasoactive intestinal peptide-secreting tumors (VIPomas) are rare functioning neuroendocrine tumors often characterized by a difficult-to-control secretory syndrome and high potential to develop metastases. We hereby present the characteristics of 15 cases of VIPomas and provide a recent literature review. METHODS: This was a retrospective data analysis of 15 patients with VIPoma from 3 different centers and literature research through PubMed database during the last 10 years. RESULTS: Fifteen patients with VIPomas (9 with hepatic metastases at diagnosis) with watery diarrhea and raised VIP levels were studied. Ten patients (67%) had grade 2 tumors, 6 of 15 had localized disease and underwent potentially curative surgery, whereas the remaining 9 received multiple systemic therapies; 3 patients died during follow-up. The median overall survival was 71 months (range, 41-154 months). Patients who were treated with curative surgery (n = 7) had longer median overall survival compared with patients who were treated with other therapeutic modalities (44 vs 33 months). CONCLUSIONS: The management of VIPomas is challenging requiring the application of multiple treatment modalities. Patients who underwent surgical treatment with curative intent appear to have higher survival rate. Central registration and larger prospective studies are required to evaluate the effect of currently employed therapies in these patients.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001347" class="uri">https://doi.org/10.1097/MPA.0000000000001347</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Complications to Chronic Pancreatitis and Etiological Risk Factors: A Continental Divide?</strong> </summary></p>
<p><em>The American journal of gastroenterology 2019 Aug;114(8):1353</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31211705" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31211705</a></p>
<p>doi: <a href="https://doi.org/10.14309/ajg.0000000000000302" class="uri">https://doi.org/10.14309/ajg.0000000000000302</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Benchmark, Textbook or Optimal Pancreatic Surgery?</strong> </summary></p>
<p><em>Annals of surgery 2019 Aug;270(2):219-220</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31188222" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31188222</a></p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003377" class="uri">https://doi.org/10.1097/SLA.0000000000003377</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):920-926</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31180981" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31180981</a></p>
<p>OBJECTIVES: The aim of this study was to compare the efficacy and safety of FOLFIRINOX (5-FU/leucovorin, irinotecan, and oxaliplatin) and gemcitabine/nab-paclitaxel (GnP) in patients with advanced pancreatic cancer. METHODS: Patients with newly diagnosed advanced pancreatic cancer in Saskatchewan, Canada, from 2011 to 2016, who received FOLFIRINOX or GnP were assessed. A Cox proportional multivariate analysis was performed to evaluate prognostic variables. RESULTS: One hundred nineteen eligible patients with median age of 61 years and male/female ratio of 70:49 were identified. Seventy-seven percent had metastatic disease. Of 119 patients, 86 (72%) received FOLFIRINOX and 33 (28%) were treated with GnP. Median progression-free survival of the FOLFIRINOX group was 6.0 months [95% confidence interval (CI), 4.5-7.5] versus 4.0 months (95% CI, 2.9-5.1) with GnP (P = 0.39). The median overall survival of the FOLFIRINOX group was 9.0 months (95% CI, 7-11) compared with 9.0 months (95% CI, 4.2-13.8) with GnP (P = 0.88). On multivariate analysis, albumin [hazard ratio (HR), 0.63; 95% CI, 0.41-0.97], male sex (HR, 0.65; 95% CI, 0.43-0.97), and second-line therapy (HR, 0.50; 95% CI, 0.28-0.86) were correlated with survival. CONCLUSIONS: Our results showed that real-world patients with advanced pancreatic cancer treated with FOLFIIRNOX or GnP had comparable survival with different safety profile.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001340" class="uri">https://doi.org/10.1097/MPA.0000000000001340</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Differences in Pancreatic Cancer Incidence Rates and Temporal Trends Across Asian Subpopulations in California (1988-2015)</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):931-933</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31180980" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31180980</a></p>
<p>OBJECTIVE: Ethnic disparities in pancreatic cancer (PanCan) incidence exist, but little is known about incidence trends in heterogeneous Asian Americans. We examined PanCan incidence and temporal patterns among detailed ethnic populations, including Asian American subgroups. METHODS: A total of 71,099 invasive exocrine PanCan cases were identified using the California Cancer Registry between 1988 and 2015. Cases were grouped into mutually exclusive groups of non-Hispanic (NH) white, NH black, Hispanic, NH Asian/Pacific Islander (API), and NH American Indian/Alaska Native (AIAN). Asians were further identified by specific ethnicity. RESULTS: The age-adjusted incidence rates (AAIRs, per 100,000) of PanCan varied significantly across racial/ethnic groups, ranging from the highest of 10.4 in NH blacks to 7.6 in NH whites, 7.1 in Hispanics, 6.2 in NH APIs, and to the lowest of 5.2 in NH AIAN. Despite the relatively low rate in the NH APIs, the rates across Asian subgroups varied significantly, with rates similar to NH whites in Japanese (8.1) and Koreans (7.5) to the low rate in South Asians (4.4). CONCLUSIONS: Significant heterogeneity of PanCan incidence in disaggregated Asian Americans is a novel finding. These results fill a gap regarding PanCan burden in Asian Americans and underscore the importance of disaggregating ethnic populations in cancer research.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001337" class="uri">https://doi.org/10.1097/MPA.0000000000001337</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Oncogenic NRG1 Fusions: A New Hope for Targeted Therapy in Pancreatic Cancer</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Aug;25(15):4589-4591</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31164372" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31164372</a></p>
<p>Approximately 8%-10% of pancreatic ductal adenocarcinoma cases are KRAS wild type. In a subset of these tumors, NRG1 gene fusions have been identified as targetable oncogenic drivers, a discovery that highlights the importance of deep molecular characterization for KRAS wild-type pancreatic cancers and provides a novel treatment strategy in this disease.See related article by Jones et al., p.4674.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-1280" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-1280</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Proton Radiotherapy for Isolated Local Recurrence of Primary Resected Pancreatic Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Aug;26(8):2587-2594</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31147994" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31147994</a></p>
<p>BACKGROUND: The optimal treatment for isolated local recurrence (ILR) of pancreatic adenocarcinoma (PDAC) after surgical resection remains unclear. This study aimed to evaluate the safety and efficacy of proton radiotherapy (PRT) for ILR of PDAC after surgery. METHODS: The medical records of patients with ILR of PDAC after surgery who underwent proton beam therapy between 2011 and 2015 at Hyogo Ion Beam Medical Center were retrospectively studied. RESULTS: The study analyzed 30 patients (14 women and 16 men) with a median age of 65years (range 38-81years) who had initially undergone pancreatoduodenectomy (n=23) or distal pancreatectomy (n=7) for their primary tumors. Upon ILR, PRT was administered with a median total cumulative dose of 67.5gray equivalent (GyE) (range 50-67.5GyE) using 19 to 25 fractions. For 25 patients, concurrent chemotherapy was administered using gemcitabine (n=18) or S-1 (n=7). Four patients (13.3%) experienced acute grade 3 gastrointestinal toxicities. After a median follow-up period of 17.6months (range 2.1-50.4months), 23 patients had experienced tumor progression and 10 had died. Nine patients (30%) experienced local tumor progression. The median overall, progression-free, and local progression-free survival rates were 26.1, 12.3, and 41.2months, respectively. Pre-PRT serum levels of cancer antigen 19-9 higher than 100U/mL and duke pancreatic monoclonal antigen type 2 higher than 150U/mL were significantly associated with shorter progression-free survival rates. CONCLUSIONS: Proton radiotherapy for ILR of PDAC after surgery is well tolerated and produces good locoregional control and should be considered for eligible patients.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07471-z" class="uri">https://doi.org/10.1245/s10434-019-07471-z</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Controversies on the endoscopic and surgical management of pain in patients with chronic pancreatitis: pros and cons!</strong> </summary></p>
<p><em>Gut 2019 08;68(8):1343-1351</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31129569" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31129569</a></p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2019-318742" class="uri">https://doi.org/10.1136/gutjnl-2019-318742</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Stromal hyaluronan accumulation is associated with low tumor grade and nodal metastases in pancreatic ductal adenocarcinoma</strong> </summary></p>
<p><em>Human pathology 2019 Aug;90():37-44</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31121193" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31121193</a></p>
<p>Pancreatic ductal adenocarcinoma is an aggressive malignancy characterized by abundant desmoplastic stroma. Hyaluronan is a prominent stromal component of pancreatic ductal adenocarcinoma and is associated with unique clinical-pathological profiles in other tumor types. The current study aimed to delineate clinical and pathological features associated with hyaluronan accumulation in pancreatic ductal adenocarcinoma using a novel hyaluronan-binding assay currently being used in a clinical trial targeting hyaluronan. Sixty-four formalin-fixed, paraffin-embedded samples of pancreatic ductal adenocarcinomas from 49 patients treated at a single tertiary care hospital were stained. Fifty-two percent of tumors had high levels of hyaluronan. High levels were associated with low tumor grade and lymph node metastases, novel associations not previously seen in pancreatic ductal adenocarcinoma. This study has elucidated a novel clinical-pathological profile in pancreatic ductal adenocarcinomas using a new assay, suggesting hyaluronan may act as a biomarker for a subset of pancreatic tumors that could be targeted by hyaluronan-degrading agents.</p>
<p>doi: <a href="https://doi.org/10.1016/j.humpath.2019.05.004" class="uri">https://doi.org/10.1016/j.humpath.2019.05.004</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A Modification Proposal of the Peritoneal Surface Disease Severity Score</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Aug;26(8):2595-2604</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31111351" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31111351</a></p>
<p>BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are currently the most accepted treatment for peritoneal metastases from colorectal cancer. Restrictive selection criteria are essential to obtain the best survival benefits for this complex procedure. The most widespread score for patient selection, the peritoneal surface disease severity score (PSDSS), does not include current biological factors that are known to influence on prognosis. We investigated the impact of including RAS mutational status in the selection criteria for these patients. METHODS: We studied the risk factors for survival by multivariate analysis using a prospective database of consecutive patients with carcinomatosis from colorectal origin treated by CRS and HIPEC in our unit from 2009 to 2017. The risk factors obtained were validated in a multicentre, international cohort, including a total of 520 patients from 15 different reference units. RESULTS: A total of 77 patients were selected for local anlisis. Only RAS mutational status (HR: 2.024; p=0.045) and PSDSS stage (HR: 2.90; p=0.009) were shown to be independent factors for overall survival. Early PSDSS stages I and II associated to RAS mutations impaired their overall survival with no significant differences with PSDSS stage III overall survival (p&gt;0.05). These results were supported by the international multicentre validation. CONCLUSIONS: By including RAS mutational status, we propose an updated RAS-PSDSS score that outperforms PSDSS alone providing a quick and feasible preoperative assessment of the expected overall survival for patients with carcinomatosis from colorectal origin undergone to CRS+HIPEC.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07378-9" class="uri">https://doi.org/10.1245/s10434-019-07378-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study</strong> </summary></p>
<p><em>The lancet. Gastroenterology &amp; hepatology 2019 Aug;4(8):611-621</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31109808" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31109808</a></p>
<p>BACKGROUND: This study aimed to assess the safety and tolerability of the immune checkpoint inhibitor nivolumab, as monotherapy or combined with chemotherapy, in Japanese patients with biliary tract cancer. METHODS: This multicentre, open-label, phase 1 trial was done at four cancer centres in Japan. Eligible patients were aged 20-79 years, had biliary tract adenocarcinoma (intrahepatic bile duct cancer, extrahepatic bile duct cancer, gallbladder cancer, or ampullary cancer), Eastern Cooperative Oncology Group performance status 0 or 1, adequate hepatic, renal, and haematological function, and tumour tissue samples for PD-L1 expression analysis. Patients with unresectable or recurrent biliary tract cancer that was refractory or intolerant to gemcitabine-based treatment regimens received nivolumab monotherapy (240 mg every 2 weeks [monotherapy cohort]). Chemotherapy-naive patients with unresectable or recurrent biliary tract cancer received nivolumab (240 mg every 2 weeks) and cisplatin (25 mg/m2) plus gemcitabine (1000 mg/m2) chemotherapy (combined therapy cohort). The primary objective was to assess tolerability and safety. The primary objective was assessed in the safety population of all patients who had received at least one dose of nivolumab. This study is registered with www.clinicaltrials.jp, number JapicCTI-153098, and follow-up is ongoing. FINDINGS: 30 patients were enrolled into each cohort between Jan 13, 2016, and April 19, 2017. Data cutoff was Aug 31, 2017. In the monotherapy cohort, the most frequently reported treatment-related adverse events were decreased appetite (five [17%]), malaise (four [13%]), and pruritus (four [13%]). Grade 3-4 treatment-related adverse events were reported by three (10%) patients (rash, maculopapular rash, and amylase increase) and treatment-related serious adverse events were reported by one (3%) patient (pleurisy). In the combined therapy cohort, the most frequently reported treatment-related adverse events were neutrophil count decrease (any grade 25 [83%]; grade 3-4 in 23 [77%] patients) and platelet count decrease (any grade 25 [83%] of 30; grade 3-4 in 15 [50%] patients). Six (20%) patients reported 11 treatment-related serious adverse events (platelet count decrease [three patients], febrile neutropenia [two patients], neutrophil count decrease, anaemia, anaphylactic reaction, decreased appetite, pyrexia, and myocarditis [one patient each]). In the monotherapy cohort, median overall survival was 52 months (90% CI 45-87), median progression-free survival was 14 months (90% CI 14-14), and one of 30 patients had an objective response. In the combined therapy cohort, median overall survival was 154 months (90% CI 118-not estimable), median progression-free survival was 42 months (90% CI 28-56), and 11 of 30 patients had an objective response. INTERPRETATION: Nivolumab had a manageable safety profile and signs of clinical activity in patients with unresectable or recurrent biliary tract cancer. This initial assessment of nivolumab for the treatment of advanced biliary tract cancer provides supportive evidence for future larger randomised studies of nivolumab in this difficult to treat cancer. FUNDING: Ono Pharmaceutical Co Ltd and Bristol-Myers Squibb Inc.</p>
<p>doi: <a href="https://doi.org/10.1016/S2468-1253(19)30086-X" class="uri">https://doi.org/10.1016/S2468-1253(19)30086-X</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Aug;25(15):4674-4681</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31068372" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31068372</a></p>
<p>PURPOSE: Gene fusions involving neuregulin 1 (NRG1) have been noted in multiple cancer types and have potential therapeutic implications. Although varying results have been reported in other cancer types, the efficacy of the HER-family kinase inhibitor afatinib in the treatment of NRG1 fusion-positive pancreatic ductal adenocarcinoma is not fully understood. EXPERIMENTAL DESIGN: Forty-seven patients with pancreatic ductal adenocarcinoma received comprehensive whole-genome and transcriptome sequencing and analysis. Two patients with gene fusions involving NRG1 received afatinib treatment, with response measured by pretreatment and posttreatment PET/CT imaging. RESULTS: Three of 47 (6%) patients with advanced pancreatic ductal adenocarcinoma were identified as KRAS wild type by whole-genome sequencing. All KRAS wild-type tumors were positive for gene fusions involving the ERBB3 ligand NRG1. Two of 3 patients with NRG1 fusion-positive tumors were treated with afatinib and demonstrated a significant and rapid response while on therapy. CONCLUSIONS: This work adds to a growing body of evidence that NRG1 gene fusions are recurrent, therapeutically actionable genomic events in pancreatic cancers. Based on the clinical outcomes described here, patients with KRAS wild-type tumors harboring NRG1 gene fusions may benefit from treatment with afatinib.See related commentary by Aguirre, p.4589.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-0191" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-0191</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Contemporary Improvements in Postoperative Mortality After Major Cancer Surgery are Associated with Weakening of the Volume-Outcome Association</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Aug;26(8):2348-2356</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31065959" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31065959</a></p>
<p>BACKGROUND: Regionalization of complex visceral surgery across the United States has followed identification of a volume-outcome association. However, improvements in postoperative mortality overall during the last decade may have weakened the strength of this association. METHODS: The National Cancer Database was used to identify patients undergoing colon, esophageal, liver, and pancreatic surgery from 2003 to 2011. Hospitals were divided into low-volume (&lt;33rd %tile), medium-volume (34-66th %tile), and high-volume (&gt;67th %tile) groups. Annual cancer-specific adjusted observed versus expected (O/E) ratios for 30- and 90-day mortality for each volume strata were calculated and plotted over time. RESULTS: In the year 2003, the O/E ratios decreased from low- to medium- to high-volume hospitals for all cancer surgeries for both 30- and 90-day mortality, indicating a strong volume-outcome relationship. For all volume strata, the O/E ratios trended downward from 2003 to 2011 for both 30- and 90-day mortality for all cancer surgeries. This trend was more pronounced for low- and medium-volume than for high-volume hospitals. Consequently, by 2011 the confidence intervals of the O/E ratios for the low-volume groups, and particularly for the medium-volume groups, overlapped those for the high-volume groups for most of the cancer surgeries studied. CONCLUSIONS: The volume-outcome association for major cancer surgery is dynamic and has attenuated over time primarily due to improvements in postoperative mortality at low- and medium-volume hospitals.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07413-9" class="uri">https://doi.org/10.1245/s10434-019-07413-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Aug;25(15):4723-4734</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31064781" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31064781</a></p>
<p>PURPOSE: Targeted thorium-227 conjugates (TTC) represent a new class of molecules for targeted alpha therapy (TAT). Covalent attachment of a 3,2-HOPO chelator to an antibody enables specific complexation and delivery of the alpha particle emitter thorium-227 to tumor cells. Because of the high energy and short penetration range, TAT efficiently induces double-strand DNA breaks (DSB) preferentially in the tumor cell with limited damage to the surrounding tissue. We present herein the preclinical evaluation of a mesothelin (MSLN)-targeted thorium-227 conjugate, BAY 2287411. MSLN is a GPI-anchored membrane glycoprotein overexpressed in mesothelioma, ovarian, pancreatic, lung, and breast cancers with limited expression in healthy tissue. EXPERIMENTAL DESIGN: The binding activity and radiostability of BAY 2287411 were confirmed bioanalytically. The mode-of-action and antitumor potency of BAY 2287411 were investigated in vitro and in vivo in cell line and patient-derived xenograft models of breast, colorectal, lung, ovarian, and pancreatic cancer. RESULTS: BAY 2287411 induced DSBs, apoptotic markers, and oxidative stress, leading to reduced cellular viability. Furthermore, upregulation of immunogenic cell death markers was observed. BAY 2287411 was well-tolerated and demonstrated significant antitumor efficacy when administered via single or multiple dosing regimens in vivo. In addition, significant survival benefit was observed in a disseminated lung cancer model. Biodistribution studies showed specific uptake and retention of BAY 2287411 in tumors and enabled the development of a mechanistic pharmacokinetic/pharmacodynamic model to describe the preclinical data. CONCLUSIONS: These promising preclinical results supported the transition of BAY 2287411 into a clinical phase I program in mesothelioma and ovarian cancer patients (NCT03507452).</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-18-3476" class="uri">https://doi.org/10.1158/1078-0432.CCR-18-3476</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>GNAS but Not Extended RAS Mutations Spectrum are Associated with a Better Prognosis in Intraductal Pancreatic Mucinous Neoplasms</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Aug;26(8):2640-2650</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31025231" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31025231</a></p>
<p>BACKGROUND: The management of intraductal papillary mucinous neoplasms (IPMNs) is mainly based on imaging features and clinical symptoms, and remains challenging. OBJECTIVE: The aim of this study was to assess GNAS, RAS family (KRAS, NRAS and HRAS), BRAF, and PIK3CA mutation status in resected IPMNs and correlate it with clinicopathological characteristics and patient survival. METHODS: Overall, 149 consecutive unselected patients who underwent pancreatectomy for IPMNs were included. After dissection from formalin-fixed and paraffin-embedded tumors, GNAS mutational screening was assessed by allelic discrimination using Taqman probes and confirmed by SNaPshot analysis. RAS family, BRAF, and PIK3CA mutational screening was assessed by high resolution melt and Sanger sequencing. RESULTS: Gastric- and intestinal-type IPMNs were the most frequent lesions (52% and 41%, respectively). Intestinal-type IPMNs were more frequently associated high-grade dysplasia (49%) and were the only IPMNs associated with colloid-type carcinoma. All pancreatobiliary IPMNs were invasive lesions, located in the main pancreatic duct. GNAS-activating mutations were strongly associated with the intestinal phenotype (p&lt;10-4), while RAS pathway mutations were not associated with any particular phenotype. Mutations within other members of the epidermal growth factor receptor (EGFR) pathway were very rare (2%). GNAS-mutated IPMNs were rarely invasive (11%) and almost exclusively (83%) of the colloid type. For invasive lesions, multivariate analyses determined that only node negativity was associated with improved cancer-specific survival, but, in univariate analysis, GNAS mutation was associated with prolonged survival. CONCLUSION: In patients selected for surgery, GNAS mutation analysis and tumor phenotype can help to better predict patient prognosis. In the near future, a more precise mutational analysis of IPMNs might help to better tailor their management.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07389-6" class="uri">https://doi.org/10.1245/s10434-019-07389-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Pancreas as a Site of Metastasis or Second Primary in Patients with Small Bowel Neuroendocrine Tumors</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Aug;26(8):2525-2532</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31011904" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31011904</a></p>
<p>BACKGROUND: The small bowel and pancreas are the most common primary sites of neuroendocrine tumors (NETs) giving rise to metastatic disease. Some patients with small bowel NETs (SBNETs) present with synchronous or metachronous pancreatic NETs (PNETs), and it is unclear whether these are separate primaries or metastases from one site to the other. METHODS: A surgical NET database including patients undergoing operations for SBNETs or PNETs was reviewed. Patients with synchronous or metachronous tumors in both the small bowel and pancreas were identified, and available tissues from primary tumors and metastases were examined using a 4-gene quantitative polymerase chain reaction (qPCR) and immunohistochemistry (IHC) panel developed for evaluating NETs of unknown primary. RESULTS: Of 338 patients undergoing exploration, 11 had NETs in both the small bowel and pancreas. Tissues from 11 small bowel tumors, 9 pancreatic tumors, and 10 metastases were analyzed. qPCR and IHC data revealed that three patients had separate SBNET and PNET primaries, and five patients had SBNETs that metastasized to the pancreas. Pancreatic tissue was unavailable in two patients, and qPCR and IHC gave discrepant results in one patient. CONCLUSIONS: NETs in both the small bowel and pancreas were found in 3% of our patients. In nearly two-thirds of evaluable patients, the pancreatic tumor was a metastasis from the SBNET primary, while in the remaining one-third of patients it represented a separate primary. Determining the origin of these tumors can help guide the choice of systemic therapy and surgical management.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07370-3" class="uri">https://doi.org/10.1245/s10434-019-07370-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: Tending Towards a Personalized Medicine for Colorectal Carcinomatosis by Adding the RAS Mutation Status in the Workup for CRS and HIPEC</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Aug;26(8):2605-2606</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31004296" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31004296</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07362-3" class="uri">https://doi.org/10.1245/s10434-019-07362-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Defining the Role of Lymphadenectomy for Pancreatic Neuroendocrine Tumors: An Eight-Institution Study of 695 Patients from the US Neuroendocrine Tumor Study Group</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Aug;26(8):2517-2524</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31004295" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31004295</a></p>
<p>BACKGROUND: Preoperative factors that reliably predict lymph node (LN) metastases in pancreatic neuroendocrine tumors (PanNETs) are unclear. The number of LNs needed to accurately stage PanNETs has not been defined. METHODS: Patients who underwent curative-intent resection of non-functional PanNETs at eight institutions from 2000 to 2016 were analyzed. Preoperative factors associated with LN metastases were identified. A procedure-specific target for LN retrieval to accurately stage patients was determined. RESULTS: Of 695 patients who underwent resection, 33% of tumors were proximal (head/uncinate) and 67% were distal (neck/body/tail). Twenty-six percent of patients (n=158) had LN-positive disease, which was associated with a worse 5-year recurrence-free survival (RFS; 60% vs.86%; p&lt;0.001). The increasing number of positive LNs was not associated with worse RFS. Preoperative factors associated with positive LNs included tumor size2cm (odds ratio [OR] 6.6; p&lt;0.001), proximal location (OR 2.5; p&lt;0.001), moderate versus well-differentiation (OR 2.1; p=0.006), and Ki-673% (OR 3.1; p&lt;0.001). LN metastases were also present in tumors without these risk factors:&lt;2cm (9%), distal location (19%), well-differentiated (23%), and Ki-67&lt;3% (16%). Median LN retrieval was 13 for pancreatoduodenectomy (PD), but only 9 for distal pancreatectomy (DP). Given that PD routinely includes a complete regional lymphadenectomy, a minimum number of LNs to accurately stage patients was not identified. However, for DP, removal of less than seven LNs failed to discriminate 5-year RFS between LN-positive and LN-negative patients (less than seven LNs: 72% vs.83%, p=0.198; seven or more LNs: 67% vs.86%; p=0.002). CONCLUSIONS: Tumor size2cm, proximal location, moderate differentiation, and Ki-673% are preoperative factors that predict LN positivity in resected non-functional PanNETs. Given the 9-23% incidence of LN metastases in patients without such risk factors, routine regional lymphadenectomy should be considered. PD inherently includes sufficient LN retrieval, while DP should aim to remove seven or more LNs for accurate staging.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07367-y" class="uri">https://doi.org/10.1245/s10434-019-07367-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Tspan8 is expressed in breast cancer and regulates E-cadherin/catenin signalling and metastasis accompanied by increased circulating extracellular vesicles</strong> </summary></p>
<p><em>The Journal of pathology 2019 Aug;248(4):421-437</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30982971" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30982971</a></p>
<p>Tspan8 exhibits a functional role in many cancer types including pancreatic, colorectal, oesophagus carcinoma, and melanoma. We present a first study on the expression and function of Tspan8 in breast cancer. Tspan8 protein was present in the majority of human primary breast cancer lesions and metastases in the brain, bone, lung, and liver. In a syngeneic rat breast cancer model, Tspan8+ tumours formed multiple liver and spleen metastases, while Tspan8- tumours exhibited a significantly diminished ability to metastasise, indicating a role of Tspan8 in metastases. Addressing the underlying molecular mechanisms, we discovered that Tspan8 can mediate up-regulation of E-cadherin and down-regulation of Twist, p120-catenin, and -catenin target genes accompanied by the change of cell phenotype, resembling the mesenchymal-epithelial transition. Furthermore, Tspan8+ cells exhibited enhanced cell-cell adhesion, diminished motility, and decreased sensitivity to irradiation. As a regulator of the content and function of extracellular vesicles (EVs), Tspan8 mediated a several-fold increase in EV number in cell culture and the circulation of tumour-bearing animals. We observed increased protein levels of E-cadherin and p120-catenin in these EVs; furthermore, Tspan8 and p120-catenin were co-immunoprecipitated, indicating that they may interact with each other. Altogether, our findings show the presence of Tspan8 in breast cancer primary lesion and metastases and indicate its role as a regulator of cell behaviour and EV release in breast cancer.  2019 The Authors. The Journal of Pathology published by John Wiley &amp; Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.</p>
<p>doi: <a href="https://doi.org/10.1002/path.5281" class="uri">https://doi.org/10.1002/path.5281</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Laparoscopic Complete Mesocolic Excision for Double Flexural Colon Cancers</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Aug;26(8):2516</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30927197" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30927197</a></p>
<p>BACKGROUND: Laparoscopic complete mesocolic excision (CME) for hepatic or splenic flexural colon cancer is considered technically demanding. The double (hepatic and splenic) flexural colon cancers are rare, and the laparoscopic CME procedure for such disease is not standardized. METHODS: This video presents laparoscopic CME for double (hepatic and splenic) flexural colon cancers using a medial and cranial approach. RESULTS: The patient was a 60-year-old woman with the diagnosis of splenic flexure cancer (cT4N1M0) and hepatic flexure cancer (cT3N0M0). Laparoscopic subtotal colectomy was performed. First, the left colic artery was divided at its origin, and the inferior mesenteric vein also was divided at the same level. The descending mesocolon was widely separated from the retroperitoneal tissues using a medial approach. Then, lymph node dissection along the surgical trunk was performed using a cranial approach. Finally, the transverse mesocolon was divided at the inferior border of the pancreas, and CME was achieved. The specimen was extracted through a small incision at the umbilicus, and side-to-side ileo-sigmoid anastomosis was performed extracorporeally. CONCLUSIONS: The approach presented in the video might be useful for standardization of laparoscopic CME for double flexural colon cancers.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07329-4" class="uri">https://doi.org/10.1245/s10434-019-07329-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Response to Comment on Letter to Editor Re Manuscript by Bannone et al. Ann Surg. 2018 Dec 20</strong> </summary></p>
<p><em>Annals of surgery 2019 Aug;270(2):e60-e61</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30870179" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30870179</a></p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003259" class="uri">https://doi.org/10.1097/SLA.0000000000003259</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Clear Cell Variant of Solid Pseudopapillary Neoplasm of the Pancreas: A Report of a Rare Variant and Review of the Literature</strong> </summary></p>
<p><em>International journal of surgical pathology 2019 Aug;27(5):535-540</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30845855" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30845855</a></p>
<p>The clear cell variant of solid pseudopapillary neoplasm (ccSPN) of the pancreas was first described in 2006. In this article, we report a case of this rare variant and review the few published reports. Both the current and previous reports show that ccSPN has several morphologic differences from conventional SPN, including clear vacuoles, fewer pseudopapillary formations, more solid/diffuse architecture, less hemorrhage, and fewer cholesterol clefts. Some of these features peculiar to ccSPN, such as solid/diffuse architecture, have been proposed to suggest aggressive behavior, though reports of ccSPN are rare and often have limited clinical follow-up. ccSPN also appears to occur more frequently in males than conventional SPNs. These clinical and pathologic features lead to unique set of differential diagnostic considerations for ccSPN, including metastatic renal cell carcinoma, perivascular epithelial cell tumor, and clear cell variants of other carcinomas. These unique features, atypical differential, and uncertain prognostic ramifications all make ccSPN an important variant to be aware of and report.</p>
<p>doi: <a href="https://doi.org/10.1177/1066896919833790" class="uri">https://doi.org/10.1177/1066896919833790</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Benchmarks in Pancreatic Surgery: A Novel Tool for Unbiased Outcome Comparisons</strong> </summary></p>
<p><em>Annals of surgery 2019 Aug;270(2):211-218</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30829701" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30829701</a></p>
<p>OBJECTIVE: To use the concept of benchmarking to establish robust and standardized outcome references after pancreatico-duodenectomy (PD). BACKGROUND: Best achievable results after PD are unknown. Consequently, outcome comparisons among different cohorts, centers or with novel surgical techniques remain speculative. METHODS: This multicenter study analyzes consecutive patients (2012-2015) undergoing PD in 23 international expert centers in pancreas surgery. Outcomes in patients without significant comorbidities and major vascular resection (benchmark cases) were analyzed to establish 20 outcome benchmarks for PD. These benchmarks were tested in a cohort with a poorer preoperative physical status (ASA class 3) and a cohort treated by minimally invasive approaches. RESULTS: Two thousand three hundred seventy-five (38%) low-risk cases out of a total of 6186 PDs were analyzed, disclosing low in-hospital mortality (1.6%) but high morbidity, with a 73% benchmark morbidity rate cumulated within 6 months following surgery. Benchmark cutoffs for pancreatic fistulas (B-C), severe complications ( grade 3), and failure-to-rescue rate were 19%, 30%, and 9%, respectively. The ASA 3 cohort showed comparable morbidity but a higher in hospital-mortality (3% vs 1.6%) and failure-to-rescue rate (16% vs 9%) than the benchmarks. The proportion of benchmark cases performed varied greatly across centers and continents for both open (9%-93%) and minimally invasive (11%-62%) PD. Centers operating mostly on complex PD cases disclosed better results than those with a majority of low-risk cases. CONCLUSION: The proposed outcome benchmarks for PD, established in a large-scale international patient cohort and tested in 2 different cohorts, may allow for meaningful comparisons between different patient cohorts, centers, countries, and surgical techniques.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003223" class="uri">https://doi.org/10.1097/SLA.0000000000003223</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Impact of Preoperative Immune Modulating Nutrition on Outcomes in Patients Undergoing Surgery for Gastrointestinal Cancer: A Systematic Review and Meta-analysis</strong> </summary></p>
<p><em>Annals of surgery 2019 Aug;270(2):247-256</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30817349" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30817349</a></p>
<p>OBJECTIVE: To define the influence of preoperative immune modulating nutrition (IMN) on postoperative outcomes in patients undergoing surgery for gastrointestinal cancer. BACKGROUND: Although studies have shown that perioperative IMN may reduce postoperative infectious complications, many of these have included patients with benign and malignant disease, and the optimal timing of such an intervention is not clear. METHODS: The Embase, Medline, and Cochrane databases were searched from 2000 to 2018, for prospective randomized controlled trials evaluating preoperative oral or enteral IMN in patients undergoing surgery for gastrointestinal cancer. The primary endpoint was the development of postoperative infectious complications. Secondary endpoints included postoperative noninfectious complications, length of stay, and up to 30-day mortality. The analysis was performed using RevMan v5.3 software. RESULTS: Sixteen studies reporting on 1387 patients (715 IMN group, 672 control group) were included. Six of the included studies reported on a mixed population of patients undergoing all gastrointestinal cancer surgery. Of the remaining, 4 investigated IMN in colorectal cancer surgery, 2 in pancreatic surgery, and another 2 in patients undergoing surgery for gastric cancer. There was 1 study each on liver and esophageal cancer. The formulation of nutrition used in all studies in the treated patients was Impact (Novartis/Nestl), which contains -3 fatty acids, arginine, and nucleotides. Preoperative IMN in patients undergoing surgery for gastrointestinal cancer reduced infectious complications [odds ratio (OR) 0.52, 95% confidence interval (CI) 0.38-0.71, P &lt; 0.0001, I = 16%, n = 1387] and length of hospital stay (weighted mean difference -1.57 days, 95% CI -2.48 to -0.66, P = 0.0007, I = 34%, n = 995) when compared with control (isocaloric isonitrogeneous feed or normal diet). It, however, did not affect noninfectious complications (OR 0.98, 95% CI 0.73-1.33, P = 0.91, I = 0%, n = 1303) or mortality (OR 0.55, 95% CI 0.18-1.68, P = 0.29, I = 0%, n = 955). CONCLUSION: Given the significant impact on infectious complications and a tendency to shorten length of stay, preoperative IMN should be encouraged in routine practice in patients undergoing surgery for gastrointestinal cancer.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003256" class="uri">https://doi.org/10.1097/SLA.0000000000003256</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>[Microcystic serous cystadenoma: An uncommon neoplasm of pancreas. Report of two cases]</strong> </summary></p>
<p><em>Annales de pathologie 2019 Aug;39(4):292-296</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30711334" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30711334</a></p>
<p>Microcystic variant of serous cystadenoma of the pancreas is a rare neoplasm; essentially located in the body or tail of the pancreas and associated with the von Hippel-Lindau. Often, patients are asymptomatic and the neoplasm is incidentally discovered. Usually radiographic manifestations are characteristic. Histopathological examination revealed uniform clear cuboidal cells; they can be confused with other clear cell neoplasms like renal cell carcinomas, well-differentiated neuroendocrine tumors and solid pseudopapillary tumors of the pancreas. Immunohistochemistry can be help to establish the diagnosis and to remove differential diagnosis. Serous cystadenoma is a benign neoplasm whose prognosis is excellent. We herein report two cases of microcystic serous cystadenomas of the pancreas diagnosed in two asymptomatic women and review analysis in the literature to remind the main features of this lesion and the main differential diagnosis.</p>
<p>doi: <a href="https://doi.org/10.1016/j.annpat.2018.12.007" class="uri">https://doi.org/10.1016/j.annpat.2018.12.007</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Response to Comment on Characterization and Optimal Management of High-risk Pancreatic Anastomoses During Pancreatoduodenectomy: Response to Goussous and Cunningham</strong> </summary></p>
<p><em>Annals of surgery 2019 Aug;270(2):e58-e59</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30499813" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30499813</a></p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003121" class="uri">https://doi.org/10.1097/SLA.0000000000003121</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comment on Interpreting Clinical Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer (BRPC)</strong> </summary></p>
<p><em>Annals of surgery 2019 Aug;270(2):e48-e50</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30499804" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30499804</a></p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003115" class="uri">https://doi.org/10.1097/SLA.0000000000003115</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth</strong> </summary></p>
<p><em>Gut 2019 08;68(8):1465-1476</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30343272" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30343272</a></p>
<p>BACKGROUND AND AIMS: Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive tumour with a poor prognosis using current treatments. Targeted therapies may offer a new avenue for more effective strategies. Dual-specificity tyrosine regulated kinase 1A (DYRK1A) is a pleiotropic kinase with contradictory roles in different tumours that is uncharacterised in PDAC. Here, we aimed to investigate the role of DYRK1A in pancreatic tumorigenesis. DESIGN: We analysed DYRK1A expression in PDAC genetic mouse models and in patient samples. DYRK1A function was assessed with knockdown experiments in pancreatic tumour cell lines and in PDAC mouse models with genetic reduction of Dyrk1a dosage. Furthermore, we explored a mechanistic model for DYRK1A activity. RESULTS: We showed that DYRK1A was highly expressed in PDAC, and that its protein level positively correlated with that of c-MET. Inhibition of DYRK1A reduced tumour progression by limiting tumour cell proliferation. DYRK1A stabilised the c-MET receptor through SPRY2, leading to prolonged activation of extracellular signal-regulated kinase signalling. CONCLUSIONS: These findings reveal that DYRK1A contributes to tumour growth in PDAC, at least through regulation of c-MET accumulation, suggesting that inhibition of DYRK1A could represent a novel therapeutic target for PDAC.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2018-316128" class="uri">https://doi.org/10.1136/gutjnl-2018-316128</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group</strong> </summary></p>
<p><em>Annals of surgery 2019 Aug;270(2):230-237</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30339627" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30339627</a></p>
<p>OBJECTIVE: To evaluate each arm independently and compare adjuvant gemcitabine (GEM) and S-1 chemotherapy after major hepatectomy (hemihepatectomy or trisectionectomy) for biliary tract cancer (BTC). BACKGROUND: Standardized adjuvant therapy is not performed after major hepatectomy for BTC, and we determined the recommended dose in the former study (KHBO1003). METHODS: We performed a multicenter, randomized phase II study. The primary measure was 1-year recurrence-free survival (RFS); the secondary measures were other RFS, overall survival (OS), and others. The following 6-month adjuvant chemotherapy was administered within 12 weeks of R0/1: GEM (1000mg/m) every 2 weeks; or S-1 (80mg/m/d) for 28 days every 6 weeks. Thirty-five patients were assigned to each arm (alpha error, 10%; beta error, 20%). RESULTS: No patients were excluded for the per-protocol analysis. There were no statistically significant differences in the patient characteristics of the 2 arms. The 1-year RFS and 1-year OS rates of the GEM arm were 51.4% and 80.0%, respectively, whereas those of the S-1 group were 62.9% and 97.1%. The comparison of the 2 arms revealed that 2-year RFS rate, 1 and 2-year OS rates, and OS curve of the S-1 arm were superior to GEM. With regard to OS, the hazard ratio of the S-1 group was 0.477 (90% confidence interval 0.245-0.927). CONCLUSION: The comparison of the survival of the 2 groups revealed that adjuvant S-1 therapy may be superior to adjuvant GEM therapy after major hepatectomy for BTC.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000002865" class="uri">https://doi.org/10.1097/SLA.0000000000002865</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Response to Comment on The Virtual Hepatectomy Changed the Practice of Liver Surgery: More Details, More Significance</strong> </summary></p>
<p><em>Annals of surgery 2019 Aug;270(2):e33</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30138165" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30138165</a></p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003009" class="uri">https://doi.org/10.1097/SLA.0000000000003009</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Determinants of Severity in Acute Pancreatitis: A Nation-wide Multicenter Prospective Cohort Study</strong> </summary></p>
<p><em>Annals of surgery 2019 Aug;270(2):348-355</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=29672416" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=29672416</a></p>
<p>OBJECTIVE: The aim of this study was to compare and validate the different classifications of severity in acute pancreatitis (AP) and to investigate which characteristics of the disease are associated with worse outcomes. SUMMARY OF BACKGROUND DATA: AP is a heterogeneous disease, ranging from uneventful cases to patients with considerable morbidity and high mortality rates. Severity classifications based on legitimate determinants of severity are important to correctly describe the course of disease. METHODS: A prospective multicenter cohort study involving patients with AP from 23 hospitals in Spain. The Atlanta Classification (AC), Revised Atlanta Classification (RAC), and Determinant-based Classification (DBC) were compared. Binary logistic multivariate analysis was performed to investigate independent determinants of severity. RESULTS: A total of 1655 patients were included; 70 patients (4.2%) died. RAC and DBC were equally superior to AC for describing the clinical course of AP. Although any kind of organ failure was associated with increased morbidity and mortality, persistent organ failure (POF) was the most significant determinant of severity. All local complications were associated with worse outcomes. Infected pancreatic necrosis correlated with high morbidity, but in the presence of POF, it was not associated to higher mortality when compared with sterile necrotizing pancreatitis. Exacerbation of previous comorbidity was associated with increased morbidity and mortality. CONCLUSION: The RAC and DBC both signify an advance in the description and differentiation of AP patients. Herein, we describe the complications of the disease independently associated to morbidity and mortality. Our findings are valuable not only when designing future studies on AP but also for the improvement of current classifications.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000002766" class="uri">https://doi.org/10.1097/SLA.0000000000002766</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection</strong> </summary></p>
<p><em>Annals of surgery 2019 Aug;270(2):340-347</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=29596120" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=29596120</a></p>
<p>OBJECTIVE: The aim of the study was to identify the survival of patients with locally advanced pancreatic cancer (LAPC) and assess the effect of surgical resection after neoadjuvant therapy on patient outcomes. BACKGROUND: An increasing number of LAPC patients who respond favorably to neoadjuvant therapy undergo surgical resection. The impact of surgery on patient survival is largely unknown. MATERIALS AND METHODS: All LAPC patients who presented to the institutional pancreatic multidisciplinary clinic (PMDC) from January 2013 to September 2017 were included in the study. Demographics and clinical data on neoadjuvant treatment and surgical resection were documented. Primary tumor resection rates after neoadjuvant therapy and overall survival (OS) were the primary study endpoints. RESULTS: A total of 415 LAPC patients were included in the study. Stratification of neoadjuvant therapy in FOLFIRINOX-based, gemcitabine-based, and combination of the two, and subsequent outcome comparison did not demonstrate significant differences in OS of 331 non-resected LAPC patients (P = 0.134). Eighty-four patients underwent resection of the primary tumor (20%), after a median duration of 5 months of neoadjuvant therapy. FOLFIRINOX-based therapy and stereotactic body radiation therapy correlated with increased probability of resection (P = 0.006). Resected patients had better performance status, smaller median tumor size (P = 0.029), and lower median CA19-9 values (P &lt; 0.001) at PMDC. Patients who underwent surgical resection had significant higher median OS compared with those who did not (35.3 vs 16.3 mo, P &lt; 0.001). The difference remained significant when non-resected patients were matched for time of neoadjuvant therapy (19.9 mo, P &lt; 0.001). CONCLUSIONS: Surgical resection of LAPC after neoadjuvant therapy is feasible in a highly selected cohort of patients (20%) and is associated with significantly longer median overall survival.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000002753" class="uri">https://doi.org/10.1097/SLA.0000000000002753</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Coexisting pancreatic serous cystadenoma and pancreatic ductal adenocarcinoma: A cytological-pathologic correlation with literature review</strong> </summary></p>
<p><em>Annals of diagnostic pathology 2019 Oct;42():87-91</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31382079" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31382079</a></p>
<p>Pancreatic serous cystadenoma (SCA) is a benign neoplastic lesion with a distinctive gross and microscopic appearance consisting of numerous thin-walled cysts lined by uniform epithelial cells with clear cytoplasm and small nuclei. The vast majority of serous cystadenomas are benign. Pancreatic SCA has rarely been reported in association with other pancreatic lesions. We present a challenging case in which a cystic and solid pancreatic mass was identified on imaging studies. FNA was performed and showed clusters of atypical cells with significant nuclear pleomorphism (&gt;4:1), disorganized, overlapping nuclei, and prominent nucleoli. The FNA diagnosis was positive for malignancy, consistent with adenocarcinoma. The patient underwent neoadjuvant therapy and pancreaticoduodenectomy. Final pathology showed a serous cystadenoma associated with small foci of high-grade PanIN. The lack of invasive adenocarcinoma in the resection specimen was most likely due to complete response of the tumor to neoadjuvant chemoradiation therapy, but it is also possible that only high-grade PanIN was present initially. To our knowledge, this is the first reported case of SCA and high grade PanIN/PDAC that was assessed by FNA. We discuss the cytologic differential diagnosis and how to avoid potential pitfalls highlighted by this case.</p>
<p>doi: <a href="https://doi.org/10.1016/j.anndiagpath.2019.07.006" class="uri">https://doi.org/10.1016/j.anndiagpath.2019.07.006</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>New Nodal Staging for Primary Pancreatic Neuroendocrine Tumors: A Multi-institutional and National Data Analysis</strong> </summary></p>
<p><em>Annals of surgery 2019 Jul;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31356277" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31356277</a></p>
<p>OBJECTIVE: To determine the prognostic role of metastatic lymph node (LN) number and the minimal number of LNs for optimal staging of patients with pancreatic neuroendocrine tumors (pNETs). BACKGROUND: Prognosis relative to number of LN metastasis (LNM), and minimal number of LNs needed to evaluate for accurate staging, have been poorly defined for pNETs. METHODS: Number of LNM and total number of LN evaluated (TNLE) were assessed relative to recurrence-free survival (RFS) and overall survival (OS) in a multi-institutional database. External validation was performed using Surveillance, Epidemiology and End Results (SEER) registry. RESULTS: Among 854 patients who underwent resection, 233 (27.3%) had at least 1 LNM. Patients with 1, 2, or 3 LNM had a comparable worse RFS versus patients with no nodal metastasis (5-year RFS, 1 LNM 65.6%, 2 LNM 68.2%, 3 LNM 63.2% vs 0 LNM 82.6%; all P &lt; 0.001). In contrast, patients with 4 LNM (proposed N2) had a worse RFS versus patients who either had 1 to 3 LNM (proposed N1) or node-negative disease (5-year RFS, 4 LNM 43.5% vs 1-3 LNM 66.3%, 0 LNM 82.6%; all P &lt; 0.05) [C-statistics area under the curve (AUC) 0.650]. TNLE 8 had the highest discriminatory power relative to RFS (AUC 0.713) and OS (AUC 0.726) among patients who had 1 to 3 LNM, and patients who had 4 LNM in the multi-institutional and SEER database (n = 2764). CONCLUSIONS: Regional lymphadenectomy of at least 8 lymph nodes was necessary to stage patients accurately. The proposed nodal staging of N0, N1, and N2 optimally staged patients.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003478" class="uri">https://doi.org/10.1097/SLA.0000000000003478</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Left-sided Portal Hypertension After Pancreaticoduodenectomy With Resection of the Portal Vein/Superior Mesenteric Vein Confluence in Patients With Pancreatic Cancer: A Project Study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery</strong> </summary></p>
<p><em>Annals of surgery 2019 Jul;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31356273" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31356273</a></p>
<p>OBJECTIVE: The aim of this study was to evaluate how often left-sided portal hypertension (LPH) develops and how LPH affects the long-term outcomes of patients with pancreatic cancer treated with pancreaticoduodenectomy (PD) and resection of the portal vein (PV)/superior mesenteric vein (SMV) confluence. SUMMARY BACKGROUND DATA: Little is known about LPH after PD with resection of the PV/SMV confluence. METHODS: Overall, 536 patients who underwent PD with PV/SMV resection were enrolled. Among them, we mainly compared the SVp group [n=285; the splenic vein (SV) was preserved] and the SVr group (n = 227; the SV was divided and not reconstructed). RESULTS: The incidence of variceal formation in the SVr group increased until 3 years after PD compared with that in the SVp group (38.7% vs 8.3%, P &lt; 0.001). Variceal bleeding occurred in the SVr group (n = 9: 4.0%) but not in the SVp group (P &lt; 0.001). In the multivariate analysis, the risk factors for variceal formation were liver disease, N factor, conventional PD, middle colic artery resection, and SV division. The only risk factor for variceal bleeding was SV division. The platelet count ratio at 6 months after PD was significantly lower in the SVr group than in the SVp group (0.97 vs 0.82, P &lt; 0.001), and the spleen-volume ratios at 6 and 12 months were significantly higher in the SVr group than in the SVp group (1.38 vs 1.00 and 1.54 vs 1.09; P &lt; 0.001 and P &lt; 0.001, respectively). CONCLUSIONS: PD with SV division causes variceal formation, bleeding, and thrombocytopenia.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003487" class="uri">https://doi.org/10.1097/SLA.0000000000003487</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer</strong> </summary></p>
<p><em>The New England journal of medicine 2019 07;381(4):317-327</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31157963" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31157963</a></p>
<p>BACKGROUND: Patients with a germline BRCA1 or BRCA2 mutation make up a small subgroup of those with metastatic pancreatic cancer. The poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib has had antitumor activity in this population. METHODS: We conducted a randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy of olaparib as maintenance therapy in patients who had a germline BRCA1 or BRCA2 mutation and metastatic pancreatic cancer and disease that had not progressed during first-line platinum-based chemotherapy. Patients were randomly assigned, in a 3:2 ratio, to receive maintenance olaparib tablets (300 mg twice daily) or placebo. The primary end point was progression-free survival, which was assessed by blinded independent central review. RESULTS: Of the 3315 patients who underwent screening, 154 underwent randomization and were assigned to a trial intervention (92 to receive olaparib and 62 to receive placebo). The median progression-free survival was significantly longer in the olaparib group than in the placebo group (7.4 months vs.3.8 months; hazard ratio for disease progression or death, 0.53; 95% confidence interval [CI], 0.35 to 0.82; P=0.004). An interim analysis of overall survival, at a data maturity of 46%, showed no difference between the olaparib and placebo groups (median, 18.9 months vs.18.1 months; hazard ratio for death, 0.91; 95% CI, 0.56 to 1.46; P=0.68). There was no significant between-group difference in health-related quality of life, as indicated by the overall change from baseline in the global quality-of-life score (on a 100-point scale, with higher scores indicating better quality of life) based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (between-group difference, -2.47 points; 95% CI, -7.27 to 2.33). The incidence of grade 3 or higher adverse events was 40% in the olaparib group and 23% in the placebo group (between-group difference, 16 percentage points; 95% CI, -0.02 to 31); 5% and 2% of the patients, respectively, discontinued the trial intervention because of an adverse event. CONCLUSIONS: Among patients with a germline BRCA mutation and metastatic pancreatic cancer, progression-free survival was longer with maintenance olaparib than with placebo. (Funded by AstraZeneca and others; POLO ClinicalTrials.gov number, NCT02184195.).</p>
<p>doi: <a href="https://doi.org/10.1056/NEJMoa1903387" class="uri">https://doi.org/10.1056/NEJMoa1903387</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Fine-needle aspiration of the liver: a 10-year single institution retrospective review</strong> </summary></p>
<p><em>Human pathology 2019 Oct;92():25-31</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31351156" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31351156</a></p>
<p>Fine-needle aspiration (FNA) of liver masses is a minimally invasive means of evaluation, with diagnostic accuracy over 85%. Given that most of the recent literature on sampling hepatic tumors was published by radiologists and gastroenterologists, we herein conduct a 10-year retrospective review of a single institutions cytopathology experience with the diagnosis of liver lesions. Electronic record review of the cytopathology files (CoPathPlus; Cerner Corp) was conducted for the 10-year interval January 2007 through December 2016. All cytology specimens designated as liver and FNA were included. Associated concurrent and subsequent surgical pathology and cytopathology cases were identified. All FNA cases were organized into four diagnostic categories: positive for malignancy, atypical, negative for malignancy, and non-diagnostic. There were 713 hepatic FNAs that were categorized as follows: positive for malignancy 467 (65.5%), atypical 49 (6.9%), negative 171 (24.0%) and non-diagnostic 26 (3.6%). Metastatic tumors (95.7%) were more common that primary (4.3%). The top two metastatic primary sites were pancreas (30.1%) and colon (12.7%). A total of 166 (23.2%) cases had concurrent core needle biopsies (CNB). 111 (66.9%) were concordant with the FNA diagnosis. Of the 55 discordant cases, 43 (25.9%) had diagnostic material only on CNB and 12 (7.2%) had diagnostic material only on FNA. The sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy were 93.4%, 96.7%, 98.2%, 84.3%, and 89.3% respectively. Irrespective of endoscopic versus percutaneous approach, hepatic FNA is a sensitive and specific means of identifying metastatic and primary malignancies of the liver.</p>
<p>doi: <a href="https://doi.org/10.1016/j.humpath.2019.07.007" class="uri">https://doi.org/10.1016/j.humpath.2019.07.007</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Reappraisal of a 2-Cm Cut-Off Size for the Management of Cystic Pancreatic Neuroendocrine Neoplasms: A Multicenter International Study</strong> </summary></p>
<p><em>Annals of surgery 2019 Jul;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31348038" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31348038</a></p>
<p>MINI: The characteristics of cystic pancreatic neuroendocrine neoplasms (cPanNENs) are largely unknown, and their clinical management remains unclear; specifically, an observational strategy for asymptomatic cPanNENs 2cm has been proposed by recent guidelines, but evidence is scarce and limited to single institutional series. In this international cohort study of 263 resected cPanNENs from 16 institutions worldwide, a preoperative size &gt;2cm was independently associated with aggressive behavior both in the whole cohort and in the subset of asymptomatic patients; notably, only 1 of 61 asymptomatic cPanNENs 2cm was aggressive. Based on these results, a watch-and-wait policy for sporadic asymptomatic cPanNENs 2cm seems justified and safe. The aim of this study was to characterize an international cohort of resected cystic pancreatic neuroendocrine neoplasms (cPanNENs) and identify preoperative predictors of aggressive behavior. The characteristics of cPanNENs are unknown and their clinical management remains unclear. An observational strategy for asymptomatic cPanNENs 2cm has been proposed by recent guidelines, but evidence is scarce and limited to single-institutional series. Resected cPanNENs (1995-2017) from 16 institutions worldwide were included. Solid lesions (&gt;50% solid component), functional tumors, and MEN-1 patients were excluded. Aggressiveness was defined as lymph node (LN) involvement, G3 grading, distant metastases, and/or recurrence. Overall, 263 resected cPanNENs were included, among which 177 (63.5%) were &gt;2cm preoperatively. A preoperative diagnosis of cPanNEN was established in 162 cases (61.6%) and was more frequent when patients underwent endoscopic ultrasound [EUS, odds ratio (OR) 2.69, 95% confidence interval (CI) 1.52-4.77] and somatostatin-receptor imaging (OR 3.681, 95% CI 1.809-7.490), and for those managed in specialized institutions (OR 3.12, 95% CI 1.57-6.21). Forty-one cPanNENs (15.6%) were considered aggressive. In the whole cohort, LN involvement on imaging, age &gt;65 years, preoperative size &gt;2cm, and pancreatic duct dilation were independently associated with aggressive behavior. In asymptomatic patients, older age and a preoperative size &gt;2cm remained independently associated with aggressiveness. Only 1 of 61 asymptomatic cPanNENs 2cm displayed an aggressive behavior. The diagnostic accuracy of cPanNENs is increased by the use of EUS and somatostatin-receptor imaging and is higher in specialized institutions. Preoperative size &gt;2cm is independently associated with aggressive behavior. Consequently, a watch-and-wait policy for sporadic asymptomatic cPanNENs 2cm seems justified and safe for most patients.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003508" class="uri">https://doi.org/10.1097/SLA.0000000000003508</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Long non-coding RNA PTTG3P functions as an oncogene by sponging miR-383 and up-regulating CCND1 and PARP2 in hepatocellular carcinoma</strong> </summary></p>
<p><em>BMC cancer 2019 Jul;19(1):731</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31340767" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31340767</a></p>
<p>BACKGROUND: Emerging evidence indicates that Long non-coding RNAs (LncRNAs) and microRNAs (miRNAs) play crucial roles in tumor progression, including hepatocellular carcinoma (HCC). However, whether there is a crosstalk between LncRNA pituitary tumor-transforming 3 (PTTG3P) and miR-383 in HCC remains unknown. This study is designed to explore the underlying mechanism by which LncRNA PTTG3P sponges miR-383 during HCC progression. METHODS: qPCR and Western blot were used to analyze LncRNA PTTG3P, miR-383 and other target genes expression. CCK-8 assay was performed to examine cell proliferation. Annexin V-PE/PI and PI staining were used to analyze cell apoptosis and cell cycle distribution by flow cytometry, respectively. Transwell migration and invasion assays were used to examine cell migration and invasion abilities. An in vivo xenograft study was performed to detect tumor growth. Luciferase reporter assay and RNA pull-down assay were carried out to detect the interaction between miR-383 and LncRNA PTTG3P. RIP was carried out to detect whether PTTG3P and miR-383 were enriched in Ago2-immunoprecipitated complex. RESULTS: In this study, we found that PTTG3P was up-regulated in HCC tissues and cells. Functional experiments demonstrated that knockdown of PTTG3P inhibited cell proliferation, migration and invasion, and promoted cell apoptosis, acting as an oncogene. Mechanistically, PTTG3P upregulated the expression of miR-383 targets Cyclin D1 (CCND1) and poly ADP-ribose polymerase 2 (PARP2) by sponging miR-383, acting as a competing endogenous RNA (ceRNA). The PTTG3P-miR-383-CCND1/PARP2 axis modulated HCC phenotypes. Moreover, PTTG3P also affected the PI3K/Akt signaling pathway. CONCLUSION: The data indicate a novel PTTG3P-miR-383-CCND1/PARP2 axis in HCC tumorigenesis, suggesting that PTTG3P may be used as a potential therapeutic target in HCC.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-5936-2" class="uri">https://doi.org/10.1186/s12885-019-5936-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Age-related morphological changes in the pancreas and their association with pancreatic carcinogenesis</strong> </summary></p>
<p><em>Pathology international 2019 Aug;69(8):450-462</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31339204" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31339204</a></p>
<p>Age-related pathological changes in the pancreas have been unclear because they are often minor and nonspecific. However, recent studies have shown that they are closely related to various pathological conditions such as pancreatic cancer and diabetes mellitus. Knowledge of age-related changes is important to determine appropriate prevention, detection, and treatment strategies for various diseases observed in elderly patients. We present a review of the pathological age-related non-neoplastic changes in the exocrine pancreas such as pancreatic fatty replacement, lobulocentric pancreatic atrophy, pancreatic duct ectasia, and metaplasia of exocrine pancreas, as well as changes in islet cells. We have discussed common pancreatic neoplasms in elderly patients, such as pancreatic intraepithelial neoplasia (PanIN), intraductal papillary mucinous neoplasms (IPMNs), and pancreatic ductal adenocarcinoma (PDAC). Age-related pathological changes play a key role in pancreatic carcinogenesis via telomere dysfunction. Further studies are warranted to clarify molecular mechanisms of pancreatic carcinogenesis in elderly patients.</p>
<p>doi: <a href="https://doi.org/10.1111/pin.12837" class="uri">https://doi.org/10.1111/pin.12837</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Morphologic Factors Predict Pain Relief Following Pancreatic Head Resection in Chronic Pancreatitis Description of the Chronic Pancreatitis Pain Relief (CPPR) Score</strong> </summary></p>
<p><em>Annals of surgery 2019 Jul;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31348039" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31348039</a></p>
<p>OBJECTIVE: This study analyzes the clinicopathologic findings and their impact on outcome of patients so as to identify which patients benefit most from surgical treatment in chronic pancreatitis, especially in regard to pain relief. SUMMARY BACKGROUND DATA: The predominant symptom of chronic pancreatitis is chronic pain resulting in reduced quality of life. It is well known that the main reason for development of the disease is abuse of alcohol and nicotine, but only little data on factors influencing outcome are available. METHODS: One thousand one hundred forty-six consecutive patients who underwent surgery for chronic pancreatitis were included. Clinicopathologic data, including morphology of the pancreas in preoperative diagnostics and the histopathologic results, were evaluated. A long-term follow-up including Quality of Life and pain scores was performed. Additionally, we describe the novel Chronic Pancreatitis Pain Relief Score (CPPR-Score) as a tool for prediction of pain relief. RESULTS: Overall the rate of pain relief was 79.8% after surgery. The presence of an inflammatory mass in the pancreatic head larger than 4cm (P &lt; 0.001), presence of a dilated main pancreatic duct of over 4mm (P &lt; 0.001), histopathologically detected severe calcifications (P = 0.001) and severe fibrosis (P &lt; 0.001) as well as ethanol induced disease (P &lt; 0.001) found to be strong independent prognostic factors for pain relief. The CPPR-Score (0-5 points) proved to be a very good predictive score for pain-relief (P &lt; 0.001). CONCLUSIONS: The rate of pain relief after surgical treatment in chronic pancreatitis is high and the commonly used procedures can be performed with acceptable morbidity and mortality. The Chronic Pancreatitis Pain Relief Score allows identifying patients who will benefit most from surgery.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003439" class="uri">https://doi.org/10.1097/SLA.0000000000003439</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Overall survival in patients over 40years old with surgically resected pancreatic carcinoma: a SEER-based nomogram analysis</strong> </summary></p>
<p><em>BMC cancer 2019 Jul;19(1):726</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31337369" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31337369</a></p>
<p>BACKGROUND: The aim of this study was to identify the determinants of overall survival (OS) within patients over 40years old with surgically resected pancreatic carcinoma (PC), and to develop a nomogram with the intention of OS predicting. METHODS: A total of 6341 patients of 40years of age or later with surgically resected PC between 2010 and 2015 were enrolled from the Surveillance, Epidemiology, and End Results (SEER) program and randomly assigned into training set (4242 cases) and validation set (2099 cases). A nomogram was constructed for predicting 1-, 2- and 3-years OS based on univairate and multivariate Cox regression. The C-index and calibration plot were adopted to assess the nomogram performance. RESULTS: Our analysis showed that age, location of carcinoma in pancreas, tumor grade, TNM stage, size of carcinoma together with lymph node ratio (LNR) were considered to be independent overall survival predictors. A nomogram based on these six factors was developed with C-index being 0.680 (95%CI: 0.667-0.693). All calibration curves of OS fitted well. The OS curves stratified by nomogram-predicted probability score (20, 10-19 and&lt;10) demonstrated statistically significant difference not only within training set but also in validation set. CONCLUSIONS: The present nomogram for OS predicting can serve as the efficacious survival-predicting model and assist in accurate decision-making for patients over 40years old with surgically resected PC.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-5958-9" class="uri">https://doi.org/10.1186/s12885-019-5958-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Metastatic low-grade endometrial stromal sarcoma of uterus presenting as a primary pancreatic tumor: case presentation and literature review</strong> </summary></p>
<p><em>Diagnostic pathology 2019 Apr;14(1):30</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31010432" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31010432</a></p>
<p>BACKGROUND: Metastatic tumors to the pancreas are uncommon, accounting for approximately 2% of pancreatic malignancies. The most common primary tumors to give rise to pancreatic metastases are carcinomas. CASE PRESENTATION: A 50-year old female patient was investigated for a cause of abdominal discomfort. She had a 2-year history of menorrhagia and dysmenorrhea which was ascribed to a fibroid uterus. On imaging, she was found to have a large solid and cystic mass in the tail of the pancreas. Imaging also confirmed a fibroid uterus. A distal pancreatectomy and splenectomy showed a 9cm circumscribed mass within, and grossly confined to, the parenchyma of the pancreatic tail. Microscopically, the pancreatic lesion was lobulated, and well-circumscribed, but focally infiltrative. It comprised sheets of uniform spindled to epithelioid cells with round to oval nuclei, coarse to vesicular chromatin, visible nucleoli, nuclear grooves and clear to eosinophilic cytoplasm. Prominent arterioles were identified. The stroma was collagenized in areas. Occasional hemosiderin-laden macrophages were seen, and focal cystic change was present. There was no evidence of nuclear pleomorphism, mitotic activity or necrosis, and there was no evidence of endometriosis despite multiple sections being taken. Immunohistochemistry showed that the tumor cells were positive for CD10, estrogen receptor (ER), progesterone receptor (PR), Wilms tumor-1 (WT-1) and smooth muscle actin (SMA). RNA sequencing detected a PHF1 rearrangement. The morphological, immunohistochemical and molecular features were of a low-grade endometrial stromal sarcoma (LG-ESS). Subsequent total hysterectomy and bilateral salpingo-oophorectomy 3months later, showed uterine fibroids and a 5cm low-grade endometrial stromal sarcoma confined to the uterus, with lymphatic invasion. CONCLUSIONS: To the best of our knowledge, this is the first documented case of metastatic endometrial stromal sarcoma of uterus presenting as a primary pancreatic neoplasm. An unexpected extra-uterine location and unusual presentation of ESS may make the diagnosis challenging, despite classic histological features. Morphological, immunohistochemical and molecular findings must be combined to render the correct diagnosis.</p>
<p>doi: <a href="https://doi.org/10.1186/s13000-019-0807-3" class="uri">https://doi.org/10.1186/s13000-019-0807-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>[Heterotopic tissue in the gastrointestinal tract]</strong> </summary></p>
<p><em>Der Pathologe 2018 Sep;39(5):402-408</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30105611" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30105611</a></p>
<p>Heterotopia of the gastrointestinal tract is acommon finding. This is due to the complex embryogenesis and the relative ease to detect heterotopic tissue during endoscopy. The reason for biopsy is mostly to rule out neoplasms or to define specific causes of inflammation. Heterotopic tissue can occur in any location of the gastrointestinal tract. The most frequent are gastric heterotopia, pancreatic heterotopia, and heterotopia of Brunners gland. On rare occasions, heterotopic tissue of salivary gland type as well as heterotopias of apocrine glands, thyroid, and prostatic tissue have been described. The most frequently involved organs are the small intestine, in particular the duodenum, the esophagus, and the stomach. Heterotopia of the large bowel occurs exclusively in the rectum. Most heterotopias do not cause symptoms and are easily diagnosed by biopsy and histology. However, depending on location, size, and the kind of underlying heterotopic tissue, they may cause significant complications, such as inflammation, ulceration and perforation, obstruction, intussusception, and severe life-threatening bleeding. Another rare but significant complication is neoplasia. Gastric heterotopias may give rise to pyloric gland adenomas within the bowel or rarely adenocarcinomas of the esophagus. Pancreatic heterotopia can be complicated by ductal type pancreatic adenocarcinomas, by acinus cell carcinomas, by intraductal papillary mucinous neoplasias, and also by endocrine tumors. The present paper summarizes our current knowledge about heterotopias in atopographic clinico-pathological manner.</p>
<p>doi: <a href="https://doi.org/10.1007/s00292-018-0466-2" class="uri">https://doi.org/10.1007/s00292-018-0466-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Brain-to-pancreas signalling axis links nicotine and diabetes</strong> </summary></p>
<p><em>Nature 2019 10;574(7778):336-337</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31619783" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31619783</a></p>
<p>doi: <a href="https://doi.org/10.1038/d41586-019-02975-w" class="uri">https://doi.org/10.1038/d41586-019-02975-w</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Beta-cell sensitivity to insulinotropic gut hormones is reduced after gastric bypass surgery</strong> </summary></p>
<p><em>Gut 2019 10;68(10):1838-1845</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30772836" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30772836</a></p>
<p>OBJECTIVE: Postprandial hyperinsulinaemia after Roux-en Y gastric bypass (GB) has been attributed to rapid nutrient flux from the gut, and an enhanced incretin effect. However, it is unclear whether surgery changes islet cell responsiveness to regulatory factors. This study tested the hypothesis that -cell sensitivity to glucagon like-peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) is attenuated after GB. DESIGN: Ten non-diabetic subjects with GB, and 9 body mass index (BMI)-matched and age-matched non-surgical controls (CN) with normal glucose tolerance had blood glucose clamped at ~7.8mM on three separate days. Stepwise incremental infusions of GLP-1 (15, 30, 60, 120 and 300ng/LBkg/h), GIP (75, 150, 300, 600 and 1200ng/LBkg/h) or saline were administered from 90 to 240min and insulin secretion measured. RESULTS: GB subjects had similar fasting glucose levels but lower fasting insulin compared with CN, likely due to increased insulin clearance. The average insulin secretion rates (ISRs) to 7.8mM glucose were ~30%lower in GB relative to CN subjects. However, incretin-stimulated ISRs, adjusted for insulin sensitivity and glucose-stimulated insulin secretion, were even more attenuated in the GB subjects, by threefold to fourfold (AUCISR(90-240 min) during GLP-1 and GIP: 478and 4412nmol in GB and 11616and 16144 in CN; p&lt;0.01). CONCLUSION: After GB, the sensitivity of insulin secretion to both glucose and incretins is diminished.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2018-317760" class="uri">https://doi.org/10.1136/gutjnl-2018-317760</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Fist-Sized Radiographic Consolidation in a Man With Difficulty Swallowing</strong> </summary></p>
<p><em>Gastroenterology 2019 10;157(4):e6-e7</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31078620" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31078620</a></p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.05.006" class="uri">https://doi.org/10.1053/j.gastro.2019.05.006</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>High Expression of Long Noncoding RNA HOTAIRM1 is Associated with the Proliferation and Migration in Pancreatic Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Pathology oncology research : POR 2019 Oct;25(4):1567-1577</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30613920" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30613920</a></p>
<p>Pancreatic ductal adenocarcinoma (PDAC) is an incurable malignancy. Long noncoding RNA (LncRNA) HOTAIRM1 (HOX antisense intergenic RNA myeloid 1) has been shown to play important roles in the progression of several type cancers. However, the exact role of HOTAIRM1 in PDAC development remains largely unknown. This study aims to evaluate the potential function of HOTAIRM1 in the development and progress of PDAC. HOTAIRM1 expression was measured by RT-qPCR in forty seven paired human PDAC tissues and five PDAC cell lines. SW1990 and PANC-1 cells were transfected with siHOTAIRM1 to achieve HOTAIRM1 silence. MTT assay and colony formation assay were used to detect the effect of HOTAIRM1 knockdown on cell proliferation. The impact of HOTAIRM1 silence on cell cycle and apoptosis was assessed by flow cytometry assay. Transwell migration assay was performed to explore the influence of HOTAIRM1 downregulation on the migratory potential of PDAC cells. Western blot assay was applied to determine the expression changes of cell cycle, apoptosis, and migration-related genes before and after downregulating HOTAIRM1. HOTAIRM1 expression was abnormally upregulated in PDAC tissues and cells when compared with the control samples, and was positively associated with the expression of KRAS gene mutation. In vitro functional experiments, HOTAIRM1 expression was significantly downregulated by transfection with siHOTAIRM1 in SW1990 and PANC cell lines. HOTAIRM1 knockdown attenuated cell proliferation by inducing cell cycle arrest at G0/G1 phase, promoted cell apoptosis, and inhibited cell migration in PDAC cells by regulating related-genes expression. In conclusion, HOTAIRM1 plays a critical role in PDAC progression, which may be a novel diagnostic and rational therapeutic target for the treatment of pancreatic ductal adenocarcinoma.</p>
<p>doi: <a href="https://doi.org/10.1007/s12253-018-00570-4" class="uri">https://doi.org/10.1007/s12253-018-00570-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Systems Oncology: Bridging Pancreatic and Castrate Resistant Prostate Cancer</strong> </summary></p>
<p><em>Pathology oncology research : POR 2019 Oct;25(4):1269-1277</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30220022" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30220022</a></p>
<p>Large investments by pharmaceutical companies in the development of new antineoplastic drugs have not been resulting in adequate advances of new therapies. Despite the introduction of new methods, technologies, translational medicine and bioinformatics, the usage of collected knowledge is unsatisfactory. In this paper, using examples of pancreatic ductal adenocarcinoma (PaC) and castrate-resistant prostate cancer (CRPC), we proposed a concept showing that, in order to improve applicability of current knowledge in oncology, the re-clustering of clinical and scientific data is crucial. Such an approach, based on systems oncology, would include bridging of data on biomarkers and pathways between different cancer types. Proposed concept would introduce a new matrix, which enables combining of already approved therapies between cancer types. Paper provides a (a) detailed analysis of similarities in mechanisms of etiology and progression between PaC and CRPC, (b) diabetes as common hallmark of both cancer types and (c) knowledge gaps and directions of future investigations. Proposed horizontal and vertical matrix in cancer profiling has potency to improve current antineoplastic therapy efficacy. Systems biology map using Systems Biology Graphical Notation Language is used for summarizing complex interactions and similarities of mechanisms in biology of PaC and CRPC.</p>
<p>doi: <a href="https://doi.org/10.1007/s12253-018-0467-8" class="uri">https://doi.org/10.1007/s12253-018-0467-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: The Accurate Prognostic Evaluation and Optimal Treatment Strategy for Ampulla of Vater Carcinoma</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(Suppl 3):621-622</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31115854" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31115854</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07465-x" class="uri">https://doi.org/10.1245/s10434-019-07465-x</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: Identifying Optimal Surgical Candidates in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(Suppl 3):551-552</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30565038" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30565038</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-018-7018-0" class="uri">https://doi.org/10.1245/s10434-018-7018-0</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Human Leukocyte Antigen (HLA) and Islet Autoantibodies Are Tools to Characterize Type 1 Diabetes in Arab Countries: Emphasis on Kuwait</strong> </summary></p>
<p><em>Disease markers 2019 11;2019():9786078</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31827651" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31827651</a></p>
<p>The incidence rate of type 1 diabetes in Kuwait had been increasing exponentially and has doubled in children  14yearsold within almost two decades. Therefore, there is a dire need for a careful systematic familial cohort study. Several immunogenetic factors affect the pathogenesis of the disease. The human leukocyte antigen (HLA) accounts for the major genetic susceptibility to the disease. The triggering agents initiate disease onset by type 1 destruction of pancreatic -cells. Both HLA and anti-islet antibodies can be used to characterize, predict susceptibility to the disease, innovate, or delay the -cell destruction. Evidence from prospective longitudinal studies suggested that the underlying disease process represents a continuum that begins before the symptoms are clinically evident. Autoimmunity of the functional pancreatic -cells results in symptomatic type 1 diabetes and lifelong insulin dependence. The autoantibodies against glutamic acid decarboxylase (GADA), insulinoma antigen-2 (IA-2A), insulin (IAA), and zinc transporter-8 (ZnT-8A) comprise the most reliable biomarkers for type 1 diabetes in both children and adults. Although Kuwait is the second among the top 10 countries with a high incidence rate of type 1 diabetes, there have been no proper diagnostic and prediction tools as per the World Health Organization. The Kuwaiti Type 1 Diabetes Study (KADS) was initiated to understand the disease pathogenesis as well as the HLA and anti-islet autoantibody profile of type 1 diabetes in Kuwait. Understanding the disease sequela in a homogenous gene pool and highly consanguineous population of Kuwaitis could help solve the challenges and pathogenesis, as well as hasten the prevention, of type 1 diabetes.</p>
<p>doi: <a href="https://doi.org/10.1155/2019/9786078" class="uri">https://doi.org/10.1155/2019/9786078</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Geriatric Nutritional Risk Index Predicts Adverse Outcomes in Human Malignancy: A Meta-Analysis</strong> </summary></p>
<p><em>Disease markers 2019 11;2019():4796598</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31827634" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31827634</a></p>
<p>Background: Geriatric Nutritional Risk Index (GNRI) has been widely used to assess the nutritional status in a variety of human pathological conditions, but the prognostic value of the GNRI in malignancies has not been evinced. Methods: Relevant studies updated on Jul 27, 2019, were retrieved in available databases, including PubMed, Web of Science, Cochrane library, Chinese CNKI, and Chinese Wan-fang. Hazard ratios (HRs) and 95% confidence intervals (CIs) were extracted and pooled by using STATA 14. Results: A total of 15 studies involving 8,046 subjects were included in this meta-analysis. Meta-analysis results evinced that low GNRI was associated with poor OS (HR = 1.95, 95% CI: 1.49-2.56, p  0.001), poor CSS (HR = 1.81, 95% CI: 1.49-2.19, p  0.001), poor DFS (HR = 1.67, 95% CI: 1.28-2.17, p  0.001), and poor PFS (HR = 1.68, 95% CI: 1.28-2.21, p  0.001), and the correlation of GNRI with OS was not changed when stratified by possible confounding factors, suggesting that malignancy patients with low GNRI would suffer from reduced survival rate and increased recurrence rate. Moreover, low GNRI was also associated with postoperative complications in malignancies. Conclusions: In summary, GNRI is associated poor prognosis in human malignancies, and GNRI should be used as a predictive indicator of adverse outcomes during malignancy treatment.</p>
<p>doi: <a href="https://doi.org/10.1155/2019/4796598" class="uri">https://doi.org/10.1155/2019/4796598</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Response to Comment on Reappraising the Concept of Conditional Survival After Pancreatectomy for Ductal Adenocarcinoma</strong> </summary></p>
<p><em>Annals of surgery 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31850980" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31850980</a></p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003747" class="uri">https://doi.org/10.1097/SLA.0000000000003747</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Frequent mutations that converge on the NFKBIZ pathway in ulcerative colitis</strong> </summary></p>
<p><em>Nature 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31853061" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31853061</a></p>
<p>Chronic inflammation is accompanied by recurring cycles of tissue destruction and repair and is associated with an increased risk of cancer1-3. However, how such cycles affect the clonal composition of tissues, particularly in terms of cancer development, remains unknown. Here we show that in patients with ulcerative colitis, the inflamed intestine undergoes widespread remodelling by pervasive clones, many of which are positively selected by acquiring mutations that commonly involve the NFKBIZ, TRAF3IP2, ZC3H12A, PIGR and HNRNPF genes and are implicated in the downregulation of IL-17 and other pro-inflammatory signals. Mutational profiles vary substantially between colitis-associated cancer and non-dysplastic tissuesin ulcerative colitis, which indicates that there are distinct mechanisms of positive selection in both tissues. In particular, mutations in NFKBIZ are highly prevalent in the epithelium of patients with ulcerative colitis but rarely found in both sporadic and colitis-associated cancer, indicating that NFKBIZ-mutant cells are selected against during colorectal carcinogenesis. In further support of this negative selection, we found that tumour formation was significantly attenuated in Nfkbiz-mutant mice and cell competition was compromised by disruption of NFKBIZ in human colorectal cancer cells. Our results highlight common and discrete mechanisms of clonal selection in inflammatory tissues, which reveal unexpected cancer vulnerabilities that could potentially be exploited for therapeutics in colorectal cancer.</p>
<p>doi: <a href="https://doi.org/10.1038/s41586-019-1856-1" class="uri">https://doi.org/10.1038/s41586-019-1856-1</a></p>
</details>
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<hr />
<p><a href="#top" target="_self">Back to top</a></p>
<hr />
<div style="page-break-after: always;"></div>
</div>
<div id="gallbladder" class="section level2">
<h2>Gallbladder</h2>
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Single-session esophagogastroduodenoscopy and endoscopic ultrasound using a forward-viewing radial scan ultrasonic endoscope</strong> </summary></p>
<p><em>BMC gastroenterology 2019 Dec;19(1):220</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31852458" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31852458</a></p>
<p>BACKGROUND: Endoscopic ultrasound is useful for obtaining high-resolution images of pancreaticobiliary diseases, but is not readily available for physical checkups. In this study, we evaluated the safety and efficacy of single-session esophagogastroduodenoscopy and endoscopic ultrasound in the detection of upper-gastrointestinal and pancreaticobiliary diseases using a forward-viewing radial scan ultrasonic endoscope. METHODS: A total of 148 patients who were scheduled for upper-gastrointestinal screening using an endoscope were prospectively included. All patients were examined by EUS in combination with EGD using a forward-viewing radial scan ultrasonic endoscope. The primary endpoint was the safety of the procedures. The secondary endpoints were the prevalence of diseases, the basal imaging capability of EUS, the procedure time, total dose of propofol, and the correlation between background factors and the prevalence of pancreatic disease. The imaging capability at each region was scored as 0 (invisible) to 2 (sufficient visualization to evaluate the organs). RESULTS: Intraoperative hypotension occurred as an adverse event of intravenous anesthesia in one patient. There were 82 pancreaticobiliary findings and 165 upper-gastrointestinal findings (malignancy not included). Follicular lymphoma of the intra-abdominal lymph nodes was detected in one patient. The mean imaging scores of each section were 1.95 (pancreatic head and papilla), 2.0 (pancreatic body), 1.99 (pancreatic tail), and 1.89 (common bile duct and gallbladder). Age, history of diabetes mellitus, and smoking history were significantly associated with the prevalence of pancreatic diseases. CONCLUSION: The simultaneous performance of EGD and EUS using a new ultrasonic endoscope is tolerable and safe for upper-gastrointestinal and pancreaticobiliary screening.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-019-1141-7" class="uri">https://doi.org/10.1186/s12876-019-1141-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>HER2 gene (ERBB2)amplification is a low-frequency driver with potential predictive value in gallbladder carcinoma</strong> </summary></p>
<p><em>Virchows Archiv : an international journal of pathology 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31838585" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31838585</a></p>
<p>Gallbladder carcinoma (GBC) is an aggressive type of cancer with a dismal prognosis. Recent case reports have highlighted the human epidermal growth factor receptor 2 (HER2) as a promising target for individualized therapyin biliary tract cancer; however, current data on HER2 positivity in GBC is contradictory. This study aimed to assess the proportion of HER2 positivity and its clinical implications in a large and well-characterized European GBC cohort. HER2 status was determined in 186 cases of surgically resected gallbladder adenocarcinoma and a subset of coexistent high-grade biliary intraepithelial neoplasia (BilIN, n = 74) in accordance with the up-to-date consensus for HER2 testing in gastric cancer by immunohistochemistry and dual-color chromogenic in situ hybridization. Positivity for HER2 was observed in 5.4% of all cases (n = 10). In those patients with concomitant high-grade BilIN, two of four positive samples also showed amplification in the precursor lesion, while in the two remaining cases, positivity was either confined to invasive tumor or high-grade BilIN, exclusively. Equivocal staining found in eleven cases was not accompanied by gene amplification. Staging of the HER2-positive group was significantly different from the HER2-negative group with most cases presenting at stage IV, paralleled by a trend towards decreased survival. One patient who received dual HER2 inhibition almost went into full clinical remission despite treatment initiation in a metastasized state. Our results reveal a low prevalence of HER2 positivity and highlight HER2 geneamplification as an early, potentially driving event in gallbladdercarcinogenesis. Prospective standardized HER2 testing and randomized control studies are needed to prove clinical efficacy of targeted HER2 inhibition in GBC.</p>
<p>doi: <a href="https://doi.org/10.1007/s00428-019-02706-6" class="uri">https://doi.org/10.1007/s00428-019-02706-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Unexpected Infant Death Due to Undiagnosed Biliary Atresia: A Case of Fatal Neglect</strong> </summary></p>
<p><em>The American journal of forensic medicine and pathology 2019 Dec;40(4):399-402</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31634153" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31634153</a></p>
<p>Biliary atresia (BA) is a fatal condition resulting in the lack of effective biliary drainage leading invariably to liver failure and cirrhosis within a year, and it is often lethal within a few months in the absence of corrective surgery or liver transplantation. In fact, BA is the most common indication for pediatric liver transplantation.Herein, we present a rare case of unexpected infant death due to BA diagnosed only postmortem in a context of child neglect and carelessness on the part of the parents. It emerged from the clinical history that after a few months, the parents no longer took their daughter to any medical checkups despite the indications and express recommendations for follow-up. The autopsy revealed agenesis of the gallbladder with BA and complete disruption of the hepatic architecture and parenchyma from biliary cirrhosis. Histological examinations documented severe biliary cirrhosis from hypoplasia of the biliary ducts.The child neglect in this case proved fatal inasmuch as an early diagnosis by a pediatrician would have likely allowed appropriate surgical treatment, thus avoiding the untimely death of the child. We highlight the importance of educating and informing parents (especially the disadvantaged) in matters of health. At the same time, primary care physicians should closely monitor the conditions and development of infants so as to recognize the early warning signs and symptoms of BA, bearing in mind that a timely diagnosis and proper surgical treatment can save the lives of most of these children.</p>
<p>doi: <a href="https://doi.org/10.1097/PAF.0000000000000511" class="uri">https://doi.org/10.1097/PAF.0000000000000511</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Systematic Selective Sampling of Cholecystectomy Specimens Is Adequate to Detect Incidental Gallbladder Adenocarcinoma</strong> </summary></p>
<p><em>The American journal of surgical pathology 2019 Dec;43(12):1668-1673</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31464710" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31464710</a></p>
<p>Many gallbladder adenocarcinomas (ACs) are detected incidentally in routine cholecystectomy specimens, yet sampling practices vary when intestinal metaplasia (IM) or dysplasia are found via routine sampling. Our practice has been to submit 5 additional sections when IM is found, but cases with dysplasia are entirely submitted. We sought to determine an appropriate sampling protocol when encountering these findings. We retrospectively identified cholecystectomy specimens with these features over a 26-month period, yielding 48 of 4059 (1%) cases. Four pathologists independently classified the (2 longitudinal and 1 cystic duct margin) original sections into 1 of 3 categories (IM, low-grade dysplasia [LGD] or high-grade dysplasia [HGD]); initial findings were correlated with final diagnoses. Sixteen (33%) cases had additional findings upon further sampling, including LGD (n=10) or HGD (n=4) and AC (n=2). HGD always accompanied malignancy. We prospectively analyzed 39 of 3133 (1%) additional cholecystectomy specimens, initially submitting the same routine sections. We submitted 5 random sections from cases with IM. Cases with LGD were first examined with 1 additional section per centimeter. All remaining tissue was submitted in all of these cases and separately reviewed. Cases with HGD were entirely submitted as both test cases with HGD in initial sections ultimately showed carcinoma. This protocol detected all cases of HGD and AC. Patients with clear cystic duct margins did not experience neoplastic progression, even if dysplasia was present elsewhere. We conclude gallbladders with HGD should be entirely submitted, LGD may be representatively sampled, and routine sampling is adequate for IM.</p>
<p>doi: <a href="https://doi.org/10.1097/PAS.0000000000001351" class="uri">https://doi.org/10.1097/PAS.0000000000001351</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes</strong> </summary></p>
<p><em>Cancer 2019 Dec;125(24):4426-4434</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31454426" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31454426</a></p>
<p>BACKGROUND: Although gemcitabine plus platinum chemotherapy is the established first-line regimen for advanced biliary cancer (ABC), there is no standard second-line therapy. This study evaluated current practice and outcomes for second-line chemotherapy in patients with ABC across 3 US academic medical centers. METHODS: Institutional registries were reviewed to identify patients who had received second-line chemotherapy for ABC from April 2010 to March 2015 along with their demographics, diagnoses and staging, treatment histories, and clinical outcomes. Overall survival from the initiation of second-line chemotherapy (OS2) was estimated with Kaplan-Meier methods. RESULTS: This study identified 198 patients with cholangiocarcinoma (intrahepatic [61.1%] or extrahepatic [14.1%]) or gallbladder carcinoma (24.8%); 52% received at least 3 lines of systemic chemotherapy. The median OS2 was 11months (95% confidence interval [CI], 8.8-13.1months). The median OS2 for patients with intrahepatic cholangiocarcinoma was 13.4months (95% CI, 10.7-17.8months), which was longer than that for patients with extrahepatic cholangiocarcinoma (6.8months; 95% CI, 5-10.6months) or gallbladder carcinoma (9.4months; 95% CI, 7.2-12.3months; P=.018). The median time to second-line treatment failure was 2.2months (95% CI, 1.8-2.7months), and it was similar across tumor locations (P=.60). CONCLUSIONS: In this large cohort of patients with ABC treated across 3 academic medical centers after the failure of first-line chemotherapy, the time to treatment failure on standard therapies was short, although the median OS2 was longer than has been reported previously, and more than half of the patients received additional lines of treatment. This multicenter collaboration represents the largest cohort studied to date of second-line chemotherapy for ABC and provides a contemporary benchmark for future clinical trials.</p>
<p>doi: <a href="https://doi.org/10.1002/cncr.32463" class="uri">https://doi.org/10.1002/cncr.32463</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Randomized Trial of Near-infrared Incisionless Fluorescent Cholangiography</strong> </summary></p>
<p><em>Annals of surgery 2019 Dec;270(6):992-999</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30614881" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30614881</a></p>
<p>BACKGROUND: Incisionless near-infrared fluorescent cholangiography (NIFC) is emerging as a promising tool to enhance the visualization of extrahepatic biliary structures during laparoscopic cholecystectomies. METHODS: We conducted a single-blind, randomized, 2-arm trial comparing the efficacy of NIFC (n = 321) versus white light (WL) alone (n = 318) during laparoscopic cholecystectomy. Using the KARL STORZ Image1 S imaging system with OPAL1 technology for NIR/ICG imaging, we evaluated the detection rate for 7 biliary structures-cystic duct (CD), right hepatic duct (RHD), common hepatic duct, common bile duct, cystic common bile duct junction, cystic gallbladder junction (CGJ), and accessory ducts -before and after surgical dissection. Secondary calculations included multivariable analysis for predictors of structure visualization and comparing intergroup biliary duct injury rates. RESULTS: Predissection detection rates were significantly superior in the NIFC group for all 7 biliary structures, ranging from 9.1% versus 2.9% to 66.6% versus 36.6% for the RHD and CD, respectively, with odds ratios ranging from 2.3 (95% CI 1.6-3.2) for the CGJ to 3.6 (1.6-9.3) for the RHD. After dissection, similar intergroup differences were observed for all structures except CD and CGJ, for which no differences were observed. Significant odds ratios ranged from 2.4 (1.7-3.5) for the common hepatic duct to 3.3 (1.3-10.4) for accessory ducts. Increased body mass index was associated with reduced detection of most structures in both groups, especially before dissection. Only 2 patients, both in the WL group, sustained a biliary duct injury. CONCLUSIONS: In a randomized controlled trial, NIFC was statistically superior to WL alone visualizing extrahepatic biliary structures during laparoscopic cholecystectomy. REGISTRATION NUMBER: NCT02702843.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003178" class="uri">https://doi.org/10.1097/SLA.0000000000003178</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Clinicopathologic and Prognostic Significance of Gallbladder and Cystic Duct Invasion in Distal Bile Duct Carcinoma</strong> </summary></p>
<p><em>Archives of pathology &amp; laboratory medicine 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31755778" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31755778</a></p>
<p>CONTEXT.: The roles of the gallbladder and cystic duct (CD) invasions in distal bile duct carcinoma (DBDC) have not been well elucidated. OBJECTIVE.: To define the characteristics and prognostic significance of gallbladder or CD invasions in patients with DBDC. DESIGN.: Organ invasion patterns with clinicopathologic features were assessed in 258 resected DBDCs. RESULTS.: CD invasions (N = 31) were associated with frequent concomitant pancreatic and/or duodenal invasions (23 of 31, 74%) and showed stromal infiltration (16 of 31, 52%) and intraductal cancerization (15 of 31, 48%) patterns. In only 2 cases, invasions with intraductal cancerization were observed in the gallbladder neck. Conversely, all pancreatic (N = 175) and duodenal (83) invasions developed through stromal infiltration. CD invasions were associated with larger tumor size (P = .001), bile duct margin positivity (P = .001), perineural invasions (P = .04), and higher N categories (P = .007). Patients with pancreatic or duodenal invasions had significantly lower survival rates than those without pancreatic (median, 31.0 versus 93.9 months) or duodenal (27.5 versus 56.8 months, P &lt; .001, both) invasions. However, those with gallbladder or CD invasions did not have different survival times (P = .13). Patients with concomitant gallbladder/CD and pancreatic/duodenal invasions demonstrated significantly lower survival rates than those without organ invasions (P &lt; .001). CONCLUSIONS.: Gallbladder invasions were rare in DBDCs as neck invasions with intraductal cancerization. CD invasions occurred by stromal infiltrations and intraductal cancerization, whereas all pancreatic and duodenal invasions had stromal infiltration patterns. Gallbladder and/or CD invasions did not affect survival rates of patients with DBDC, while pancreatic and duodenal invasions affected survival rates. Therefore, these differences in survival rates may originate from the different invasive patterns of DBDCs.</p>
<p>doi: <a href="https://doi.org/10.5858/arpa.2019-0218-OA" class="uri">https://doi.org/10.5858/arpa.2019-0218-OA</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Overexpression of EIF5A2 is associated with poor survival and aggressive tumor biology in gallbladder cancer</strong> </summary></p>
<p><em>Histology and histopathology 2019 Nov;():18186</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31745968" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31745968</a></p>
<p>Gallbladder cancer (GBC) is a malignant tumor of the biliary tract. The main problem affecting the treatment of gallbladder cancer is late diagnosis and poor prognosis. EIF5A2 is one of two isoforms of the EIF5A family and is reported to be a new oncogenic protein in many human cancers. In this study, our results showed for the first time that EIF5A2 was overexpressed in GBC samples compared with non-tumor tissue. Overexpression of EIF5A2 was associated with lymph node metastasis, tumor differentiation, UICC (Union for International Cancer Control) staging, histological type, metastasis, and tumor size. Overexpression of EIF5A2 in gallbladder carcinoma tissues is also associated with poor prognosis in patients. The interference of EIF5A2 significantly inhibited the proliferation, cell cycle, migration and colony formation of GBC-SD cells in vitro. Our results suggest that EIF5A2 is a target oncogene and may be an important prognostic biomarker in the pathogenesis of gallbladder cancer.</p>
<p>doi: <a href="https://doi.org/10.14670/HH-18-180" class="uri">https://doi.org/10.14670/HH-18-180</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Re-resection in Incidental Gallbladder Cancer: Survival and the Incidence of Residual Disease</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31741109" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31741109</a></p>
<p>BACKGROUND: Re-resection for incidental gallbladder cancer (iGBC) is associated with improved survival but little is known about residual disease (RD) and prognostic factors. In this study, survival after re-resection, RD, and prognostic factors are analyzed. METHODS: Patients with iGBC were identified from the Netherlands Cancer Registry, and pathology reports of re-resected patients were reviewed. Survival and prognostic factors were analyzed. RESULTS: Overall, 463 patients were included; 24% (n=110) underwent re-resection after a median interval of 66days. RD was present in 35% of patients and was most frequently found in the lymph nodes (23%). R0 resection was achieved in 93 patients (92%). Median overall survival (OS) of patients without re-resection was 13.7 (95% confidence interval [CI] 11.6-15.6), compared with 52.6months (95% CI 36.3-68.8) in re-resected patients (p&lt;0.001). After re-resection, median OS was superior in patients without RD versus patients with RD (not reached vs.23.1months; p&lt;0.001). In patients who underwent re-resection, RD in the liver (hazard ratio [HR] 5.54; p&lt;0.001) and lymph nodes (HR 2.35; p=0.005) were the only significant prognostic factors in multivariable analysis. Predictive factors for the presence of RD were pT3 stage (HR 25.3; p=0.003) and pN1 stage (HR 23.0; p=0.022). CONCLUSION: Re-resection for iGBC is associated with improved survival but remains infrequently used and is often performed after the optimal timing interval. RD is the only significant prognostic factor for survival after re-resection and can be predicted by pT and pN stages.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-08074-4" class="uri">https://doi.org/10.1245/s10434-019-08074-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Non-neoplastic Polyps of the Gallbladder: A Clinicopathologic Analysis of 447 Cases</strong> </summary></p>
<p><em>The American journal of surgical pathology 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31725469" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31725469</a></p>
<p>There is no systematic histopathologic analysis of non-neoplastic polyps in the gallbladder. In this study, in addition to a computer search for cases designated as polyp, a systematic review of 2533 consecutive routinely sampled archival and 203 totally submitted prospective cholecystectomies were analyzed for &gt;2mm polyps (cut-off was based on radiologic sensitivity). A total of 447 non-neoplastic polyps were identified. The frequency was 3% in archival cases and 5% in totally submitted cases. Only 21 (5%) were 1cm. The average age was 52 years, and the female to male ratio was 3.1. Two distinct categories were delineated: (1) injury-related polyps (n=273): (a) Fibro(myo)glandular polyps (n=214) were small (mean=0.4cm), broad-based, often multiple (45%), almost always (98%) gallstone-associated, and were composed of a mixture of (myo)fibroblastic tissue/lobular glandular units with chronic cholecystitis. Dysplasia seen in 9% seemed to be secondary involvement. (b) Metaplastic pyloric glands forming polypoid collections (n=42). (c) Inflammatory-type polyps associated with acute/subacute injury (11 granulation tissue, 3 xanthogranulomatous, 3 lymphoid). (2) Cholesterol polyps (n=174) occurred in uninjured gallbladders, revealing a very thin stalk, edematous cores devoid of glands but with cholesterol-laden macrophages in 85%, and cholesterolosis in the uninvolved mucosa in 60%. Focal low-grade dysplasia was seen in 3%, always confined to the polyp, unaccompanied by carcinoma. In conclusion, non-neoplastic polyps are seen in 3% of cholecystectomies and are often small. Injury-related fibromyoglandular polyps are the most common. Cholesterol polyps have distinctive cauliflower architecture, often in a background of uninjured gallbladders with cholesterolosis and may lack the cholesterol-laden macrophages in the polyp itself. Although dysplastic changes can involve non-neoplastic polyps, they do not seem to be the cause of invasive carcinoma by themselves.</p>
<p>doi: <a href="https://doi.org/10.1097/PAS.0000000000001405" class="uri">https://doi.org/10.1097/PAS.0000000000001405</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Incidental Gallbladder Cancer: Permission to Operate</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31722073" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31722073</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-08080-6" class="uri">https://doi.org/10.1245/s10434-019-08080-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Migration of gastric cancer is suppressed by recombinant Newcastle disease virus (rL-RVG) via regulating 7-nicotinic acetylcholine receptors/ERK- EMT</strong> </summary></p>
<p><em>BMC cancer 2019 Oct;19(1):976</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31640627" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31640627</a></p>
<p>BACKGROUND: Nicotinic acetylcholine receptors (nAChRs) have been reported to be overexpressed in malignancies in humans and is associated with tumorigenesis and cell migration. In previous studies of gastric cancer, alpha7 nicotinic acetylcholine receptor (7-nAChR) overexpression leads to epithelial-mesenchymal transition (EMT) and promotes the migration of gastric cancer cells. Recombinant avirulent LaSota strain of Newcastle disease virus (NDV) expressing the rabies virus glycoprotein (rL-RVG) may promote apoptosis of gastric cancer cells and reduces the migration of lung cancer metastasis. However, whether rL-RVG inhibits migration of gastric cancer cells and what the underlying functional mechanism is remains unknown. METHODS: The gastric cancer cell lines BGC and SGC were randomly divided into 3 groups: rL-RVG, NDV and Phosphate Buffered Solution (PBS) control groups. Furthermore,we adopted ACB and MLA,7nAChR-siRNA for the overexpression and silencing of 7-nAChR.Corynoxenine was used for inhibiting the MEK-ERK pathway. Western blot, Immunofluoresce,cell proliferation assays,cell migration analyses through wound-healing assays and Transwell assays were used to explore the underlying mechanisms. A mouse xenograft model was used to investigate the effects of rL-RVG,NDV on tumor growth. RESULTS: In this study, our findings demonstrate that rL-RVG suppressed the migration of gastric cancer cells and reduced EMT via 7-nAChR in vitro. Furthermore rL-RVG decreased the phosphorylation levels of the MEK/ERK signaling pathway such as down-regulating the expression of P-MEK and P-ERK. Additionally, rL-RVG also reduced the expression level of mesenchymal markers N-cadherin and Vimentin and enhanced the expression of the epithelial marker E-cadherin. Lastly, rL-RVG inhibited nicotinic acetylcholine receptors (nAChRs) to suppress cell migration and epithelial to mesenchymal transition (EMT) in gastric cell. We also found that rL-RVG suppresses the growth of gastric cancer subcutaneous tumor cells in vivo. CONCLUSION: rL-RVG inhibits 7-nAChR-MEK/ERK-EMT to suppress migration of gastric cancer cells.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6225-9" class="uri">https://doi.org/10.1186/s12885-019-6225-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Ultrastructural Characteristics of Gallbladder Epithelial Inclusions Mimicking Cystoisospora</strong> </summary></p>
<p><em>American journal of clinical pathology 2020 Jan;153(1):88-93</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31600399" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31600399</a></p>
<p>OBJECTIVES: There is recently reported increased prevalence of Isospora organisms in cholecystectomy specimens from immunocompetent patients, especially in acalculous cholecystectomies. We performed an ultrastructural and molecular evaluation of these specimens. METHODS: From 28 gallbladders with intraepithelial inclusions, two specimens with diffuse involvement of the gallbladder epithelium were analyzed by electron microscopy. Polymerase chain reaction was performed on five samples for the ITS2 region of C belli and eukaryotic 18S region. The 18S products were sequenced by next-generation sequencing. RESULTS: Electron microscopic analysis showed cytoplasmic condensations leading to vacuole formation. In contrast with true C belli, there were no identifiable organelles or organization. None of these cases showed amplified products other than human on molecular analysis. CONCLUSIONS: Electron microscopic analysis demonstrates that the inclusions are condensed cytoplasmic material and not true organisms.</p>
<p>doi: <a href="https://doi.org/10.1093/ajcp/aqz137" class="uri">https://doi.org/10.1093/ajcp/aqz137</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Outcomes Following an Index Emergency Admission With Cholecystitis: A National Cohort Study</strong> </summary></p>
<p><em>Annals of surgery 2019 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31567508" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31567508</a></p>
<p>OBJECTIVE: The objective of this study was to evaluate the differences between patients who undergo cholecystectomy following index admission for cholecystitis, and those who are managed nonoperatively. SUMMARY BACKGROUND DATA: Index emergency cholecystectomy following acute cholecystitis is widely recommended by national guidelines, but its effect on clinical outcomes remains uncertain. METHODS: Data collected routinely from the Hospital Episode Statistics database (all admissions to National Health Service organizations in England and Wales) were extracted between April 1, 2002 and March 31, 2015. Analyses were limited to patients aged over 18 years with a primary diagnosis of cholecystitis. Exclusions included records with missing or invalid datasets, patients who had previously undergone a cholecystectomy, patients who had died without a cholecystectomy, and those undergoing cholecystectomy for malignancy, pancreatitis, or choledocholithiasis. Patients were grouped as either no cholecystectomy where they had never undergone a cholecystectomy following discharge, or cholecystectomy. The latter group was then subdivided as emergency cholecystectomy when cholecystectomy was performed during their index emergency admission, or interval cholecystectomy when a cholecystectomy was performed within 12 months following a subsequent (emergency or elective) admission. Propensity Score Matching was used to match emergency and interval cholecystectomy groups. Main outcome measures included 1) One-year total length of hospital stay due to biliary causes following an index emergency admission with cholecystitis. 2) One-year mortality; defined as death occurring within 1 year following the index emergency admission with acute cholecystitis. RESULTS: Of the 99,139 patients admitted as an emergency with acute cholecystitis, 51.1% (47,626) did not undergo a cholecystectomy within 1 year of index admission. These patients were older, with more comorbidities (Charlson Comorbidity Score  5 in 23.5% vs.8.1%, P &lt; 0.001) when compared to patients who did have a cholecystectomy. While all-cause 1-year mortality was higher in the nonoperated versus the operated group (12.2% vs.2.0%, P &lt; 0.001), gallbladder-related deaths were significantly lower than all other causes of death in the non-operated group (3.3% vs.8.9%, P &lt; 0.001). Following matching, 1-year total hospital admission time was significantly higher following emergency compared with interval cholecystectomy (17.7 d vs.13 d, P &lt; 0.001). CONCLUSIONS: Over 50% of patients in England did not undergo cholecystectomy following index admission for acute cholecystitis. Mortality was higher in the nonoperated group, which was mostly due to non-gallbladder pathologies but total hospital admission time for biliary causes was lower over 12 months. Increasing the numbers of emergency cholecystectomy may risk over-treating patients with acute cholecystitis and increasing their time spent admitted to hospital.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003599" class="uri">https://doi.org/10.1097/SLA.0000000000003599</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Chronic Inflammatory and Proliferative Lesions of the Gallbladder in Aged Pigs</strong> </summary></p>
<p><em>Veterinary pathology 2019 Sep;():300985819875749</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31551021" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31551021</a></p>
<p>Primary epithelial tumors of the gallbladder are rarely reported in animals. In this study, 9 aged pigs (6-12 years old) were histopathologically examined for gallbladder proliferative lesions. At necropsy, a large gallstone occupied the lumen of the gallbladder of 3 pigs. Histopathological examination revealed chronic cholecystitis in all 9 pigs, mucosal hyperplasia in 2 pigs, adenoma in 1 pig, and adenocarcinoma in 2 pigs. Bacilli were detected in the gallbladder lumen of 6 pigs by Warthin-Starry stain. Mucosal hyperplasia, adenoma, and adenocarcinoma were characterized by papillary projections of the mucosa with occasional acinar structures. Tumor invasion of the surrounding tissue was observed in the cases of adenocarcinoma. On Alcian blue and periodic acid-Schiff double-stained sections, the acinar structure of gallbladder mucosa in chronic cholecystitis and mucosal hyperplasia was stained in a mosaic pattern, indicating pyloric gland metaplasia. The results of immunohistochemistry revealed a CD10-positive epithelial brush border and mucin (MUC) 2-positive goblet cells in chronic cholecystitis, adenoma, and adenocarcinomas, indicating intestinal metaplasia. Immunoreactivity of MUC5 AC and cytokeratin 19 was weaker in adenoma and adenocarcinomas compared with the normal and hyperplastic gallbladder mucosa. The number of p53-positive nuclei and the Ki-67 index were higher in adenocarcinomas compared with benign lesions. These results suggest that chronic cholecystitis associated with gallstones and/or bacterial infections may contribute to metaplastic changes and development of gallbladder tumors in aged pigs. Alteration of mucin, cytokeratin, and p53 profiles in gallbladder proliferative lesions in pigs were similar to that in humans, suggesting a common pathogenesis in tumor development.</p>
<p>doi: <a href="https://doi.org/10.1177/0300985819875749" class="uri">https://doi.org/10.1177/0300985819875749</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Transpapillary Endoscopic Removal of Gallbladder Stones Through a Fully Covered Metallic Stent</strong> </summary></p>
<p><em>The American journal of gastroenterology 2019 Oct;114(10):1571</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31403962" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31403962</a></p>
<p>doi: <a href="https://doi.org/10.14309/ajg.0000000000000367" class="uri">https://doi.org/10.14309/ajg.0000000000000367</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Primary Gallbladder Neuroendocrine Tumors: Insights into a Rare Histology Using a Large National Database</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Oct;26(11):3577-3585</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31102094" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31102094</a></p>
<p>BACKGROUND: Primary gallbladder neuroendocrine tumors (NETs) are rare, poorly understood cancers infrequently encountered at even the largest of tertiary referral centers. We therefore sought to identify a large cohort of patients with gallbladder NETs using a national database, with the aim of defining treatment modalities employed and survival associated with these uncommon malignancies. METHODS: Patients with primary gallbladder NETs were identified in the National Cancer Database, and clinicopathologic characteristics were recorded. A univariate log-rank survival analysis was completed for patients who underwent resection. Parameters found to be significant were entered into a multivariate accelerated failure time analysis. For context, survival comparisons were included for patients who underwent resections for NETs at any gastrointestinal site and for gallbladder adenocarcinoma. RESULTS: Overall, 754 patients with gallbladder NETs were identified. Patients were predominantly female (n=518, 69%), White (n=503, 67%), presented with stage IV disease (n=295, 39%) and had high-grade lesions (n=312, 41%). The majority underwent resection (n=480, 64%), primarily simple cholecystectomy (n=431, 90%), whereas a minority received multimodal therapy (n=145, 21%). Among patients who underwent resection, older age (p=0.001), large cell histology (p=0.012), and positive margins (p=0.030) were independently associated with worse overall survival. Patients with gallbladder NETs had improved survival relative to those with gallbladder adenocarcinoma (p=0.001), but significantly worse survival than patients with NETs from other gastrointestinal sites (p&lt;0.001). CONCLUSIONS: Primary gallbladder NETs are aggressive lesions that carry a worse prognosis than NETs of other gastrointestinal sites. Older age, positive margins, and large cell histology are associated with abbreviated survival after resection.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07440-6" class="uri">https://doi.org/10.1245/s10434-019-07440-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cytoplasmic Fibrillar Aggregates in Gallbladder Epithelium Are a Frequent Mimic of Cystoisospora in Pediatric Cholecystectomy Specimens</strong> </summary></p>
<p><em>Archives of pathology &amp; laboratory medicine 2019 Oct;143(10):1259-1264</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30969156" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30969156</a></p>
<p>CONTEXT.: Cystoisospora belli is an intracellular parasite associated with gastrointestinal disease in immunocompromised hosts. Although infection has been classically associated with intestinal disease, studies have identified Cystoisospora in the gallbladder of immunocompetent patients based on hematoxylin-eosin morphology. Recently, the identity of this histologic finding as Cystoisospora has been questioned based on negative results of nucleic acid studies. OBJECTIVE.: To determine the prevalence of this histologic feature in pediatric patients, we retrospectively reviewed all cholecystectomy specimens from a pediatric hospital during a 24-month period. DESIGN.: In 180 cholecystectomy specimens, we identified 11 cases (6.1%) with classical histologic features previously described to represent Cystoisospora organisms. To further investigate these structures, we retrieved tissue from paraffin-embedded blocks and performed electron microscopy. RESULTS.: Ultrastructural examination identified ovoid perinuclear cytoplasmic structures composed of dense fibrillar aggregates rather than organisms. Patients with positive cases were similar in age to controls (positive cases: mean patient age 13.4 years [range, 2-23 years]; negative cases: mean patient age 14.7 years [range, 12 weeks-31 years]; P = .35). There was no significant association of this finding with cholelithiasis (54.5% versus 65.1%, P = .52), cholesterolosis (0% versus 22.5%, P = .12), acute cholecystitis (9.1% versus 10.1%, P &gt; .99), or chronic cholecystitis (45.5% versus 66.3%, P = .20). CONCLUSIONS.: To our knowledge, this is the first positive identification of these structures as cytoplasmic fibrillar aggregates rather than parasitic inclusions by ultrastructural examination, and the first study of this histologic finding in pediatric cholecystectomies.</p>
<p>doi: <a href="https://doi.org/10.5858/arpa.2018-0335-OA" class="uri">https://doi.org/10.5858/arpa.2018-0335-OA</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study</strong> </summary></p>
<p><em>The American journal of gastroenterology 2019 Sep;114(9):1502-1511</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31356229" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31356229</a></p>
<p>OBJECTIVES: Irritable bowel syndrome with diarrhea (IBS-D) is a functional gastrointestinal disorder with limited effective treatment options. We evaluated the efficacy and safety of eluxadoline in patients with IBS-D who reported inadequate symptom control with prior loperamide. METHODS: Three hundred forty-six adults with IBS-D (Rome III criteria) were randomly assigned to placebo or eluxadoline 100 mg twice daily for 12 weeks. Patients recorded daily IBS-D symptoms, including worst abdominal pain (WAP) and stool consistency (through Bristol Stool Scale). The primary endpoint was proportion of composite responders, defined as patients who met daily composite response criteria (40% WAP improvement and &lt;5 Bristol Stool Scale score) for at least 50% of treatment days, and recorded 60 days of diary entries over the 12-week period. RESULTS: Over 12 weeks, a significantly greater proportion of eluxadoline patients achieved the primary composite responder endpoint compared to placebo (22.7% vs 10.3%, P = 0.002), and component endpoints of improvements in stool consistency (27.9% vs 16.7%, P = 0.01) and WAP (43.6% vs 31.0%, P = 0.02). Additionally, a greater proportion of eluxadoline patients met the composite responder endpoint assessed at monthly intervals compared to placebo (weeks 1-4: 14.0% vs 6.9%, P = 0.03; weeks 5-8: 26.7% vs 14.9%, P = 0.006; weeks 9-12: 30.8% vs 16.7%, P = 0.002). Rates of adverse events were comparable in both groups (37.4% vs 35.3%); no treatment-related serious adverse event, cases of sphincter of Oddi spasm, or pancreatitis were reported. DISCUSSION: Eluxadoline appears safe and effective for treating IBS-D symptoms in patients with an intact gallbladder reporting inadequate relief with prior loperamide use.</p>
<p>doi: <a href="https://doi.org/10.14309/ajg.0000000000000327" class="uri">https://doi.org/10.14309/ajg.0000000000000327</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>[Tumor-suspected focal lesion on the renal hilus]</strong> </summary></p>
<p><em>Der Pathologe 2019 Sep;40(5):546-547</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31240450" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31240450</a></p>
<p>Mucosal structures of anon-neoplastic organ can result in apitfall diagnosis of adenocarcinoma in the case of a wrong correlation with other organs, in this case caused by an adherent gallbladder to the hilar structures of the right kidney. Clinical and radiological data are absolutely crucial for a correct classification.</p>
<p>doi: <a href="https://doi.org/10.1007/s00292-019-0621-4" class="uri">https://doi.org/10.1007/s00292-019-0621-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Colorectal metastasis to the gallbladder mimicking a primary gallbladder malignancy: histopathological and molecular characteristics</strong> </summary></p>
<p><em>Histopathology 2019 Sep;75(3):394-404</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31044440" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31044440</a></p>
<p>AIMS: Outcomes of colorectal cancer (CRC) treatment and survival have steadily improved during the past decades, accompanied by an increased risk of developing second primary tumours and metastatic tumours at unusual sites. Metastatic CRC can show mucosal colonisation, thereby mimicking a second primary tumour. This potential confusion could lead to incorrect diagnosis and consequently inadequate treatment of the patient. The aim of this study was to differentiate between metastatic CRC and a second primary (gallbladder cancer, GBC) using a combination of standard histopathology and molecular techniques. METHODS AND RESULTS: Ten consecutive patients with both CRC and GBC were identified in our region using the Dutch National Pathology Archive (PALGA). Two patients served as negative controls. Histology of GBC was reviewed by nine pathologists. A combination of immunohistochemistry, microsatellite analysis, genomewide DNA copy number analysis and targeted somatic mutation analysis was used to aid in differential diagnosis. In two patients, CRC and GBC were clonally related, as confirmed by somatic mutation analysis. For one case, this was confirmed by genomewide DNA copy number analysis. However, in both cases, pathologists initially considered the GBC as a second primary tumour. CONCLUSIONS: Metastatic CRC displaying mucosal colonisation is often misinterpreted as a second primary tumour. A combination of traditional histopathology and molecular techniques improves this interpretation, and lowers the risk of inadequate treatment.</p>
<p>doi: <a href="https://doi.org/10.1111/his.13892" class="uri">https://doi.org/10.1111/his.13892</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>IL-33 overexpression in gallbladder cancers associated with pancreatobiliary maljunction</strong> </summary></p>
<p><em>Histopathology 2019 Sep;75(3):365-375</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30882917" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30882917</a></p>
<p>AIMS: To investigate whether genetic or inflammatory pro-oncogenic factors are relevant to the increased risk of gallbladder cancers in patients with pancreaticobiliary maljunction (PBM). METHODS AND RESULTS: Mutations in KRAS exon 2 were examined by a highly sensitive, droplet digital PCR platform using surgically resected specimens of PBM-associated (n=31) and non-associated gallbladder cancers (n=49). The tissue expression of IL-6 and IL-33, which are suspected to promote biliary carcinogenesis, was analysed by quantitative real-time PCR and in-situ hybridisation. The incidence of KRAS mutations was similarly low in PBM-associated (five of 32 cases; 16%) and non-associated cancers (four of 49 cases; 8%) (P=0.272). The tissue expression of IL-33 mRNA, but not IL-6 mRNA, was significantly higher in PBM-associated gallbladder cancers than in gallbladder cancers without PBM (P=0.004). A similar degree of IL-33 overexpression was also observed in the background non-cancerous mucosa in cases of PBM-associated gallbladder cancers, and was significantly greater than that in PBM cases with cholecystitis alone (P&lt;0.001). The results of in-situ hybridisation indicated that the source of IL-33 production in PBM-associated carcinomas was the endothelium, cancer cells and non-neoplastic biliary epithelium. In a combined PBM-associated and non-associated cohort, IL-33 overexpression in gallbladder cancers correlated with less aggressive features (e.g.a lower pT stage and longer overall survival), similar to recently reported findings on large-duct cholangiocarcinomas. CONCLUSIONS: KRAS mutations do not appear to be associated with a high risk of malignancy in PBM, while IL-33 overexpression may provide a pro-oncogenic microenvironment in the gallbladder mucosa of patients with PBM.</p>
<p>doi: <a href="https://doi.org/10.1111/his.13863" class="uri">https://doi.org/10.1111/his.13863</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Emphysematous Cholecystitis</strong> </summary></p>
<p><em>The New England journal of medicine 2019 Aug;381(8):e14</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31433924" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31433924</a></p>
<p>doi: <a href="https://doi.org/10.1056/NEJMicm1814551" class="uri">https://doi.org/10.1056/NEJMicm1814551</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>An Uncommon Case of Double-Hit Mantle Cell Lymphoma That Demonstrates a Transformation Process</strong> </summary></p>
<p><em>American journal of clinical pathology 2020 Jan;153(1):49-57</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31433838" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31433838</a></p>
<p>OBJECTIVES: Mantle cell lymphoma (MCL) is a mature B-cell lymphoma characterized by CCND1/IGH rearrangement. We reported a case of MCL harboring both CCND1/IGH and MYC/IGH rearrangements that also presented with an aggressive clinical course. METHODS: Biopsy specimens were evaluated by morphological staining, immunohistochemistry, flow cytometry, conventional cytogenetics, fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS). RESULTS: Morphological and immunohistochemical staining of gallbladder samples demonstrated blastoid variant MCL. However, in the bone marrow sample, FISH indicated rearrangements in CCND1/IGH and MYC/IGH. Flow cytometry identified two groups of malignant lymphocytes. We sorted these two groups of cells. NGS then revealed that both cell types carried CCND1/IGH rearrangements and TP53 mutations. Furthermore, the CD19+/CD10+ cells carried additional MYC/IGH rearrangement and NOTCH2 mutation. CONCLUSIONS: The rearrangement of MYC and a mutation in NOTCH2 probably induced the transformation of MCL cells in this patient. This uncommon double-hit MCL case clearly demonstrates a transformation process.</p>
<p>doi: <a href="https://doi.org/10.1093/ajcp/aqz133" class="uri">https://doi.org/10.1093/ajcp/aqz133</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Expression of fatty-acid-binding protein 5 in intrahepatic and extrahepatic cholangiocarcinoma: the possibility of different energy metabolisms in anatomical location</strong> </summary></p>
<p><em>Medical molecular morphology 2019 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31432248" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31432248</a></p>
<p>The biliary tract cancer (BTC) covers a range of carcinomas, including intrahepatic cholangiocarcinoma (ICC), cholangiolocellular carcinoma (CoCC), perihilar cholangiocarcinoma (perihilar CC), extrahepatic cholangiocarcinoma (ECC), and gallbladder cancer (GBC), defined according to the anatomical location. These adenocarcinomas mostly comprise biliary epithelial cell-derived malignant cells. In addition to anatomical differences, there are morphological and biological differences in BTC starting from embryonic development of the tissues extending to physiological differences. Fatty acid-binding proteins (FABPs) are closely associated with the energy metabolism. Using surgical specimens from 74 BTCs, we performed immunohistochemistry for FABP5 and its associated molecules, including peroxisome proliferator-activated receptor  (PPAR), PPAR coactivator 1 (PGC-1), and estrogen-related receptor  (ERR). We found that the expression patterns of small BTCs (ICC and CoCC) considerably differed from those of large BTCs (perihilar CC, ECC, and GBC). Expression of FABP5 and PGC-1 in large BTCs was high compared with those of small BTCs, but no difference in the expression of PPAR and ERR was observed. FABP5 appears to play a role in malignant progression in large BTCs. Small and large BTCs possess different energy metabolism systems owing to their different anatomical locations and course of carcinogenesis, although all BTCs originate from biliary epithelial cells.</p>
<p>doi: <a href="https://doi.org/10.1007/s00795-019-00230-9" class="uri">https://doi.org/10.1007/s00795-019-00230-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Detection of NRG1 Gene Fusions in Solid Tumors</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Aug;25(16):4966-4972</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30988082" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30988082</a></p>
<p>PURPOSE: NRG1 gene fusions are rare but potentially actionable oncogenic drivers that are present in some solid tumors. Details regarding the incidence of these gene rearrangements are lacking. Here, we assessed the incidence of NRG1 fusions across multiple tumor types and described fusion partners. EXPERIMENTAL DESIGN: Tumor specimens submitted for molecular profiling at a Clinical Laboratory Improvement Amendments (CLIA)-certified genomics laboratory and that underwent fusion testing by anchored multiplex PCR for targeted RNA sequencing were retrospectively identified. The overall and tumor-specific incidence was noted, as was the specific fusion partner. RESULTS: Out of 21,858 tumor specimens profiled from September 2015 to December 2018, 41 cases (0.2%) harbored an NRG1 fusion. Multiple fusion partners were identified. Fusion events were seen across tumor types. The greatest incidence was in non-small cell lung cancer (NSCLC, 25), though this represented only 0.3% of NSCLC cases tested. Other tumor types harboring an NRG1 fusion included gallbladder cancer, renal cell carcinoma, bladder cancer, ovarian cancer, pancreatic cancer, breast cancer, neuroendocrine tumor, sarcoma, and colorectal cancer. CONCLUSIONS: NRG1 fusions can be detected at a low incidence across multiple tumor types with significant heterogeneity in fusion partner.See related commentary by Dimou and Camidge, p.4865.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-0160" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-0160</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A 12-year trend analysis of the incidence of gastrointestinal cancers in East Azerbaijan: last updated results of an ongoing population-based cancer registry</strong> </summary></p>
<p><em>BMC cancer 2019 Aug;19(1):782</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31391032" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31391032</a></p>
<p>BACKGROUND: The most recent results of Global Cancer Statistics indicated that gastrointestinal cancers, including gastric, colorectal, esophageal, and liver cancers, are among the most commonly diagnosed cancers worldwide. Previous reports from cancer registries in East Azerbaijan have shown that there is a high incidence of gastrointestinal cancer in this region, so we performed a trend analysis to determine the pattern of change over the last decade. METHODS: In total, 12years of cancer registry data were collected from different sources in East Azerbaijan, and a data quality check was performed to ensure clean data. Using the 2000 World Health Organization standard population, we then generated age-standardized incidence rates (ASRs) for different cancers, and for each year from 1383 to 1394 of the Persian calendar (i.e., 19 March 2004 to 20 March 2015). Annual percent changes (APCs) and Average annual percent changes (AAPCs) in the ASRs for esophageal, gastric, small intestine, colorectal, anal, liver, gallbladder, and pancreatic cancers were calculated using Joinpoint Software (Version 4.5.0.1, June 2017). RESULTS: An increase in most types of cancer was observed during the study period. The ASR for colorectal cancer increased from 2.9 to 13.6 per 100,000 women (APC, 9.7%) and from 2.2 to 17.8 per 100,000 men (APC, 10.2%). The ASR for gastric cancer showed a slight increasing trend from 10.5 to 13.5 per 100,000 women (APC, 1.3%) and from 3.1 to 29.9 per 100,000 men (APC, 3.2%). However, trend analysis showed a decreasing pattern for the ASR of esophageal cancer in both genders (APC,-3%), with APCs of -1.1% in females and-0.4% in males. CONCLUSIONS: The latest results of the East Azerbaijan Population-Based Cancer Registry indicate that gastrointestinal cancers remain common, with significant increasing trends in their ASRs. Improved screening and early detection are needed in this region.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6008-3" class="uri">https://doi.org/10.1186/s12885-019-6008-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Classification of the cystic duct patterns and endoscopic transpapillary cannulation of the gallbladder to prevent post-ERCP cholecystitis</strong> </summary></p>
<p><em>BMC gastroenterology 2019 Aug;19(1):139</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31382888" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31382888</a></p>
<p>BACKGROUND: Endoscopic transpapillary cannulation of the gallbladder is useful but challenging. This study aimed to investigate cystic duct anatomy patterns, which may guide cystic duct cannulation. METHODS: A total of 226 patients who underwent endoscopic transpapillary cannulation of the gallbladder were analyzed retrospectively. RESULTS: According to the cystic duct take-off, 226 cystic duct patterns were divided into 3 patterns: Type I (193, 85.4%), located on the right and angled up; Type II (7, 3.1%), located on the right and angled down; and Type III (26, 11.5%), located on the left and angled up. Type I was further divided into three subtypes: Line type, S type (S1, not surrounding the common bile duct; S2, surrounding the common bile duct), and  type (1, forward ; 2, reverse ). Types I and III cystic ducts were easier to be cannulated with a higher success rate (85.1 and 86.4%, respectively) compared with Type II cystic duct (75%) despite no statistically significant difference. The reasons for the failure of gallbladder cannulation included invisible cyst duct take-off, severe cyst duct stenosis, impacted stones in cyst duct or neck of the gallbladder, sharply angled cyst duct, and markedly dilated cyst duct with the tortuous valves of Heister. CONCLUSION: Classification of cystic duct patterns was helpful in guiding endoscopic transpapillary gallbladder cannulation.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-019-1053-6" class="uri">https://doi.org/10.1186/s12876-019-1053-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Acute Recurrent and Chronic Pancreatitis as Initial Manifestations of Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator-Related Disorders</strong> </summary></p>
<p><em>Pancreas 2019 08;48(7):888-893</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31268981" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31268981</a></p>
<p>OBJECTIVES: Recurrent pancreatitis is considered a rare manifestation of cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction; this case series highlights that pancreatitis can be a presenting symptoms of cystic fibrosis (CF) or a CFTR-related disorder (CFTR-RD). METHODS: Retrospective review of patients younger than 30 years diagnosed as having acute recurrent pancreatitis (ARP) or chronic pancreatitis (CP) and subsequently diagnosed as having CF or CFTR-RD. RESULTS: Among 18 patients, median time from diagnosis of ARP/CP to diagnosis of CF was 0.4 years (range, 0-33 years). Eight were classified as having CF by elevated sweat chloride testing (SCT). Five had intermediate SCT (30-59 mmol/L) with 2 pathogenic mutations. Five had CFTR-RD with intermediate SCT and 0 to 1 pathogenic mutations. Eight patients (44%) had exocrine pancreatic insufficiency, and pancreatic fluid collections were more common in this group. Based on the CFTR mutation, 6 patients were eligible for CFTR potentiator therapy, although none received it during the study period. Nine of the 18 had 1 other likely CF manifestations, including sinusitis (33%), nasal polyps (11%), pneumonia (22%), and gallbladder disease (22%). CONCLUSIONS: Cystic fibrosis or CFTR-RD can present as ARP/CP. Complete diagnostic testing for CFTR-RD in patients with ARP/CP will broaden treatment options and help to identify comorbid illness.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001350" class="uri">https://doi.org/10.1097/MPA.0000000000001350</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Epithelial Inclusions in Gallbladder May Mimic Parasite Infection</strong> </summary></p>
<p><em>American journal of clinical pathology 2019 Aug;152(3):399-402</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31189015" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31189015</a></p>
<p>doi: <a href="https://doi.org/10.1093/ajcp/aqz054" class="uri">https://doi.org/10.1093/ajcp/aqz054</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study</strong> </summary></p>
<p><em>The lancet. Gastroenterology &amp; hepatology 2019 Aug;4(8):611-621</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31109808" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31109808</a></p>
<p>BACKGROUND: This study aimed to assess the safety and tolerability of the immune checkpoint inhibitor nivolumab, as monotherapy or combined with chemotherapy, in Japanese patients with biliary tract cancer. METHODS: This multicentre, open-label, phase 1 trial was done at four cancer centres in Japan. Eligible patients were aged 20-79 years, had biliary tract adenocarcinoma (intrahepatic bile duct cancer, extrahepatic bile duct cancer, gallbladder cancer, or ampullary cancer), Eastern Cooperative Oncology Group performance status 0 or 1, adequate hepatic, renal, and haematological function, and tumour tissue samples for PD-L1 expression analysis. Patients with unresectable or recurrent biliary tract cancer that was refractory or intolerant to gemcitabine-based treatment regimens received nivolumab monotherapy (240 mg every 2 weeks [monotherapy cohort]). Chemotherapy-naive patients with unresectable or recurrent biliary tract cancer received nivolumab (240 mg every 2 weeks) and cisplatin (25 mg/m2) plus gemcitabine (1000 mg/m2) chemotherapy (combined therapy cohort). The primary objective was to assess tolerability and safety. The primary objective was assessed in the safety population of all patients who had received at least one dose of nivolumab. This study is registered with www.clinicaltrials.jp, number JapicCTI-153098, and follow-up is ongoing. FINDINGS: 30 patients were enrolled into each cohort between Jan 13, 2016, and April 19, 2017. Data cutoff was Aug 31, 2017. In the monotherapy cohort, the most frequently reported treatment-related adverse events were decreased appetite (five [17%]), malaise (four [13%]), and pruritus (four [13%]). Grade 3-4 treatment-related adverse events were reported by three (10%) patients (rash, maculopapular rash, and amylase increase) and treatment-related serious adverse events were reported by one (3%) patient (pleurisy). In the combined therapy cohort, the most frequently reported treatment-related adverse events were neutrophil count decrease (any grade 25 [83%]; grade 3-4 in 23 [77%] patients) and platelet count decrease (any grade 25 [83%] of 30; grade 3-4 in 15 [50%] patients). Six (20%) patients reported 11 treatment-related serious adverse events (platelet count decrease [three patients], febrile neutropenia [two patients], neutrophil count decrease, anaemia, anaphylactic reaction, decreased appetite, pyrexia, and myocarditis [one patient each]). In the monotherapy cohort, median overall survival was 52 months (90% CI 45-87), median progression-free survival was 14 months (90% CI 14-14), and one of 30 patients had an objective response. In the combined therapy cohort, median overall survival was 154 months (90% CI 118-not estimable), median progression-free survival was 42 months (90% CI 28-56), and 11 of 30 patients had an objective response. INTERPRETATION: Nivolumab had a manageable safety profile and signs of clinical activity in patients with unresectable or recurrent biliary tract cancer. This initial assessment of nivolumab for the treatment of advanced biliary tract cancer provides supportive evidence for future larger randomised studies of nivolumab in this difficult to treat cancer. FUNDING: Ono Pharmaceutical Co Ltd and Bristol-Myers Squibb Inc.</p>
<p>doi: <a href="https://doi.org/10.1016/S2468-1253(19)30086-X" class="uri">https://doi.org/10.1016/S2468-1253(19)30086-X</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Gallbladder Papilloma in a Child Unmasking Metachromatic Leukodystrophy: A Case Report With Review of Literature</strong> </summary></p>
<p><em>Fetal and pediatric pathology 2019 Aug;38(4):345-351</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30912695" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30912695</a></p>
<p>Background: Metachromatic leukodystrophy (MLD) is a lipid storage disease characterized the accumulation of sulfatides in different viscera including the gallbladder. Case report: A 2-year-old girl had upper right quadrant lesion that was preoperatively thought to be a biliary cystadenoma. Histologically, the gallbladder lesion was a tubulo-villous papilloma with multiple foci of papillary mucosal hyperplasia. Many storage histiocytes containing metachromatic granules, characteristic of MLD, were present in the tips of the papillae. MLD was later confirmed by enzyme studies. Conclusion: Gallbladder papilloma can be the presenting feature of MLD.</p>
<p>doi: <a href="https://doi.org/10.1080/15513815.2019.1588442" class="uri">https://doi.org/10.1080/15513815.2019.1588442</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Incidental Hepatic Tissue Obtained via Routine Cholecystectomy</strong> </summary></p>
<p><em>International journal of surgical pathology 2019 Aug;27(5):499-505</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30520351" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30520351</a></p>
<p>Background. The hepatic tissue that may occupy specimens from routine cholecystectomies has yet to be studied. Our objectives were to determine the prevalence of hepatic tissue obtained at routine cholecystectomy, to determine whether such hepatic tissue can histologically withstand technical artifacts commonly associated with cholecystectomy, and to determine whether examining such hepatic tissue has diagnostic utility. Materials and Methods. We retrospectively reviewed 50 specimens from routine cholecystectomies that were performed by surgeons who lacked knowledge of our study. All 50 specimens were grossed according to standard protocol, with only limited, nontargeted sampling of the rough nonperitonealized margin, and were received without fixative. Results. Twelve specimens (24.0%) contained hepatic tissue. The hepatic tissue measured up to 44.5-mm long and 1.8-mm wide and contained up to 11 complete portal tracts. Hepatic tissue in 3 specimens satisfied criteria for adequacy established for core biopsies based on number of portal tracts or size. Despite cautery and delayed fixation, all hepatic tissue had surprisingly well-preserved histology. Pathologic findings included nonalcoholic fatty liver disease, von Meyenburg complex, chronic cholestasis, and senescence. Conclusions. The hepatic tissue that accompanies specimens from routine cholecystectomies may be relatively common, can be large, is well preserved, and can harbor diagnostically useful information.</p>
<p>doi: <a href="https://doi.org/10.1177/1066896918817374" class="uri">https://doi.org/10.1177/1066896918817374</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Immunohistochemical Assessment of the Expression of Biliary Transportation Proteins MRP2 and MRP3 in Hepatocellular Carcinoma and in Cholangiocarcinoma</strong> </summary></p>
<p><em>Pathology oncology research : POR 2019 Oct;25(4):1363-1371</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=29464551" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=29464551</a></p>
<p>Multidrug resistance-associated protein 2 (MRP2) is a multi-specific organic anion transporter predominantly expressed in the canalicular membrane of hepatocytes, epithelial cells from gallbladder and apical membranes of proximal tubular kidney epithelium whereas multidrug resistance-associated protein 3 (MRP3) is present in the basolateral membrane of hepatocytes and cholangiocytes. This study aims to detect the expression of these transporters in hepatocellular carcinoma (HCC) and in cholangiocarcinoma (CC), searching for evidences for future studies on differential diagnosis and on clinical essays. The immunohistochemical reactivity (IHC) of these transporters was assessed in tissue microarrays of 80 HCC and 56 CC cases using monoclonal antibodies and compared with anatomopathological (AP) variables. The positivity of MRP2 was observed in 92.3% of HCC and in 96.3% of CC. The detection of high MRP2 expression in HCC was not significantly different (p&gt;0.05) according to the size, number of nodules architectural pattern and growth pattern of HCC and CC. Regarding histological grades, 22/22 well moderately differentiated HCC versus 50/56 poorly differentiated HCC were positive for MRP2. A trend for lower expression in poor differentiation HCC was found. And 50/50 well/moderately differentiated CC versus 2/4 poorly/undifferentiated CC were positive for MRP2. This result showed a reduced expression (p=0,0004) in poorly differentiated CC. MRP3 positivity was observed in 18.8% of HCC and was not significantly different according to AP parameters. MRP3 was expressed in 44.5% CC, with a trend for lower expression in less differentiated CC and significantly lower rates in the ductular histological subtype (p=0.023). The high expression of MRP2 in HCC and in CC is conserved regardless most of the anatomopathological parameters, except for a trend of lower expression in less differentiated HCC and CC. The observation of lower MRP3 expression in less differentiated CC and, especially, in the histological subtype with expression of hepatic progenitor cell phenotypes leads to future opportunities to evaluate the expression of this marker in cholangiocarcinomas.</p>
<p>doi: <a href="https://doi.org/10.1007/s12253-018-0386-8" class="uri">https://doi.org/10.1007/s12253-018-0386-8</a></p>
</details>
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<hr />
<p><a href="#top" target="_self">Back to top</a></p>
<hr />
<div style="page-break-after: always;"></div>
</div>
<div id="bile-ducts" class="section level2">
<h2>Bile Ducts</h2>
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Single-session esophagogastroduodenoscopy and endoscopic ultrasound using a forward-viewing radial scan ultrasonic endoscope</strong> </summary></p>
<p><em>BMC gastroenterology 2019 Dec;19(1):220</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31852458" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31852458</a></p>
<p>BACKGROUND: Endoscopic ultrasound is useful for obtaining high-resolution images of pancreaticobiliary diseases, but is not readily available for physical checkups. In this study, we evaluated the safety and efficacy of single-session esophagogastroduodenoscopy and endoscopic ultrasound in the detection of upper-gastrointestinal and pancreaticobiliary diseases using a forward-viewing radial scan ultrasonic endoscope. METHODS: A total of 148 patients who were scheduled for upper-gastrointestinal screening using an endoscope were prospectively included. All patients were examined by EUS in combination with EGD using a forward-viewing radial scan ultrasonic endoscope. The primary endpoint was the safety of the procedures. The secondary endpoints were the prevalence of diseases, the basal imaging capability of EUS, the procedure time, total dose of propofol, and the correlation between background factors and the prevalence of pancreatic disease. The imaging capability at each region was scored as 0 (invisible) to 2 (sufficient visualization to evaluate the organs). RESULTS: Intraoperative hypotension occurred as an adverse event of intravenous anesthesia in one patient. There were 82 pancreaticobiliary findings and 165 upper-gastrointestinal findings (malignancy not included). Follicular lymphoma of the intra-abdominal lymph nodes was detected in one patient. The mean imaging scores of each section were 1.95 (pancreatic head and papilla), 2.0 (pancreatic body), 1.99 (pancreatic tail), and 1.89 (common bile duct and gallbladder). Age, history of diabetes mellitus, and smoking history were significantly associated with the prevalence of pancreatic diseases. CONCLUSION: The simultaneous performance of EGD and EUS using a new ultrasonic endoscope is tolerable and safe for upper-gastrointestinal and pancreaticobiliary screening.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-019-1141-7" class="uri">https://doi.org/10.1186/s12876-019-1141-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Utility and limitations of Albumin RNA in situ hybridization in the diagnosis of hepatobiliary lesions and metastatic carcinomas to the liver</strong> </summary></p>
<p><em>Histopathology 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31834956" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31834956</a></p>
<p>BACKGROUND: Albumin messenger RNA in situ hybridization (RISH) is a sensitive and specific marker for hepatocellular carcinoma (HCCs). Intrahepatic cholangiocarcinoma (ICC) shows variable sensitivity, whereas extrahepatic cholangiocarcinomas (ECCs) and metastatic carcinomas are usually negative. We studied the clinical utility and limitations of albumin RISH in a cohort of HCCs, ICCs, ECCs, bile duct adenomas (BDAs), bile duct hamartomas (BDHs) and metastatic carcinomas to the liver; and investigated the variability in sensitivity observed for this marker in ICCs. DESIGN: We identified 122 cases (40 resections and 82 biopsies) of hepatobiliary lesions and metastatic carcinomas. Albumin RISH was performed using the RNAscope (Leica Biosystems, Buffalo Grove, IL), the Bond III autostainer and probe Hs-ALB-01 (ACD, Newark, CA) with negative (DapB) and positive probes (PPIB) for RNA. ICCs were categorized according to the classification proposed by Hayashi et al.in small duct (SD), large duct (LD) and indeterminate (IND) subtypes. RESULTS: Albumin RISH was positive in all 17 HCCs, and focally in 75% of BDAs. All 28 non-hepatic carcinomas, 13 BDHs and 9 ECCs were negative. 35/47 (74.4%) ICCs expressed albumin with 35/37 (94.6%) being of SD subtype, 2/3 (66.6%) of the IND subtype and 1/7 (14.2%) of the LD subtype, P&lt;0.003. CONCLUSION: Albumin RISH performed on resection specimens or on small core biopsies is a sensitive and specific marker for HCCs. It is highly sensitive and moderately specific in the diagnosis of ICC with small gland morphology, but not in ICCs with large duct morphology and in metastatic carcinoma. The variability in sensitivity of albumin RISH in ICCs may depend on the subtypes of ICCs.</p>
<p>doi: <a href="https://doi.org/10.1111/his.14046" class="uri">https://doi.org/10.1111/his.14046</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Pancreatic cancer organoids recapitulate disease and allow personalized drug screening</strong> </summary></p>
<p><em>Proceedings of the National Academy of Sciences of the United States of America 2019 Dec;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31818951" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31818951</a></p>
<p>We report the derivation of 30 patient-derived organoid lines (PDOs) from tumors arising in the pancreas and distal bile duct. PDOs recapitulate tumor histology and contain genetic alterations typical of pancreatic cancer. In vitro testing of a panel of 76 therapeutic agents revealed sensitivities currently not exploited in the clinic, and underscores the importance of personalized approaches for effective cancer treatment. The PRMT5 inhibitor EZP015556, shown to target MTAP (a gene commonly lost in pancreatic cancer)-negative tumors, was validated as such, but also appeared to constitute an effective therapy for a subset of MTAP-positive tumors. Taken together, the work presented here provides a platform to identify novel therapeutics to target pancreatic tumor cells using PDOs.</p>
<p>doi: <a href="https://doi.org/10.1073/pnas.1911273116" class="uri">https://doi.org/10.1073/pnas.1911273116</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Fitz-Hugh-Curtis Syndrome</strong> </summary></p>
<p><em>The New England journal of medicine 2019 Nov;381(22):e38</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31774961" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31774961</a></p>
<p>doi: <a href="https://doi.org/10.1056/NEJMicm1813625" class="uri">https://doi.org/10.1056/NEJMicm1813625</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Complementary Value of Magnetic Resonance Imaging and Vibration-Controlled Transient Elastography for Risk Stratification in Primary Sclerosing Cholangitis</strong> </summary></p>
<p><em>The American journal of gastroenterology 2019 Dec;114(12):1878-1885</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31738286" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31738286</a></p>
<p>OBJECTIVES: Magnetic resonance (MR) risk scores and liver stiffness (LS) have individually been shown to predict clinical outcomes in primary sclerosing cholangitis (PSC). The aim of this study was to assess their complementary prognostic value. METHODS: Patients with PSC from 3 European centers with a 3-dimensional MR cholangiography available for central reviewing and a valid LS measurement assessed by vibration-controlled transient elastography by FibroScan performed within a 6-month interval were included in a longitudinal retrospective study. The MR score (Anali) without gadolinium (Gd) was calculated according to the formula: (1  dilatation of intrahepatic bile ducts) + (2  dysmorphy) + (1  portal hypertension). The primary end point was survival without liver transplantation or cirrhosis decompensation. The prognostic values of LS and Anali score without Gd were assessed using Cox proportional hazard models. RESULTS: One hundred sixty-two patients were included. Over a total follow-up of 753 patient-years, 40 patients experienced an adverse outcome (4 liver transplantations, 6 liver-related deaths, and 30 cirrhosis decompensations). LS and Anali score without Gd were significantly correlated ( = 0.51, P &lt; 0.001) and were independently associated with the occurrence of an adverse outcome. Optimal prognostic thresholds were 10.5 kPa for LS and 2 for the Anali score without Gd. Hazard ratios (95% confidence interval) were 2.07 (1.06-4.06) and 3.78 (1.67-8.59), respectively. The use in combination of these 2 thresholds allowed us to separate patients into low-, medium-, and high-risk groups for developing adverse outcomes. The 5-year cumulative rates of adverse outcome in these 3 groups were 8%, 16%, and 38% (P &lt; 0.001), respectively. DISCUSSION: The combined use of MRI and vibration-controlled transient elastography permits easy risk stratification of patients with PSC.</p>
<p>doi: <a href="https://doi.org/10.14309/ajg.0000000000000461" class="uri">https://doi.org/10.14309/ajg.0000000000000461</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Unexpected Infant Death Due to Undiagnosed Biliary Atresia: A Case of Fatal Neglect</strong> </summary></p>
<p><em>The American journal of forensic medicine and pathology 2019 Dec;40(4):399-402</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31634153" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31634153</a></p>
<p>Biliary atresia (BA) is a fatal condition resulting in the lack of effective biliary drainage leading invariably to liver failure and cirrhosis within a year, and it is often lethal within a few months in the absence of corrective surgery or liver transplantation. In fact, BA is the most common indication for pediatric liver transplantation.Herein, we present a rare case of unexpected infant death due to BA diagnosed only postmortem in a context of child neglect and carelessness on the part of the parents. It emerged from the clinical history that after a few months, the parents no longer took their daughter to any medical checkups despite the indications and express recommendations for follow-up. The autopsy revealed agenesis of the gallbladder with BA and complete disruption of the hepatic architecture and parenchyma from biliary cirrhosis. Histological examinations documented severe biliary cirrhosis from hypoplasia of the biliary ducts.The child neglect in this case proved fatal inasmuch as an early diagnosis by a pediatrician would have likely allowed appropriate surgical treatment, thus avoiding the untimely death of the child. We highlight the importance of educating and informing parents (especially the disadvantaged) in matters of health. At the same time, primary care physicians should closely monitor the conditions and development of infants so as to recognize the early warning signs and symptoms of BA, bearing in mind that a timely diagnosis and proper surgical treatment can save the lives of most of these children.</p>
<p>doi: <a href="https://doi.org/10.1097/PAF.0000000000000511" class="uri">https://doi.org/10.1097/PAF.0000000000000511</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes</strong> </summary></p>
<p><em>Cancer 2019 Dec;125(24):4426-4434</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31454426" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31454426</a></p>
<p>BACKGROUND: Although gemcitabine plus platinum chemotherapy is the established first-line regimen for advanced biliary cancer (ABC), there is no standard second-line therapy. This study evaluated current practice and outcomes for second-line chemotherapy in patients with ABC across 3 US academic medical centers. METHODS: Institutional registries were reviewed to identify patients who had received second-line chemotherapy for ABC from April 2010 to March 2015 along with their demographics, diagnoses and staging, treatment histories, and clinical outcomes. Overall survival from the initiation of second-line chemotherapy (OS2) was estimated with Kaplan-Meier methods. RESULTS: This study identified 198 patients with cholangiocarcinoma (intrahepatic [61.1%] or extrahepatic [14.1%]) or gallbladder carcinoma (24.8%); 52% received at least 3 lines of systemic chemotherapy. The median OS2 was 11months (95% confidence interval [CI], 8.8-13.1months). The median OS2 for patients with intrahepatic cholangiocarcinoma was 13.4months (95% CI, 10.7-17.8months), which was longer than that for patients with extrahepatic cholangiocarcinoma (6.8months; 95% CI, 5-10.6months) or gallbladder carcinoma (9.4months; 95% CI, 7.2-12.3months; P=.018). The median time to second-line treatment failure was 2.2months (95% CI, 1.8-2.7months), and it was similar across tumor locations (P=.60). CONCLUSIONS: In this large cohort of patients with ABC treated across 3 academic medical centers after the failure of first-line chemotherapy, the time to treatment failure on standard therapies was short, although the median OS2 was longer than has been reported previously, and more than half of the patients received additional lines of treatment. This multicenter collaboration represents the largest cohort studied to date of second-line chemotherapy for ABC and provides a contemporary benchmark for future clinical trials.</p>
<p>doi: <a href="https://doi.org/10.1002/cncr.32463" class="uri">https://doi.org/10.1002/cncr.32463</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Histologic pattern is better correlated with clinical outcomes than biochemical classification in patients with drug-induced liver injury</strong> </summary></p>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019 Dec;32(12):1795-1805</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31300804" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31300804</a></p>
<p>Histologically, drug-induced liver injury could be classified into acute hepatitis, chronic hepatitis, acute cholestasis, chronic cholestasis, and cholestatic hepatitis. The correlation between these histologic patterns and long-term clinical outcomes has not been well established. Therefore, we conducted a retrospective cohort study to investigate the association of histologic patterns and long-term clinical outcomes defined as biochemical normalization, persistent abnormal liver biochemistry or death at designated time points. In this study, biochemical classification was determined by R-values; histologic injury pattern was determined by morphological features. Predictive ability of clinical outcomes by these two classifications was assessed using Receiver Operating Characteristic Curves. Logistic regression was performed to identify histologic factors associated with outcomes. Totally, 88 patients with drug-induced liver injury were included for final analysis. Biochemical and histologic classification were consistent in 50 (57%) cases. 53 (60%) cases showed biochemical normalization within 6 months, and a further 11 (13%), 16 (18%), and 6 (7%) cases within 1, 2, and 3 years, respectively. Compared with biochemical classification, histologic injury pattern had better predictive ability for abnormal biochemistry at 6 months (Areas under Receiver Operating Characteristic Curves 0.92 versus 0.60, P&lt;0.001) and 1 year (Areas under Receiver Operating Characteristic Curves 0.94 versus 0.69, P&lt;0.001). Interlobular bile duct loss in &gt;25% portal areas was independently associated with abnormal biochemistry at 6 months, 1 year, and 2 years. In conclusion, histologic injury pattern is better correlated with clinical outcome at 6 months and 1 year than biochemical classification. Moderate bile duct loss is an important histologic feature associated with persistent biochemical abnormality at 6 months, 1 year, and 2 years.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-019-0314-9" class="uri">https://doi.org/10.1038/s41379-019-0314-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis</strong> </summary></p>
<p><em>Gut 2019 12;68(12):2170-2178</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30910856" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30910856</a></p>
<p>OBJECTIVE: Scheduled endoscopic dilatation of dominant strictures (DS) in primary sclerosing cholangitis (PSC) might improve outcome relative to endoscopic treatment on demand, but evidence is limited. Since randomisation is difficult in clinical practice, we present a large retrospective study comparing scheduled versus on-demand endoscopic retrograde cholangiopancreatography (ERCP) based on patient preferences. DESIGN: Between 1987 and 2017, all new patients with PSC had been offered scheduled ERCP with dilatation of a DS if diagnosed; the latter was repeated at defined intervals until morphological resolution, independent of clinical symptoms (treatment group). Patients who refused participation were clinically evaluated annually and received endoscopic treatment only on demand (control group). The primary clinical endpoint was transplantation-free survival. Secondary outcomes were overall survival, bacterial cholangitis episodes, hepatic decompensation of liver cirrhosis and endoscopy-related adverse events. RESULTS: The final study included 286 patients, 133 (46.5%) receiving scheduled ERCP and 153 (53.5%) receiving on-demand ERCP. After a mean follow-up of 9.9 years, the rate of transplantation-free survival was higher in patients receiving scheduled ERCP (51% vs 29.3%; p&lt;0.001), as was transplantation-free survival time (median: 17.9 vs 15.2 years; log-rank: p=0.008). However, the benefit of scheduled ERCP was significant only in patients with the initial (17.1%) or later (45.5%) diagnosis of a DS (17.8 vs 11.1 years; log-rank: p&lt;0.001). IBD (p=0.03), DS (p=0.006), higher Mayo Risk Score (p=0.02) and non-adherence to scheduled endoscopy (p=0.005) were independently associated with transplantation-free survival. CONCLUSION: In our large retrospective study, regular ERCP with endoscopic balloon dilatation significantly benefits patients with PSC with DS, diagnosed both at initial presentation and during surveillance, even if asymptomatic. Further studies have to find out how to best identify stricture patients non-invasively.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2018-316801" class="uri">https://doi.org/10.1136/gutjnl-2018-316801</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Randomized Trial of Near-infrared Incisionless Fluorescent Cholangiography</strong> </summary></p>
<p><em>Annals of surgery 2019 Dec;270(6):992-999</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30614881" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30614881</a></p>
<p>BACKGROUND: Incisionless near-infrared fluorescent cholangiography (NIFC) is emerging as a promising tool to enhance the visualization of extrahepatic biliary structures during laparoscopic cholecystectomies. METHODS: We conducted a single-blind, randomized, 2-arm trial comparing the efficacy of NIFC (n = 321) versus white light (WL) alone (n = 318) during laparoscopic cholecystectomy. Using the KARL STORZ Image1 S imaging system with OPAL1 technology for NIR/ICG imaging, we evaluated the detection rate for 7 biliary structures-cystic duct (CD), right hepatic duct (RHD), common hepatic duct, common bile duct, cystic common bile duct junction, cystic gallbladder junction (CGJ), and accessory ducts -before and after surgical dissection. Secondary calculations included multivariable analysis for predictors of structure visualization and comparing intergroup biliary duct injury rates. RESULTS: Predissection detection rates were significantly superior in the NIFC group for all 7 biliary structures, ranging from 9.1% versus 2.9% to 66.6% versus 36.6% for the RHD and CD, respectively, with odds ratios ranging from 2.3 (95% CI 1.6-3.2) for the CGJ to 3.6 (1.6-9.3) for the RHD. After dissection, similar intergroup differences were observed for all structures except CD and CGJ, for which no differences were observed. Significant odds ratios ranged from 2.4 (1.7-3.5) for the common hepatic duct to 3.3 (1.3-10.4) for accessory ducts. Increased body mass index was associated with reduced detection of most structures in both groups, especially before dissection. Only 2 patients, both in the WL group, sustained a biliary duct injury. CONCLUSIONS: In a randomized controlled trial, NIFC was statistically superior to WL alone visualizing extrahepatic biliary structures during laparoscopic cholecystectomy. REGISTRATION NUMBER: NCT02702843.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003178" class="uri">https://doi.org/10.1097/SLA.0000000000003178</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Clinicopathologic and Prognostic Significance of Gallbladder and Cystic Duct Invasion in Distal Bile Duct Carcinoma</strong> </summary></p>
<p><em>Archives of pathology &amp; laboratory medicine 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31755778" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31755778</a></p>
<p>CONTEXT.: The roles of the gallbladder and cystic duct (CD) invasions in distal bile duct carcinoma (DBDC) have not been well elucidated. OBJECTIVE.: To define the characteristics and prognostic significance of gallbladder or CD invasions in patients with DBDC. DESIGN.: Organ invasion patterns with clinicopathologic features were assessed in 258 resected DBDCs. RESULTS.: CD invasions (N = 31) were associated with frequent concomitant pancreatic and/or duodenal invasions (23 of 31, 74%) and showed stromal infiltration (16 of 31, 52%) and intraductal cancerization (15 of 31, 48%) patterns. In only 2 cases, invasions with intraductal cancerization were observed in the gallbladder neck. Conversely, all pancreatic (N = 175) and duodenal (83) invasions developed through stromal infiltration. CD invasions were associated with larger tumor size (P = .001), bile duct margin positivity (P = .001), perineural invasions (P = .04), and higher N categories (P = .007). Patients with pancreatic or duodenal invasions had significantly lower survival rates than those without pancreatic (median, 31.0 versus 93.9 months) or duodenal (27.5 versus 56.8 months, P &lt; .001, both) invasions. However, those with gallbladder or CD invasions did not have different survival times (P = .13). Patients with concomitant gallbladder/CD and pancreatic/duodenal invasions demonstrated significantly lower survival rates than those without organ invasions (P &lt; .001). CONCLUSIONS.: Gallbladder invasions were rare in DBDCs as neck invasions with intraductal cancerization. CD invasions occurred by stromal infiltrations and intraductal cancerization, whereas all pancreatic and duodenal invasions had stromal infiltration patterns. Gallbladder and/or CD invasions did not affect survival rates of patients with DBDC, while pancreatic and duodenal invasions affected survival rates. Therefore, these differences in survival rates may originate from the different invasive patterns of DBDCs.</p>
<p>doi: <a href="https://doi.org/10.5858/arpa.2019-0218-OA" class="uri">https://doi.org/10.5858/arpa.2019-0218-OA</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Time to revisit indications for cholecystectomy - Authors reply</strong> </summary></p>
<p><em>Lancet (London, England) 2019 11;394(10211):1804</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31741452" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31741452</a></p>
<p>doi: <a href="https://doi.org/10.1016/S0140-6736(19)32615-7" class="uri">https://doi.org/10.1016/S0140-6736(19)32615-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Time to revisit indications for cholecystectomy</strong> </summary></p>
<p><em>Lancet (London, England) 2019 11;394(10211):1803-1804</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31741451" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31741451</a></p>
<p>doi: <a href="https://doi.org/10.1016/S0140-6736(19)32478-X" class="uri">https://doi.org/10.1016/S0140-6736(19)32478-X</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Acute obstructive cholangitis due to fishbone in the common bile duct: a case report and review of the literature</strong> </summary></p>
<p><em>BMC gastroenterology 2019 Nov;19(1):177</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31699035" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31699035</a></p>
<p>BACKGROUND: Choledocholithiasis is an endemic condition in the world. Although rare, foreign body migration with biliary complications needs to be considered in the differential diagnosis for patients presenting with typical symptoms even many years after cholecystectomy, EPCP, war-wound, foreign body ingestion or any other particular history before. It is of great clinical value as the present review may offer some help when dealing with choledocholithiasis caused by foreign bodies. CASE PRESENTATION: We reported a case of choledocholithiasis caused by fishbone from choledochoduodenal anastomosis regurgitation. Moreover, we showed up all the instances of choledocholithiasis caused by foreign bodies published until June 2018 and wrote the worlds first literature review of foreign bodies in the bile duct of 144 cases. The findings from this case suggest that the migration of fishbone can cause various consequences, one of these, as we reported here, is as a core of gallstone and a cause of choledocholithiasis. CONCLUSION: The literature review declared the choledocholithiasis caused by foreign bodies prefer the wrinkly and mainly comes from three parts: postoperative complications, foreign body ingestion, and post-war complications such as bullet injury and shrapnel wound. The Jonckheere-Terpstra test indicated the ERCP was currently the treatment of choice. It is a very singular case of choledocholithiasis caused by fishbone, and the present review is the first one concerning choledocholithiasis caused by foreign bodies all over the world.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-019-1088-8" class="uri">https://doi.org/10.1186/s12876-019-1088-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Neuroendocrine carcinoma diagnosis from bile duct cytological specimens: A retrospective single-center study</strong> </summary></p>
<p><em>Diagnostic cytopathology 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31697402" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31697402</a></p>
<p>Neuroendocrine carcinoma (NEC) in the extrahepatic bile duct is extremely rare and clinically aggressive. Cytological examination of bile and/or bile duct brushing specimens plays an important role in the diagnosis of carcinoma of the extrahepatic bile duct, but only a few articles have described the cytological features of NEC in this area. Thus, we retrospectively analyzed the cytological features of NEC in bile and/or bile duct brushing specimens. Patients with a histopathological diagnosis of NEC who underwent bile and/or bile duct brush cytological examination were enrolled in this study. The cytological features, including the background, arrangement, and shape of the neoplastic cells, and nuclear and cytoplasmic features were reviewed. Six patients with small cell NEC were enrolled, and two of them had pancreatic tumors directly invading the bile duct wall. The cytological specimens showed small and/or large neoplastic cell clusters with occasional single cells in all cases. The neoplastic cells had a high nuclear/cytoplasmic ratio and round-to-oval nuclei with powdery chromatin, inconspicuous nucleoli, and scant cytoplasm. Nuclear molding was a characteristic finding in all cases. One case had an adenocarcinoma component, which was also present in the cytological specimen. Cytological examination of bile and/or bile duct brushing specimens can be useful for the diagnosis of small cell NEC. This is an extremely rare but aggressive carcinoma, and its diagnosis by identifying characteristic cytological features may facilitate early detection and treatment.</p>
<p>doi: <a href="https://doi.org/10.1002/dc.24334" class="uri">https://doi.org/10.1002/dc.24334</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Recurrent Rearrangements in PRKACA and PRKACB in Intraductal Oncocytic Papillary Neoplasms of the Pancreas and Bile Duct</strong> </summary></p>
<p><em>Gastroenterology 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31678302" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31678302</a></p>
<p>BACKGROUND &amp; AIMS: Intraductal oncocytic papillary neoplasms (IOPNs) of the pancreas and bile duct contain epithelial cells with numerous, large mitochondria and are cystic precursors to pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CCA), respectively. However, IOPNs do not have the genomic alterations found in other pancreatobiliary neoplasms. In fact, no recurrent genomic alterations have been described in IOPNs. PDACs without activating mutations in KRAS contain gene rearrangements, so we investigated whether IOPNs have recurrent fusions in genes. METHODS: We analyzed 20 resected pancreatic IOPNs and 3 resected biliary IOPNs using a broad RNA-based targeted sequencing panel to detect cancer-related fusion genes. Four invasive PDACs and 2 intrahepatic cholangiocarcinomas from the same patients as the IOPNs, were also available for analysis. Samples of pancreatic cyst fluid (n=5, collected before surgery) and bile duct brushings (n=2) were analyzed for translocations. For comparison, we analyzed pancreatobiliary lesions from 126 patients without IOPN (controls). RESULTS: All IOPNs evaluated were found to have recurring fusions of ATP1B1-PRKACB (n = 13), DNAJB1-PRKACA (n = 6), or ATP1B1-PRKACA (n = 4). These fusions were also found in corresponding invasive PDACs and intrahepatic cholangiocarcinomas, as well as in matched pancreatic cyst fluid and bile duct brushings. These gene rearrangements were absent from all 126 control pancreatobiliary lesions. CONCLUSIONS: We identified fusions in PRKACA and PRKACB genes in pancreatic and biliary IOPNs, as well as in PDACs and pancreatic cyst fluid and bile duct cells from the same patients. We did not identify these gene fusions in 126 control pancreatobiliary lesions. These fusions might be used to identify patients at risk for IOPNs and their associated invasive carcinomas.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.10.028" class="uri">https://doi.org/10.1053/j.gastro.2019.10.028</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma</strong> </summary></p>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31676785" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31676785</a></p>
<p>Recently discovered DNAJB1-PRKACA oncogenic fusions have been considered diagnostic for fibrolamellar hepatocellular carcinoma. In this study, we describe six pancreatobiliary neoplasms with PRKACA fusions, five of which harbor the DNAJB1-PRKACA fusion. All neoplasms were subjected to a hybridization capture-based next-generation sequencing assay (MSK-IMPACT), which enables the identification of sequence mutations, copy number alterations, and selected structural rearrangements involving 410 genes (n=6) and/or to a custom targeted, RNA-based panel (MSK-Fusion) that utilizes Archer Anchored Multiplex PCR technology and next-generation sequencing to detect gene fusions in 62 genes (n=2). Selected neoplasms also underwent FISH analysis, albumin mRNA in-situ hybridization, and arginase-1 immunohistochemical labeling (n=3). Five neoplasms were pancreatic, and one arose in the intrahepatic bile ducts. All revealed at least focal oncocytic morphology: three cases were diagnosed as intraductal oncocytic papillary neoplasms, and three as intraductal papillary mucinous neoplasms with mixed oncocytic and pancreatobiliary or gastric features. Four cases had an invasive carcinoma component composed of oncocytic cells. Five cases revealed DNAJB1-PRKACA fusions and one revealed an ATP1B1-PRKACA fusion. None of the cases tested were positive for albumin or arginase-1. Our data prove that DNAJB1-PRKACA fusion is neither exclusive nor diagnostic for fibrolamellar hepatocellular carcinoma, and caution should be exercised in diagnosing liver tumors with DNAJB1-PRKACA fusions as fibrolamellar hepatocellular carcinoma, particularly if a pancreatic lesion is present. Moreover, considering DNAJB1-PRKACA fusions lead to upregulated protein kinase activity and that this upregulated protein kinase activity has a significant role in tumorigenesis of fibrolamellar hepatocellular carcinoma, protein kinase inhibition could have therapeutic potential in the treatment of these pancreatobiliary neoplasms as well, once a suitable drug is developed.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-019-0398-2" class="uri">https://doi.org/10.1038/s41379-019-0398-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Case 34-2019: A 16-Year-Old Boy with Jaundice</strong> </summary></p>
<p><em>The New England journal of medicine 2019 10;381(18):1763-1772</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31665582" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31665582</a></p>
<p>doi: <a href="https://doi.org/10.1056/NEJMcpc1904047" class="uri">https://doi.org/10.1056/NEJMcpc1904047</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>CK20 and lymph node involvement predict adverse outcome of malignant intraductal papillary neoplasm of the bile duct</strong> </summary></p>
<p><em>Histology and histopathology 2019 Oct;():18179</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31657857" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31657857</a></p>
<p>OBJECTIVES: To identify prognostic factors of malignant intraductal papillary neoplasm of the bile duct (m-IPNB). MATERIALS AND METHODS: We included 38 consecutive cases which underwent surgical resection and diagnosed as IPNB with malignant component from January 2003 to January 2017. Clinicopathological variables were collected to conduct survival analysis and identify prognostic factors. RESULTS: The median OS of m-IPNB was 76.0 months, with 1-, 3-, and 5-year survival rates of 97.2%, 73.5%, and 59.8%, respectively. The median RFS was 48.0 months with 1-, 3-, and 5-year RFS rate was 83.2%, 59.8%, and 44.6%, respectively. Univariate analysis showed that elevation of CEA, lymph node involvement, resection margin status, degree of periductal invasion, and positive expression of CK20 were associated with both OS and RFS of m-IPNB. After multivariate Cox models analysis, lymph node involvement and positive expression of CK20 were identified as independent prognostic factors for OS, while lymph node involvement and resection margin status were independent prognostic factors for RFS. The median OS of patients with m-IPNB involving lymphatic metastases and positive expression of CK20 was 27.08.8 months and 51.012.4 months, respectively. The median RFS of cases with lymph node involvement and R1 resection was 10.03.3 months and 25.06.9 months, respectively. However, there was no significant difference in OS or RFS between cases of pancreaticobiliary and intestinal subtype. CONCLUSIONS: Lymph node involvement and positive expression of CK20 are independent prognostic factors for shorter OS of m-IPNB, while patients with lymph node involvement and positive resection margin are at higher risk of tumor recurrence.</p>
<p>doi: <a href="https://doi.org/10.14670/HH-18-179" class="uri">https://doi.org/10.14670/HH-18-179</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Bile duct involvement by hepatocellular carcinoma: A rare occurrence and poor prognostic indicator in bile duct brushing samples</strong> </summary></p>
<p><em>Cancer cytopathology 2019 Nov;127(11):691-699</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31518056" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31518056</a></p>
<p>BACKGROUND: Hepatocellular carcinoma (HCC) rarely involves the biliary tree and may be inadvertently sampled on bile duct brushings (BDBs). METHODS: The pathology archives of 5 institutions were searched for BDBs with HCC involvement. RESULTS: A total of 17 BDBs from 14 patients were obtained. There was a male:female ratio of 6:1; the median age of the patients was 59.5years (range, 22-80years). The median hepatic tumor size was 6.2cm (range, 2.2-13.0cm). HCC risk factors included viral hepatitis (5 patients), cirrhosis (5 patients), hemochromatosis (1 patient), and alcoholic steatohepatitis (1 patient). Jaundice with elevated bilirubin, liver enzymes, and -fetoprotein was common. Endoscopic retrograde cholangiopancreatography demonstrated bile duct dilatation, polypoid intraductal masses (5 samples), clots/debris (2 samples), or strictures (4 samples). All BDBs had single and clustered large cells with naked atypical nuclei, granular cytoplasm, high nuclear/cytoplasmic ratios, and nuclei with prominent macronucleoli. Less common findings included clear/microvesicular cytoplasm (35%), papillae (29%), and anisonucleosis (35%). Classic HCC features (widened trabeculae [35%], endothelial wrapping [24%], multinucleation [24%], and cytoplasmic bile pigment [35%]) were uncommon. A total of 11 BDBs were diagnosed as malignant (10 with HCC and 1 with cholangiocarcinoma), 2 were diagnosed as atypical, and 1 BDB was diagnosed as negative; approximately two-thirds were found to have polysomy on fluorescence in situ hybridization. Approximately 71% of patients died of disease at a median of 3.5months. CONCLUSIONS: HCC may extend into the intrahepatic and/or extrahepatic biliary tree, causing masses and/or strictures that may be sampled on BDB. Although cytologically malignant, the classic features of HCC are uncommon, which can cause misdiagnosis. Cytopathologists should be mindful of this differential when evaluating BDBs, particularly when concomitant liver masses and/or HCC risk factors are present. Because of the associated high mortality and rapid rate of death, its presence should be conveyed clearly in pathology reports.</p>
<p>doi: <a href="https://doi.org/10.1002/cncy.22185" class="uri">https://doi.org/10.1002/cncy.22185</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A practical approach to the pathology of neonatal cholestatic liver disease</strong> </summary></p>
<p><em>Seminars in diagnostic pathology 2019 Nov;36(6):375-388</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31455583" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31455583</a></p>
<p>Navigating the complexities of interpreting a liver biopsy performed on a neonate with conjugated/direct hyperbilirubinemia can be an arduous task given these biopsies are infrequently encountered. The list of entities is long and yet there are only a few histologic patterns of liver injury. The first step for the pathologist is to determine the histologic pattern, which will guide further inquiry into the useful clinical information to have while evaluating the biopsy. Ultimately, the goal is to identify those conditions that will benefit from early intervention. We begin with a review of biliary development to help understand what findings may be physiologic versus pathologic, particularly in premature infants. Then we review eight cases that cover the three most common histologic patterns of injury in patients with neonatal cholestasis: biliary obstructive, neonatal hepatitis, and paucity of intrahepatic bile ducts. The entities that serve as prototypes for these histologic patterns are covered, including biliary atresia, idiopathic neonatal hepatitis, and Alagille syndrome, along with rarer entities that have histologic overlap. The cases with accompanying tables and algorithms are intended to help place the histologic findings in the context of the overall clinical work-up, including genetic testing.</p>
<p>doi: <a href="https://doi.org/10.1053/j.semdp.2019.07.004" class="uri">https://doi.org/10.1053/j.semdp.2019.07.004</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Immunoglobulin G4-related hepatobiliary disease</strong> </summary></p>
<p><em>Seminars in diagnostic pathology 2019 Nov;36(6):423-433</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31358425" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31358425</a></p>
<p>Immunoglobuline G4-related disease (IgG4-RD) is a systemic disease that can involve virtually any organs including the biliary tract and liver. The biliary tract involvement of IgG4-RD is known as IgG4-sclerosing cholangitis (IgG4-SC) and may or may not present with an inflammatory pseudotumor. Large bile ducts such as extrahepatic, hilar, and perihilar ducts are typically affected and demonstrate marked bile duct wall thickening and develop strictures. Histologically, the involved ducts show transmural dense lymphoplasmacytic infiltrates with storiform fibrosis extending into peribiliary glands and periductal soft tissue. The luminal epithelium is usually preserved. Tissue eosinophilia and obliterative phlebitis are also frequently noted. Liver biopsy findings of IgG4-SC are heterogeneous and rather nonspecific, but two features specific to IgG4-SC have been described: &gt;10 IgG4-positive plasma cell/HPF and small portal-based fibroinflammatory nodules. Secondary changes, due to downstream bile duct obstruction are often appreciated. When considering the differential diagnosis, primary sclerosing cholangitis and cholangiocarcinoma are great clinical and histologic mimics of IgG4-SC. Liver involvement in IgG4-RD has not been well characterized and includes IgG4-hepatopathy and IgG4-related autoimmune hepatitis (AIH). IgG4-hepatopathy is a generic term covering hepatic lesions related to IgG4-RD and /or IgG4-SC. It includes primary liver parenchymal changes inherent to IgG4-RD, liver parenchymal involvement of IgG4-SC, and secondary changes related to IgG4-SC. IgG4-related AIH is characterized by clinical and histologic features of classical AIH but with prominent (&gt;10/HPF) IgG4-positive plasma cells. It is unclear whether this represents a hepatic manifestation of IgG4-RD or a subset of AIH with increased IgG4-positive plasma cells at the present time. Synchronous or metachronous involvement of other organs, offers a clue to make this distinction. IgG4 immunohistochemistry has an important role in diagnosing IgG4-RD. But the diagnosis cannot be made solely based on the number of IgG4-positive plasma cells, and results need to be interpreted with caution as increased IgG4-positive plasma cells can be seen in other inflammatory conditions or even in malignancy.</p>
<p>doi: <a href="https://doi.org/10.1053/j.semdp.2019.07.007" class="uri">https://doi.org/10.1053/j.semdp.2019.07.007</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Checkpoint inhibitor-induced liver injury: A novel form of liver disease emerging in the era of cancer immunotherapy</strong> </summary></p>
<p><em>Seminars in diagnostic pathology 2019 Nov;36(6):434-440</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31358424" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31358424</a></p>
<p>Liver injury triggered by immune checkpoint inhibitors has been increasingly seen in clinical practice, and the incidence is likely to rise further in the next several years because of expanded indications for cancer immunotherapy. Tissue damage driven by disrupted immune tolerance against self-antigens is called an immune-related adverse event (irAE). irAEs in the liver histologically presents panlobular hepatitis (70%), isolated central zonal necrosis (20%), primarily granulomatous hepatitis (5%), and other minor forms of tissue injury (5%). Infiltrating cells are mainly lymphocytes and occasional eosinophils. Unlike classic autoimmune hepatitis (AIH), plasma cell infiltration is not conspicuous. Immunostaining reveals a large number of CD8+ T lymphocytes and a markedly smaller number of CD4+ cells or CD20+ B lymphocytes. The unique CD3+/CD20+ and CD4+/CD8+ ratios shifted in favor of CD8+ cytotoxic T lymphocytes are helpful to discriminate irAEs from other conditions (e.g., AIH, idiosyncratic drug-induced liver injury). Another hepatobiliary manifestation of irAEs is sclerosing cholangitis clinically characterized by elevations of biliary enzymes, diffuse duct wall thickening, and duct dilatation. Lymphocytic infiltration can be observed by endoscopic biopsies from the thick extrahepatic bile ducts, and liver needle biopsies may also show severe lymphocytic cholangitis resembling primary biliary cholangitis. An important differential diagnosis of irAEs is previously asymptomatic or subclinical liver disease unmasked by cancer immunotherapy, which is often challenging and requires close clinicopathological correlations.</p>
<p>doi: <a href="https://doi.org/10.1053/j.semdp.2019.07.009" class="uri">https://doi.org/10.1053/j.semdp.2019.07.009</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Mutational profiling and immunohistochemical analysis of a surgical series of ampullary carcinomas</strong> </summary></p>
<p><em>Journal of clinical pathology 2019 Nov;72(11):762-770</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31256008" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31256008</a></p>
<p>AIMS: Knowledge regarding the genetic features of ampullary carcinoma (AC) in European patients is limited. The utility of tumour markers for the establishment of a malignant diagnosis in biopsies from the ampullary region has not been fully elucidated. We aimed to describe the clinical, pathological, immunohistochemical (IHC) and genetic features of a Danish series of surgically resected ACs. METHODS: Surgically resected ACs (n=59) were examined regarding (1) clinicopathological features, (2) histological subtypes, (3) expression of IMP3, maspin, MUC5AC and S100P and (4) next-generation sequencing using a hybrid capture-based platform (Illumina HiSeq2500), including 315 cancer-related genes plus introns from 28 genes often rearranged or altered in cancer. Tumour mutational burden (TMB) and microsatellite instability (MSI) were also evaluated. RESULTS: Pancreatobiliary adenocarcinomas (PB-AC), intestinal adenocarcinomas (INT-AC), other ampullary tumours and mixed adenocarcinomas represented 45.8%, 23.7%, 16.9% and 13.6%. The proportion of IHC-positive ACs (score 2) was: Maspin (94.9%), IMP3 (67.8%), S100P (39.0%) and MUC5AC (18.6%). Most frequently altered genes were TP53 (59.3%), KRAS (40.7%), APC (27.8%), SMAD4 (20.4%), CDKN2A (16.7%) and ARID2/PIK3CA (each 11.1%). MUC5AC and S100P were frequently expressed in PB-AC, APC alterations frequent in INT-AC, SOX9 alterations were exclusive in INT-AC and MDM2 and FRS2 alterations in PB-AC. Four of 49 ACs (8.2%) were TMB-high/MSI-high and showed loss of MLH1 and PMS2. CONCLUSIONS: PB-AC was the most frequent histological subtype of AC. Maspin and IMP3 were the IHC tumour markers with the highest sensitivity. Adenocarcinoma subtypes differed regarding several genetic alterations, whose predictive value remains to be evaluated.</p>
<p>doi: <a href="https://doi.org/10.1136/jclinpath-2019-205912" class="uri">https://doi.org/10.1136/jclinpath-2019-205912</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Targeted next-generation sequencing identifies distinct clinicopathologic and molecular entities of intraductal papillary neoplasms of the bile duct</strong> </summary></p>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019 Nov;32(11):1637-1645</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31231124" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31231124</a></p>
<p>Intraductal papillary neoplasm of the bile duct (IPNB) is a mass-forming neoplasm in the bile duct considered to be the biliary counterpart of pancreatic intraductal papillary mucinous neoplasm (IPMN). By its cell lineage, IPNB can be classified into gastric, intestinal, pancreatobiliary, and oncocytic types. Recently, a group of Japanese and Korean pathologists proposed that IPNB be classified into two types, with type 1, being the histological counterpart of IPMN and type 2, having a more complex histological architecture. We used targeted next-generation sequencing to study the molecular change of 37 IPNBs and identified frequent mutations of KRAS (49%), GNAS (32%), RNF43 (24%), APC (24%), TP53 (24%), and CTNNB1 (11%) in IPNBs. Intestinal-type IPNB was associated with KRAS, GNAS, and RNF43 mutations. Japan-Korea consensus type 1 was associated with KRAS and GNAS mutations. All four IPNBs with CTNNB1 mutations were of pancreatobiliary type and located in the extrahepatic bile duct. A hierarchical analysis identified three distinct groups within IPNB: group 1 was Japan-Korea consensus type 1 tumors with macroscopic mucin, old age, and frequent KRAS, GNAS, and RNF43 mutations. Group 2 was Japan-Korea consensus type 2 with intestinal differentiation and frequent KRAS mutation but rare GNAS mutation, MUC2 expression, and macroscopic mucin. Group 3 was characterized by CTNNB1 mutation, extrahepatic location, lack of expression of intestinal markers, Japan-Korea consensus type 2, and lack of mutations in KRAS, APC, RNF43, and GNAS. Our results indicated that IPNB is a heterogeneous disease and that the activation of Ras-mitogen-activated protein kinase (MAPK), Wnt/-catenin, and G-protein-coupled receptor (GPCR)-cAMP signaling is the main oncogenic mechanism of IPNB.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-019-0306-9" class="uri">https://doi.org/10.1038/s41379-019-0306-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Oesophageal and scaly skin lesions associated with chronic cholestatic liver disease</strong> </summary></p>
<p><em>Gut 2019 11;68(11):1960-2018</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30878948" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30878948</a></p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2019-318502" class="uri">https://doi.org/10.1136/gutjnl-2019-318502</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Adult onset of genetic disorders in bile acid transport in the liver</strong> </summary></p>
<p><em>Human pathology 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31669892" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31669892</a></p>
<p>Although severe deficiencies of canalicular transporter enzymes due to biallelic mutations are well known as causes of progressive cholestatic liver disease in children, it is increasingly recognized that milder disease may occur if a single, heterozygous gene mutation is present. This mild disease, generally presenting initially in adulthood, may have a variety of clinical and histological appearances. Bland canalicular cholestasis is the prototypic change but it is now clear that some gene mutations, particularly in ABCB4 (encoding MDR3), can cause other patterns that include early cholesterol calculus formation, bile duct injury and disappearance, ductular reactions mimicking large duct obstruction and, in rare cases, progressive fibrosis. Since the features can be subtle and not diagnostic in isolation, it is generally the combination of a biliary pattern of injury combined with a suggestive clinical and family history that allows the diagnosis to be suspected. Increased awareness and improved access to genetic testing is likely to result in more frequent diagnosis of these disorders.</p>
<p>doi: <a href="https://doi.org/10.1016/j.humpath.2019.10.006" class="uri">https://doi.org/10.1016/j.humpath.2019.10.006</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study</strong> </summary></p>
<p><em>BMC cancer 2019 Oct;19(1):983</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31640620" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31640620</a></p>
<p>BACKGROUND: To determine the safety and efficacy of transarterial chemoembolization (TACE) combined with radiofrequency ablation (hereafter, TACE-RFA) in treating Barcelona Clinic Liver Cancer (BCLC) Stage A or B (hereafter, BCLC A/B) hepatocellular carcinoma (HCC) patients, and to explore the range of tumor sizes suitable for combination therapy. METHODS: This retrospective study assessed the consecutive medical records of HCC patients with BCLC A/B who received TACE-RFA or TACE from September 2009 to September 2018. Progression-free survival (PFS), overall survival (OS), therapeutic response, and complications were compared between the two groups. RESULTS: Among 2447 patients who received TACE-RFA or TACE, 399 eligible patients were enrolled in our study, including 128 patients in the TACE-RFA group and 271 patients in the TACE group. Compared with the TACE group, the PFS and OS rates of 1,3,5,8years in the TACE-RFA group were significantly better, with higher objective tumor regression rate and better disease control rate. RFA treatment did not increase the risk of death in patients with HCC, and both liver subcapsular hematoma and bile duct injury were improved by symptomatic treatment. Serum -fetoprotein level and treatment method were important independent prognostic factors for OS, whereas albumin, hepatitis B and treatment method were important independent prognostic factors for PFS. Subgroup analysis showed that patients in the TACE-RFA group always showed better OS and PFS. CONCLUSIONS: TACE-RFA had an advantage over TACE alone in prolonging PFS and improving OS in HCC patients with BCLC A/B, and can benefit patients regardless of tumor size.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-019-6237-5" class="uri">https://doi.org/10.1186/s12885-019-6237-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Central Hepatic Regenerative Nodules in Alagille Syndrome: A Clinicopathological Review</strong> </summary></p>
<p><em>Fetal and pediatric pathology 2019 Oct;():1-11</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31608763" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31608763</a></p>
<p>Objective: This review aims to highlight the clinicopathological characteristics and differential diagnosis of central hepatic regenerative nodules (CHRNs) in patients with Alagille syndrome. Methods: A review of the literature for cases of CHRNs and their differential diagnoses in patients with Alagille syndrome was performed and the main findings were collated. Results: Large, regenerative hepatic nodules are seen in approximately 30% of patients with Alagille syndrome. They are thought to be a functional adaptation to vascular changes rather than a neoplastic process. The nodules are typically centrally located, and normal hepatic vasculature coursing through the lesions are noted radiologically. Microscopically, they are characterized by well-circumscribed hepatic lesions with preserved architecture, lesser degrees of fibrosis and relative preservation of interlobular bile ducts compared to the background cirrhotic liver. Conclusion: Regenerative nodules are common in Alagilles syndrome, and should be distinguished from hepatocellular carcinomas and adenomas for appropriate management and prognostication.</p>
<p>doi: <a href="https://doi.org/10.1080/15513815.2019.1675834" class="uri">https://doi.org/10.1080/15513815.2019.1675834</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma Model</strong> </summary></p>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Oct;25(20):6148-6159</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31337646" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31337646</a></p>
<p>PURPOSE: Cholangiocarcinoma is a malignancy of bile duct with a poor prognosis. Conventional chemotherapy and radiotherapy are generally ineffective, and surgical resection is the only curative treatment for cholangiocarcinoma. L1-cell adhesion molecule (L1CAM) has been known as a novel prognostic marker and therapeutic target for cholangiocarcinoma. This study aimed to evaluate the feasibility of immuno-PET imaging-based radioimmunotherapy using radiolabeled anti-L1CAM antibody in cholangiocarcinoma xenograft model. EXPERIMENTAL DESIGN: We prepared a theranostic convergence bioradiopharmaceutical using chimeric anti-L1CAM antibody (cA10-A3) conjugated with 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) chelator and labeled with 64Cu or 177Lu and evaluated the immuno-PET or SPECT/CT imaging and biodistribution with 64Cu-/177Lu-cA10-A3 in various cholangiocarcinoma xenograft models. Therapeutic efficacy and response monitoring were performed by 177Lu-cA10-A3 and 18F-FDG-PET, respectively, and immunohistochemistry was done by TUNEL and Ki-67. RESULTS: Radiolabeled cA10-A3 antibodies specifically recognized L1CAM in vitro, clearly visualized cholangiocarcinoma tumors in immuno-PET and SPECT/CT imaging, and differentiated the L1CAM expression level in cholangiocarcinoma xenograft models. 177Lu-cA10-A3 (12.95 MBq/100 g) showed statistically significant reduction in tumor volumes (P &lt; 0.05) and decreased glucose metabolism (P &lt; 0.01). IHC analysis revealed 177Lu-cA10-A3 treatment increased TUNEL-positive and decreased Ki-67-positive cells, compared with saline, cA10-A3, or 177Lu-isotype. CONCLUSIONS: Anti-L1CAM immuno-PET imaging using 64Cu-cA10-A3 could be translated into the clinic for characterizing the pharmacokinetics and selecting appropriate patients for radioimmunotherapy. Radioimmunotherapy using 177Lu-cA10-A3 may provide survival benefit in L1CAM-expressing cholangiocarcinoma tumor. Theranostic convergence bioradiopharmaceutical strategy would be applied as imaging biomarker-based personalized medicine in L1CAM-expressing patients with cholangiocarcinoma.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-19-1157" class="uri">https://doi.org/10.1158/1078-0432.CCR-19-1157</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Diagnosis of Congenital Hepatic Fibrosis in Adulthood</strong> </summary></p>
<p><em>American journal of clinical pathology 2020 Jan;153(1):119-125</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31584623" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31584623</a></p>
<p>OBJECTIVES: We studied clinicopathologic features of congenital hepatic fibrosis (CHF) that could aid the diagnosis of this relatively rare condition during adulthood. METHODS: Five consecutive adult CHF cases were identified in a single institution. RESULTS: Clinical manifestations of CHF varied from asymptomatic to requiring liver transplantation. Three of five cases had other disease associations, including Joubert syndrome, Caroli disease, polycystic kidney disease, and congenital anomaly of hepatic vasculature. No unique common radiologic findings were found. Histologically, all cases showed characteristic abnormal interlobular bile ducts embedded in fibrotic portal stroma, with varying degrees of liver fibrosis. CONCLUSIONS: While other disease associations and characteristic liver histomorphology are helpful clues to suspect the diagnosis of CHF in adult patients, other differential diagnoses should be excluded clinically and radiologically. This study highlights the importance of a multidisciplinary diagnostic approach by pathologists, radiologists, and hepatologists for the accurate diagnosis of CHF during adulthood.</p>
<p>doi: <a href="https://doi.org/10.1093/ajcp/aqz140" class="uri">https://doi.org/10.1093/ajcp/aqz140</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Myeloid sarcoma of bile ducts presenting as obstructive jaundice - A case report</strong> </summary></p>
<p><em>Indian journal of pathology &amp; microbiology 2019 10;62(4):602-604</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31611450" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31611450</a></p>
<p>Myeloid sarcoma is an extra medullary manifestation of acute myeloid leukemia (AML). Primary involvement of the biliary tract with myeloid sarcoma presenting as obstructive jaundice without evidence of leukemia is very rare. Here we present a case of 72 year old lady, who initially presented with features of biliary obstruction and was clinically considered as cholangiocarcinoma. She was diagnosed as myeloid sarcoma involving right and left hepatic duct, common bile duct (CBD) on histopathological and immunohistochemistry (IHC) examination after surgical resection. Since she did not show evidence of leukemia on peripheral blood and bone marrow examination treatment was deferred. However, she developed full blown picture of AML within two months and succumbed to her disease. We conclude that obstructive jaundice can be the presenting symptom in myeloid sarcoma without evidence of AML in peripheral blood and bone marrow. However, these cases have to be treated aggressively to obtain remission.</p>
<p>doi: <a href="https://doi.org/10.4103/IJPM.IJPM_371_18" class="uri">https://doi.org/10.4103/IJPM.IJPM_371_18</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Brush Cytology Performance for the Assessment of Biliopancreatic Strictures</strong> </summary></p>
<p><em>Acta cytologica 2019 Sep;():1-8</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31550713" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31550713</a></p>
<p>INTRODUCTION: Brush cytology is commonly used during endoscopic retrograde cholangiopancreatography for the diagnostic evaluation of biliopancreatic strictures. However, since the overall sensitivity of brush cytology is poor, the exclusion of malignancy is difficult. Recognition of factors related to the patient, technique or lesion may help improve the diagnostic yield of brush cytology. The objective of this study was to evaluate the diagnostic yield of brush cytology in the assessment of biliopancreatic strictures and identify predictive factors associated with a positive diagnosis of malignancy. METHODS: Retrospective study that evaluated all consecutive patients that underwent brush cytology for the investigation of biliopancreatic strictures in a tertiary center, between January 2012 and January 2018. RESULTS: One hundred and sixty-five patients that underwent 182 procedures were included. A diagnosis of malignancy was confirmed in 110 patients (66.7%), of whom 62 had positive brush cytology (sensitivity 53.7%, specificity 98.5%, accuracy 69.8%). On the multivariate analysis, age 68 years (OR 4.83, 95% CI 1.04-22.37) and lesions suspicious of metastasis on cross-sectional imaging (OR 8.58, 95% CI 1.70-43.38) were independently associated with a positive result. Subanalysis of the patients presenting with these two factors (n = 26) revealed an increase in the diagnostic yield (sensitivity 80.8%). CONCLUSION: Age 68 years and lesions suspicious of metastasis on cross-sectional imaging are independent factors associated with a positive result. Patient selection taking these factors into account may increase the diagnostic yield of brush cytology.</p>
<p>doi: <a href="https://doi.org/10.1159/000502791" class="uri">https://doi.org/10.1159/000502791</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells</strong> </summary></p>
<p><em>Gut 2019 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31530714" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31530714</a></p>
<p>OBJECTIVE: Liver fibrosis constitutes a major health problem worldwide due to its rapidly increasing prevalence and the lack of specific and effective treatments. Growing evidence suggests that signalling through cytokine-activated Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathways regulates liver fibrosis and regeneration. Rilpivirine (RPV) is a widely used anti-HIV drug not reported to produce hepatotoxicity. We aimed to describe the potential hepatoprotective effects of RPV in different models of chronic liver injury, focusing on JAK-STAT signalling regulation. DESIGN: The effects of RPV on hepatic steatosis, inflammation and fibrogenesis were studied in a nutritional mouse model of non-alcoholic fatty liver disease, carbon tetrachloride-induced fibrosis and bile duct ligation-induced fibrosis. Primary human hepatic stellate cells (hHSC) and human cell lines LX-2 and Hep3B were used to investigate the underlying molecular mechanisms. RESULTS: RPV exerted a clear anti-inflammatory and antifibrotic effect in all the in vivo models of liver injury employed, and enhanced STAT3-dependent proliferation in hepatocytes and apoptosis in HSC through selective STAT1 activation. These results were reproduced in vitro; RPV undermined STAT3 activation and triggered STAT1-mediated pathways and apoptosis in HSC. Interestingly, this selective pro-apoptotic effect completely disappeared when STAT1 was silenced. Conditioned medium experiments showed that HSC apoptosis activated STAT3 in hepatocytes in an interleukin-6-dependent mechanism. CONCLUSION: RPV ameliorates liver fibrosis through selective STAT1-dependent induction of apoptosis in HSC, which exert paracrinal effects in hepatocytes, thus promoting liver regeneration. RPVs actions may represent an effective strategy to treat chronic liver diseases of different aetiologies and help identify novel therapeutic targets.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2019-318372" class="uri">https://doi.org/10.1136/gutjnl-2019-318372</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Liver biopsy in primary biliary cholangitis: is sinusoidal fibrosis the missing key?</strong> </summary></p>
<p><em>Journal of clinical pathology 2019 Oct;72(10):669-676</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31371396" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31371396</a></p>
<p>AIMS: The role of liver biopsy in primary biliary cholangitis (PBC) is controversial, as is the optimal method of histological assessment. We compared the Ludwig and Ishak systems and three components of the Japanese (Nakanuma) staging system to evaluate their clinical and biochemical correlations and prognostic value. METHODS: We reviewed biopsies from 106 patients with PBC, derived from a previous trial of colchicine therapy with 24-34 years follow-up, following which five clinical outcomes were evaluated: hepatic decompensation, cholestatic PBC death/liver transplant, portal hypertensive PBC death, all PBC deaths and overall survival. RESULTS: Ludwig and Ishak stages correlated well with prognostically significant parameters, including serum bilirubin, and both Mayo and Child Scores. Serum aspartate aminotransferase correlated with interface hepatitis (IFH), and alkaline phosphatase with orcein deposition, bile duct (BD) loss and cholestasis. Ludwig correlated with all five clinical outcomes, while Ishak stage was only significantly correlated with two. While sinusoidal fibrosis, orcein deposition, BD loss and cholestasis all predicted hepatic death/transplant, after correction for Mayo Score, the only histological parameters predictive of clinical outcomes were IFH (associated with two) and sinusoidal fibrosis (associated with all five). CONCLUSION: Liver biopsy is required in the diagnosis of around 20% of patients with PBC. The Ludwig system is of more prognostic value than both Ishak and any of the three individual components of the Nakanuma staging system, but the major histological parameter providing independent prognostic value beyond the Mayo Score is sinusoidal fibrosis.</p>
<p>doi: <a href="https://doi.org/10.1136/jclinpath-2019-205958" class="uri">https://doi.org/10.1136/jclinpath-2019-205958</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Imbalance of Genes Encoding Natural Killer Immunoglobulin-Like Receptors and Human Leukocyte Antigen in Patients With Biliary Cancer</strong> </summary></p>
<p><em>Gastroenterology 2019 10;157(4):1067-1080.e9</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31229495" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31229495</a></p>
<p>BACKGROUND &amp; AIMS: Bile duct tumors are rare and have poor prognoses. Natural killer (NK) cells are frequent in human liver and infiltrate these tumors but do not control their progression. Responses of NK cells are regulated by NK immunoglobulin-like receptors (KIRs), which interact with HLA class I ligands. We aimed to characterize the features of the KIR gene loci and their ligands in patients with bile duct cancer (BDC). METHODS: We performed combined multidimensional characterization of genes that encode KIRs and their ligands in blood samples from patients with BDC from Sweden, followed for up to 8 years after diagnosis (n= 148), in 2 geographically matched cohorts of healthy individuals from Northern Europe (n= 204 and n= 900), and in healthy individuals from 6 geographically unrelated populations (n= 2917). We used real-time polymerase chain reaction, RNA sequencing, immunohistochemistry, and flow cytometry to evaluate NK-cell presence, as well as KIR and KIR-ligand expression in bile duct tumors and control tissues. RESULTS: Patients with bile duct tumors had multiple alterations at the KIR gene loci. KIR loci are grouped into genotypes that encode more inhibitory (group A) and more activating (group B) receptors, which can be subdivided into centromeric and telomeric fragments. Patients with BDC had a lower prevalence of KIR2DL3, which was linked to disequilibrium in centromeric A/B and B/B genotypes, compared with control individuals. The associations between KIRs and KIR ligands differed between patients with BDC and control individuals; patients had an altered balance between activating and inhibitory KIRs. KIR-positive NK cells infiltrated biliary tumors that expressed matched KIR ligands. CONCLUSIONS: In a multidimensional analysis of DNA from blood samples of patients with BDC in Europe, we found patients to have multiple alterations at the KIR and HLA gene loci compared with control individuals. These alterations might affect NK-cell tumor surveillance. NK cells from bile duct tumors expressed KIRs and were found in tumors that expressed cognate ligands. This should be considered in development of immune-based therapies for BDC.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.06.023" class="uri">https://doi.org/10.1053/j.gastro.2019.06.023</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Gene Expression Signatures Associated With Survival Times of Pediatric Patients With Biliary Atresia Identify Potential Therapeutic Agents</strong> </summary></p>
<p><em>Gastroenterology 2019 10;157(4):1138-1152.e14</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31228442" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31228442</a></p>
<p>BACKGROUND &amp; AIMS: Little is known about the factors that affect outcomes of patients with biliary atresia and there are no medical therapies that increase biliary drainage. METHODS: Liver biopsies and clinical data were obtained from infants with cholestasis and from children without liver disease (controls); messenger RNA (mRNA) was isolated, randomly assigned to discovery (n= 121) and validation sets (n= 50), and analyzed by RNA sequencing. Using the Superpc R package followed by Cox regression analysis, we sought to identify gene expression profiles that correlated with survival without liver transplantation at 24 months of age. We also searched for combinations of gene expression patterns, clinical factors, and laboratory results obtained at diagnosis and at 1 and 3 months after surgery that associated with transplant-free survival for 24 months of age. We induced biliary atresia in BALB/c mice by intraperitoneal administration of Rhesus rotavirus type A. Mice were given injections of the antioxidants N-acetyl-cysteine (NAC) or manganese (III) tetrakis-(4-benzoic acid)porphyrin. Blood and liver tissues were collected and analyzed by histology and immunohistochemistry. RESULTS: We identified a gene expression pattern of 14 mRNAs associated with shorter vs longer survival times in the discovery and validation sets (P &lt; .001). This gene expression signature, combined with level of bilirubin 3 months after hepatoportoenterostomy, identified children who survived for 24 months with an area under the curve value of 0.948 in the discovery set and 0.813 in the validation set (P &lt; .001). Computer models correlated a cirrhosis-associated transcriptome with decreased times of transplant-free survival; this transcriptome included activation of genes that regulate the extracellular matrix and numbers of activated stellate cells and portal fibroblasts. Many mRNAs expressed at high levels in liver tissues from patients with 2-year transplant-free survival had enriched scores for glutathione metabolism. Among mice with biliary atresia given injections of antioxidants, only NAC reduced histologic features of liver damage and serum levels of aminotransferase, gamma-glutamyl transferase, and bilirubin. NAC also reduced bile duct obstruction and liver fibrosis and increased survival times. CONCLUSIONS: In studies of liver tissues from infants with cholestasis, we identified a 14-gene expression pattern that associated with transplant-free survival for 2 years. mRNAs encoding proteins that regulate fibrosis genes were increased in liver tissues from infants who did not survive for 2 years, whereas mRNAs that encoded proteins that regulate glutathione metabolism were increased in infants who survived for 2 years. NAC reduced liver injury and fibrosis in mice with biliary atresia, and increased survival times. Agents such as NAC that promote glutathione metabolism might be developed for treatment of biliary atresia.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.06.017" class="uri">https://doi.org/10.1053/j.gastro.2019.06.017</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Programmed cell death ligand-1 (PD-L1) expression in extrahepatic biliary tract cancers: a comparative study using 22C3, SP263 and E1L3N anti-PD-L1 antibodies</strong> </summary></p>
<p><em>Histopathology 2019 Oct;75(4):526-536</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31081949" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31081949</a></p>
<p>AIMS: Pembrolizumab has shown promising results for patients with programmed cell death ligand-1 (PD-L1)-positive advanced biliary tract cancer in an ongoing clinical trial. However, data on PD-L1 expression in bile duct cancers is limited, and the frequency of PD-L1 positivity varies, which may be partly due to the assay used. The aim of this study was to evaluate PD-L1 expression status in bile duct cancers by using 22C3, SP263 and E1L3N antibodies. METHODS AND RESULTS: We evaluated PD-L1 expression in tissue microarrays of 183 extrahepatic bile duct cancers, including 89 perihilar and 94 distal bile duct cancers, by using 22C3, SP263 and E1L3N. When the 22C3 assay was used, tumoral PD-L1 was shown to be expressed in 16.9% of cases at a 1% threshold. When the SP263 and E1L3N assays were used, tumoral PD-L1 was shown to be expressed in 26% and 7.1% of cases, respectively. When whole tissue sections were examined, 59.6% of PD-L1-positive cases showed a low percentage (&lt;10%) of positive tumour cells. Tumoral PD-L1 positivity was associated with poor histological differentiation (P=0.017) and the biliary epithelial phenotype (P=0.041). High tumoral PD-L1 expression (10%) was associated with worse overall survival (OS) and disease-free survival (DFS) (OS, P=0.012; DFS, P=0.042). CONCLUSIONS: PD-L1 was expressed in a small subset of patients with bile duct cancer, and the percentage of positive tumour cells was low in PD-L1-positive cases. The SP263 assay showed the highest PD-L1 positivity in both tumour cells and immune cells, followed by the 22C3 and E1L3N assays. High PD-L1 expression was associated with a poor prognosis in extrahepatic bile duct cancer patients.</p>
<p>doi: <a href="https://doi.org/10.1111/his.13901" class="uri">https://doi.org/10.1111/his.13901</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Antipruritic effect of bezafibrate and serum autotaxin measures in patients with primary biliary cholangitis</strong> </summary></p>
<p><em>Gut 2019 10;68(10):1902-1903</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30228218" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30228218</a></p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2018-317426" class="uri">https://doi.org/10.1136/gutjnl-2018-317426</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Minimally Invasive Treatment for Severe Acute Pancreatitis With Superior Mesenteric Vein and Common Bile Duct Stenosis: A Case Report and Review of the Literature</strong> </summary></p>
<p><em>Pancreas 2019 Sep;48(8):e61-e63</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31425486" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31425486</a></p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001379" class="uri">https://doi.org/10.1097/MPA.0000000000001379</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Analysis of microRNA expression in brush cytology specimens improves the diagnosis of pancreatobiliary cancer</strong> </summary></p>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et al.] 2019 Sep;19(6):873-879</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31400934" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31400934</a></p>
<p>BACKGROUND/OBJECTIVES: Malignant pancreatobiliary strictures are in many cases clinically indistinguishable and present a major problem to endoscopy specialists. Intraductal sampling procedures such as brush cytology are commonly used for diagnosis with a sensitivity that is low for a diagnostic test used in daily clinical practice. MicroRNA (miR) alterations detected in many cancers are disease-specific, which can be utilized in clinical applications. The aim of the present study was to analyze whether determination of miR expression levels in intraductal brush cytology specimens is a feasible approach to improve the diagnosis of pancreatobiliary cancer. METHODS: Brush cytology specimens have been collected during endoscopic retrograde cholangio-pancreatography (ERCP) and analyzed by routine cytology and ancillary miR assays. Total RNA was extracted using the miRNeasy Mini Kit and the expression of miRs frequently dysregulated in pancreatobiliary cancer (miR-16, miR-21, miR-196a, miR-221) were analyzed by quantitative real-time PCR using RNU6B as internal control. RESULTS: Routine cytology resulted in no false positive diagnoses, however, the combined sensitivity remained at 53.8%. Expression (Ct values) of miR-16 (p=0.0039), miR-196a (p=0.0003) and miR-221 (p=0.0049) showed a clear statistical significance between malignant and benign pancreatobiliary specimens (n=35). Malignancy could be detected combining routine cytology and the miR-196a single marker expression levels with a sensitivity of 84.6% (92.9% in biliary strictures) with no false positives. CONCLUSIONS: The results offer the first direct demonstration that microRNAs are readily detectable in brush cytology specimens obtained during ERCP, and have the potential to help the cytological diagnosis of pancreatobiliary malignancy.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2019.04.001" class="uri">https://doi.org/10.1016/j.pan.2019.04.001</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Ursodeoxycholic acid for intrahepatic cholestasis in pregnancy</strong> </summary></p>
<p><em>Lancet (London, England) 2019 09;394(10201):810-812</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31378393" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31378393</a></p>
<p>doi: <a href="https://doi.org/10.1016/S0140-6736(19)31607-1" class="uri">https://doi.org/10.1016/S0140-6736(19)31607-1</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>A Rare Complication of a Rare Disease</strong> </summary></p>
<p><em>Gastroenterology 2019 09;157(3):616-618</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31377276" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31377276</a></p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.05.053" class="uri">https://doi.org/10.1053/j.gastro.2019.05.053</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>[Tumor-suspected focal lesion on the renal hilus]</strong> </summary></p>
<p><em>Der Pathologe 2019 Sep;40(5):546-547</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31240450" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31240450</a></p>
<p>Mucosal structures of anon-neoplastic organ can result in apitfall diagnosis of adenocarcinoma in the case of a wrong correlation with other organs, in this case caused by an adherent gallbladder to the hilar structures of the right kidney. Clinical and radiological data are absolutely crucial for a correct classification.</p>
<p>doi: <a href="https://doi.org/10.1007/s00292-019-0621-4" class="uri">https://doi.org/10.1007/s00292-019-0621-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Aryl Hydrocarbon Receptor Signaling Prevents Activation of Hepatic Stellate Cells and Liver Fibrogenesis in Mice</strong> </summary></p>
<p><em>Gastroenterology 2019 09;157(3):793-806.e14</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31170413" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31170413</a></p>
<p>BACKGROUND &amp; AIMS: The role of aryl hydrocarbon receptor (AhR) in liver fibrosis is controversial because loss and gain of AhR activity both lead to liver fibrosis. The goal of this study was to investigate how the expression of AhR by different liver cell types, hepatic stellate cells (HSCs) in particular, affects liver fibrosis in mice. METHODS: We studied the effects of AhR on primary mouse and human HSCs, measuring their activation and stimulation of fibrogenesis using RNA-sequencing analysis. C57BL/6J mice were given the AhR agonists 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or 2-(1H-indole-3-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE); were given carbon tetrachloride (CCl4); or underwent bile duct ligation. We also performed studies in mice with disruption of Ahr specifically in HSCs, hepatocytes, or Kupffer cells. Liver tissues were collected from mice and analyzed by histology, immunohistochemistry, and immunoblotting. RESULTS: AhR was expressed at high levels in quiescent HSCs, but the expression decreased with HSC activation. Activation of HSCs from AhR-knockout mice was accelerated compared with HSCs from wild-type mice. In contrast, TCDD or ITE inhibited spontaneous and transforming growth factor -induced activation of HSCs. Mice with disruption of Ahr in HSCs, but not hepatocytes or Kupffer cells, developed more severe fibrosis after administration of CCl4 or bile duct ligation. C57BL/6J mice given ITE did not develop CCl4-induced liver fibrosis, whereas mice without HSC AhR given ITE did develop CCl4-induced liver fibrosis. In studies of mouse and humanHSCs, we found that AhR prevents transforming growth factor -induced fibrogenesis by disrupting the interaction of Smad3 with -catenin, which prevents the expression of genes that mediate fibrogenesis. CONCLUSIONS: In studies of human and mouse HSCs, we found that AhR prevents HSC activation and expression of genes required for liver fibrogenesis. Development of nontoxic AhR agonists or strategies to activate AhR signaling in HSCs might be developed to prevent or treat liver fibrosis.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.05.066" class="uri">https://doi.org/10.1053/j.gastro.2019.05.066</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>The Pathologic and Genetic Characteristics of the Intestinal Subtype of Intraductal Papillary Neoplasms of the Bile Duct</strong> </summary></p>
<p><em>The American journal of surgical pathology 2019 Sep;43(9):1212-1220</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31166202" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31166202</a></p>
<p>The present study aimed to identify the pathologic and genetic characteristics of intestinal subtype of intraductal papillary neoplasm of the bile duct (iIPNB) showing columnar cells with pseudostratified, cigar-shaped nuclei, and basophilic or amphophilic cytoplasm with the diffuse immunohistochemical expression of CK20 and/or CDX2. A total of 34 cases of iIPNB were pathologically examined according to their anatomic location (the bile duct) and were then compared with the intestinal subtype of intraductal papillary mucinous neoplasm (iIPMN) of the pancreas (n=22). Mutations of 26 somatic genes were examined in formalin-fixed paraffin-embedded tissue specimens from 21 cases of iIPNB using the TruSight Tumor 26 gene panel and next-generation sequencing. iIPNB cases were divided into intrahepatic (n=6) and extrahepatic (n=28) categories. Intrahepatic IPNBs showed a less-complicated villous-papillary pattern, while extrahepatic IPNBs showed a papillary pattern with tubular and/or villous components and predominant high-grade dysplasia with complicated architectures. MUC5AC was frequently and extensively expressed in intrahepatic iIPNBs and iIPMNs but not in extrahepatic iIPNBs. CD10 was frequently expressed in extrahepatic IPNBs but not in intrahepatic iIPNBs or iIPMN. Genetic mutations of TP53 and PIK3CA, which were infrequent or absent in iIPMNs, were frequently detected in extrahepatic iIPNBs, while KRAS and GNAS, which were commonly observed in iIPMNs, were frequently detected in intrahepatic iIPNBs. Intrahepatic iIPNBs showed villous-papillary growth with features reminiscent of iIPMNs, while extrahepatic iIPNBs showed papillary growth with tubular and/or villous components, complicated histology and variable differences from iIPMNs, suggesting differences in the tumorigenesis of iIPNBs along the biliary tree.</p>
<p>doi: <a href="https://doi.org/10.1097/PAS.0000000000001295" class="uri">https://doi.org/10.1097/PAS.0000000000001295</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Robotic Left Hepatectomy and Roux-en-Y Hepaticojejunostomy After Bile Duct Injury</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Sep;26(9):2981-2984</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31147989" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31147989</a></p>
<p>BACKGROUND: Bile duct injuries after cholecystectomy remain a major concern because their incidence has not changed through the years despite technical advances. This video presents a robotic left hepatectomy and Roux-en-Y hepaticojejunostomy as a treatment for a complex bile duct injury after laparoscopic cholecystectomy. METHODS: A 52-year-old man underwent laparoscopic cholecystectomy at another institution 8years previously, which resulted in a bile duct injury. His postoperative period was complicated by jaundice and cholangitis. He was treated with endoscopic retrograde cholangiopancreatography and multiple endoprostheses for 3years, after which the endoprostheses were removed, and he was sent to the authors institution. Computed tomography showed that the left liver had signs of disturbed perfusion and dilation of the left intrahepatic bile duct. The patient was asymptomatic and refused any further attempt at surgical correction of the lesion. He was accompanied for 5years. Magnetic resonance imaging showed progressive atrophy of the left liver. Finally, 3months before this writing, he presented with intermittent episodes of cholangitis. A multidisciplinary team decided to perform left hepatectomy with Roux-en-Y hepatojejunostomy via a robotic approach. The left liver was atrophied, and left hepatectomy was performed. Fluorescence imaging was used to identify the right bile duct. At opening of the right bile duct, small stones were found and removed. Antecolic Roux-en-Y hepaticojejunostomy then was performed. RESULTS: The operative time was 335min. Recovery was uneventful, and the patient was discharged on postoperative day 4. CONCLUSIONS: Robotic repair of bile duct injuries is feasible and safe, even when liver resection is necessary. This video may help oncologic surgeons to perform this complex procedure.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07474-w" class="uri">https://doi.org/10.1245/s10434-019-07474-w</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cytomorphology of intraductal papillary neoplasm of the biliary tract</strong> </summary></p>
<p><em>Diagnostic cytopathology 2019 Sep;47(9):922-926</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31116517" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31116517</a></p>
<p>Intraductal papillary neoplasms of the bile duct (IPNBs) are papillary epithelial proliferations with delicate fibrovascular cores within dilated bile ducts. They are thought to be premalignant lesions with potential to progress invasive tumors. To our knowledge, there are no prior descriptions of IPNB cytomorphology. A 58-year-old male presented with painless jaundice and elevated liver function tests was found to have an intraluminal mass within the left hepatic duct. A bile duct brushing diagnosed as atypical cells present showed a cellular specimen composed of papillary groups and linear strips of mostly cuboidal/columnar cells with mild atypia and vacuolated cytoplasm. A left hepatic lobectomy including extrahepatic bile ducts showed the mass consisted of papillary cores lined by pancreatobiliary-type epithelium with mild-to-severe atypia, consistent with IPNB with a focus suspicious for invasion. The cytomorphologic features described in the current case suggest intraductal papillary neoplasm but may not be specific since similar features could be seen in other bile duct tumors and even in nonneoplastic conditions such as stent or cholelithiasis. However, it is worthwhile to report papillary hyperplasia with atypia in common bile duct brushings in order to avoid a false-negative diagnosis, especially in the context of a filling defect by images which does not appear to be a stone.</p>
<p>doi: <a href="https://doi.org/10.1002/dc.24212" class="uri">https://doi.org/10.1002/dc.24212</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Acute Methamphetamine-Induced Hepatic and Pancreatic Ischemia</strong> </summary></p>
<p><em>The American journal of forensic medicine and pathology 2019 Sep;40(3):285-288</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31033491" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31033491</a></p>
<p>Methamphetamine is a central nervous system stimulant that induces arousal, a positive mood, cardiac stimulation, and an acute improvement in cognitive domains. Its illicit exploitation is rapidly growing in North America. Typically, extended use of the drug induces organ damage via vasoconstriction and subsequent ischemia. This case specifically discusses hepatic and pancreatic pathology resulting from methamphetamine overdose alongside an unusual discovery of globally necrotic von Meyenburg complexes.</p>
<p>doi: <a href="https://doi.org/10.1097/PAF.0000000000000486" class="uri">https://doi.org/10.1097/PAF.0000000000000486</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>An Unusual Cause of Acute Pancreatitis in a Young Woman</strong> </summary></p>
<p><em>Gastroenterology 2019 09;157(3):619-621</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30615872" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30615872</a></p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2018.11.080" class="uri">https://doi.org/10.1053/j.gastro.2018.11.080</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Non Syndromic Paucity of Interlobular Bile Ducts in Children - A Clinicopathological Study</strong> </summary></p>
<p><em>Fetal and pediatric pathology 2019 Aug;():1-17</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31437071" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31437071</a></p>
<p>Background: Non syndromic paucity of interlobular bile ducts (NS-PILBD) constitutes a miniscule of infantile cholestasis. Method: Clinical details, investigations, surgical findings, management and outcome of cases of NS-PILBD at liver biopsy were analyzed. Specific histopathological features including bile duct to portal tract ratio were studied. Results: Eighteen cases (1993-2013) are detailed. Clinical presentation and investigations were similar to biliary atresia. Hepatic scintigraphy showed no gut excretion in 13/18 and operative cholangiogram was normal in all. Liver biopsy showed a median Scheuer fibrosis stage of 2, the mean bile duct/portal tract ratio was 0.29. The average age at last follow up of twelve cases was 54.9months . Ten were asymptomatic and anicteric, the liver function tests had normalized over 3-15months. Conclusion: Histopathology differentiated NS-PILBD from other causes of infantile cholestasis .The idiopathic form generally had a favorable long term outcome with medical management.</p>
<p>doi: <a href="https://doi.org/10.1080/15513815.2019.1652376" class="uri">https://doi.org/10.1080/15513815.2019.1652376</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Emphysematous Cholecystitis</strong> </summary></p>
<p><em>The New England journal of medicine 2019 Aug;381(8):e14</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31433924" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31433924</a></p>
<p>doi: <a href="https://doi.org/10.1056/NEJMicm1814551" class="uri">https://doi.org/10.1056/NEJMicm1814551</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Intrahepatic cholestasis: suggested future investigations</strong> </summary></p>
<p><em>Lancet (London, England) 2019 08;394(10198):e17</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31272691" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31272691</a></p>
<p>doi: <a href="https://doi.org/10.1016/S0140-6736(19)31391-1" class="uri">https://doi.org/10.1016/S0140-6736(19)31391-1</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Intrahepatic cholestasis: suggested future investigations - Authors reply</strong> </summary></p>
<p><em>Lancet (London, England) 2019 08;394(10198):e18</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31272690" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31272690</a></p>
<p>doi: <a href="https://doi.org/10.1016/S0140-6736(19)31389-3" class="uri">https://doi.org/10.1016/S0140-6736(19)31389-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Fragile X mental retardation protein protects against tumour necrosis factor-mediated cell death and liver injury</strong> </summary></p>
<p><em>Gut 2020 01;69(1):133-145</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31409605" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31409605</a></p>
<p>OBJECTIVE: The Fragile X mental retardation (FMR) syndrome is a frequently inherited intellectual disability caused by decreased or absent expression of the FMR protein (FMRP). Lack of FMRP is associated with neuronal degradation and cognitive dysfunction but its role outside the central nervous system is insufficiently studied. Here, we identify a role of FMRP in liver disease. DESIGN: Mice lacking Fmr1 gene expression were used to study the role of FMRP during tumour necrosis factor (TNF)-induced liver damage in disease model systems. Liver damage and mechanistic studies were performed using real-time PCR, Western Blot, staining of tissue sections and clinical chemistry. RESULTS: Fmr1null mice exhibited increased liver damage during virus-mediated hepatitis following infection with the lymphocytic choriomeningitis virus. Exposure to TNF resulted in severe liver damage due to increased hepatocyte cell death. Consistently, we found increased caspase-8 and caspase-3 activation following TNF stimulation. Furthermore, we demonstrate FMRP to be critically important for regulating key molecules in TNF receptor 1 (TNFR1)-dependent apoptosis and necroptosis including CYLD, c-FLIPS and JNK, which contribute to prolonged RIPK1 expression. Accordingly, the RIPK1 inhibitor Necrostatin-1s could reduce liver cell death and alleviate liver damage in Fmr1null mice following TNF exposure. Consistently, FMRP-deficient mice developed increased pathology during acute cholestasis following bile duct ligation, which coincided with increased hepatic expression of RIPK1, RIPK3 and phosphorylation of MLKL. CONCLUSIONS: We show that FMRP plays a central role in the inhibition of TNF-mediated cell death during infection and liver disease.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2019-318215" class="uri">https://doi.org/10.1136/gutjnl-2019-318215</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Decompressive laparotomy for abdominal compartment syndrome resulting from severe acute pancreatitis: a case report</strong> </summary></p>
<p><em>BMC gastroenterology 2019 Aug;19(1):141</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31395017" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31395017</a></p>
<p>BACKGROUND: Abdominal compartment syndrome (ACS) is associated with mortality in patients with critical illness such as severe acute pancreatitis, but it remains unclear whether decompressive laparotomy for ACS can improve the prognosis of patients. CASE PRESENTATION: A woman in her 60s visited our hospital because of upper abdominal pain. On the basis of her laboratory data and abdominal contrast-enhanced computed tomography findings, acute gallstone pancreatitis was diagnosed. She underwent endoscopic sphincterotomy for the removal of the common bile duct stone. Then, a drainage tube was placed in the bile duct. However, on the 5th hospital day, her intra-abdominal pressure increased to 22mmHg and renal dysfunction was observed, which led to the diagnosis of ACS. As intensive medical treatments did not improve her ACS, she underwent decompressive laparotomy on the 9th hospital day. Postoperatively, her laboratory data and intravesical pressure improved, and she was discharged from the hospital after abdominal closure, continuous drainage, and antibiotic therapy. CONCLUSION: As the effectiveness of decompressive laparotomy for ACS has not been established, this treatment indication remains controversial. Decompressive laparotomy is considered useful for the management of ACS, if it is performed at an appropriate time, as in the present case.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-019-1059-0" class="uri">https://doi.org/10.1186/s12876-019-1059-0</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Classification of the cystic duct patterns and endoscopic transpapillary cannulation of the gallbladder to prevent post-ERCP cholecystitis</strong> </summary></p>
<p><em>BMC gastroenterology 2019 Aug;19(1):139</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31382888" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31382888</a></p>
<p>BACKGROUND: Endoscopic transpapillary cannulation of the gallbladder is useful but challenging. This study aimed to investigate cystic duct anatomy patterns, which may guide cystic duct cannulation. METHODS: A total of 226 patients who underwent endoscopic transpapillary cannulation of the gallbladder were analyzed retrospectively. RESULTS: According to the cystic duct take-off, 226 cystic duct patterns were divided into 3 patterns: Type I (193, 85.4%), located on the right and angled up; Type II (7, 3.1%), located on the right and angled down; and Type III (26, 11.5%), located on the left and angled up. Type I was further divided into three subtypes: Line type, S type (S1, not surrounding the common bile duct; S2, surrounding the common bile duct), and  type (1, forward ; 2, reverse ). Types I and III cystic ducts were easier to be cannulated with a higher success rate (85.1 and 86.4%, respectively) compared with Type II cystic duct (75%) despite no statistically significant difference. The reasons for the failure of gallbladder cannulation included invisible cyst duct take-off, severe cyst duct stenosis, impacted stones in cyst duct or neck of the gallbladder, sharply angled cyst duct, and markedly dilated cyst duct with the tortuous valves of Heister. CONCLUSION: Classification of cystic duct patterns was helpful in guiding endoscopic transpapillary gallbladder cannulation.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-019-1053-6" class="uri">https://doi.org/10.1186/s12876-019-1053-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis</strong> </summary></p>
<p><em>Gut 2019 08;68(8):1356-1378</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31154395" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31154395</a></p>
<p>These guidelines on the management of primary sclerosing cholangitis (PSC) were commissioned by the British Society of Gastroenterology liver section. The guideline writing committee included medical representatives from hepatology and gastroenterology groups as well as patient representatives from PSC Support. The guidelines aim to support general physicians, gastroenterologists and surgeons in managing adults with PSC or those presenting with similar cholangiopathies which may mimic PSC, such as IgG4 sclerosing cholangitis. It also acts as a reference for patients with PSC to help them understand their own management. Quality of evidence is presented using the AGREE II format. Guidance is meant to be used as a reference rather than for rigid protocol-based care as we understand that management of patients often requires individual patient-centred considerations.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2018-317993" class="uri">https://doi.org/10.1136/gutjnl-2018-317993</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study</strong> </summary></p>
<p><em>The lancet. Gastroenterology &amp; hepatology 2019 Aug;4(8):611-621</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31109808" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31109808</a></p>
<p>BACKGROUND: This study aimed to assess the safety and tolerability of the immune checkpoint inhibitor nivolumab, as monotherapy or combined with chemotherapy, in Japanese patients with biliary tract cancer. METHODS: This multicentre, open-label, phase 1 trial was done at four cancer centres in Japan. Eligible patients were aged 20-79 years, had biliary tract adenocarcinoma (intrahepatic bile duct cancer, extrahepatic bile duct cancer, gallbladder cancer, or ampullary cancer), Eastern Cooperative Oncology Group performance status 0 or 1, adequate hepatic, renal, and haematological function, and tumour tissue samples for PD-L1 expression analysis. Patients with unresectable or recurrent biliary tract cancer that was refractory or intolerant to gemcitabine-based treatment regimens received nivolumab monotherapy (240 mg every 2 weeks [monotherapy cohort]). Chemotherapy-naive patients with unresectable or recurrent biliary tract cancer received nivolumab (240 mg every 2 weeks) and cisplatin (25 mg/m2) plus gemcitabine (1000 mg/m2) chemotherapy (combined therapy cohort). The primary objective was to assess tolerability and safety. The primary objective was assessed in the safety population of all patients who had received at least one dose of nivolumab. This study is registered with www.clinicaltrials.jp, number JapicCTI-153098, and follow-up is ongoing. FINDINGS: 30 patients were enrolled into each cohort between Jan 13, 2016, and April 19, 2017. Data cutoff was Aug 31, 2017. In the monotherapy cohort, the most frequently reported treatment-related adverse events were decreased appetite (five [17%]), malaise (four [13%]), and pruritus (four [13%]). Grade 3-4 treatment-related adverse events were reported by three (10%) patients (rash, maculopapular rash, and amylase increase) and treatment-related serious adverse events were reported by one (3%) patient (pleurisy). In the combined therapy cohort, the most frequently reported treatment-related adverse events were neutrophil count decrease (any grade 25 [83%]; grade 3-4 in 23 [77%] patients) and platelet count decrease (any grade 25 [83%] of 30; grade 3-4 in 15 [50%] patients). Six (20%) patients reported 11 treatment-related serious adverse events (platelet count decrease [three patients], febrile neutropenia [two patients], neutrophil count decrease, anaemia, anaphylactic reaction, decreased appetite, pyrexia, and myocarditis [one patient each]). In the monotherapy cohort, median overall survival was 52 months (90% CI 45-87), median progression-free survival was 14 months (90% CI 14-14), and one of 30 patients had an objective response. In the combined therapy cohort, median overall survival was 154 months (90% CI 118-not estimable), median progression-free survival was 42 months (90% CI 28-56), and 11 of 30 patients had an objective response. INTERPRETATION: Nivolumab had a manageable safety profile and signs of clinical activity in patients with unresectable or recurrent biliary tract cancer. This initial assessment of nivolumab for the treatment of advanced biliary tract cancer provides supportive evidence for future larger randomised studies of nivolumab in this difficult to treat cancer. FUNDING: Ono Pharmaceutical Co Ltd and Bristol-Myers Squibb Inc.</p>
<p>doi: <a href="https://doi.org/10.1016/S2468-1253(19)30086-X" class="uri">https://doi.org/10.1016/S2468-1253(19)30086-X</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Evaluation of histologic changes in the livers of patients with early and late hepatic artery thrombosis</strong> </summary></p>
<p><em>Human pathology 2019 Aug;90():8-13</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31075300" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31075300</a></p>
<p>Hepatic artery thrombosis (HAT) following orthotopic liver transplantation (OLT) can cause hepatic parenchymal necrosis and ischemic cholangiopathy. This study investigates additional histologic features that may suggest HAT in post-OLT liver specimens. For 94 liver specimens (explanted allografts and biopsies) from patients with a clinical or pathologic diagnosis of HAT, we recorded length of time between OLT and procedure, categorizing cases into early HAT (;30days since OLT) and late HAT (&gt;30days since OLT). Common histologic findings in HAT included lobular necrosis (60 cases, 64%), portal inflammation (68 cases, 72%), ductular reaction (73 cases, 78%), lobular cholestasis (70 cases, 74%), and bile-tinged macrophages (40 cases, 43%). Ductular cholestasis was seen in 30 cases (32%); 10 of those patients were clinically septic. Bile in veins was seen in 16 (17%) cases and arteritis in 6 (6%) cases. Findings more common in resection than biopsy specimens included lobular necrosis (P&lt;.0001), hemorrhage (P=.0044), ductular cholestasis (P=.0003), and bile-tinged macrophages (P&lt;.0001). Lobular necrosis was more common in early HAT (P=.0002), and ductular reaction (P=.006) and bile in veins (P=.03) were more common in late HAT. Histologic changes in HAT vary based on specimen type and whether HAT is early or late. In late HAT, biliary injury might occur after a prolonged period of ischemia, with subsequent bile duct necrosis, bile in veins, and remodeling (eg, ductular reaction). Bile in veins is an unusual finding that may occur in HAT, although it can be seen in bile infarcts from other causes.</p>
<p>doi: <a href="https://doi.org/10.1016/j.humpath.2019.04.019" class="uri">https://doi.org/10.1016/j.humpath.2019.04.019</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Intraoperative Air Leak Test to Prevent Bile Leak After Right Posterior Sectionectomy with En Bloc Diaphragm Resection for Metastatic Teratoma</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Aug;26(8):2579</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31065963" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31065963</a></p>
<p>BACKGROUND: The intraoperative air cholangiogram, or air leak test (ALT), at the time of hepatectomy can significantly reduce the rates of bile leak and symptomatic fluid collection after high-risk procedures.1,2 Because a bile leak in the setting of an en bloc diaphragm resection and mesh reconstruction would be a particularly dreaded complication, this video shows the technique for resection, reconstruction, and ALT. PRESENTATION: The video presents the case of a 29-year-old woman who had metastatic teratoma with an 87-cm liver metastasis in segment 7 and diaphragm invasion to the level of the right hepatic vein. OPERATION: The authors performed a formal right posterior sectionectomy with en bloc diaphragm resection. The 128-cm diaphragmatic defect was reconstructed using biologic mesh (Surgimend, Integra LifeSciences, Plainsboro, NJ). An intraoperative ALT (air injection into the cystic duct with finger compression of the distal bile duct) identified several areas of bubbles from biliary radicles on the cut surface of the liver, which were ligated with 4-0 polypropylene. The ALT was repeated until no bubbles remained. Because no evidence of bubbles was observed, no surgical drain was needed. The patient did well postoperatively with no complications. CONCLUSION: In cases of combined liver and diaphragmatic resection, prevention of bile leak, with subsequent contamination of the diaphragm repair and even the thoracic cavity, is particularly vital. An easily replicated intraoperative air leak test can mitigate the risk of bile leak and organ-space infection, as well as associated sequelae on quality of life, return to intended oncologic therapy, and oncologic outcomes.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07410-y" class="uri">https://doi.org/10.1245/s10434-019-07410-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Microbiota as a cornerstone in the development of primary sclerosing cholangitis: paving the path for translational diagnostic and therapeutic approaches</strong> </summary></p>
<p><em>Gut 2019 08;68(8):1353-1355</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31028154" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31028154</a></p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2019-318487" class="uri">https://doi.org/10.1136/gutjnl-2019-318487</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Spontaneous Pneumobilia and Hematemesis</strong> </summary></p>
<p><em>Gastroenterology 2019 08;157(2):e8-e9</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30959037" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30959037</a></p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.03.053" class="uri">https://doi.org/10.1053/j.gastro.2019.03.053</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Liver Masses</strong> </summary></p>
<p><em>Gastroenterology 2019 08;157(2):e3-e4</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30959031" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30959031</a></p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.03.057" class="uri">https://doi.org/10.1053/j.gastro.2019.03.057</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis</strong> </summary></p>
<p><em>Gut 2019 08;68(8):1477-1492</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30872395" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30872395</a></p>
<p>OBJECTIVE: There is a striking association between human cholestatic liver disease (CLD) and inflammatory bowel disease. However, the functional implications for intestinal microbiota and inflammasome-mediated innate immune response in CLD remain elusive. Here we investigated the functional role of gut-liver crosstalk for CLD in the murine Mdr2 knockout (Mdr2-/-) model resembling human primary sclerosing cholangitis (PSC). DESIGN: Male Mdr2-/-, Mdr2-/- crossed with hepatocyte-specific deletion of caspase-8 (Mdr2-/- /Casp8hepa) and wild-type (WT) control mice were housed for 8 or 52weeks, respectively, to characterise the impact of Mdr2 deletion on liver and gut including bile acid and microbiota profiling. To block caspase activation, a pan-caspase inhibitor (IDN-7314) was administered. Finally, the functional role of Mdr2-/- -associated intestinal dysbiosis was studied by microbiota transfer experiments. RESULTS: Mdr2-/- mice displayed an unfavourable intestinal microbiota signature and pronounced NLRP3 inflammasome activation within the gut-liver axis. Intestinal dysbiosis in Mdr2-/- mice prompted intestinal barrier dysfunction and increased bacterial translocation amplifying the hepatic NLRP3-mediated innate immune response. Transfer of Mdr2-/- microbiota into healthy WT control mice induced significant liver injury in recipient mice, highlighting the causal role of intestinal dysbiosis for disease progression. Strikingly, IDN-7314 dampened inflammasome activation, ameliorated liver injury, reversed serum bile acid profile and cholestasis-associated microbiota signature. CONCLUSIONS: MDR2-associated cholestasis triggers intestinal dysbiosis. In turn, translocation of endotoxin into the portal vein and subsequent NLRP3 inflammasome activation contribute to higher liver injury. This process does not essentially depend on caspase-8 in hepatocytes, but can be blocked by IDN-7314.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2018-316670" class="uri">https://doi.org/10.1136/gutjnl-2018-316670</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Statin use and reduced risk of biliary tract cancers in the UK Clinical Practice Research Datalink</strong> </summary></p>
<p><em>Gut 2019 08;68(8):1458-1464</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30448774" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30448774</a></p>
<p>OBJECTIVE: To evaluate the association between statin use and risk of biliary tract cancers (BTC). DESIGN: This is a nested case-control study conducted in the UK Clinical Practice Research Datalink. We included cases diagnosed with incident primary BTCs, including cancers of the gall bladder, bile duct (ie, both intrahepatic and extrahepatic cholangiocarcinoma), ampulla of Vater and mixed type, between 1990 and 2017. For each case, we selected five controls who did not develop BTCs at the time of case diagnosis, matched by sex, year of birth, calendar time and years of enrolment in the general practice using incidence density sampling. Exposures were defined as two or more prescription records of statins 1year prior to BTC diagnosis or control selection. ORs and 95% CIs for associations between statins and BTC overall and by subtypes were estimated using conditional logistic regression, adjusted for relevant confounders. RESULTS: We included 3118 BTC cases and 15519 cancer-free controls. Current statin use versus non-use was associated with a reduced risk of all BTCs combined (adjusted OR=0.88, 95%CI 0.79 to 0.98). The reduced risks were most pronounced among long-term users, as indicated by increasing number of prescriptions (ptrend=0.016) and cumulative dose of statins (ptrend=0.008). The magnitude of association was similar for statin use and risk of individual types of BTCs. The reduced risk of BTCs associated with a record of current statin use versus non-use was more pronounced among persons with diabetes (adjusted OR=0.72, 95%CI 0.57 to 0.91). Among non-diabetics, the adjusted OR for current statin use versus non-use was 0.91 (95% CI 0.81 to 1.03, pheterogeneity=0.007). CONCLUSION: Compared with non-use of statins, current statin use is associated with 12% lower risk of BTCs; no association found with former statin use. If replicated, particularly in countries with a high incidence of BTCs, our findings could pave the way for evaluating the value of statins for BTC chemoprevention.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2018-317504" class="uri">https://doi.org/10.1136/gutjnl-2018-317504</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Oral vancomycin induces clinical and mucosal remission of colitis in children with primary sclerosing cholangitis-ulcerative colitis</strong> </summary></p>
<p><em>Gut 2019 08;68(8):1533-1535</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30131321" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=30131321</a></p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2018-316599" class="uri">https://doi.org/10.1136/gutjnl-2018-316599</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Clinical value of DPOC for detecting and removing residual common bile duct stones (video)</strong> </summary></p>
<p><em>BMC gastroenterology 2019 Jul;19(1):135</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31349795" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31349795</a></p>
<p>BACKGROUND: This study aims to evaluate the efficacy and safety of detecting and removing residual common bile duct stones (CBDS) using direct peroralcholangioscopy (DPOC) after performing endoscopic retrograde cholangiopancreatography (ERCP) for stone retrieval. METHODS: From January 5, 2017 to December 27, 2017, a total of 164 cases of choledocholithiasis were treated by ERCP for stone retrieval. According to the inclusion and exclusion criteria, the remaining 79 cases (39 males; mean age: 63.3years old, range: 52-79years old) were enrolled in the present study. The maximum transverse stone diameter was 6-15mm (12.74.2mm), as determined by ERCP. Furthermore, there were 57 cases of multiple stones (number of stones: two in 41 cases, three in nine cases, and4 in seven cases), 13 cases of post-mechanical lithotripsy, and nine cases of broken stones. RESULTS: The overall success rate of DPOC was 94.9% (75/79). Furthermore, 18.7%(14/75) of cases were directly inserted, 72%(54/75) of cases required guide wire assistance, and 9.3%(7/75) of cases were successfully inserted with overtube assistance. The average insertion time was 7-17min (4.92.9min). Residual stones were detected in 19 cases (25.3%), and all of which were&lt;5mm in diameter. Moreover, five cases of formed stones were removed by basket and balloon catheter, while the remaining cases were cleaned after irrigation and suction. There were no serious complications. CONCLUSION: DPOC is safe and effective for both the detection and removal of residual CBDS after conventional ERCP.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-019-1045-6" class="uri">https://doi.org/10.1186/s12876-019-1045-6</a></p>
</details>
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<hr />
<p><a href="#top" target="_self">Back to top</a></p>
<hr />
<div style="page-break-after: always;"></div>
</div>
<div id="ampulla" class="section level2">
<h2>Ampulla</h2>
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Novel concepts in the pathophysiology and treatment of functional dyspepsia</strong> </summary></p>
<p><em>Gut 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31784469" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31784469</a></p>
<p>Emerging data increasingly point towards the duodenum as a key region underlying the pathophysiology of functional dyspepsia (FD), one of the most prevalent functional GI disorders. The duodenum plays a major role in the control and coordination of gastroduodenal function. Impaired duodenal mucosal integrity and low-grade inflammation have been associated with altered neuronal signalling and systemic immune activation, and these alterations may ultimately lead to dyspeptic symptoms. Likely luminal candidates inducing the duodenal barrier defect include acid, bile, the microbiota and food antigens although no causal association with symptoms has been convincingly demonstrated. Recognition of duodenal pathology in FD will hopefully lead to the discovery of new biomarkers and therapeutic targets, allowing biologically targeted rather than symptom-based therapy. In this review, we summarise the recent advances in the diagnosis and treatment of FD with a focus on the duodenum.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2019-318536" class="uri">https://doi.org/10.1136/gutjnl-2019-318536</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Comparison of two techniques for a comprehensive gut histopathological analysis: Swiss Roll versus Intestine Strips</strong> </summary></p>
<p><em>Experimental and molecular pathology 2019 Dec;111():104302</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31465765" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31465765</a></p>
<p>Assessing the gut mucosa milieu is important to grade the inflammatory process in conditions such as food hypersensitivity, allergy, gut parasitosis, etc. However, the gastrointestinal tract comprises a challenging system to evaluate, due to its thin tubular structure and mucosa, which suffer fast autolysis after death. Irrespective of the preferred inflammatory score system, it is important to choose the technique that will render the best tissue analysis. Thus, our aim was to compare two of the most frequently used methods to collect, process and analyze gut segments, the Swiss Roll and the Intestinal Strips. Normal C57Bl/6 mice were randomly assigned to Rolls or Strips group. After an overdose of anesthetics, segments of the duodenum, jejunum and ileum were collected and prepared accordingly for histological processing and analysis. Our results show the villi in the Rolls tend to be shorter and wider than those in the Strips in the duodenum and jejunum but not the ileum. No significant differences were observed in intra-epithelial lymphocytes and goblet cells counts. Finally, we staged each segment using our histomorphometric classification system, which revealed that although all animals presented a normal intestinal mucosa, those assigned to the Rolls group had their mucosa staged in the Infiltrative Stage while the Strips group had their mucosa staged as Normal. In conclusion, Swiss Rolls might be desirable for a wider assessment of the intestine, as it allows large segments to be analyzed at once, while Strips are better suited when detailed evaluation of each villus is intended.</p>
<p>doi: <a href="https://doi.org/10.1016/j.yexmp.2019.104302" class="uri">https://doi.org/10.1016/j.yexmp.2019.104302</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Cystic biliary atresia or atretic choledochal cyst: A continuum in infantile obstructive cholangiopathy</strong> </summary></p>
<p><em>Fetal and pediatric pathology 2019 Dec;38(6):477-483</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31204550" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31204550</a></p>
<p>Introduction: Both cystic biliary atresia and choledochal cyst present as infantile obstructive cholangiopathy. Methods: We detail an infant with congenital biliary dilatation and obstructive cholangiopathy where clinicoradiological features (antenatally imaged subhepatic cyst, early onset jaundice, intrahepatic dilated biliary radicals) suggested a choledochal cyst but operative findings (lack of a distal communication of cyst with duodenum) and histomorphological features (cicatricial collagen and myofibroblastic hyperplasia in the cyst wall; ductal plate malformation, ductular cholestasis and strong expression of CD56 in the liver) were those associated with biliary atresia. Conclusion: The observations support the contention that BA and CC may be interim entities in a continuum of manifestation of the same pathology.</p>
<p>doi: <a href="https://doi.org/10.1080/15513815.2019.1627621" class="uri">https://doi.org/10.1080/15513815.2019.1627621</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>ASO Author Reflections: The Accurate Prognostic Evaluation and Optimal Treatment Strategy for Ampulla of Vater Carcinoma</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Dec;26(Suppl 3):621-622</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31115854" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31115854</a></p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07465-x" class="uri">https://doi.org/10.1245/s10434-019-07465-x</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Case 36-2019: A 34-Year-Old Man with Dyspnea, Odynophagia, and Abdominal Pain</strong> </summary></p>
<p><em>The New England journal of medicine 2019 11;381(21):2052-2061</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31747731" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31747731</a></p>
<p>doi: <a href="https://doi.org/10.1056/NEJMcpc1909625" class="uri">https://doi.org/10.1056/NEJMcpc1909625</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Blood in the Duodenum</strong> </summary></p>
<p><em>Gastroenterology 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31743737" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31743737</a></p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2019.10.049" class="uri">https://doi.org/10.1053/j.gastro.2019.10.049</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Main Pancreatic Duct to Parenchymal Thickness Ratio at Preoperative Imaging is Associated with Overall Survival in Upfront Resected Pancreatic Cancer</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31722071" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31722071</a></p>
<p>BACKGROUND: Pancreatic cancer induces parenchymal atrophy and duct dilation. The aim of this study was to evaluate whether these radiologic modifications are associated with outcomes. METHODS: Upfront pancreaticoduodenectomy patients with available preoperative contrast enhanced CT scan imaging were retrospectively analyzed. Thickness of the pancreas, size of the main pancreatic duct (MPD), and distance of the tumor from the ampulla were assessed. A training cohort was selected, including short- (3-12months following surgery) and long-term (36months) survivors. Identified survival determinants were validated in the overall cohort. RESULTS: Two-hundred-sixteen patients were analyzed. In the training cohort (N=118), 68 patients (57.6%) were in the short-term and 50 (42.4%) in the long-term survival group. The short-term survival group had significantly higher CA 19-9 levels (p=0.027), larger tumors (32.612.1mm vs.26.511.6mm, p=0.007), poorer differentiation (p=0.003), higher rate of R&lt;1mm resections (54% vs.32%, p=0.008), and reduced receipt of adjuvant chemotherapy (p=0.020). The MPD-to-pancreatic thickness ratio was significantly lower in the short-term survivors (3.66.2 vs.8.212.0, p=0.016). In the entire cohort, an MPD-to-pancreatic thickness ratio 3.5 was associated with improved OS [median 33.0months IQR (19.7-48.1) versus 17months IQR (14.8-19.2), p=0.004], and confirmed by a Cox-proportional hazards model independently associated with OS (HR=0.58; p=0.009), together with tumor size (HR=1.02; p=0.012), R1/R2 status (HR=1.53; p=0.029), and receipt of adjuvant treatment (HR=0.61; p=0.021). CONCLUSIONS: High MPD-to-pancreatic thickness ratio was associated with improved long-term survival in pancreaticoduodenectomy for cancer. Whether these features are related to tumor chronicity, indolent biology, or local growth over metastasis remains to be determined.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-08040-0" class="uri">https://doi.org/10.1245/s10434-019-08040-0</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Fine needle aspiration cytology of primary and metastatic Gastrointestinal stromal tumour</strong> </summary></p>
<p><em>Cytopathology : official journal of the British Society for Clinical Cytology 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31698512" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31698512</a></p>
<p>AIM: To explore the cytological spectrum of the gastrointestinal stromal tumour (GIST) including its metastatic sites. MATERIAL AND METHODS: A Total of 42 patients (45 sites) diagnosed withGIST or its metastases on fine-needle aspiration cytology (FNAC) were studied over a period of 5 years. May Grunwald Giemsa (MGG) and Hematoxylin and Eosin stained smears were reviewed and analyzed for the cytomorphological spectrum ofGIST. RESULTS: Primary GIST alone was seen in 24 cases, E-GIST in 8 cases, metastasis in 11 cases (one patient showing metastasis at 2 distinct sites) whereas concurrent primary and metastatic lesions were noted in 2 cases. Amongst primary sites, the most commonly affected location was stomach (n-22), followed by ileum (n-2), duodenum (n-1) and rectum (n-1). EGIST was seen in retroperitoneum and pelvis (n-3 each), omentum and mediastinum (n-1 each). FNAC was done from 11 metastatic sites of GIST which included liver, gall bladder fossa, chest wall and thigh. The classic spindle cell arrangement was the predominant cytological pattern. About 8.8 % cases showed predominant epithelioid cell morphology and 15.5% cases had a mixed cytomorphology comprising of both spindle cell and epithelioid cell patterns. Nuclear pseudoinclusions, perinuclear vacuoles and multinucleation were seen in four cases. Immunocytochemistry on cell block sections for confirmation was performed in 18 cases and all these cases showed strong c-kit positivity. CONCLUSION: In this largest case series of cytomorphological diagnosis of GIST, we describe the cytomorphology and immunocytochemistry of primary and metastatic GIST. GISTs with predominant epithelioid cell morphology may pose a diagnostic dilemma therefore in all suspected cases of GIST, immunocytochemistry for c-Kit and/or DOG1 should be employed on cell block preparations to confirm the diagnosis of GIST.</p>
<p>doi: <a href="https://doi.org/10.1111/cyt.12785" class="uri">https://doi.org/10.1111/cyt.12785</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Robotic Treatment for Large Duodenal Gastrointestinal Stromal Tumor</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31696397" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31696397</a></p>
<p>BACKGROUND: Duodenal gastrointestinal stromal tumors (D-GISTs) represent a rare entity.1 Surgery is the primary treatment choice for localized or potentially resectable D-GISTs. The main principle is the complete excision of the lesion with microscopically negative margins, without performing lymph node dissection.2 Nevertheless, the best surgical choice is still controversial since the strategy depends not only on the tumor size but also on its anatomic location.3,4 As a result, surgical management ranges from a major resection such as pancreaticoduodenectomy to more conservative procedures.5-8 This video presents a duodenal sparing robotic resection of a large GIST of the second-third duodenal portion. METHODS: A 49-year-old healthy female complained episodes of melena. Endoscopy with endoscopic ultrasound identified a 6-cm lesion of the second-third portion of the duodenum with recent bleeding, arising from muscolaris propria. A computed tomography scan confirmed a large mass suspected to be a GIST without metastases or involvement of the ampulla of Vater. On the basis of these findings, after a multidisciplinary consultation, she was offered robotic surgery with a radical intent. RESULTS: A duodenal-sparing da VinciSi resection with robot-sewn primary duodenal closure was performed. After an uneventful postoperative course, the patient was discharged on post-operative day 7. Final pathology revealed a high-grade risk D-GIST with free margins: adjuvant Imatinib was recommended.9 At 4years follow-up, no recurrence has been detected. CONCLUSIONS: A robotic approach might be considered in cases of large D-GISTs amenable to a conservative R0 surgery. This system provides several technical advantages that facilitate otherwise complex resection and reconstruction.10.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-08041-z" class="uri">https://doi.org/10.1245/s10434-019-08041-z</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Robotic Extended Right Hemicolectomy with Complete Mesocolic Excision and D3 Lymph Node Dissection</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Nov;26(12):3990-3991</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31407176" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31407176</a></p>
<p>BACKGROUND: Recent studies have shown the benefits of complete mesocolic excision and extended lymphadenectomy (D3 lymph node dissection) in patients with colon cancer.1-3 METHODS: We present the case of a 62-year-old male with hepatic flexure adenocarcinoma. No metastatic disease was identified by computed tomography. A robot-assisted extended right hemicolectomy with complete mesocolic excision, D3 lymph node dissection, and resection of the mesentery with intact visceral peritoneum was performed. RESULTS: The trocars are placed in the right lower (8mm), lower midline (8mm), and left upper (12mm) quadrants. The camera port is placed superior to the umbilicus, and the assistant port is placed in the left lower quadrant. The robotic right lower port is used to place the cecum on tension in order to outline the ileocolic pedicle. The assistant retracts the transverse colon cephalad to outline the superior mesenteric artery and vein. Using two robotic arms, the surgeon begins dissection over the superior mesenteric vein inferior to the ileocolic pedicle. Cephalad dissection along the superior mesenteric vein proceeds with reflection of the mesentery and D3 lymph nodes laterally to allow en bloc resection. The ileocolic and middle colic vessels are identified, ligated and divided at their origins. The plane is then developed between the right colon mesentery and the retroperitoneum, including Gerotas fascia, duodenum, and head of the pancreas, in a medial-to-lateral fashion, with care taken to ensure an intact visceral peritoneum is maintained. The proximal transverse colon, hepatic flexure, and ascending colon are mobilized by taking down lateral attachments. The intervening mesentery is transected, and perfusion is assessed with indocyanine green fluorescence imaging. An intracorporeal, isoperistaltic, side-to-side anastomosis is performed using the 45-mm robotic stapler. The common enterotomy is sewn closed in two layers. Pathology showed T3N0 adenocarcinoma with all negative margins. CONCLUSION: Extended right hemicolectomy with complete mesocolic excision and D3 lymph node dissection is facilitated by a robotic approach, which improves visualization and instrument dexterity.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07692-2" class="uri">https://doi.org/10.1245/s10434-019-07692-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Clinical and Histopathologic Predictors of Disaccharidase Deficiency in Duodenal Biopsy Specimens</strong> </summary></p>
<p><em>American journal of clinical pathology 2019 Nov;152(6):742-746</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31332425" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31332425</a></p>
<p>OBJECTIVES: Disaccharidase (DS) activity in duodenal biopsy specimens is the gold standard for diagnosing DS deficiency. We investigated strategies to reduce the need for DS testing and whether clinical or histopathologic factors predict DS deficiency. METHODS: A retrospective chart review analyzed 1,678 DS results in children, biopsy indication(s), and duodenal histopathology. RESULTS: One or more DSs were abnormal in 42.8%. Sufficient lactase predicted sucrase, palatinase, and maltase sufficiency (negative predictive value 97.7%). Three patients had sucrase-isomaltase deficiency (0.2%). DS deficiency was more common in biopsy specimens for positive celiac serology (78.0%). Villous blunting, intraepithelial lymphocytosis, and active inflammation predicted DS deficiency; a combination of any two had an 81.4% positive predictive value. CONCLUSIONS: Utilization could be reduced by only testing cases with normal duodenal histopathology and ongoing clinical suspicion for DS deficiency after reviewing pathology. In cases with suspected celiac disease and/or mucosal injury, DS deficiency is common and likely secondary, limiting test utility.</p>
<p>doi: <a href="https://doi.org/10.1093/ajcp/aqz091" class="uri">https://doi.org/10.1093/ajcp/aqz091</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Mutational profiling and immunohistochemical analysis of a surgical series of ampullary carcinomas</strong> </summary></p>
<p><em>Journal of clinical pathology 2019 Nov;72(11):762-770</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31256008" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31256008</a></p>
<p>AIMS: Knowledge regarding the genetic features of ampullary carcinoma (AC) in European patients is limited. The utility of tumour markers for the establishment of a malignant diagnosis in biopsies from the ampullary region has not been fully elucidated. We aimed to describe the clinical, pathological, immunohistochemical (IHC) and genetic features of a Danish series of surgically resected ACs. METHODS: Surgically resected ACs (n=59) were examined regarding (1) clinicopathological features, (2) histological subtypes, (3) expression of IMP3, maspin, MUC5AC and S100P and (4) next-generation sequencing using a hybrid capture-based platform (Illumina HiSeq2500), including 315 cancer-related genes plus introns from 28 genes often rearranged or altered in cancer. Tumour mutational burden (TMB) and microsatellite instability (MSI) were also evaluated. RESULTS: Pancreatobiliary adenocarcinomas (PB-AC), intestinal adenocarcinomas (INT-AC), other ampullary tumours and mixed adenocarcinomas represented 45.8%, 23.7%, 16.9% and 13.6%. The proportion of IHC-positive ACs (score 2) was: Maspin (94.9%), IMP3 (67.8%), S100P (39.0%) and MUC5AC (18.6%). Most frequently altered genes were TP53 (59.3%), KRAS (40.7%), APC (27.8%), SMAD4 (20.4%), CDKN2A (16.7%) and ARID2/PIK3CA (each 11.1%). MUC5AC and S100P were frequently expressed in PB-AC, APC alterations frequent in INT-AC, SOX9 alterations were exclusive in INT-AC and MDM2 and FRS2 alterations in PB-AC. Four of 49 ACs (8.2%) were TMB-high/MSI-high and showed loss of MLH1 and PMS2. CONCLUSIONS: PB-AC was the most frequent histological subtype of AC. Maspin and IMP3 were the IHC tumour markers with the highest sensitivity. Adenocarcinoma subtypes differed regarding several genetic alterations, whose predictive value remains to be evaluated.</p>
<p>doi: <a href="https://doi.org/10.1136/jclinpath-2019-205912" class="uri">https://doi.org/10.1136/jclinpath-2019-205912</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Poorly Cohesive (Signet Ring Cell) Carcinoma of the Ampulla of Vater</strong> </summary></p>
<p><em>International journal of surgical pathology 2019 Oct;():1066896919880968</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31612756" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31612756</a></p>
<p>In the ampulla of Vater, carcinomas with diffuse-infiltrative/signet ring cell morphology, designated as poorly cohesive carcinoma (PCC) in the WHO classification, are very rare and poorly characterized. Nine cases with a classical PCC morphology constituting &gt;50% of the tumor were identified. Mean age was 64.8 years (vs 64.6 in ampullary carcinomas [ACs]) and 6 were males, 3 females. The mean invasive tumor size was 2.5 cm (vs 1.9 in ACs). Other morphologic patterns displayed included cord-like infiltration (n=2), plasmacytoid cells (n=2), and microglandular component (n=4), including goblet cell adenocarcinoma-like foci. None of the cases were associated with dysplasia. By immunohistochemistry, the carcinomas did not show intestinal differentiation (CDX2 0/9, CK20 1/9, MUC2 3/9), MUC1 was positive in 4/9, MUC5AC was positive in 7/8. E-cadherin loss was noted in 4/9. All cases were advanced stage (6/9-pT3, 3/9-pT4) (vs 43% in ACs). Lymph node metastases were identified in 44% (vs 45% in AC). Six patients (67%) died of disease at a median of 25 months, 3 were alive at 13, 15, and 60 months. Overall median survival was significantly worse than that of intestinal-type ACs (26 vs 122 months, P = .006) and trended toward worse than pancreatobiliary type (26 vs 42 months, P = .1). In conclusion, PCCs constitute 2.45% of all ACs. These present as advanced tumors and express upper-gastrointestinal immunoprofile with frequent MUC5AC labeling, which may be helpful in identifying subtle infiltration in the surface mucosa since MUC5AC is not expressed in the ampullary mucosa. Patients have poor prognosis.</p>
<p>doi: <a href="https://doi.org/10.1177/1066896919880968" class="uri">https://doi.org/10.1177/1066896919880968</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Size and Importance of Socioeconomic Status-Based Disparities in Use of Surgery in Nonadvanced Stage Gastrointestinal Cancers</strong> </summary></p>
<p><em>Annals of surgical oncology 2019 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31605347" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31605347</a></p>
<p>BACKGROUND: The size and importance of socioeconomic status (SES)-based disparities in use of surgery for non-advanced stage gastrointestinal (GI) cancers have not been quantified. METHODS: The exposure in this study of patients age 18-80 with one of nine non-advanced stage GI cancers in the 2007-2015 SEER database was a census tract-level SES composite. Multivariable models assessed associations of SES with use of surgery. Causal mediation analysis was used to estimate the proportion of survival disparities in SES quintiles 1 versus 5 that were mediated by disparities in use of surgery. RESULTS: Lowest SES quintile patients underwent surgery at significantly lower rates than highest quintile patients in each cancer. SES-based disparities in use of surgery were large and graded in esophagus adenocarcinoma, intrahepatic and extrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma. Smaller but clinically relevant disparities were present in stomach, ampulla, and small bowel adenocarcinoma, whereas disparities were small in colorectal adenocarcinoma. Five-year all-stage overall survival (OS) was correlated with the size of disparities in use of surgery in SES quintiles 1 versus 5 (r=-0.87; p=0.003). Mean OS was significantly longer (range 3.5-8.9months) in SES quintile 5 versus 1. Approximately one third of SES-based survival disparities in poor prognosis GI cancers were mediated by disparities in use of surgery. The size of disparities in use of surgery in SES quintiles 1 versus 5 was correlated with the proportion mediated (r=0.98; p&lt;0.001). CONCLUSIONS: Low SES patients with poor prognosis GI cancers are at substantial risk of undertreatment. Disparities in use of surgery contribute to diminished survival.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-019-07922-7" class="uri">https://doi.org/10.1245/s10434-019-07922-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<p><summary> - <strong>Response to Comment on Letter to the Editor Minimally Invasive Versus Open Distal Pancreatectomy (LEOPARD)</strong> </summary></p>
<p><em>Annals of surgery 2019 Dec;270(6):e136-e137</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31425333" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31425333</a></p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000003541" class="uri">https://doi.org/10.1097/SLA.0000000000003541</a></p>
</details>
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<hr />
<p><a href="#top" target="_self">Back to top</a></p>
<hr />
<div style="page-break-after: always;"></div>
<hr />
<p><a href="#top" target="_self">Back to top</a></p>
<hr />
<div style="page-break-after: always;"></div>
</div>
</div>
<div id="feedback" class="section level1">
<h1>Feedback</h1>
<p><a href="https://docs.google.com/forms/d/e/1FAIpQLSeD3Z9J6Y7eMmiyM12f_SfAmHUlykb1zxZcwO6lg7cebGYQIQ/viewform">Google Feedback Form</a></p>
<script>var DISQUSWIDGETS,disqus_domain,disqus_shortname;
typeof DISQUSWIDGETS==="undefined"&&(DISQUSWIDGETS=function(){var f=document,a=f.getElementById("dsq-count-scr"),a=a&&a.src.match(/(https?:)?\/\/(?:www\.)?([\w_\-]+)\.((?:dev\.)?disqus\.(?:com|org)(?::\d+)?)/i),e={},s=f.head||f.body,j={},q={identifier:1,url:2};e.domain=a&&a[3]||disqus_domain||"disqus.com";e.forum=a&&a[2]||disqus_shortname;e.proto=a&&a[1]||"";e.getCount=function(b){var c;c=encodeURIComponent;var a=e.proto+"//"+e.forum+"."+e.domain+"/count-data.js?",d=[],k=0,l=10,r="",b=b||{};b.reset&&
(j={},r="&_="+ +new Date);for(var b=[f.getElementsByTagName("A"),f.getElementsByClassName&&f.getElementsByClassName("disqus-comment-count")||[]],m,i,g,h,n=0;n<b.length;n++){m=b[n];for(var o=0;o<m.length;o++){i=m[o];g=i.getAttribute("data-disqus-identifier");h=i.hash==="#disqus_thread"&&i.href.replace("#disqus_thread","")||i.getAttribute("data-disqus-url");if(g)h=q.identifier;else if(h)g=h,h=q.url;else continue;var p;j.hasOwnProperty(g)?p=j[g]:(p=j[g]={elements:[],type:h},d.push(c(h)+"="+c(g)));p.elements.push(i)}}d.sort();
for(c=d.slice(k,l);c.length;)b=f.createElement("script"),b.src=a+c.join("&")+r,s.appendChild(b),k+=10,l+=10,c=d.slice(k,l)};e.displayCount=function(b){for(var c,a,d,e=b.counts,b=b.text.comments;c=e.shift();)if(a=j[c.id]){switch(c.comments){case 0:d=b.zero;break;case 1:d=b.one;break;default:d=b.multiple}c=d.replace("{num}",c.comments);a=a.elements;for(d=a.length-1;d>=0;d--)a[d].innerHTML=c}};return e}());DISQUSWIDGETS.getCount();</script>
<div id="disqus_thread">

</div>
<script>

/**
*  RECOMMENDED CONFIGURATION VARIABLES: EDIT AND UNCOMMENT THE SECTION BELOW TO INSERT DYNAMIC VALUES FROM YOUR PLATFORM OR CMS.
*  LEARN WHY DEFINING THESE VARIABLES IS IMPORTANT: https://disqus.com/admin/universalcode/#configuration-variables*/
/*
var disqus_config = function () {
this.page.url = PAGE_URL;  // Replace PAGE_URL with your page's canonical URL variable
this.page.identifier = PAGE_IDENTIFIER; // Replace PAGE_IDENTIFIER with your page's unique identifier variable
};
*/
(function() { // DON'T EDIT BELOW THIS LINE
var d = document, s = d.createElement('script');
s.src = 'https://pbpath-org.disqus.com/embed.js';
s.setAttribute('data-timestamp', +new Date());
(d.head || d.body).appendChild(s);
})();
</script>
<noscript>
Please enable JavaScript to view the <a href="https://disqus.com/?ref_noscript">comments powered by Disqus.</a>
</noscript>
<hr />
<p><a href="#top" target="_self">Back to top</a></p>
<hr />
<div style="page-break-after: always;"></div>
<!-- rnb-text-end -->
</div>

<div id="rmd-source-code">LS0tCnRpdGxlOiAiUGFuY3JlYXRvYmlsaWFyeSBQYXRob2xvZ3kgU29jaWV0eSBKb3VybmFsIFdhdGNoIgpvdXRwdXQ6CiAgaHRtbF9ub3RlYm9vazoKICAgIGNvZGVfZm9sZGluZzogbm9uZQogICAgZmlnX2NhcHRpb246IHllcwogICAgaGlnaGxpZ2h0OiBudWxsCiAgICB0aGVtZTogcGFwZXIKZGF0ZTogIkxhc3QgVXBkYXRlIG9uIGByIGZvcm1hdChTeXMuRGF0ZSgpKWAiCnN1YnRpdGxlOiBSZWNlbnQgQXJ0aWNsZXMgdGhhdCB3aWxsIGJlIFNlbGVjdGVkCi0tLQoKYGBge3IgZ2xvYmFsX29wdGlvbnMsIGluY2x1ZGU9RkFMU0V9CmtuaXRyOjpvcHRzX2NodW5rJHNldChjYWNoZSA9IFRSVUUpCmBgYAoKCmBgYHtyIGxpYnJhcnksIGluY2x1ZGU9RkFMU0V9CnN1cHByZXNzUGFja2FnZVN0YXJ0dXBNZXNzYWdlcyhsaWJyYXJ5KCJ0aWR5dmVyc2UiKSkKc3VwcHJlc3NQYWNrYWdlU3RhcnR1cE1lc3NhZ2VzKGxpYnJhcnkoInJlYWR4bCIpKQpzdXBwcmVzc1BhY2thZ2VTdGFydHVwTWVzc2FnZXMobGlicmFyeSgiUmVmTWFuYWdlUiIpKQoKYGBgCgoKYGBge3IgZGF0YSBsb2FkLCBpbmNsdWRlPUZBTFNFfQphcnRpY2xlcyA8LSByZWFkUkRTKCJ+L0pvdXJuYWxXYXRjaFBCUGF0aC9hcnRpY2xlcy5yZHMiKQpgYGAKCgo8IS0tIE9wZW4gYWxsIGxpbmtzIGluIG5ldyB0YWItLT4gIAo8YmFzZSB0YXJnZXQ9Il9ibGFuayIvPiAgCgoKCi0tLQoKIyBQQlBhdGggSm91cm5hbCBXYXRjaCBBcnRpY2xlcyB7LnRhYnNldCAudGFic2V0LWZhZGUgLnRhYnNldC1waWxsc30KCgpgYGB7ciBzdHJpbmdzICwgaW5jbHVkZT1GQUxTRX0KUHViTWVkU3RyaW5nIDwtICJQdWJNZWQ6IGh0dHBzOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLz90ZXJtPSIKCmRvaVN0cmluZyA8LSAiZG9pOiBodHRwczovL2RvaS5vcmcvIgoKYGBgCgoKCi0tLQoKKipXZWxsY29tZSB0byB0aGUgUEJQYXRoIEpvdXJuYWwgV2F0Y2ghKiogCgpUaGlzIGJpLW1vbnRobHkgam91cm5hbCB3YXRjaCBmZWF0dXJlcyBleGNpdGluZyByZWNlbnRseSBwdWJsaXNoZWQgcGFuY3JlYXMgYW5kIGJpbGlhcnkgcGF0aG9sb2d5IGFydGljbGVzIHRoYXQgd2lsbCBwcm92aWRlIHVwIHRvIGRhdGUgbWVkaWNhbCBrbm93bGVkZ2UgaW4gb3VyIGZpZWxkLiBUaGVzZSBhcnRpY2xlcyB3aWxsIGJlIHNob3djYXNlZCBpbiBzZXZlcmFsIGNvbnZlbmllbnQgY2F0ZWdvcmllcywgaW5jbHVkaW5nIHN1cmdpY2FsIHBhdGhvbG9neSwgY3l0b3BhdGhvbG9neSwgYW5kIG1vbGVjdWxhciBwYXRob2xvZ3kgYW1vbmcgb3RoZXJzLiBUaGUgYXJ0aWNsZXMgaW4gZWFjaCBjYXRlZ29yeSBhcmUgaW4gbm8gcGFydGljdWxhciBvcmRlci4gU2VlIHRoZSBsaXN0IG9mIGpvdXJuYWxzIHdlIHNlYXJjaCByZWd1bGFybHkgW2hlcmVdKGh0dHA6Ly9wYnBhdGgub3JnL3BicGF0aC1qb3VybmFsLXdhdGNoLykuIFByZXZpb3VzIG1vbnRoc+KAmSBpc3N1ZXMgbWF5IGJlIGZvdW5kIGluIG91ciAqW2FyY2hpdmVdKGh0dHA6Ly9wYnBhdGgub3JnL2pvdXJuYWwtd2F0Y2gtYXJjaGl2ZS8pKiBhbmQgeW91IG1heSBzZWUgW2RyYWZ0cyBvZiB0aGUgdXBjb21pbmcgaXNzdWUgaGVyZV0oaHR0cDovL3BicGF0aC5vcmcvam91cm5hbC13YXRjaC11cGNvbWluZy1pc3N1ZS8pLiAgCgpXZSBlbmNvdXJhZ2UgbWVtYmVycyB0byBhY3RpdmVseSBwYXJ0aWNpcGF0ZSBieSByZWNvbW1lbmRpbmcgbmV3IGFydGljbGVzIGFuZCBwcm92aWRpbmcgZmVlZGJhY2sgdXNpbmcgdGhlIFtmb3JtcyBwcm92aWRlZCBiZWxvdy5dKCNmZWVkYmFjayl7dGFyZ2V0PSJfc2VsZiJ9ICAKCioqV2UgaG9wZSB0aGF0IHlvdSB3aWxsIGVuam95IHRoZSBuZXcgUEJQYXRoIEpvdXJuYWwgV2F0Y2ghKioKCi0tLQoKPGEgaHJlZj0iI3RvcCIgdGFyZ2V0PSJfc2VsZiI+QmFjayB0byB0b3A8L2E+CgotLS0KClxwYWdlYnJlYWsKCgojIyBQYW5jcmVhcwoKCmBgYHtyIHBhbmNyZWFzUmVjZW50LCAgY2hpbGQ9J34vSm91cm5hbFdhdGNoUEJQYXRoL19wYW5jcmVhc1JlY2VudC5SbWQnfQpgYGAKCi0tLQoKPGEgaHJlZj0iI3RvcCIgdGFyZ2V0PSJfc2VsZiI+QmFjayB0byB0b3A8L2E+CgotLS0KClxwYWdlYnJlYWsKCiMjIEdhbGxibGFkZGVyCgoKYGBge3IgZ2FsbGJsYWRkZXJSZWNlbnQsICBjaGlsZD0nfi9Kb3VybmFsV2F0Y2hQQlBhdGgvX2dhbGxibGFkZGVyUmVjZW50LlJtZCd9CmBgYAoKCgotLS0KCjxhIGhyZWY9IiN0b3AiIHRhcmdldD0iX3NlbGYiPkJhY2sgdG8gdG9wPC9hPgoKLS0tCgpccGFnZWJyZWFrCgojIyBCaWxlIER1Y3RzCgoKYGBge3IgYmlsZWR1Y3RzUmVjZW50LCAgY2hpbGQ9J34vSm91cm5hbFdhdGNoUEJQYXRoL19iaWxlZHVjdHNSZWNlbnQuUm1kJ30KYGBgCgoKCi0tLQoKPGEgaHJlZj0iI3RvcCIgdGFyZ2V0PSJfc2VsZiI+QmFjayB0byB0b3A8L2E+CgotLS0KClxwYWdlYnJlYWsKCiMjIEFtcHVsbGEKCgoKYGBge3IgYW1wdWxsYVJlY2VudCwgIGNoaWxkPSd+L0pvdXJuYWxXYXRjaFBCUGF0aC9fYW1wdWxsYVJlY2VudC5SbWQnfQpgYGAKCgoKLS0tCgo8YSBocmVmPSIjdG9wIiB0YXJnZXQ9Il9zZWxmIj5CYWNrIHRvIHRvcDwvYT4KCi0tLQoKXHBhZ2VicmVhawoKCgotLS0KCjxhIGhyZWY9IiN0b3AiIHRhcmdldD0iX3NlbGYiPkJhY2sgdG8gdG9wPC9hPgoKLS0tCgpccGFnZWJyZWFrCgoKIyBGZWVkYmFjawoKCltHb29nbGUgRmVlZGJhY2sgRm9ybV0oaHR0cHM6Ly9kb2NzLmdvb2dsZS5jb20vZm9ybXMvZC9lLzFGQUlwUUxTZUQzWjlKNlk3ZU1taXlNMTJmX1NmQW1IVWx5a2IxenhaY3dPNmxnN2NlYkdZUUlRL3ZpZXdmb3JtKSAgCgoKPHNjcmlwdCBpZD0iZHNxLWNvdW50LXNjciIgc3JjPSIvL3BicGF0aC1vcmcuZGlzcXVzLmNvbS9jb3VudC5qcyIgYXN5bmM+PC9zY3JpcHQ+CjxkaXYgaWQ9ImRpc3F1c190aHJlYWQiPjwvZGl2Pgo8c2NyaXB0PgoKLyoqCiogIFJFQ09NTUVOREVEIENPTkZJR1VSQVRJT04gVkFSSUFCTEVTOiBFRElUIEFORCBVTkNPTU1FTlQgVEhFIFNFQ1RJT04gQkVMT1cgVE8gSU5TRVJUIERZTkFNSUMgVkFMVUVTIEZST00gWU9VUiBQTEFURk9STSBPUiBDTVMuCiogIExFQVJOIFdIWSBERUZJTklORyBUSEVTRSBWQVJJQUJMRVMgSVMgSU1QT1JUQU5UOiBodHRwczovL2Rpc3F1cy5jb20vYWRtaW4vdW5pdmVyc2FsY29kZS8jY29uZmlndXJhdGlvbi12YXJpYWJsZXMqLwovKgp2YXIgZGlzcXVzX2NvbmZpZyA9IGZ1bmN0aW9uICgpIHsKdGhpcy5wYWdlLnVybCA9IFBBR0VfVVJMOyAgLy8gUmVwbGFjZSBQQUdFX1VSTCB3aXRoIHlvdXIgcGFnZSdzIGNhbm9uaWNhbCBVUkwgdmFyaWFibGUKdGhpcy5wYWdlLmlkZW50aWZpZXIgPSBQQUdFX0lERU5USUZJRVI7IC8vIFJlcGxhY2UgUEFHRV9JREVOVElGSUVSIHdpdGggeW91ciBwYWdlJ3MgdW5pcXVlIGlkZW50aWZpZXIgdmFyaWFibGUKfTsKKi8KKGZ1bmN0aW9uKCkgeyAvLyBET04nVCBFRElUIEJFTE9XIFRISVMgTElORQp2YXIgZCA9IGRvY3VtZW50LCBzID0gZC5jcmVhdGVFbGVtZW50KCdzY3JpcHQnKTsKcy5zcmMgPSAnaHR0cHM6Ly9wYnBhdGgtb3JnLmRpc3F1cy5jb20vZW1iZWQuanMnOwpzLnNldEF0dHJpYnV0ZSgnZGF0YS10aW1lc3RhbXAnLCArbmV3IERhdGUoKSk7CihkLmhlYWQgfHwgZC5ib2R5KS5hcHBlbmRDaGlsZChzKTsKfSkoKTsKPC9zY3JpcHQ+Cjxub3NjcmlwdD5QbGVhc2UgZW5hYmxlIEphdmFTY3JpcHQgdG8gdmlldyB0aGUgPGEgaHJlZj0iaHR0cHM6Ly9kaXNxdXMuY29tLz9yZWZfbm9zY3JpcHQiPmNvbW1lbnRzIHBvd2VyZWQgYnkgRGlzcXVzLjwvYT48L25vc2NyaXB0PgogICAgICAgICAgICAgICAgICAgICAgICAgICAgCgoKLS0tCgo8YSBocmVmPSIjdG9wIiB0YXJnZXQ9Il9zZWxmIj5CYWNrIHRvIHRvcDwvYT4KCi0tLQoKXHBhZ2VicmVhawoKCg==</div>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.header').parent('thead').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});

$(document).ready(function () {
  $('.knitsql-table').addClass('kable-table');
  var container = $('.kable-table');
  container.each(function() {

    // move the caption out of the table
    var table = $(this).children('table');
    var caption = table.children('caption').detach();
    caption.insertBefore($(this)).css('display', 'inherit');
  });
});

</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open')
  });
});
</script>

<!-- code folding -->
<script>
$(document).ready(function () {
  window.initializeSourceEmbed("RecentPBPathJW.Rmd");
});
</script>


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
